Compositions for the treatment of disease

ABSTRACT

The invention provides compositions and methods for the preparation, manufacture and therapeutic use of viral vectors, such as adeno-associated virus (AAV) particles having viral genomes encoding one or more antibodies or antibody fragments or antibody-like polypeptides, for the prevention and/or treatment of diseases and/or disorders.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a 35 U.S.C. § 371 U.S. National Stage Entry of International Application No. PCT/US2017/030061 filed Apr. 28, 2017, which claims priority to U.S. Provisional Patent Application No. 62/329,468, entitled COMPOSITIONS FOR THE TREATMENT OF DISEASE, filed Apr. 29, 2016 and U.S. Provisional Patent Application No. 62/329,479, entitled COMPOSITIONS FOR THE TREATMENT OF DISEASE, filed Apr. 29, 2016; the contents of each of which are herein incorporated by reference in their entirety.

REFERENCE TO SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Oct. 29, 2018 is named 20571302US371 SL and is 14,170,304 bytes in size.

FIELD OF THE INVENTION

The invention relates to compositions and methods for vectored antibody delivery (VAD).

BACKGROUND OF THE INVENTION

Antibody-based therapies have been developed for a wide variety of diseases, disorders and conditions, including infectious and non-infectious diseases. The U.S. Food and Drug Administration (FDA) has approved antibodies for treatment of cancers, autoimmune and immune system disorders, ocular diseases, nervous system diseases, inflammations, and infections, amongst many others. Naturally, antibodies are components of the adaptive immune response and they function by recognizing specific foreign antigens and stimulating humoral immunity responses. As a consequence, antibodies may be applied to the treatment, prevention, management, diagnosis and research of diseases, disorders and/or conditions.

Antibodies have relatively short half-lives and this presents an ongoing and long-felt challenge for antibody-based therapies. In order to achieve a sufficiently high concentration of an antibody for long lasting therapeutic effects, antibody therapies are traditionally delivered by repeated administration, e.g. by multiple injections. This dosing regimen results in an inconsistent level of antibody throughout the treatment period, limited efficiency per administration, high cost of administration and consumption of the antibody. Hence, there remains a need in the art for delivery of antibodies and antibody-based therapeutics through alternative routes or modalities of administration.

One such alternative route of administration is by expression vector (e.g. plasmid or viral vector), including but not limited to, adeno-associated viral vectors (AAVs). Adeno-associated viral vectors are widely used in gene therapy approaches due to a number of advantageous features. As dependoparvoviruses, AAV are non-replicating in infected cells and therefore not associated with any known disease. Further, AAVs may be introduced to a wide variety of host cells, do not integrate into the genome of the host cell, and are capable of infecting both quiescent and dividing cells. AAVs transduce non-replicating and long-lived cells in vivo, resulting in long term expression of the protein of interest. Further, AAVs can be manipulated with cellular and molecular biology techniques to produce non-toxic particles carrying a payload encoded in the AAV viral genome that can be delivered to a target tissue or set of cells with limited or no side-effects. Given the foregoing, the use of AAVs for vectored antibody delivery (VAD) would allow for longer lasting efficacy, fewer dose treatments, and more consistent levels of the antibody throughout the treatment period.

In vectored antibody delivery (VAD) an AAV is used as the delivery modality for a nucleic acid sequence encoding the antibody, which results in in vivo expression of the encoded payload, e.g., functional antibody.

The mechanism underlying VAD is thought to proceed through the following steps. First the AAV vector enters the cell via endocytosis, then escapes from the endosomal compartment and is transported to the nucleus wherein the viral genome is released and converted into a double-stranded episomal molecule of DNA by the host. The transcriptionally active episome results in the expression of encoded antibodies that may then be secreted from the cell into the circulation. VAD may therefore enable continuous, sustained and long-term delivery of antibodies administered by a single injection of an AAV particle.

Previous studies of an AAV-mediated antibody technique known as vectored immunoprophylaxis (VIP) have focused on neutralization of human immunodeficiency virus (HIV) (see, e.g. Johnson et al., 2009, Nature Med., 15, 901-906, Saunders et al., 2015, J. Virol., 89(16), 8334-8345, Balasz et al., 2012, Nature 481, 81-84, the contents of which are incorporated herein by reference in their entirety). Balasz et al. reported a long-term, even lifelong, expression of monoclonal antibody at high concentration from a single intramuscular administration in mice that resulted in full protection against HIV infection. AAV-mediated VIP has also been demonstrated against influenza strains (see, e.g. Balasz et al. Nat. Biotechnol., 2013, 31(7):647-52) and Plasmodium falciparum, a sporozoite causing malaria infection (see, e.g. Deal at al., 2014, PNAS, 111 (34), 12528-12532), as well as cancer, RSV and drug addiction (see, e.g. review by Schnepp and Johnson, Microbiol. Spectrum 2(4), 2014). Though promising, these studies emphasize efforts to merely prevent disease. There still remains a need for improved methods of prevention, and new antibody-mediated therapies for research, diagnosis, and treatment of disease.

The present invention addresses this need by providing novel AAV particles having viral genomes engineered to encode antibodies and antibody-based compositions and methods of using these constructs (e.g., VAD) for the treatment, prevention, diagnosis and research of diseases, disorders and/or conditions. The present invention further embraces optimized AAV particles for delivery of nucleic acids (e.g., viral genomes) encoding antibodies and antibody-based compositions to a subject in need thereof.

SUMMARY OF THE INVENTION

The invention provides AAV particles comprising a capsid and a viral genome, said viral genome comprising at least one inverted terminal repeat (ITR) region and a payload region, said payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, said first nucleic acid segment encoding one or more polypeptides given in Tables 3-42, variants and fragments thereof. The capsid of the AAV particle may be any of the serotypes described herein and/or described in Table 1.

In one aspect, the first nucleic acid segment may encode one or more polypeptides such as, but not limited to, an antibody heavy chain, an antibody light chain, a linker, and combinations thereof. The first nucleic acid segment may encode one or more polypeptides which is humanized. As a non-limiting example, the first nucleic acid segment encodes from 5′ to 3′, an antibody heavy chain, a linker, and an antibody light chain. As another non-limiting example, the first nucleic acid segment encodes from 5′ to 3′, an antibody light chain, a linker, and an antibody heavy chain. As yet another non-limiting example, the first nucleic acid segment encodes one or more antibody heavy chains. As yet another non-limiting example, the first nucleic acid segment encodes one or more antibody light chains.

In one aspect, the first nucleic acid segment encodes an antibody, having at least 95% identity to any of the sequences of Tables 3-42 (SEQ ID NO: 2948-9220).

In one aspect, the regulatory sequence may comprise a promoter such as but not limited to, human elongation factor 1α-subunit (EF1α), cytomegalovirus (CMV) immediate-early enhancer and/or promoter, chicken β-actin (CBA) and its derivative CAG, 1(glucuronidase (GUSB), or ubiquitin C (UBC). Tissue-specific expression elements can be used to restrict expression to certain cell types such as, but not limited to, muscle specific promoters, B cell promoters, monocyte promoters, leukocyte promoters, macrophage promoters, pancreatic acinar cell promoters, endothelial cell promoters, lung tissue promoters, astrocyte promoters, or nervous system promoters which can be used to restrict expression to neurons, astrocytes, or oligodendrocytes.

In one aspect, the linker in the viral genome is selected from one or more of the linkers given in Table 2.

In one aspect, the AAV particles described herein may comprise a viral genome which is single stranded.

In one aspect, the AAV particles described herein may comprise a viral genome which is self-complementary.

In one aspect, the AAV particles described herein may comprise a viral genome comprising at least one intron sequence.

In one aspect, the AAV particles described herein may comprise a viral genome comprising at least one stuffer sequence to adjust the length of the viral genome to increase efficacy and/or efficiency.

In one aspect, the AAV particles described herein may comprise at least one region which has been codon optimized. As a non-limiting example, the viral genome may be codon optimized. As another non-limiting example, the first nucleic acid segment is codon-optimized.

In one aspect, the AAV particles described herein may comprise a viral genome with 2 ITR regions. At least one of the ITR regions may be derived from the same or different parental serotype of the capsid. As a non-limiting example, at least one ITR region is derived from AAV2.

In one aspect, the AAV particles comprise a viral genome which comprises a second nucleic acid segment. The second nucleic acid segment may encode an aptamer, siRNA, saRNA, ribozyme, microRNA, mRNA or combination thereof.

In one aspect, the AAV particles comprise a viral genome which comprises a second nucleic acid segment encoding an siRNA designed to target the mRNA that encodes the target of the antibody encoded by the first nucleic acid segment.

In one aspect, the AAV particles comprise a viral genome which comprises a second nucleic acid segment encoding a microRNA, the microRNA is selected to target the mRNA that encodes the target of the antibody encoded by the first nucleic acid segment.

In one aspect, the AAV particles comprise a viral genome which comprises a second nucleic acid segment encoding an mRNA, the mRNA encodes one or more peptides inhibitors of the same target of the antibody encoded by the first nucleic acid segment.

In one aspect, the AAV particles comprise a viral genome which comprises a third nucleic acid segment. The third nucleic acid segment may encode a nuclear export signal, a polynucleotide or polypeptide which acts as a regulator of expression of the viral genome in which it is encoded, a polynucleotide or polypeptide which acts as a regulator of expression of the payload region of the viral genome in which it is encoded and/or a polynucleotide or polypeptide which acts as a regulator of expression of the first nucleic acid segment of the payload region of the viral genome in which it is encoded.

The invention provides AAV particles comprising a capsid and a viral genome, said viral genome comprising at least one inverted terminal repeat (ITR) region and a payload region comprising a regulatory sequence operably linked to at least a first nucleic acid segment, the first nucleic acid segment encoding a bispecific antibody derived from any of the sequences listed in Tables 3-42 or portions or fragments thereof.

The invention provides methods of producing a functional antibody in a subject in need thereof, comprising administering to a subject the AAV particles described herein. The level or amount of the functional antibody in the target cell or tissue after administration to the subject may be from about 0.001 ug/mL to 100 mg/mL. The functional antibody may be encoded by a single first nucleic acid segment of a viral genome within the AAV particle. The functional antibody may be encoded by two different viral genomes, the two different viral genomes may be packaged in separate capsids.

The invention provides a pharmaceutical composition comprising an AAV particle described herein in a pharmaceutically acceptable excipient. As a non-limiting example, the pharmaceutically acceptable excipient is saline. As a non-limiting example, the pharmaceutically acceptable excipient is 0.001% pluronic in saline.

The invention provides methods of producing a functional antibody in a subject in need thereof, comprising administering to a subject the AAV particles described herein by a delivery route such as, but not limited to, enteral (into the intestine), gastroenteral, epidural (into the dura mater), oral (by way of the mouth), transdermal, intracerebral (into the cerebrum), intracerebroventricular (into the cerebral ventricles), epicutaneous (application onto the skin), intradermal, (into the skin itself), subcutaneous (under the skin), nasal administration (through the nose), intravenous (into a vein), intravenous bolus, intravenous drip, intra-arterial (into an artery), intramuscular (into a muscle), intracardiac (into the heart), intraosseous infusion (into the bone marrow), intrathecal (into the spinal canal), intraparenchymal (into brain tissue), intraperitoneal, (infusion or injection into the peritoneum), intravesical infusion, intravitreal, (through the eye), intracavernous injection (into a pathologic cavity) intracavitary (into the base of the penis), intravaginal administration, intrauterine, extra-amniotic administration, transdermal (diffusion through the intact skin for systemic distribution), transmucosal (diffusion through a mucous membrane), transvaginal, insufflation (snorting), sublingual, sublabial, enema, eye drops (onto the conjunctiva), or in ear drops, auricular (in or by way of the ear), buccal (directed toward the cheek), conjunctival, cutaneous, dental (to a tooth or teeth), electro-osmosis, endocervical, endosinusial, endotracheal, extracorporeal, hemodialysis, infiltration, interstitial, intra-abdominal, intra-amniotic, intra-articular, intrabiliar, intrabronchial, intrabursal, intracartilaginous (within a cartilage), intracaudal (within the cauda equine), intracisternal (within the cisterna magna cerebellomedularis), intracorneal (within the cornea), dental intracoronal, intracoronary (within the coronary arteries), intracorporus cavernosum (within the dilatable spaces of the corporus cavernosa of the penis), intradiscal (within a disc), intraductal (within a duct of a gland), intraduodenal (within the duodenum), intradural (within or beneath the dura), intraepidermal (to the epidermis), intraesophageal (to the esophagus), intragastric (within the stomach), intragingival (within the gingivae), intraileal (within the distal portion of the small intestine), intralesional (within or introduced directly to a localized lesion), intraluminal (within a lumen of a tube), intralymphatic (within the lymph), intramedullary (within the marrow cavity of a bone), intrameningeal (within the meninges), intramyocardial (within the myocardium), intraocular (within the eye), intraovarian (within the ovary), intrapericardial (within the pericardium), intrapleural (within the pleura), intraprostatic (within the prostate gland), intrapulmonary (within the lungs or its bronchi), intrasmal (within the nasal or periorbital sinuses), intraspinal (within the vertebral column), intrasynovial (within the synovial cavity of a joint), intratendinous (within a tendon), intratesticular (within the testicle), intrathecal (within the cerebrospinal fluid at any level of the cerebrospinal axis), intrathoracic (within the thorax), intratubular (within the tubules of an organ), intraturnor (within a tumor), intratympanic (within the aurus media), intravascular (within a vessel or vessels), intraventricular (within a ventricle), iontophoresis (by means of electric current where ions of soluble salts migrate into the tissues of the body), irrigation (to bathe or flush open wounds or body cavities), laryngeal (directly upon the larynx), nasogastric (through the nose and into the stomach), occlusive dressing technique (topical route administration which is then covered by a dressing which occludes the area), ophthalmic (to the external eye), oropharyngeal (directly to the mouth and pharynx), parenteral, percutaneous, periarticular, pendural, perineural, penodontal, rectal, respiratory (within the respiratory tract by inhaling orally or nasally for local or systemic effect), retrobulbar (behind the pons or behind the eyeball), soft tissue, subarachnoid, subconjunctival, submucosal, topical, transplacental (through or across the placenta), transtracheal (through the wall of the trachea), transtympanic (across or through the tympanic cavity), ureteral (to the ureter), urethral (to the urethra), vaginal, caudal block, diagnostic, nerve block, biliary perfusion, cardiac perfusion, photophoresis and spinal.

The invention provides methods of treating and/or preventing a disease or disorder in a subject comprising administering to the subject an AAV particle described herein. The administration may be at a prophylactically effective dose such as, but not limited to, from about 1 ug/mL to about 500 ug/mL of expressed polypeptide or 1×10e4 to 1×10e16 VG/mL from the pharmaceutical composition. The pharmaceutical composition may be administered at least once. The pharmaceutical composition may be administered daily, weekly, monthly or yearly. The pharmaceutical composition may be co-administered as part of a combination therapy.

The invention provides methods of producing an antibody in a subject by administering the AAV particles described herein, where the antibody is not a virus neutralizing antibody.

The invention provides methods of producing an antibody in a subject by administering the AAV particles described herein, where the antibody is not an HIV or HCV virus neutralizing antibody.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, features and advantages will be apparent from the following description of particular embodiments of the invention, as illustrated in the accompanying drawings. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating the principles of various embodiments of the invention.

FIG. 1 is a schematic of vectored antibody delivery.

FIG. 2 is a schematic of a viral genome of the invention.

FIG. 3 is a schematic of payload regions FIG. 3 discloses SEQ ID NO: 9221.

DETAILED DESCRIPTION OF THE INVENTION I. Compositions of the Invention

According to the present invention, compositions for delivering functional antibodies and/or antibody-based compositions by adeno-associated viruses (AAVs) are provided. AAV particles of the invention may be provided via any of several routes of administration, to a cell, tissue, organ, or organism min vivo, ex vivo or in vitro.

As used herein, an “AAV particle” is a virus which comprises a viral genome with at least one payload region and at least one inverted terminal repeat (ITR) region.

As used herein. “viral genome” or “vector genome” refers to the nucleic acid sequence(s) encapsulated in an AAV particle. Viral genomes comprise at least one payload region encoding polypeptides of the invention, e.g., antibodies, antibody-based compositions or fragments thereof.

As used herein, a “payload” or “payload region” is any nucleic acid molecule which encodes one or more polypeptides of the invention. At a minimum, a payload region comprises nucleic acid sequences that encode an antibody, an antibody-based composition, or a fragment thereof, but may also optionally comprise one or more functional or regulatory elements to facilitate transcriptional expression and/or polypeptide translation.

The nucleic acid sequences and polypeptides disclosed herein may be engineered to contain modular elements and/or sequence motifs assembled to enable expression of the antibodies or antibody-based compositions of the invention. In some embodiments, the nucleic acid sequence comprising the payload region may comprise one or more of a promoter region, an intron, a Kozak sequence, an enhancer or a poly adenylation sequence. Payload regions of the invention typically encode antibodies or antibody based compositions, which may include an antibody heavy chain domain, an antibody light chain domain, both antibody heavy and light chain domains, or fragments of the foregoing in combination with each other or in combination with other polypeptide moieties. In some cases, payload regions may also encode one or more linkers or joining regions between antibody heavy and light chain domains or fragments. The order of expression, structural position, or concatemer count (heavy chain, light chain, or linker) may be different within or among different payload regions. The identity, position and number of linkers expressed by payload regions may also vary.

The payload regions of the invention may be delivered to one or more target cells, tissues, organs or organisms within the viral genome of an AAV particle.

Adeno-Associated Viruses (AAVs) and AAV Particles

Viruses of the Parvoviridae family are small non-enveloped icosahedral capsid viruses characterized by a single stranded DNA genome. Parvovindae family viruses consist of two subfamilies: Parovirinae, which infect vertebrates, and Densovinnae, which infect invertebrates. Due to its relatively simple structure, easily manipulated using standard molecular biology techniques, this virus family is useful as a biological tool. The genome of the virus may be modified to contain a minimum of components for the assembly of a functional recombinant virus, or viral particle, which is loaded with or engineered to express or deliver a desired payload, which may be delivered to a target cell, tissue, organ, or organism.

The parvoviruses and other members of the Parvoviridae family are generally described in Kenneth I. Berns, “Parvoviridae: The Viruses and Their Replication,” Chapter 69 in FIELDS VIROLOGY (3d Ed. 1996), the contents of which are incorporated by reference in their entirety.

The Parvoviridae family comprises the Dependovirus genus which includes adeno-associated viruses (AAV) capable of replication in vertebrate hosts including, but not limited to, human, primate, bovine, canine, equine, and ovine species.

The AAV vector genome is a linear, single-stranded DNA (ssDNA) molecule approximately 5,000 nucleotides (nt) in length. The AAV viral genome can comprise a payload region and at least one inverted terminal repeat (ITR) or ITR region. ITRs traditionally flank the coding nucleotide sequences for the non-structural proteins (encoded by Rep genes) and the structural proteins (encoded by capsid genes or Cap genes). While not wishing to be bound by theory, an AAV viral genome typically comprises two ITR sequences. The AAV vector genome comprises a characteristic T-shaped hairpin structure defined by the self-complementary terminal 145 nt of the 5′ and 3′ ends of the ssDNA which form an energetically stable double stranded region. The double stranded hairpin structures comprise multiple functions including, but not limited to, acting as an origin for DNA replication by functioning as primers for the endogenous DNA polymerase complex of the host viral replication cell.

In addition to the encoded heterologous payload, AAV vectors may comprise the viral genome, in whole or in part, of any naturally occurring and/or recombinant AAV serotype nucleotide sequence or variant. AAV variants may have sequences of significant homology at the nucleic acid (genome or capsid) and amino acid levels (capsids), to produce constructs which are generally physical and functional equivalents, replicate by similar mechanisms, and assemble by similar mechanisms. Chiorini et al., J. Vir. 71: 6823-33(1997); Srivastava et al., J. Vir. 45:555-64 (1983), Chiorini et al., J. Vir. 73:1309-1319 (1999); Rutledge et al., J. Vir. 72:309-319 (1998); and Wu et al., J. Vir. 74: 8635-47 (2000), the contents of each of which are incorporated herein by reference in their entirety.

In one embodiment, AAV particles of the present invention are recombinant AAV viral vectors which are replication defective, lacking sequences encoding functional Rep and Cap proteins within their viral genome. These defective AAV vectors may lack most or all parental coding sequences and essentially carry only one or two AAV ITR sequences and the nucleic acid of interest for delivery to a cell, a tissue, an organ or an organism.

In one embodiment, the viral genome of the AAV particles of the present invention comprise at least one control element which provides for the replication, transcription and translation of a coding sequence encoded therein. Not all of the control elements need always be present as long as the coding sequence is capable of being replicated, transcribed and/or translated in an appropriate host cell. Non-limiting examples of expression control elements include sequences for transcription initiation and/or termination, promoter and/or enhancer sequences, efficient RNA processing signals such as splicing and polyadenylation signals, sequences that stabilize cytoplasmic mRNA, sequences that enhance translation efficacy (e.g., Kozak consensus sequence), sequences that enhance protein stability, and/or sequences that enhance protein processing and/or secretion.

According to the present invention. AAV particles for use in therapeutics and/or diagnostics comprise a virus that has been distilled or reduced to the minimum components necessary for transduction of a nucleic acid payload or cargo of interest. In this manner, AAV particles are engineered as vehicles for specific delivery while lacking the deleterious replication and/or integration features found in wild-type viruses.

AAV vectors of the present invention may be produced recombinantly and may be based on adeno-associated virus (AAV) parent or reference sequences. As used herein, a “vector” is any molecule or moiety which transports, transduces or otherwise acts as a carrier of a heterologous molecule such as the nucleic acids described herein.

In addition to single stranded AAV viral genomes (e.g., ssAAVs), the present invention also provides for self-complementary AAV (scAAVs) viral genomes scAAV vector genomes contain DNA strands which anneal together to form double stranded DNA. By skipping second strand synthesis, scAAVs allow for rapid expression in the cell.

In one embodiment, the AAV particle of the present invention is an scAAV.

In one embodiment, the AAV particle of the present invention is an ssAAV.

Methods for producing and/or modifying AAV particles are disclosed in the art such as pseudotyped AAV vectors (PCT Patent Publication Nos. WO200028004; WO200123001; WO2004112727; WO 2005005610 and WO2005072364, the content of each of which is incorporated herein by reference in its entirety).

AAV particles may be modified to enhance the efficiency of delivery. Such modified AAV particles can be packaged efficiently and be used to successfully infect the target cells at high frequency and with minimal toxicity. In some embodiments, the capsids of the AAV particles are engineered according to the methods described in US Publication Number US 20130195801, the contents of which are incorporated herein by reference in their entirety.

In one embodiment, the AAV particles comprising a payload region encoding the polypeptides of the invention may be introduced into mammalian cells.

AAV Serotypes

AAV particles of the present invention may comprise or be derived from any natural or recombinant AAV serotype. According to the present invention, the AAV particles may utilize or be based on a serotype selected from any of the following AAV1, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV5, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV12, AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42-1b, AAV42-2, AAV42-3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, AAV42-8, AAV42-10, AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AAV43-25, AAV43-5, AAV44.1, AAV44.2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAV1-7/rh.48, AAV1-8/rh.49, AAV2-15/rh.62, AAV2-3/rh.61, AAV2-4/rh.50, AAV2-5/rh.51, AAV3.1/hu.6, AAV3.1/hu.9, AAV3-9/rh.52, AAV3-11/rh.53, AAV4-8/r11.64, AAV4-9/rh.54, AAV4-19/rh.55, AAV5-3/rh.57, AAV5-22/rh.58, AAV7.3/hu.7, AAV16.8/hu.10, AAV16.12/hu.11, AAV29.3/bb.1, AAV29.5/bb.2, AAV106.1/hu.37, AAV114.3/hu.40, AAV127.2/hu.41, AAV127.5/hu.42, AAV128.3/hu.44, AAV130.4/hu.48, AAV145.1/hu.53, AAV145.5/hu.54, AAV145.6/hu.55, AAV161.10/hu.60, AAV161.6/hu.61, AAV33.12/hu.17, AAV33.4/hu.15, AAV33.8/hu.16, AAV52/hu.19, AAV52.1/hu.20, AAV58.2/hu.25, AAVA3.3, AAVA3.4, AAVA3.5, AAVA3.7, AAVC1, AAVC2, AAVC5, AAV-DJ, AAV-DJ8, AAVF3, AAVF5, AAVH2, AAVrh.72, AAVhu.8, AAVrh.68, AAVrh.70, AAVpi.1, AAVpi.3, AAVpi.2, AAVrh.60, AAVrh.44, AAVrh.65, AAVrh.55, AAVrh.47, AAVrh.69, AAVrh.45, AAVrh.59, AAVhu.12, AAVH6, AAVLK03, AAVH-1/hu.1, AAVH-5/hu.3, AAVLG-10/rh.40, AAVLG-4/rh.38, AAVLG-9/hu.39, AAVN721-8/rh.43, AAVCh.5, AAVCh.5Ra, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVCy.5R1, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2, AAVhu.3, AAVhu.4, AAVhu.5, AAVhu.6, AAVhu.7, AAVhu.9, AAVhu.10, AAVhu.11, AAVhu.13, AAVhu.15, AAVhu.16, AAVhu.17, AAVhu.18, AAVhu.20, AAVhu.21, AAVhu.22, AAVhu.23.2, AAVhu.24, AAVhu.25, AAVhu.27, AAVhu.28, AAVhu.29, AAVhu.29R, AAVhu.31, AAVhu.32, AAVhu.34, AAVhu.35, AAVhu.37, AAVhu.39, AAVhu.40, AAVhu.41, AAVhu.42, AAVhu.43, AAVhu.44, AAVhu.44R1, AAVhu44R2, AAVhu.44R3, AAVhu.45, AAVhu.46, AAVhu.47, AAVhu.48, AAVhu.48R1, AAVhu.48R2, AAVhu.48R3, AAVhu.49, AAVhu.51, AAVhu.52, AAVhu.54, AAVhu.55, AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14/9, AAVhu.t 19, AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54. AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64R1, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, caprine AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-1LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV-LK16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-mniRNA-101, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV Shuffle 100-1, AAV Shuffle 100-3, AAV Shuffle 100-7, AAV Shuffle 10-2, AAV Shuffle 10-6, AAV Shuffle 10-8, AAV Shuffle 100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.11, AAVhu.53, AAV4-8/rh.64, AAVLG-9/hu.39, AAV54.5/hu.23, AAV54.2/hu.22, AAV54.7/hu.24, AAV54.1/hu.21, AAV54.4R/hu.27, AAV46.2/hu.28, AAV46.6/hu.29, AAV128.1/hu.43, true type AAV (ttAAV), UPENN AAV10, Japanese AAV10 serotypes, AAV CBr-7.1, AAV CBr-7.10, AAV CBr-7.2, AAV CBr-7.3, AAV CBr-7.4, AAV CBr-7.5, AAV CBr-7.7, AAV CBr-7.8, AAV CBr-B7.3, AAV CBr-B7.4, AAV CBr-E1, AAV CBr-E2, AAV CBr-E3, AAV CBr-E4, AAV CBr-E5, AAV CBr-e5, AAV CBr-E6, AAV CBr-E7, AAV CBr-E8, AAV CHt-1, AAV CHt-2, AAV CHt-3, AAV CHt-6.1, AAV CHt-6.10, AAV CHt-6.5, AAV CHt-6.6, AAV CHt-6.7, AAV CHt-6.8, AAV CHt-P1, AAV CHt-P2, AAV CHt-P5, AAV CHt-P6, AAV CHt-P8, AAV CHt-P9, AAV CKd-1, AAV CKd-10, AAV CKd-2, AAV CKd-3, AAV CKd-4, AAV CKd-6, AAV CKd-7, AAV CKd-8, AAV CKd-B1, AAV CKd-B2, AAV CKd-B3, AAV CKd-B4, AAV CKd-B5, AAV CKd-B6, AAV Ckd-B7, AAV Ckd-B8, AAV CKd-H1, AAV CKd-H2, AAV CKd-H3, AAV CKd-H4, AAV CKd-H5, AAV CKd-H6, AAV CKd-N3, AAV CKd-N4, AAV CKd-N9, AAV CLg-F1, AAV CLg-F2, AAV CLg-F3, AAV CLg-F4, AAV CLg-F5, AAV CLg-F6, AAV CLg-F7, AAV CLg-F8, AAV CLv-1, AAV CLv1-1, AAV Clv1-10, AAV CLv1-2, AAV CLv-12, AAV CLv1-3, AAV CLv-13, AAV CLv1-4, AAV Clv1-7, AAV Clv1-8, AAV Clv1-9, AAV CLv-2, AAV CLv-3, AAV CLv-4, AAV CLv-6, AAV CLv-8, AAV CLv-D1, AAV CLv-D2, AAV CLv-D3, AAV CLv-D4, AAV Clv-D5, AAV CLv-D6, AAV CLv-D7, AAV CLv-D8, AAV CL-E1, AAV CL-K1, AAV CLv-K3, AAV CLv-K6, AAV CLv-L4, AAV CLv-L5, AAV CLv-L6, AAV CLv-M1, AAV CLv-M11, AAV CLv-M2, AAV CLv-M5, AAV CLv-M6, AAV CLv-M7, AAV CLv-M8, AAV CLv-M9, AAV CLv-R1, AAV CLv-R2, AAV CLv-R3, AAV CLv-R4, AAV CLv-R5, AAV CLv-R6, AAV CLv-R7, AAV CLv-R8, AAV CLv-R9, AAV CSp-1, AAV CSp-10, AAV CSp-1, AAV CSp-2, AAV CSp-3, AAV CSp-4, AAV CSp-6, AAV CSp-7, AAV CSp-8, AAV CSp-8.10, AAV CSp-8.2, AAV CSp-8.4, AAV CSp-8.5, AAV CSp-8.6, AAV CSp-8.7, AAV CSp-8.8, AAV CSp-8.9, AAV CSp-9, AAV.hu.48R3, AAV.VR-355, AAV3B, AAV4, AAV5, AAVF1/HSC1, AAVF11/HSC11, AAVF12/HSC12, AAVF13/HSC13, AAVF14/HSC14, AAVF15/HSC15, AAVF16/HSC16, AAVF17/HSC17, AAVF2/HSC2, AAVF3/HSC3, AAVF4/HSC4, AAVF5/HSC5, AAVF6/HSC6, AAVF7/HSC7, AAVF8/HSC8, AAVF9/HSC9, PHP.B. PHP.A, G2B-26, G2B-13, TH1.1-32 and/or TH1.1-35 and variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Publication No. US20030138772, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV1 (SEQ ID NO: 6 and 64 of US20030138772), AAV2 (SEQ ID NO: 7 and 70 of US20030138772), AAV3 (SEQ ID NO: 8 and 71 of US20030138772), AAV4 (SEQ ID NO: 63 of US20030138772), AAV5 (SEQ ID NO-114 of US20030138772), AAV6 (SEQ ID NO: 65 of US20030138772), AAV7 (SEQ ID NO: 1-3 of US20030138772), AAV8 (SEQ ID NO: 4 and 95 of US20030138772), AAV9 (SEQ ID NO: 5 and 100 of US20030138772), AAV10 (SEQ ID NO: 117 of US20030138772), AAV11 (SEQ ID NO-118 of US20030138772), AAV12 (SEQ ID NO: 119 of US20030138772), AAVrh10 (amino acids 1 to 738 of SEQ ID NO: 81 of US20030138772), AAV16.3 (US20030138772 SEQ ID NO. 10), AAV29.3/bb.1 (US20030138772 SEQ ID NO: 11), AAV29.4 (US20030138772 SEQ ID NO:12), AAV29.5/bb.2 (US20030138772 SEQ ID NO: 13), AAV1.3 (US20030138772 SEQ ID NO: 14), AAV13.3 (US20030138772 SEQ ID NO: 15), AAV24.1 (US20030138772 SEQ ID NO: 16), AAV27.3 (US20030138772 SEQ ID NO: 17), AAV7.2 (US20030138772 SEQ ID NO: 18), AAVC1 (US20030138772 SEQ ID NO: 19), AAVC3 (US20030138772 SEQ ID NO: 20), AAVC5 (US20030138772 SEQ ID NO: 21), AAVF1 (US20030138772 SEQ ID NO: 22), AAVF3 (US20030138772 SEQ ID NO: 23), AAV F5 (US20030138772 SEQ ID NO: 24), AAVH6 (US20030138772 SEQ ID NO: 25), AAVH2 (US20030138772 SEQ ID NO: 26), AAV42-8 (US20030138772 SEQ ID NO: 27), AAV42-15 (US20030138772 SEQ ID NO: 28), AAV42-5b (US20030138772 SEQ ID NO: 29), AAV42-1b (US20030138772 SEQ ID NO: 30), AAV42-13 (US20030138772 SEQ ID NO: 31), AAV42-3a (US20030138772 SEQ ID NO: 32), AAV42-4 (US20013138772 SEQ ID NO: 33), AAV42-5a (US20030138772 SEQ ID NO: 34), AAV42-10 (US20030138772 SEQ ID NO: 35), AAV42-3b (US20030138772 SEQ ID NO: 36), AAV42-11 (US20030138772 SEQ ID NO: 37), AAV42-6b (US20030138772 SEQ ID NO: 38), AAV43-1 (US20030138772 SEQ ID NO: 39), AAV43-5 (US20030138772 SEQ ID NO: 40), AAV43-12 (US20030138772 SEQ ID NO: 41), AAV43-20 (US20030138772 SEQ ID NO: 42), AAV43-21 (US20030138772 SEQ ID NO: 43), AAV43-23 (US20030138772 SEQ ID NO: 44), AAV43-25 (US20030138772 SEQ ID NO: 45), AAV44.1 (US20030138772 SEQ ID NO: 46), AAV44.5 (US20030138772 SEQ ID NO: 47), AAV223.1 (US20030138772 SEQ ID NO: 48), AAV223.2 (US20030138772 SEQ ID NO: 49), AAV223.4 (US20030138772 SEQ ID NO: 50), AAV223.5 (US20030138772 SEQ ID NO: 51), AAV223.6 (US20030138772 SEQ ID NO: 52), AAV223.7 (US20030138772 SEQ ID NO: 53), AAVA3.4 (US20030138772 SEQ ID NO: 54), AAVA3.5 (US20030138772 SEQ ID NO: 55), AAVA3.7 (US20030138772 SEQ ID NO: 56), AAVA3.3 (US20030138772 SEQ ID NO: 57), AAV42.12 (US20030138772 SEQ ID NO: 58), AAV44.2 (US20030138772 SEQ ID NO: 59), AAV42-2 (US20030138772 SEQ ID NO: 9), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Publication No. US20150159173, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV2 (SEQ ID NO: 7 and 23 of US20150159173), rh20 (SEQ ID NO: 1 of US20150159173), rh32/33 (SEQ ID NO: 2 of US20150159173), rh39 (SEQ ID NO: 3, 20 and 36 of US20150159173), rh46 (SEQ ID NO: 4 and 22 of US20150159173), rh73 (SEQ ID NO: 5 of US20150159173), rh74 (SEQ ID NO: 6 of US20150159173), AAV6.1 (SEQ ID NO:29 of US20150159173), rh.8 (SEQ ID NO: 41 of US20150159173), rh.48.1 (SEQ ID NO: 44 of US20150159173), hu.44 (SEQ ID NO: 45 of US20150159173), hu.29 (SEQ ID NO: 42 of US20150159173), hu.48 (SEQ ID NO: 38 of US20150159173), rh54 (SEQ ID NO:49 of US20150159173), AAV2 (SEQ ID NO: 7 of US20150159173), cy.5 (SEQ ID NO: 8 and 24 of US20150159173), rh.10 (SEQ ID NO: 9 and 25 of US20150159173), rh.13 (SEQ ID NO: 10 and 26 of US20150159173), AAV1 (SEQ ID NO: 11 and 27 of US20150159173), AAV3 (SEQ ID NO: 12 and 28 of US20150159173), AAV6 (SEQ ID NO: 13 and 29 of US20150159173), AAV7 (SEQ ID NO: 14 and 30 of US20150159173), AAV8 (SEQ ID NO: 15 and 31 of US20150159173), hu.13 (SEQ ID NO: 16 and 32 of US20150159173), hu.26 (SEQ ID NO: 17 and 33 of US20150159173), hu.37 (SEQ ID NO: 18 and 34 of US20150159173), hu.53 (SEQ ID NO: 19 and 35 of US20150159173), rh.43 (SEQ ID NO: 21 and 37 of US20150159173), rh2 (SEQ ID NO: 39 of US20150159173), rh.37 (SEQ ID NO: 40 of US20150159173), rh.64 (SEQ ID NO: 43 of US20150159173), rh.48 (SEQ ID NO: 44 of US20150159173), ch 5 (SEQ ID NO: 46 of US20150159173), rh.67 (SEQ ID NO: 47 of US20150159173), rh.58 (SEQ ID NO: 48 of US20150159173), or variants thereof including, but not limited to Cy5R1, Cy5R2, Cy5R3, Cy5R4, rh.13R, rh.37R2, rh.2R, rh.8R, rh.48.1, rh.48.2, rh.48.12, hu.44R1, hu.44R2, hu.44R3, hu.29R, ch.5R1, rh64R1, rh64R2, AAV6.2, AAV6.1, AAV6.12, hu.48R1, hu.48R2, and hu.48R3.

In some embodiments, the AAV serotype may be, or have, a sequence as described in U.S. Pat. No. 7,198,951, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV9 (SEQ ID NO: 1-3 of U.S. Pat. No. 7,198,951), AAV2 (SEQ ID NO: 4 of U.S. Pat. No. 7,198,951), AAV1 (SEQ ID NO: 5 of U.S. Pat. No. 7,198,951), AAV3 (SEQ ID NO: 6 of U.S. Pat. No. 7,198,951), and AAV8 (SEQ ID NO: 7 of U.S. Pat. No. 7,198,951).

In some embodiments, the AAV serotype may be, or have, a mutation in the AAV9 sequence as described by N Pulicherla et al. (Molecular Therapy 19(6): 1070-1078 (2011), herein incorporated by reference in its entirety), such as but not limited to, AAV9.9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84.

In some embodiments, the AAV serotype may be, or have, a sequence as described in U.S. Pat. No. 6,156,303, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV3B (SEQ ID NO: 1 and 10 of U.S. Pat. No. 6,156,303), AAV6 (SEQ ID NO: 2, 7 and 11 of U.S. Pat. No. 6,156,303), AAV2 (SEQ ID NO: 3 and 8 of U.S. Pat. No. 6,156,303), AAV3A (SEQ ID NO: 4 and 9, of U.S. Pat. No. 6,156,303), or derivatives thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Publication No US20140359799, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV8 (SEQ ID NO:1 of US20140359799), AAVDJ (SEQ ID NO: 2 and 3 of US20140359799), or variants thereof.

In some embodiments, the serotype may be AAVDJ or a variant thereof, such as AAVDJ8 (or AAV-DJ8), as described by Grimm et al. (Journal of Virology 82(12): 5887-5911 (2008), herein incorporated by reference in its entirety). The amino acid sequence of AAVDJ8 may comprise two or more mutations in order to remove the heparin binding domain (HBD). As a non-limiting example, the AAV-DJ sequence described as SEQ ID NO: 1 in U.S. Pat. No. 7,588,772, the contents of which are herein incorporated by reference in their entirety, may comprise two mutations: (1) R587Q where arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gin) and (2) R590T where arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr). As another non-limiting example, may comprise three mutations: (1) K406R where lysine (K; Lys) at amino acid 406 is changed to arginine (R; Arg), (2) R587Q where arginine (R; Arg) at amino acid 587 is changed to glutamine (Q; Gln) and (3) R590T where arginine (R; Arg) at amino acid 590 is changed to threonine (T; Thr).

In some embodiments, the AAV serotype may be, or have, a sequence of AAV4 as described in International Publication No. WO1998011244, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to AAV4 (SEQ ID NO: 1-20 of WO1998011244).

In some embodiments, the AAV serotype may be, or have, a mutation in the AAV2 sequence to generate AAV2C9 as described in International Publication No. WO2014144229 and herein incorporated by reference in its entirety.

In some embodiments, the AAV serotype may be, or have, a sequence as described in International Publication No. WO2005033321, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to AAV3-3 (SEQ ID NO:217 of WO2005033321), AAV1 (SEQ ID NO: 219 and 202 of WO2005033321), AAV106.1/hu.37 (SEQ ID No: 10 of WO2005033321), AAV114.3/hu.40 (SEQ ID No: 11 of WO2005033321), AAV127.2/hu.41 (SEQ ID NO:6 and 8 of WO2005033321), AAV128.3/hu.44 (SEQ ID No. 81 of WO2005033321), AAV130.4/hu.48 (SEQ ID NO: 78 of WO2005033321), AAV145.1/hu.53 (SEQ ID No: 176 and 177 of WO2005033321), AAV145.6/hu.56 (SEQ ID NO: 168 and 192 of WO2005033321), AAV16.12hu.11 (SEQ ID NO: 153 and 57 of WO2005033321), AAV16.8/hu.10 (SEQ ID NO: 156 and 56 of WO2005033321), AAV61.10hu.60 (SEQ ID No-170 of WO2005033321), AAV161.6/hu.61 (SEQ ID No: 174 of WO2005033321), AAV1-7/rh.48 (SEQ ID NO: 32 of WO2005033321), AAV1-8/rh.49 (SEQ ID NOs: 103 and 25 of WO2005033321), AAV2 (SEQ ID NO: 211 and 221 of WO2005033321), AAV2-15rh.62 (SEQ ID No: 33 and 114 of WO2005033321), AAV2-3/rh.61 (SEQ ID NO: 21 of WO2005033321), AAV2-4/rh.50 (SEQ ID No: 23 and 108 of WO2005033321), AAV2-5/rh.51 (SEQ ID NO: 104 and 22 of WO02005033321), AAV3.1/hu.6 (SEQ ID NO: 5 and 84 of WO20 (5033321), AAV3.4/hu.9 (SEQ ID NO: 155 and 58 of WO2005033321), AAV3-11/rh.53 (SEQ ID NO: 186 and 176 of WO2005033321), AAV3-3 (SEQ ID NO: 200 of WO2005033321), AAV33.12/hu.17 (SEQ ID NO:4 of WO2005033321), AAV33.4/hu.15 (SEQ ID No: 50 of WO2005033321), AAV33.8/hu.16 (SEQ ID No: 51 of WO2005033321), AAV3-9/rh.52 (SEQ ID NO: 96 and 18 of WO2005033321), AAV4-19/rh.55 (SEQ ID NO: 117 of WO2005033321), AAV4-4 (SEQ ID NO: 201 and 218 of WO2005033321), AAV4-9/rh.54 (SEQ ID NO: 116 of WO2005033321), AAV5 (SEQ ID NO: 199 and 216 of WO2005033321), AAV52.1/hu.20 (SEQ ID NO: 63 of WO2005033321), AAV52hu.19 (SEQ ID NO:133 of WO2005033321), AAV5-22/rh.58 (SEQ ID No: 27 of WO2005033321), AAV5-3/rh.57 (SEQ ID NO: 105 of WO2005033321), AAV5-3/rh.57 (SEQ ID No. 26 of WO2005033321), AAV58.2hu.25 (SEQ ID No: 49 of WO2005033321), AAV6 (SEQ ID NO: 203 and 220 of WO2005033321), AAV7 (SEQ ID NO: 222 and 213 of WO20050333321), AAV7.3/hu.7 (SEQ ID No: 55 of WO2005033321), AAV8 (SEQ ID NO: 223 and 214 of WO02005033321), AAVH-1/hu.1 (SEQ ID No: 46 of WO2005033321), AAVH-5/hu.3 (SEQ ID No: 44 of WO2005033321), AAVhu.11 (SEQ ID NO: 144 of WO2005033321), AAVhu.10 (SEQ ID NO: 156 of WO2005033321), AAVhu.1 (SEQ ID NO: 153 of WO20050333321), AAVhu.12 (WO2005033321 SEQ ID NO: 59), AAVhu.13 (SEQ ID NO: 129 of WO2005033321), AAVhu.14AAV9 (SEQ ID NO: 123 and 3 of WO2005033321), AAVhu.15 (SEQ ID NO: 147 of WO2005033321), AAVhu.16 (SEQ ID NO: 148 of WO02005033321), AAVhu.17 (SEQ ID NO: 83 of WO02005033321), AAVhu.18 (SEQ ID NO: 149 of WO2005033321), AAVhu.19 (SEQ ID NO: 133 of WO205033321), AAVhu.2 (SEQ ID NO:143 of WO2005033321), AAVhu.20 (SEQ ID NO:134 of WO2005033321), AAVhu.21 (SEQ ID NO: 135 of WO2005033321), AAVhu.22 (SEQ ID NO: 138 of WO2005033321), AAVhu.23.2 (SEQ ID NO: 137 of WO20050333321), AAVhu.24 (SEQ ID NO: 136 of WO2005033321), AAVhu.25 (SEQ ID NO: 146 of WO2005033321), AAVhu.27 (SEQ ID NO: 140 of WO2005033321), AAVhu.29 (SEQ ID NO: 132 of WO2005033321), AAVhu.3 (SEQ ID NO: 145 of WO20050333321), AAVhu.31 (SEQ ID NO: 121 of WO2005033321), AAVhu.32 (SEQ ID NO: 122 of WO2005033321), AAVhu.34 (SEQ ID NO. 125 of WO2005033321), AAVhu.35 (SEQ ID NO: 164 of WO2005033321), AAVhu.37 (SEQ ID NO: 88 of WO2005033321), AAVhu.39 (SEQ ID NO: 102 of WO2005033321), AAVhu.4 (SEQ ID NO: 141 of WO2005033321), AAVhu.40 (SEQ ID NO: 87 of WO2005033321), AAVhu.41 (SEQ ID NO: 91 of WO2005033321), AAVhu.42 (SEQ ID NO: 85 of WO2005033321), AAVhu.43 (SEQ ID NO:160 of WO2005033321), AAVhu.44 (SEQ ID NO-144 of WO2005033321), AAVhu.45 (SEQ ID NO: 127 of WO2005033321), AAVhu.46 (SEQ ID NO. 159 of WO2005033321), AAVhu.47 (SEQ ID NO: 128 of WO2005033321), AAVhu.48 (SEQ ID NO:157 of WO2005033321), AAVhu.49 (SEQ ID NO:189 of WO2005033321), AAVhu.51 (SEQ ID NO: 190 of WO2005033321), AAVhu.52 (SEQ ID NO: 191 of WO2005033321), AAVhu.53 (SEQ ID NO: 186 of WO2005033321), AAVhu.54 (SEQ ID NO: 188 of WO205033321), AAVhu.55 (SEQ ID NO: 187 of WO2005033321), AAVhu.56 (SEQ ID NO-192 of WO2005033321), AAVhu.57 (SEQ ID NO:193 of WO2005033321), AAVhu.58 (SEQ ID NO: 194 of WO2005033321), AAVhu.6 (SEQ ID NO: 84 of WO2005033321), AAVhu.60 (SEQ ID NO: 184 of WO2005033321), AAVhu.61 (SEQ ID NO: 185 of WO2005033321), AAVhu.63 (SEQ ID NO: 195 of WO2005033321), AAVhu.64 (SEQ ID NO: 196 of WO2005033321), AAVhu.66 (SEQ ID NO: 197 of WO2005033321), AAVhu.67 (SEQ ID NO: 198 of WO2005033321), AAVhu.7 (SEQ ID NO: 150 of WO2005033321), AAVhu.8 (WO2005033321 SEQ ID NO: 12), AAVhu.9 (SEQ ID NO: 155 of WO2005033321), AAVLG-10/rh.40 (SEQ ID No: 14 of WO2005033321), AAVLG-4/rh.38 (SEQ ID NO: 86 of WO2005033321), AAVLG-4/rh.38 (SEQ ID No: 7 of WO2005033321), AAVN721-8/rh.43 (SEQ ID NO:163 of WO2005033321), AAVN721-8/rh.43 (SEQ ID No: 43 of WO2005033321), AAVpi.1 (WO2005033321 SEQ ID NO: 28), AAVpi.2 (WO2005033321 SEQ ID NO: 30), AAVpi.3 (WO2005033321 SEQ ID NO: 29), AAVrh.38 (SEQ ID NO: 86 of WO2005033321), AAVrh.40 (SEQ ID NO: 92 of WO2005033321), AAVrh.43 (SEQ ID NO: 163 of WO2005033321), AAVrh.44 (WO2005033321 SEQ ID NO: 34), AAVrh.45 (WO2005033321 SEQ ID NO: 41), AAVrh.47 (WO2005033321 SEQ ID NO: 38), AAVrh.48 (SEQ ID NO: 115 of WO2005033321), AAVrh.49 (SEQ ID NO: 103 of WO2005033321), AAVrh.50 (SEQ ID NO: 108 of WO2005033321), AAVrh.51 (SEQ ID NO: 104 of WO2005033321), AAVrh.52 (SEQ ID NO: 96 of WO2005033321), AAVrh.53 (SEQ ID NO: 97 of WO2005033321), AAVrh.55 (WO2005033321 SEQ ID NO: 37), AAVrh.56 (SEQ ID NO: 152 of WO20050333321), AAVrh.57 (SEQ ID NO: 105 of WO2005033321), AAVrh.58 (SEQ ID NO: 106 of WO2005033321), AAVrh.59 (WO2005033321 SEQ ID NO: 42), AAVrh.60 (WO2005033321 SEQ ID NO: 31), AAVrh.61 (SEQ ID NO: 107 of WO2005033321), AAVrh.62 (SEQ ID NO: 114 of WO2005033321), AAVrh.64 (SEQ ID NO: 99 of WO2005033321), AAVrh.65 (WO2005033321 SEQ ID NO: 35), AAVrh.68 (WO2005033321 SEQ ID NO: 16), AAVrh.69 (WO2005033321 SEQ ID NO: 39), AAVrh.70 (WO2005033321 SEQ ID NO: 20), AAVrh.72 (WO2005033321 SEQ ID NO: 9), or variants thereof including, but not limited to, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVcy.6, AAVrh.12, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.25/42 15, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.14. Non-limiting examples of variants include SEQ ID NO: 13, 15, 17, 19, 24, 36, 40, 45, 47, 48, 51-54, 60-62, 64-77, 79, 80, 82, 89, 90, 93-95, 98, 100, 101, 109-113, 118-120, 124, 126, 131, 139, 142, 151, 154, 158, 161, 162, 165-183, 202, 204-212, 215, 219, 224-236, of WO2005033321, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the AAV serotype may be, or have, a sequence as described in International Publication No. WO2015168666, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAVrh8R (SEQ ID NO: 9 of WO2015168666), AAVrh8R A586R mutant (SEQ ID NO: 10 of WO2015168666), AAVrh8R R533A mutant (SEQ ID NO: 11 of WO2015168666), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in U.S. Pat. No. 9,233,131, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAVhE1.1 (SEQ ID NO:44 of U.S. Pat. No. 9,233,131), AAVhEr1.5 (SEQ ID NO:45 of U.S. Pat. No. 9,233,131), AAVhER1.14 (SEQ ID NO:46 of U.S. Pat. No. 9,233,131), AAVhEr1.8 (SEQ ID NO:47 of U.S. Pat. No. 9,233,131), AAVhEr1.16 (SEQ ID NO:48 of U.S. Pat. No. 9,233,131), AAVhEr1.18 (SEQ ID NO:49 of U.S. Pat. No. 9,233,131), AAVhEr1.35 (SEQ ID NO:50 of U.S. Pat. No. 9,233,131), AAVhEr1.7 (SEQ ID NO:51 of U.S. Pat. No. 9,233,131), AAVhEr1.36 (SEQ ID NO:52 of U.S. Pat. No. 9,233,131), AAVhEr2.29 (SEQ ID NO:53 of U.S. Pat. No. 9,233,131), AAVhEr2.4 (SEQ ID NO:54 of U.S. Pat. No. 9,233,131), AAVhEr2.16 (SEQ ID NO:55 of U.S. Pat. No. 9,233,131), AAVhEr2.30 (SEQ ID NO:56 of U.S. Pat. No. 9,233,131), AAVhEr2.31 (SEQ ID NO:58 of U.S. Pat. No. 9,233,131), AAVhEr2.36 (SEQ ID NO:57 of U.S. Pat. No. 9,233,131), AAVhER1.23 (SEQ ID NO:53 of U.S. Pat. No. 9,233,131), AAVhEr3.1 (SEQ ID NO:59 of U.S. Pat. No. 9,233,131), AAV2.5T (SEQ ID NO:42 of U.S. Pat. No. 9,233,131), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Patent Publication No. US20150376607, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV-PAEC (SEQ ID NO: 1 of US20150376607), AAV-LK01 (SEQ ID NO:2 of US20150376607), AAV-LK02 (SEQ ID NO:3 of US20150376607), AAV-LK03 (SEQ ID NO:4 of US20150376607), AAV-LK04 (SEQ ID NO:5 of US20150376607), AAV-LK05 (SEQ ID NO:6 of US20150376607), AAV-LK06 (SEQ ID NO:7 of US20150376607), AAV-LK07 (SEQ ID NO:8 of US20150376607), AAV-LK08 (SEQ ID NO:9 of US20150376607), AAV-LK09 (SEQ ID NO:10 of US20150376607), AAV-LK10 (SEQ ID NO: 11 of US20150376607), AAV-LK11 (SEQ ID NO: 12 of US20150376607), AAV-LK12 (SEQ ID NO: 13 of US20150376607), AAV-LK13 (SEQ ID NO:14 of US20150376607), AAV-LK14 (SEQ ID NO:15 of US20150376607), AAV-LK15 (SEQ ID NO:16 of US20150376607), AAV-LK16 (SEQ ID NO:17 of US20150376607), AAV-LK17 (SEQ ID NO:18 of US20150376607), AAV-LK8 (SEQ ID NO:19 of US20150376607), AAV-LK19 (SEQ ID NO:20 of US20150376607), AAV-PAEC2 (SEQ ID NO:21 of US20150376607), AAV-PAEC4 (SEQ ID NO:22 of US20150376607), AAV-PAEC6 (SEQ ID NO:23 of US20150376607), AAV-PAEC7 (SEQ ID NO:24 of US20150376607), AAV-PAEC8 (SEQ ID NO:25 of US20150376607), AAV-PAEC11 (SEQ ID NO:26 of US20150376607), AAV-PAEC12 (SEQ ID NO:27, of US20150376607), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in U.S. Pat. No. 9,163,261, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV-2-pre-miRNA-101 (SEQ ID NO: 1 U.S. Pat. No. 9,163,261), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Patent Publication No. US20150376240, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV-8h (SEQ ID NO: 6 of US20150376240), AAV-8b (SEQ ID NO: 5 of US20150376240), AAV-h (SEQ ID NO: 2 of US20150376240), AAV-b (SEQ ID NO: 1 of US20150376240), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Patent Publication No. US20160017295, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV SM 10-2 (SEQ ID NO: 22 of US20160017295), AAV Shuffle 100-1 (SEQ ID NO: 23 of US2016017295), AAV Shuffle 100-3 (SEQ ID NO: 24 of US20160017295), AAV Shuffle 100-7 (SEQ ID NO: 25 of US20160017295), AAV Shuffle 10-2 (SEQ ID NO: 34 of US20160017295), AAV Shuffle 10-6 (SEQ ID NO: 35 of US20160017295), AAV Shuffle 10-8 (SEQ ID NO: 36 of US20160017295), AAV Shuffle 100-2 (SEQ ID NO: 37 of US20160017295), AAV SM 10-1 (SEQ ID NO: 38 of US20160017295), AAV SM 10-8 (SEQ ID NO: 39 of US20160017295), AAV SM 100-3 (SEQ ID NO: 40 of US20160017295), AAV SM 100-10) (SEQ ID NO: 41 of US20160017295), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in United States Patent Publication No. US20150238550, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, BNP61 AAV (SEQ ID NO: 1 of US20150238550), BNP62 AAV (SEQ ID NO: 3 of US20150238550), BNP63 AAV (SEQ ID NO: 4 of US20150238550), or variants thereof.

In some embodiments, the AAV serotype may be or may have a sequence as described in United States Patent Publication No. US20150315612, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAVrh.50 (SEQ ID NO: 108 of US20150315612), AAVrh.43 (SEQ ID NO: 163 of US20150315612), AAVrh.62 (SEQ ID NO. 114 of US20150315612), AAVrh.48 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO:133 of US20150315612), AAVhu.11 (SEQ ID NO: 153 of US20150315612), AAVhu.53 (SEQ ID NO: 186 of US20150315612), AAV4-8/rh.64 (SEQ ID No: 15 of US20150315612), AAVLG-9/hu.39 (SEQ ID No: 24 of US20150315612), AAV54.5/hu.23 (SEQ ID No: 60 of US20150315612), AAV54.2/hu.22 (SEQ ID No. 67 of US20150315612), AAV54.7/hu.24 (SEQ ID No: 66 of US20150315612), AAV54.1/hu.21 (SEQ ID No: 65 of US20150315612), AAV54.4R/hu.27 (SEQ ID No: 64 of US20150315612), AAV46.2/hu.28 (SEQ ID No: 68 of US20150315612), AAV46.6hu.29 (SEQ ID No: 69 of US20150315612), AAV128.1/hu.43 (SEQ ID No: 80 of US20150315612), or variants thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in International Publication No. WO2015121501, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, true type AAV (ttAAV) (SEQ ID NO: 2 of WO2015121501. “UPenn AAV10” (SEQ ID NO: 8 of WO2015121501), “Japanese AAV10” (SEQ ID NO: 9 of WO2015121501), or variants thereof.

According to the present invention, AAV capsid serotype selection or use may be from a variety of species. In one embodiment, the AAV may be an avian AAV (AAAV). The AAAV serotype may be, or have, a sequence as described in U.S. Pat. No. 9,238,800, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAAV (SEQ ID NO: 1, 2, 4, 6, 8, 10, 12, and 14 of U.S. Pat. No. 9,238,800), or variants thereof.

In one embodiment, the AAV may be a bovine AAV (BAAV). The BAAV serotype may be, or have, a sequence as described in U.S. Pat. No. 9,193,769, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, BAAV (SEQ ID NO: 1 and 6 of U.S. Pat. No. 9,193,769), or variants thereof. The BAAV serotype may be or have a sequence as described in U.S. Pat. No. 7,427,396, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, BAAV (SEQ ID NO: 5 and 6 of U.S. Pat. No. 7,427,396), or variants thereof.

In one embodiment, the AAV may be a caprine AAV. The caprine AAV serotype may be, or have, a sequence as described in U.S. Pat. No. 7,427,396, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, caprine AAV (SEQ ID NO: 3 of U.S. Pat. No. 7,427,396), or variants thereof.

In other embodiments, the AAV may be engineered as a hybrid AAV from two or more parental serotypes. In one embodiment, the AAV may be AAV2G9 which comprises sequences from AAV2 and AAV9. The AAV2G9 AAV serotype may be, or have, a sequence as described in United States Patent Publication No. US2016017005, the contents of which are herein incorporated by reference in its entirety.

In one embodiment, the AAV may be a serotype generated by the AAV9 capsid library with mutations in amino acids 390-627 (VP1 numbering) as described by Pulicherla et al. (Molecular Therapy 19(6):1070-1078 (2011), the contents of which are herein incorporated by reference in their entirety. The serotype and corresponding nucleotide and amino acid substitutions may be, but is not limited to, AAV9.1 (G1594C; D5321HI), AAV6.2 (T1418A and T1436X; V473D and 1479K), AAV9.3 (T1238A; F413Y), AAV9.4 (T1250C and A1617T; F417S), AAV9.5 (A1235G, A1314T, A1642G, C1760T; Q412R, T548A, A587V), AAV9.6 (T1231A; F411I), AAV9.9 (G1203A, G1785T; W595C), AAV9.10 (A1500G, T1676C; M559T), AAV9.11 (A1425T, A1702C, A1769T; T568P, Q590L), AAV9.13 (A1369C, A1720T; N457H, T574S), AAV9.14 (T1340A, T1362C, T1560C, G1713A; L447H), AAV9.16 (A1775T; Q592L), AAV9.24 (T1507C, T1521G; W503R), AAV9.26 (A1337G, A1769C; Y446C, Q590P), AAV9.33 (A1667C; D556A), AAV9.34 (A1534G, C1794T; N512D), AAV9.35 (A1289T, T1450, C1494T, A1515T, C1794A, G1816A; Q430L, Y484N, N98K, V6061), AAV9.40 (A1694T, E565V), AAV9.41 (A1348T, T1362C; T450S), AAV9.44 (A1684C, A1701T, A1737G; N562H, K567N), AAV9.45 (A1492T, C804T; N498Y, L602F), AAV9.46 (G1441C, T1525C, T1549G; G481R, W509R, L517V), 9.47 (G1241A, G1358A, A1669G, C1745T; S414N, G453D, K557E, T582I), AAV9.48 (C1445T, A1736T; P482L, Q579L), AAV9.50 (A1638T, C1683T, T1805A; Q546H, L602H), AAV9.53 (G1301A, A1405C, C1664T, G1811T; R134Q, S469R, A555V, G604V), AAV9.54 (C1531A, T1609A; L511I, L537M), AAV9.55 (T1605A; F535L), AAV9.58 (C1475T, C1579A; T492I, H527N), AAV.59 (T1336C; Y446H), AAV9.61 (A1493T; N4981), AAV9.64 (C1531A, A1617T; L511I), AAV9.65 (C1335T, T1530C, C1568A; A523D), AAV9.68 (C1510A; P504T), AAV9.80 (G1441A, G481R), AAV9.83 (C1402A, A1500T; P468T, E500D), AAV9.87 (T1464C, T1468C; S49(P), AAV9.90 (A1196T; Y399F), AAV9.91 (T1316G, A1583T, C1782G, T1806C; L439R, K5281), AAV9.93 (A1273G, A1421G, A1638C, C1712T, G1732A, A1744T, A1832T; S425G, Q474R, Q546H, P571L, G578R, T582S, D611V), AAV9.94 (A1675T; M559L) and AAV9.95 (T1605A; F535L).

In some embodiments, the AAV serotype may be, or have, a sequence as described in International Publication No. WO2016049230, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to AAVF1/HSC1 (SEQ ID NO: 2 and 20 of WO2016049230), AAVF2/HSC2 (SEQ ID NO: 3 and 21 of WO2016049230), AAVF3/HSC3 (SEQ ID NO: 5 and 22 of WO20160(49230), AAVF4/HSC4 (SEQ ID NO: 6 and 23 of WO2016049230), AAVF5/HSC5 (SEQ ID NO: 11 and 25 of WO2016049230), AAVF6/HSC6 (SEQ ID NO: 7 and 24 of WO2016049230), AAVF7/HSC7 (SEQ ID NO: 8 and 27 of WO2016049230), AAVF8/HSC8 (SEQ ID NO: 9 and 28 of WO20160(49230), AAVF9/HSC9 (SEQ ID NO: 10 and 29 of WO2016049230), AAVF11/HSC11 (SEQ ID NO: 4 and 26 of WO2016049230), AAVF12/HSC12 (SEQ ID NO: 12 and 30) of WO2016049230), AAVF13/HSC13 (SEQ ID NO: 14 and 31 of WO2016049230), AAVF14/HSC14 (SEQ ID NO: 15 and 32 of WO2016049230), AAVF15/HSC15 (SEQ ID NO: 16 and 33 of WO2016049230), AAVF16/HSC16 (SEQ ID NO: 17 and 34 of WO2016049230), AAVF177/HSC17 (SEQ ID NO. 13 and 35 of WO2016049230), or variants or derivatives thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in U.S. Pat. No. 8,734,809, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV CBr-E1 (SEQ ID NO: 13 and 87 of U.S. Pat. No. 8,734,809), AAV CBr-E2 (SEQ ID NO: 14 and 88 of U.S. Pat. No. 8,734,809), AAV CBr-E3 (SEQ ID NO: 15 and 89 of U.S. Pat. No. 8,734,809), AAV CBr-E4 (SEQ ID NO: 16 and 90 of U.S. Pat. No. 8,734,809), AAV CBr-E5 (SEQ ID NO: 17 and 91 of U.S. Pat. No. 8,734,809), AAV CBr-e5 (SEQ ID NO: 18 and 92 of U.S. Pat. No. 8,734,809), AAV CBr-E6 (SEQ ID NO:19 and 93 of U.S. Pat. No. 8,734,809), AAV CBr-E7 (SEQ ID NO: 20 and 94 of U.S. Pat. No. 8,734,809), AAV CBr-E8 (SEQ ID NO: 21 and 95 of U.S. Pat. No. 8,734,809), AAV CLv-D1 (SEQ ID NO: 22 and 96 of U.S. Pat. No. 8,734,809), AAV CLv-D2 (SEQ ID NO: 23 and 97 of U.S. Pat. No. 8,734,809), AAV CLv-D3 (SEQ ID NO: 24 and 98 of U.S. Pat. No. 8,734,809), AAV CLv-D4 (SEQ ID NO: 25 and 99 of U.S. Pat. No. 8,734,809), AAV CLv-D5 (SEQ ID NO: 26 and 100 of U.S. Pat. No. 8,734,809), AAV CLv-D6 (SEQ ID NO: 27 and 101 of U.S. Pat. No. 8,734,809), AAV CLv-D7 (SEQ ID NO: 28 and 102 of U.S. Pat. No. 8,734,809), AAV CLv-D8 (SEQ ID NO: 29 and 103 of U.S. Pat. No. 8,734,809, AAV CLv-E1 (SEQ ID NO: 13 and 87 of U.S. Pat. No. 8,734,809), AAV CLv-R1 (SEQ ID NO: 30 and 104 of U.S. Pat. No. 8,734,809), AAV CLv-R2 (SEQ ID NO: 31 and 105 of U.S. Pat. No. 8,734,809), AAV CLv-R3 (SEQ ID NO: 32 and 106 of U.S. Pat. No. 8,734,809), AAV CLv-R4 (SEQ ID NO: 33 and 107 of U.S. Pat. No. 8,734,809), AAV CLv-R5 (SEQ ID NO: 34 and 108 of U.S. Pat. No. 8,734,809), AAV CLv-R6 (SEQ ID NO: 35 and 109 of U.S. Pat. No. 8,734,809), AAV CLv-R7 (SEQ ID NO: 36 and 110 of U.S. Pat. No. 8,734,809), AAV CLv-R8 (SEQ ID NO: 37 and 111 of U.S. Pat. No. 8,734,809), AAV CL-R9 (SEQ ID NO: 38 and 112 of U.S. Pat. No. 8,734,809), AAV CLg-F1 (SEQ ID NO: 39 and 113 of U.S. Pat. No. 8,734,809), AAV CLg-F2 (SEQ ID NO: 40 and 114 of U.S. Pat. No. 8,734,809), AAV CLg-F3 (SEQ ID NO: 41 and 115 of U.S. Pat. No. 8,734,809), AAV CLg-F4 (SEQ ID NO: 42 and 116 of U.S. Pat. No. 8,734,809), AAV CLg-F5 (SEQ ID NO: 43 and 117 of U.S. Pat. No. 8,734,809), AAV CLg-F6 (SEQ ID NO: 43 and 117 of U.S. Pat. No. 8,734,809), AAV CLg-F7 (SEQ ID NO: 44 and 118 of U.S. Pat. No. 8,734,809), AAV CLg-F8 (SEQ ID NO: 43 and 117 of U.S. Pat. No. 8,734,809), AAV CSp-1 (SEQ ID NO: 45 and 119 of U.S. Pat. No. 8,734,809), AAV CSp-10 (SEQ ID NO: 46 and 120 of U.S. Pat. No. 8,734,809), AAV CSp-11 (SEQ ID NO: 47 and 121 of U.S. Pat. No. 8,734,809), AAV CSp-2 (SEQ ID NO: 48 and 122 of U.S. Pat. No. 8,734,809), AAV CSp-3 (SEQ ID NO: 49 and 123 of U.S. Pat. No. 8,734,809), AAV CSp-4 (SEQ ID NO: 50 and 124 of U.S. Pat. No. 8,734,809), AAV CSp-6 (SEQ ID NO: 51 and 125 of U.S. Pat. No. 734,809), AAV CSp-7 (SEQ ID NO-52 and 126 of U.S. Pat. No. 8,734,809), AAV CSp-8 (SEQ ID NO: 53 and 127 of U.S. Pat. No. 8,734,809), AAV CSp-9 (SEQ ID NO: 54 and 128 of U.S. Pat. No. 8,734,809), AAV CHt-2 (SEQ ID NO: 55 and 129 of U.S. Pat. No. 8,734,809), AAV CHt-3 (SEQ ID NO: 56 and 130 of U.S. Pat. No. 8,734,809), AAV CKd-1 (SEQ ID NO: 57 and 131 of U.S. Pat. No. 8,734,809), AAV CKd-10 (SEQ ID NO: 58 and 132 of U.S. Pat. No. 8,734,809), AAV CKd-2 (SEQ ID NO: 59 and 133 of U.S. Pat. No. 8,734,809), AAV CKd-3 (SEQ ID NO: 60 and 134 of U.S. Pat. No. 8,734,809), AAV CKd-4 (SEQ ID NO: 61 and 135 of U.S. Pat. No. 8,734,809), AAV CKd-6 (SEQ ID NO: 62 and 136 of U.S. Pat. No. 8,734,809), AAV CKd-7 (SEQ ID NO: 63 and 137 of U.S. Pat. No. 8,734,809), AAV CKd-8 (SEQ ID NO: 64 and 138 of U.S. Pat. No. 8,734,809), AAV CLv-1 (SEQ ID NO: 35 and 139 of U.S. Pat. No. 8,734,809), AAV CLv-12 (SEQ ID NO: 66 and 140 of U.S. Pat. No. 8,734,809), AAV CLv-13 (SEQ ID NO: 67 and 141 of U.S. Pat. No. 8,734,809), AAV CLv-2 (SEQ ID NO: 68 and 142 of U.S. Pat. No. 8,734,809), AAV CLv-3 (SEQ ID NO: 69 and 143 of U.S. Pat. No. 8,734,809), AAV CLv-4 (SEQ ID NO: 70 and 144 of U.S. Pat. No. 8,734,809), AAV CLv-6 (SEQ ID NO: 71 and 145 of U.S. Pat. No. 8,734,809), AAV CLv-8 (SEQ ID NO: 72 and 146 of U.S. Pat. No. 8,734,809), AAV CKd-B1 (SEQ ID NO: 73 and 147 of U.S. Pat. No. 8,734,809), AAV CKd-B2 (SEQ ID NO: 74 and 148 of U.S. Pat. No. 8,734,809), AAV CKd-B3 (SEQ ID NO: 75 and 149 of U.S. Pat. No. 8,734,809), AAV CKd-B4 (SEQ ID NO: 76 and 150) of U.S. Pat. No. 8,734,809), AAV CKd-B5 (SEQ ID NO: 77 and 151 of U.S. Pat. No. 8,734,809), AAV CKd-B6 (SEQ ID NO: 78 and 152 of U.S. Pat. No. 8,734,809), AAV CKd-B7 (SEQ ID NO: 79 and 153 of U.S. Pat. No. 8,734,809), AAV CKd-B8 (SEQ ID NO: 80 and 154 of U.S. Pat. No. 8,734,809), AAV CKd-H1 (SEQ ID NO: 81 and 155 of U.S. Pat. No. 8,734,809), AAV CKd-H2 (SEQ ID NO: 82 and 156 of U.S. Pat. No. 8,734,809), AAV CKd-H3 (SEQ ID NO: 83 and 157 of U.S. Pat. No. 8,734,809), AAV CKd-H4 (SEQ ID NO: 84 and 158 of U.S. Pat. No. 8,734,809), AAV CKd-H5 (SEQ ID NO: 85 and 159 of U.S. Pat. No. 8,734,809), AAV CKd-H6 (SEQ ID NO: 77 and 151 of U.S. Pat. No. 8,734,809), AAV CHt-1 (SEQ ID NO: 86 and 160 of 8734809), AAV CLv1-1 (SEQ ID NO: 171 of U.S. Pat. No. 8,734,809), AAV CLv1-2 (SEQ ID NO: 172 of U.S. Pat. No. 8,734,809), AAV CLv1-3 (SEQ ID NO: 173 of U.S. Pat. No. 734,809), AAV CLv1-4 (SEQ ID NO: 174 of U.S. Pat. No. 8,734,809), AAV Clv1-7 (SEQ ID NO: 175 of U.S. Pat. No. 8,734,809), AAV Clv1-8 (SEQ ID NO: 176 of U.S. Pat. No. 8,734,809), AAV Clv1-9 (SEQ ID NO: 177 of U.S. Pat. No. 8,734,809), AAV Clv-10 (SEQ ID NO: 178 of U.S. Pat. No. 8,734,809), AAV.VR-355 (SEQ ID NO: 181 of U.S. Pat. No. 8,734,809), AAV.hu.48R3 (SEQ ID NO: 183 of U.S. Pat. No. 8,734,809), or variants or derivatives thereof.

In some embodiments, the AAV serotype may be, or have, a sequence as described in International Publication No. WO02016065001, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to AAV CHt-P2 (SEQ ID NO: 1 and 51 of WO2016065001), AAV CHt-P5 (SEQ ID NO: 2 and 52 of WO2016065001), AAV CHt-P9 (SEQ ID NO: 3 and 53 of WO2016065001), AAV CBr-7.1 (SEQ ID NO: 4 and 54 of WO2016065001), AAV CBr-7.2 (SEQ ID NO: 5 and 55 of WO2016065001), AAV CBr-7.3 (SEQ ID NO: 6 and 56 of WO2016065001), AAV CBr-7.4 (SEQ ID NO: 7 and 57 of WO2016065001), AAV CBr-7.5 (SEQ ID NO: 8 and 58 of WO2016065001), AAV CBr-7.7 (SEQ ID NO: 9 and 59 of WO2016065001), AAV CBr-7.8 (SEQ ID NO: 10 and 60 of WO2016065001), AAV CBr-7.10 (SEQ ID NO: 11 and 61 of WO2016065001), AAV CKd-N3 (SEQ ID NO: 12 and 62 of WO2016065001), AAV CKd-N4 (SEQ ID NO: 13 and 63 of WO2016065001), AAV CKd-N9 (SEQ ID NO: 14 and 64 of WO2016065001), AAV CLv-L4 (SEQ ID NO: 15 and 65 of WO2016065001), AAV CLv-L5 (SEQ ID NO: 16 and 66 of WO2016065001), AAV CLv-L6 (SEQ ID NO: 17 and 67 of WO2016065001), AAV CLv-K1 (SEQ ID NO: 18 and 68 of WO2016065001), AAV CLv-K3 (SEQ ID NO: 19 and 69 of WO2016065001), AAV CLv-K6 (SEQ ID NO: 20 and 70 of WO2016065001), AAV CLv-M (SEQ ID NO: 21 and 71 of WO2016065001), AAV CLv-M11 (SEQ ID NO: 22 and 72 of WO2016065001), AAV CLv-M2 (SEQ ID NO: 23 and 73 of WO2016065001), AAV CLv-M5 (SEQ ID NO: 24 and 74 of WO2016065001), AAV CLv-M6 (SEQ ID NO: 25 and 75 of WO2016065001), AAV CLv-M7 (SEQ ID NO: 26 and 76 of WO2016065001), AAV CLv-M8 (SEQ ID NO: 27 and 77 of WO2016065001), AAV CLv-M9 (SEQ ID NO: 28 and 78 of WO2016065001), AAV CHt-P1 (SEQ ID NO: 29 and 79 of WO2016065001), AAV CHt-P6 (SEQ ID NO: 30 and 80 of WO2016065001), AAV CHt-P8 (SEQ ID NO: 31 and 81 of WO2016065001), AAV CHt-6.1 (SEQ ID NO: 32 and 82 of WO2016065001), AAV CHt-6.10 (SEQ ID NO: 33 and 83 of WO2016065001), AAV CHt-6.5 (SEQ ID NO: 34 and 84 of WO2016065001), AAV CHt-6.6 (SEQ ID NO: 35 and 85 of WO2016065001), AAV CHt-6.7 (SEQ ID NO: 36 and 86 of WO2016065001), AAV CHt-6.8 (SEQ ID NO: 37 and 87 of WO2016065001), AAV CSp-8.10 (SEQ ID NO: 38 and 88 of WO2016065001), AAV CSp-8.2 (SEQ ID NO: 39 and 89 of WO2016065001), AAV CSp-8.4 (SEQ ID NO: 40 and 90 of WO2016065001), AAV CSp-8.5 (SEQ ID NO: 41 and 91 of WO2016065001), AAV CSp-8.6 (SEQ ID NO: 42 and 92 of WO2016065001), AAV CSp-8.7 (SEQ ID NO: 43 and 93 of WO2016065001), AAV CSp-8.8 (SEQ ID NO: 44 and 94 of WO2016065001), AAV CSp-8.9 (SEQ ID NO: 45 and 95 of WO2016065001), AAV CBr-B7.3 (SEQ ID NO: 46 and 96 of WO2016065001), AAV CBr-B7.4 (SEQ ID NO: 47 and 97 of WO2016065001), AAV3B (SEQ ID NO: 48 and 98 of WO2016065001), AAV4 (SEQ ID NO: 49 and 99 of WO2016065001), AAV5 (SEQ ID NO: 50 and 100 of WO2016065001), or variants or derivatives thereof.

In one embodiment, the AAV may be a serotype selected from any of those found in Table 1.

In one embodiment, the AAV may comprise a sequence, fragment or variant thereof, of the sequences in Table 1.

In one embodiment, the AAV may be encoded by a sequence, fragment or variant as described in Table 1.

TABLE 1 AAV Serotypes Serotype SEQ ID NO Reference Information AAV1 1 US20150159173 SEQ ID NO: 11, US2015 315612 SEQ ID NO: 202 AAV1 2 US20160017295 SEQ ID NO: 1US20030138772 SEQ ID NO: 64, US20150159173 SEQ ID NO: 27, US20150315612 SEQ ID NO: 219, US7198951 SEQ ID NO: 5 AAV1 3 US20030138772 SEQ ID NO: 6 AAV1.3 4 US20030138772 SEQ ID NO: 14 AAV10 5 US20030 38772 SEQ ID NO: 117 AAV10 6 WO20151501 SEQ ID NO: 9 AAV10 7 WO2015121501 SEQ ID NO: 8 AAV11 8 US20030138772 SEQ ID NO: 118 AAV12 9 US20030138772 SEQ ID NO: 119 AAV2 10 US20150159173 SEQ ID NO: 7, US20150315612 SEQ ID NO: 211 AAV2 11 US20030138772 SEQ ID NO: 70, US20150159173 SEQ ID NO: 23, US20150315612 SEQ ID NO: 221, US20160017295 SEQ ID NO: 2, US6156303 SEQ ID NO: 4, US7198951 SEQ ID NO: 4, WO2015121501 SEQ ID NO: 1 AAV2 12 US6156303 SEQ ID NO: 8 AAV2 13 US20030138772 SEQ ID NO: 7 AAV2 14 US6156303 SEQ ID NO: 3 AAV2.5T 15 US9233131 SEQ ID NO: 42 AAV223.10 16 US20030138772 SEQ ID NO: 75 AAV223.2 17 US20030138772 SEQ ID NO: 49 AAV223.2 18 US20030138772 SEQ ID NO: 76 AAV223.4 19 US20030138772 SEQ ID NO: 50 AAV223.4 20 US20030138772 SEQ ID NO: 73 AAV223.5 21 US20030138772 SEQ ID NO: 51 AAV223.5 22 US20030138772 SEQ ID NO: 74 AAV223.6 23 US20030138772 SEQ ID NO: 52 AAV223.6 24 US20030138772 SEQ ID NO: 78 AAV223.7 25 US20030138772 SEQ ID NO: 53 AAV223.7 26 US20030138772 SEQ ID NO: 77 AAV29.3 27 US20030138772 SEQ ID NO: 82 AAV29.4 28 US20030138772 SEQ ID NO: 12 AAV29.5 29 US20030138772 SEQ ID NO: 83 AAV29.5 30 US20030138772 SEQ ID NO: 13 (AAVbb.2) AAV3 31 US20150159173 SEQ ID NO: 12 AAV3 32 US20030138772 SEQ ID NO: 71, US2015019173 SEQ ID NO: 28, US20160017295 SEQ ID NO: 3, US7198951 SEQ ID NO: 6 AAV3 33 US20030138772 SEQ ID NO: 8 AAV3.3b 34 US20030138772 SEQ ID NO: 72 AAV3-3 35 US20150315612 SEQ ID NO: 200 AAV3-3 36 US20150315612 SEQ ID NO: 217 AAV3a 37 US6156303 SEQ ID NO: 5 AAV3a 38 US6156303 SEQ ID NO: 9 AAV3b 39 US6156303 SEQ ID NO: 6 AAV3b 40 US6156303 SEQ ID NO: 10 AAV3b 41 US6156303 SEQ ID NO: 1 AAV4 42 US20140348794 SEQ ID NO: 17 AAV4 43 US20140348794 SEQ ID NO: 5 AAV4 44 US20140348794 SEQ ID NO: 3 AAV4 45 US20140348794 SEQ ID NO: 14 AAV4 46 US20140348794 SEQ ID NO: 15 AAV4 47 US20140348794 SEQ ID NO: 19 AAV4 48 US20140348794 SEQ ID NO: 12 AAV4 49 US20140348794 SEQ ID NO: 13 AAV4 50 US20140348794 SEQ ID NO: 7 AAV4 51 US20140348794 SEQ ID NO: 8 AAV4 52 US20140348794 SEQ ID NO: 9 AAV4 53 US20140348794 SEQ ID NO: 2 AAV4 54 US20140348794 SEQ ID NO: 10 AAV4 55 US20140348794 SEQ ID NO: 11 AAV4 56 US20140348794 SEQ ID NO: 18 AAV4 57 US20030138772 SEQ ID NO: 63, US20160017295 SEQ ID NO: 4, US20140348794 SEQ ID NO: 4 AAV4 58 US20140348794 SEQ ID NO: 16 AAV4 59 US20140348794 SEQ ID NO: 20 AAV4 60 US20140348794 SEQ ID NO: 6 AAV4 61 US20140348794 SEQ ID NO: 1 AAV42.2 62 US20030138772 SEQ ID NO: 9 AAV42.2 63 US20030138772 SEQ ID NO: 102 AAV42.3b 64 US20030138772 SEQ ID NO: 36 AAV42.3B 65 US20030138772 SEQ ID NO: 107 AAV42.4 66 US20030138772 SEQ ID NO: 33 AAV42.4 67 US20030138772 SEQ ID NO: 88 AAV42.8 68 US20030138772 SEQ ID NO: 27 AAV42.8 69 US20030138772 SEQ ID NO: 85 AAV43.1 70 US20030138772 SEQ ID NO: 39 AAV43.1 71 US20030138772 SEQ ID NO: 92 AAV43.12 72 US20030138772 SEQ ID NO: 41 AAV43.12 73 US20030138772 SEQ ID NO: 93 AAV43.20 74 US20030138772 SEQ ID NO: 42 AAV43.20 75 US20030138772 SEQ ID NO: 99 AAV43.21 76 US20030138772 SEQ ID NO: 43 AAV43.21 77 US20030138772 SEQ ID NO: 96 AAV43.23 78 US20030138772 SEQ ID NO: 44 AAV43.23 79 US20030138772 SEQ ID NO: 98 AAV43.25 80 US20030138772 SEQ ID NO: 45 AAV43.25 81 US20030138772 SEQ ID NO: 97 AAV43.5 82 US20030138772 SEQ ID NO: 40 AAV43.5 83 US20030138772 SEQ ID NO: 94 AAV4-4 84 US20150315612 SEQ ID NO: 201 AAV4-4 85 US20150315612 SEQ ID NO: 218 AAV44.1 86 US20030138772 SEQ ID NO: 46 AAV44.1 87 US20030138772 SEQ ID NO: 79 AAV44.5 88 US20030138772 SEQ ID NO: 47 AAV44.5 89 US20030138772 SEQ ID NO: 80 AAV4407 90 US20150315612 SEQ ID NO: 90 AAV5 91 US7427396 SEQ ID NO: 1 AAV5 92 US20030138772 SEQ ID NO: 114 AAV5 93 US20160017295 SEQ ID NO: 5, US7427396 SEQ ID NO: 2, US2015035612 SEQ ID NO: 216 AAV5 94 US20150315612 SEQ ID NO: 199 AAV6 95 US20150159173 SEQ ID NO: 13 AAV6 96 US20030138772 SEQ ID NO: 65, US20150159173 SEQ ID NO: 29, US20160017295 SEQ ID NO: 6, US6156303 SEQ ID NO: 7 AAV6 97 US6156303 SEQ ID NO: 11 AAV6 98 US6156303 SEQ ID NO: 2 AAV6 99 US20150315612 SEQ ID NO: 203 AAV6 100 US20150315612 SEQ ID NO: 220 AAV6.1 101 US20150159173 AAV6.12 102 US20150159173 AAV6.2 103 US20150159173 AAV7 104 US20150159173 SEQ ID NO: 14 AAV7 105 US20150315612 SEQ ID NO: 183 AAV7 106 US20030138772 SEQ ID NO: 2, US20150159173 SEQ ID NO: 30, US20150315612 SEQ ID NO: 181, US20160017295 SEQ ID NO:7 AAV7 107 US20030138772 SEQ ID NO: 3 AAV7 108 US20030138772 SEQ ID NO: 1, US20150315612 SEQ ID NO: 180 AAV7 109 US20150315612 SEQ ID NO: 213 AAV7 110 US20150315612 SEQ ID NO: 222 AAV8 111 US20150159173 SEQ ID NO: 15 AAV8 112 US20150376240 SEQ ID NO: 7 AAV8 113 US20030138772 SEQ ID NO: 4, US20150315612 SEQ ID NO: 182 AAV8 114 US20030138772 SEQ ID NO: 95, US20140359799 SEQ ID NO: 1, US20150159173 SEQ ID NO: 31, US20160017295 SEQ ID NO: 8, US7198951 SEQ ID NO: 7, US20150315612 SEQ ID NO: 223 AAV8 115 US20150376240 SEQ ID NO: 8 AAV8 116 US20150315612 SEQ ID NO: 214 AAV-8b 117 US20150376240 SEQ ID NO: 5 AAV-8b 118 US20150376240 SEQ ID NO: 3 AAV-8h 119 US20150376240 SEQ ID NO: 6 AAV-8h 120 US20150376240 SEQ ID NO: 4 AAV9 121 US20030138772 SEQ ID NO: 5 AAV9 122 US7198951 SEQ ID NO: 1 AAV9 123 US20160017295 SEQ ID NO: 9 AAV9 124 US20030138772 SEQ ID NO: 100, US7198951 SEQ ID NO: 2 AAV9 125 US7198951 SEQ ID NO: 3 AAV9 126 US7906111 SEQ ID NO: 3; WO2015038958 SEQ ID NO: 11 (AAVhu.14) AAV9 127 US7906111 SEQ ID NO: 123; WO2015038958 SEQ ID NO: 2 (AAVhu.14) AAVA3.1 128 US20030138772 SEQ ID NO: 120 AAVA3.3 129 US20030138772 SEQ ID NO: 57 AAVA3.3 130 US20030138772 SEQ ID NO: 66 AAVA3.4 131 US20030138772 SEQ ID NO: 54 AAVA3.4 132 US20030138772 SEQ ID NO: 68 AAVA3.5 133 US20030138772 SEQ ID NO: 55 AAVA3.5 134 US20030138772 SEQ. ID NO: 69 AAVA3.7 135 US20030138772 SEQ ID NO: 56 AAVA3.7 136 US20030138772 SEQ ID NO: 67 AAV29.3 137 US20030138772 SEQ ID NO: 11 (AA.Vbb.1) AAVC2 138 US20030138772 SEQ ID NO: 61 AAVCh.5 139 US20150159173 SEQ ID NO: 46, US20150315612 SEQ ID NO: 234 AAVcy.2 140 US20030138772 SEQ ID NO: 15 (AAV13.3) AAV24.1 141 US20030138772 SEQ ID NO: 101 AAVcy.3 142 US20030138772 SEQ ID NO: 16 (AAV24.1) AAV27.3 143 US20030138772 SEQ ID NO: 104 AAVcy.4 144 US20030138772 SEQ ID NO: 17 (AAV27.3) AAVcy.5 145 US20150115612 SEQ ID NO: 227 AAV7.2 146 US20030138772 SEQ ID NO: 103 AAVcy.5 147 US20030138772 SEQ ID NO: 18 (AAV7.2) AAV16.3 148 US20030138772 SEQ ID NO: 105 AAVcy.6 149 US20030138772 SEQ ID NO: 10 (AAV16.3) AAVcy.5 150 US20150159173 SEQ ID NO: 8 AAVcy.5 151 US20150159173 SEQ ID NO: 24 AAVCy.5R1 152 US20150159173 AAVCy.5R2 153 US20150159173 AAVCy.5R3 154 US20150159173 AAVCy.5R4 155 US20150159173 AAVDJ 156 US20140359799 SEQ ID NO: 3, US7588772 SEQ ID NO: 2 AAVDJ 157 US20140359799 SEQ ID NO: 2, US7588772 SEQ ID NO: 1 AAVDJ-8 158 US7588772; Grimm et al 2008 AAVDJ-8 159 US7588772; Grimm et al 2008 AAVF5 160 US20030138772 SEQ ID NO: 110 AAVH2 161 US20030138772 SEQ ID NO: 26 AAVH6 162 US20030138772 SEQ ID NO: 25 AAVhE1.1 163 US9233131 SEQ ID NO: 44 AAVhEr1.14 164 US9233131 SEQ ID NO: 46 AAVhEr1.16 165 US9233131 SEQ ID NO: 48 AAVhEr1.18 166 US9233131 SEQ ID NO: 49 AAVhEr1.23 167 US9233131 SEQ ID NO: 53 (AAVhEr2.29) AAVhEr1.35 168 US9233131 SEQ ID NO: 50 AAVhEr1.36 169 US9233131 SEQ ID NO: 52 AAVhEr1.5 170 US9233131 SEQ ID NO: 45 AAVhEr1.7 171 US9233131 SEQ ID NO: 51 AAVhEr1.8 172 US9233131 SEQ ID NO: 47 AAVhEr2.16 173 US9233131 SEQ ID NO: 55 AAVhEr2.30 174 US9233131 SEQ ID NO. 56 AAVhEr2.31 175 US9233131 SEQ ID NO: 58 AAVhEr2.36 176 US9233131 SEQ ID NO: 57 AAVhEr2.4 177 US9233131 SEQ ID NO: 54 AAVhEr3.1 178 US9233131 SEQ ID NO: 59 AAVhu.1 179 US20150315612 SEQ ID NO: 46 AAVhu.1 180 US20150315612 SEQ ID NO: 144 AAVhu.10 181 US20150315612 SEQ ID NO: 56 (AAV16.8) AAVhu.10 182 US20150315612 SEQ ID NO: 156 (AAV16.8) AAVhu.11 183 US20150315612 SEQ ID NO: 57 (AAV16.12) AAVhu.11 184 US20150315612 SEQ ID NO: 153 (AAV16.12) AAVhu.12 185 US20150315612 SEQ ID NO: 59 AAVhu.12 186 US20150315612 SEQ ID NO: 154 AAVhu.13 187 US20150159173 SEQ ID NO: 16, US20150315612 SEQ ID NO: 71 AAVhu.13 188 US20150159173 SEQ ID NO: 32, US20150315612 SEQ ID NO: 129 AAVhu.136.1 189 US20150315612 SEQ ID NO: 165 AAVhu.140.1 190 US20150315612 SEQ ID NO: 166 AAVhu.140.2 191 US20150315612 SEQ ID NO: 167 AAVhu.145.6 192 US20150315612 SEQ ID No: 178 AAVhu.15 193 US20150315612 SEQ ID NO: 147 AAVhu.15 194 US20150315612 SEQ ID NO: 50 (AAV33.4) AAVhu.156.1 195 US20150315612 SEQ ID No: 179 AAVhu.16 196 US20150315612 SEQ ID NO: 148 AAVhu.16 197 US20150315612 SEQ ID NO: 51 (AAV33.8) AAVhu.17 198 US20150315612 SEQ ID NO: 83 AAVhu.17 199 US20150315612 SEQ ID NO: 4 (AAV33.12) AAVhu.172.1 200 US20150315612 SEQ ID NO: 171 AAVhu.172.2 201 US20150315612 SEQ ID NO: 172 AAVhu.173.4 202 US20150315612 SEQ ID NO: 173 AAVhu.173.8 203 US20150315612 SEQ ID NO: 175 AAVhu.18 204 US20150315612 SEQ ID NO: 52 AAVhu.18 205 US20150315612 SEQ ID NO: 149 AAVhu.19 206 US20150315612 SEQ ID NO: 62 AAVhu.19 207 US20150315612 SEQ ID NO: 133 AAVhu.2 208 US20150315612 SEQ ID NO: 48 AAVhu.2 209 US20150315612 SEQ ID NO: 143 AAVhu.20 210 US20150315612 SEQ ID NO: 63 AAVhu.20 211 US20150315612 SEQ ID NO: 134 AAVhu.21 212 US20150315612 SEQ ID NO: 65 AAVhu.21 213 US20150315612 SEQ ID NO: 135 AAVhu.22 214 US20150315612 SEQ ID NO: 67 AAVhu.22 215 US20150315612 SEQ ID NO: 138 AAVhu.23 216 US20150315612 SEQ ID NO: 60 AAVhu.23.2 217 US20150315612 SEQ ID NO: 137 AAVhu.24 218 US20150315612 SEQ ID NO: 66 AAVhu.24 219 US20150315612 SEQ ID NO: 136 AAVhu.25 220 US20150315612 SEQ ID NO: 49 AAVhu.25 221 US20150315612 SEQ ID NO: 146 AAVhu.26 222 US20150159173 SEQ ID NO: 17, US20150315612 SEQ ID NO: 61 AAVhu.26 223 US20150159173 SEQ ID NO: 33, US20150315612 SEQ ID NO: 139 AAVhu.27 224 US20150315612 SEQ ID NO: 64 AAVhu.27 225 US20150315612 SEQ ID NO: 140 AAVhu.28 226 US20150315612 SEQ ID NO: 68 AAVhu.28 227 US20150315612 SEQ ID NO: 130 AAVhu.29 228 US20150315612 SEQ ID NO: 69 AAVhu.29 229 US20150159173 SEQ ID NO: 42, US20150315612 SEQ ID NO: 132 AAVhu.29 230 US20150315612 SEQ ID NO: 225 AAVhu.29R 231 US20150159173 AAVhu.3 232 US20150315612 SEQ ID NO: 44 AAVhu.3 233 US20150315612 SEQ ID NO: 145 AAVhu.30 234 US20150315612 SEQ ID NO: 70 AAVhu.30 235 US20150315612 SEQ ID NO: 131 AAVhu.31 236 US20150315612 SEQ ID NO: 1 AAVhu.31 237 US20150315612 SEQ ID NO: 121 AAVhu.32 238 US20150315612 SEQ ID NO: 2 AAVhu.32 239 US20150315612 SEQ ID NO: 122 AAVhu.33 240 US20150315612 SEQ ID NO: 75 AAVhu.33 241 US20150315612 SEQ ID NO: 124 AAVhu.34 242 US20150315612 SEQ ID NO: 72 AAVhu.34 243 US20150315612 SEQ ID NO: 125 AAVhu.35 244 US20150315612 SEQ ID NO: 73 AAVhu.35 245 US20150315612 SEQ ID NO: 164 AAVhu.36 246 US20150315612 SEQ ID NO: 74 AAVhu.36 247 US20150315612 SEQ ID NO: 126 AAVhu.37 248 US20150159173 SEQ ID NO: 34, US20150315612 SEQ ID NO: 88 AAVhu.37 249 US20150315612 SEQ ID NO: 10, US20150159173 SEQ ID NO: 18 (AAV106.1) AAVhu.38 250 US20150315612 SEQ ID NO: 161 AAVhu.39 251 US20150315612 SEQ ID NO: 102 AAVhu.39 252 US20150315612 SEQ ID NO: 24 (AAVLG-9) AAVhu.4 253 US20150315612 SEQ ID NO: 47 AAVhu.4 254 US20150315612 SEQ ID NO: 141 AAVhu.40 255 US20150315612 SEQ ID NO: 87 AAVhu.40 256 US20150315612 SEQ ID No: 11 (AAV114.3) AAVhu.41 257 US20150315612 SEQ ID NO: 91 AAVhu.41 258 US20150315612 SEQ ID NO: 6 (AAV127.2) AAVhu.42 259 US20150315612 SEQ ID NO: 85 AAVhu.42 260 US20150315612 SEQ ID NO: 8 (AAV127.5) AAVhu.43 261 US20150315612 SEQ ID NO: 160 AAVhu.43 262 US20150315612 SEQ ID NO: 236 AAVhu.43 263 US20150315612 SEQ ID NO: 80 (AAV128.1) AAVhu.44 264 US20150159173 SEQ ID NO: 45, US20150315612 SEQ ID NO: 158 AAVhu.44 265 US20150315612 SEQ ID NO: 81 (AAV128.3) AAVhu.44R1 266 US20150159173 AAVhu.44R2 267 US20150159173 AAVhu.44R3 268 US20150159173 AAVhu.45 269 US20150315612 SEQ ID NO: 76 AAVhu.45 270 US20150315612 SEQ ID NO: 127 AAVhu.46 271 US20150315612 SEQ ID NO: 82 AAVhu.46 272 US20150315612 SEQ ID NO: 159 AAVhu.46 273 US20150315612 SEQ ID NO: 224 AAVhu.47 274 US20150315612 SEQ ID NO: 77 AAVhu.47 275 US20150315612 SEQ ID NO: 128 AAVhu.48 276 US20150159173 SEQ ID NO: 38 AAVhu.48 277 US20150315612 SEQ ID NO: 157 AAVhu.48 278 US20150315612 SEQ ID NO: 78 (AAV130.4) AAVhu.48R1 279 US20150159173 AAVhu.48R2 280 US20150159173 AAVhu.48R3 281 US20150159173 AAVhu.49 282 US20150315612 SEQ ID NO: 209 AAVhu.49 283 US20150315612 SEQ ID NO: 189 AAVhu.5 284 US20150315612 SEQ ID NO: 45 AAVhu.5 285 US20150315612 SEQ ID NO: 142 AAVhu.51 286 US20150315612 SEQ ID NO: 208 AAVhu.51 287 US20150315612 SEQ ID NO: 190 AAVhu.52 288 US20150315612 SEQ ID NO: 210 AAVhu.52 289 US20150315612 SEQ ID NO: 191 AAVhu.53 290 US20150159173 SEQ ID NO: 19 AAVhu.53 291 US20150159173 SEQ ID NO: 35 AAVhu.53 292 US20150315612 SEQ ID NO: 176 (AAV145.1) AAVhu.54 293 US20150315612 SEQ ID NO: 188 AAVhu.54 294 US20150315612 SEQ ID No: 177 (AAV145.5) AAVhu.55 295 US20150315612 SEQ ID NO: 187 AAVhu.56 296 US20150315612 SEQ ID NO: 205 AAVhu.56 297 US20150315612 SEQ ID NO: 168 (AAV145.6) AAVhu.56 298 US20150315612 SEQ ID NO: 192 (AAV145.6) AAVhu.57 299 US20150315612 SEQ ID NO: 206 AAVhu.57 300 US20150315612 SEQ ID NO: 169 AAVhu.57 301 US20150315612 SEQ ID NO: 193 AAVhu.58 302 US20150315612 SEQ ID NO: 207 AAVhu.58 303 US20150315612 SEQ ID NO: 194 AAVhu.6 304 US20150315612 SEQ ID NO: 5 (AAV3.1) AAVhu.6 305 US20150315612 SEQ ID NO: 84 (AAV3.1) AAVhu.60 306 US20150315612 SEQ ID NO: 184 AAVhu.60 307 US20150315612 SEQ ID NO: 170 (AAV161.10) AAVhu.61 308 US20150315612 SEQ ID NO: 185 AAVhu.61 309 US20150315612 SEQ ID NO: 174 (AAV161.6) AAVhu.63 310 US20150315612 SEQ ID NO: 204 AAVhu.63 311 US20150315612 SEQ ID NO: 195 AAVhu.64 312 US20150315612 SEQ ID NO: 212 AAVhu.64 313 US20150315612 SEQ ID NO: 196 AAVhu.66 314 US20150315612 SEQ ID NO: 197 AAVhu.67 315 US20150315612 SEQ ID NO: 215 AAVhu.67 316 US20150315612 SEQ ID NO: 198 AAVhu.7 317 US20150315612 SEQ ID NO: 226 AAVhu.7 318 US20150315612 SEQ ID NO: 150 AAVhu.7 319 US20150315612 SEQ ID NO: 55 (AAV7.3) AAVhu.71 320 US20150315612 SEQ ID NO: 79 AAVhu.8 321 US20150315612 SEQ ID NO: 53 AAVhu.8 322 US20150315612 SEQ ID NO: 12 AAVhu.8 323 US20150315612 SEQ ID NO: 151 AAVhu.9 324 US20150315612 SEQ ID NO: 58 (AAV3.1) AAVhu.9 325 US20150315612 SEQ ID NO: 155 (AAV3.1) AAV-LK01 326 US20150376607 SEQ ID NO: 2 AAV-LK01 327 US20150376607 SEQ ID NO: 29 AAV-LK02 328 US20150376607 SEQ ID NO: 3 AAV-LK02 329 US20150376607 SEQ ID NO: 30 AAV-LK03 330 US20150376607 SEQ ID NO: 4 AAV-LK03 331 WO2015121501 SEQ ID NO: 12, US20150376607 SEQ ID NO: 31 AAV-LK04 332 US20150376607 SEQ ID NO: 5 AAV-LK04 333 US20150376607 SEQ ID NO: 32 AAV-LK05 334 US20150376607 SEQ ID NO: 6 AAV-LK05 335 US20150376607 SEQ ID NO: 33 AAV-LK06 336 US20150376607 SEQ ID NO: 7 AAV-LK06 337 US20150376607 SEQ ID NO: 34 AAV-LK07 338 US20150376607 SEQ ID NO: 8 AAV-LK07 339 US20150376607 SEQ ID NO: 35 AAV-LK08 340 US20150376607 SEQ ID NO: 9 AAV-LK08 341 US20150376607 SEQ ID NO: 36 AAV-LK09 342 US20150376607 SEQ ID NO: 10 AAV-LK09 343 US20150376607 SEQ ID NO: 37 AAV-LK10 344 US20150376607 SEQ ID NO: 11 AAV-LK10 345 US20150376607 SEQ ID NO: 38 AAV-LK11 346 US20150376607 SEQ ID NO: 12 AAV-LK11 347 US20150376607 SEQ ID NO: 39 AAV-LK12 348 US20150376607 SEQ ID NO: 13 AAV-LK12 349 US20150376607 SEQ ID NO: 40 AAV-LK13 350 US20150376607 SEQ ID NO: 14 AAV-LK13 351 US20150376607 SEQ ID NO: 41 AAV-LK14 352 US20150376607 SEQ ID NO: 15 AAV-LK14 353 US20150376607 SEQ ID NO: 42 AAV-LK15 354 US20150376607 SEQ ID NO: 16 AAV-LK15 355 US20150376607 SEQ ID NO: 43 AAV-LK16 356 US20150376607 SEQ ID NO: 17 AAV-LK16 357 US20150376607 SEQ ID NO: 44 AAV-LKI7 358 US20150376607 SEQ ID NO: 18 AAV-LK17 359 US20150376607 SEQ ID NO: 45 AAV-LK18 360 US20150376607 SEQ ID NO: 19 AAV-LK18 361 US20150376607 SEQ ID NO: 46 AAV-LK19 362 US20150376607 SEQ ID NO: 20 AAV-LK19 363 US20150376607 SEQ ID NO: 47 AAV-PAEC 364 US20150376607 SEQ ID NO: 1 AAV-PAEC 365 US20150376607 SEQ ID NO: 48 AAV-PAEC11 366 US20150376607 SEQ ID NO: 26 AAV-PAEC11 367 US20150376607 SEQ ID NO: 54 AAV-PAEC12 368 US20150376607 SEQ ID NO: 27 AAV-PAEC12 369 US20150376607 SEQ ID NO: 51 AAV-PAEC13 370 US20150376607 SEQ ID NO: 28 AAV-PAEC13 371 US20150376607 SEQ ID NO: 49 AAV-PAEC2 372 US20150376607 SEQ ID NO: 21 AAV-PAEC2 373 US20150376607 SEQ ID NO: 56 AAV-PAEC4 374 US20150376607 SEQ ID NO: 22 AAV-PAEC4 375 US20150376607 SEQ ID NO: 55 AAV-PAEC6 376 US20150376607 SEQ ID NO: 23 AAV-PAEC6 377 US20150376607 SEQ ID NO: 52 AAV-PAEC7 378 US20150376607 SEQ ID NO: 24 AAV-PAEC7 379 US20150376607 SEQ ID NO: 53 AAV-PAEC8 380 US20150376607 SEQ ID NO: 25 AAV-PAEC8 381 US20150376607 SEQ ID NO: 50 AAVpi.1 382 US20150315612 SEQ ID NO: 28 AAVpi.1 383 US20150315612 SEQ ID NO: 93 AAVpi.2 384 US20150315612 SEQ ID NO: 30 AAVpi.2 385 US20150315612 SEQ ID NO: 95 AAVpi.3 386 US20150315612 SEQ ID NO: 29 AAVpi.3 387 US20150315612 SEQ ID NO: 94 AAVrh.10 388 US20150159173 SEQ ID NO: 9 AAVrh.10 389 US20150159173 SEQ ID NO: 25 AAV44.2 390 US20030138772 SEQ ID NO: 59 AAVrh.10 391 US20030138772 SEQ ID NO: 81 (AAV44.2) AAV42.1B 392 US20030138772 SEQ ID NO: 90 AAVrh.12 393 US20030138772 SEQ ID NO: 30 (AAV42.1b) AAVrh.13 394 US20150159173 SEQ ID NO: 10 AAVrh.13 395 US20150159173 SEQ ID NO: 26 AAVrh.13 396 US20150315612 SEQ ID NO: 228 AAVrh.13R 397 US20150159173 AAV42.3A 398 US20030138772 SEQ ID NO: 87 AAVrh.14 399 US20030138772 SEQ ID NO: 32 (AAV42.3a) AAV42.5A 400 US20030138772 SEQ ID NO: 89 AAVrh.17 401 US20030138772 SEQ ID NO: 34 (AAV42.5a) AAV42.5B 402 US20030138772 SEQ ID NO: 91 AAVrh.18 403 US20030138772 SEQ ID NO: 29 (AAV42.5b) AAV42.6B 404 US20030138772 SEQ ID NO: 112 AAVrh.19 405 US20030138772 SEQ ID NO: 38 (AAV42.6b) AAVrh.2 406 US20150159173 SEQ ID NO: 39 AAVrh.2 407 US20150315612 SEQ ID NO: 231 AAVrh.20 408 US20150159173 SEQ ID NO: 1 AAV42.10 409 US20030138772 SEQ ID NO: 106 AAVrh.21 410 US20030138772 SEQ ID NO: 35 (AAV42.10) AAV42.11 411 US20030138772 SEQ ID NO: 108 AAVrh.22 412 US20030138772 SEQ ID NO: 37 (AAV42.11) AAV42.12 413 US20030138772 SEQ ID NO: 113 AAVrh.23 414 US20030138772 SEQ ID NO: 58 (AAV42.12) AAV42.13 415 US20030138772 SEQ ID NO: 86 AAVrh..24 416 US20030138772 SEQ ID NO: 31 (AAV42.13) AAV42.15 417 US20030138772 SEQ ID NO: 84 AAVrh.25 418 US20030138772 SEQ ID NO: 28 (AAV42.15) AAVrh.2R 419 US20150159173 AAVrh.31 420 US20030138772 SEQ ID NO: 48 (AAV223.1) AAVC1 421 US20030138772 SEQ ID NO: 60 AAVrh.32 422 US20030138772 SEQ ID NO: 19 (AAVC1) AAVrh.32/33 423 US20150159173 SEQ ID NO: 2 AAVrh.33 424 US20030138772 SEQ ID NO: 20 (AAVC3) AAVC5 425 US20030138772 SEQ ID NO: 62 AAVrh.34 426 US20030138772 SEQ ID NO: 21 (AAVC5) AAVF1 427 US20030138772 SEQ ID NO: 109 AAVrh.35 428 US20030138772 SEQ ID NO: 22 (AAVF1) AAVF3 429 US20030138772 SEQ ID NO: 111 AAVrh.36 430 US20030138772 SEQ ID NO: 23 (AAVF3) AAVrh.37 431 US20030138772 SEQ ID NO: 24 AAVrh.37 432 US20150159173 SEQ ID NO: 40 AAVrh.37 433 US20150315612 SEQ ID NO: 229 AAVrh.37R2 434 US20150159173 AAVrh.38 435 US20150315612 SEQ ID NO: 7 (AAVLG-4) AAVrh.38 436 US20150315612 SEQ ID NO: 86 (AAVLG-4) AAVrh.39 437 US20150159173 SEQ ID NO: 20, US20150315612 SEQ ID NO: 13 AAVrh.39 438 US20150159173 SEQ ID NO: 3, US20150159173 SEQ ID NO: 36, US20150315612 SEQ ID NO: 89 AAVrh.40 439 US20150315612 SEQ ID NO: 92 AAVrh.40 440 US20150315612 SEQ ID No: 14 (AAVLG-10) AAVrh.43 441 US20150315612 SEQ ID NO: 43, US20150159173 SEQ ID NO: 21 (AAVN721-8) AAVrh.43 442 US20150315612 SEQ ID NO: 163, US20150159173 SEQ ID NO: 37 (AAVN721-8) AAVrh.44 443 US20150315612 SEQ ID NO: 34 AAVrh.44 444 US20150315612 SEQ ID NO: 111 AAVrh.45 445 US20150315612 SEQ ID NO: 41 AAVrh.45 446 US20150315612 SEQ ID NO: 109 AAVrh.46 447 US20150159173 SEQ ID NO: 22, US20150315612SEQ ID NO: 19 AAVrh.46 448 US20150159173 SEQ ID NO: 4, US20150315612 SEQ ID NO: 101 AAVrh.47 449 US20150315612 SEQ ID NO: 38 AAVrh.47 450 US20150315612 SEQ ID NO: 118 AAVrh.48 451 US20150159173 SEQ ID NO: 44, US20150315612 SEQ ID NO: 115 AAVrh.48.1 452 US20150159173 AAVrh.48.1.2 453 US20150159173 AAVrh.48.2 454 US20150159173 AAVrh.48 455 US20150315612 SEQ ID NO: 32 (AAV1-7) AAVrh.49 456 US20150315612 SEQ ID NO: 25 (AAV1-8) AAVrh.49 457 US20150315612 SEQ ID NO: 103 (AAV1-8) AAVrh.50 458 US20150315612 SEQ ID NO: 23 (AAV2-4) AAVrh.50 459 US20150315612 SEQ ID NO: 108 (AAV2-4) AAVrh.51 460 US20150315612 SEQ ID NO: 22 (AAV2-5) AAVrh.51 461 US20150315612 SEQ ID NO: 104 (AAV2-5) AAVrh.52 462 US20150315612 SEQ ID NO: 18 (AAV3-9) AAVrh.52 463 US20150315612 SEQ ID NO: 96 (AAV3-9) AAVrh.53 464 US20150315612 SEQ ID NO: 97 AAVrh.53 465 US20150315612 SEQ ID NO: 17 (AAV3-11) AAVrh.53 466 US20150315612 SEQ ID NO: 186 (AAV3-11) AAVrh.54 467 US20150315612 SEQ ID NO: 40 AAVrh.54 468 US20150159173 SEQ ID NO: 49, US20150315612 SEQ ID NO: 116 AAVrh.55 469 US20150315612 SEQ ID NO: 37 AAVrh.55 470 US20150315612 SEQ ID NO: 117 (AAV4-19) AAVrh.56 471 US20150315612 SEQ ID NO: 54 AAVrh.56 472 US20150315612 SEQ ID NO: 152 AAVrh.57 473 US20150315612 SEQ ID NO: 26 AAVrh.57 474 US20150315612 SEQ ID NO: 105 AAVrh.58 475 US20150315612 SEQ ID NO: 27 AAVrh.58 476 US20150159173 SEQ ID NO: 48, US20150315612 SEQ ID NO: 106 AAVrh.58 477 US20150315612 SEQ ID NO: 232 AAVrh.59 478 US20150315612 SEQ ID NO: 42 AAVrh.59 479 US20150315612 SEQ ID NO: 110 AAVrh.60 480 US20150315612 SEQ ID NO: 31 AAVrh.60 481 US20150315612 SEQ ID NO: 120 AAVrh.61 482 US20150315612 SEQ ID NO: 107 AAVrh.61 483 US20150315612 SEQ ID NO: 21 (AAV2-3) AAVrh.62 484 US20150315612 SEQ ID NO: 33 (AAV2-15) AAVrh.62 485 US20150315612 SEQ ID NO: 114 (AAV2-15) AAVrh.64 486 US20150315612 SEQ ID No: 15 AAVrh.64 487 US20150159173 SEQ ID NO: 43, US20150315612 SEQ ID NO: 99 AAVrh.64 488 US20150315612 SEQ ID NO: 233 AAVRh.64R1 489 US20150159173 AAVRh.64R2 490 US20150159173 AAVrh.65 491 US20150315612 SEQ ID NO: 35 AAVrh.65 492 US20150315612 SEQ ID NO: 112 AAVrh.67 493 US20150315612 SEQ ID NO: 36 AAVrh.67 494 US20150315612 SEQ ID NO: 230 AAVrh.67 495 US20150159173 SEQ ID NO: 47, US20150315612 SEQ ID NO: 113 AAVrh.68 496 US20150315612 SEQ ID NO: 16 AAVrh.68 497 US20150315612 SEQ ID NO: 100 AAVrh.69 498 US20150315612 SEQ ID NO: 39 AAVrh.69 499 US20150315612 SEQ ID NO: 119 AAVrh.70 500 US20150315612 SEQ ID NO: 20 AAVrh.70 501 US20150315612 SEQ ID NO: 98 AAVrh.71 502 US20150315612 SEQ ID NO: 162 AAVrh.72 503 US20150315612 SEQ ID NO: 9 AAVrh.73 504 US20150159173 SEQ ID NO: 5 AAVrh.74 505 US20150159173 SEQ ID NO: 6 AAVrh.8 506 US20150159173 SEQ ID NO: 41 AAVrh.8 507 US20150315612 SEQ ID NO: 235 AAVrh.8R 508 US20150159173, WO2015168666 SEQ ID NO: 9 AAVrh.8R 509 WO2015168666 SEQ ID NO: 10 A586R mutant AAVrh.8R 510 WO2015168666 SEQ ID NO: 11 R533A mutant BAAV 511 US9193769 SEQ ID NO: 8 (bovine AAV) BAAV 512 US9193769 SEQ ID NO: 10 (bovine AAV) BAAV 513 US9193769 SEQ ID NO: 4 (bovine AAV) BAAV 514 US9193769 SEQ ID NO: 2 (bovine AAV) BAAV 515 US9193769 SEQ ID NO: 6 (bovine AAV) BAAV 516 US9193769 SEQ ID NO: 1 (bovine AAV) BAAV 517 US9193769 SEQ ID NO: 5 (bovine AAV) BAAV 518 US9193769 SEQ ID NO: 3 (bovine AAV) BAAV 519 US9193769 SEQ ID NO: 11 (bovine AAV) BAAV 520 US7427396 SEQ ID NO: 5 (bovine AAV) BAAV 521 US7427396 SEC ID NO: 6 (bovine AAV) BAAV 522 US9193769 SEQ ID NO: 7 (bovine AAV) BAAV 523 US9193769 SEQ ID NO: 9 (bovine AAV) BNP61 AAV 524 US20150238550 SEQ ID NO: 1 BNP61 AAV 525 US20150238550 SEQ ID NO: 2 BNP62 AAV 526 US20150238550 SEQ ID NO: 3 BNP63 AAV 527 US20150238550 SEQ ID NO: 4 caprine AAV 528 US7427396 SEQ ID NO: 3 caprine AAV 529 US7427396 SEQ ID NO: 4 true type 530 WO2015121501 SEQ ID NO: 2 AAV (ttAAV) AAAV 531 US9238800 SEQ ID NO: 12 (Avian AAV) AAAV 532 US9238800 SEQ ID NO: 2 (Avian AAV) AAAV 533 US9238800 SEQ ID NO: 6 (Avian AAV) AAAV 534 US9238800 SEQ ID NO: 4 (Avian AAV) AAAV 535 US9238800 SEQ ID NO: 8 (Avian AAV) AAAV 536 US9238800 SEQ ID NO: 14 (Avian AAV) AAAV 537 US9238800 SEQ ID NO: 10 (Avian AAV) AAAV 538 US9238800 SEQ ID NO: 15 (Avian AAV) AAAV 539 US9238800 SEQ ID NO: 5 (Avian AAV) AAAV 540 US9238800 SEQ ID NO: 9 (Avian AAV) AAAV 541 US9238800 SEQ ID NO: 3 (Avian AAV) AAAV 542 US9238800 SEQ ID NO: 7 (Avian AAV) AAAV 543 US9238800 SEQ ID NO: 11 (Avian AAV) AAAV 544 US9238800 SEQ ID NO: 13 (Avian AAV) AAAV 545 US9238800 SEQ ID NO: 1 (Avian AAV) AAV Shuffle 546 US20160017295 SEQ ID NO: 23 100-1 AAV Shuffle 547 US20160017295 SEQ ID NO: 11 100-1 AAV Shuffle 548 US20160017295 SEQ ID NO: 37 100-2 AAV Shuffle 549 US20160017295 SEQ ID NO: 29 100-2 AAV Shuffle 550 US20160017295 SEQ ID NO: 24 100-3 AAV Shuffle 551 US20160017295 SEQ ID NO: 12 100-3 AAV Shuffle 552 US20160017295 SEQ ID NO: 25 100-7 AAV Shuffle 553 US20160017295 SEQ ID NO: 13 100-7 AAV Shuffle 554 US20160017295 SEQ ID NO: 34 10-2 AAV Shuffle 555 US20160017295 SEQ ID NO: 26 10-2 AAV Shuffle 556 US20160017295 SEQ ID NO: 35 10-6 AAV Shuffle 557 US20160017295 SEQ ID NO: 27 10-6 AAV Shuffle 558 US20160017295 SEQ ID NO: 36 10-8 AAV Shuffle 559 US20160017295 SEQ ID NO: 28 10-8 AAV SM 560 US20160017295 SEQ ID NO: 41 100-10 AAV SM 561 US20160017295 SEQ ID NO: 33 100-10 AAV SM 562 US20160017295 SEQ ID NO: 40 100-3 AAV SM 563 US20160017295 SEQ ID NO: 32 100-3 AAV SM 10-1 564 US20160017295 SEQ ID NO: 38 AAV SM 10-1 565 US20160017295 SEQ ID NO: 30 AAV SM 10-2 566 US20160017295 SEQ ID NO: 10 AAV SM 10-2 567 US20160017295 SEQ ID NO: 22 AAV SM 10-8 568 US20160017295 SEQ ID NO: 39 AAV SM 10-8 569 US20160017295 SEQ ID NO: 31 AAVF1/HSC1 570 WO2016049230 SEQ ID NO: 20 AAVF2/HSC2 571 WO2016049230 SEQ ID NO: 21 AAVF3/HSC3 572 WO2016019230 SEQ ID NO: 22 AAVF4/HSC4 573 WO2016049230 SEQ ID NO: 23 AAVF5/HSC5 574 WO2016049230 SEQ ID NO: 25 AAVF6/HSC6 575 WO2016049230 SEQ ID NO: 24 AAVF7/HSC7 576 WO2016049130 SEQ ID NO: 27 AAVF8/HSC8 577 WO2016049230 SEQ ID NO: 28 AAVF9/HSC9 578 WO2016049130 SEQ ID NO: 29 AAVF11/HSC11 579 WO2016049230 SEQ ID NO: 26 AAVF12/HSC12 580 WO2016049230 SEQ ID NO: 30 AAVF13/HSC13 581 WO2016049230 SEQ ID NO: 31 AAVF14/HSC14 582 WO2016049230 SEQ ID NO: 32 AAVF15/HSC15 583 WO2016049230 SEQ ID NO: 33 AAVF16/HSC16 584 WO2016049230 SEQ ID NO: 34 AAVF17/HSC17 585 WO2016049230 SEQ ID NO: 35 AAVF1/HSC1 586 WO2016049230 SEQ ID NO: 2 AAVF2/HSC2 587 WO2016049230 SEQ ID NO: 3 AAVF3/HSC3 588 WO2016049230 SEQ ID NO: 5 AAVF4/HSC4 589 WO2016049230 SEQ ID NO: 6 AAVF5/HSC5 590 WO2016049230 SEQ ID NO: 11 AAVF6/HSC6 591 WO2016049230 SEQ ID NO: 7 AAVF7/HSC7 592 WO2016049230 SEQ ID NO: 8 AAVF8/HSC8 593 WO2016049230 SEQ ID NO: 9 AAVF9/HSC9 594 WO2016049230 SEQ ID NO: 10 AAVF11/HSC11 595 WO2016049230 SEQ ID NO: 4 AAVF12/HSC12 596 WO2016049230 SEQ ID NO: 12 AAVF13/HSC13 597 WO2016049230 SEQ ID NO: 14 AAVF14/HSC14 598 WO2016049230 SEQ ID NO: 15 AAVF15/HSC15 599 WO2016049230 SEQ ID NO: 16 AAVF16/HSC16 600 WO2016049230 SEQ ID NO: 17 AAVF17/HSC17 601 WO2016049230 SEQ ID NO: 13 AAV CBr-E1 602 US8734809 SEQ ID NO: 13 AAV CBr-E2 603 US8734809 SEQ ID NO: 14 AAV CBr-E3 604 US8734809 SEQ ID NO: 15 AAV CBr-E4 605 US8734809 SEQ ID NO: 16 AAV CBr-E5 606 US8734809 SEQ ID NO: 17 AAV CBr-e5 607 US8734809 SEQ ID NO: 18 AAV CBr-E6 608 US8734809 SEQ ID NO: 19 AAV CBr-E7 609 US8734809 SEQ ID NO: 20 AAV CBr-E8 610 US8734809 SEQ ID NO: 21 AAV CLv-D1 611 US8734809 SEQ ID NO: 22 AAV CLv-D2 612 US8734809 SEQ ID NO: 23 AAV CLv-D3 613 US8734809 SEQ ID NO: 24 AAV CLv-D4 614 US8734809 SEQ ID NO: 25 AAV CLv-D5 615 US8734809 SEQ ID NO: 26 AAV CLv-D6 616 US8734809 SEQ ID NO: 27 AAV CLv-D7 617 US8734809 SEQ ID NO: 28 AAV CLv-D8 618 US8734809 SEQ ID NO: 29 AAV CLv-E1 619 US8734809 SEQ ID NO: 13 AAV CLv-R1 620 US8734809 SEQ ID NO: 30 AAV CLv-R2 621 US8734809 SEQ ID NO: 31 AAV CLv-R3 622 US8734809 SEQ ID NO: 32 AAV CLv-R4 623 US8734809 SEQ ID NO: 33 AAV CLv-R5 624 US8734809 SEQ ID NO: 34 AAV CLv-R6 625 US8734809 SEQ ID NO: 35 AAV CLv-R7 626 US8734809 SEQ ID NO: 36 AAV CLv-R8 627 US8734809 SEQ ID NO: 37 AAV CLv-R9 628 US8734809 SEQ ID NO: 38 AAV CLg-F1 629 US8734809 SEQ ID NO: 39 AAV CLg-F2 630 US8734809 SEQ ID NO: 40 AAV CLg-F3 631 US8734809 SEQ ID NO: 41 AAV CLg-F4 632 US8734809 SEQ ID NO: 42 AAV CLg-F5 633 US8734809 SEQ ID NO: 43 AAV CLg-F6 634 US8734809 SEQ ID NO: 43 AAV CLg-F7 635 US8734809 SEQ ID NO: 44 AAV CLg-F8 636 US8734809 SEQ ID NO: 43 AAV CSp-1 637 US8734809 SEQ ID NO: 45 AAV CSp-10 638 US8734809 SEQ ID NO: 46 AAV CSp-11 639 US8734809 SEQ ID NO: 47 AAV CSp-2 640 US8734809 SEQ ID NO: 48 AAV CSp-3 641 US8734809 SEQ ID NO: 49 AAV CSp-4 642 US8734809 SEQ ID NO: 50 AAV CSp-6 643 US8734809 SEQ ID NO: 51 AAV CSp-7 644 US8734809 SEQ ID NO: 52 AAV CSp-8 645 US8734809 SEQ ID NO: 53 AAV CSp-9 646 US8734809 SEQ ID NO: 54 AAV CHt-2 647 US8734809 SEQ ID NO: 55 AAV CHt-3 648 US8734809 SEQ ID NO: 56 AAV CKd-1 649 US8734809 SEQ ID NO: 57 AAV CKd-10 650 US8734809 SEQ ID NO: 58 AAV CKd-2 651 US8734809 SEQ ID NO: 59 AAV CKd-3 652 US8734809 SEQ ID NO: 60 AAV CKd-4 653 US8734809 SEQ ID NO: 61 AAV CKd-6 654 US8734809 SEQ ID NO: 62 AAV CKd-7 655 US8734809 SEQ ID NO: 63 AAV CKd-8 656 US8734809 SEQ ID NO: 64 AAV CLv-1 657 US8734809 SEQ ID NO: 65 AAV CLv-12 658 US8734809 SEQ ID NO: 66 AAV CLv-13 659 US8734809 SEQ ID NO: 67 AAV CLv-2 660 US8734809 SEQ ID NO: 68 AAV CLv-3 661 US8734809 SEQ ID NO: 69 AAV CLv-4 662 US8734809 SEQ ID NO: 70 AAV CLv-6 663 US8734809 SEQ ID NO: 71 AAV CLv-8 664 US8734809 SEQ ID NO: 72 AAV CKd-B1 665 US8734809 SEQ ID NO: 73 AAV CKd-B2 666 US8734809 SEQ ID NO: 74 AAV CKd-B3 667 US8734809 SEQ ID NO: 75 AAV CKd-B4 668 US8734809 SEQ ID NO: 76 AAV CKd-B5 669 US8734809 SEQ ID NO: 77 AAV CKd-B6 670 US8734809 SEQ ID NO: 78 AAV CKd-B7 671 US8734809 SEQ ID NO: 79 AAV CKd-B8 672 US8734809 SEQ ID NO: 80 AAV CKd-H1 673 US8734809 SEQ ID NO: 81 AAV CKd-H2 674 US8734809 SEQ ID NO: 82 AAV CKd-H3 675 US8734809 SEQ ID NO: 83 AAV CKd-H4 676 US8734809 SEQ ID NO: 84 AAV CKd-H5 677 US8734809 SEQ ID NO: 85 AAV CKd-H6 678 US8734809 SEQ ID NO: 77 AAV CHt-1 679 US8734809 SEQ ID NO: 86 AAV CLv1-1 680 US8734809 SEQ ID NO: 171 AAV CLv1-2 681 US8734809 SEQ ID NO: 172 AAV CLv1-3 682 US8734809 SEQ ID NO: 173 AAV CLv1-4 683 US8734809 SEQ ID NO: 174 AAV Clv1-7 684 US8734809 SEQ ID NO: 175 AAV Clv1-8 685 US8734809 SEQ ID NO: 176 AAV Clv1-9 686 US8734809 SEQ ID NO: 177 AAV Clv1-10 687 US8734809 SEQ ID NO: 178 AAV.VR-355 688 US8734809 SEQ ID NO: 181 AAV.hu.48R3 689 US8734809 SEQ ID NO: 183 AAV CBr-E1 690 US8734809 SEQ ID NO: 87 AAV CBr-E2 691 US8734809 SEQ ID NO: 88 AAV CBr-E3 692 US8734809 SEQ ID NO: 89 AAV CBr-E4 693 US8734809 SEQ ID NO: 90 AAV CBr-E5 694 US8734809 SEQ ID NO: 91 AAV CBr-e5 695 US8734809 SEQ ID NO: 92 AAV CBr-E6 696 US8734809 SEQ ID NO: 93 AAV CBr-E7 697 US8734809 SEQ ID NO: 94 AAV CBr-E8 698 US8734809 SEQ ID NO: 95 AAV CLv-D1 699 US8734809 SEQ ID NO: 96 AAV CLv-D2 700 US8734809 SEQ ID NO: 97 AAV CLv-D3 701 US8734809 SEQ ID NO: 98 AAV CLv-D4 702 US8734809 SEQ ID NO: 99 AAV CLv-D5 703 US8734809 SEQ ID NO: 100 AAV CLv-D6 704 US8734809 SEQ ID NO: 101 AAV CLv-D7 705 US8734809 SEQ ID NO: 102 AAV CLv-D8 706 US8734809 SEQ ID NO: 103 AAV CLv-E1 707 US8734809 SEQ ID NO: 87 AAV CLv-R1 708 US8734809 SEQ ID NO: 104 AAV CLv-R2 709 US8734809 SEQ ID NO: 105 AAV CLv-R3 710 US8734809 SEQ ID NO: 106 AAV CLv-R4 711 US8734809 SEQ ID NO: 107 AAV CLv-R5 712 US8734809 SEQ ID NO: 108 AAV CLv-R6 713 US8734809 SEQ ID NO: 109 AAV CLv-R7 714 US8734809 SEQ ID NO: 110 AAV CLv-R8 715 US8734809 SEQ ID NO: 111 AAV CLv-R9 716 US8734809 SEQ ID NO: 112 AAV CLg-F1 717 US8734809 SEQ ID NO: 113 AAV CLg-F2 718 US8734809 SEQ ID NO: 114 AAV CLg-F3 719 US8734809 SEQ ID NO: 115 AAV CLg-F4 720 US8734809 SEQ ID NO: 116 AAV CLg-F5 721 US8734809 SEQ ID NO: 117 AAV CLg-F6 722 US8734809 SEQ ID NO: 117 AAV CLg-F7 723 US8734809 SEQ ID NO: 118 AAV CLg-F8 724 US8734809 SEQ ID NO: 117 AAV CSp-1 725 US8734809 SEQ ID NO: 119 AAV CSp-10 726 US8734809 SEQ ID NO: 120 AAV CSp-11 727 US8734809 SEQ ID NO: 121 AAV CSp-2 728 US8734809 SEQ ID NO: 122 AAV CSp-3 729 US8734809 SEQ ID NO: 123 AAV CSp-4 730 US8734809 SEQ ID NO: 124 AAV CSp-6 731 US8734809 SEQ ID NO: 125 AAV CSp-7 732 US8734809 SEQ ID NO: 126 AAV CSp-8 733 US8734809 SEQ ID NO: 127 AAV CSp-9 734 US8734809 SEQ ID NO: 128 AAV CHt-2 735 US8734809 SEQ ID NO: 129 AAV CHt-3 736 US8734809 SEQ ID NO: 130 AAV CKd-1 737 US8734809 SEQ ID NO: 131 AAV CKd-10 738 US8734809 SEQ ID NO: 132 AAV CKd-2 739 US8734809 SEQ ID NO: 133 AAV CKd-3 740 US8734809 SEQ ID NO: 134 AAV CKd-4 741 US8734809 SEQ ID NO: 135 AAV CKd-6 742 US8734809 SEQ ID NO: 136 AAV CKd-7 743 US8734809 SEQ ID NO: 137 AAV CKd-8 744 US8734809 SEQ ID NO: 138 AAV CLv-1 745 US8734809 SEQ ID NO: 139 AAV CLv-12 746 US8734809 SEQ ID NO: 140 AAV CLv-13 747 US8734809 SEQ ID NO: 141 AAV CLv-2 748 US8734809 SEQ ID NO: 142 AAV CLv-3 749 US8734809 SEQ ID NO: 143 AAV CLv-4 750 US8734809 SEQ ID NO: 144 AAV CLv-6 751 US8734809 SEQ ID NO: 145 AAV CLv-8 752 US8734809 SEQ ID NO: 146 AAV CKd-B1 753 US8734809 SEQ ID NO: 147 AAV CKd-B2 754 US8734809 SEQ ID NO: 148 AAV CKd-B3 755 US8734809 SEQ ID NO: 149 AAV CKd-B4 756 US8734809 SEQ ID NO: 150 AAV CKd-B5 757 US8734809 SEQ ID NO: 151 AAV CKd-B6 758 US8734809 SEQ ID NO: 152 AAV CKd-B7 759 US8734809 SEQ ID NO: 153 AAV CKd-B8 760 US8734809 SEQ ID NO: 154 AAV CKd-H1 761 US8734809 SEQ ID NO: 155 AAV CKd-H2 762 US8734809 SEQ ID NO: 156 AAV CKd-H3 763 US8734809 SEQ ID NO: 157 AAV CKd-H4 764 US8734809 SEQ ID NO: 158 AAV CKd-H5 765 US8734809 SEQ ID NO: 159 AAV CKd-H6 766 US8734809 SEQ ID NO: 151 AAV CHt-1 767 US8734809 SEQ ID NO: 160 AAV CHt-P2 768 WO2016065001 SEQ ID NO: 1 AAV CHt-P5 769 WO2016065001 SEQ ID NO: 2 AAV CHt-P9 770 WO2016065001 SEQ ID NO: 3 AAV CBr-7.1 771 WO2016065001 SEQ ID NO: 4 AAV CBr-7.2 772 WO2016065001 SEQ ID NO: 5 AAV CBr-7.3 773 WO2016065001 SEQ ID NO: 6 AAV CBr-7.4 774 WO2016065001 SEQ ID NO: 7 AAV CBr-7.5 775 WO2016065001 SEQ ID NO: 8 AAV CBr-7.7 776 WO2016065001 SEQ ID NO: 9 AAV CBr-7.8 777 WO2016065001 SEQ ID NO: 10 AAV CBr-7.10 778 WO2016065001 SEQ ID NO: 11 AAV CKd-N3 779 WO2016065001 SEQ ID NO: 12 AAV CKd-N4 780 WO2016065001 SEQ ID NO: 13 AAV CKd-N9 781 WO2016065001 SEQ ID NO: 14 AAV CLv-L4 782 WO2016065001 SEQ ID NO: 15 AAV CLv-L5 783 WO2016065001 SEQ ID NO: 16 AAV CLv-L6 784 WO2016065001 SEQ ID NO: 17 AAV CLv-K1 785 WO2016065001 SEQ ID NO: 18 AAV CLv-K3 786 WO2016065001 SEQ ID NO: 19 AAV CLv-K6 787 WO2016065001 SEQ ID NO: 20 AAV CLv-M1 788 WO2016065001 SEQ ID NO: 21 AAV CLv-M11 789 WO2016065001 SEQ ID NO: 22 AAV CLv-M2 790 WO2016065001 SEQ ID NO: 23 AAV CLv-M5 791 WO2016065001 SEQ ID NO: 24 AAV CLv-M6 792 WO2016065001 SEQ ID NO: 25 AAV CLv-M7 793 WO2016065001 SEQ ID NO: 26 AAV CLv-M8 794 WO2016065001 SEQ ID NO: 27 AAV CLv-M9 795 WO2016065001 SEQ ID NO: 28 AAV CHt-P1 796 WO2016065001 SEQ ID NO: 29 AAV CHt-P6 797 WO2016065001 SEQ ID NO: 30 AAV CHt-P8 798 WO2016065001 SEQ ID NO: 31 AAV CHt-6.1 799 WO2016065001 SEQ ID NO: 32 AAV CHt-6.10 800 WO2016065001 SEQ ID NO: 33 AAV CHt-6.5 801 WO2016065001 SEQ ID NO: 34 AAV CHt-6.6 802 WO2016065001 SEQ ID NO: 35 AAV CHt-6.7 803 WO2016065001 SEQ ID NO: 36 AAV CHt-6.8 804 WO2016065001 SEQ ID NO: 37 AAV CSp-8.10 805 WO2016065001 SEQ ID NO: 38 AAV CSp-8.2 806 WO2016065001 SEQ ID NO: 39 AAV CSp-8.4 807 WO2016065001 SEQ ID NO: 40 AAV CSp-8.5 808 WO2016065001 SEQ ID NO: 41 AAV CSp-8.6 809 WO2016065001 SEQ ID NO: 42 AAV CSp-8.7 810 WO2016065001 SEQ ID NO: 43 AAV CSp-8.8 811 WO2016065001 SEQ ID NO: 44 AAV CSp-8.9 812 WO2016065001 SEQ ID NO: 45 AAV CBr-B7.3 813 WO2016065001 SEQ ID NO: 46 AAV CBr-B7.4 814 WO2016065001 SEQ ID NO: 47 AAV3B 815 WO2016065001 SEQ ID NO: 48 AAV4 816 WO2016065001 SEQ ID NO: 49 AAV5 817 WO2016065001 SEQ ID NO: 50 AAV CHt-P2 818 WO2016065001 SEQ ID NO: 51 AAV CHt-P5 819 WO2016065001 SEQ ID NO: 52 AAV CHt-P9 820 WO2016065001 SEQ ID NO: 53 AAV CBr-7.1 821 WO2016065001 SEQ ID NO: 54 AAV CBr-7.2 822 WO2016065001 SEQ ID NO: 55 AAV CBr-7.3 823 WO2016065001 SEQ ID NO: 56 AAV CBr-7.4 824 WO2016065001 SEQ ID NO: 57 AAV CBr-7.5 825 WO2016065001 SEQ ID NO: 58 AAV CBr-7.7 826 WO2016065001 SEQ ID NO: 59 AAV CBr-7.8 827 WO2016065001 SEQ ID NO: 60 AAV CBr-7.10 828 WO2016065001 SEQ ID NO: 61 AAV CKd-N3 829 WO2016065001 SEQ ID NO: 62 AAV CKd-N4 830 WO2016065001 SEQ ID NO: 63 AAV CKd-N9 831 WO2016065001 SEQ ID NO: 64 AAV CLv-L4 832 WO2016065001 SEQ ID NO: 65 AAV CLv-L5 833 WO2016065001 SEQ ID NO: 66 AAV CLv-L6 834 WO2016065001 SEQ ID NO: 67 AAV CLv-K1 835 WO2016065001 SEQ ID NO: 68 AAV CLv-K3 836 WO2016065001 SEQ ID NO: 69 AAV CLv-K6 837 WO2016065001 SEQ ID NO: 70 AAV CLv-M1 838 WO2016065001 SEQ ID NO: 71 AAV CLv-M11 839 WO2016065001 SEQ ID NO: 72 AAV CLv-M2 840 WO2016065001 SEQ ID NO: 73 AAV CLv-M5 841 WO2016065001 SEQ ID NO: 74 AAV CLv-M6 842 WO2016065001 SEQ ID NO: 75 AAV CLv-M7 843 WO2016065001 SEQ ID NO: 76 AAV CLv-M8 844 WO2016065001 SEQ ID NO: 77 AAV CLv-M9 845 WO2016065001 SEQ ID NO: 78 AAV CHt-P1 846 WO2016065001 SEQ ID NO: 79 AAV CHt-P6 847 WO2016065001 SEQ ID NO: 80 AAV CHt-P8 848 WO2016065001 SEQ ID NO: 81 AAV CHt-6.1 849 WO2016065001 SEQ ID NO: 82 AAV CHt-6.10 850 WO2016065001 SEQ ID NO: 83 AAV CHt-6.5 851 WO2016065001 SEQ ID NO: 84 AAV CHt-6.6 852 WO2016065001 SEQ ID NO: 85 AAV CHt-6.7 853 WO2016065001 SEQ ID NO: 86 AAV CHt-6.8 854 WO2016065001 SEQ ID NO: 87 AAV CSp-8.10 855 WO2016065001 SEQ ID NO: 88 AAV CSp-8.2 856 WO2016065001 SEQ ID NO: 89 AAV CSp-8.4 857 WO2016065001 SEQ ID NO: 90 AAV CSp-8.5 858 WO2016065001 SEQ ID NO: 91 AAV CSp-8.6 859 WO2016065001 SEQ ID NO: 92 AAV CSp-8.7 860 WO2016065001 SEQ ID NO: 93 AAV CSp-8.8 861 WO2016065001 SEQ ID NO: 94 AAV CSp-8.9 862 WO2016065001 SEQ ID NO: 95 AAV CBr-B7.3 863 WO2016065001 SEQ ID NO: 96 AAV CBr-B7.4 864 WO2016065001 SEQ ID NO: 97 AAV3B 865 WO2016065001 SEQ ID NO: 98 AAV4 866 WO2016065001 SEQ ID NO: 99 AAV5 867 WO2016065001 SEQ ID NO: 100 AAVPHP.B 868 WO2015038958 SEQ ID NO: 8 and 13; GenBankALU85156.1 or G2B-26 AAVPHP.B 869 WO2015038958 SEQ ID NO: 9 AAVG2B-13 870 WO2015038958 SEQ ID NO: 12 AAVTH1.1-32 871 WO2015038958 SEQ ID NO: 14 AAVTH1.1-35 872 WO2015038958 SEQ ID NO: 15

Each of the patents, applications and/or publications listed in Table 1 are hereby incorporated by reference in their entirety.

In one embodiment, the AAV serotype may be, or may have a sequence as described in International Patent Publication WO2015038958, the contents of which are herein incorporated by reference in their entirety, such as, but not limited to, AAV9 (SEQ ID NO: 2 and 11 of WO2015038958 or SEQ ID NO: 127 and 126 respectively herein), PHP.B (SEQ ID NO: 8 and 9 of WO2015038958, herein SEQ ID NO: 868 and 869), G2B-13 (SEQ ID NO: 12 of WO2015038958, herein SEQ ID NO: 870), G2B-26 (SEQ ID NO: 13 of WO2015038958, herein SEQ ID NO: 868 and 869), TH1.1-32 (SEQ ID NO: 14 of WO2015038958, herein SEQ ID NO: 871), TH1.1-35 (SEQ ID NO: 15 of WO2015038958, herein SEQ ID NO: 872) or variants thereof. Further, any of the targeting peptides or amino acid inserts described in WO2015038958, may be inserted into any parent AAV serotype, such as, but not limited to, AAV9 (SEQ ID NO: 126 for the DNA sequence and SEQ ID NO: 127 for the amino acid sequence). In one embodiment, the amino acid insert is inserted between amino acids 586-592 of the parent AAV (e.g., AAV9). In another embodiment, the amino acid insert is inserted between amino acids 588-589 of the parent AAV sequence. The amino acid insert may be, but is not limited to, any of the following amino acid sequences, TLAVPFK (SEQ ID NO: 1 of WO2015038958; herein SEQ ID NO: 873), KFPVALT (SEQ ID NO: 3 of WO2015038958, herein SEQ ID NO: 874), LAVPFK (SEQ ID NO: 31 of WO2015038958; herein SEQ ID NO: 875), AVPFK (SEQ ID NO: 32 of WO2015038958; herein SEQ ID NO: 876), VPFK (SEQ ID NO: 33 of WO02015038958; herein SEQ ID NO: 877), TLAVPF (SEQ ID NO: 34 of WO2015038958; herein SEQ ID NO: 878), TLAVP (SEQ ID NO: 35 of WO2015038958; herein SEQ ID NO: 879), TLAV (SEQ ID NO: 36 of WO2015038958; herein SEQ ID NO: 880), SVSKPFL (SEQ ID NO: 28 of WO2015038958; herein SEQ ID NO: 881), FTLTTPK (SEQ ID NO: 29 of WO2015038958; herein SEQ ID NO: 882), MNATKNV (SEQ ID NO: 30 of WO2015038958; herein SEQ ID NO: 883), QSSQTPR (SEQ ID NO: 54 of WO2015038958; herein SEQ ID NO: 884), ILGTGTS (SEQ ID NO: 55 of WO2015038958; herein SEQ ID NO: 885), TRTNPEA (SEQ ID NO: 56 of WO2015038958; herein SEQ ID NO: 886), NGGTSSS (SEQ ID NO:58 of WO2015038958; herein SEQ ID NO:887), or YTLSQGW (SEQ ID NO: 60 of WO2015038958; herein SEQ ID NO: 888). Non-limiting examples of nucleotide sequences that may encode the amino acid inserts include the following, AAGTITCCTGTGGKCGTTGACT (for SEQ ID NO: 3 of WO2015038958; herein SEQ ID NO: 889), ACYTTGGCGGTGCCTITYAAG (SEQ ID NO: 24 and 49 of WO2015038958; herein SEQ ID NO: 890), AGTGTGAGTAAGCCITIITG (SEQ ID NO: 25 of WO2015038958; herein SEQ ID NO. 891), TTACGTTGACGACGCCTAAG (SEQ ID NO: 26 of WO2015038958; herein SEQ ID NO:892), ATGAATGCTACGAAGAATGTG (SEQ ID NO: 27 of WO2015038958; herein SEQ ID NO: 893), CAGTCGTCGCAGACGCCTAGG (SEQ ID NO: 48 of WO2015038958; herein SEQ ID NO: 894), ATTCTGGGGACTCGGTACTTCG (SEQ ID NO: 50) and 52 of WO2015038958; herein SEQ ID NO: 895), ACGCGGACTAATCCTGAGGCT (SEQ ID NO-51 of WO2015038958; herein SEQ ID NO:896), AATGCiGGGGACTAGTAGTTCT (SEQ ID NO: 53 of WO2015038958; herein SEQ ID NO: 897), or TATACTTTGTCGCAGGGTTGG (SEQ ID NO: 59 of WO2015038958, herein SEQ ID NO: 898).

Viral Genome Component: Inverted Terminal Repeats (ITRs)

The AAV particles of the present invention comprise a viral genome with at least one ITR region and a payload region. In one embodiment, the viral genome has two ITRs. These two ITRs flank the payload region at the 5′ and 3′ ends. The ITRs function as origins of replication comprising recognition sites for replication. ITRs comprise sequence regions which can be complementary and symmetrically arranged. ITRs incorporated into viral genomes of the invention may be comprised of naturally occurring polynucleotide sequences or recombinantly derived polynucleotide sequences.

The ITRs may be derived from the same serotype as the capsid, selected from any of the serotypes listed in Table 1, or a derivative thereof. The ITR may be of a different serotype than the capsid. In one embodiment, the AAV particle has more than one ITR, In a non-limiting example, the AAV particle has a viral genome comprising two ITRs. In one embodiment, the ITRs are of the same serotype as one another. In another embodiment, the ITRs are of different serotypes. Non-limiting examples include zero, one or both of the ITRs having the same serotype as the capsid. In one embodiment both ITRs of the viral genome of the AAV particle are AAV2 ITRs.

Independently, each ITR may be about 100 to about 150 nucleotides in length. An ITR may be about 100-105 nucleotides in length, 106-110 nucleotides in length, 111-115 nucleotides in length, 116-120 nucleotides in length, 121-125 nucleotides in length, 126-130 nucleotides in length, 131-135 nucleotides in length, 136-140 nucleotides in length, 141-145 nucleotides in length or 146-150 nucleotides in length. In one embodiment, the ITRs are 140-142 nucleotides in length. Non-limiting examples of ITR length are 102, 140, 141, 142, 145 nucleotides in length, and those having at least 95% identity thereto

Viral Genome Component: Promoters

In one embodiment, the payload region of the viral genome comprises at least one element to enhance the transgene target specificity and expression (See e.g., Powell et al. Viral Expression Cassette Elements to Enhance Transgene Target Specificity and Expression in Gene Therapy, 2015; the contents of which are herein incorporated by reference in its entirety). Non-limiting examples of elements to enhance the transgene target specificity and expression include promoters, endogenous miRNAs, post-transcriptional regulatory elements (PREs, polyadenylation (PolyA) signal sequences and upstream enhancers (USEs), CMV enhancers and introns.

A person skilled in the art may recognize that expression of the polypeptides of the invention in a target cell may require a specific promoter, including but not limited to, a promoter that is species specific, inducible, tissue-specific, or cell cycle-specific (Parr et al., Nat. Med. 3:1145-9 (1997) the contents of which are herein incorporated by reference in their entirety).

In one embodiment, the promoter is deemed to be efficient when it drives expression of the polypeptide(s) encoded in the payload region of the viral genome of the AAV particle.

In one embodiment, the promoter is a promoter deemed to be efficient when it drives expression in the cell being targeted.

In one embodiment, the promoter drives expression of the polypeptides of the invention (e.g., a functional antibody) for a period of time in targeted tissues. Expression driven by a promoter may be for a period of 1 hour, 2, hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 1 week, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 2 weeks, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 3 weeks, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years or more than 10 years. Expression may be for 1-5 hours, 1-12 hours, 1-2 days, 1-5 days, 1-2 weeks, 1-3 weeks, 1-4 weeks, 1-2 months, 1-4 months, 1-6 months, 2-6 months, 3-6 months, 3-9 months, 4-8 months, 6-12 months, 1-2 years, 1-5 years, 2-5 years, 3-6 years, 3-8 years, 4-8 years or 5-10 years.

In one embodiment, the promoter drives expression of the polypeptides of the invention (e.g., a functional antibody) for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 2 years, 3 years 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, 12 years, 13 years, 14 years, 15 years, 16 years, 17 years, 18 years, 19 years, 20 years, 21 years, 22 years, 23 years, 24 years, 25 years, 26 years, 27 years, 28 years, 29 years, 30 years, 31 years, 32 years, 33 years, 34 years, 35 years, 36 years, 37 years, 38 years, 39 years, 40 years, 41 years, 42 years, 43 years, 44 years, 45 years, 46 years, 47 years, 48 years, 49 years, 50 years, 55 years, 60 years, 65 years, or more than 65 years.

Promoters may be naturally occurring or non-naturally occurring. Non-limiting examples of promoters include viral promoters, plant promoters and mammalian promoters. In some embodiments, the promoters may be human promoters. In some embodiments, the promoter may be truncated.

Promoters which drive or promote expression in most tissues include, but are not limited to, human elongation factor 1α-subunit (EF1α), cytomegalovirus (CMV) immediate-early enhancer and/or promoter, chicken β-actin (CBA) and its derivative CAG, β glucuronidase (GUSB), or ubiquitin C (UBC). Tissue-specific expression elements can be used to restrict expression to certain cell types such as, but not limited to, muscle specific promoters, B cell promoters, monocyte promoters, leukocyte promoters, macrophage promoters, pancreatic acinar cell promoters, endothelial cell promoters, lung tissue promoters, astrocyte promoters, or nervous system promoters which can be used to restrict expression to neurons, astrocytes, or oligodendrocytes.

Non-limiting examples of muscle-specific promoters include mammalian muscle creatine kinase (MCK) promoter, mammalian desmin (DES) promoter, mammalian troponin I (TNNI2) promoter, and mammalian skeletal alpha-actin (ASKA) promoter (see, e.g. U.S. Patent Publication US 20110212529, the contents of which are herein incorporated by reference in their entirety).

Non-limiting examples of tissue-specific expression elements for neurons include neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B-chain (PDGF-β), synapsin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca²⁺/calmodulin-dependent protein kinase II (CaM KII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light (NFL) or heavy (NFH), β-globin minigene nβ2, preproenkephalin (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2) promoters. Non-limiting examples of tissue-specific expression elements for astrocytes include glial fibrillary acidic protein (GFAP) and EAAT2 promoters. A non-limiting example of a tissue-specific expression element for oligodendrocytes includes the myelin basic protein (MBP) promoter.

In one embodiment, the promoter may be less than 1 kb. The promoter may have a length of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 501), 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or more than 800 nucleotides. The promoter may have a length between 200-300, 200-400, 200-500, 200-60, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800 or 700-800.

In one embodiment, the promoter may be a combination of two or more components of the same or different starting or parental promoters such as, but not limited to, CMV and CBA, Each component may have a length of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or more than 800. Each component may have a length between 200-300, 200-400, 200-500, 200-600, 200-700), 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800 or 700-800. In one embodiment, the promoter is a combination of a 382 nucleotide CMV-enhancer sequence and a 260 nucleotide CBA-promoter sequence.

In one embodiment, the viral genome comprises a ubiquitous promoter. Non-limiting examples of ubiquitous promoters include CMV, CBA (including derivatives CAG, CBh, etc.), EF-1α, PGK, UBC, GUSB (hGBp), and UCOE (promoter of HNRPA2B1-CBX3). Yu et al. (Molecular Pain 2011, 7-63, the contents of which are herein incorporated by reference in their entirety) evaluated the expression of eGFP under the CAG, EF1α, PGK and UBC promoters in rat DRG cells and primary DRG cells using lentiviral vectors and found that UBC showed weaker expression than the other 3 promoters and only 10-12% glial expression was seen for all promoters Soderblom et al. (E. Neuro 2015; the contents of which are herein incorporated by reference in its entirety) evaluated the expression of eGFP in AAV8 with CMV and UBC promoters and AAV2 with the CMV promoter after injection in the motor cortex. Intranasal administration of a plasmid containing a UBC or EF1a promoter showed a sustained airway expression greater than the expression with the CMV promoter (See e.g., Gill et al., Gene Therapy 2001, Vol. 8, 1539-1546; the contents of which are herein incorporated by reference in their entirety). Husain et al. (Gene Therapy 2009 the contents of which are herein incorporated by reference in its entirety) evaluated an HβH construct with a hGUSB promoter, a HSV-1LAT promoter and an NSE promoter and found that the HβH construct showed weaker expression than NSE in mouse brain. Passini and Wolfe (J. Virol. 2001, 12382-12392, the contents of which are herein incorporated by reference in its entirety) evaluated the long term effects of the HβH vector following an intraventricular injection in neonatal mice and found that there was sustained expression for at least 1 year. Low expression in all brain regions was found by Xu et al. (Gene Therapy 2001, 8, 1323-1332; the contents of which are herein incorporated by reference in their entirety) when NFL and NFH promoters were used as compared to the CMV-lacZ, CMV-luc, EF, GFAP, hENK, nAChR, PPE, PPE+wpre, NSE (0.3 kb), NSE (1.8 kb) and NSE (1.8 kb 4 wpre). Xu et al. found that the promoter activity in descending order was NSE (1.8 kb), EF, NSE (0.3 kb), GFAP, CMV, hENK, PPE, NFL and NFH. NFL is a 650 nucleotide promoter and NFH is a 920 nucleotide promoter which are both absent in the liver but NFH is abundant in the sensory proprioceptive neurons, brain and spinal cord and NFH is present in the heart. Scn8a is a 470 nucleotide promoter which expresses throughout the DRG, spinal cord and brain with particularly high expression seen in the hippocampal neurons and cerebellar Purkinje cells, cortex, thalamus and hypothalamus (See e.g., Drews et al. Identification of evolutionary conserved functional noncoding elements in the promoter region of the sodium channel gene SCN8A, Mamm Genome (2007) 18:723-731; and Raymond et al Expression of Alternatively Spliced Sodium Channel α-subunit genes, Journal of Biological Chemistry (2004) 279(44) 46234-46241; the contents of each of which are herein incorporated by reference in their entireties).

Any of promoters taught by the aforementioned Yu, Soderblom. Gill, Husamin, Passini, Xu, Drews or Raymond may be used in the present inventions.

In one embodiment, the promoter is not cell specific.

In one embodiment, the promoter is a ubiquitin c (UBC) promoter. The UBC promoter may have a size of 300-350 nucleotides. As a non-limiting example, the UBC promoter is 332 nucleotides.

In one embodiment, the promoter is a β-glucuronidase (GUSB) promoter. The CrUSB promoter may have a size of 350-400 nucleotides. As a non-limiting example, the GUSB promoter is 378 nucleotides.

In one embodiment, the promoter is a neurofilament light (NFL) promoter. The NFL promoter may have a size of 600-700 nucleotides. As a non-limiting example, the NFL promoter is 650 nucleotides.

In one embodiment, the promoter is a neurofilament heavy (NFH) promoter. The NFL promoter may have a size of 900-950 nucleotides. As a non-limiting example, the NFH promoter is 920 nucleotides.

In one embodiment, the promoter is a scn8a promoter. The scn8a promoter may have a size of 450-500 nucleotides. As a non-limiting example, the scn8a promoter is 470 nucleotides.

In one embodiment, the promoter is a phosphoglycerate kinase 1 (PGK) promoter.

In one embodiment, the promoter is a chicken β-actin (CBA) promoter.

In one embodiment, the promoter is a cytomegalovirus (CMV) promoter.

In one embodiment, the promoter is a liver or a skeletal muscle promoter. Non-limiting examples of liver promoters include human α-1-antitrypsin (hAAT) and thyroxine binding globulin (TBG). Non-limiting examples of skeletal muscle promoters include Desmin. MCK or synthetic C5-12.

In one embodiment, the promoter is a RNA pol III promoter. As a non-limiting example, the RNA pol III promoter is U6. As a non-limiting example, the RNA pol III promoter is H1.

In one embodiment, the viral genome comprises two promoters. As a non-limiting example, the promoters are an EF1α promoter and a CMV promoter.

In one embodiment, the viral genome comprises an enhancer element, a promoter and/or a 5′UTR intron. The enhancer element, also referred to herein as an “enhancer,” may be, but is not limited to, a CMV enhancer, the promoter may be, but is not limited to, a CMV. CBA. UBC, GUSB, NSE, Synapsin, MeCP2, and GFAP promoter and the 5′UTR/intron may be, but is not limited to, SV40, and CBA-MVM. As a non-limiting example, the enhancer, promoter and/or intron used in combination may be: (1) CMV enhancer. CMV promoter. SV40 5′UTR intron, (2) CMV enhancer, CBA promoter, SV 40 5′UTR intron, (3) CMV enhancer, CBA promoter, CBA-MVM 5′UTR intron; (4) UBC promoter; (5) GUSB promoter; (6) NSF promoter; (7) Synapsin promoter; (8) MeCP2 promoter and (9) GFAP promoter.

In one embodiment, the viral genome comprises an engineered promoter.

In another embodiment, the viral genome comprises a promoter from a naturally expressed protein.

Viral Genome Component: Untranslated Regions (UTRs)

By definition, wild type untranslated regions (UTRs) of a gene are transcribed but not translated. Generally, the 5′ UTR starts at the transcription start site and ends at the start codon and the 3′ UTR starts immediately following the stop codon and continues until the termination signal for transcription.

Features typically found in abundantly expressed genes of specific target organs may be engineered into UTRs to enhance the stability and protein production. As a non-limiting example, a 5′ UTR from mRNA normally expressed in the liver (e.g., albumin, serum amyloid A, Apolipoprotein A/B/E, transferrin, alpha fetoprotein, erythropoietin, or Factor VIII) may be used in the viral genomes of the AAV particles of the invention to enhance expression in hepatic cell lines or liver.

While not wishing to be bound by theory, wild-type 5′ untranslated regions (UTRs) include features which play roles in translation initiation. Kozak sequences, which are commonly known to be involved in the process by which the ribosome initiates translation of many genes, are usually included in 5′ UTRs. Kozak sequences have the consensus CCR(A/G)CCAUGG, where R is a purine (adenine or guanine) three bases upstream of the start codon (ATG), which is followed by another ‘G’.

In one embodiment, the 5′UTR in the viral genome includes a Kozak sequence.

In one embodiment, the 5′UTR in the viral genome does not include a Kozak sequence.

While not wishing to be bound by theory, wild-type 3′ UTRs are known to have stretches of Adenosines and Uridines embedded therein. These AU rich signatures are particularly prevalent in genes with high rates of turnover. Based on their sequence features and functional properties, the AU rich elements (AREs) can be separated into three classes (Chen et al, 1995, the contents of which are herein incorporated by reference in its entirety); Class I AREs, such as, but not limited to, c-Myc and MyoD, contain several dispersed copies of an AUUUA motif within U-rich regions. Class II AREs, such as, but not limited to, GM-CSF and TNF-a, possess two or more overlapping UUAUUUA(U/AXU/A) nonamers. Class III ARES, such as, but not limited to, c-Jun and Myogenin, are less well defined. These U rich regions do not contain an AUUUA motif. Most proteins binding to the AREs are known to destabilize the messenger, whereas members of the ELAV family, most notably HuR, have been documented to increase the stability of mRNA. HuR binds to AREs of all the three classes. Engineering the HuR specific binding sites into the 3′ UTR of nucleic acid molecules will lead to HuR binding and thus, stabilization of the message in vivo.

Introduction, removal or modification of 3′ UTR AU rich elements (AREs) can be used to modulate the stability of polynucleotides. When engineering specific polynucleotides, e.g., payload regions of viral genomes, one or more copies of an ARE can be introduced to make polynucleotides less stable and thereby curtail translation and decrease production of the resultant protein. Likewise, AREs can be identified and removed or mutated to increase the intracellular stability and thus increase translation and production of the resultant protein.

In one embodiment, the 3′ UTR of the viral genome may include an oligo(dT) sequence for templated addition of a poly-A tail.

In one embodiment, the viral genome may include at least one miRNA seed, binding site or full sequence, microRNAs (or miRNA or miR) are 19-25 nucleotide noncoding RNAs that bind to the sites of nucleic acid targets and down-regulate gene expression either by reducing nucleic acid molecule stability or by inhibiting translation. A microRNA sequence comprises a “seed” region, i.e., a sequence in the region of positions 2-8 of the mature microRNA, which sequence has perfect Watson-Crick complementarity to the miRNA target sequence of the nucleic acid.

In one embodiment, the viral genome may be engineered to include, alter or remove at least one miRNA binding site, sequence or seed region.

Any UTR from any gene known in the art may be incorporated into the viral genome of the AAV particle. These UTRs, or portions thereof, may be placed in the same orientation as in the gene from which they were selected or they may be altered in orientation or location. In one embodiment, the UTR used in the viral genome of the AAV particle may be inverted, shortened, lengthened, made with one or more other 5′ UTRs or 3′ UTRs known in the art. As used herein, the term “altered” as it relates to a UTR, means that the UTR has been changed in some way in relation to a reference sequence. For example, a 3′ or 5′ UTR may be altered relative to a wild type or native UTR by the change in orientation or location as taught above or may be altered by the inclusion of additional nucleotides, deletion of nucleotides, swapping or transposition of nucleotides.

In one embodiment, the viral genome of the AAV particle comprises at least one artificial UTRs which is not a variant of a wild type UTR.

In one embodiment, the viral genome of the AAV particle comprises UTRs which have been selected from a family of transcripts whose proteins share a common function, structure, feature or property.

Viral Genome Component: Polyadenylation Sequence

In one embodiment, the viral genome of the AAV particles of the present invention comprise at least one polyadenylation sequence. The viral genome of the AAV particle may comprise a poly adenylation sequence between the 3′ end of the payload coding sequence and the 5′ end of the 3′ITR

In one embodiment, the polyadenylation sequence or “polyA sequence” may range from absent to about 500 nucleotides in length. The polyadenylation sequence may be, but is not limited to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, and 500) nucleotides in length.

In one embodiment, the polyadenylation sequence is 50-100 nucleotides in length.

In one embodiment, the polyadenylation sequence is 50-150 nucleotides in length.

In one embodiment, the polyadenylation sequence is 50-160 nucleotides in length.

In one embodiment, the polyadenylation sequence is 50-200 nucleotides in length.

In one embodiment, the polyadenylation sequence is 60-100 nucleotides in length.

In one embodiment, the polyadenylation sequence is 60-150 nucleotides in length.

In one embodiment, the polyadenylation sequence is 60-160 nucleotides in length.

In one embodiment, the polyadenylation sequence is 60-200) nucleotides in length.

In one embodiment, the polyadenylation sequence is 70-100 nucleotides in length.

In one embodiment, the polyadenylation sequence is 70-150 nucleotides in length.

In one embodiment, the polyadenylation sequence is 70-160 nucleotides in length.

In one embodiment, the polyadenylation sequence is 70-200 nucleotides in length.

In one embodiment, the polyadenylation sequence is 80-100 nucleotides in length.

In one embodiment, the polyadenylation sequence is 80-150 nucleotides in length.

In one embodiment, the polyadenylation sequence is 80-160 nucleotides in length.

In one embodiment, the polyadenylation sequence is 80-200 nucleotides in length.

In one embodiment, the polyadenylation sequence is 90-100 nucleotides in length.

In one embodiment, the polyadenylation sequence is 90-150 nucleotides in length.

In one embodiment, the polyadenylation sequence is 90-160 nucleotides in length.

In one embodiment, the polyadenylation sequence is 90-200 nucleotides in length.

Viral Genome Component: Linkers

Viral genomes of the invention may be engineered with one or more spacer or linker regions to separate coding or non-coding regions.

In one embodiment, the payload region of the AAV particle may optionally encode one or more linker sequences. In some cases, the linker may be a peptide linker that may be used to connect the polypeptides encoded by the payload region (i.e., light and heavy antibody chains during expression). Some peptide linkers may be cleaved after expression to separate heavy and light chain domains, allowing assembly of mature antibodies or antibody fragments. Linker cleavage may be enzymatic. In some cases, linkers comprise an enzymatic cleavage site to facilitate intracellular or extracellular cleavage. Some payload regions encode linkers that interrupt polypeptide synthesis during translation of the linker sequence from an mRNA transcript. Such linkers may facilitate the translation of separate protein domains (e.g., heavy and light chain antibody domains) from a single transcript. In some cases, two or more linkers are encoded by a payload region of the viral genome. Non-limiting examples of linkers that may be encoded by the payload region of an AAV particle viral genome are given in Table 2.

TABLE 2 Linkers Linker No. Description SEQ ID NO L1 Internal ribosome entry site (IRES)  899 L2 Foot and month disease vims 2A (F2A)  900 L3 Porcine teschovirus-1 virus 2A (P2A)  901 L4 Furin cleavage site (F)  902 L5 5xG4S (SEQ ID NO: 9221)  903 L6 1,4-alpha-glucan-branching enzyme CHP L7 1,4-alpha-glucan-branching enzyme  904 L8 1,4-beta-N-acetylmuramidase FKK L9 1,4-beta-N-acetylmuramidase  905 L10 1,4-beta-N-acetylmuramidase  906 L11 1,4-beta-N-acetylmuramidase  907 L12 1,4-beta-N-acetylmuramidase  908 L13 1,4-beta-N-acetylmuramidase  909 L14 1,4-beta-N-acetylmuramidase  910 L15 1,4-beta-N-acetylmuramidase  911 L16 1,4-beta-N-acetylmuramidase  912 L17 1,4-beta-N-acetylmuramidase  913 L18 1,4-beta-N-acetylmuramidase  914 L19 150aa long hypothetical transcriptional regulator  915 L20 150aa long hypothetical transcriptional regulator  916 L21 1-deoxy-D-xylulose 5-phosphate reductoisomerase  917 L22 1-deoxy-D-xylulose 5-phosphate reductoisomerase  918 L23 1-deoxy-D-xylulose 5-phosphate reductoisomerase  919 L24 1-deoxy-D-xylulose 5-phosphate reductoisomerase  920 L25 235aa long hypothetical biotin-[acetyl-CoA-carboxylase] ligase  921 L26 235aa long hypothetical biotin-[acetyl-CoA-carboxylase] ligase  922 L27 235aa long hypothetical biotin-[acetyl-CoA-carboxylase] ligase  923 L28 2-dehydropantoate 2-reductase  924 L29 2-dehydropantoate 2-reductase  925 L30 2-dehydropantoate 2-reductase  926 L31 2-dehydropantoate 2-reductase  927 L32 2-dehydropantoate 2-reductase  928 L33 2-dehydropantoate 2-reductase  929 L34 2-dehydropantoate 2-reductase, putative  930 L35 2-dehydropantoate 2-reductase, putative  931 L36 4-alpha-glucanotransferase  932 L37 4-alpha-glucanotransferase  933 L38 4-alpha-glucanotransferase  934 L39 4-diphosphocytidyl-2C-methyl-D-erythritol kinase HAA L40 4-diphosphocytidyl-2C-methyl-D-erythritol kinase  935 L41 4-diphosphocytidyl-2C-methyl-D-erythritol kinase  936 L42 4-diphosphocytidyl-2C-methyl-D-erythritol kinase  937 L43 4-diphosphocytidyl-2C-methyl-D-erythritol kinase  938 L44 4-hydroxyphenylpyruvate dioxygenase  939 L45 5-13 amino acids from the N termini of human Ck and CH1 domains linker  940 L46 5-13 amino acids from the N termini of human Ck and CH1 domains linker ERK L47 5-13 amino acids from the N termini of human Ck and CH1 domains linker  941 L48 5-13 amino acids from the N termini of human Ck and CH1 domains linker  942 L49 5-13 amino acids from the N termini of human Ck and CH1 domains linker  943 L50 5-13 amino acids from the N termini of human Ck and CH1 domains linker  944 L51 5′-exonuclease  945 L52 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase ARL L53 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase  946 L54 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase  947 L55 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase  948 L56 5-methyltetrahydropteroyltriglutamate--homocysteinemethyltransferase  949 L57 5′-nucleotidase  950 L58 5′-nucleotidase  951 L59 5′-nucleotidase  952 L60 5′-nucleotidase  953 L61 704aa long hypothetical glycosyltransferase  954 L62 704aa long hypothetical glycosyltransferase  955 L63 80 kDa nuclear cap binding protein  956 L64 80 kDa nuclear cap binding protein  957 L65 80 kDa nuclear cap binding protein  958 L66 80 kDa nuclear cap binding protein  959 L67 Acetaldehyde dehydrogenase (acylating)  960 L68 Acetaldehyde dehydrogenase (acylating)  961 L69 Acetolactate synthase isozyme III small subunit  962 L70 Acetylcholine receptor protein, alpha chain  963 L71 Acetylcholine receptor protein, beta chain  964 L72 Aconitate hydratase 2  965 L73 Aconitate hydratase 2  966 L74 Aconitate hydratase 2  967 L75 Aconitate hydratase 2  968 L76 Aconitate hydratase 2  969 L77 Acriflavine resistance protein B DWY L78 Acriflavine resistance protein B GGS L79 Acriflavine resistance protein B IDQ L80 Acriflavine resistance protein B NKV L81 Acriflavine resistance protein B SEA L82 Acriflavine resistance protein B  970 L83 Acriflavine resistance protein B  971 L84 Acriflavine resistance protein B  972 L85 Acriflavine resistance protein B  973 L86 Acriflavine resistance protein B  974 L87 Acriflavine resistance protein B  975 L88 Acriflavine resistance protein B  976 L89 Acriflavine resistance protein B  977 L90 Acriflavine resistance protein B  978 L91 Acriflavine resistance protein B  979 L92 Acriflavine resistance protein B  980 L93 Acriflavine resistance protein B  981 L94 Acriflavine resistance protein B  982 L95 Acriflavine resistance protein B  983 L96 Acriflavine resistance protein B  984 L97 Acriflavine resistance protein B  985 L98 Acriflavine resistance protein B  986 L99 Acriflavine resistance protein B  987 L100 Acriflavine resistance protein B  988 L101 Acriflavine resistance protein B  989 L102 Acriflavine resistance protein B  990 L103 Acriflavine resistance protein B  991 L104 Acriflavine resistance protein B  992 L105 Acriflavine resistance protein B  993 L106 Acyl-CoA thioesterase II  994 L107 Acyl-CoA thioesterase II  995 L108 Acyl-CoA thioesterase II  996 L109 Acyl-CoA thioesterase II  997 L110 Acyl-CoA thioesterase II  998 L111 Acyl-coenzyme A thioesterase 4  999 L112 Acyl-coenzyme A thioesterase 4 1000 L113 Acyl-coenzyme A thioesterase 4 1001 L114 Acyl-coenzyme A thioesterase 4 1002 L115 Acyl-coenzyme A thioesterase 4 1003 L116 Adenine glycosylase 1004 L117 Adenylate cyclase 1005 L118 Aerolysin 1006 L119 Aerolysin 1007 L120 Agglutinin DWK L121 Agglutinin isolectin 1 1008 L122 Agglutinin isolectin 1 1009 L123 Aldehyde ferredoxin oxidoreductase 1010 L124 Aldehyde oxidoreductase 1011 L125 Aldehyde oxidoreductase 1012 L126 Aldehyde oxidoreductase 1013 L127 Aldehyde oxidoreductase 1014 L128 Aldehyde oxidoreductase 1015 L129 Alkyl hydroperoxide reductase subunit F 1016 L130 Alkyl hydroperoxide reductase subunit F 1017 L131 Alkyl hydroperoxide reductase subunit F 1018 L132 Alkyl hydroperoxide reductase subunit F 1019 L133 Alkyl hydroperoxide reductase subunit F 1020 L134 Alkyl hydroperoxide reductase subunit F 1021 L135 Alkyl hydroperoxide reductase subunit F 1022 L136 Alkyl hydroperoxide reductase subunit F 1023 L137 Alkyl hydroperoxide reductase subunit F 1024 L138 Alkyl hydroperoxide reductase subunit F 1025 L139 Allantoicase 1026 L140 Allantoicase 1027 L141 Alliin lyase 1 SAV L142 Alliin lyase 1 1028 L143 Alliin lyase 1 1029 L144 Alliin lyase 1 1030 L145 Alliin lyase 1 1031 L146 Alpha amylase 1032 L147 Alpha amylase 1033 L148 Alpha-actinin 1 1034 L149 Alpha-actinin 1 1035 L150 Alpha-adaptin C 1036 L151 Alpha-amylase 1037 L152 Alpha-glucuronidase LSD L153 Alpha-glucuronidase 1038 L154 Alpha-glucuronidase 1039 L155 Alpha-glucuronidase 1040 L156 Alpha-glucuronidase 1041 L157 Alpha-glucuronidase 1042 L158 Alpha-glucuronidase 1043 L159 Alpha-glucuronidase 1044 L160 Alpha-glucuronidase 1045 L161 Alpha-glucuronidase 1046 L162 Alpha-glucuronidase 1047 L163 Alpha-glucuronidase 1048 L164 Alpha-glucuronidase 1049 L165 Alpha-glucuronidase 1050 L166 Alpha-glucuronidase 1051 L167 Alpha-glucuronidase 1052 L168 Alpha-glucuronidase 1053 L169 Alpha-glucuronidase 1054 L170 Alpha-glucuronidase 1055 L171 Alpha-glucuronidase 1056 L172 Alpha-glucuronidase 1057 L173 Alpha-glucuronidase 1058 L174 Alpha-L-arabinofuranosidase B 1059 L175 Alpha-mannosidase 1060 L176 Alr2269 protein 1061 L177 AMP nucleosidase 1062 L178 AMP nucleosidase 1063 L179 AMP nucleosidase 1064 L180 Angiopoietin-1 receptor DAG L181 Angiopoietin-1 receptor NSG L182 Angiopoietin-1 receptor TSA L183 Angiopoietin-1 receptor VPR L184 Angiopoietin-1 receptor 1065 L185 Angiopoietin-1 receptor 1066 L186 Angiopoietin-1 receptor 1067 L187 Angiopoietin-1 receptor 1068 L188 Angiopoietin-1 receptor 1069 L189 Angiopoietin-1 receptor 1070 L190 Angiopoietin-1 receptor 1071 L191 Angiopoietin-1 receptor 1072 L192 Angiopoietin-1 receptor 1073 L193 Angiopoietin-1 receptor 1074 L194 Angiopoietin-1 receptor 1075 L195 Angiopoietin-1 receptor 1076 L196 Angiopoietin-1 receptor 1077 L197 Angiopoietin-1 receptor 1078 L198 Angiopoietin-1 receptor 1079 L199 Angiopoietin-1 receptor 1080 L200 Angiopoietin-1 receptor 1081 L201 Angiopoietin-1 receptor 1082 L202 Angiopoietin-1 receptor 1083 L203 Angiopoietin-1 receptor 1084 L204 Angiopoietin-1 receptor 1085 L205 Annexin A2 QNK L206 Annexin A2 1086 L207 Annexin A2 1087 L208 Anthranilate phosphoribosyltransferase 1088 L209 AP-2 complex subunit beta-2 1089 L210 Archaeosine tRNA-guanine transglycosylase LGI L211 Archaeosine tRNA-guanine transglycosylase 1090 L212 Archaeosine tRNA-guanine transglycosylase 1091 L213 Archaeosine tRNA-guanine transglycosylase 1092 L214 Archaeosine tRNA-guanine transglycosylase 1093 L215 Archaeosine tRNA-guanine transglycosylase 1094 L216 Archaeosine tRNA-guanine transglycosylase 1095 L217 Archaeosine tRNA-guanine transglycosylase 1096 L218 Archeal exosome RNA binding protein rrp4 1097 L219 Archeal exosome RNA binding protein rrp4 1098 L220 Archeal exosome RNA binding protein rrp4 1099 L221 Arginyl-tRNA synthetase IDY L222 Arginyl-tRNA synthetase 1100 L223 Arginyl-tRNA synthetase 1101 L224 Arginyl-tRNA synthetase 1102 L225 Arrestin 1103 L226 Arrestin 1104 L227 Arsenite oxidase 1105 L228 Artificial linker PGS L229 Artificial linker ATK L230 Artificial linker ASK L231 Artificial linker 1106 L232 Artificial tinker 1107 L233 Artificial linker 1108 L234 Artificial linker 1109 L235 Artificial tinker 1110 L236 Artificial linker 1111 L237 ATP phosphoribosyltransferase ANR L238 ATP-dependent DNA helicase YDP L239 ATP-dependent DNA helicase 1112 L240 ATP-dependent DNA helicase 1113 L241 ATP-dependent DNA helicase 1114 L242 ATP-dependent DNA helicase 1115 L243 ATP-dependent DNA helicase 1116 L244 ATP-dependent DNA helicase 1117 L245 ATP-dependent DNA helicase 1118 L246 ATP-dependent DNA helicase 1119 L247 AT-rich DNA-binding protein 1120 L248 AT-rich DNA-binding protein 1121 L249 Axonin-1 DEG L250 Axonin-1 ECF L251 Axonin-1 1122 L252 Axonin-1 1123 L253 Axonin-1 1124 L254 Axonin-1 1125 L255 Axonin-1 1126 L256 Axonin-1 1127 L257 Axonin-1 1128 L258 Bacilysin biosynthesis protein BacB 1129 L259 Bacilysin biosynthesis protein BacB 1130 L260 Bacilysin biosynthesis protein BacB 1131 L261 Bacilysin biosynthesis protein BacB 1132 L262 Bacilysin biosynthesis protein BacB 1133 L263 Bacteriophage Mu transposase 1134 L264 Bacteriophage Mu transposase 1135 L265 Benzoyl-CoA-dihydrodiol lyase 1136 L266 Benzoyl-CoA-dihydrodiol lyase 1137 L267 Benzoyl-CoA-dihydrodiol lyase 1138 L268 Benzoyl-CoA-dihydrodiol lyase 1139 L269 Benzoyl-CoA-dihydrodiol lyase 1140 L270 Benzoylformate decarboxylase 1141 L271 Benzoylformate decarboxylase 1142 L272 Benzoylformate decarboxylase 1143 L273 Beta-amylase 1144 L274 Beta-galactosidase AIS L275 Beta-galactosidase 1145 L276 Beta-galactosidase 1146 L277 Beta-galactosidase 1147 L278 Beta-galactosidase 1148 L279 Beta-galactosidase 1149 L280 Beta-galactosidase 1150 L281 Beta-galactosidase 1151 L282 Beta-galactosidase 1152 L283 Beta-galactosidase 1153 L284 Beta-galactosidase 1154 L285 Beta-galactosidase 1155 L286 Beta-galactosidase 1156 L287 Beta-galactosidase 1157 L288 Beta-galactosidase 1158 L289 Beta-galactosidase 1159 L290 Beta-galactosidase 1160 L291 Beta-galactosidase 1161 L292 Beta-galactosidase 1162 L293 Beta-galactosidase 1163 L294 Beta-galactosidase 1164 L295 Beta-galactosidase 1165 L296 Beta-galactosidase 1166 L297 Beta-N-acetylhexosaminidase QRE L298 Beta-N-acetylhexosaminidase 1167 L299 Beta-N-acetylhexosaminidase 1168 L300 Beta-N-acetylhexosaminidase 1169 L301 Bifunctional NMN adenylyltransferase/Nudix hydrolase 1170 L302 Bifunctional purine biosynthesis protein PURH 1171 L303 Biliverdin reductase A EHV L304 Biliverdin reductase A LME L305 Biliverdin reductase A 1172 L306 Biliverdin reductase A 1173 L307 Biodegradative arginine decarboxylase TVQ L308 Biodegradative arginine decarboxylase 1174 L309 Biodegradative arginine decarboxylase 1175 L310 Biodegradative arginine decarboxylase 1176 L311 Biodegradative arginine decarboxylase 1177 L312 Biodegradative arginine decarboxylase 1178 L313 Biodegradative arginine decarboxylase 1179 L314 Biodegradative arginine decarboxylase 1180 L315 Biodegradative arginine decarboxylase 1181 L316 Biodegradative arginine decarboxylase 1182 L317 Biodegradative arginine decarboxylase 1183 L318 Biodegradative arginine decarboxylase 1184 L319 Biodegradative arginine decarboxylase 1185 L320 Biotin carboxylase 1186 L321 Bowman-Birk trypsin inhibitor 1187 L322 Bpt4 gene 59 helicase assembly protein KQI L323 BRCA1-associated RING domain protein 1 1188 L324 BRCA1-associated RING domain protein 1 1189 L325 BRCA1-associated RING domain protein 1 1190 L326 Breast cancer 2 1191 L327 Breast cancer 2 1192 L328 Breast cancer 2 1193 L329 Breast cancer 2 1194 L330 Breast cancer 2 1195 L331 Breast cancer 2 1196 L332 Butyrate response factor 2 1197 L333 C4b-binding protein YKR L334 C4b-binding protein 1198 L335 C5a peptidase 1199 L336 C5a peptidase 1200 L337 C5a peptidase 1201 L338 C5a peptidase 1202 L339 C5a peptidase 1203 L340 C5a peptidase 1204 L341 C5a peptidase 1205 L342 C5a peptidase 1206 L343 C5a peptidase 1207 L344 C5a peptidase 1208 L345 C5a peptidase 1209 L346 C5a peptidase 1210 L347 C5a peptidase 1211 L348 Calcium-binding protein 1212 L349 CarA 1213 L350 CarA 1214 L351 Carbamoyl phosphate synthetase (small chain) 1215 L352 Carbamoyl phosphate synthetase (small chain) 1216 L353 Carbamoyl phosphate synthetase (small chain) 1217 L354 Carbamoyl phosphate synthetase (small chain) 1218 L355 Carbamoyl phosphate synthetase (small chain) 1219 L356 Carbon monoxide dehydrogenase/acetyl-CoA synthase subunitalpha 1220 L357 Carboxypeptidase Gp180 residues 503-882 HRG L358 Catabolite activation-like protein 1221 L359 Catabolite activation-like protein 1222 L360 Catechol 2,3-dioxygenase 1223 L361 Cation-independent mannose 6-phosphate receptor 1224 L362 CD3 epsilon and gamma ectodomain fragment complex 1225 L363 CD3 epsilon and gamma ectodomain fragment complex 1226 L364 Cell filamentation protein SNP L365 Cell filamentation protein 1227 L366 Cell filamentation protein 1228 L367 Cellular coagulation factor XIII zymogen DIT L368 Cellular coagulation factor XIII zymogen NSD L369 Cellular coagulation factor XIII zymogen TDT L370 Cellular coagulation factor XIII zymogen 1229 L371 Cellular coagulation factor XIII zymogen 1230 L372 Cellular coagulation factor XIII zymogen 1231 L373 Cellular coagulation factor XIII zymogen 1232 L374 Cellular coagulation factor XIII zymogen 1233 L375 Cellular coagulation factor XIII zymogen 1234 L376 Cellular coagulation factor XIII zymogen 1235 L377 Cellular coagulation factor XIII zymogen 1236 L378 Cellular coagulation factor XIII zymogen 1237 L379 Cellular coagulation factor XIII zymogen 1238 L380 Cellular coagulation factor XIII zymogen 1239 L381 Cellular coagulation factor XIII zymogen 1240 L382 Cellular coagulation factor XIII zymogen 1241 L383 Cellular coagulation factor XIII zymogen 1242 L384 Cellular coagulation factor XIII zymogen 1243 L385 Cellular coagulation factor XIII zymogen 1244 L386 Cellular coagulation factor XIII zymogen 1245 L387 Cellular coagulation factor XIII zymogen 1246 L388 Cellular coagulation factor XIII zymogen 1247 L389 Cellulase 1248 L390 Cellulase 1249 L391 Cellulase 1250 L392 Cellulase 1251 L393 Cellulase 1252 L394 Cellulase 1253 L395 Cellulase 1254 L396 Cellulase 1255 L397 Cellulase 1256 L398 Cellulase linker 1257 L399 Cellulase linker 1258 L400 Cellulase linker 1259 L401 Cellulase linker 1260 L402 Chaperone protein FimC KLR L403 Chaperone protein FimC QAA L404 Chaperone protein FimC 1261 L405 Chaperone protein FimC 1262 L406 Chaperone protein HscB RHP L407 Chaperone protein HscB 1263 L408 CheB methylesterase 1264 L409 CheB methylesterase 1265 L410 CheB methylesterase 1266 L411 Chelatase, putative 1267 L412 Chemotaxis receptor methyltransferase cheR 1268 L413 Chemotaxis receptor methyltransferase cheR 1269 L414 Chemotaxis receptor methyltransferase cheR 1270 L415 Cholesterol oxidase 1271 L416 Cholesterol oxidase 1272 L417 Cholesterol oxidase 1273 L418 Cholesterol oxidase 1274 L419 Cholesterol oxidase 1275 L420 Cholesterol oxidase 1276 L421 Cholesterol oxidase 1277 L422 Cholesterol oxidase 1278 L423 Cholesterol oxidase 1279 L424 Cholesterol oxidase 1280 L425 Cholesterol oxidase 1281 L426 Cholesterol oxidase 1282 L427 Chromatin structure-remodeling complex protein RSC4 KNL L428 Chromatin structure-remodeling complex protein RSC4 1283 L429 Chromatin structure-remodeling complex protein RSC4 1284 L430 Chromatin structure-remodeling complex protein RSC4 1285 L431 Chromodomain-helicase-DNA-binding protein 1 1286 L432 Chromodomain-helicase-DNA-binding protein 1 1287 L433 Cleavable disulfide 1288 L434 Cleavable disulfide 1289 L435 Cleavable disulfide 1290 L436 Cleavable disulfide 1291 L437 Cleavable disulfide 1292 L438 Cleavable disulfide 1293 L439 Cleavable disulfide 1294 L440 Cleavable disulfide 1295 L441 Cleavable disulfide 1296 L442 Cleavable disulfide 1297 L443 Cleavable disulfide 1298 L444 Colicin Ia 1299 L445 Collagen adhesin 1300 L446 Complement C3 beta chain 1301 L447 Complement C3 beta cliain 1302 L448 Complement C3 beta chain 1303 L449 Complement C3 beta cliain 1304 L450 Complement decay-accelerating factor EIY L451 Complement factor H KRP L452 Complement receptor type 2 1305 L453 Conserved hypothetical protein 1306 L454 Conserved hypothetical protein MTH1747 DIR L455 Conserved hypothetical protein MTH1747 1307 L456 Conserved hypothetical protein MTH1747 1308 L457 Conserved hypothetical protein MTH1747 1309 L458 Conserved hypothetical protein MTH1747 1310 L459 Conserved hypothetical protein MTH1747 1311 L460 Conserved hypothetical protein MTH1747 1312 L461 Conserved hypothetical protein MTH1747 1313 L462 Conserved protein (MTH177) 1314 L463 Creatine amidinohydrolase 1315 L464 Cruciferin 1316 L465 Cruciferin 1317 L466 Cruciferin 1318 L467 Cruciferin 1319 L468 Cruciferin 1320 L469 Cruciferin 1321 L470 Cruciferin 1322 L471 CSL3 1323 L472 CSL3 1324 L473 CTP synthase 1325 L474 CTP synthase 1326 L475 Cullin homolog HKN L476 Cullin homolog 1327 L477 Cullin homolog 1328 L478 Cullin homolog 1329 L479 Cullin homolog 1330 L480 Cullin homolog 1331 L481 Cyclin A2 1332 L482 Cysteine-rich secretory protein 1333 L483 Cytidine deaminase 1334 L484 Cytidine deaminase 1335 L485 Cytidine deaminase 1336 L486 Cytochrome b-c1 complex subunit Rieske, mitochondrial 1337 L487 Cytochrome c oxidase subunit 2 QAV L488 Cytochrome c oxidase subunit 2 1338 L489 Cytochrome c oxidase subunit 2 1339 L490 Cytochrome c oxidase subunit 2 1340 L491 Cytochrome c oxidase subunit 2 1341 L492 Cytochrome c4 GGK L493 Cytochrome c4 QGM L494 D-aminopeptidase 1342 L495 DDMC 1343 L496 DDMC 1344 L497 Deltex protein 1345 L498 Deoxyuridine 5′-triphosphate nucleotidohydrolase 1346 L499 Diaminopimelate epimerase 1347 L500 Diaminopimelate epimerase 1348 L501 Diaminopimelate epimerase 1349 L502 Di-heme peroxidase SGC L503 Di-heme peroxidase 1350 L504 Dihydropyrimidine dehydrogenase 1351 L505 Dihydropyrimidine dehydrogenase 1352 L506 Dihydropyrimidine dehydrogenase 1353 L507 Dihydropyrimidine dehydrogenase 1354 L508 Dihydropyrimidine dehydrogenase 1355 L509 Dihydropyrimidine dehydrogenase 1356 L510 Dihydropyrimidine dehydrogenase 1357 L511 Dihydropyrimidine dehydrogenase 1358 L512 Dihydropyrimidine dehydrogenase 1359 L513 Dihydropyrimidine dehydrogenase 1360 L514 Dihydropyrimidine dehydrogenase 1361 L515 Dihydropyrimidine dehydrogenase 1362 L516 Dihydropyrimidine dehydrogenase 1363 L517 Dihydropyrimidine dehydrogenase 1364 L518 Dihydropyrimidine dehydrogenase 1365 L519 Dihydropyrimidine dehydrogenase 1366 L520 Dihydropyrimidine dehydrogenase 1367 L521 Dihydropyrimidine dehydrogenase 1368 L522 Dihydropyrimidine dehydrogenase 1369 L523 Dihydropyrimidine dehydrogenase 1370 L524 Dihydropyrimidine dehydrogenase 1371 L525 Dihydropyrimidine dehydrogenase 1372 L526 Dihydropyrimidine dehydrogenase 1373 L527 Dihydropyrimidine dehydrogenase 1374 L528 Dihydropyrimidine dehydrogenase 1375 L529 Dihydropyrimidine dehydrogenase 1376 L530 Dihydropyrimidine dehydrogenase 1377 L531 Dihydropyrimidine dehydrogenase 1378 L532 Dihydropyrimidine dehydrogenase 1379 L533 Dihydropyrimidine dehydrogenase 1380 L534 Dihydropyrimidine dehydrogenase 1381 L535 Discoidin-1 subunit A 1382 L536 Discoidin-1 subunit A 1383 L537 Discoidin-1 subunit A 1384 L538 Dissimilatory copper-containing nitritereductase 1385 L539 D-lactate dehydrogenase DTF L540 D-lactate dehydrogenase 1386 L541 D-lactate dehydrogenase 1387 L542 D-lactate dehydrogenase 1388 L543 D-lactate dehydrogenase 1389 L544 D-lactate dehydrogenase 1390 L545 D-lactate dehydrogenase 1391 L546 DNA damage-binding protein 1 LCA L547 DNA damage-binding protein 1 1392 L548 DNA damage-binding protein 1 1393 L549 DNA damage-binding protein 1 1394 L550 DNA damage-binding protein 1 1395 L551 DNA damage-binding protein 1 1396 L552 DNA damage-binding protein 1 1397 L553 DNA damage-binding protein 1 1398 L554 DNA damage-binding protein 1 1399 L555 DNA damage-binding protein 1 1400 L556 DNA damage-binding protein 1 1401 L557 DNA damage-binding protein 1 1402 L558 DNA damage-binding protein 1 1403 L559 DNA damage-binding protein 1 1404 L560 DNA damage-binding protein 1 1405 L561 DNA damage-binding protein 1 1406 L562 DNA damage-binding protein 1 1407 L563 DNA damage-binding protein 1 1408 L564 DNA damage-binding protein 1 1409 L565 DNA damage-binding protein 1 1410 L566 DNA damage-binding protein 1 1411 L567 DNA damage-binding protein 1 1412 L568 DNA damage-binding protein 1 1413 L569 DNA gyrase B ALS L570 DNA gyrase B 1414 L571 DNA gyrase B 1415 L572 DNA gyrase B 1416 L573 DNA gyrase B 1417 L574 DNA gyrase B 1418 L575 DNA gyrase B 1419 L576 DNA gyrase B 1420 L577 DNA gyrase B 1421 L578 DNA gyrase B 1422 L579 DNA gyrase B 1423 L580 DNA gyrase B 1424 L581 DNA ligase 1425 L582 DNA ligase 1426 L583 DNA ligase 1427 L584 DNA ligase 1428 L585 DNA ligase 1429 L586 DNA mismatch repair protein MutS MDA L587 DNA mismatch repair protein MutS SII L588 DNA mismatch repair protein MutS 1430 L589 DNA mismatch repair protein MutS 1431 L590 DNA mismatch repair protein MutS 1432 L591 DNA mismatch repair protein MutS 1433 L592 DNA mismatch repair protein MutS 1434 L593 DNA polymerase FSP L594 DNA polymerase RQF L595 DNA polymerase 1435 L596 DNA polymerase 1436 L597 DNA polymerase 1437 L598 DNA polymerase 1438 L599 DNA polymerase 1439 L600 DNA polymerase 1440 L601 DNA polymerase 1441 L602 DNA polymerase 1442 L603 DNA polymerase alpha subunit B 1443 L604 DNA polymerase alpha subunit B 1444 L605 DNA polymerase alpha subunit B 1445 L606 DNA polymerase alpha subunit B 1446 L607 DNA polymerase alpha subunit B 1447 L608 DNA polymerase alpha subunit B 1448 L609 DNA polymerase alpha subunit B 1449 L610 DNA polymerase alpha subunit B 1450 L611 DNA polymerase alpha subunit B 1451 L612 DNA polymerase alpha subunit B 1452 L613 DNA polymerase eta ALS L614 DNA polymerase eta 1453 L615 DNA polymerase eta 1454 L616 DNA polymerase eta 1455 L617 DNA polymerase eta 1456 L618 DNA polymerase eta 1457 L619 DNA polymerase I AGV L620 DNA polymerase I ELE L621 DNA polymerase I 1458 L622 DNA primase DHK L623 DNA primase 1459 L624 DNA primase 1460 L625 DNA primase 1461 L626 DNA primase 1462 L627 DNA primase 1463 L628 DNA primase 1464 L629 DNA primase 1465 L630 DNA primase/helicase AGY L631 DNA primase/helicase 1466 L632 DNA primase/helicase 1467 L633 DNA primase/helicase 1468 L634 DNA primase/helicase 1469 L635 DNA primase/helicase 1470 L630 DNA primase/helicase 1471 L637 DNA primase/helicase 1472 L638 DNA primase/helicase 1473 L639 DNA primase/helicase 1474 L640 DNA primase/helicase 1475 L641 DNA topoisomerase 2 EES L642 DNA topoisomerase 2 IPI L643 DNA topoisomerase 2 KEL L644 DNA topoisomerase 2 1476 L645 DNA topoisomerase 2 1477 L646 DNA topoisomerase 2 1478 L647 DNA topoisomerase 2 1479 L648 DNA topoisomerase 2 1480 L649 DNA topoisomerase 2 1481 L650 DNA topoisomerase 2 1482 L651 DNA topoisomerase 2 1483 L652 DNA topoisomerase 2 1484 L653 DNA topoisomerase I 1485 L654 DNA topoisomerase I 1486 L655 DNA topoisomerase I 1487 L656 DNA topoisomerase II, alpha isozyme PDL L657 DNA topoisomerase II, alpha isozyme 1488 L658 DNA topoisomerase II, alpha isozyme 1489 L659 DNA topoisomerase II, alpha isozyme 1490 L660 DNA topoisomerase II, alpha isozyme 1491 L661 DNA topoisomerase II, alpha isozyme 1492 L662 DNA topoisomerase II, alpha isozyme 1493 L663 DNA topoisomerase II, alpha isozyme 1494 L664 DNA topoisomerase II, alpha isozyme 1495 L665 DNA topoisomerase VI A subunit 1496 L666 DNA topoisomerase VI A subunit 1497 L667 DNA topoisomerase VI A subunit 1498 L668 DNA topoisomerase VI A subunit 1499 L669 DNA topoisomerase VI A subunit 1500 L670 DNA topoisomerase VI A subunit 1501 L671 DNA-3-methyladenine glycosylase 2 1502 L672 DNA-binding response regulator MtrA 1503 L673 DNA-directed RNA polymerase beta chain 1504 L674 DNA-directed RNA polymerase beta chain 1505 L675 DNA-directed RNA polymerase beta chain 1506 L676 DNA-directed RNA polymerase beta chain 1507 L677 DNA-directed RNA polymerase beta chain 1508 L678 DNA-directed RNA polymerase beta chain 1509 L679 DNA-directed RNA polymerase beta chain 1510 L680 DNA-directed RNA polymerase beta chain 1511 L681 DNA-directed RNA polymerase II 14.2 kDa polypeptide 1512 L682 DNA-directed RNA polymerase II 14.2 kDa polypeptide 1513 L683 DNA-directed RNA polymerase, subunit E′ (rpoe1) 1514 L684 DNA-directed RNA polymerase, subunit E′ (rpoe1) 1515 L685 DNA-directed RNA polymerases I, II, and III 27 kDa polypeptide IIP L686 DNA-directed RNA polymerases I, II, and III 27 kDa polypeptide 1516 L687 DNA-directed RNA polymerases I, II, and III 27 kDa polypeptide 1517 L688 DNA-directed RNA polymerases I, II, and III 27 kDa polypeptide 1518 L689 DNA-directed RNA polymerases I, II, and III 27 kDa polypeptide 1519 L690 Drosophila neuroglian 1520 L691 Dystroglycan 1521 L692 Dystrophin 1522 L693 Dystrophin 1523 L694 Dystrophin 1524 L695 Dystrophin 1525 L696 Dystrophin 1526 L697 Dystrophin 1527 L698 Dystrophin 1528 L699 E2A DNA-binding protein 1529 L700 E2A DNA-binding protein 1530 L701 E3 sumo-protein ligase SIZ1 1531 L702 E3 sumo-protein ligase SIZ1 1532 L703 E3 sumo-protein ligase SIZ1 1533 L704 Early switch protein xol-l 2.2k splice form 1534 L705 EGF-like module containing mucin-like hormonereceptor-like 2 precursor 1535 L706 EGF-like module containing mucin-like hormonereceptor-like 2 precursor 1536 L707 Elongation factor 1-gamma 1 1537 L708 Elongation factor 1-gamma 1 1538 L709 Elongation factor g 1539 L710 Elongation factor G 1540 L711 Elongation factor G 1541 L712 Elongation factor G 1542 L713 Elongation factor G 1543 L714 Elongation factor G 1544 L715 Elongation factor G 1545 L716 Elongation factor G 1546 L717 Elongation factor G 1547 L718 Elongation factor G 1548 L719 Elongation factor P 1549 L720 Elongation factor Ts 1550 L721 Elongation factor Ts 1551 L722 Elongation factor Ts 1552 L723 Elongation factor Tu (ef-Tu) 1553 L724 Endoglucanase 1554 L725 Endonuclease PI-SceI 1555 L726 Endonuclease PI-SceI 1556 L727 Endonuclease PI-SceI 1557 L728 Endonuclease PI-SceI 1558 L729 Endonuclease PI-SceI 1559 L730 Endonuclease PI-SceI 1560 L731 Endonuclease PI-SceI 1561 L732 Endonuclease PI-SceI 1562 L733 Endonuclease PI-SceI 1563 L734 Enterobactin synthetase component F 1564 L735 Enterobactin synthetase component F 1565 L736 Enterobactin synthetase component F 1566 L737 Enterobactin synthetase component F 1567 L738 Enterobactin synthetase component F 1568 L739 Enterobactin synthetase component F 1569 L740 Enterobactin synthetase component F 1570 L741 Enterobactin synthetase component F 1571 L742 Enterobactin synthetase component F 1572 L743 Enterochelin esterase 1573 L744 Epo receptor EVV L745 Epo receptor 1574 L746 Erythrocyte binding antigen region II 1575 L747 Erythrocyte binding antigen region II 1576 L748 Erythrocyte binding antigen region II 1577 L749 Erythrocyte binding antigen region II 1578 L750 Erythrocyte binding antigen region II 1579 L751 E-selectin 1580 L752 Esterase EstA SAP L753 Esterase EstA 1581 L754 Esterase EstA 1582 L755 Eukaryotic peptide chain release factor GTP-binding subunit 1583 L756 Exonuclease I RQP L757 Exonuclease I 1584 L758 FascIclIn I SDP L759 FascIclIn I 1585 L760 Fibrillin-1 1586 L761 Fibrillin-1 1587 L762 Fibrillin-1 1588 L763 Fibrillin-1 1589 L764 Fibrillin-1 1590 L765 Fibronectin 1591 L766 Fibronectin 1592 L767 Fibronectin 1593 L768 Flagellar hook protein FlgE 1594 L769 Flagellar hook protein FlgE 1595 L770 Flagellar hook protein FlgE 1596 L771 Flagellar hook protein FlgE 1597 L772 Flagellar hook protein FlgE 1598 L773 Flagellar hook protein FlgE 1599 L774 Flagellar hook protein FlgE 1600 L775 Flavohemoprotein 1601 L776 Flexible G/S rich linker G L777 Flexible G/S rich linker S L778 Flexible G/S rich linker GG L779 Flexible G/S rich linker GS L780 Flexible G/S rich linker GGS L781 Flexible G/S rich linker GGG L782 Flexible G/S rich linker 1602 L783 Flexible G/S rich linker 1603 L784 Flexible G/S rich linker 1604 L785 Flexible G/S rich linker 1605 L786 Flexible G/S rich linker 1606 L787 Flexible G/S rich linker 1607 L788 Flexible G/S rich linker 1608 L789 Flexible G/S rich linker 1609 L790 Flexible G/S rich linker 1610 L791 Flexible G/S rich linker 1611 L792 Flexible G/S rich linker 1612 L793 Flexible G/S rich linker 1613 L794 Flexible G/S rich linker 1614 L795 Flexible G/S rich linker 1615 L796 Focal adhesion kinase 1 1616 L797 FolC bifunctional protein 1617 L798 FolC bifunctional protein 1618 L799 FolC bifunctional protein 1619 L800 FolC bifunctional protein 1620 L801 FolC bifunctional protein 1621 L802 FolC bifunctioiial protein 1622 L803 FolC bifunctional protein 1623 L804 FolC bifunctional protein 1624 L805 Follistatin 1625 L806 Formate dehydrogenase (large subunit) YDK L807 Formate dehydrogenase (large subunit) 1626 L808 Formate dehydrogenase (large subunit) 1627 L809 Formate dehydrogenase (large subunit) 1628 L810 Formate dehydrogenase (large subunit) 1629 L811 Formate dehydrogenase (large subunit) 1630 L812 Formate dehydrogenase (large subunit) 1631 L813 Formate dehydrogenase (large subunit) 1632 L814 Formate dehydrogenase (large subunit) 1633 L815 Formate dehydrogenase (large subunit) 1634 L816 Formate dehydrogenase (large subunit) 1635 L817 Formate dehydrogenase (large subunit) 1636 L818 Formate dehydrogenase(large subunit) 1637 L819 Formate dehydrogenase, nitrate-inducible major subunit 1638 L820 Formate dehydrogenase, nitrate-inducible, major subunit 1639 L821 Formate dehydrogenase, nitrate-inducible, major subunit 1640 L822 Formate dehydrogenase, nitrate-inducible, major subunit 1641 L823 Formate dehydrogenase, nitrate-inducible, major subunit 1642 L824 Formate dehydrogenase, nitrate-inducible, major subunit 1643 L825 Formate dehydrogenase, nitrate-inducible, major subunit 1644 L826 Formate dehydrogenase, nitrate-inducible, major subunit 1645 L827 Formate dehydrogenase, nitrate-inducible, major subunit 1646 L828 Formate dehydrogenase, nitrate-inducible, major subunit 1647 L829 Formate dehydrogenase, nitrate-inducible, major subunit 1648 L830 Formate dehydrogenase, nitrate-inducible, major subunit 1649 L831 Formate dehydrogenase, nitrate-inducible, major subunit 1650 L832 Formate dehydrogenase, nitrate-inducible, major subunit 1651 L833 Fumarylacetoacetate hydrolase 1652 L834 Galactose oxidase GSV L835 Galactose oxidase GWK L836 Galactose oxidase IAE L837 Galactose oxidase KRQ L838 Galactose oxidase QDT L839 Galactose oxidase TPN L840 Galactose oxidase 1653 L841 Galactose oxidase 1654 L842 Galactose oxidase 1655 L843 Galactose oxidase 1656 L844 Galactose oxidase 1657 L845 Galactose oxidase 1658 L846 Galactose oxidase 1659 L847 Galactose oxidase 1660 L848 Galactose oxidase 1661 L849 Galactose oxidase 1662 L850 Galactose oxidase 1663 L851 Galactose oxidase 1664 L852 Galactose oxidase 1665 L853 Galactose oxidase 1666 L854 Galactose oxidase 1667 L855 Galactose oxidase 1668 L856 Galactose oxidase 1669 L857 Galactose oxidase 1670 L858 Galactose oxidase 1671 L859 Galactose oxidase 1672 L860 Galactose oxidase 1673 L861 Galactose oxidase 1674 L862 Galactose oxidase 1675 L863 Galactose oxidase 1676 L864 Gamma B-crystallin 1677 L865 Gamma-delta T-cell receptor 1678 L866 Gelation factor DSS L867 Gelation factor 1679 L868 Gelation factor 1680 L869 Gelation factor 1681 L870 Gene activator alpha 1682 L871 Gingipain R 1683 L872 Glucodextranase 1684 L873 Glucodextranase 1685 L874 Glucodextranase 1686 L875 Glucosamine-fructose-6-phosphate aminotransferase YEQ L876 Glucosamine-fructose-6-phosphate aminotransferase 1687 L877 Glucosamine-fructose-6-phosphate aminotransferase 1688 L878 Glucosamine-fructose-6-phosphate aminotransferase 1689 L879 Glucosamine-fructose-6-phosphate aminotransferase 1690 L880 Glucosamine-fructose-6-phosphate aminotransferase 1691 L881 Glucosamine-fructose-6-phosphate aminotransferase 1692 L882 Glucosamine-fructose-6-phosphate aminotransferase 1693 L883 Glucosamine-fructose-6-phosphate aminotransferase 1694 L884 Glucosamine-fructose-6-phosphate aminotransferase 1695 L885 Glucosamine-fructose-6-phosphate aminotransferase 1696 L886 Glucose-1-phosphate adenylyltransferase small subunit 1697 L887 Glucose-1-phosphate adenylyltransferase small subunit 1698 L888 Glucose-6-phosphate isomerase KNA L889 Glucose-6-phosphate isomerase VGF L890 Glucose-6-phosphate isomerase 1699 L891 Glucose-6-phosphate isomerase 1700 L892 Glucose-6-phosphate isomerase, conjectural 1701 L893 Glutamate dehydrogenase 1702 L894 Glutamate dehydrogenase 1703 L895 Glutamate receptor interacting protein 1704 L896 Glutamate synthase [NADPH] large chain 1705 L897 Glutamate synthase [NADPH] large chain 1706 L898 Glutamate synthase [NADPH] large chain 1707 L899 Glutamate synthase [NADPH] large chain 1708 L900 Glutamate synthase [NADPH] large chain 1709 L901 Glutamate synthase [NADPH] large chain 1710 L902 Glutamate synthase [NADPH] large chain 1711 L903 Glutamine synthetase 1712 L904 Glutamine synthetase 1713 L905 Glutamyl-tRNA synthetase 1714 L906 Glutamyl-tRNA synthetase 1715 L907 Glutamyl-tRNA synthetase 1716 L908 Glutamyl-tRNA synthetase 1717 L909 Glutamyl-tRNA synthetase 1718 L910 Glutamyl-tRNA synthetase 1719 L911 Glutamyl-tRNA synthetase 1720 L912 Glutamyl-tRNA synthetase 1721 L913 Glutaredoxin 2 1722 L914 Glutathione S-transferase 1723 L915 Glutathione S-transferase 1724 L916 Glutathione S-transferase 1725 L917 Glutathione S-transferase 1-6 1726 L918 Glutathione S-transferase A1 1727 L919 Glutathione S-transferase I NKP L920 Glutathione S-transferase I 1728 L921 Glutathione synthetase 1729 L922 Glutathione transferase GST1-4 1730 L923 Glutathione transferase GST1-4 1731 L924 Glutathione transferase sigma class 1732 L925 Glvcerol-3-phosphate dehydrogenase [NAD(P)+] 1733 L926 Glycine cleavage system transcriptional repressor, putative 1734 L927 Glycolipid-anchored surface protein 2 1735 L928 Glycolipid-anchored surface protein 2 1736 L929 Glycyl-tRNA synthetase KFA L930 Glycyl-tRNA synthetase 1737 L931 Glycyl-tRNA synthetase 1738 L932 Glycyl-tRNA synthetase 1739 L933 Glycyl-tRNA synthetase 1740 L934 Glycyl-tRNA synthetase 1741 L935 Glycyl-tRNA synthetase 1742 L936 Glycyl-tRNA synthetase 1743 L937 Glycyl-tRNA synthetase 1744 L938 Glycyl-tRNA synthetase 1745 L939 Growth hormone receptor 1746 L940 Growth hormone receptor 1747 L941 Harmonin 1748 L942 HasR protein 1749 L943 HasR protein 1750 L944 Hemin transport protein HemS 1751 L945 Hemin transport protein HemS 1752 L946 Hemin transport protein HemS 1753 L947 Hemoglobin 1754 L948 Hemolytic lectin CEL-iii 1755 L949 Hepatocyte nuclear factor 6 1756 L950 Histidyl-tRNA synthetase 1757 L951 HNH homing endonuclease 1758 L952 HNH homing endonuclease 1759 L953 HNH homing endonuclease 1760 L954 Homoserine dehydrogenase 1761 L955 Homoserine kinase 1762 L956 Homoserine kinase 1763 L957 Homoserine kinase 1764 L958 Homoserine kinase 1765 L959 HTH-type transcriptional regulator MqsA (Ygit/B3021) 1766 L960 HTH-type transcriptional repressor 1767 L961 HTH-type transcriptional repressor YvoA 1768 L962 Human IgG1 middle hinge linker 1769 L963 Human IgG1 upper hinge linker 1770 L964 Human IgG3 middle hinge linker 1771 L965 Human IgG3m15 middle hinge linker 1772 L966 Human IgG4 lower hinge linker 1773 L967 Human IgG4 middle hinge linker 1774 L968 Human IgG4 upper hinge linker 1775 L969 Hybrid cluster protein 1776 L970 Hybrid cluster protein 1777 L971 Hybrid cluster protein 1778 L972 Hybrid cluster protein 1779 L973 Hybrid cluster protein 1780 L974 Hypothetical conserved protein, GK1056 1781 L975 Hypothetical membrane spanning protein 1782 L976 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1783 L977 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1784 L978 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1785 L979 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1786 L980 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1787 L981 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1788 L982 Hypothetical methylmalonyl-CoA decarboxylase alpha subunit 1789 L983 Hypothetical protein AEP L984 Hypothetical protein 1790 L985 Hypothetical protein APE0525 PTL L986 Hypothetical protein APE0525 1791 L987 Hypothetical protein LOC449832 1792 L988 Hypothetical protein LOC449832 1793 L989 Hypothetical protein PA4388 1794 L990 Hypothetical protein PA5201 ASE L991 Hypothetical protein PA5201 QDP L992 Hypothetical protein PA5201 VKL L993 Hypothetical protein PA5201 1795 L994 Hypothetical protein PA5201 1796 L995 Hypothetical protein PA5201 1797 L996 Hypothetical protein PA5201 1798 L997 Hypothetical protein PA5201 1799 L998 Hypothetical protein PA5201 1800 L999 Hypothetical protein PA5201 1801 L1000 Hypothetical protein PA5201 1802 L1001 Hypothetical protein PA5201 1803 L1002 Hypothetical protein PA5201 1804 L1003 Hypothetical protein PA5201 1805 L1004 Hypothetical protein PA5201 1806 L1005 Hypothetical protein PA5201 1807 L1006 Hypothetical protein PA5201 1808 L1007 Hypothetical protein PA5201 1809 L1008 Hypothetical protein PA5201 1810 L1009 Hypothetical protein PA5201 1811 L1010 Hypothetical protein PA5201 1812 L1011 Hypothetical protein PA5201 1813 L1012 Hypothetical protein PA5201 1814 L1013 Hypothetical protein PH0495 ASN L1014 Hypothetical protein PH0495 1815 L1015 Hypothetical protein PH0495 1816 L1016 Hypothetical protein PH0495 1817 L1017 Hypothetical protein PH0495 1818 L1018 Hypothetical protein PH0510 1819 L1019 Hypothetical protein PH0510 1820 L1020 Hypothetical protein PH1313 1821 L1021 Hypothetical protein PH1313 1822 L1022 Hypothetical protein SLR0953 1823 L1023 Hypothetical protein SLR0953 1824 L1024 Hypothetical protein SLR0953 1825 L1025 Hypothetical protein SLR0953 1826 L1026 Hypothetical protein SLR0953 1827 L1027 Hypothetical protein YIGZ 1828 L1028 Hypothetical protein YIGZ 1829 L1029 Hypothetical protein YJIA 1830 L1030 Hypothetical protein YJIA 1831 L1031 Hypothetical protein YJIA 1832 L1032 Hypothetical protein YJIA 1833 L1033 Hypothetical protein YJIA 1834 L1034 Hypothetical tRNA/rRNA methyltransferase YJFH 1835 L1035 Hypothetical tRNA/rRNA methyltransferase YJFH 1836 L1036 IclR transcriptional regulator 1837 L1037 IclR transcriptional regulator 1838 L1038 IclR transcriptional regulator 1839 L1039 IclR transcriptional regulator 1840 L1040 Integrase 1841 L1041 Interferon, alpha-inducible protein (clone IFI-15k) 1842 L1042 Interleukin-1 receptor, type I AIF L1043 Interleukin-1 receptor, type I 1843 L1044 Interleukin-1 receptor, type I 1844 L1045 Interleukin-1 receptor, type I 1845 L1046 Interleukin-12 subunit p40 FFI L1047 Interleukin-12 subunit p40 1846 L1048 Interleukin-12 subunit p40 1847 L1049 Interleukin-12 subunit p40 1848 L1050 Interleukin-12 subunit p40 1849 L1051 Interleukin-12 subunit p40 1850 L1052 Interleukin-12 subunit p40 1851 L1053 Interleukin-12 subunit p40 1852 L1054 Interletiktn-2 receptor alpha chain 1853 L1055 Interleukin-2 receptor alpha chain 1854 L1056 Internalin B VTQ L1057 Internalin B 1855 L1058 Internalin B 1856 L1059 Internalin B 1857 L1060 Internalin B 1858 L1061 Internalin B 1859 L1062 Internalin B 1860 L1063 Internalin B 1861 L1064 Internalin B 1862 L1065 Internalin B 1863 L1066 Internalin B 1864 L1067 Internalin B 1865 L1068 Internalin B 1866 L1069 Intimin SLV L1070 Intimin 1867 L1071 Intimin 1868 L1072 Intimin 1869 L1073 Intron-encoded DNA endonuclease I-anil 1870 L1074 Intron-encoded DNA endonuclease I-anil 1871 L1075 Invasin KST L1076 Invasin 1872 L1077 Invasin 1873 L1078 Invasin 1874 L1079 Invasin 1875 L1080 Invasin 1876 L1081 Invasin 1877 L1082 Invasin 1878 L1083 Invasin 1879 L1084 Invasin 1880 L1085 Invasin 1881 L1086 Invasin 1882 L1087 Invasin 1883 L1088 Iron hydrogenase 1 GAE L1089 Iron hydrogenase 1 1884 L1090 Iron hydrogenase 1 1885 L1091 Iron hydrogenase 1 1886 L1092 Iron hydrogenase 1 1887 L1093 Iron hydrogenase 1 1888 L1094 Iron hydrogenase 1 1889 L1095 Iron hydrogenase 1 1890 L1096 Iron hydrogenase 1 1891 L1097 Iron hydrogenase 1 1892 L1098 Iron hydrogenase 1 1893 L1099 Iron hydrogenase 1 1894 L1100 Iron hydrogenase 1 1895 L1101 Iron hydrogenase 1 1896 L1102 Iron transport protein 1897 L1103 Isoflavanone 4′-O-methyltransferase 1898 L1104 Isoflavanone 4′-O-methyltransferase 1899 L1105 Junctional adhesion molecule 1 1900 L1106 Junctional adhesion molecule 1 1901 L1107 Junctional adhesion molecule 1 1902 L1108 Kanamycin nucleotidyltransferase 1903 L1109 Kanamycin nucleotidyltransferase 1904 L1110 Kanamycin nucleotidyltransferase 1905 L1111 Kanamycin nucleotidyltransferase 1906 L1112 Kelch-like protein 11 1907 L1113 Kexin ISE L1114 Kexin 1908 L1115 Kexin 1909 L1116 Kexin 1910 L1117 Kexin 1911 L1118 Kexin 1912 L1119 Kexin 1913 L1120 Kexin 1914 L1121 Ku70 1915 L1122 Ku70 1916 L1123 Ku70 1917 L1124 Ku70 1918 L1125 Ku80 1919 L1126 Laccase-1 1920 L1127 Laccase-1 1921 L1128 Laccase-1 1922 L1129 Laccase-1 1923 L1130 Laminin DKC L1131 L-aspartate dehydrogenase SAS L1132 L-aspartate dehydrogenase 1924 L1133 L-aspartate dehydrogenase 1925 L1134 Leucine dehydrogenase 1926 L1135 Leucine dehydrogenase 1927 L1136 Light chain of HyHel10 antibody fragment (fab) 1928 L1137 Lin2111 protein 1929 L1138 Lin2111 protein 1930 L1139 Lipopolysaccharide-responsive and beige-like anchor protein 1931 L1140 Lipopolysaccharide-responsive and beige-like anchor protein 1932 L1141 Lipovitellin (LV-1N, LV-1C) 1933 L1142 Lipovitellin (LV-1N, LV-1C) 1934 L1143 Lipovitellin (LV-1N, LV-1C) 1935 L1144 Lipovitellin (LV-1N, LV-1C) 1936 L1145 Lipovitellin (LV-1N, LV-1C) 1937 L1146 Lipoxygenase-1 1938 L1147 Lipoxygenase-1 1939 L1148 Low affinity immunoglobulin gamma Fc region receptor II-A 1940 L1149 Luciferase 1941 L1150 LysR-type regulatory protein 1942 L1151 Macrolide-specific efflux protein MacA ATE L1152 Macrolide-specific efflux protein MacA 1943 L1153 Macrolide-specific efflux protein MacA 1944 L1154 Magnesium transporter, putative 1945 L1155 Main hemagglutinin component 1946 L1156 Major centromere autoantigen B 1947 L1157 Major surface antigen p30 1948 L1158 Major surface antigen p30 1949 L1159 Major vault protein 1950 L1160 Major vault protein 1951 L1161 Maltose phosphorylase 1952 L1162 Maltose phosphorylase 1953 L1163 Maltose phosphorylase 1954 L1164 Maltose phosphorylase 1955 L1165 Maltose phosphorylase 1956 L1166 Manganese-dependent inorganic pyrophosphatase 1957 L1167 Manganese-dependent inorganic pyrophosphatase 1958 L1168 Mannan-binding lectin 1959 L1169 Mannan-binding lectin 1960 L1170 Mannan-binding lectin 1961 L1171 Mannitol dehydrogenase HNA L1172 Mannitol dehydrogenase 1962 L1173 Membrane cofactor protein RET L1174 Membrane cofactor protein 1963 L1175 Membrane-associated prostaglandin E synthase-2 1964 L1176 Membrane-associated prostaglandin E synthase-2 1965 L1177 Membrane-associated prostaglandin E synthase-2 1966 L1178 Membrane-associated prostaglandin E synthase-2 1967 L1179 Membrane-associated prostaglandin E synthase-2 1968 L1180 Membrane-bound lytic murein transglycosylase A 1969 L1181 Methionyl-tRNA synthetase 1970 L1182 Methyl-accepting chemotaxis protein VRP L1183 Methyl-accepting chemotaxis protein 1971 L1184 Methyl-accepting chemotaxis protein 1972 L1185 Methyl-accepting chemotaxis protein 1973 L1186 Methyl-coenzyme M reductase 1974 L1187 Methyl-coenzyme M reductase 1975 L1188 Methyl-coenzyme M reductase 1976 L1189 Methyl-coenzyme M reductase 1977 L1190 Methylene tetrahydromethanopterin dehydrogenase 1978 L1191 Methylene tetrahydromethanopterin dehydrogenase 1979 L1192 Mg2+ transporter MgtE 1980 L1193 Mg2+ transporter MgtE 1981 L1194 Mg2+ transporter MgtE 1982 L1195 Mitochondrial aconitase 1983 L1196 Mitochondrial aconitase 1984 L1197 Modification methylase TaqI EGK L1198 Modification methylase TaqI PAT L1199 Modification methylase TaqI 1985 L1200 Modification methylase TaqI 1986 L1201 Modification methylase TaqI 1987 L1202 Modification methylase TaqI 1988 L1203 Modification methylase TaqI 1989 L1204 Modification methylase TaqI 1990 L1205 Modification methylase TaqI 1991 L1206 Modification methylase TaqI 1992 L1207 Multidrag-efflux transporter 1 regulator 1993 L1208 Muramoyl-pentapeptide carboxypeptidase 1994 L1209 MutL 1995 L1210 MutL 1996 L1211 MutL 1997 L1212 MutL 1998 L1213 MutL 1999 L1214 MutL 2000 L1215 MutL 2001 L1216 MutL 2002 L1217 MutL 2003 L1218 MutM (Fpg) protein 2004 L1219 MutM (Fpg) protein 2005 L1220 MutM (Fpg) protein 2006 L1221 MutM (Fpg) protein 2007 L1222 Myotubularin-related protein 2 THW L1223 Myotubularin-related protein 2 2008 L1224 Myotubularin-related protein 2 2009 L1225 Myotubularin-related protein 2 2010 L1226 Myotubularin-related protein 2 2011 L1227 Myotubularin-related protein 2 2012 L1228 N utilization substance protein A EIP L1229 N utilization substance protein A 2013 L1230 N utilization substance protein A 2014 L1231 N utilization substance protein A 2015 L1232 N-acetylglucosamine kinase CAY L1233 N-acetylglucosamine kinase ISP L1234 N-acetylglucosamine kinase 2016 L1235 N-acyl-D-glutamate deacylase 2017 L1236 N-acyl-D-glutamate deacylase 2018 L1237 N-acyl-D-glutamate deacylase 2019 L1238 N-acyl-D-glutamate deacylase 2020 L1239 N-acyl-D-glutamate deacylase 2021 L1240 N-acyl-D-glutamate deacylase 2022 L1241 N-acyl-D-glutamate deacylase 2023 L1242 NAD-dependent malic enzyme 2024 L1243 NAD-dependent malic enzyme 2025 L1244 NADH peroxidase ADT L1245 NADH peroxidase AVG L1246 NADH peroxidase TLI L1247 NADH peroxidase 2026 L1248 NADH peroxidase 2027 L1249 NADH peroxidase 2028 L1250 NADH peroxidase 2029 L1251 NADH peroxidase 2030 L1252 NADH peroxidase 2031 L1253 NADH pyrophosphatase 2032 L1254 Naphthalene 1,2-dioxygenase alpha subunit 2033 L1255 Naphthalene 1,2-dioxygenase alpha subunit 2034 L1256 NEDD8-activating enzyme E1 catalytic subunit 2035 L1257 NEDD8-activating enzyme E1 regulatory subunit 2036 L1258 NEDD8-activating enzyme E1 regulatory subunit 2037 L1259 NEDD8-activating enzyme E1 regulatory subunit 2038 L1260 Nei endonuclease VIII-Like 1 2039 L1261 Nei endonuclease VIII-Like 1 2040 L1262 Nei endonuclease VIII-Like 1 2041 L1263 Nei endonuclease VIII-Like 1 2042 L1264 Neural cell adhesion molecule 2 2043 L1265 Neural cell adhesion molecule 2 2044 L1266 Neural cell adhesion molecule 2 2045 L1267 Neural cell adhesion molecule 2 2046 L1268 Neural cell adhesion molecule 2 2047 L1269 Neuroplastin 2048 L1270 Neuroplastin 2049 L1271 Neuroplastin 2050 L1272 Neutrophil cytosol factor 1 2051 L1273 Nickel responsive regulator 2052 L1274 NifU-like protein 2, chloroplast 2053 L1275 Nitric oxide reductase ILM L1276 Nitric oxide reductase 2054 L1277 Nitric oxide reductase 2055 L1278 Nitric oxide reductase 2056 L1279 Nitric oxide reductase 2057 L1280 Nitric oxide reductase 2058 L1281 NK receptor 2059 L1282 Nuclear factor of activated t-cells, cytoplasmic2 2060 L1283 Nucleolin RED12 2061 L1284 O-GlcNAcase NagJ 2062 L1285 Orange carotenoid protein EGV L1286 Orange carotenoid protein 2063 L1287 Orange carotenoid protein 2064 L1288 Orn/Lys/Arg decarboxylase family protein LEL L1289 Orn/Lys/Arg decarboxylase family protein 2065 L1290 Orn/Lys/Arg decarboxylase family protein 2066 L1291 Orn/Lys/Arg decarboxylase family protein 2067 L1292 Orn/Lys/Arg decarboxylase family protein 2068 L1293 Orn/Lys/Arg decarboxylase family protein 2069 L1294 Orn/Lys/Arg decarboxylase family protein 2070 L1295 Orn/Lys/Arg decarboxylase family protein 2071 L1296 Osteoclast-stimulating factor 1 2072 L1297 Oxygen-independent coproporphyrinogen III oxidase 2073 L1298 Oxygen-independent coproporphyrinogen III oxidase 2074 L1299 Oxygen-independent coproporphyrinogen III oxidase 2075 L1300 Oxygen-independent coproporphyrinogen III oxidase 2076 L1301 Oxygen-independent coproporphyrinogen III oxidase 2077 L1302 Oxygen-independent coproporphyrinogen III oxidase 2078 L1303 Oxygen-independent coproporphyrinogen III oxidase 2079 L1304 Oxygen-independent coproporphyrinogen III oxidase 2080 L1305 Oxygen-independent coproporphyrinogen III oxidase 2081 L1306 Oxygen-independent coproporphyrinogen III oxidase 2082 L1307 Paraneoplastic encephalomyelitis antigen HuD 2083 L1308 Paraneoplastic encephalomyelitis antigen HuD 2084 L1309 Penicillin binding protein 4 2085 L1310 Penicillin binding protein 4 2086 L1311 Penicillin binding protein 4 2087 L1312 Penicillin binding protein 4 2088 L1313 Penicillin binding protein 4 2089 L1314 Penicillin binding protein 4 2090 L1315 Penicillin binding protein 4 2091 L1316 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F DGV L1317 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F 2092 L1318 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F 2093 L1319 Peptide-N(4)-(N-acetyl-beta-D-glucosaminyl)asparagine amidase F 2094 L1320 Peroxisomal primary amine oxidase 2095 L1321 Peroxisomal primary amine oxidase 2096 L1322 Peroxisome biogenesis factor 1 2097 L1323 Pesticidial crystal protein Cry2Aa 2098 L1324 Pesticidial crystal protein Cry2Aa 2099 L1325 Pesticidial crystal protein Cry2Aa 2100 L1326 Phase 1 flagellin DLT L1327 Phase 1 flagellin 2101 L1328 Phase 1 flagellin 2102 L1329 Phase 1 flagellin 2103 L1330 Phase 1 flagellin 2104 L1331 Phase 1 flagellin 2105 L1332 Phase 1 flagellin 2106 L1333 Phase 1 flagellin 2107 L1334 Phase 1 flagellin 2108 L1335 Phase 1 flagellin 2109 L1336 Phase 1 flagellin 2110 L1337 Phase 1 flagellin 2111 L1338 Phase 1 flagellin 2112 L1339 Phenylalanyl-tRNA synthetase beta chain LGL L1340 Phenylalanyl-tRNA synthetase beta chain 2113 L1341 Phenylalanyl-tRNA synthetase beta chain 2114 L1342 Phenylalanyl-tRNA synthetase beta chain 2115 L1343 Phenylalanyl-tRNA synthetase beta chain 2116 L1344 Phenylalanyl-tRNA synthetase beta chain 2117 L1345 Phenylalanyl-tRNA synthetase beta chain 2118 L1346 Phenylalanyl-tRNA synthetase beta chain 2119 L1347 Phenylalanyl-tRNA synthetase beta chain 2120 L1348 Phenylalanyl-tRNA synthetase beta chain 2121 L1349 Phenylalanyl-tRNA synthetase beta chain 2122 L1350 Phenylalanyl-tRNA synthetase beta chain 2123 L1351 Phenylalanyl-tRNA synthetase beta chain 2124 L1352 Phenylalanyl-tRNA synthetase beta chain 2125 L1353 Phosphatase 2126 L1354 Phosphatase 2127 L1355 Phosphatase 2128 L1356 Phosphatidylinositol transfer protein Sec14p YGT L1357 Phosphatidylinositol transfer protein Sec14p 2129 L1358 Phosphatidylinositol transfer protein Sec14p 2130 L1359 Phosphatidylserine synthase 2131 L1360 Phosphatidylserine synthase 2132 L1361 Phosphatidylserine synthase 2133 L1362 Phosphoglycolate phosphatase 2134 L1363 Phosphoglycolate phosphatase 2135 L1364 Phosphoglycolate phosphatase 2136 L1365 Phosphoglycolate phosphatase 2137 L1366 Phospholipase D 2138 L1367 Phospholipase D 2139 L1368 Phospholipase D 2140 L1369 Phosphoribosylamine-glycine ligase 2141 L1370 Phosphoribosylamine-glycine ligase 2142 L1371 Phosphotransferase system, enzyme I 2143 L1372 Photosystem II d1 protease 2144 L1373 Photosystem II d1 protease 2145 L1374 Photosystem II d1 protease 2146 L1375 Photosystem II d1 protease 2147 L1376 Photosystem II d1 protease 2148 L1377 Phthalate dioxygenase reductase 2149 L1378 P-hydroxybenzoate hydroxylase DGL L1379 P-hydroxybenzoate hydroxylase IDL L1380 P-hydroxybenzoate hydroxylase RLK L1381 P-hydroxybenzoate hydroxylase 2150 L1382 P-hydroxybenzoate hydroxylase 2151 L1383 P-hydroxybenzoate hydroxylase 2152 L1384 P-hydroxybenzoate hydroxylase 2153 L1385 P-hydroxybenzoate hydroxylase 2154 L1386 P-hydroxybenzoate hydroxylase 2155 L1387 P-hydroxybenzoate hydroxylase 2156 L1388 P-hydroxybenzoate hydroxylase 2157 L1389 P-hydroxybenzoate hydroxylase 2158 L1390 P-hydroxybenzoate hydroxylase 2159 L1391 P-hydroxybenzoate hydroxylase 2160 L1392 P-hydroxybenzoate hydroxylase 2161 L1393 P-hydroxybenzoate hydroxylase 2162 L1394 P-hydroxybenzoate hydroxylase 2163 L1395 P-hydroxybenzoate hydroxylase 2164 L1396 P-hydroxybenzoate hydroxylase 2165 L1397 P-hydroxybenzoate hydroxylase 2166 L1398 Phytase LNF L1399 Phytase QSN L1400 Phytase 2167 L1401 Phytase 2168 L1402 Phytase 2169 L1403 Phytase 2170 L1404 Phytase 2171 L1405 Phytase 2172 L1406 Phytase 2173 L1407 Phytase 2174 L1408 Pirin LKS L1409 Pirin SGE L1410 Pirin 2175 L1411 Pirin 2176 L1412 Pirin 2177 L1413 Pirin 2178 L1414 Pirin 2179 L1415 Pirin 2180 L1416 Poly(A) polymerase 2181 L1417 Poly(A) polymerase 2182 L1418 Poly(A) polymerase 2183 L1419 Poly(A) polymerase 2184 L1420 Poly(A) polymerase 2185 L1421 Poly(A) polymerase 2186 L1422 Poly(A) polymerase 2187 L1423 Poly(A) polymerase 2188 L1424 Poly(A) polymerase 2189 L1425 Poly(A) polymerase 2190 L1426 Poly(A) polymerase 2191 L1427 Poly(A) polymerase 2192 L1428 Poly(rC)-binding protein 2 2193 L1429 Polymerase x 2194 L1430 Polymerase x 2195 L1431 Polypeptide N-acetylgalactosaminyltransferase 2 2196 L1432 Polypeptide N-acetylgalactosaminyltransferase 2 2197 L1433 Polyphosphate kinase 2198 L1434 Polyphosphate kinase 2199 L1435 Polyphosphate kinase 2200 L1436 Polypyrimidine tract-binding protein 2201 L1437 Porcine pancreatic spasmolytic polypeptide 2202 L1438 Possible 3-mercaptopyruvate sulfurtransferase LFR L1439 Possible 3-mercaptopyruvate sulfurtransferase YGM L1440 Possible 3-mercaptopyruvate sulfurtransferase 2203 L1441 Possible 3-mercaptopyruvate sulfurtransferase 2204 L1442 Possible 3-mercaptopyruvate sulfurtransferase 2205 L1443 Postsynaptic density protein 95 2206 L1444 Postsynaptic density protein 95 2207 L1445 Predicted sugar phosphatases of the HAD superfamily IAI L1446 Predicted sugar phosphatases of the HAD superfamily 2208 L1447 Predicted sugar phosphatases of the HAD superfamily 2209 L1448 Predicted sugar phosphatases of the HAD superfamily 2210 L1449 Predicted sugar phosphatases of the HAD superfamily 2211 L1450 Predicted sugar phosphatases of the HAD superfamily 2212 L1451 Predicted sugar phosphatases of the HAD superfamily 2213 L1452 Predicted sugar phosphatases of the HAD superfamily 2214 L1453 Predicted sugar phosphatases of the HAD superfamily 2215 L1454 Preprotein translocase SecA ITF L1455 Preprotein translocase SecA LID L1456 Preprotein translocase SecA 2216 L1457 Preprotein translocase SecA 2217 L1458 Preprotein translocase SecA 2218 L1459 Preprotein translocase SecA 2219 L1460 Preprotein translocase SecA 2220 L1461 Preprotein translocase SecA 2221 L1462 Preprotein translocase SecA 2222 L1463 Preprotein translocase SecA 2223 L1464 Preprotein translocase SecA 2224 L1465 Preprotein translocase SecA 2225 L1466 Preprotein translocase SecA 2226 L1467 Preprotein translocase SecA 2227 L1468 Preprotein translocase SecA 2228 L1469 Preprotein translocase SecA 2229 L1470 Preprotein translocase SecA 2230 L1471 Preprotein translocase SecA 2231 L1472 Preprotein translocase SecA 2232 L1473 PrfA ING L1474 Probable 16s rRNA-processing protein RimM 2233 L1475 Probable biphenyl-2,3-diol 1,2-dioxygenase BphC 2234 L1476 Probable chorismate mutase LLA L1477 Probable chorismate mutase 2235 L1478 Probable chorismate mutase 2236 L1479 Probable ferredoxin-dependent nitrite reductase NirA VPL L1480 Probable ferredoxin-dependent nitrite reductase NirA WGI L1481 Probable ferredoxin-dependent nitrite reductase NirA 2237 L1482 Probable ferredoxin-dependent nitrite reductase NirA 2238 L1483 Probable ferredoxin-dependent nitrite reductase NirA 2239 L1484 Probable ferredoxin-dependent nitrite reductase NirA 2240 L1485 Probable ferredoxin-dependent nitrite reductase NirA 2241 L1486 Probable ferredoxin-dependent nitrite reductase NirA 2242 L1487 Probable ferredoxin-dependent nitrite reductase NirA 2243 L1488 Probable ferredoxin-dependent nitrite reductase NirA 2244 L1489 Probable ferredoxin-dependent nitrite reductase NirA 2245 L1490 Probable ferredoxin-dependent nitrite reductase NirA 2246 L1491 Probable ferredoxin-dependent nitrite reductase NirA 2247 L1492 Probable ferredoxin-dependent nitrite reductase NirA 2248 L1493 Probable galactokinase 2249 L1494 Probable galactokinase 2250 L1495 Probable galactokinase 2251 L1496 Probable galactokinase 2252 L1497 Probable galactokinase 2253 L1498 Probable galactokinase 2254 L1499 Probable galactokinase 2255 L1500 Probable galactokinase 2256 L1501 Probable galactokinase 2257 L1502 Probable galactokinase 2258 L1503 Probable galactokinase 2259 L1504 Probable galactokinase 2260 L1505 Probable glutathione S-transferase 2261 L1506 Probable GST-related protein 2262 L1507 Probable HPr(Ser) kinase/phosphatase 2263 L1508 Probable thiosulfate sulfur transferase 2264 L1509 Probable thiosulfate sulfur transferase 2265 L1510 Probable thiosulfate sulfur transferase 2266 L1511 Probable thiosulfate sulfur transferase 2267 L1512 Probable thiosulfate sulfur transferase 2268 L1513 Probable thiosulfate sulfur transferase 2269 L1514 Probable thiosulfate sulfur transferase 2270 L1515 Probable thiosulfate sulfur transferase 2271 L1516 Probable tRNA pseudouridine synthase D 2272 L1517 Probable tRNA pseudouridine synthase D 2273 L1518 Probable tRNA pseudouridine synthase D 2274 L1519 Probable tRNA pseudouridine synthase D 2275 L1520 Probable tRNA pseudouridine synthase D 2276 L1521 Probable tRNA pseudouridine synthase D 2277 L1522 Programed cell death protein 8 SKE L1523 Programed cell death protein 8 TLQ L1524 Programed cell death protein 8 2278 L1525 Programed cell death protein 8 2279 L1526 Programed cell death protein 8 2280 L1527 Programed cell death protein 8 2281 L1528 Programed cell death protein 8 2282 L1529 Programed cell death protein 8 2283 L1530 Programed cell death protein 8 2284 L1531 Programed cell death protein 8 2285 L1532 Programed cell death protein 8 2286 L1533 Programed cell death protein 8 2287 L1534 Programed cell death protein 8 2288 L1535 Programed cell death protein 8 2289 L1536 Programed cell death protein 8 2290 L1537 Programed cell death protein 8 2291 L1538 Programed cell death protein 8 2292 L1539 Programed cell death protein 8 2293 L1540 Programed cell death protein 8 2294 L1541 Programed cell death protein 8 2295 L1542 Proline oxidase 2296 L1543 Prolyl-tRNA synthetase 2297 L1544 Prostaglandin G/H synthase 1 PEI L1545 Prostaglandin G/H synthase 1 2298 L1546 Protease 2299 L1547 Protease 2300 L1548 Protease 2301 L1549 Protease DegS 2302 L1550 Protease DegS 2303 L1551 Protease DegS 2304 L1552 Protease DegS 2305 L1553 Protease III NAR L1554 Protease III RNP L1555 Protease III 2306 L1556 Protease III 2307 L1557 Protease III 2308 L1558 Protease III 2309 L1559 Protease III 2310 L1560 Protease III 2311 L1561 Protease III 2312 L1562 Protease III 2313 L1563 Protease III 2314 L1564 Protease III 2315 L1565 Protease III 2316 L1566 Protease III 2317 L1567 Protease III 2318 L1568 Protease III 2319 L1569 Protease III 2320 L1570 Protease III 2321 L1571 Protease III 2322 L1572 Protease III 2323 L1573 Protease III 2324 L1574 Protease III 2325 L1575 Protection of telomeres 1 2326 L1576 Protection of telomeres 1 2327 L1577 Protein (CD58) 2328 L1578 Protein (CRP1) 2329 L1579 Protein (DNA polymerase) 2330 L1580 Protein (DNA polymerase) 2331 L1581 Protein (DNA polymerase) 2332 L1582 Protein (electron transfer flavoprotein) 2333 L1583 Protein (electron transfer flavoprotein) 2334 L1584 Protein (Ffh) 2335 L1585 Protein (Ffh) 2336 L1586 Protein (Ffh) 2337 L1587 Protein (Ffh) 2338 L1588 Protein (Ffh) 2339 L1589 Protein (FokI restriction endonuclease) 2340 L1590 Protein (FokI restriction endonuclease) 2341 L1591 Protein (FokI restriction endonuclease) 2342 L1592 Protein (FokI restriction endonuclease) 2343 L1593 Protein (FokI restriction endonuclease) 2344 L1594 Protein (FokI restriction endonuclease) 2345 L1595 Protein (FokI restriction endonuclease) 2346 L1596 Protein (FokI restriction endonuclease) 2347 L1597 Protein (FokI restriction endonuclease) 2348 L1598 Protein (neural cell adhesion molecule) 2349 L1599 Protein (neural cell adhesion molecule) 2350 L1600 Protein (neural cell adhesion molecule) 2351 L1601 Protein (nine-haem cytochrome c) FTH L1602 Protein (nine-haem cytochrome c) 2352 L1603 Protein (nine-haem cytochrome c) 2353 L1604 Protein (nine-haem cytochrome c) 2354 L1605 Protein (nine-haem cytochrome c) 2355 L1606 Protein (nine-haem cytochrome c) 2356 L1607 Protein (nine-haem cytochrome c) 2357 L1608 Protein (nine-haem cytochrome c) 2358 L1609 Protein (nine-haem cytochrome c) 2359 L1610 Protein (protease/helicase NS3) 2360 L1611 Protein (protease/helicase NS3) 2361 L1612 Protein (protease/helicase NS3) 2362 L1613 Protein (protease/helicase NS3) 2363 L1614 Protein disulfide oxidoreductase 2364 L1615 Protein disulfide oxidoreductase 2365 L1616 Protein disulfide-isomerase A4 2366 L1617 Protein kinase PKR 2367 L1618 Protein kinase PKR 2368 L1619 Protein TolB VNK L1620 Protein TolB 2369 L1621 Protein TolB 2370 L1622 Protein TolB 2371 L1623 Protein TolB 2372 L1624 Protein TolB 2373 L1625 Protein TolB 2374 L1626 Protein translation elongation factor 1A 2375 L1627 Protein transport protein Sec24 DRN L1628 Protein transport protein Sec24 2376 L1629 Protein transport protein Sec24 2377 L1630 Protein transport protein Sec24 2378 L1631 Protein transport protein Sec24 2379 L1632 Protein transport protein Sec24 2380 L1633 Protein transport protein Sec24 2381 L1634 Protein transport protein Sec24 2382 L1635 Protein transport protein Sec24 2383 L1636 Pseudouridine synthase CBF5 AIQ L1637 Pseudouridine synthase CBF5 2384 L1638 Pseudouridine synthase CBF5 2385 L1639 Putative acetylglutamate synthase 2386 L1640 Putative acetylglutamate synthase 2387 L1641 Putative acetylglutamate synthase 2388 L1642 Putative family 31 glucosidase Yicl 2389 L1643 Putative family 31 glucosidase Yicl 2390 L1644 Putative family 31 glucosidase Yicl 2391 L1645 Putative glutathione transferase 2392 L1646 Putative glutathione transferase 2393 L1647 Putative glutathione transferase 2394 L1648 Putative GNTR-family transcriptional regulator 2395 L1649 Putative GNTR-family transcriptional regulator 2396 L1650 Putative GNTR-family transcriptional regulator 2397 L1651 Putative HTH-type transcriptional regulator PH0061 2398 L1652 Putative HTH-type transcriptional regulator PH1519 2399 L1653 Putative HTH-type transcriptional regulator PH1519 2400 L1654 Putative metallopeptidase 2401 L1655 Putative N-acetylmannosamine kinase 2402 L1656 Putative N-acetylmannosamine kinase 2403 L1657 Putative N-acetylmannosamine kinase 2404 L1658 Putative NADP oxidoreductase BF3122 2405 L1659 Putative NADP oxidoreductase BF3122 2406 L1660 Putative NADP oxidoreductase BF3122 2407 L1661 Putative NADP oxidoreductase BF3122 2408 L1662 Putative oxidoreductase 2409 L1663 Putative secreted alpha-galactosidase PLP L1664 Putative secreted alpha-galactosidase TNG L1665 Putative secreted alpha-galactosidase 2410 L1666 Putative secreted alpha-galactosidase 2411 L1667 Putative secreted alpha-galactosidase 2412 L1668 Putative tagatose-6-phosphate ketose/aldose isomerase DKA L1669 Putative tagatose-6-phosphate ketose/aldose isomerase 2413 L1670 Putative tagatose-6-phosphate ketose/aldose isomerase 2414 L1671 Putative tagatose-6-phosphate ketose/aldose isomerase 2415 L1672 Putative transcriptional regulator GntR 2416 L1673 Putative transcriptional repressor (TetR/AcrR family) KFR L1674 Putative transcriptional repressor (TetR/AcrR family) 2417 L1675 Putative uncharacterized protein 2418 L1676 Putative uncharacterized protein 2419 L1677 Putative uncharacterized protein 2420 L1678 Putative uncharacterized protein 2421 L1679 Putative uncharacterized protein 2422 L1680 Putative uncharacterized protein 2423 L1681 Putative uncharacterized protein 2424 L1682 Putative uncharacterized protein 2425 L1683 Putative uncharacterized protein 2426 L1684 Pyruvate decarboxylase CAA L1685 Pyruvate decarboxylase 2427 L1686 Pyruvate decarboxylase 2428 L1687 Pyruvate decarboxylase 2429 L1688 Pyruvate decarboxylase 2430 L1689 Pyruvate decarboxylase 2431 L1690 Pyruvate dehydrogenase [lipoamide] kinase isozyme 2, mitochondrial YVP L1691 Pyruvate dehydrogenase [lipoamide] kinase isozyme 2, mitochondrial 2432 L1692 Pyruvate dehydrogenase [lipoamide] kinase isozyme 2, mitochondrial 2433 L1693 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 2434 L1694 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 2435 L1695 Pyruvate dehydrogenase E1 component subunit beta, mitochondrial 2436 L1696 Pyruvate phosphate dikinase FNP L1697 Pyruvate phosphate dikinase SAL L1698 Pyruvate phosphate dikinase 2437 L1699 Pyruvate phosphate dikinase 2438 L1700 Pyruvate phosphate dikinase 2439 L1701 Pyruvate phosphate dikinase 2440 L1702 Pyruvate phosphate dikinase 2441 L1703 Pyruvate phosphate dikinase 2442 L1704 Pyruvate phosphate dikinase 2443 L1705 Pyruvate phosphate dikinase 2444 L1706 Pyruvate phosphate dikinase 2445 L1707 Pyruvate phosphate dikinase 2446 L1708 Pyruvate-ferredoxin oxidoreductase VRL L1709 Pyruvate-ferredoxin oxidoreductase 2447 L1710 Pyruvate-ferredoxin oxidoreductase 2448 L1711 Pyruvate-ferredoxin oxidoreductase 2449 L1712 Pyruvate-ferredoxin oxidoreductase 2450 L1713 Pyruvate-ferredoxin oxidoreductase 2451 L1714 Pyruvate-ferredoxin oxidoreductase 2452 L1715 Pyruvate-ferredoxin oxidoreductase 2453 L1716 Pyruvate-ferredoxin oxidoreductase 2454 L1717 Pyruvate-ferredoxin oxidoreductase 2455 L1718 Pyruvate-ferredoxin oxidoreductase 2456 L1719 Pyruvate-ferredoxin oxidoreductase 2457 L1720 Pyruvate-ferredoxin oxidoreductase 2458 L1721 Pyruvate-ferredoxin oxidoreductase 2459 L1722 Pyruvate-ferredoxin oxidoreductase 2460 L1723 Pyruvate-ferredoxin oxidoreductase 2461 L1724 Pyruvate-ferredoxin oxidoreductase 2462 L1725 Pyruvate-ferredoxin oxidoreductase 2463 L1726 Pyruvate-ferredoxin oxidoreductase 2464 L1727 Pyruvate-ferredoxin oxidoreductase 2465 L1728 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2466 L1729 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2467 L1730 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2468 L1731 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2469 L1732 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2470 L1733 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2471 L1734 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2472 L1735 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2473 L1736 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2474 L1737 Quinohemoprotein amine dehydrogenase 60 kDa subunit 2475 L1738 Rag1 2476 L1739 Rag1 2477 L1740 Receptor-type tyrosine-protein phosphatase Mu 2478 L1741 Receptor-type tyrosine-protein phosphatase Mu 2479 L1742 RecG 2480 L1743 RecG 2481 L1744 RecG 2482 L1745 RecG 2483 L1746 RecG 2484 L1747 RecG 2485 L1748 RecG 2486 L1749 RecG 2487 L1750 RecG 2488 L1751 RecG 2489 L1752 RecG 2490 L1753 RecG 2491 L1754 Recombination endonuclease VII 2492 L1755 Recombining binding protein suppressor of hairless 2493 L1756 Restriction endonuclease ERV L1757 Restriction endonuclease 2494 L1758 Restriction endonuclease 2495 L1759 Restriction endonuclease 2496 L1760 Retinaldehyde-binding protein 1 QYP L1761 Retinaldehyde-binding protein 1 2497 L1762 Retinaldehyde-binding protein 1 2498 L1763 Retinoblastoma pocket 2499 L1764 RfcS ITD L1765 RfcS LTE L1766 RfcS 2500 L1767 RfcS 2501 L1768 RfcS 2502 L1769 RfcS 2503 L1770 RfcS 2504 L1771 Rhamnogalacturonase B 2505 L1772 Rhamnogalacturonase B 2506 L1773 Rhamnogalacturonase B 2507 L1774 Rhamnogalacturonase B 2508 L1775 Rhamnogalacturonase B 2509 L1776 Rhodniin 2510 L1777 Rhodniin 2511 L1778 Riboflavin synthase 2512 L1779 Ribonuclease D 2513 L1780 Ribonuclease D 2514 L1781 Ribonuclease D 2515 L1782 Ribonuclease TTHA0252 2516 L1783 Ribonuclease TTHA0252 2517 L1784 Ribonuclease TTHA0252 2518 L1785 Ribonuclease THHA0252 2519 L1786 Ribonuclease TTHA0252 2520 L1787 Ribonuclease TTHA0252 2521 L1788 Ribonucleotide reductase r1 protein 2522 L1789 Ribonucleotide reductase r1 protein 2523 L1790 Ribonucleotide reductase r1 protein 2524 L1791 Ribonucleotide reductase r1 protein 2525 L1792 Ribonucleotide reductase r1 protein 2526 L1793 Ribonucleotide reductase r1 protein 2527 L1794 Ribosome maturation factor RimM 2528 L1795 Ribulose-1,5 bisphosphate carboxylase/oxygenase RHA large subunit N-methyltransferase L1796 Ribulose-1,5 bisphosphate carboxylase/oxygenase 2529 large subunit N-methyltransferase L1797 Rigid extended P-rich 2530 L1798 Rigid extended P-rich 2531 L1799 Rigid extended P-rich 2532 L1800 Rigid extended P-rich 2533 L1801 Rigid extended P-rich 2534 L1802 Rigid extended P-rich 2535 L1803 Rigid extended P-rich 2536 L1804 Rigid extended P-rich 2537 L1805 Rigid extended P-rich 2538 L1806 Rigid extended P-rich 2539 L1807 Rigid extended P-rich 2540 L1808 Rigid extended P-rich 2541 L1809 Rigid extended P-rich 2542 L1810 Rigid extended P-rich 2543 L1811 Rigid extended P-rich 2544 L1812 Rigid helical 2545 L1813 Rigid helical 2546 L1814 Rigid helical 2547 L1815 Rigid helical 2548 L1816 Rigid helical 2549 L1817 Rigid helical 2550 L1818 Rigid helical 2551 L1819 Rigid helical 2552 L1820 RNA binding domain of rho transcription termination factor 2553 L1821 RNA binding protein ZFa 2554 L1822 Rob transcription factor 2555 L1823 Rob transcription factor 2556 L1824 RP2 lipase 2557 L1825 Rubreiythrin 2558 L1826 S-adenosylmethionine synthetase 2559 L1827 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 QFD L1828 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2560 L1829 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2561 L1830 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2562 L1831 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2563 L1832 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2564 L1833 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2565 L1834 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2566 L1835 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2567 L1836 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2568 L1837 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2569 L1838 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2570 L1839 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2571 L1840 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2572 L1841 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2573 L1842 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2574 L1843 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2575 L1844 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2576 L1845 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2577 L1846 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2578 L1847 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2579 L1848 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2580 L1849 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2581 L1850 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2582 L1851 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2583 L1852 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 2584 L1853 Scavenger mRNA-decapping enzyme DcpS ETC L1854 Scavenger mRNA-decapping enzyme DcpS NIT L1855 Scavenger mRNA-decapping enzyme DcpS 2585 L1856 Scavenger mRNA-decapping enzyme DcpS 2586 L1857 Sec18p (residues 22-210) 2587 L1858 Sec18p (residues 22-210) 2588 L1859 Sensor protein 2589 L1860 Sensor protein 2590 L1861 Septum site-determining protein MinC 2591 L1862 Serine acetyltransferase 2592 L1863 Serine protease/NTPase/helicase NS3 2593 L1864 Serine protease/NTPase/helicase NS3 2594 L1865 Serine protease/NTPase/helicase NS3 2595 L1866 Serine rich linker 2596 L1867 Serine rich linker 2597 L1868 Serine rich linker 2598 L1869 Serine rich linker 2599 L1870 Serine rich linker 2600 L1871 Serine rich linker 2601 L1872 Serine rich linker 2602 L1873 Seryl-tRNA synthetase 2603 L1874 Sialidase 2604 L1875 Sialidase B SLT L1876 Sialidase B VRE L1877 Sialidase B 2605 L1878 Sialidase B 2606 L1879 Sialidase B 2607 L1880 Sialidase B 2608 L1881 Sialidase B 2609 L1882 Sialidase B 2610 L1883 SIgnal peptIdase I SRR L1884 SIgnal peptIdase I 2611 L1885 SIgnal peptIdase I 2612 L1886 SIgnal peptIdase I 2613 L1887 SIgnal peptIdase I 2614 L1888 SIgnal peptIdase I 2615 L1889 SIgnal peptIdase I 2616 L1890 SIgnal peptIdase I 2617 L1891 SIgnal peptIdase I 2618 L1892 SIgnal peptIdase I 2619 L1893 SIgnal peptIdase I 2620 L1894 Signal recognition particle protein 2621 L1895 Signal transducer and activator of transcription1-alpha/beta NDE L1896 Signal transducer and activator of transcription1-alpha/beta SSF L1897 Signal transducer and activator of transcription1-alpha/beta 2622 L1898 Signal transducer and activator of transcription1-alpha/beta 2623 L1899 Signal transducer and activator of transcription1-alpha/beta 2624 L1900 Signal transducer and activator of transcription1-alpha/beta 2625 L1901 Signal transduction protein CBL 2626 L1902 Signal transduction protein CBL 2627 L1903 Similar to RAD54-like AKP L1904 Similar to RAD54-like EYF L1905 Similar to RAD54-like RFE L1906 Similar to RAD54-like 2628 L1907 Similar to RAD54-like 2629 L1908 Similar to RAD54-like 2630 L1909 Similar to RAD54-like 2631 L1910 Similar to RAD54-like 2632 L1911 Similar to RAD54-like 2633 L1912 Similar to RAD54-like 2634 L1913 Similar to RAD54-like 2635 L1914 Similar to RAD54-like 2636 L1915 Similar to RAD54-like 2637 L1916 SKD1 protein LMQ L1917 SKD1 protein 2638 L1918 SKD1 protein 2639 L1919 SKD1 protein 2640 L1920 SKD1 protein 2641 L1921 SKD1 protein 2642 L1922 Sll1358 protein 2643 L1923 Sll1358 protein 2644 L1924 Sll1358 protein 2645 L1925 Sll1358 protein 2646 L1926 Soluble IFN alpba/beta receptor 2647 L1927 Soluble IFN alpha/beta receptor 2648 L1928 Sporozoite-specific SAG protein 2649 L1929 Staphylococcal accessory regulator a homologue 2650 L1930 Staphylococcal nuclease domain-containing protein 1 2651 L1931 Staphylococcal nuclease domain-containing protein 1 2652 L1932 Staphylococcal nuclease domain-containing protein 1 2653 L1933 Staphylococcal nuclease domain-containing protein 1 2654 L1934 Staphylococcal nuclease domain-containing protein 1 2655 L1935 Staphylococcal nuclease domain-containing protein 1 2656 L1936 Stat protein 2657 L1937 Stat protein 2658 L1938 Stat protein 2659 L1939 Stat protein 2660 L1940 Stat protein 2661 L1941 Stat protein 2662 L1942 Stat protein 2663 L1943 Stat protein 2664 L1944 Stat protein 2665 L1945 Stat protein 2666 L1946 Stat protein 2667 L1947 Stat protein 2668 L1948 Stat protein 2669 L1949 Stat protein 2670 L1950 Stat protein 2671 L1951 Subtilisin-like protease 2672 L1952 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2673 L1953 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2674 L1954 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2675 L1955 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2676 L1956 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2677 L1957 Succinyl-CoA ligase [GDP-forming] alpha-chain, mitochondrial 2678 L1958 Succinyl-CoA synthetase beta chain ADG L1959 Succinyl-CoA synthetase beta chain RQP L1960 Succinyl-CoA synthetase beta chain 2679 L1961 Succinyl-CoA synthetase beta chain 2680 L1962 Succinyl-CoA synthetase beta chain 2681 L1963 Succinyl-CoA synthetase beta chain 2682 L1964 Succinyl-CoA synthetase beta chain 2683 L1965 Succinyl-CoA synthetase beta chain 2684 L1966 Succinyl-CoA: 3-ketoacid-coenzyme A transferase 2685 L1967 Sulfurtransferase 2686 L1968 Superantigen SMEZ-2 2687 L1969 Superoxide dismutase 1 copper chaperone 2688 L1970 Surface layer protein 2689 L1971 Surface layer protein 2690 L1972 Surface layer protein 2691 L1973 Surface layer protein 2692 L1974 Surface layer protein 2693 L1975 Surface layer protein 2694 L1976 Surface layer protein 2695 L1977 Surface layer protein 2696 L1978 T lymphocyte activation antigen 2697 L1979 T lymphocyte activation antigen 2698 L1980 T-cell receptor alpha chain C region 2699 L1981 Terminal oxygenase component of carbazole 2700 L1982 Tetanus neurotoxin 2701 L1983 Tetracycline repressor protein class D 2702 L1984 The GTP-binding protein Obg 2703 L1985 The GTP-binding protein Obg 2704 L1986 The GTP-binding protein Obg 2705 L1987 The GTP-binding protein Obg 2706 L1988 Thioredoxin domain-containing protein 4 2707 L1989 Thioredoxin domain-containing protein 4 2708 L1990 Thiosulfate sulfurtransferase IDP L1991 Thiosulfate sulfurtransferase 2709 L1992 Thiosulfate sulfurtransferase 2710 L1993 Thiosulfate sulfurtransferase 2711 L1994 Thiosulfate sulfurtransferase 2712 L1995 Threonyl-tRNA synthetase 2713 L1996 Threonyl-tRNA synthetase 2714 L1997 Threonyl-tRNA synthetase 2715 L1998 Threonyl-tRNA synthetase 2716 L1999 Threonyl-tRNA synthetase 2717 L2000 Threonyl-tRNA synthetase 2718 L2001 Threonyl-tRNA synthetase 2719 L2002 Threonyl-tRNA synthetase 2720 L2003 Threonyl-tRNA synthetase 2721 L2004 Threonyl-tRNA synthetase 1 2722 L2005 Threonyl-tRNA synthetase 1 2723 L2006 Threonyl-tRNA synthetase 1 2724 L2007 Threonyl-tRNA synthetase 1 2725 L2008 Threonyl-tRNA synthetase 1 2726 L2009 Threonyl-tRNA synthetase 1 2727 L2010 Threonyl-tRNA synthetase 1 2728 L2011 Threonyl-tRNA synthetase 1 2729 L2012 Thrombospondin 1 2730 L2013 Tick-borne encephalitis virus glycoprotein 2731 L2014 Titin 2732 L2015 Titin 2733 L2016 TLR1789 protein 2734 L2017 TLR1789 protein 2735 L2018 Topoisomerase I 2736 L2019 Topoisomerase I 2737 L2020 Toxic shock syndrome toxin-1 2738 L2021 Toxic shock syndrome toxin-1 2739 L2022 Toxic shock syndrome toxin-1 2740 L2023 Toxic shock syndrome toxin-1 2741 L2024 T-plasminogen activator F1-G VPV L2025 T-plasminogen activator F1-G 2742 L2026 TpsB transporter FhaC 2743 L2027 TpsB transporter FhaC 2744 L2028 TpsB transporter FhaC 2745 L2029 Transcarbamylase 2746 L2030 Transcarbamylase 2747 L2031 Transcription antiterminator LicT 2748 L2032 Transcription elongation factor GreB 2749 L2033 Transcription initiation factor IIa gamma chain 2750 L2034 Transcription initiation factor IIb 2751 L2035 Transcription initiation factor IIb 2752 L2036 Transcriptional regulator (NtrC family) 2753 L2037 Transcriptional regulator AefR 2754 L2038 Transcriptional regulator AefR 2755 L2039 Transcriptional regulator AefR 2756 L2040 Transcriptional regulator AefR 2757 L2041 Transcriptional regulator AefR 2758 L2042 Transcriptional regulator, AsnC family 2759 L2043 Transcriptional regulator, AsnC family 2760 L2044 Transcriptional regulator, AsnC family 2761 L2045 Transcriptional regulator, biotin repressor family 2762 L2046 Transcriptional regulator, Crp/Fnr family 2763 L2047 Transcriptional regulator, GntR family 2764 L2048 Transcriptional regulator, HTH_3 family 2765 L2049 Transcriptional regulator, HTH_3 family 2766 L2050 Transcriptional regulator, HTH_3 family 2767 L2051 Transcriptional regulator, HTH_3 family 2768 L2052 Transcriptional regulator, HTH_3 family 2769 L2053 Transcriptional regulator, laci family 2770 L2054 Transcriptional regulatory protein ZraR 2771 L2055 Transcriptional regulatory protein ZraR 2772 L2056 Transcriptional regulatory protein ZraR 2773 L2057 Transcriptional regulatory protein ZraR 2774 L2058 Transcriptional regulatory protein ZraR 2775 L2059 Transcriptional regulatory protein ZraR 2776 L2060 Transcriptional regulatory protein ZraR 2777 L2061 Transferrin receptor protein VSN L2062 Transferrin receptor protein 2778 L2063 Transferrin receptor protein 2779 L2064 Transferrin receptor protein 2780 L2065 Transferrin receptor protein 2781 L2066 Translation initiation factor 5A 2782 L2067 Translation initiation factor 5A 2783 L2068 Translation initiation factor 5A 2784 L2069 Translation initiation factor IF2/eIF5b 2785 L2070 Translation initiation factor IF2/eIF5b 2786 L2071 Transposable element mariner, complete CDS 2787 L2072 Tricorn protease 2788 L2073 Tricorn protease 2789 L2074 Tricorn protease 2790 L2075 Trigger factor 2791 L2076 Trigger factor 2792 L2077 Trigger factor 2793 L2078 TRNA CCA-adding enzyme RRI L2079 TRNA CCA-adding enzyme 2794 L2080 TRNA CCA-adding enzyme 2795 L2081 TRNA CCA-adding enzyme 2796 L2082 TRNA CCA-adding enzyme 2797 L2083 TRNA nucleotidyltransferase 2798 L2084 TRNA-splicing endonuclease 2799 L2085 Tt1467 protein LEA L2086 Tt1467 protein 2800 L2087 Tumor suppressor p53-binding protein 1 2801 L2088 Tumor suppressor p53-binding protein 1 2802 L2089 Tumor suppressor p53-binding protein 1 2803 L2090 Tumor suppressor p53-binding protein 1 2804 L2091 Type A flavoprotein FprA 2805 L2092 Type A flavoprotein FprA 2806 L2093 Type A flavoprotein FprA 2807 L2094 Type A flavoprotein FprA 2808 L2095 Type A flavoprotein FprA 2809 L2096 Type I restriction enzyme specificity protein MG438 QMH L2097 Type I restriction enzyme specificity protein MG438 2810 L2098 Type I restriction enzyme specificity protein MG438 2811 L2099 Type I restriction-modification enzyme, S subunit 2812 L2100 Type I restriction-modification enzyme, S subunit 2813 L2101 Type I site-specific restriction-modification system, R (restriction) subunit 2814 L2102 Type I site-specific restriction-modification system, R (restriction) subunit 2815 L2103 Type I site-specific restriction-modification system, R (restriction) subunit 2816 L2104 Type II DNA topoisomerase VI subunit B 2817 L2105 Type II DNA topoisomerase VI subunit B 2818 L2106 Type II DNA topoisomerase VI subunit B 2819 L2107 Type II DNA topoisomerase VI subunit B 2820 L2108 Type II DNA topoisomerase VI subunit B 2821 L2109 Type II DNA topoisomerase VI subunit B 2822 L2110 Type II DNA topoisomerase VI subunit B 2823 L2111 Type II DNA topoisomerase VI subunit B 2824 L2112 Type II DNA topoisomerase VI subunit B 2825 L2113 Type II DNA topoisomerase VI subunit B 2826 L2114 Type II DNA topoisomerase VI subunit B 2827 L2115 Type VI secretion system component 2828 L2116 Type VI secretion system component 2829 L2117 Type VI secretion system component 2830 L2118 Tyrosine-protein kinase receptor UFO 2831 L2119 Tyrosine-protein kinase receptor UFO 2832 L2120 Tyrosine-protein kinase ZAP-70 2833 L2121 Tyrosine-protein kinase ZAP-70 2834 L2122 Tyrosyl-DNA phosphodiesterase 2835 L2123 Tyrosyl-DNA phosphodiesterase 2836 L2124 Ubiquitin carboxyl-terminal hydrolase 7 2837 L2125 UDP-galactopyranose mutase 2838 L2126 UDP-galactopyranose mutase 2839 L2127 UDP-galactopyranose mutase 2840 L2128 UDP-galactopyranose mutase 2841 L2129 UDP-galactopyranose mutase 2842 L2130 UDP-glucose dehydrogenase 2843 L2131 UDP-N-acetylmuramate-L-alanine ligase 2844 L2132 UDP-N-acetylmuramate-L-alanine ligase 2845 L2133 UDP-N-acetylmuramoylalanine--D-glutamate ligase 2846 L2134 UDP-N-acetylmuramoylalanine--D-glutamate ligase 2847 L2135 UDP-N-acetylmuramoylalanine-D-glutamyl-lysine-D-alanyl-D-alanine 2848 ligase, MurF protein L2136 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2849 L2137 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2850 L2138 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2851 L2139 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2852 L2140 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2853 L2141 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2854 L2142 UDP-N-acetylmuramoylalanyl-D-glutamate--2,6-diaminopimelate ligase 2855 L2143 Uncharacterized conserved protein 2856 L2144 Uncharacterized conserved protein 2857 L2145 Uncharacterized GST-like protein yfcF 2858 L2146 Uncharacterized GST-like proteinprotein 2859 L2147 Uncharacterized GST-like proteinprotein 2860 L2148 Uncharacterized GST-like proteinprotein 2861 L2149 Uncharacterized protein 2862 L2150 Uncharacterized protein 2863 L2151 Uncharacterized protein BT_1490 2864 L2152 Uncharacterized protein ypfl TLR L2153 Uncharacterized protein ypfl VHP L2154 Uncharacterized protein ypfl 2865 L2155 Uncharacterized protein ypfl 2866 L2156 Uncharacterized protein ypfl 2867 L2157 Uncharacterized protein ypfl 2868 L2158 Uncharacterized protein ypfl 2869 L2159 Uncharacterized protein ypfl 2870 L2160 Uncharacterized protein ypfl 2871 L2161 Uncharacterized protein ypfl 2872 L2162 Uncharacterized protein ypfl 2873 L2163 Uncharacterized protein ypfl 2874 L2164 Uncharacterized protein ypfl 2875 L2165 Uncharacterized protein ypfl 2876 L2166 Uncharacterized protein ypfl 2877 L2167 Uncharacterized protein ypfl 2878 L2168 Uncharacterized protein ypfl 2879 L2169 Unknown protein 2880 L2170 Unknown protein 2881 L2171 UPF0131 protein ykqA 2882 L2172 UPF0131 protein ykqA 2883 L2173 UPF0131 protein ykqA 2884 L2174 UPF0348 protein MJ0951 2885 L2175 UPF0348 protein MJ0951 2886 L2176 UPF0348 protein MJ0951 2887 L2177 UPF0348 protein MJ0951 2888 L2178 UPF0348 protein MJ0951 2889 L2179 UPF0348 protein MJ0951 2890 L2180 UPF0348 protein MJ0951 2891 L2181 UPF0348 protein MJ0951 2892 L2182 URE2 protein 2893 L2183 Uridine diphospho-N-acetylenolpyruvylglucosaminereductase TAK L2184 Uridine diphospho-N-acetylenolpyruvylglucosaminereductase 2894 L2185 Uridine diphospho-N-acetylenolpyruvylglucosaminereductase 2895 L2186 Uridine diphospho-N-acetylenolpyruvylglucosaminereductase 2896 L2187 Uridine diphospho-N-acetylenolpyruvylglucosaminereductase 2897 L2188 Urokinase plasminogen activator surface receptor 2898 L2189 Urokinase plasminogen activator surface receptor 2899 L2190 Vascular cell adhesion molecule-1 2900 L2191 VCP-like ATPase 2901 L2192 VCP-like ATPase 2902 L2193 Viral CASP8 and FADD-like apoptosis regulator 2903 L2194 Vitamin K-dependent protein Z 2904 L2195 VP1 protein 2905 L2196 V-type ATP synthase alpha chain 2906 L2197 Xaa-Pro aminopeptidase 2907 L2198 Xaa-Pro aminopeptidase 2908 L2199 Xaa-Pro aminopeptidase 2909 L2200 Xaa-Pro aminopeptidase 2910 L2201 Xanthine dehydrogenase 2911 L2202 Xanthine dehydrogenase 2912 L2203 Xanthine dehydrogenase 2913 L2204 Xanthine dehydrogenase 2914 L2205 X-prolyl dipeptidyl aminopeptidase KSY L2206 X-prolyl dipeptidyl aminopeptidase LDG L2207 X-prolyl dipeptidyl aminopeptidase LLE L2208 X-prolyl dipeptidyl aminopeptidase TVS L2209 X-prolyl dipeptidyl aminopeptidase 2915 L2210 X-prolyl dipeptidyl aminopeptidase 2916 L2211 X-prolyl dipeptidyl aminopeptidase 2917 L2212 X-prolyl dipeptidyl aminopeptidase 2918 L2213 X-prolyl dipeptidyl aminopeptidase 2919 L2214 X-prolyl dipeptidyl aminopeptidase 2920 L2215 X-prolyl dipeptidyl aminopeptidase 2921 L2216 X-prolyl dipeptidyl aminopeptidase 2922 L2217 X-prolyl dipeptidyl aminopeptidase 2923 L2218 X-prolyl dipeptidyl aminopeptidase 2924 L2219 X-prolyl dipeptidyl aminopeptidase 2925 L2220 X-prolyl dipeptidyl aminopeptidase 2926 L2221 X-prolyl dipeptidyl aminopeptidase 2927 L2222 X-prolyl dipeptidyl aminopeptidase 2928 L2223 X-prolyl dipeptidyl aminopeptidase 2929 L2224 X-prolyl dipeptidyl aminopeptidase 2930 L2225 X-prolyl dipeptidyl aminopeptidase 2931 L2226 X-prolyl dipeptidyl aminopeptidase 2932 L2227 X-prolyl dipeptidyl aminopeptidase 2933 L2228 X-prolyl dipeptidyl aminopeptidase 2934 L2229 X-prolyl dipeptidyl aminopeptidase 2935 L2230 X-prolyl dipeptidyl aminopeptidase 2936 L2231 X-prolyl dipeptidyl aminopeptidase 2937 L2232 X-prolyl dipeptidyl aminopeptidase 2938 L2233 Xylosidase/arabinosidase 2939 L2234 Xylosidase/arabinosidase 2940 L2235 Xylosidase/arabinosidase 2941 L2236 Xylosidase/arabinosidase 2942 L2237 Xylosidase/arabinosidase 2943 L2238 Xylosidase/arabinosidase 2944 L2239 Xylosidase/arabinosidase 2945 L2240 YkoF 2946 L2241 YkuI protein 2947

Internal ribosomal entry site (IRES) is a nucleotide sequence (>500 nucleotides) that allows for initiation of translation in the middle of an mRNA sequence (Kim. J. H. et al., 2011 PLoS One (4): e18556; the contents of which are herein incorporated by reference in its entirety). Use of an IRES sequence ensures co-expression of genes before and after the IRES, though the sequence following the IRES may be transcribed and translated at lower levels than the sequence preceding the IRES sequence.

2A peptides are small “self-cleaving” peptides (18-22 amino acids) derived from viruses such as foot-and-mouth disease virus (F2A), porcine teschovirus-1 (P2A). Thoseaasigna virus (T2A), or equine rhinitis A virus (E2A). The 2A designation refers specifically to a region of picornavirus polyproteins that lead to a ribosomal skip at the glycyl-prolyl bond in the C-terminus of the 2A peptide (Kim. J. H. et al., 2011. PLoS One 6(4): e18556; the contents of which are herein incorporated by reference in its entirety). This skip results in a cleavage between the 2A peptide and its immediate downstream peptide. As opposed to IRES linkers, 2A peptides generate stoichiometric expression of proteins flanking the 2A peptide and their shorter length can be advantageous in generating viral expression vectors.

Some payload regions encode linkers comprising furin cleavage sites. Furin is a calcium dependent serine endoprotease that cleaves proteins just downstream of a basic amino acid target sequence (Arg-X-(Arg,Lys)-Arg) (Thomas. G., 2002. Nature Reviews Molecular Cell Biology 3(10); 753-66; the contents of which are herein incorporated by reference in its entirety). Furin is enriched in the trans-golgi network where it is involved in processing cellular precursor proteins. Furin also plays a role in activating a number of pathogens. This activity can be taken advantage of for expression of polypeptides of the invention.

In some embodiments, the payload region may encode one or more linkers comprising cathepsin, matrix metalloproteinases or legumain cleavage sites. Such linkers are described e.g. by Cizeau and Macdonald in International Publication No. WO2008052322, the contents of which are herein incorporated in their entirety. Cathepsins are a family of proteases with unique mechanisms to cleave specific proteins Cathepsin B is a cysteine protease and cathepsin D is an aspartyl protease. Matrix metalloproteinases are a family of calcium-dependent and zinc-containing endopeptidases. Legumain is an enzyme catalyzing the hydrolysis of (-Asn-Xaa-) bonds of proteins and small molecule substrates.

In some embodiments, payload regions may encode linkers that are not cleaved. Such linkers may include a simple amino acid sequence, such as a glycine rich sequence. In some cases, linkers may comprise flexible peptide linkers comprising glycine and serine residues. The linker may comprise flexible peptide linkers of different lengths, e.g. nxG4S, where n=1-10 (SEQ ID NO:9222) and the length of the encoded linker varies between 5 and 50 amino acids. In a non-limiting example, the linker may be 5xG4S (SEQ ID NO: 9221) encoded by SEQ ID NO: 903. These flexible linkers are small and without side chains so they tend not to influence secondary protein structure while providing a flexible linker between antibody segments (George. R. A., et al., 2002. Protein Engineering 15(11): 871-9; Huston, J. S. et al., 1988. PNAS 85:5879-83, and Shan. D. et al., 1999. Journal of Immunology, 162(11):6589-95; the contents of each of which are herein incorporated by reference in their entirety). Furthermore, the polarity of the serine residues improves solubility and prevents aggregation problems.

In some embodiments, payload regions of the invention may encode small and unbranched serine-rich peptide linkers, such as those described by Huston et al, in U.S. Pat. No. 5,525,491, the contents of which are herein incorporated in their entirety Polypeptides encoded by the payload region of the invention, linked by serine-rich linkers, have increased solubility.

In some embodiments, payload regions of the invention may encode artificial linkers, such as those described by Whitlow and Filpula in U.S. Pat. No. 5,856,456 and Ladner et al, in U.S. Pat. No. 4,946,778, the contents of each of which are herein incorporated by their entirety.

Viral Genome Component: Introns

In one embodiment, the payload region comprises at least one element to enhance the expression such as one or more introns or portions thereof. Non-limiting examples of introns include, MVM (67-97 bps), F.IX truncated intron 1 (300 bps), β-globin SD/immunoglobulin heavy chain splice acceptor (250 bps), adenovirus splice donor/immunoglobin splice acceptor (500 bps), SV40 late splice donor/splice acceptor (19S/16S) (180 bps) and hybrid adenovirus splice donor/IgG splice acceptor (230 bps).

In one embodiment, the intron or intron portion may be 100-500 nucleotides in length. The intron may have a length of 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490 or 500, The intron may have a length between 80-100, 80-120, 80-140, 80-160, 80-180, 80-200, 80-250, 80-300, 80-350, 80-400, 80-450, 80-500, 200-300, 200-400, 200-500, 300-400, 300-500, or 400-500.

Payloads of the Invention

The AAV particles of the present disclosure comprise at least one payload region. As used herein. “payload” or “payload region” refers to one or more polynucleotides or polynucleotide regions encoded by or within a viral genome or an expression product of such polynucleotide or polynucleotide region, e.g., a transgene, a polynucleotide encoding a polypeptide or multi-polypeptide or a modulatory nucleic acid or regulatory nucleic acid Payloads of the present invention typically encode polypeptides (e.g., antibodies or antibody-based compositions) or fragments or variants thereof.

The payload region may be constructed in such a way as to reflect a region similar to or mirroring the natural organization of an mRNA.

The payload region may comprise a combination of coding and non-coding nucleic acid sequences.

In some embodiments, the AAV payload region may encode a coding or non-coding RNA.

In one embodiment, the AAV particle comprises a viral genome with a payload region comprising nucleic acid sequences encoding more than one polypeptide of interest (e.g., an antibody). In such an embodiment, a viral genome encoding more than one polypeptide may be replicated and packaged into a viral particle. A target cell transduced with a viral particle comprising more than one polypeptide may express each of the polypeptides in a single cell.

In one embodiment, as shown in FIG. 1, an AAV particle comprises a viral genome with a payload region comprising a nucleic acid sequence encoding a heavy chain and a light chain of an antibody. The heavy chain and light chain are expressed and assembled to form the antibody which is secreted.

In one embodiment, the payload region may comprise the components as shown in FIG. 2. The payload region 110 is located within the viral genome 100. At the 5′ and/or the 3′ end of the payload region 110 there may be at least one inverted terminal repeat (ITR) 120. Within the payload region, there is a promoter region 130, an intron region 140 and a coding region 150. When the coding region 150 comprises a heavy chain region 151 and light chain region 152 of an antibody, the two chains may be separated by a linker region 155.

In one embodiment, the coding region may comprise a heavy and light chain sequence and a linker. As shown in FIG. 3, the payload region may comprise a heavy chain and light chain sequence separated by a linker and/or a cleavage site. In one embodiment, the heavy and light chain sequence is sequence separated by an IRES sequence (1 and 2) In one embodiment, the heavy and light chain sequence is separated by a foot and mouth virus sequence (3 and 4). In one embodiment, the heavy and light chain sequence is separated by a foot and mouth virus sequence and a furin cleavage site (5 and 6) In one embodiment, the heavy and light chain sequence is separated by a porcine teschovirus-1 virus sequence (7 and 8) In one embodiment, the heavy and light chain sequence is separated by a porcine teschovirus-1 virus and a furin cleavage site (9 and 10). In one embodiment, the heavy and light chain sequence is separated by a 5xG4S (SEQ ID NO: 9221) sequence (11).

Where the AAV particle payload region encodes a polypeptide, the polypeptide may be a peptide or protein. A protein encoded by the AAV particle payload region may comprise an antibody, an antibody related composition, a secreted protein, an intracellular protein, an extracellular protein, and/or a membrane protein. The encoded proteins may be structural or functional. In addition to the antibodies or antibody-based composition, proteins encoded by the payload region may include, in combination, certain mammalian proteins involved in immune system regulation. The AAV viral genomes encoding polypeptides described herein may be useful in the fields of human disease, viruses, infections veterinary applications and a variety of in vivo and in vitro settings.

In some embodiments, the AAV particles are useful in the field of medicine for the treatment, prophylaxis, palliation or amelioration of neurological diseases and/or disorders.

Antibodies and Antibody-Based Compositions

Payload regions of the AAV particles of the invention may encode polypeptides that form one or more functional antibodies or antibody-based compositions. As used herein, the term “antibody” is referred to in the broadest sense and specifically covers various embodiments including, but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies formed from at least two intact antibodies), and antibody fragments (e.g., diabodies) so long as they exhibit a desired biological activity (e.g., “functional”). Antibodies are primarily amino-acid based molecules but may also comprise one or more modifications (including, but not limited to the addition of sugar moieties, fluorescent moieties, chemical tags, etc.)

As used herein, “antibody-based” or “antibody-derived” compositions are monomeric or multi-meric polypeptides which comprise at least one amino-acid region derived from a known or parental antibody sequence and at least one amino acid region derived from a non-antibody sequence, e.g., mammalian protein.

Payload regions may encode polypeptides that form or function as any antibody, including antibodies that are known in the art and/or antibodies that are commercially available. The encoded antibodies may be therapeutic, diagnostic, or for research purposes. Further, polypeptides of the invention may include fragments of such antibodies or antibodies that have been developed to comprise one or more of such fragments (e.g., variable domains or complementarity determining regions (CDRs)).

In one embodiment, the viral genome of the AAV particles may comprise nucleic acids which have been engineered to enable expression of antibodies, antibody fragments, or components of any of those described in U.S. Pat. No. 7,041,807 related to YYX epitope; US20090175884, US20110305630, US20130330275 related to misfolded proteins in cancer; US20040175775 related to PrP in eye fluid, US20030114360 related to copolymers and methods of treating prion-related diseases: WO2009121176 insulin-induced gene peptide compositions, US20030022243, WO2003000853 related to protein aggregation assays; WO200078344 related to prion protein peptides and uses thereof. Each of these publications are incorporated by reference in their entireties.

Antibody Generation

In some embodiments, viral genomes of the AAV particles of the invention may encode antibodies or antibody-based compositions produced using methods known in the art. Such methods may include, but are not limited to immunization and display technologies (e.g., phage display, yeast display, and ribosomal display). Antibodies may be developed, for example, using any naturally occurring or synthetic antigen. As used herein, an “antigen” is an entity which induces or evokes an immune response in an organism. An immune response is characterized by the reaction of the cells, tissues and/or organs of an organism to the presence of a foreign entity. Such an immune response typically leads to the production by the organism of one or more antibodies against the foreign entity, e.g., antigen or a portion of the antigen. As used herein. “antigens” also refer to binding partners for specific antibodies or binding agents in a display library.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be derived from antibodies produced using hybridoma technology. Host animals (e.g. mice, rabbits, goats, and llamas) may be immunized by an injection with an antigenic protein to elicit lymphocytes that specifically bind to the antigen. Lymphocytes may be collected and fused with immortalized cell lines to generate hybridomas which can be cultured in a suitable culture medium to promote growth. The antibodies produced by the cultured hybridomas may be subjected to analysis to determine binding specificity of the antibodies for the target antigen. Once antibodies with desirable characteristics are identified, corresponding hybridomas may be subcloned through limiting dilution procedures and grown by standard methods. The antibodies produced by these cells may be isolated and purified using standard immunoglobulin purification procedures.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be produced using heavy and light chain variable region cDNA sequences selected from hybridomas or from other sources. Sequences encoding antibody variable domains expressed by hybridomas may be determined by extracting RNA molecules from antibody-producing hybridoma cells and producing cDNA by reverse transcriptase polymerase chain reaction (PCR). PCR may be used to amplify cDNA using primers specific for heavy and light chain sequences. PCR products may then be subcloned into plasmids for sequence analysis. Antibodies may be produced by insertion of resulting variable domain sequences into expression vectors.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be generated using display technologies. Display technologies used to generate polypeptides of the invention may include any of the display techniques (e.g display library screening techniques) disclosed in International Patent Application No. WO2014074532, the contents of which are herein incorporated by reference in their entirety. In some embodiments, synthetic antibodies may be designed, selected or optimized by screening target antigens using display technologies (e.g. phage display technologies). Phage display libraries may comprise millions to billions of phage particles, each expressing unique antibody fragments on their viral coats. Such libraries may provide richly diverse resources that may be used to select potentially hundreds of antibody fragments with diverse levels of affinity for one or more antigens of interest (McCafferty, et al., 1990. Nature, 348:552-4; Edwards. B. M. et al., 2003. JMB, 334: 103-18; Schofield, D. et al., 2007. Genome Biol. 8. R254 and Pershad, K. et al., 2010 Protein Engineering Design and Selection, 23.279-88; the contents of each of which are herein incorporated by reference in their entirety). Often, the antibody fragments present in such libraries comprise scFv antibody fragments, comprising a fusion protein of V_(H) and V_(L) antibody domains joined by a flexible linker. In some cases, scFvs may contain the same sequence with the exception of unique sequences encoding variable loops of the CDRs. In some cases, scFvs are expressed as fusion proteins, linked to viral coat proteins (e.g. the N-terminus of the viral pIII coat protein) V_(L) chains may be expressed separately for assembly with V_(H) chains in the periplasm prior to complex incorporation into viral coats. Precipitated library members may be sequenced from the bound phage to obtain cDNA encoding desired scFvs. Antibody variable domains or CDRs from such sequences may be directly incorporated into antibody sequences for recombinant antibody production, or mutated and utilized for further optimization through in vitro affinity maturation.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be produced using yeast surface display technology, wherein antibody variable domain sequences may be expressed on the cell surface of Saccharomyces cerevisiae. Recombinant antibodies may be developed by displaying the antibody fragment of interest as a fusion to e.g. Aga2p protein on the surface of the yeast, where the protein interacts with proteins and small molecules in a solution, scFvs with affinity towards desired receptors may be isolated from the yeast surface using magnetic separation and flow cytometry. Several cycles of yeast surface display and isolation may be done to attain scFvs with desired properties through directed evolution.

In one embodiment, the sequence of the polypeptides to be encoded in the viral genomes of the invention (e.g., antibodies) may be designed by VERSITOPE™ Antibody Generation and other methods used by BIOATLA® and described in United States Patent Publication No. US20130281303, the contents of which are herein incorporated by reference in their entirety. In brief, recombinant monoclonal antibodies are derived from B-cells of a host immuno-challenged with one or more target antigens. These methods of antibody generation do not rely on immortalized cell lines, such as hybridoma, thereby avoiding some of the associated challenges i.e., genetic instability and low production capacity, producing high affinity and high diversity recombinant monoclonal antibodies. In one embodiment, the method is a natural diversity approach. In another embodiment, the method is a high diversity approach.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be generated using BIOATLA® natural diversity approach. In the natural diversity approach of generating recombinant monoclonal antibodies described in United States Patent Publication No. US20130281303, the original pairings of variable heavy (V_(H)) and variable light (V_(L)) domains are retained from the host, yielding recombinant monoclonal antibodies that are naturally paired. These may be advantageous due to a higher likelihood of functionality as compared to non-natural pairings of V_(H) and V_(L). To produce the recombinant monoclonal antibodies, first a non-human host (i.e., rabbit, mouse, hamster, guinea pig, camel or goat) is immuno-challenged with an antigen of interest. In some embodiments, the host may be a previously challenged human patient. In other embodiments, the host may not have been immuno-challenged. B-cells are harvested from the host and screened by fluorescence activated cell sorting (FACS), or other method, to create a library of B-cells enriched in B-cells capable of binding the target antigen. The cDNA obtained from the mRNA of a single B-cell is then amplified to generate an immunoglobulin library of V_(H) and V_(L) domains. This library of immunoglobulins is then cloned into expression vectors capable of expressing the V_(H) and V_(L) domains, wherein the V_(H) and V_(L) domains remain naturally paired. The library of expression vectors is then used in an expression system to express the V_(H) and V_(L) domains in order to create an antibody library. Screening of the antibody library yields antibodies able to bind the target antigen, and these antibodies can be further characterized. Characterization may include one or more of the following: isoelectric point, thermal stability, sedimentation rate, folding rate, neutralization or antigen activity, antagonist or agonistic activity, expression level, specific and non-specific binding, inhibition of enzymatic activity, rigidity/flexibility, shape, charge, stability across pH, in solvents, under UV radiation, in mechanical stress conditions, or in sonic conditions, half-life and glycosylation.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be generated using BIOATLA® high diversity approach. In the high diversity approach of generating recombinant monoclonal antibodies described in United States Patent Publication No. US20130281303, additional pairings of variable heavy (V_(H)) and variable light (V_(L)) domains are attained. To produce the recombinant monoclonal antibodies, B-cells harvested from the host are screened by fluorescence activated cell sorting (FACS), panning, or other method, to create a library of B-cells enriched in B-cells capable of binding the target antigen. The cDNA obtained from the mRNA of the pooled B-cells is then amplified to generate an immunoglobulihn library of V_(H) and V_(L) domains. This library of immunoglobulins is then used in a biological display system (mammalian, yeast or bacterial cell surface display systems) to generate a population of cells displaying antibodies, fragments or derivatives comprising the V_(H) and V_(L) domains wherein, the antibodies, fragments or derivatives comprise V_(H) and V_(L) domain combinations that were not present in the B-cells in vivo. Screening of the cell population by FACS, with the target antigen, yields a subset of cells capable of binding the target antigen and the antibodies displayed on these cells can be further characterized. In an alternate embodiment of the high diversity approach, the immunoglobulin library comprises only V_(H) domains obtained from the B-cells of the immuno-challenged host, while the V_(L) domain(s) are obtained from another source.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be evolved using BIOATLA® comprehensive approaches. The methods of generating recombinant monoclonal antibodies as described in United States Patent Publication No. US20130281303, further comprises evolving the recombinant antibody by comprehensive positional evolution (CPE™), CPE™ followed by comprehensive protein synthesis (CPS™), PCR shuffling, or other method.

In one embodiment, the sequence of the polypeptides to be encoded in the viral genomes of the invention (e.g., antibodies) may be derived from any of the BIOATLA® protein evolution methods described in International Publication WO2012009026, the contents of which are herein incorporated by reference in their entirety. In this method, mutations are systematically performed throughout the polypeptide or molecule of interest, a map is created providing useful informatics to guide the subsequent evolutionary steps. Not wishing to be bound by theory, these evolutionary methods typically start with a template polypeptide and a mutant is derived therefrom, which has desirable properties or characteristics. Non-limiting examples of evolutionary techniques include polymerase chain reaction (PCR), error prone PCR, oligonucleotide-directed mutagenesis, cassette mutagenesis, shuffling, assembly PCR, sexual PCR mutagenesis, in vivo mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis, in vitro mutagenesis, ligase chain reaction, oligonucleotide synthesis or any combination thereof.

In one embodiment, the BIOATLA® evolution method is Comprehensive Positional Evolution (CPE™). In CPE, naturally occurring amino acid variants are generated for each of the codons of the template polypeptide, wherein 63 different codon options exist for each amino acid variant. A set of polypeptides with single amino acid mutations are generated and the mutations are then confirmed by sequencing or other method known in the art and each amino acid change screened for improved function, neutral mutations, inhibitory mutations, expression and compatibility with the host system. An EvoMap™ is created that describes in detail the effects of each amino acid mutation on the properties and characteristics of that polypeptide. The data from the EvoMap™ may be utilized to produce polypeptides with more than one amino acid mutation, wherein the resultant multi-site mutant polypeptides can be screened for desirable characteristics.

In one embodiment, the BIOATLA® evolution method is Synergy Evolution, wherein an EvoMap™ is used to identify amino acid positions to introduce 2-20 mutations simultaneously to produce a combinatorial effect. The resulting multi-site mutant polypeptides may be screened on one or more pre-determined characteristics to identify “upmutants” wherein the function of the mutant is improved as compared to the parent polypeptide. In one embodiment, Synergy Evolution is used to enhance binding affinity of an antibody.

In one embodiment, the BIOATLA® evolution method is Flex Evolution, wherein an EvoMap™ is used to identify fully mutable sites within a polypeptide that may then be targeted for alteration, such as introduction of glycosylation sites or chemical conjugation.

In one embodiment, the BIOATLA® evolution method is Comprehensive Positional Insertion Evolution (CPI™), wherein an amino acid is inserted after each amino acid of a template polypeptide to generate a set of lengthened poly peptides. CPI may be used to insert 1, 2, 3, 4, or 5 amino acids at each new position. The resultant lengthened polypeptides are sequenced and assayed for one or more pre-determined properties and evaluated in comparison to its template or parent molecule. In one embodiment, the binding affinity and immunogenicity of the resultant poly peptides are assayed. In one embodiment, the lengthened poly peptides are further mutated and mapped to identify polypeptides with desirable characteristics.

In one embodiment, the BIOATLA® evolution approach is Comprehensive Positional Deletion Evolution (CPD™), wherein each amino acid of the template polypeptide is individually and systematically deleted one at a time. The resultant shortened polypeptides are then sequenced and evaluated by assay for at least one pre-determined feature. In one embodiment, the shortened polypeptides are further mutated and mapped to identify polypeptides with desirable characteristics.

In one embodiment, the BIOATLA® evolution approach is Combinatorial Protein Synthesis (CPS™), wherein mutants identified in CPE, CPI, CPD or other evolutionary technique are combined for polypeptide synthesis. These combined mutant polypeptides are then screened for enhanced properties and characteristics. In one embodiment CPS is combined with any of the aforementioned evolutionary or polypeptide synthesis methods.

In one embodiment, the sequence of the polypeptides to be encoded in the viral genomes of the invention (e.g., antibodies) may be derived from the BIOATLA® Comprehensive Integrated Antibody Optimization (CIAO!™) described in U.S. Pat. No. 8,859,467, the contents of which are herein incorporated by reference in their entirety. The CIAO!™ method allows for simultaneous evolution of polypeptide performance and expression optimization, within a eukaryotic cell host (i.e., mammalian or yeast cell host). First, an antibody library is generated in a mammalian cell production host by antibody cell surface display, wherein the generated antibody library targets a particular antigen of interest. The antibody library is then screened by any method known in the art, for one or more properties or characteristics. One or more antibodies of the library, with desirable properties or characteristics are chosen for further poly peptide evolution by any of the methods known in the art, to produce a library of mutant antibodies by antibody cell surface display in a mammalian cell production host. The generated mutant antibodies are screened for one or more predetermined properties or characteristics, whereby an upmutant is selected, wherein the upmutant has enhanced or improved characteristics as compared to the parent template poly peptide.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be humanized by the methods of BIOATLA® as described in United States Patent Publication US20130303399, the contents of which are herein incorporated by reference in their entirety. In this method, for generating enhanced full length humanized antibodies in mammalian cells, no back-mutations are required to retain affinity to the antigen and no CDR grafting or phage-display is necessary. The generated humanized antibody has reduced immunogenicity and equal or greater affinity for the target antigen as compared to the parent antibody. The variable regions or CDRs of the generated humanized antibody are derived from the parent or template, whereas the framework and constant regions are derived from one or more human antibodies. To start, the parent, or template antibody is selected, cloned and each CDR sequence identified and synthesized into a CDR fragment library. Double stranded DNA fragment libraries for V_(H) and V_(L) are synthesized from the CDR fragment encoding libraries, wherein at least one CDR fragment library is derived from the template antibody and framework (FW) fragment encoding libraries, wherein the FW fragment library is derived from a pool of human frameworks obtained from natively expressed and functional human antibodies. Stepwise liquid phase ligation of FW and CDR encoding fragments is then used to generate both V_(H) and V_(L) fragment libraries. The V_(H) and V_(L) fragment libraries are then cloned into expression vectors to create a humanization library, which is further transfected into cells for expression of full length humanized antibodies, and used to create a humanized antibody library. The humanized antibody library is then screened to determine expression level of the humanized antibodies, affinity or binding ability for the antigen, and additional improved or enhanced characteristics, as compared to the template or parent antibody. Non-limiting examples of characteristics that may be screened include equilibrium dissociation constant (K_(D)), stability, melting temperature (T_(m)), pI, solubility, expression level, reduced immunogenicity and improved effector function.

In one embodiment, the sequences of the polypeptides to be encoded in the viral genomes of the invention may be generated by the BIOATLA® method for preparing conditionally active antibodies as described in International Publications WO02016033331 and WO2016036916, the contents of which are herein incorporated by reference in their entirety. As used herein, the term “conditionally active” refers to a molecule that is active at an aberrant condition. Further, the conditionally active molecule may be virtually inactive at normal physiological conditions. Aberrant conditions may result from changes in pH, temperature, osmotic pressure, osmolality, oxidative stress, electrolyte concentration, and/or chemical or proteolytic resistance, as non-limiting examples.

The method of preparing a conditionally active antibody is described in International Publications WO2016033331 and WO2016036916 and summarized herewithin. Briefly, a wild-type polypeptide is selected and the DNA is evolved to create mutant DNAs. Non-limiting examples of evolutionary techniques that may be used to evolve the DNA include polymerase chain reaction (PCR), error prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR sexual PCR mutagenesis, in vivo mutagenesis, site-specific mutagenesis, gene reassembly, gene site saturated mutagenesis, in vitro mutagenesis, ligase chain reaction, oligonucleotide synthesis or any combination thereof. Once mutant DNAs are created, they are expressed in a eukaryotic cell production host (i.e., fungal, insect, mammalian, adenoviral, plant), wherein a mutant polypeptide is produced. The mutant poly peptide and the corresponding wild-type polypeptide are then subjected to assays under both normal physiological conditions and aberrant conditions in order to identify mutants that exhibit a decrease in activity in the assay at normal physiological conditions as compared to the wild-type polypeptide and/or an increase in activity in the assay under aberrant conditions, as compared to the corresponding wild-type polypeptide. The desired conditionally active mutant may then be produced in the aforementioned eukaryotic cell production host.

In one embodiment, the conditionally active antibody is a “mirac protein” as described by BIOATLA® in U.S. Pat. No. 8,709,755, the contents of which are herein incorporated by reference in their entirety. As used herein “mirac protein” refers to a conditionally active antibody that is virtually inactive at body temperature but active at lower temperatures.

In one embodiment, the sequence of the polypeptides to be encoded in the viral genomes of the invention (e.g., antibodies) may be derived based on any of the BIOATLA™ methods including, but not limited to, VERSITOPE™ Antibody Generation, natural diversity approaches and high diversity approaches for generating monoclonal antibodies, methods for generation of conditionally active polypeptides, humanized antibodies, mirac proteins, multi-specific antibodies or cross-species active mutant polypeptides. Comprehensive Integrated Antibody Optimization (CIAO!®), Comprehensive Positional Evolution (CPE™). Synergy Evolution, Flex Evolution, Comprehensive Positional Insertion Evolution (CPI™). Comprehensive Positional Deletion Evolution (CPD™), Combinatorial Protein Synthesis (CPS®), or any combination thereof. These methods are described in U.S. Pat. Nos. 8,859,467 and 8,709,755 and United States Publication Nos US20130281303, US20130303399, US20150065690, US20150252119, US20150086562 and US20100138945, and International Publication Nos. WO201505888, WO2012009026, WO2011109726, WO2016036916, and WO2016033331, the contents of each of which are herein incorporated by reference in their entirety.

Antibody Fragments and Variants

In some embodiments, antibody fragments encoded by payloads of the invention comprise antigen binding regions from intact antibodies. Examples of antibody fragments may include, but are not limited to Fab, Fab′, F(ab′)₂, and Fv fragments; diabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, each with a single antigen-binding site. Also produced is a residual “Fc” fragment, whose name reflects its ability to crystallize readily. Pepsin treatment yields an F(ab′)₂ fragment that has two antigen-binding sites and is still capable of cross-linking antigen. Compounds and/or compositions of the present invention may comprise one or more of these fragments. For the purposes herein, an “antibody” may comprise a heavy and light variable domain as well as an Fc region.

In one embodiment, the Fc region may be a modified Fc region, as described in US Patent Publication US20150065690, wherein the Fc region may have a single amino acid substitution as compared to the corresponding sequence for the wild-type Fc region, wherein the single amino acid substitution yields an Fc region with preferred properties to those of the wild-type Fc region. Non-limiting examples of Fc properties that may be altered by the single amino acid substitution include bind properties or response to pH conditions

As used herein, the term “native antibody” refers to a usually heterotetrameric glycoprotein of about 150,000 Daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Genes encoding antibody heavy and light chains are known and segments making up each have been well characterized and described (Matsuda, F. et al., 1998. The Journal of Experimental Medicine, 188(11); 2151-62 and Li. A. et al., 2004. Blood, 103(12, 4602-9, the content of each of which are herein incorporated by reference in their entirety). Each light chain is linked to a heavy chain by one covalent disulfide bond, while the number of disulfide linkages varies among the heavy chains of different immunoglobulin isotypes. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at one end a variable domain (V_(H)) followed by a number of constant domains. Each light chain has a variable domain at one end (V_(L)) and a constant domain at its other end; the constant domain of the light chain is aligned with the first constant domain of the heavy chain, and the light chain variable domain is aligned with the variable domain of the heavy chain.

As used herein, the term “variable domain” refers to specific antibody domains found on both the antibody heavy and light chains that differ extensively in sequence among antibodies and are used in the binding and specificity of each particular antibody for its particular antigen. Variable domains comprise hypervariable regions. As used herein, the term “hypervariable region” refers to a region within a variable domain comprising amino acid residues responsible for antigen binding. The amino acids present within the hypervariable regions determine the structure of the complementarity determining regions (CDRs) that become part of the antigen-binding site of the antibody. As used herein, the term “CDR” refers to a region of an antibody comprising a structure that is complimentary to its target antigen or epitope Other portions of the variable domain, not interacting with the antigen, are referred to as framework (FW) regions. The antigen-binding site (also known as the antigen combining site or paratope) comprises the amino acid residues necessary to interact with a particular antigen. The exact residues making up the antigen-binding site are typically elucidated by co-crystallography with bound antigen, however computational assessments can also be used based on comparisons with other antibodies (Strohl, W. R. Therapeutic Antibody Engineering. Woodhead Publishing, Philadelphia Pa. 2012 Ch. 3, p 47-54, the contents of which are herein incorporated by reference in their entirety). Determining residues making up CDRs may include the use of numbering schemes including, but not limited to, those taught by Kabat [Wu. T. T. et al., 1970, JEM, 132(2):211-50 and Johnson, G. et al., 2000, Nucleic Acids Res. 28(1): 214-8, the contents of each of which are herein incorporated by reference in their entirety], Chothia [Chothia and Lesk. J. Mol Biol 196, 901 (1987), Chothia et al., Nature 342, 877 (1989) and Al-Lazikani, B. et al., 1997, J. Mol. Biol. 273(4):927-48, the contents of each of which are herein incorporated by reference in their entirety], Lefranc (Lefranc, M. P. et al., 2005, Immunome Res 1:3) and Honegger (Honegger, A. and Pluckthun, A. 2001. J. Mol. Biol. 309(3):657-70, the contents of which are herein incorporated by reference in their entirety).

V_(H) and V_(L) domains have three CDRs each. V_(L) CDRs are referred to herein as CDR-L1, CDR-L2 and CDR-L3, in order of occurrence when moving from N- to C-terminus along the variable domain polypeptide. V_(H) CDRs are referred to herein as CDR-H1, CDR-H2 and CDR-H3, in order of occurrence when moving from N- to C-terminus along the variable domain polypeptide. Each of CDRs have favored canonical structures with the exception of the CDR-H3, which comprises amino acid sequences that may be highly variable in sequence and length between antibodies resulting in a variety of three-dimensional structures in antigen-binding domains (Nikoloudis, D. et al., 2014 Peer J 2:e456; the contents of which are herein incorporated by reference in their entirety). In some cases. CDR-H3s may be analyzed among a panel of related antibodies to assess anti body, diversity. Various methods of determining CDR sequences are known in the art and may be applied to known antibody sequences (Strohl. W. R. Therapeutic Antibody Engineering. Woodhead Publishing, Philadelphia Pa. 2012. Ch. 3, p 47-54, the contents of which are herein incorporated by reference in their entirety).

As used herein, the term “Fv” refers to an antibody fragment comprising the minimum fragment on an antibody needed to form a complete antigen-binding site. These regions consist of a dimer of one heavy chain and one light chain variable domain in tight, non-covalent association. Fv fragments can be generated by proteolytic cleavage, but are largely unstable. Recombinant methods are known in the art for generating stable Fv fragments, typically through insertion of a flexible linker between the light chain variable domain and the heavy chain variable domain [to form a single chain F, (scFv)] or through the introduction of a disulfide bridge between heavy and light chain variable domains (Strohl, W. R. Therapeutic Antibody Engineering Woodhead Publishing. Philadelphia Pa. 2012 Ch. 3, p 46-47, the contents of which are herein incorporated by reference in their entirety).

As used herein, the term “light chain” refers to a component of an antibody from any vertebrate species assigned to one of two clearly distinct types, called kappa and lambda based on amino acid sequences of constant domains. Depending on the amino acid sequence of the constant domain of their heavy chains, antibodies can be assigned to different classes. There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA, and IgA2.

As used herein, the term “single chain Fv” or “scFv” refers to a fusion protein of V_(H) and V_(L) antibody domains, wherein these domains are linked together into a single polypeptide chain by a flexible peptide linker. In some embodiments, the Fv polypeptide linker enables the scFv to form the desired structure for antigen binding. In some embodiments, scFvs are utilized in conjunction with phage display, yeast display or other display methods where they may be expressed in association with a surface member (e.g. phage coat protein) and used in the identification of high affinity peptides for a given antigen.

As used herein, the term “bispecific antibody” refers to an antibody capable of binding two different antigens. Such antibodies typically comprise regions from at least two different antibodies. Bispecific antibodies may include any of those described in Riethmuller, G, 2012. Cancer Immunity, 12:12-18, Marvin, J. S. et al., 2005. Acta Pharmacologica Sinuca, 26(6).649-58 and Schaefer, W. et al., 2011. PNAS. 108(27) 11187-92, the contents of each of which are herein incorporated by reference in their entirety.

As used herein, the term “diabody” refers to a small antibody fragment with two antigen-binding sites. Diabodies comprise a heavy chain variable domain V_(H) connected to a light chain variable domain V_(L) in the same polypeptide chain. By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, for example EP 404,097; WO 93/11161; and Hollinger et al. (Hollinger, P. et al., “Diabodies” Small bivalent and bispecific antibody fragments. PNAS. 1993, 90:6444-8) the contents of each of which are incorporated herein by reference in their entirety.

The term “intrabody” refers to a form of antibody that is not secreted from a cell in which it is produced, but instead targets one or more intracellular proteins. Intrabodies may be used to affect a multitude of cellular processes including, but not limited to intracellular trafficking, transcription, translation, metabolic processes, proliferative signaling and cell division. In some embodiments, methods of the present invention may include intrabody-based therapies. In some such embodiments, variable domain sequences and/or CDR sequences disclosed herein may be incorporated into one or more constructs for intrabody-based therapy.

As used herein, the term “monoclonal antibody” refers to an antibody obtained from a population of substantially homogeneous cells (or clones), i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variants that may arise during production of the monoclonal antibodies, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen

The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. The monoclonal antibodies herein include “chimeric” antibodies (immunoglobulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies.

As used herein, the term “humanized antibody” refers to a chimeric antibody comprising a minimal portion from one or more non-human (e.g., murine) antibody source(s) with the remainder derived from one or more human immunoglobulin sources. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from the hypervariable region from an antibody of the recipient are replaced by residues from the hypervariable region from an antibody of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity, and/or capacity.

In some embodiments, viral genomes of the present invention may encode antibody, mimetics. As used herein, the term “antibody mimetic” refers to any molecule which mimics the function or effect of an antibody and which binds specifically and with high affinity to their molecular targets. In some embodiments, antibody mimetics may be monobodies, designed to incorporate the fibronectin type III domain (Fn3) as a protein scaffold (U.S. Pat. Nos. 6,673,901; 6,348,584). In some embodiments, antibody mimetics may be those known in the art including, but are not limited to affibody molecules, affilins, affitins, anticalins, avimers, Centyrins, DARPINS™, Fynomers and Kunitz and domain peptides. In other embodiments, antibody mimetics may include one or more non-peptide regions.

As used herein, the term “antibody variant” refers to a modified antibody (in relation to a native or starting antibody) or a biomolecule resembling a native or starting antibody in structure and/or function (e.g., an antibody mimetic). Antibody variants may be altered in their amino acid sequence, composition or structure as compared to a native antibody. Antibody variants may include, but are not limited to, antibodies with altered isotypes (e.g., IgA, IgD, IgE, IgG₁, IgG₂, IgG₃, IgG₄, or IgM), humanized variants, optimized variants, multispecific antibody variants (e.g., bispecific variants), and antibody fragments.

The preparation of antibodies, whether monoclonal or polyclonal, is known in the art. Techniques for the production of antibodies are well known in the art and described, e.g. in Harlow and Lane “Antibodies. A Laboratory Manual”, Cold Spring Harbor Laboratory Press, 1988, Harlow and Lane “Using Antibodies: A Laboratory Manual” Cold Spring Harbor Laboratory Press, 1999 and “Therapeutic Antibody Engineering: Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry” Woodhead Publishing, 2012.

Multispecific Antibodies

In some embodiments, payloads of the invention may encode antibodies that bind more than one epitope. As used herein, the terms “multibody” or “multispecific antibody” refer to an antibody wherein two or more variable regions bind to different epitopes. The epitopes may be on the same or different targets. In certain embodiments, a multi-specific antibody is a “bispecific antibody,” which recognizes two different epitopes on the same or different antigens.

In one embodiment, multi-specific antibodies may be prepared by the methods used by BIOATLA® and described in International Patent publication WO201109726, the contents of which are herein incorporated by reference in their entirety. First a library of homologous, naturally occurring antibodies is generated by any method known in the art (i.e., mammalian cell surface display), then screened by FACSAria or other screening method, for multi-specific antibodies that specifically bind to two or more target antigens. In one embodiment, the identified multi-specific antibodies are further evolved by any method known in the art, to produce a set of modified multi-specific antibodies. These modified multi-specific antibodies are screened for binding to the target antigens. In one embodiment, the multi-specific antibody may be further optimized by screening the evolved modified multi-specific antibodies for optimized or desired characteristics.

In one embodiment, multi-specific antibodies may be prepared by the methods used by BIOATLA® and described in Unites States Publication No. US20150252119, the contents of which are herein incorporated by reference in their entirety. In one approach, the variable domains of two parent antibodies, wherein the parent antibodies are monoclonal antibodies are evolved using any method known in the art in a manner that allows a single light chain to functionally complement heavy chains of two different parent antibodies. Another approach requires evolving the heavy chain of a single parent antibody to recognize a second target antigen. A third approach involves evolving the light chain of a parent antibody so as to recognize a second target antigen. Methods for polypeptide evolution are described in International Publication WO2012009026, the contents of which are herein incorporated by reference in their entirety, and include as non-limiting examples. Comprehensive Positional Evolution (CPE), Combinatorial Protein Synthesis (CPS). Comprehensive Positional Insertion (CPI), Comprehensive Positional Deletion (CPD), or any combination thereof. The Fc region of the multi-specific antibodies described in United States Publication No. US20150252119 may be created using a knob-in-hole approach, or any other method that allows the Fc domain to form heterodimers. The resultant multi-specific antibodies may be further evolved for improved characteristics or properties such as binding affinity for the target antigen.

Bispecific Antibodies

In some embodiments, payloads of the invention may encode bispecific antibodies. Bispecific antibodies are capable of binding two different antigens. Such antibodies typically comprise antigen-binding regions from at least two different antibodies. For example, a bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein composed of fragments of two different monoclonal antibodies, thus allowing the BsAb to bind to two different types of antigen.

In some cases, payloads encode bispecific antibodies comprising antigen-binding regions from two different anti-tau antibodies. For example, such bispecific antibodies may comprise binding regions from two different antibodies selected from Tables 3-42. Bispecific antibody frameworks may include any of those described in Riethmuller, G., 2012. Cancer Immunity, 12:12-18; Marvin, J. S. et al., 2005. Acta Pharmacologica Sinica, 26(6):649-58, and Schaefer, W. et al., 2011. PNAS. 108(27); 11187-92, the contents of each of which are herein incorporated by reference in their entirety.

New generations of BsMAb, called “trifunctional bispecific” antibodies, have been developed. These consist of two heavy and two light chains, one each from two different antibodies, where the two Fab regions (the arms) are directed against two antigens, and the Fc region (the foot) comprises the two heavy chains and forms the third binding site.

Of the two paratopes that form the tops of the variable domains of a bispecific antibody, one can be directed against a target antigen and the other against a T-lymphocytes antigen like CD3. In the case of trifunctional antibodies, the Fc region may additionally bind to a cell that expresses Fc receptors, like a macrophage, a natural killer (NK) cell or a dendritic cell. In sum, the targeted cell is connected to one or two cells of the immune system, which subsequently destroy it.

Other types of bispecific antibodies have been designed to overcome certain problems, such as short half-life, immunogenicity and side-effects caused by cytokine liberation. They include chemically linked Fabs, consisting only of the Fab regions, and various types of bivalent and trivalent single-chain variable fragments (scFvs), fusion proteins mimicking the variable domains of two antibodies. The furthest developed of these newer formats are the bi-specific T-cell engagers (BuTEs) and mAb2's, antibodies engineered to contain an Fcab antigen-binding fragment instead of the Fe constant region.

Using molecular genetics, two scFvs can be engineered in tandem into a single polypeptide, separated by a linker domain, called a “tandem scFv” (tascFv). TascFvs have been found to be poorly soluble and require refolding when produced in bacteria, or they may be manufactured in mammalian cell culture systems, which avoids refolding requirements but may result in poor yields. Construction of a tascFv with genes for two different scFvs yields a “bispecific single-chain variable fragments” (bis-scFvs). Only two tascFvs have been developed clinically by commercial firms, both are bispecific agents in active early phase development by Micromet for oncologic indications, and are described as “Bispecific T-cell Engagers (BiTE).” Blinatumomab is an anti-CD19/anti-CD3 bispecific tascFv that potentiates T-cell responses to B-cell non-Hodgkin lymphoma in Phase 2. MT110 is an anti-EP-CAM/anti-CD3 bispecific tascFv that potentiates T-cell responses to solid tumors in Phase 1. Bispecific, tetravalent “TandAbs” are also being researched by Affimed (Nelson, A. L., MAbs. 2010. January-February, 2(1):77-83).

In some embodiments, payloads may encode antibodies comprising a single antigen-binding domain. These molecules are extremely small, with molecular weights approximately one-tenth of those observed for full-sized mAbs. Further antibodies may include “nanobodies” derived from the antigen-binding variable heavy chain regions (V_(HHS)) of heavy chain antibodies found in camels and llamas, which lack light chains (Nelson. A. L., MAbs. 2010 January-February; 2(1):77-83).

Disclosed and claimed in PCT Publication WO02014144573 to Memorial Sloan-Kettering Cancer Center are multimerization technologies for making dimeric multispecific binding agents (e.g., fusion proteins comprising antibody components) with improved properties over multispecific binding agents without the capability of dimerization.

In some cases, payloads of the invention may encode tetravalent bispecific antibodies (TetBiAbs as disclosed and claimed in PCT Publication WO2014144357) TetBiAbs feature a second pair of Fab fragments with a second antigen specificity attached to the C-terminus of an antibody, thus providing a molecule that is bivalent for each of the two antigen specificities. The tetravalent antibody is produced by genetic engineering methods, by linking an antibody heavy chain covalently to a Fab light chain, which associates with its cognate, co-expressed Fab heavy chain.

In some aspects, payloads of the invention may encode biosynthetic antibodies as described in U.S. Pat. No. 5,091,513, the contents of which are herein incorporated by reference in their entirety. Such antibody may include one or more sequences of amino acids constituting a region which behaves as a biosynthetic antibody binding site (BABS). The sites comprise 1) non-covalently associated or disulfide bonded synthetic V_(H) and V_(L) dimers, 2) V_(H)-V_(L) or V_(L)-V_(H) single chains wherein the V_(H) and V_(L) are attached by a polypeptide linker, or 3) individuals V_(H) or V_(L) domains. The binding domains comprise linked CDR and FR regions, which may be derived from separate immunoglobulins. The biosynthetic antibodies may also include other polypeptide sequences which function, e.g., as an enzyme, toxin, binding site, or site of attachment to an immobilization media or radioactive atom. Methods are disclosed for producing the biosynthetic antibodies, for designing BABS having any specificity that can be elicited by in vivo generation of antibody, and for producing analogs thereof.

In some embodiments, payloads may encode antibodies with antibody acceptor frameworks taught in U.S. Pat. No. 8,399,625. Such antibody acceptor frameworks may be particularly well suited accepting CDRs from an antibody of interest. In some cases. CDRs from anti-tau antibodies known in the art or developed according to the methods presented herein may be used.

Miniaturized Antibody

In one embodiment, the antibody encoded by the payloads of the invention may be a “miniaturized” antibody. Among the best examples of mAb miniaturization are the small modular immunopharmaceuticals (SMIPs) from Trubion Pharmaceuticals. These molecules, which can be monovalent or bivalent, are recombinant single-chain molecules containing one V_(L), one V_(H) antigen-binding domain, and one or two constant “effector” domains, all connected by linker domains. Presumably, such a molecule might offer the advantages of increased tissue or tumor penetration claimed by fragments while retaining the immune effector functions conferred by constant domains. At least three “miniaturized” SMIPs have entered clinical development. TRU-015, an anti-CD20 SMIP developed in collaboration with Wyeth, is the most advanced project, having progressed to Phase 2 for rheumatoid arthritis (RA). Earlier attempts in systemic lupus erythrematosus (SLE) and B cell lymphomas were ultimately discontinued. Trubion and Facet Biotechnology are collaborating in the development of TRU-016, an anti-CD37 SMIP, for the treatment of CLL and other lymphoid neoplasias, a project that has reached Phase 2. Wyeth has licensed the anti-CD20 SMIP SBI-087 for the treatment of autoimmune diseases, including RA, SLE and possibly multiple sclerosis, although these projects remain in the earliest stages of clinical testing. (Nelson, A. L., MAbs. 2010. January-February; 2(1):77-83).

Diabodies

In some embodiments, payloads of the invention may encode diabodies. Diabodies are functional bispecific single-chain antibodies (bscAb). These bivalent antigen-binding molecules are composed of non-covalent dimers of scFvs, and can be produced in mammalian cells using recombinant methods. (See, e.g., Mack et al. Proc. Natl. Acad. Sci., 92, 7021-7025, 1995). Few diabodies have entered clinical development. An iodine-123-labeled diabody version of the anti-CEA chimeric antibody cT84.66 has been evaluated for pre-surgical immunoscintigraphic detection of colorectal cancer in a study sponsored by the Beckman Research Institute of the City of Hope (Clinicaltrials.gov NCT00647153) (Nelson, A. L., MAbs 2010. January-February; 2(1):77-83)

Unibody

In some embodiments, payloads may encode a “unibody,” in which the hinge region has been removed from IgG4 molecules. While IgG4 molecules are unstable and can exchange light-heavy chain heterodimers with one another, deletion of the hinge region prevents heavy chain-heavy chain pairing entirely, leaving highly specific monovalent light-heavy heterodimers, while retaining the Fc region to ensure stability and half-life in vivo. This configuration may minimize the risk of immune activation or oncogenic growth, as IgG4 interacts poorly with FcRs and monovalent unibodies fail to promote intracellular signaling complex formation. These contentions are, however, largely supported by laboratory, rather than clinical, evidence. Other antibodies may be “miniaturized” antibodies, which are compacted 100 kDa antibodies (see, e.g., Nelson, A. L., MAbs. 2010. January-February; 2(1):77-83).

Intrabodies

In some embodiments, payloads of the invention may encode intrabodies. Intrabodies are a form of antibody that is not secreted from a cell in which it is produced, but instead targets one or more intracellular proteins. Intrabodies are expressed and function intracellularly, and may be used to affect a multitude of cellular processes including, but not limited to intracellular trafficking, transcription, translation, metabolic processes, proliferative signaling and cell division. In some embodiments, methods described herein include intrabody-based therapies. In some such embodiments, variable domain sequences and/or CDR sequences disclosed herein are incorporated into one or more constructs for intrabody-based therapy. For example, intrabodies may target one or more glycated intracellular proteins or may modulate the interaction between one or more glycated intracellular proteins and an alternative protein.

More than two decades ago, intracellular antibodies against intracellular targets were first described (Biocca, Neuberger and Cattaneo EMBO J. 9: 101-108, 1990). The intracellular expression of intrabodies in different compartments of mammalian cells allows blocking or modulation of the function of endogenous molecules (Biocca, et al., EMBO J 9: 101-108, 1990; Colby et al., Proc. Natl. Acad. Sci. U.S.A. 101: 17616-21, 2004) Intrabodies can alter protein folding, protein-protein, protein-DNA, protein-RNA interactions and protein modification. They can induce a phenotypic knockout and work as neutralizing agents by direct binding to the target antigen, by diverting its intracellular trafficking or by inhibiting its association with binding partners. They have been largely employed as research tools and are emerging as therapeutic molecules for the treatment of human diseases such as viral pathologies, cancer and misfolding diseases. The fast growing bio-market of recombinant antibodies provides intrabodies with enhanced binding specificity, stability and solubility, together with lower immunogenicity, for their use in therapy (Biocca, abstract in Antibody Expression and Production Cell Engineering Volume 7, 2011, pp. 179-195).

In some embodiments, intrabodies have advantages over interfering RNA (iRNA); for example, iRNA has been shown to exert multiple non-specific effects, whereas intrabodies have been shown to have high specificity and affinity to target antigens. Furthermore, as proteins, intrabodies possess a much longer active half-life than iRNA. Thus, when the active half-life of the intracellular target molecule is long, gene silencing through iRNA may be slow to yield an effect, whereas the effects of intrabody expression can be almost instantaneous. Lastly, it is possible to design intrabodies to block certain binding interactions of a particular target molecule, while sparing others.

Intrabodies are often single chain variable fragments (scFvs) expressed from a recombinant nucleic acid molecule and engineered to be retained intracellularly (e.g., retained in the cytoplasm, endoplasmic reticulum, or periplasm). Intrabodies may be used, for example, to ablate the function of a protein to which the intrabody binds. The expression of intrabodies may also be regulated through the use of inducible promoters in the nucleic acid expression vector comprising the intrabody. Intrabodies may be produced for use in the viral genomes of the invention using methods known in the art, such as those disclosed and reviewed in. (Marasco et al., 1993 Proc. Natl. Acal. Sci. USA, 90; 7889-7893; Chen et al., 1994, Hum. Gene Ther. 5:595-601; Chen et al., 1994, Proc. Natl. Acad. Sci. USA, 91: 5932-5936; Macieiewski et al, 1995, Nature Med., 1: 667-673; Marasco, 1995, Immunotech, 1: 1-19; Mhashilkar, et al., 1995, EMBO J. 14: 1542-51; Chen et al., 1996, Hum. Gene Therap., 7: 1515-1525, Marasco, Gene Ther. 4:11-15, 1997, Rondon and Marasco, 1997, Annu. Rev. Microbiol. 51: 257-283; Cohen, et al., 1998, Oncogene 17:2445-56; Proba et al., 1998, J. Mol. Biol. 275:245-253; Cohen et al., 1998, Oncogene 17:2445-2456; Hassanzadeh, et al., 1998, FEBS Lett. 437:81-6; Richardson et al., 1998, Gene Ther 5:635-44; Ohage and Steipe, 1999, J. Mol. Biol 291:1119-1128; Ohage et al., 1999, J. Mol. Biol. 291:1129-1134; Wirtz and Steipe, 1999, Protein Sci. 8:2245-2250; Zhu et al., 1999, J. Immunol Methods 231:207-222; Arafat et al., 2000, Cancer Gene Ther. 7:1250-6; der Maur et al., 2002, J. Biol. Chem. 277:45075-85, Mhashilkar et al., 2002, Gene Ther. 9:307-19; and Wheeler et al., 2003, FASEB J. 17: 1733-5, and references cited therein). In particular, a CCR5 intrabody has been produced by Steinberger et al., 2000), Proc. Natl. Acad. Sci. USA 97:805-810). See generally Marasco. W A. 1998, “Intrabodies: Basic Research and Clinical Gene Therapy Applications” Springer: New York, and for a review of scFvs, see Pluckthun in “The Pharmacology of Monoclonal Antibodies,” 1994, vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315.

Sequences from donor antibodies may be used to develop intrabodies. Intrabodies are often recombinantly expressed as single domain fragments such as isolated V_(H) and V_(L) domains or as a single chain variable fragment (scFv) antibody within the cell. For example, intrabodies are often expressed as a single polypeptide to form a single chain antibody comprising the variable domains of the heavy and light chains joined by a flexible linker polypeptide. Intrabodies typically lack disulfide bonds and are capable of modulating the expression or activity of target genes through their specific binding activity. Single chain antibodies can also be expressed as a single chain variable region fragment joined to the light chain constant region.

As is known in the art, an intrabody can be engineered into recombinant polynucleotide vectors to encode sub-cellular trafficking signals at its N or C terminus to allow expression at high concentrations in the sub-cellular compartments where a target protein is located. For example, intrabodies targeted to the endoplasmic reticulum (ER) are engineered to incorporate a leader peptide and, optionally, a C-terminal ER retention signal, such as the KDEL amino acid motif (SEQ ID NO: 9223). Intrabodies intended to exert activity in the nucleus are engineered to include a nuclear localization signal. Lipid moieties are joined to intrabodies in order to tether the intrabody to the cytosolic side of the plasma membrane. Intrabodies can also be targeted to exert function in the cytosol. For example, cytosolic intrabodies are used to sequester factors within the cytosol, thereby preventing them from being transported to their natural cellular destination.

There are certain technical challenges with intrabody expression. In particular, protein conformational folding and structural stability of the newly-synthesized intrabody within the cell is affected by reducing conditions of the intracellular environment.

Intrabodies of the invention may be promising therapeutic agents for the treatment of misfolding diseases, including Alzheimer's, Parkinson's, Huntington's and prion diseases, because of their virtually infinite ability to specifically recognize the different conformations of a protein, including pathological isoforms, and because they can be targeted to the potential sites of aggregation (both intra- and extracellular sites). These molecules can work as neutralizing agents against anmyloidogenic proteins by preventing their aggregation, and/or as molecular shunters of intracellular traffic by rerouting the protein from its potential aggregation site (Cardinale, and Biocca, Curr Mol. Med 2008, 8:2-11)

Maxibodies

In one embodiment, the payloads of the invention encode a maxibody (bivalent scFV fused to the amino terminus of the Fc (CH2-CH3 domains) of IgG,

Chimeric Antigen Receptors

In some embodiments, the polypeptides encoded by the viral genomes of the invention (e.g., antibodies) may be used to generate chimeric antigen receptors (CARs) as described by BIOATLA® in International Publications WO2016033331 and WO2016036916, the contents of which are herein incorporated by reference in their entirety. As used herein, a “chimeric antigen receptor (CAR)” refers to an artificial chimeric protein comprising at least one antigen specific targeting region (ASTR), wherein the antigen specific targeting region comprises a full-length antibody or a fragment thereof that specifically binds to a target antigen. The ASTR may comprise any of the following; a full length heavy or light chain, an Fab fragment, a single chain Fv fragment, a divalent single chain antibody, or a diabody. As a non-limiting example the ASTR of a CAR may be any of the antibodies listed in Tables 3-42, antibody-based compositions or fragments thereof. Any molecule that is capable of binding a target antigen with high affinity can be used in the ASTR of a CAR. In one embodiment, the CAR may have more than one ASTR. These ASTRs may target two or more antigens or two or more epitopes of the same antigen. In one embodiment, the CAR is conditionally active. In one embodiment, the CAR is used to produce a genetically engineered cytotoxic cell carrying the CAR and capable of targeting the antigen bound by the ASTR.

Chimeric antigen receptors (CARs) are particularly useful in the treatment of cancers, though also therapeutically effective in treatment of a wide variety of other diseases and disorders. Non-limiting examples of disease categories that may be treated with CARs or CAR-based therapeutics include autoimmune disorders, B-cell mediated diseases, inflammatory diseases, neuronal disorders, cardiovascular disease and circulatory disorders, or infectious diseases. Not wishing to be bound by theory, CARs traditionally work by targeting antigens presented on the surface of or on the inside of cells to be destroyed e.g., cancer tumor cells, by the cytotoxic cell of the CAR.

Senescent Cell Surface Protein Antibodies

In some embodiments, the AAV particles may comprise nucleic acids which have been engineered to express of antibodies that selectively bind to surface marker proteins of senescent cells. For example, the antibodies may selectively bind to proteins that are in misfolded conformation. The binding antibodies may reduce the number of senescent cells and be used to treat age-related conditions, such as, but not limited to. Alzheimer's disease, cardiovascular disease, emphysema, sarcopenia, and tumorigenesis as well as conditions more cosmetic in nature such as signs of skin aging including wrinkling, sagging, discoloration, age-related tissue dysfunction, tumor formation, and other age-related conditions.

In one embodiment, the expressed antibodies binding to epitopes of senescent cell surface proteins may be, but are not limited to, such as prion epitopes presented by SEQ ID NOs: 1-14 of International Publication No. WO2014186878, CD44 epitopes presented by SEQ ID NOs: 47-51 of International Publication No. WO2014186878; TNFR epitopes presented by SEQ ID NOs: 52-56 of International Publication No. WO2014186878; NOTCH1 epitope presented by SEQ ID NOs: 57-61 of International Publication No. WO2014186878; FasR epitopes presented by SEQ ID NOs: 62-66 of International Publication No. WO2014186878; epidermal growth factor epitopes presented by SEQ ID NOs: 67-81 of International Publication No. WO2014186878; CD38 epitopes presented by SEQ ID NOs: 82-86 of International Publication No. WO2014186878, the contents of each of which are herein incorporated by reference in their entirety.

In one embodiment, the expressed antibodies may comprise peptides binding to senescent cell surface prion proteins, such as, but not limited to, those presented by SEQ ID NOs: 15-36 of International Publication No. WO2014186878, the contents of which are herein incorporated by reference in their entirety.

In one embodiment, the expressed antibody may be AMF-3a-118 or AMF 3d-19 (SEQ ID NO: 89-92 and 103-106 of International publication WO2014186878, respectively, the contents of which are herein incorporated by reference in their entirety) targeting senescent cell surface protein FasR, In one embodiment, the expressed antibody may be Ab c-120 (SEQ ID NO: 37-40 of International publication WO2014186878, the contents of which are herein incorporated by reference in their entirety) targeting senescent cell surface protein PrP.

Payload Antibodies of the Invention

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences listed in Tables 3-42.

In some embodiments, the payload region of the AAV particle comprises a nucleic acid sequence encoding a payload antibody with at least 50% identity to one or more payload antibody polypeptides listed in Tables 3-42. The encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more of the payload antibody polypeptides listed in Tables 3-42.

In one embodiment, the full sequence of the encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more of the payload antibody polypeptides listed in Tables 3-42.

In one embodiment, the variable region sequence(s) of the encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 064%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more of the pay load antibody polypeptides listed in Tables 3-42.

In one embodiment, the heavy chain of the encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65% 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more of the payload heavy chain antibody polypeptides listed in Tables 3-42.

In one embodiment, the light chain of the encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more of the payload light chain antibody polypeptides listed in Tables 3-42.

In one embodiment, the CDR region of the encoded antibody polypeptide may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to the CDRs of one or more of the payload antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 90% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 91% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 92% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 93% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 94% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 95% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 96% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 97% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 98% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 99% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In one embodiment, the payload antibody has 100% identity to one or more of the antibody polypeptides listed in Tables 3-42.

In some embodiments, the payload region of the AAV particle comprises a nucleic acid sequence with at least 50% identity to one or more nucleic acid sequences listed in Tables 3-42. The payload nucleic acid sequence may have 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 90% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 91% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 92% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 93% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 94% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 95% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 96% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 97% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 98% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 99% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload nucleic acid sequence has 100% identity to one or more of the nucleic acid sequences listed in Tables 3-42.

In one embodiment, the payload region of the AAV particle comprises a nucleic acid sequence encoding a polypeptide which is an antibody, an antibody-based composition, or a fragment thereof. As a non-limiting example, the antibody may be one or more of the polypeptides listed in Tables 3-42. As another non-limiting example, the antibody may be one or more of the heavy chain sequences listed in Tables 3-42. As a non-limiting example, the antibody may be one or more of the light chain sequences listed in Tables 3-42.

In one embodiment, the payload region of the AAV particle comprises a nucleic acid sequence encoding a polypeptide comprising a heavy chain and a light chain sequence listed in Tables 3-42. The payload region may also comprise a linker between the heavy and light chain sequences. The linker may be a sequence known in the art or described in Table 2.

In one embodiment, the payload region of the AAV particle comprises a nucleic acid sequence encoding a polypeptide comprising a heavy chain and a light chain sequence listed in Tables 3-42, where the heavy chain sequence is from a different antibody than the light chain sequence. The payload region may also comprise a linker between the heavy and light chain sequences. The linker may be a sequence known in the art or described in Table 2.

In one embodiment, the payload region comprises, in the 5′ to 3′ direction, an antibody light chain sequence, a linker and a heavy chain sequence.

In one embodiment, the payload region comprises a nucleic acid sequence encoding, in the 5′ to 3′ direction, an antibody light chain sequence from Tables 3-42, a linker from Table 2 and a heavy chain sequence from Tables 3-42.

In one embodiment, the payload region comprises, in the 5′ to 3′ direction, an antibody heavy chain sequence, a linker and a light chain sequence.

In one embodiment, the payload region comprises a nucleic acid sequence encoding, in the 5′ to 3′ direction, an antibody heavy chain sequence from Tables 3-42, a linker from Table 2 and a light chain sequence from Tables 3-42.

In one embodiment, the payload region comprises a nucleic acid sequence encoding a single heavy chain. As a non-limiting example, the heavy chain is an amino acid sequence or fragment thereof described in Tables 3-42.

Shown in Tables 3-42 are a listing of antibodies and their polynucleotides and/or polypeptides sequences. These sequences may be encoded by or included in the AAV particles of the present invention. Variants or fragments of the antibody sequences described in Tables 3-42 may be utilized in the AAV particles of the present invention.

In some embodiments, the AAV particles may comprise codon-optimized versions of the nucleic acids encoding the polypeptides listed in Tables 3-42. In some cases, the payload region of the AAV particles of the invention may encode one or more isoforms or variants of these heavy and light chain antibody domains. Such variants may be humanized or optimized antibody domains comprising one or more complementarity determining regions (CDRs) from the heavy and light chains listed in Tables 3-42. Methods of determining CDRs are well known in the art and are described herein Payload regions may encode antibody variants with one or more heavy chain variable domain (V_(H)) or light chain variable domain (V_(L)) derived from the antibody sequences in Tables 3-42. In some cases, such variants may include bispecific antibodies. Bispecific antibodies encoded by payload regions of the invention may comprise variable domain pairs from two different antibodies.

In one embodiment, the AAV particles may comprise a heavy and a light chain of an antibody described herein and two promoters. As a non-limiting example, the AAV particles may comprise a nucleic acid sequence of a genome as described in FIG. 1 or FIG. 2 of US Patent Publication No. US20030219733, the contents of which are herein incorporated by reference in its entirety. As another non-limiting example, the AAV particles may be a dual-promoter AAV for antibody expression as described by Lewis et al. (J. of Virology, September 2002, Vol. 76(17), p 8769-8775; the contents of which are herein incorporated by reference in its entirety).

Foodborne Illness and Gastroenteritis Related Antibodies

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the gastrointestinal and food illness related payload antibody polypeptides listed in Tables 3-9.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 3 against Clostridium difficile toxins

TABLE 3 Antibodies against Clostridium Difficile toxins SEQ Antibody Antibody Reference ID No. Description Name Information NO CD1 Camelid heavy chain only, WO2015100409 2948 Toxin A and B, SEQ ID NO: 164 CD2 Camelid heavy chain only, WO2015100409 2949 Toxin A and B, SEQ ID NO: 165 CD3 Camelid heavy chain only, WO2015100409 2950 Toxin A and B, SEQ ID NO: 166 CD4 Camelid heavy chain only, WO2015100409 2951 Toxin A and B, SEQ ID NO: 167 CD5 Heavy chain variable region, PA-39 U.S. Pat. No. 2952 toxin A 8,986,697 SEQ ID NO: 1 CD6 Heavy chain variable region, PA-39 U.S. Pat. No. 2953 toxin A 8,986,697 SEQ ID NO: 2 CD7 Heavy chain variable region, PA-50 U.S. Pat. No. 2954 toxin A 8,986,697 SEQ ID NO: 5 CD8 Heavy chain variable region, PA-50 U.S. Pat. No. 2955 toxin A 8,986,697 SEQ ID NO: 6 CD9 Heavy chain variable region, US20130202618 2956 toxin A SEQ ID NO: 1 CD10 Heavy chain variable region, US20130202618 2957 toxin A SEQ ID NO: 2 CD11 Heavy chain variable region, US20130202618 2958 toxin A SEQ ID NO: 5 CD12 Heavy chain variable region, US20130202618 2959 toxin A SEQ ID NO: 6 CD13 Heavy chain variable region, H1H3067N US20130230531 2960 toxin A and/or toxin B SEQ ID NO: 34 CD14 Heavy chain variable region, H1H3134N US20130230531 2961 toxin A and/or toxin B SEQ ID NO: 18 CD15 Heavy chain variable region, H1H3117N US20130230531 2962 toxin A and/or toxin B SEQ ID NO: 2 CD16 Heavy chain variable region, H1H3123N US20130230531 2963 toxin A and/or toxin B SEQ ID NO: 66 CD17 Heavy chain variable region, H1H3121N US20130230531 2964 toxin A and/or toxin B SEQ ID NO: 50 CD18 Heavy chain variable region, H1H3124N US20130230531 2965 toxin A and/or toxin B SEQ ID NO: 82 CD19 Heavy chain variable region, H1H3328P US20130230531 2966 toxin A and/or toxin B SEQ ID NO: 130 CD20 Heavy chain variable region, H1H3324P US20130230531 2967 toxin A and/or toxin B SEQ ID NO: 98 CD21 Heavy chain variable region, H1H3325P US20130230531 2968 toxin A and/or toxin B SEQ ID NO: 114 CD22 Heavy chain variable region, H1H3330P US20130230531 2969 toxin A and/or toxin B SEQ ID NO: 146 CD23 Heavy chain variable region, H1H3350P US20130230531 2970 toxin A and/or toxin B SEQ ID NO: 162 CD24 Heavy chain variable region, H1H3347P US20130230531 2971 toxin A and/or toxin B SEQ ID NO: 274 CD25 Heavy chain variable region, H1H3335P US20130230531 2972 toxin A and/or toxin B SEQ ID NO: 194 CD26 Heavy chain variable region, H1H3344P US20130230531 2973 toxin A and/or toxin B SEQ ID NO: 258 CD27 Heavy chain variable region, H1H3339P US20130230531 2974 toxin A and/or toxin B SEQ ID NO: 226 CD28 Heavy chain variable region, H1H3337P US20130230531 2975 toxin A and/or toxin B SEQ ID NO: 210 CD29 Heavy chain variable region, H1H3343P US20130230531 2976 toxin A and/or toxin B SEQ ID NO: 242 CD30 Heavy chain variable region, H1H3411P US20130230531 2977 toxin A and/or toxin B SEQ ID NO: 354 CD31 Heavy chain variable region, H1H3354P US20130230531 2978 toxin A and/or toxin B SEQ ID NO: 290 CD32 Heavy chain variable region, H1H3317P US20130230531 2979 toxin A and/or toxin B SEQ ID NO: 178 CD33 Heavy chain variable region, H1H3355P US20130230531 2980 toxin A and/or toxin B SEQ ID NO: 306 CD34 Heavy chain variable region, H1H3394P US20130230531 2981 toxin A and/or toxin B SEQ ID NO. 322 CD35 Heavy chain variable region, H1H3401P US20130230531 2982 toxin A and/or toxin B SEQ ID NO: 338 CD36 Heavy chain variable region, PA-41 U.S. Pat. No. 2983 toxin B 8,986,697 SEQ ID NO: 8 CD37 Heavy chain variable region, PA-41 U.S. Pat. No. 2984 toxin B 8,986,697 SEQ ID NO: 9 CD38 Heavy chain variable region, US20130202618 2985 toxin B SEQ ID NO: 8 CD39 Heavy chain variable region, US20130202618 2986 toxin B SEQ ID NO: 9 CD40 Heavy chain, toxin A 3D8 U.S. Pat. No. 2987 8,609,111 SEQ ID NO: 1 CD41 Heavy chain, toxin A 1B11 U.S. Pat. No. 2988 8,609,111 SEQ ID NO: 2 CD42 Heavy chain, toxin A 33.3H2 U.S. Pat. No. 2989 8,609,111 SEQ ID NO: 3 CD43 Heavy chain, toxin A US20140004118 2990 SEQ ID NO: 89 CD44 Heavy chain, toxin A US20140004118 2991 SEQ ID NO: 93 CD45 Heavy chain, toxin B US20130058962 2992 SEQ ID NO: 65 CD46 Heavy chain, toxin B Bezlotoxumab 2993 CD47 Heavy-chain-only, toxin A US20130058962 2994 SEQ ID NO: 59 CD48 Heavy-chain-only, toxin A US20130058962 2995 SEQ ID NO: 60 CD49 Heavy-chain-only, toxin A US20130058962 2996 SEQ ID NO: 61 CD50 Heavy-chain-only, toxin A US20130058962 2997 SEQ ID NO: 62 CD51 Heavy-chain-only, toxin A US20130058962 2998 SEQ ID NO: 63 CD52 Heavy-chain-only, toxin A US20130058962 2999 SEQ ID NO: 64 CD53 Heavy-chain-only, toxin A US20130058962 3000 SEQ ID NO: 87 CD54 Heavy-chain-only, toxin A US20130058962 3001 SEQ ID NO: 95 CD55 Heavy-chain-only, toxin B 124-152 U.S. Pat. No. 3002 8,609,111 SEQ ID NO: 54 CD56 Heavy-chain-only, toxin B US20130058962 3003 SEQ ID NO: 66 CD57 Heavy-chain-only, toxin B US20130058962 3004 SEQ ID NO: 67 CD58 Heavy-chain-only, toxin B US20130058962 3005 SEQ ID NO: 68 CD59 Heavy-chain-only, toxin B US20130058962 3006 SEQ ID NO: 69 CD60 Heavy-chain-only, toxin B US20130058962 3007 SEQ ID NO: 70 CD61 Heavy-chain-only, toxin B US20130058962 3008 SEQ ID NO: 71 CD62 Heavy-chain-only, toxin B US20130058962 3009 SEQ ID NO: 72 CD63 Heavy-chain-only, toxin B US20130058962 3010 SEQ ID NO: 73 CD64 Heavy-chain-only, toxin B US20130058962 3011 SEQ ID NO: 74 CD65 Heavy-chain-only, toxin B US20130058962 3012 SEQ ID NO: 75 CD66 Heavy-chain-only, toxin B US20130058962 3013 SEQ ID NO: 76; SEQ ID NO: 87; SEQ ID NO: 95 CD67 Light chain variable region, toxin PA-39 U.S. Pat. No. 3014 A 8,986,697 SEQ ID NO: 3 CD68 Light chain variable region, toxin PA-39 U.S. Pat. No. 3015 A 8,986,697 SEQ ID NO: 4 CD69 Light chain variable region, toxin PA-50 U.S. Pat. No. 3016 A 8,986,697 SEQ ID NO: 7 CD70 Light chain variable region, toxin US20130202618 3017 A SEQ ID NO: 3 CD71 Light chain variable region, toxin US20130202618 3018 A SEQ ID NO: 4 CD72 Light chain variable region, toxin US20130202618 3019 A SEQ ID NO: 7 CD73 Light chain variable region, toxin H1H3067N US20130230531 3020 A and/or toxin B SEQ ID NO: 42 CD74 Light chain variable region, toxin H1H3134N US20130230531 3021 A and/or toxin B SEQ ID NO: 26 CD75 Light chain variable region, toxin H1H3117N US20130230531 3022 A and/or toxin B SEQ ID NO: 10 CD76 Light chain variable region, toxin H1H3123N US20130230531 3023 A and/or toxin B SEQ ID NO: 74 CD77 Light chain variable region, toxin H1H3121N US20130230531 3024 A and/or toxin B SEQ ID NO: 58 CD78 Light chain variable region, toxin H1H3124N US20130230531 3025 A and/or toxin B SEQ ID NO: 90 CD79 Light chain variable region, toxin H1H3328P US20130230531 3026 A and/or toxin B SEQ ID NO: 138 CD80 Light chain variable region, toxin H1H3324P US20130230531 3027 A and/or toxin B SEQ ID NO: 106 CD81 Light chain variable region, toxin H1H3325P US20130230531 3028 A and/or toxin B SEQ ID NO: 122 CD82 Light chain variable region, toxin H1H3330P US20130230531 3029 A and/or toxin B SEQ ID NO: 154 CD83 Light chain variable region, toxin H1H3350P US20130230531 3030 A and/or toxin B SEQ ID NO: 170 CD84 Light chain variable region, toxin H1H3347P US20130230531 3031 A and/or toxin B SEQ ID NO: 282 CD85 Light chain variable region, toxin H1H3335P US20130230531 3032 A and/or toxin B SEQ ID NO: 202 CD86 Light chain variable region, toxin H1H3344P US20130230531 3033 A and/or toxin B SEQ ID NO: 266 CD87 Light chain variable region, toxin H1H3339P US20130230531 3034 A and/or toxin B SEQ ID NO: 234 CD88 Light chain variable region, toxin H1H3337P US20130230531 3035 A and/or toxin B SEQ ID NO: 218 CD89 Light chain variable region, toxin H1H3343P US20130230531 3036 A and/or toxin B SEQ ID NO: 250 CD90 Light chain variable region, toxin H1H3411P US20130230531 3037 A and/or toxin B SEQ ID NO: 362 CD91 Light chain variable region, toxin H1H3354P US20130230531 3038 A and/or toxin B SEQ ID NO: 298 CD92 Light chain variable region, toxin H1H3317P US20130230531 3039 A and/or toxin B SEQ ID NO: 186 CD93 Light chain variable region, toxin H1H3355P US20130230531 3040 A and/or toxin B SEQ ID NO: 314 CD94 Light chain variable region, toxin H1H3394P US20130230531 3041 A and/or toxin B SEQ ID NO: 330 CD95 Light chain variable region, toxin H1H3401P US20130230531 3042 A and/or toxin B SEQ ID NO: 346 CD96 Light chain variable region, toxin PA-41 U.S. Pat. No. 3043 B 8,986,697 SEQ ID NO: 10 CD97 Light chain variable region, toxin US20130202618 3044 B SEQ ID NO: 10 CD98 Light chain, toxin A 3D8 U.S. Pat. No. 3045 8,609,111 SEQ ID NO: 4 CD99 Light chain, toxin A 1B11 U.S. Pat. No. 3046 8,609,111 SEQ ID NO: 5 CD100 Light chain, toxin A 33.3H2 U.S. Pat. No. 3047 8,609,111 SEQ ID NO: 6 CD101 Light chain, toxin A US20140004118 3048 SEQ ID NO: 91 CD102 Light chain, toxin A US20140004118 3049 SEQ ID NO: 95 CD103 Light chain, toxin B 124-152 U.S. Pat. No. 3050 8,609,111 SEQ ID NO: 58 CD104 Light chain, toxin B Bezlotoxumab 3051 CD105 Recombinant camelid heavy WO2015100409 3052 chain only, Toxin A and B SEQ ID NO: 87 CD106 Recombinant camelid heavy WO2015100409 3053 chain only, Toxin A and B SEQ ID NO: 95 CD107 Recombinant camelid heavy- WO2015100409 3054 chain-only, toxin A SEQ ID NO: 59 CD108 Recombinant camelid heavy- WO2015100409 3055 chain-only, toxin A SEQ ID NO: 60 CD109 Recombinant camelid heavy- WO2015100409 3056 chain-only, toxin A SEQ ID NO: 61 CD110 Recombinant camelid heavy- WO2015100409 3057 chain-only, toxin A SEQ ID NO: 62 CD111 Recombinant camelid heavy- WO2015100409 3058 chain-only, toxin A SEQ ID NO: 63 CD112 Recombinant camelid heavy- WO2015100409 3059 chain-only, toxin A SEQ ID NO: 64 CD113 Recombinant camelid heavy- WO2015100409 3060 chain-only, toxin B SEQ ID NO: 65 CD114 Recombinant camelid heavy- WO2015100409 3061 chain-only, toxin B SEQ ID NO: 66 CD115 Recombinant camelid heavy- WO2015100409 3062 chain-only, toxin B SEQ ID NO: 67 CD116 Recombinant camelid heavy- WO2015100409 3063 chain-only, toxin B SEQ ID NO: 68 CD117 Recombinant camelid heavy- WO2015100409 3064 chain-only, toxin B SEQ ID NO: 69 CD118 Recombinant camelid heavy- WO2015100409 3065 chain-only, toxin B SEQ ID NO: 70 CD119 Recombinant camelid heavy- WO2015100409 3066 chain-only, toxin B SEQ ID NO: 71 CD120 Recombinant camelid heavy- WO2015100409 3067 chain-only, toxin B SEQ ID NO: 72 CD121 Recombinant camelid heavy- WO2015100409 3068 chain-only, toxin B SEQ ID NO: 73 CD122 Recombinant camelid heavy- WO2015100409 3069 chain-only, toxin B SEQ ID NO: 74 CD123 Recombinant camelid heavy- WO2015100409 3070 chain-only, toxin B SEQ ID NO: 75 CD124 Recombinant camelid heavy- WO2015100409 3071 chain-only, toxin B SEQ ID NO: 76 CD125 Toxin A Actoxumab 3072 CD126 Toxin A Actoxumab 3073 CD127 Toxin A MK3415A U.S. Pat. No. 3074 (Actoxumab + 7,625,559 bezlotoxumab) SEQ ID NO: 1 CD128 Toxin A MK3415A U.S. Pat. No. 3075 (Actoxumab + 7,625,559 bezlotoxumab) SEQ ID NO: 4 CD129 Toxin A MK3415A U.S. Pat. No. 3076 (Actoxumab + 7,625,559 bezlotoxumab) SEQ ID NO: 54 CD130 Toxin A MK3415A U.S. Pat. No. 3077 (Actoxumab + 7,625,559 bezlotoxumab) SEQ ID NO: 58 CD131 Toxin A A4.2 US20130230537 3078 SEQ ID NO: 34 CD132 Toxin A A5.1 US20130230537 3079 SEQ ID NO: 35 CD133 Toxin A A19.2 US20130230537 3080 SEQ ID NO: 36 CD134 Toxin A A20.1 US20130230537 3081 SEQ ID NO: 37 CD135 Toxin A A24.1 US20130230537 3082 SEQ ID NO: 38 CD136 Toxin A A26.8 US20130230537 3083 SEQ ID NO: 39 CD137 Toxin B B5.2 US20130230537 3084 SEQ ID NO: 40 CD138 Toxin B B7.3 US20130230537 3085 SEQ ID NO: 41 CD139 Toxin B B13.6 US20130230537 3086 SEQ ID NO: 42 CD140 Toxin B B15.3 US20130230537 3087 SEQ ID NO: 43 CD141 Toxin B B15.5 US20130230537 3088 SEQ ID NO: 44

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 4 against Campylobacter jejuni

TABLE 4 Antibodies against Campylobacter jejuni SEQ Antibody Reference ID No. Description Antibody Name Information NO CAMP1 Consensus FlagV1 WO2014063253 3089 SEQ ID NO: 7 CAMP2 — FlagV1M WO2014063253 3090 SEQ ID NO: 8 CAMP3 — F1agV1F23M WO2014063253 3091 SEQ ID NO: 9 CAMP4 — FlagV1MDSB WO2014063253 3092 SEQ ID NO: 10 CAMP5 — FlagV1MDSB WO2014063253 3093 SEQ ID NO: 11 CAMP6 Consensus FlagV6 WO2014063253 3094 SEQ ID NO: 12 CAMP7 — FlagV6M WO2014063253 3095 SEQ ID NO: 13 CAMP8 — F1agV6F23M WO2014063253 3096 SEQ ID NO: 14 CAMP9 — FlagV6MDSB WO2014063253 3097 SEQ ID NO: 15 CAMP10 — FlagV6F23MDSB WO2014063253 3098 SEQ ID NO: 16

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 5 against bacterial infections of the intestine.

TABLE 5 Antibodies against bacterial infections of the intestine SEQ Antibody Antibody Reference ID No. Description Name Information NO BACG1 Antibody against Listeria monocytogenes Antibody CN103497252 3099 from SEQ ID NO: 1 CN103497252 BACG2 Bivalent monovalent antibody against Pseudomonas, anti- U.S. Pat. No. 3100 Clostridium, Staphylococcus, Pasteurella, Yersinia, LYS3- 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, long SEQ ID NO: 22 Salmonella, Shigella, and Listeria, Clostridium, hinge/Cys- Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Tag Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG3 Heavy chain only, Antibody against Pseudomonas, LYS2 U.S. Pat. No. 3101 Clostridium, Staphylococcus, Pasteurella, Yersinia, VHH 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 18 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG4 Heavy chain only, Antibody against Pseudomonas, LYS3 U.S. Pat. No. 3102 Clostridium, Staphylococcus, Pasteurella, Yersinia, VHH 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 24 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG5 Heavy chain segment including variable region, F10 U.S. Pat. No. 3103 Starhylococcus enterotoxin B 8,895,704 SEQ ID NO: 30 BACG6 Heavy chain variable region. Antibody against, P. mAb 741 U.S. Pat. No. 3104 aeruginosa, Proteus Vulgaris, non-pathogenic E. coli, 8,263,078 Citrobacter freundii, Serratia marcenscens, Enterobacter SEQ ID NO: 1 cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonella typhimurium, Salmonella muenchen, Proteus mirabilis and Enteropathogenic E. coli, BACG7 Heavy chain variable region, Antibody against, P. mAb 763 U.S. Pat. No. 3105 aeruginosa, Proteus Vulgaris, non-pathogenic E. Coli, 8,263,078 Citrobacter freundii, Serratia marcenscens, Enterobacter SEQ ID NO: 2 cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonella typhimurium, Salmonella muenchen, Proteus mirabilis and Enteropathogenic E. coli., BACG8 Heavy chain variable region, antibody against flagellin U.S. Pat. No. 3106 from Salmonella or Pseudomonas 8,173,130 SEQ ID NO: 1 BACG9 Heavy chain variable region, Antibody against Gram INO 743 US20100239583 3107 negative (E. coli, Salmonella, Serratia, Proteus, SEQ ID NO: 1 Enterobacter, Citrobacter, Campylobacter and Pseudomonas) BACG10 Heavy chain variable region, Antibody against Abba3 U.S. Pat. No. 3108 Helicobacter pyroli 8,025,880 SEQ ID NO: 18 BACG11 Heavy chain variable region, Antibody against IgHV3-48*3 U.S. Pat. No. 3109 Helicobacter pyroli 8,025,880 SEQ ID NO: 20 BACG12 Heavy chain variable region, Antibody against clone 5 U.S. Pat. No. 3110 Helicobacter pyroli 8,025,880 SEQ. ID NO: 21 BACG13 Heavy chain variable region, Antibody against C4 U.S. Pat. No. 3111 Helicobacter pyroli 8,025,880 SEQ ID NO: 22 BACG14 Heavy chain variable region, Antibody against IgHV1-18*01 U.S. Pat. No. 3112 Helicobacter pyroli 8,025,880 SEQ ID NO: 23 BACG15 Heavy chain variable region, Antibody against C5 U.S. Pat. No. 3113 Helicobacter pyroli 8,025,880 SEQ ID NO: 24 BACG16 Heavy chain variable region, antibody against many SWLA3 WO2003007989 3114 pathogens, SEQ ID NO: 4 BACG17 Heavy chain variable region, antibody against SWLA3 US20040052814 3115 Streptococcus mutans, Escherichia coli, Shigella SEQ ID NO: 4 dysenteriae, Salmonella typhimurium, Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa BACG18 Heavy chain variable region, antibody against SWLA3 US20040052814 3116 Streptococcus mutans, Escherichia coli, Shigella SEQ ID NO: 8 dysenteriae, Salmonella typhimurium, Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa BACG19 Heavy chain, antibody against E coli, Shigella, Ab1 WO2012162253 3117 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 4 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG20 Heavy chain, antibody against E coli, Shigella, Ab2 WO2012162253 3118 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ. ID NO: 14 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG21 Heavy chain, antibody against E coli, Shigella, Ab3 WO2012162253 3119 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 24 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG22 Heavy chain, antibody against E coli, Shigella, Ab4 WO2012162253 3120 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 34 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG23 Heavy chain, antibody against E coli, Shigella, Ab5 WO2012162253 3121 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 44 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG24 Heavy chain, antibody against E coli, Shigella, Ab6 WO2012162253 3122 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 54 Clostridium difficile, iotavirus, RSV, HIV, nomoyirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG25 Heavy chain, antibody against E coli, Shigella, Ab7 WO2012162253 3123 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 64 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG26 Heavy chain, antibody against E coli, Shigella, Ab8 WO2012162253 3124 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 74 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG27 Heavy chain, antibody against E coli, Shigella, Ab9 WO2012162253 3125 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 84 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG28 Heavy chain, antibody against E coli, Shigella, Ab10 WO2012162253 3126 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 94 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG29 Heavy chain, antibody against E coli, Shigella, Ab11 WO2012162253 3127 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 104 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG30 Heavy chain, antibody against E coli, Shigella, Ab12 WO2012162253 3128 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID NO: 114 Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG31 Heavy chain, antibody against E coli, Shigella, Ab13 WO2012162253 3129 Entaamoeba histolytica, Salmonella. Campylobacter, or SEQ ID NO: 124 Clostridium difficile, iotavirus, RSV, HIV, nomoyirus, adenovirus, and astrovirus, other diseases causing diarrhea, BACG32 Heavy chain, antibody against E coli, Shigella, Ab14 WO2012162253 3130 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 134 adenovirus, and astrovirus, other diseases causing diarrhea, BACG33 Heavy chain, Antibody against Escherichia coli WO2014070117 3131 infection, Staphylococcus infection SEQ ID NO: 3 BACG34 Heavy chain, Antibody against Listeria 6H8 U.S. Pat. No. 3132 monocytogenes or WR-tubercle bacillus 8,445,643 SEQ ID NO: 5 BACG35 Heavy chain, Antibody against Pseudomonas, U.S. Pat. No. 3133 Clostridium, Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli. SEQ ID NO: 25 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG36 Heavy chain, Antibody against Pseudomonas, U.S. Pat. No. 3134 Clostridium, Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 26 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG37 Heavy chain, Starhylococcus enterotoxin B 100C9 U.S. Pat. No. 3135 8,895,704 SEQ ID NO: 34 BACG38 Heavy chain, Starhylococcus enterotoxin B 79G9+ U.S. Pat. No. 3136 8,895,704 SEQ ID NO: 38 BACG39 Heavy chain, Starhylococcus enterotoxin B 79G9 U.S. Pat. No. 3137 8,895,704 SEQ ID NO: 126 BACG40 Heavy chain, Starhylococcus enterotoxin B 154G12 U.S. Pat. No. 3138 8,895,704 SEQ ID NO: 142 BACG41 Light chain variable region, Antibody against, P. mAb 741 U.S. Pat. No. 3139 aeruginosa, Proteus Vulgaris, non-pathogenic E. coli, 8,263,078 Citrobacter freundii, Serratia marcenscens, Enterobacter SEQ ID NO: 3 cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonella typhimurium, Salmonella muenchen, Proteus mirabilis and Enteropathogenic E. coli BACG42 Light chain variable region, Antibody against, P. mAb 763 U.S. Pat. No. 3140 aeruginosa, Proteus Vulgaris, non-pathogenic E. coli, 8,263,078 Citrobacter freundii, Serratia marcenscens, Enterobacter SEQ ID NO: 4 cloacae, Campylobacter jejuni, Helicobacter pylori, Salmonella typhimurium, Salmonella muenchen, Proteus mirabilis and Enteropathogenic E. coli BACG43 Light chain variable region, Antibody against E coli, Ab1 WO2012162253 3141 Shigella, Entaamoeba histolytica, Salmonella, SEQ ID NO: 1 Campylobacter, or Clostridium difficile, rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus, other diseases causing diarrhea BACG44 Light chain variable region, antibody against flagellin U.S. Pat. No. 3142 from Salmonella or Pseudomonas 8,173,130 SEQ ID NO: 3 BACG45 Light chain variable region, Antibody against Gram INO 743 US20100239583 3143 negative (E. coli, Salmonella, Serratia, Proteus, SEQ ID NO: 2 Enterobacter, Citrobacter, Campylobacter and Pseudomonas) BACG46 Light chain variable region, Antibody against Abba3 U.S. Pat. No. 3144 Helicobacter pyroli 8,025,880 SEQ ID NO: 19 BACG47 Light chain variable region, Antibody against many SWLA3 WO2003007989 3145 pathogens SEQ ID NO: 7 BACG48 Light chain, Antibody against E. coli, Shigaella, Ab 1 US201200294822 3146 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID NO: 2 or Clostridium difficile or a virus selected from rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus BACG49 Light chain, Antibody against E. coli, Shigaella, Ab 1 US201200294822 3147 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID NO: 4 or Clostridium difficile or a virus selected from rotavirus, RSV, HIV, norvovirus, adenovirus, and astrovirus BACG50 Light chain, Antibody against E. coli, Shigaella, Ab 2 US201200294822 3148 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 12 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG51 Light chain, Antibody against E. coli, Shigaella, Ab 2 US201200294822 3149 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 14 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG52 Light chain, Antibody against E. coli, Shigaella, Ab 3 US201200294822 3150 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 22 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG53 Light chain, Antibody against E. coli, Shigaella, Ab 3 US201200294822 3151 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 24 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG54 Light chain, Antibody against E. coli, Shigaella, Ab 4 US201200294822 3152 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 32 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG55 Light chain, Antibody against E. coli, Shigaella, Ab 4 US201200294822 3153 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 34 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG56 Light chain, Antibody against E. coli, Shigaella, Ab 5 US201200294822 3154 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 42 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG57 Light chain, Antibody against E. coli, Shigaella, Ab 5 US201200294822 3155 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 44 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG58 Light chain, Antibody against E. coli, Shigaella, Ab 6 US201200294822 3156 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 52 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG59 Light chain, Antibody against E. coli, Shigaella, Ab 6 US201200294822 3157 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 54 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG60 Light chain, Antibody against E. coli, Shigaella, Ab 7 US201200294822 3158 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 62 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG61 Light chain, Antibody against E. coli, Shigaella, Ab 7 US201200294822 3159 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 64 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG62 Light chain, Antibody against E. coli, Shigaella, Ab 8 US201200294822 3160 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 72 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG63 Light chain, Antibody against E. coli, Shigaella, Ab 8 US201200294822 3161 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 74 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG64 Light chain, Antibody against E. coli, Shigaella, Ab 9 US201200294822 3162 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected front rotavirus, NO: 82 RSV, HIV, norvovirus, adenovirus, and astrovirus BAC065 Light chain, Antibody against E coli, Shigaella, Ab 9 US201200294822 3163 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 84 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG66 Light chain, Antibody against E. coli, Shigaella, Ab 10 US201200294822 3164 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 92 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG67 Light chain, Antibody against E. coli, Shigaella, Ab 10 US201200294822 3165 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 94 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG68 Light chain, Antibody against E. coli, Shigaella, Ab 11 US201200294822 3166 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 102 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG69 Light chain, Antibody against E. coli, Shigaella, Ab 11 US201200294822 3167 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 104 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG70 Light chain, Antibody against E. coli, Shigaella, Ab 12 US201200294822 3168 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 112 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG71 Light chain, Antibody against E. coli, Shigaella, Ab 12 US201200294822 3169 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 114 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG72 Light chain, Antibody against E. coli, Shigaella, Ab 13 US201200294822 3170 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 122 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG73 Light chain, Antibody against E. coli, Shigaella, Ab 13 US201200294822 3171 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 124 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG74 Light chain, Antibody against E. coli, Shigaella, Ab 14 US201200294822 3172 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 132 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG75 Light chain, Antibody against E. coli, Shigaella, Ab 14 US201200294822 3173 Entaamoeba histolvtica, Salmonella, Campylobacter, SEQ ID or Clostridium difficile or a virus selected from rotavirus, NO: 134 RSV, HIV, norvovirus, adenovirus, and astrovirus BACG76 Light chain, Antibody against E coli, Shigella, Ab2 WO2012162253 3174 Entaamoeba histolvtica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 11 adenovirus, and astrovirus, other diseases causing diarrhea BACG77 Light chain, Antibody against E coli, Shigella, Ab3 WO2012162253 3175 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 22 adenovirus, and astrovirus, other diseases causing diarrhea BACG78 Light chain, Antibody against E coli, Shigella, Ab4 WO2012162253 3176 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 31 adenovirus, and astrovirus, other diseases causing diarrhea BACG79 Light chain, Antibody against E coli, Shigella, Ab5 WO2012162253 3177 Entaamoeba histolytica, Salmonella. Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 42 adenovirus, and astrovirus, other diseases causing diarrhea BACG80 Light chain, Antibody against E coli, Shigella, Ab6 WO2012162253 3178 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostidium difficile, rotavirus, RSV, HIV, norvovirus, NO: 52 adenovirus, and astrovirus, other diseases causing diarrhea BACG81 Light chain, Antibody against E coli, Shigella, Ab7 WO2012162253 3179 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 61 adenovirus, and astrovirus, other diseases causing diarrhea BACG82 Light chain, Antibody against E coli, Shigella, Ab8 WO2012162253 3180 Entaamoeba histolytica, Salmonella. Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 71 adenovirus, and astrovirus, other diseases causing diarrhea BACG83 Light chain, Antibody against E coli, Shigella, Ab9 WO2012162253 3181 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 82 adenovirus, and astrovirus, other diseases causing diarrhea BACG84 Light chain, Antibody against E coli, Shigella, Ab10 WO2012162253 3182 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 91 adenovirus, and astrovirus, other diseases causing diarrhea BACG85 Light chain, Antibody against E coli, Shigella, Ab11 WO2012162253 3183 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 102 adenovirus, and astrovirus, other diseases causing diarrhea BACG86 Light chain, Antibody against E coli, Shigella, Ab12 WO2012162253 3184 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 112 adenovirus, and astrovirus, other diseases causing diarrhea BACG87 Light chain, Antibody against E coli, Shigella, Ab13 WO2012162253 3185 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, notvovirus, NO: 122 adenovirus, and astrovirus, other diseases causing diarrhea BACG88 Light chain, Antibody against E coli, Shigella, Ab14 WO2012162253 3186 Entaamoeba histolytica, Salmonella, Campylobacter, or SEQ ID Clostridium difficile, rotavirus, RSV, HIV, norvovirus, NO: 132 adenovirus, and astrovirus, other diseases causing diarrhea BACG89 Light chain, Antibody against Escherichia coli infection, WO2014070117 3187 Staphylococcus infection SEQ ID NO: 4 BACG90 Light chain, Antibody against Listeria monocytogenes or 6H8 U.S. Pat. No. 3188 WR-tubercle bacillus 8,445,643 SEQ ID NO: 6 BACG91 Light chain, Staphylococcus enterotoxin B F10 U.S. Pat. No. 3189 8,895,704 SEQ ID NO: 28 BACG92 Light chain, Staphylococcus enterotoxin B 100C9 U.S. Pat. No. 3190 8,895,704 SEQ ID NO: 32 BACG93 Light chain, Staphylococcus enterotoxin B 79G9 U.S. Pat. No. 3191 8,895,704 SEQ ID NO: 36 BACG94 Light chain, Staphylococcus enterotoxin B 154G12 U.S. Pat. No. 3192 8,895,704 SEQ ID NO: 134 BACG95 ScFv, Antibody against Clostridium perfringens, anti- ScFv-1A8 Zhao, B. and 3193 alpha toxin 1A8 Xu, C. “Cloning and sequencing of the ScFv-2E3 gene anti- alpha toxin of clostridium perfringens type A”, Chin. J. Vet. Sci. 20, 246-248 (2000), CNBI Accession # AAU11282 BACG96 ScFv, Antibody against Clostridium perfringens, anti- ScFv-2E3 Zhao, B. and 3194 alpha toxin 2E3 Xu, C. “Cloning and sequencing of the ScFv-2E3 gene anti- alpha toxin of clostridium perfringens type A”, Chin. J. Vet. Sci. 20, 246-248 (2000), NCBI Accession # AAU11283 BACG97 Variable fragment, Antibody against Pseudomonas, αTT2 U.S. Pat. No. 3195 Clostridium, Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 8 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria BACG98 Variable fragment, antibody against Pseudomonas, αTT1 U.S. Pat. No. 3196 Clostridium, Staphylococcus, Pasteurella, Yersinia, 7,655,759 Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, SEQ ID NO: 7 Salmonella, Shigella, and Listeria, Clostridium, Staphylococcus, Pseudomonas, Pasteurella, Yersinia, Bacillus anthracis, Neisseria, Vibrio, enterotoxic E. coli, Salmonella, Shigella, and Listeria bacteria,

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 6 against Hepatitis A and/or Hepatitis E.

TABLE 6 Antibodies against Hepatitis A and Hepatitis E Antibody SEQ No. Description Antibody Name Reference Information ID NO HEPAE1 Heavy chain variable region, HEV-Fab-216 CN1486990A; CN100497391C 3197 HEV Ab, a humanized neutralizing genetically engineered antibody HEPAE2 Heavy chain variable region, HEV-Fab-315 CN1486990A; CN100497391C 3198 HEV Ab, a humanized neutralizing genetically engineered antibody HEPAE3 Heavy chain variable region, HEV-Fab-319 CN1486990A; CN100497391C 3199 HEV Ab, a humanized neutralizing genetically engineered antibody HEPAE4 Heavy chain variable region, HEV-Fab-328 CN1486990A; CN100497391C 3200 HEV Ab, a humanized neutralizing genetically engineered antibody HEPAE5 Heavy chain variable region, HEV-Fab-404 CN1486990A; CN100497391C 3201 HEV Ab, a humanized neutralizing genetically engineered antibody HEPAE6 Heavy chain variable region, 13D8 US7786264 SEQ ID NO. 8; 3202 HEV monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE7 Heavy chain variable region, 16D7 US7786264 SEQ ID NO. 20; 3203 HEV monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE8 Heavy chain variable region, 8C11 US7786264 SEQ ID NO. 12; 3204 HEV monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE9 Heavy chain variable region, 8H3 US7786264 SEQ ID NO. 16; 3205 HEV monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE10 Heavy chain variable region, HEV # 31 US7148323 SEQ ID NO: 3; 3206 HEV neutralizing antibody US20050233316; US6930176; WO2001040270 HEPAE11 Heavy chain variable region, HEV # 4 US7786264 SEQ ID NO: 1; 3207 HEV neutralizing antibody US20050233316; US6930176; WO2001040270 HEPAE12 Heavy chain variable region, anti-HAV Kim S. J., et al., Neutralizing 3208 partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86899.1(124aa) HEPAE13 Heavy chain variable region, anti-HAV Kim S. J., et al., Neutralizing 3209 partial. HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86898.1(129aa) HEPAE14 Heavy chain variable region, anti-HAV Kim S. J., et al., Neutralizing 3210 partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86897.1(129aa) HEPAE15 Heavy chain variable region, anti-HA V Kim S. J., et al., Neutralizing 3211 partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86896.1(129aa) HEPAE16 Heavy chain, HEV antibody 8g12 Gu Y., et al., Structural basis for 3212 (mouse monoclonal antibody), tire neutralization of hepatitis E E2 glycoprotein virus by a cross-genotype antibody; Cell Res. 25 (5), 604-620 (2015); NCBI Accession # 4PLJ_H (229aa) HEPAE17 Heavy chain, HEV antibody Tang X., et al., Proc. Natl. Acad. 3213 (mouse monoclonal antibody), E2 Sci. U.S.A. 108 (25), 10266- glycoprotein 10271 (2011); NCBI Accession # 3RKD_H(230aa) HEPAE18 Light chain variable region, HAV # 14 US7635476 SEQ ID NO: 4; 3214 gamma1, HAV, US7282205; US20040260067; US20070287667; WO2003040341 HEPAE19 Light chain variable region, HAV # 4 US7635476 SEQ ID NO: 1; 3215 gamma1, HAV, US7282205; US20040260067; US20070287667; WO2003040341 HEPAE20 Light chain variable region, HAV # 5 US7635476 SEQ ID NO: 2; 3216 gamma1, HAV, US7282205; US20040260067; US20070287667; WO2003040341 HEPAE21 Light chain variable region, HAV # 6 US7635476 SEQ ID NO: 3; 3217 gamma1, HAV, US7282205; US20040260067; US20070287667; WO2003040341 HEPAE22 Light chain variable region, HEV HEV-Fab-216 CN1486990A; CN100497391C 3218 Ab, a humanized neutralizing genetically engineered antibody HEPAE23 Light chain variable region, HEV HEV-Fab-315 CN1486990A; CN100497391C 3219 Ab, a humanized neutralizing genetically engineered antibody HEPAE24 Light chain variable region, HEV HEV-Fab-319 CN1486990A; CN100497391C 3220 Ab, a humanized neutralizing genetically engineered antibody HEPAE25 Light chain variable region, HEV HEV-Fab-328 CN1486990A; CN100497391C 3221 Ab, a humanized neutralizing genetically engineered antibody HEPAE26 Light chain variable region, HEV HEV-Fab-404 CN1486990A; CN100497391C 3222 Ab, a humanized neutralizing genetically engineered antibody HEPAE27 Light chain variable region, WO2011114353 SEQ ID NO: 25 3223 monovalent, HAV HEPAE28 Light chain variable region, anti-HAV Kim S. J., et al., Neutralizing 3224 partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCB1 Accession # AAO86903.1(107aa) HEPAE29 Light chain variable region, anti-HAV Kim S. J., el al., Neutralizing 3225 partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86902.1(107aa) HEPAE30 Light cliain variable region, anti-HAV Kim S. J., el al., Neutralizing partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004), NCBI Accession # AAO86901.1(107aa) HEPAE31 Light chain variable region, anti-HAV Kim S. J., et al., Neutralizing partial, HAV capsid human monoclonal antibodies to hepatitis A virus recovered by phage display; Virology 318 (2), 598-607 (2004). NCB I Accession # AAO86900.1(107aa) HEPAE32 Light chain variable, HEV 13D8 US7786264 SEQ ID NO. 6; 3228 monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE33 Light chain variable, HEV 16D7 US7786264 SEQ ID NO. 18; 3229 monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE34 Light chain variable, HEV 8C11 US7786264 SEQ ID NO: 10; 3230 monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE35 Light chain variable, HEV 8H3 US7786264 SEQ ID NO. 14; 3231 monoclonal antibody US20060233822; US20100003281; EP1452541; EP2322625 HEPAE36 Light chain variable, HEV HEV # 31 US7148323 SEQ ID NO: 4; 3232 monoclonal antibody US20050233316; US6930176; WO2001040270 HEPAE37 Light chain variable, HEV HEV # 4 US7148323 SEQ ID NO: 2; 3233 monoclonal antibody US20050233316; US6930176; WO2001040270 HEPAE38 Light chain, E2 glycoprotein, 8g12 Gu Y., et al., Structural basis for 3234 HEV antibody (mouse the neutralization of hepatitis E monoclonal antibody) virus by a cross-genotype antibody; Cell Res. 25 (5), 604- 620 (2015); NCBI Accession # 4PLJ_L (212aa) HEPAE39 Light chain, E2 glycoprotein, Tang X., et al., Proc. Natl. Acad. 3235 HEV antibody (mouse Sci. U.S.A. 108(25), 10266- monoclonal antibody) 10271 (2011), NCBI Accession # 3RKD_C (214aa) HEPAE40 Monovalent Heavy chain variable WO2011114353 SEQ ID NO: 24 3236 region, HAV HEPAE41 ScFv, HAV, Monovalent human WO2011114353 SEQ ID NO: 27 3237 antibody

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in Chinese Pub. No. CN103923881, CN103923882, CN1605628, CN1318565, CN1163512, the contents of each of which are herein incorporated by reference in their entirety, against HAV.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 7 against Norwalk virus.

TABLE 7 Antibodies against Norwalk virus Antibody Antibody SEQ No. Description Name Reference Information ID NO NORV1 Heavy chain variable region, B7 WO2014126921 SEQ ID NO: 8 3238 Norwalk virus NORV2 Light chain variable region, B7 WO2014126921 SEQ ID NO: 16 3239 Norwalk virus NORV3 Heavy chain variable region, B72 WO2014126921 SEQ ID NO: 120 3240 Norwalk virus NORV4 Light chain variable region, B72 WO2014126921 SEQ ID NO: 128 3241 Norwalk virus NORV5 Heavy chain variable region, C9 WO2014126921 SEQ ID NO: 88 3242 Norwalk virus NORV6 Light chain variable region, C9 WO2014126921 SEQ ID NO: 96 3243 Norwalk virus NORV7 Heavy chain variable region, D4 WO2014126921 SEQ ID NO: 136 3244 Norwalk virus NORV8 Light chain variable region, D4 WO2014126921 SEQ ID NO: 144 3245 Norwalk virus NORV9 Heavy chain variable region, D8 WO2014126921 SEQ ID NO: 24 3246 Norwalk virus NORV10 Light chain variable region, D8 WO2014126921 SEQ ID NO: 32 3247 Norwalk virus NORV1 Heavy chain variable region, E5 WO2014126921 SEQ ID NO: 40 3248 Norwalk virus NORV12 Light chain variable region, E5 WO2014126921 SEQ ID NO: 48 3249 Norwalk virus NORV13 Heavy chain variable region, FI1 WO2014126921 SEQ ID NO: 72 3250 Norwalk virus NORV14 Light chain variable region, FI1 WO2014126921 SEQ ID NO: 80 3251 Norwalk virus NORV15 Heavy chain variable region, G3 WO2014126921 SEQ ID NO: 104 3252 Norwalk virus NORV16 Light chain variable region, G3 WO2014126921 SEQ ID NO: 112 3253 Norwalk virus NORV17 Heavy chain variable region, G4 WO2014126921 SEQ ID NO: 56 3254 Norwalk virus NORV18 Light chain variable region, G4 WO2014126921 SEQ ID NO: 64 3255 Norwalk virus NORV19 Heavy chain variable region, WO2014183052 SEQ ID NO: 1 3256 Norwalk or MD2004 virus NORV20 Heavy chain variable region, WO2014183052 SEQ ID NO: 2 3257 Norwalk or MD2004 virus NORV21 Heavy chain variable region, WO2014183052 SEQ ID NO: 3 3258 Norwalk or MD2004 virus NORV22 Heavy chain variable region, WO2014183052 SEQ ID NO: 4 3259 Norwalk or MD2004 virus NORV23 Heavy chain variable region, WO2014183052 SEQ ID NO: 5 3260 Norwalk or MD2004 virus NORV24 Heavy chain variable region, WO2014183052 SEQ ID NO: 6 3261 Norwalk or MD2004 virus NORV25 Heavy chain variable region, WO2014183052 SEQ ID NO: 7 3262 Norwalk or MD2004 virus NORV26 Heavy chain variable region, WO2014183052 SEQ ID NO: 8 3263 Norwalk or MD2004 virus NORV27 Heavy chain variable region, WO2014183052 SEQ ID NO: 9 3264 Norwalk or MD2004 virus NORV28 Heavy chain variable region, WO2014183052 SEQ ID NO: 10 3265 Norwalk or MD2004 virus NORV29 Heavy chain variable region, WO2014183052 SEQ ID NO: 11 3266 Norwalk or MD2004 virus NORV30 Heavy chain variable region, WO2014183052 SEQ ID NO: 12 3267 Norwalk or MD2004 virus NORV31 Heavy chain variable region, WO2014183052 SEQ ID NO: 13 3268 Norwalk or MD2004 virus NORV32 Heavy chain variable region, WO2014183052 SEQ ID NO: 14 3269 Norwalk or MD2004 virus NORV33 Heavy chain variable region, WO2014183052 SEQ ID NO: 15 3270 Norwalk or MD2004 virus NORV34 Heavy chain variable region, WO2014183052 SEQ ID NO: 16 3271 Norwalk or MD2004 virus NORV35 Heavy chain variable region, WO2014183052 SEQ ID NO: 17 3272 Norwalk or MD2004 virus NORV36 Heavy chain variable region, WO2014183052 SEQ ID NO: 18 3273 Norwalk or MD2004 virus NORV37 Heavy chain variable region, WO2014183052 SEQ ID NO: 19 3274 Norwalk or MD2004 virus NORV38 Heavy chain variable region, WO2014183052 SEQ ID NO: 20 3275 Norwalk or MD2004 virus NORV39 Heavy chain variable region, WO2014183052 SEQ ID NO: 21 3276 Norwalk or MD2004 virus NORV40 Heavy chain variable region, WO2014183052 SEQ ID NO: 22 3277 Norwalk or MD2004 virus NORV41 Heavy chain variable region, WO2014183052 SEQ ID NO: 23 3278 Norwalk or MD2004 virus NORV42 Heavy chain variable region, WO2014183052 SEQ ID NO: 24 3279 Norwalk or MD2004 virus NORV43 Heavy chain variable region, WO2014183052 SEQ ID NO: 25 3280 Norwalk or MD2004 virus NORV44 Heavy chain variable region, WO2014183052 SEQ ID NO: 26 3281 Norwalk or MD2004 virus NORV45 Heavy chain variable region, WO2014183052 SEQ ID NO: 27 3282 Norwalk or MD2004 virus NORV46 Heavy chain variable region, WO2014183052 SEQ ID NO: 28 3283 Norwalk or MD2004 virus NORV47 Heavy chain variable region, WO2014183052 SEQ ID NO: 29 3284 Norwalk or MD2004 virus NORV48 Heavy chain variable region, WO2014183052 SEQ ID NO: 30 3285 Norwalk or MD2004 virus

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 8 against Rotavirus.

TABLE 8 Antibodies against rotavirus Antibody SEQ No. Description Reference Information ID NO ROTV1 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 1 3286 ROTV2 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 2 3287 ROTV3 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 3 3288 R0TV4 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 4 3289 ROTV5 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 5 3290 ROTV6 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 6 3291 ROTV7 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 7 3292 ROTV8 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 8 3293 ROTV9 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 9 3294 ROTV10 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 10 3295 ROTV11 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 11 3296 ROTV12 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 12 3297 ROTV13 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 13 3298 ROTV14 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 14 3299 ROTV15 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 15 3300 ROTV16 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 16 3301 ROTV17 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 17 3302 ROTV18 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 18 3303 ROTV19 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 19 3304 ROTV20 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 20 3305 ROTV21 Heavy chain single domain US8105592; US20090226418 SEQ ID NO: 21 3306 ROTV22 Human VP6 polypeptide US20030166139 SEQ ID NO: 2 3307 ROTV23 Human VP6 polypeptide US20030166139 SEQ ID NO: 4 3308 ROTV24 Aiyegbo, M. S., et al ″Human RotavirUSVp6- 3309 Specific Antibodies Mediate intracellular Neutralization By Binding To A Quater Structure in The Transcriptional Pore″, Plos One 8, 61101 (2013), NCBI Accession # 4HFW_B ROTV25 Aiyegbo, M. S., et al ″Human RotavirUSVp6- 3310 Specific Antibodies Mediate intracellular Neutralization By Binding To A Quater Structure in The Transcriptional Pore″, Plos One 8, 61101 (2013), NCBI Accession # 4HFW_B

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 9 against Entamoeba histolytica.

TABLE 9 Antibodies against Entainoeba Histolytica Antibody No.; SEQ Antibody Name Description Reference Information ID NO ENTH1 Heavy chain (partial sequence) gamma., Cheng, X. J. et al., Exp. Parasitol. 96 3311 Entamoeba histolytica antibody (1), 52-56 (2000), NCBI Accession # BAA97670.1 (220aa) ENTH2 Heavy chain (partial sequence) gamma, Tachibana, H. et al., Clin. Diagn. Lab. 3312 Entamoeba histolytica Antibody Immunol. 6 (3), 383-387 (1999), NCBI Accession # BAA82104.1 (222aa) ENTH3 Heavy chain (partial sequence) gamma, Tachibana, H. et al., Clin. Diagn. Lab. 3313 Entamoeba histolytica Antibody Immunol. 6 (3), 383-387 (1999), NCBI Accession # BAA82101.1 (226aa) ENTH4 Heavy chain (partial sequence) IgG, Tachibana, H., et al., Infect. Immun. 77 3314 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03695.1 (220aa) Monoclonal Antibodies ENTH5 Heavy chain (partial sequence) IgG, Tachibana, H., el al., Infect. Immun. 77 3315 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03694.1 (226aa) Monoclonal Antibodies ENTH6 Heavy chain (partial sequence) IgG, Tachibana, H., et al., Infect. Immun. 77 3316 Entamoeba histolytica Intermediate (1), 549-556(2009), NCBI Accession # Subunit Lectin-Specific Human BAH03693.1 (221aa) Monoclonal Antibodies ENTH7 Heavy chain (partial sequence) IgG, Tachibana. H., et al., Infect. Immun. 77 3317 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03692.1 (223aa) Monoclonal Anybodies ENTH8 Light chain (partial sequence) IgG, Tachibana, H., et al., Infect. Immun. 77 3318 Entamoeba histolytica intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03699.1 (219aa) Monoclonal Antibodies ENTH9 Light chain (partial sequence) IgG, Tachibana. H., et al., Infect. Immun. 77 3319 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03698.1 (220aa) Monoclonal Antibodies ENTH10 Light chain (partial sequence) IgG, Tachibana, H., et al., Infect. Immun. 77 3320 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03697.1 (214aa) Monoclonal Antibodies ENTH11 Light chain (partial sequence) IgG, Tachibana, H., et al., Infect. Immun. 77 3321 Entamoeba histolytica Intermediate (1), 549-556 (2009), NCBI Accession # Subunit Lectin-Specific Human BAH03696.1 (214aa) Monoclonal Antibodies ENTH12 Light chain (partial sequence) kappa, Cheng, X. J. et al., Exp. Parasitol. 96 (1), 3322 Entamoeba histolytica antibody 52-56 (2000), NCBI Accession # BAA97671.1 (214aa) ENTH13 Light chain (partial sequence) kappa, Tachibana, H. et al., Clin. Diagn. Lab. 3323 Entamoeba histolytica antibody Immunol. 6 (3), 383-387 (1999), NCBI Accession # BAA821051 (215aa) ENTH14 Light chain (partial sequence) kappa, Tachibana, H. et al., Clin. Diagn. Lab. 3324 Entamoeba histolytica antibody Immunol. 6 (3), 383-387 (1999), NCBI Accession # BAA82100.1 (214aa) ENTH15/ Single chain Fv Antibody 350-E2 NCBI Accession # AEY80059.1 (274aa) 3325 350-E2 against Entamoeba histolytica ENTH16/ Single chain Fv Antibody JR4A11 NCBI Accession # AEY80058.1 (287aa) 3326 JR4A11 Entamoeba histolytica

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides, fragments or variants thereof described in International Pub. No. WO2001012646, the contents of which are herein incorporated by reference in their entirety, against listena monocytogenes, salmonella and/or leishmania.

Neglected Tropical Diseases

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the neglected tropical disease related payload antibody polypeptides listed in Tables 10-13.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 10 against Dengue Fever Virus.

TABLE 10 Antibodies against Dengue Fever Virus Antibody Antibody SEQ No. Description Name Reference Information ID NO DENG1 Bispecific, DENV serotype 1, m366 US20150218255 SEQ ID NO: 96 3327 DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG2 Fab Fragment Fab 14c10 Teoh, E. P., el al., Sci Transl Med 4 3328 (139), 139RA83 (2012), NCBI Accession # 4CAU_E(230 aa) DENG3 Heavy chain 5j7 Fab Fibriansah, G., el al., A highly 3329 potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins; Nat Commun 6, 6341 (2015), NCBI Accession # 3J6U_H (135aa) DENG4 Heavy Chain Ede1 C8 Dejnirattisai, W., et al., A new 3330 class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UTA_H (272 aa) DENG5 Heavy Chain Fab 2h12 Midgley, C.M., et al., J, Immunol. 3331 188 (1), 4971-4979 (2012), NCBI Accession # 4AL8_H (217 aa) DENG6 Heavy Chain Fab Fragment Of 1f4 Fab Fibriansah. G., et al., A potent anti- 3332 Antibodv 1f4 dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface; EMBO Mol Med 6 (3), 358-371 (2014), NCBI Accession # 4C2I_H (232 aa) DENG7 Heavy chain variable region 9F12 WO2010093335 SEQ ID NO: 4 3333 DENG8 Heavy chain variable region, 9F12 US20150218255 SEQ ID NO: 83 3334 DENV serotype l, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG9 Heavy chain variable region, m366 US20150218255 SEQ ID NO: 4 3335 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG10 Heavy chain variable region, m366.6 US20150218255 SEQ ID NO: 24 3336 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG11 Heavy chain variable region, m360.6 US20150218255 SEQ ID NO: 44 3337 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG12 Heavy chain variable region, HMB-DV-1 US9073981 SEQ ID NO: 13 3338 DENV-I, DENV-2, DENV-3, DENV-4 DENG13 Heavy chain variable region, HMB-DV-2 US9073981 SEQ ID NO: 29 3339 DENV-I, DENV-2, DENV-3, DENV-4 DENG14 Heavy chain variable region, HMB-DV-3 US9073981 SEQ ID NO: 45 3340 DENV-I, DENV-2, DENV-3, DENV-4 DENG15 Heavy chain variable region, HMB-DV-4 US9073981 SEQ ID NO: 61 3341 DENV-I, DENV-2, DENV-3, DENV-4 DENG16 Heavy chain variable region, HMB-DV-4 US9073981 SEQ ID NO: 65 3342 DENV-I, DENV-2, DENV-3, DENV-4 DENG17 Heavy chain variable region, HMB-DV-5 US9073981 SEQ ID NO: 79 3343 DENV-I, DENV-2, DEN V-3, DENV-4 DENG18 Heavy chain variable region, HMB-DV-6, US9073981 SEQ ID NO: 95 3344 DENV-I, DENV-2, DENV-3, HMB-DV-7 DENV-4 DENG19 Heavy chain variable region, HMB-DV-8 US9073981 SEQ ID NO: 117 3345 DENV-I, DENV-2, DENV-3, DENV-4 DENG20 Heavy chain variable region, HMB-DV-9 US9073981 SEQ ID NO: 131 3346 DENV-I, DENV-2, DENV-3, DENV-4 DENG21 Heavy chain variable region, HMB-DV-10 US9073981 SEQ ID NO: 145 3347 DENV-I, DENV-2, DENV-3, DENV-4 DENG22 Heavy chain variable region, HMB-DV-11 US9073981 SEQ ID NO: 151 3348 DENV-I, DENV-2, DENV-3, DENV-4 DENG23 Heavy chain variable region, HMB-DV-12 US9073981 SEQ ID NO: 165 3349 DENV-I, DENV-2, DENV-3, DENV-4 DENG24 Heavy chain variable region, HMB-DV-13 US9073981 SEQ ID NO: 181 3350 DENV-I, DENV-2, DENV-3, DENV-4 DENG25 Heavy chain variable region, HMB-DV-14 US9073981 SEQ ID NO: 195 3351 DENV-I, DENV-2, DENV-3, DENV-4 DENG26 Heavy chain variable region, DV- A68 US20150225474 SEQ ID NO: 19 3352 1, DV-2, DV-3, and DV-10 DENG27 Heavy chain variable region, DV- A100 US20150225474 SEQ ID NO: 20 3353 1, DV-2, DV-3, and DV-11 DENG28 Heavy chain variable region, DV- C58 US20150225474 SEQ ID NO: 21 3354 1, DV-2, DV-3, and DV-12 DENG29 Heavy chain variable region, DV- C98 US20150225474 SEQ ID NO: 32 3355 1, DV-2, DV-3, and DV-13 DENG30 Heavy chain variable region, DV- A11 US20150225474 SEQ ID NO: 33 3356 1, DV-2, DV-3, and DV-14 DENG31 Heavy chain variable region, DV- B11 US20150225474 SEQ ID NO: 36 3357 1, DV-2, DV-3, and DV-15 DENG32 Heavy chain variable region, DV- D88 US20150225474 SEQ ID NO: 1 3358 1, DV-2, DV-3, and PV-4 DENG33 Heavy chain variable region, DV- mAb11 WO2014144061 SEQ ID NO: 1 3359 1, DV-2, PV-3, and DV-1 DENG34 Heavy chain variable region, DV- F38 US20150225474 SEQ ID NO: 80 3360 1, DV-2, DV-3, and PV-5 DENG35 Heavy chain variable region, DV- A48 US20150225474 SEQ ID NO: 16 3361 1, DV-2, PV-3. and DV-6 DENG36 Heavy drain variable region, DV- C8S US20150225474 SEQ ID NO: 17 3362 1, DV-2, PV-3, and DV-7 DENG37 Heavy chain variable region, DV- F108 US20150225474 SEQ ID NO: 18 3363 1, DV-2, DV-3, and PV-8 DENG38 Heavy chain variable region, DV- B48 US20150225474 SEQ ID NO: 18 3364 1, DV-2, PV-3, and PV-9 DENG39 Heavy chain, Antigen-binding 2d22 Fibriansah, G., et al., DENGUE 3365 Fragment Of Human Antibody VIRUS. Cryo-EM structure of an 2d22 antibody that neutralizes dengue virus type 2 by locking E protein dimers; Science 349 (6243), 88-91 (2015), NCBI Accession # 5A1Z_K (128 aa) DENG40 Heavy chain, Dengue virus NS-1 US7473424; US20040209244; 3366 protein WO2004067567; EP1592712 SEQ ID NO: 3 DENG41 Heavy chain, Dengue virus DB32-6 US8637035 SEQ ID NO: 1 3367 serotype 2 DENG42 Heavy chain, Dengue virus DB2-3 US8637035 SEQ ID NO: 13 3368 serotype 2 DENG43 Heavy chain, Dengue virus DB13-19 US8637035 SEQ ID NO: 14 3369 serotype 2 DENG44 Heavy chain, Dengue virus DB23-3 US8637035 SEQ ID NO: 15 3370 serotype 2 DENG45 Heavy chain. Dengue virus DB25-2 US8637035 SEQ ID NO: 16 3371 serotype 2 DENG46 Heavy chain, Dengue virus DB42-3 US8637035 SEQ ID NO: 17 3372 serotype 2 DENG47 Heavy chain, Dengue virus type 1A5 US8337853 SEQ ID NO: 97 3373 10 DENG48 Heavy chain. Dengue virus type 2H7 US8337853 SEQ ID NO: 113 3374 11 DENG49 Heavy chain, Dengue virus type 2H5 US8337853 SEQ ID NO: 129 3375 12 DENG50 Heavy chain, Dengue virus type 3A2 US20130089543 SEQ ID NO: 145 3376 13 DENG51 Heavy chain, Dengue virus type 1B2 US20130089543 SEQ ID NO: 161 3377 14 DENG52 Heavy chain. Dengue virus type 1A10 US20130089543 SEQ ID NO: 177 3378 13 DENG53 Heavy chain, Dengue virus type 4 5H2 US7622113 SEQ ID NO: 1 3379 DENG54 Heavy chain, Dengue virus type 5 5H7 US7622113 SEQ ID NO: 17 3380 DENG55 Heavy chain, Dengue vires type 6 3Cl US7622113 SEQ ID NO: 33 3381 DENG56 Heavy chain, Dengue virus type 7 3E4 US7622113 SEQ ID NO: 49 3382 DENG57 Heavy chain, Dengue virus type 8 7G4 US7622113 SEQ ID NO: 65 3383 DENG58 Heavy chain, Dengue virus type 9 5D9 US7622113 SEQ ID NO: 81 3384 DENG59 Heavy chain, DV 1 14c10 clone US20130259871 Fig 4b 3385 8 DENG60 Heavy chain, DV-1, DV-2, DV-3, Antibody US20140056913 SEQ ID NO: 1 3386 and DV-4 4e11 DENG61 Heavy chain, DV-1, DV-2, DV-3, Variant of US20140056913 SEQ ID NO: 21 3387 and DV-4 4E11 DENG62 Heavy chain, DV-1, DV-2, DV-3, 4E5A WO20155123362 SEQ ID NO: 29 3388 and DV-4 DENG63 Light Chain 5j7 Fab Fibriansah, G., et al., A highly 3389 potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins; Nat Commun 6, 6341 (2015), NCBI Accession # 3J6U_L (118aa) DENG64 Light Chain Ede1 C8 Dejnirattisai, W., et al., A new 3390 class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UTA_L (217 aa) DENG65 Light Chain Fab 2h12 Midgley, C. M., et al., J, Immunol. 3391 188 (10), 4971-4979 (2012), NCBI Accession # 4AL8_L (213 aa) DENG66 Light Chain Fab Fragment Of 1f4 Fab Fibriansah, G., et al., A potent anti- 3392 Antibody 1f4 dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface; EMBO Mol Med 6 (3), 358-371 (2014), NCBI Accession # 4C2I_N (239 aa) DENG67 Light chain variable region 9F12 WO2010093335 SEQ ID NO: 6 DENG68 Light chain variable region, 9F12 US20150218255 SEQ ID NO: 84 3393 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG69 Light chain variable region, m366 US20150218255 SEQ ID NO: 6 3394 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG70 Light chain variable region, m366.6 US20150218255 SEQ ID NO: 26 3395 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 DENG71 Light chain variable region, m360.6 US20150218255 SEQ ID NO: 46 3396 DENV serotype 1, DENV serotype 2, DENV serotype 3, and DENV serotype 4 HMB-DV-1 US9073981 SEQ ID NO: 14 3397 DENG72 Light chain variable region, DENV-I, DENV-2, DENV-3, DENV-4 DENG73 Light chain variable region, HMB-DV-2 US9073981 SEQ ID NO: 30 3398 DENV-I, DENV-2, DENV-3, DENV-4 DENG74 Light chain variable region, HMB-DV-3 US9073981 SEQ ID NO: 46 3399 DENV-I, DENV-2, DENV-3, DENV-4 DENG75 Light chain variable region, HMB-DV-4 US9073981 SEQ ID NO: 62 3401 DENV-I, DENV-2, DENV-3, DENV-4 DENG76 Light chain variable region, HMB-DV-5 US9073981 SEQ ID NO: 80 3402 DENV-I, DENV-2, DENV-3, DENV-4 DENG77 Light chain variable region, HMB-DV-6 US9073981 SEQ ID NO: 96 3403 DENV-I, DENV-2, DENV-3, DENV-4 DENG78 Light chain variable region, HMB-DV-7 US9073981 SEQ ID NO: 103 3404 DENV-I, DENV-2, DENV-3, DENV-4 DENG79 Light chain variable region, HNfB-DV-8 US9073981 SEQ ID NO: 118 3405 DENV-I, DENV-2, DENV-3, DENV-4 DENG80 Light chain variable region, HMB-DV-9 US9073981 SEQ ID NO: 132 3406 DENV-I, DENV-2, DENV-3, DENV-4 DENG81 Light chain variable region, HMB-DV-10, US9073981 SEQ ID NO: 146 3407 DENV-I, DENV-2, DENV-3, HMB-DV-11 DENV-4 DENG82 Light chain variable region, HMB-DV-12 US9073981 SEQ ID NO: 166 3408 DENV-I, DENV-2, DENV-3, DENV-4 DENG83 Light chain variable region, HMB-DV-13 US9073981 SEQ ID NO: 182 3409 DENV-I, DENV-2, DENV-3, DENV-4 DENG84 Light chain variable region, HMB-DV-14 US9073981 SEQ ID NO: 196 3410 DENV-I, DENV-2, DENV-3, DENV-4 DENG85 Light chain variable region, DV-1, D88, F38, US20150225474 SEQ ID NO: 2 3411 DV-2, DV-3, and DV-4 A48, C88, F108, B48, A68, A100, C58, C78, C68, D98, D188, C128, C98 DENG86 Light chain variable region, DV-1, C78 US20S50225474 SEQ ID NO: 23 3412 DV-2, DV-3, and DV-4 DENG87 Light chain variable region, DV-1, C68 US20150225474 SEQ ID NO: 25 3413 DV-2, DV-3, and DV-4 DENG88 Light chain variable region, DV-1, D98 US20150225474 SEQ ID NO: 27 3414 DV-2, DV-3, and DV-4 DENG89 Light chain variable region, DV-1, D188 US20150225474 SEQ ID NO: 29 3415 DV-2, DV-3, and DV-4 DENG90 Light chain variable region, DV-1, C128 US20150225474 SEQ ID NO: 31 3416 DV-2, DV-3, and DV-4 DENG91 Light chain variable region, DV-1, A11, B11 US20150225474 SEQ ID NO: 34 3417 DV-2, DV-3, and DV-4 DENG92 Light chain variable region, DV-1, mAb11 WO2014144061 SEQ ID NO: 3 3418 DV-2, DV-3, and DV-4 DENG93 Light chain, Antigen-binding 2d22 Fibriansah, G., el al., DENGUE 3419 Fragment Of Human Antibody VIRUS. Cryo-EM structure of an 2d22 antibody that neutralizes dengue virus type 2 by locking E protein dimers; Science 349 (6243), 88-91 (2015), NCBI Accession # 5A1Z_L (115 aa) DENG94 Light cliain, Dengue virus NS-1 US7473424; US20040209244; 3420 protein WO2004067567; EP1592712 SEQ ID NO: 4 DENG95 Light chain, Dengue virus DB32-6 US8637035 SEQ ID NO: 5 3421 serotype 2 DENG96 Light chain, Dengue virus DB2-3, US8637035 SEQ ID NO: 19 3422 serotype 2 DB-19 DENG97 Light chain, Dengue virus DB23-3 US8637035 SEQ ID NO: 20 3423 serotype 2 DENG98 Light chain, Dengue virus DB25-2 US8637035 SEQ ID NO: 21 3424 serotype 2 DENG99 Light chain, Dengue virus DB42-3 US8637035 SEQ ID NO: 22 3425 serotype 2 DENG100 Light chain, Dengue virus 5H2 US7622113 SEQ ID NO: 9 3426 serotype 4 DENG101 Light chain, Dengue virus 5A7 US7622113 SEQ ID NO: 25 3427 serotype 4 DENG102 Light chain, Dengue virus 3C1 US7622113 SEQ ID NO: 41 3428 serotype 4 DENG103 Light chain, Dengue virus 3E4 US7622113 SEQ ID NO: 57 3429 serotype 4 DENG104 Light chain, Dengue virus 7G4 US7622113 SEQ ID NO: 73 3430 serotype 4 DENG105 Light chain, Dengue virus 5D9 US7622153 SEQ II) NO: 89 3431 serotype 4 DENG106 Light chain, Dengue virus 1A5 US8337853 SEQ ID NO: 105 3432 serotype 4 DENG107 Light chain, Dengue virus 2H7 US8337853 SEQ ID NO: 121 3433 serotype 4 DENG108 Light chain, Dengue virus 2H5 US8337853 SEQ ID NO: 137 3434 serotype 4 DENG109 Light chain, Dengue virus 3A2 US20130089543 SEQ ID NO: 153 3435 serotype 4 DENG110 Light chain, Dengue virus 1B2 US20130089543 SEQ ID NO: 169 3436 serotype 4 DENG111 Light chain, Dengue virus 1A10 US20130089543 SEQ ID NO: 185 3437 serotype 4 DENG112 Light chain, DV 1 14c10 clone US20130259871 Fig 4b 3438 8 DENG113 Light chain, DV-l, DV-2, DV-3, Antibody US20140056913 SEQ ID NO: 2 3439 and DV-4 4e11 DENG114 Light chain, DV-l, DV-2, DV-3, Variant of US20140056913 SEQ ID NO: 22 3440 and DV-4 4E11 DENG115 Light chain, DV-l, DV-2, DV-3, 4E5A WO20155123362 SEQ ID NO: 30 3441 and DV-4 DENG116 scFv 9F12 WO2010093335 SEQ ID NO: 8 3442 DENG117 Scfv Fragment Ede211 Dejnirattisai, W., et al., A new 3443 class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UT7_L(153 aa) DENG118 Scfv Fragment Ede2 A11 Dejnirattisai, W., et al, A new 3444 class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UT7_H (150 aa) DENG119 Ede2A11 Dejnirattisai, W., et al., A new 3445 class of lightly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UTB_L (218 aa) 3446 DENG120 Ede1 C10 Dejnirattisai, W., et al., A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UT9_L (154aa) DENG121 Ede1 C10 Dejnirattisai, W., et al., A new 3447 class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol 16 (2), 170-177 (2015), NCBI Accession # 4UT9_H (144 aa) DENG122 Ede2 B7 Dejnirattisai. W. et al., A new 3448 class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UT6_L (218 aa) DENG123 Ede2 B7 Dejnirattisai, W., et al., A new 3449 class of highly potent, broadly neutralizing antibodies isolated from viremic patients injected with dengue virus; Nat. Immunol. 16 (2), 170-177 (2015), NCBI Accession # 4UT6_H (283 aa)

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides, fragments or variants thereof described in International Pub. No. WO2013089647 and WO2013035345, U.S. Pat. Nos. 8,637,035 and 887,187, US Publication No. US20050123900, and Chinese Patent Publication No. CN102757480, the contents of which are herein incorporated by reference in their entirety, against Listeria monocytogenes, salmonella and/or leishmania.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 11 against Rabies Virus

TABLE 11 Antibodies against Rabies Virus Antibody SEQ No. Description Antibody Name Reference Information ID NO RABV1 Fab Heavy Chain Fd region CN101696242 SEQ ID NO: 9 3450 RABV2 Fab Light chain CN101696242 SEQ ID NO: 10 3451 RABV3 Heavy chain US6890532 SEQ ID NO: 3 3452 RABV4 Heavy chain Mab JB.1 US7071319 SEQ ID NO: 10 3453 RABV5 Heavy chain Mab 57 US7071319 SEQ ID NO: 14 3454 RABV6 Heavy chain CR04-098 US9005624 SEQ ID NO: 335 3455 RABV7 Heavy chain CR57, US9005624 SEQ ID NO: 123 3456 Rafivirumab RABV8 Heavy chain CR57, Rafivirumab RABV9 Heavy chain CRJB US9005624 SEQ ID NO: 127 3458 RABV10 Heavy chain Foravirumab 3459 RABV11 Heavy chain, Anti-rabies SOJB Presniak, M. et al. 3460 immunoglobulin ″Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposure prophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AA017822.1 RABV12 Heavy chain variable region CN101696242 SEQ ID NO: 4 3461 RABV13 Heavy chain variable region SC04-001 US9005624 SEQ ID NO: 26 3462 RABV14 Heavy chain variable region SC04-004 US9005624 SEQ ID NO: 27 3463 RABV15 Heavy chain variable region SC04-008 US9005624 SEQ ID NO: 28 3464 RABV16 Heavy chain variable region SC04-010 US9003624 SEQ ID NO: 29 3465 RABV17 Heavy chain variable region SC04-018 US9005624 SEQ ID NO: 30 3466 RABV18 Heavy chain variable region SC04-021 US9005624 SEQ ID NO: 31 3467 RABV19 Heavy chain variable region SC04-026 US9005624 SEQ ID NO: 32 3468 RABV20 Heavy chain variable region SC04-031 US9005624 SEQ ID NO: 33 3469 RABV21 Heavy chain variable region SC04-038 US9005624 SEQ ID NO: 44 3470 RABV22 Heavy chain variable region SC04-040 US9005624 SEQ ID NO: 35 3471 RABV23 Heavy chain variable region SC04-060 US9005624 SEQ ID NO: 36 3472 RABV24 Heavy chain variable region SC04-073 US9005624 SEQ ID NO: 37 3473 RABV25 Heavy chain variable region SC04-097 US9005624 SEQ ID NO: 38 3474 RABV26 Heavy chain variable region SC04-098 US9005624 SEQ ID NO: 39 3475 RABV27 Heavy chain variable region SC04-103 US9005624 SEQ ID NO: 40 3476 RABV28 Heavy chain variable region SC04-104 US9005624 SEQ ID NO: 41 3477 RABV29 Heavy chain variable region SC04-108 US9005624 SEQ ID NO: 42 3478 RABV30 Heavy chain variable region SC04-120 US9005624 SEQ ID NO: 43 3479 RABV31 Heavy chain variable region SC04-125 US9005624 SEQ ID NO: 44 3480 RABV32 Heavy chain variable region SC04-126 US9005624 SEQ ID NO: 45 3481 RABV33 Heavy chain variable region SC04-140 US9005624 SEQ ID NO: 46 3482 RABV34 Heavy chain variable region SC04-144 US9005624 SEQ ID NO: 47 3483 RABV35 Heavy chain variable region SC04-146 US9005624 SEQ ID NO: 48 3484 RABV36 Heavy chain variable region SC04-164 US9005624 SEQ ID NO: 49 3485 RABV37 Heavy chain variable region RVFab5 WO201113757 SEQ ID NO: 2 3486 RABV38 Heavy chain variable region RVFab8 WO2011137570 SEQ ID NO: 2 3487 RABV39 Heavy chain variable region CN101337990 SEQ ID NO: 2 3488 RABV40 Heavy chain variable region CN101337990 SEQ ID NO: 8 3489 RABV41 Heavy chain variable region R8 VH CN104193823 SEQ ID NO: 1 3490 RABV42 Heavy chain variable region R5 VH CN104193823 SEQ ID NO: 2 3491 RABV43 Heavy chain variable region R7 VH, R9 VH CN104193823 SEQ ID NO: 3 3492 RABV44 Heavy chain variable region CN101235086 SEQ ID NO: 38 3493 RABV45 Heavy chain, Anti-rabies Prosniak, M. et al. 3494 SOJA immunoglobulin ″Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposnre prophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AAO17823.1 RABV46 Light chain US6890532 SEQ ID NO: 4 3495 RABV47 Light chain Mab JB.1 US7071319 SEQ ID NO: 12 3496 RABV48 Light chain Mab 57 US7071319 SEQ ID NO: 16 3497 RABV49 Light chain CR04-098 US9005624 SEQ ID NO: 337 3498 RABV50 Light chain CR57, US9005624 SEQ ID NO: 125 3499 Rafivirumab RABV51 Light chain CR57, 3500 Rafivirumab RABV52 Light chain CRJB US9005624 SEQ ID NO: 129 3501 RABV53 Light chain Foravirumab 3502 RABV54 Light chain Kappa, Anti-rabies Prosniak, M. et al. 3503 SOJA immunoglobulin ″Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposnre prophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AAO17825.1 RABV55 Light chain kappa, Anti-rabies Prosniak, M. et al. 3504 SOJA immunoglobulin [Homo ″Development of a cocktail of sapiens] recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposnre prophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AAO17821.1 RABV56 Light chain Lambda, Anti-rabies Prosniak, M. et al. 3505 S057 immunoglobulin ″Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposnre prophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AAO17824.1 RABV57 Light cliain lambda, Anti-rabies Prosniak, M. et al. 3506 SOJB immunoglobulin ″Development of a cocktail of recombinant-expressed human rabies virus-neutralizing monoclonal antibodies for postexposnre prophylaxis of rabies″, J. Infect. Dis. 188 (1), 53-56 (2003), NCBI Accession # AAO17826.1 RABV58 Light chain variable region SC04-001 US9005624 SEQ ID NO: 50 3507 RABV59 Light chain variable region SC04-00-1 US9005624 SEQ ID NO: 51 3508 RABV60 Light chain variable region SC04-008 US9005624 SEQ ID NO: 52 3509 RABV61 Light chain variable region SC04-010 US9005624 SEQ ID NO: 55 3510 RABV62 Light chain variable region SC04-018 US9005624 SEQ ID NO: 54 3511 RABV63 Light chain variable region SC04-021 US9005624 SEQ ID NO: 55 3512 RABV64 Light chain variable region SC04-026 US9005624 SEQ ID NO: 56 3513 RABV65 Light chain variable region SC04-031 US9005624 SEQ ID NO: 57 3514 RABV66 Light chain variable region SC04-038 US9005624 SEQ ID NO: 58 3515 RABV67 Light chain variable region SC04-040 US9005624 SEQ ID NO: 59 3516 RABV68 Light chain variable region SC04-060 US9005624 SEQ ID NO: 60 3517 RABV69 Light chain variable region SC04-073 US9005624 SEQ ID NO: 61 3518 RABV70 Light chain variable region SC04-097 US9005624 SEQ ID NO: 62 3519 RABV71 Light chain variable region SC04-098 US9005624 SEQ ID NO: 63 3520 RABV72 Light chain variable region SC04-103 US9005624 SEQ ID NO: 64 3521 RABV73 Light chain variable region SC04-104 US9005624 SEQ ID NO: 65 3522 RABV74 Light chain variable region SC04-108 US9005624 SEQ ID NO: 66 3523 RABV75 Light chain variable region SC04-120 US9005624 SEQ ID NO: 67 3524 RABV76 Light chain variable region SC04-125 US9005624 SEQ ID NO: 68 3525 RABV77 Light chain variable region SC04-126 US9005624 SEQ ID NO: 69 3526 RABV78 Light chain variable region SC04-140 US9005624 SEQ ID NO: 70 3527 RABV79 Light chain variable region SC04-144 US9005624 SEQ ID NO: 71 3528 RABV80 Light chain variable region SC04-146 US9005624 SEQ ID NO: 72 3529 RABV81 Light chain variable region SC04-164 US9005624 SEQ ID NO: 73 3530 RABV82 Light chain variable region RVFab5 WO201113757 SEQ ID NO: 1 3531 RABV83 Light chain variable region RVFab8 WO2011137570 SEQ ID NO: 1 3432 RABV84 Light chain variable region CN101337990 SEQ ID NO: 4 3433 RABV85 Light chain variable region CN101337990 SEQ ID NO: 10 3434 RABV86 Light chain variable region R8 VL CN104193823 SEQ ID NO: 4 3435 RABV87 Light chain variable region R5 VL CN104193823 SEQ ID NO: 5 3436 RABV88 Light chain variable region R7 VL CN104193823 SEQ ID NO: 6 3437 RABV89 Light chain variable region R9 VL CN104193823 SEQ ID NO: 7 3438 RABV90 Light chain variable region CN101696242 SEQ ID NO: 8 3439 RABV91 Light chain variable region CN101235086 SEQ ID NO: 39 3440

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 12 against Chagas Virus.

TABLE 12 Antibodies against Chagas Virus Antibody SEQ No. Description Reference Information ID NO CHAG1 Heavy Chain Of The Fab Fragment, Buschiazzo et al., PLoS Pathol. 8 (1), E1002474 3541 Trypanosoma cruzi trans-sialidase (2012), NCBI Accession # 3OPZ_J (222aa) CHAG2 Light chain of Fab fragment, Buschiazzo et al., PLoS Pathog. 8 (1), E1002474 3542 Trypanosoma cmzi trans-sialidase (2012), NCBI Accession # 3OPZ_N (213aa)

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 13 against Chikungunya Virus.

TABLE 13 Antibodies against Chikungunya Virus Antibody Antibody SEQ No. Description Name Reference Information ID NO CHIK1 Heavy chain Fab 9.8b Sun, S. et al., Structural analyses at pseudo 3543 fragment atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization, Elife 2, E00435 (2013), NCBI Accession # 4GO9_H (218 aa) CHIK2 Heavy chain 5F101717E2 US20130189279 SEQ ID NO: 6 3544 variable CHIK3 Heavy chain 8B10F8 US20130189279 SEQ ID NO: 26 3545 variable CHIK4 Light chain Fab 9.8b Sun, S. et al., Structural analyses at pseudo 3546 fragment atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization, Elife 2, E00435 (2013), NCBI Accession # 4GO9_L (212 aa) CHIK5 Light chain 5F10F175E2 US20130189279 SEQ ID NO: 8 3547 variable CHIK6 Light chain 8B10F8 US20130189279 SEQ ID NO 3548 variable

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof encoding antibodies described International Pub No. WO1983001785 and U.S. Pat. No. 5,827,671, the contents of each of which are herein incorporated by reference in their entirety, against the protozoan parasite Leishmania.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof encoding antibodies against the Buruli ulcer (Mycobacterium ulcerans), Leprosy/Hansen's disease (Mycobacterium leprae), Leishmaniasis, Cysticercosis, Dracunculiasis (Guinea Worm Disease), Echinococcosis, Fascioliasis, Human African Trypanosomiasis (African Sleeping Sickness), Lymphatic filariasis, Onchocerciasis, Schistosomiasis, Soil-transmitted Helminths (STH).

Toxins

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the toxin related payload antibody polypeptides listed in Tables 14-17.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 14 against Ricin Toxin.

TABLE 14 Antibodies against Ricin Toxin Antibody Antibody SEQ No. Description Name Reference Information ID NO RICN1 Candid heavy-chain only RTA:JIV-F5 WO2015100409 SEQ ID NO: 124 3549 RICN2 Candid heavy-chain only JIV-F6 WO2015100409 SEQ ID NO: 126 3550 RICN3 Candid heavy-chain only JIV-G 12 WO2015100409 SEQ ID NO: 128 3551 RICN4 Candid heavy-chain only JIY-A7 WO2015100409 SEQ ID NO: 130 3552 RICN5 Candid heavy-chain only JIY-D9 WO2015100409 SEQ ID NO: 132 3553 RICN6 Candid heavy-chain only JIY-D10 WO2015100409 SEQ ID NO: 134 3554 RICN7 Candid heavy-chain only JIY-E1 WO2015100409 SEQ ID NO: 136 3555 RICN8 Candid heavy-chain only JIY-E3 WO2015100409 SEQ ID NO: 138 3556 RICN9 Candid heavy-chain only JIY-E5 WO2015100409 SEQ ID NO: 140 3557 RICN10 Candid heavy-chain only JIY-F10 WO2015100409 SEQ ID NO: 142 3558 RICN11 Candid heavy-chain only JIY-G11 WO2015100409 SEQ ID NO: 144 3559 RICN12 Candid heavy-chain only RTB:JIW-B1 WO2015100409 SEQ ID NO: 146 3560 RICN13 Candid heavy-chain only JIW-C12 WO2015100409 SEQ ID NO: 148 3561 RICN14 Candid heavy-chain only JIW-D12 WO2015100409 SEQ ID NO: 150 3562 RICN15 Candid heavy-chain only JIW-G5 WO2015100409 SEQ ID NO: 152 3563 RICN16 Candid heavy-chain only JIW-G 10 WO2015100409 SEQ ID NO: 154 3564 RICN17 Candid heavy-chain only JIZ-B7 WO2015100409 SEQ ID NO: 156 3565 RICN18 Candid heavy-chain only JIZ-B9 WO2015100409 SEQ ID NO: 158 3566 RICN19 Candid heavy-chain only JIZ-D8 WO2015100409 SEQ ID NO: 160 3567 RICN20 Candid heavy-chain only JIZ-G4 WO2015100409 SEQ ID NO: 162 3568

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 15 against Anthrax.

TABLE 15 Antibodies against Anthrax Antibody Antibody SEQ No. Description Name Reference Information ID NO ANTH1 Camelid heavy-chain only JHD-B6 WO2015100409 SEQ ID NO: 100 3569 ANTH2 Camelid heavy-chain only JHE-D9 WO2015100409 SEQ ID NO: 102 3570 ANTH3 Camelid heavy-chain only JIJ-A12 WO2015100409 SEQ ID NO: 104 3571 ANTH4 Camelid heavy-chain only JIJ-B8 WO2015100409 SEQ ID NO: 106 3572 ANTH5 Camelid heavy-chain only JIJ-C11 WO2015100409 SEQ ID NO: 108 3573 ANTH6 Camelid heavy-chain only JIJ-D3 WO2015100409 SEQ ID NO: 110 3574 ANTH7 Camelid heavy-chain only JIJ-E9 WO2015100409 SEQ ID NO: 112 3575 ANTH8 Camelid heavy-chain only JIJ-F11 WO2015100409 SEQ ID NO: 114 3576 ANTH9 Camelid heavy-chain only JIK-B8 WO2015100409 SEQ ID NO: 116 3577 ANTH10 Camelid heavy-chain only JI-B 10 WO2015100409 SEQ ID NO: 118 3578 ANTH11 Camelid heavy-chain only JIK-B 12 WO2015100409 SEQ ID NO: 120 3579 ANTH12 Camelid heavy-chain only JIK-F4 WO2015100409 SEQ ID NO: 122 3580 ANTH13 CDR WO2003063768 SEQ ID NO: 1 3581 ANTH14 CDR WO2003063768 SEQ ID NO: 2 3582 ANTH15 CDR WO2003063768 SEQ ID NO: 3 3583 ANTH16 Heavy chain US8617548 SEC ID NO: 2 3584 ANTH17 Heavy chain IQNPA Lambda US7658925 SEQ ID NO: 2 3585 ANTH18 Heavy chain IQNLF Lambda US7658925 SEQ ID NO: 6 3586 ANTH19 Heavy chain 1A5 US20090022736 SEQ ID NO: 1 3587 ANTH20 Heavy chain 4A12 US20090022736 SEQ ID NO: 3 3588 ANTH21 Heavy chain 24B1 US20090022736 SEQ ID NO: 5 3589 ANTH22 Heavy chain 24G4 US20090022736 SEQ ID NO: 7 3590 ANTH23 Heavy chain 32E12 US20090022736 SEQ ID NO: 9 3591 ANTH24 Heavy chain 33F4 US20090022736 SEQ ID NO: 11 3592 ANTH25 Heavy chain scfv 2LF EP2778173 SEQ ID NO: 9 3593 ANTH26 Heavy chain US20040258699 SEQ ID NO: 78 3594 ANTH27 Heavy chain US20040258699 SEQ ID NO: 79 3595 ANTH28 Heavy chain US20040258699 SEQ ID NO: 80 3596 ANTH29 Heavy chain US20040258699 SEQ ID NO: 81 3597 ANTH30 Heavy chain US20040258699 SEQ ID NO: 82 3598 ANTH31 Heavy chain US20040258699 SEQ ID NO: 83 3599 ANTH32 Heavy chain US20040258699 SEQ ID NO: 84 3600 ANTH33 Heavy chain US20040258699 SEQ ID NO: 85 3601 ANTH34 Heavy chain US20040258699 SEQ ID NO: 86 3602 ANTH35 Heavy chain US20040258699 SEQ ID NO: 87 3603 ANTH36 Heavy chain US20040258699 SEQ ID NO: 88 3604 ANTH37 Heavy chain US20040258699 SEQ ID NO: 89 3605 ANTH38 Heavy chain US20040258699 SEQ ID NO: 90 3606 ANTH39 Heavy chain US20040258699 SEQ ID NO: 91 3607 ANTH40 Heavy chain US20040258699 SEQ ID NO: 92 3608 ANTH41 Heavy chain US20040258699 SEQ ID NO: 93 3609 ANTH42 Heavy chain US20040258699 SEQ ID NO: 94 3610 ANTH43 Heavy chain US20040258699 SEQ ID NO: 95 3611 ANTH44 Heavy chain US20040258699 SEQ ID NO: 96 3612 ANTH45 Heavy chain US20040258699 SEQ ID NO: 97 3613 ANTH46 Heavy chain US20040258699 SEQ ID NO: 98 3614 ANTH47 Heavy chain US20040258699 SEQ ID NO: 99 3615 ANTH48 Heavy chain US20040258699 SEQ ID NO: 100 3616 ANTH49 Heavy chain US20040258699 SEQ ID NO: 101 3617 ANTH50 Heavy chain US20040258699 SEQ ID NO: 102 3618 ANTH51 Heavy chain US20040258699 SEQ ID NO: 103 3619 ANTH52 Heavy chain US20040258699 SEQ ID NO: 104 3620 ANTH53 Heavy chain US20040258699 SEQ ID NO: 105 3621 ANTH54 Heavy chain US20040258699 SEQ ID NO: 106 3622 ANTH55 Heavy chain US20040258699 SEQ ID NO: 107 3623 ANTH56 Heavy chain US20040258699 SEQ ID NO: 108 3624 ANTH57 Heavy chain US20040258699 SEQ ID NO: 109 3625 ANTH58 Heavy chain US20040258699 SEQ ID NO: 110 3626 ANTH59 Heavy chain US20040258699 SEQ ID NO: 111 3627 ANTH60 Heavy chain US20040258699 SEQ ID NO: 112 3628 ANTH61 Heavy chain US20040258699 SEQ ID NO: 113 3629 ANTH62 Heavy chain US20040258699 SEQ ID NO: 114 3630 ANTH63 Heavy chain US20040258699 SEQ ID NO: 115 3631 ANTH64 Heavy chain US20040258699 SEQ ID NO: 116 3632 ANTH65 Heavy chain US20040258699 SEQ ID NO: 117 3633 ANTH66 Heavy chain US20040258699 SEQ ID NO: 118 3634 ANTH67 Heavy chain and light chain 14B7 scFV US7902344; US6916474 SEQ ID 3635 variable region NO: 21 ANTH68 Heavy chain fd region W1 US8685396 SEQ ID NO: 1 3636 ANTH69 Heavy chain fd region W2 US8685396 SEQ ID NO: 17 3637 ANTH70 Heavy chain W5 US8685396 SEQ ID NO: 33 3638 ANTH71 Heavy chain A63-6 US8685396 SEQ ID NO: 34 3639 ANTH72 Heavy chain F3-6 US8685396 SEQ ID NO: 35 3640 ANTH73 Heavy chain F5-1 US8685396 SEQ ID NO: 36 3641 ANTH74 Heavy chain variable region ETI-204 US2010156196 SEQ ID NO: 1 3642 ANTH75 Heavy chain variable region 6.20 WO2015107307 SEQ ID NO: 1 3643 ANTH76 Heavy chain variable region 33PA83 WO2009071860 SEQ ID NO: 1 3644 ANTH77 Heavy chain variable region anti-γDPGA US8501182 SEQ ID NO: 1 3645 antibody ANTH78 Heavy chain variable region 4C US8501182 SEQ ID NO: 3 3646 ANTH79 Heavy chain variable region 11D US8501182 SEQ ID NO: 5 3647 ANTH80 Heavy chain variable region F20G75 WO2007131363 SEQ ID NO: 16 3648 ANTH81 Heavy chain variable region F20G76 WO2007131363 SEQ ID NO: 18 3649 ANTH82 Heavy chain variable region F20G77 WO2007131363 SEQ ID NO: 20 3650 ANTH83 Heavy chain variable region V2 variant US8507655 SEQ ID NO: 7 3651 ANTH84 Heavy chain variable region 6.20 variant US8507655 SEQ ID NO: 9 3652 ANTH85 Heavy chain variable region J24.15 variant US8507653 SEQ ID NO: 11 3653 ANTH86 Heavy chain variable region J24.7 variant US8507655 SEQ ID NO: 13 3654 ANTH87 Heavy chain variable region V2 variant human US85076S5 SEQ ID NO: 15 3655 ANTH88 Heavy chain variable region 6.20 variant US8S07655 SEQ ID NO: 17 3656 human ANTH89 Heavy chain variable region J24.15 variant US8507655 SEQ ID NO: 19 3657 human ANTH90 Heavy chain variable region J24.7 variant US8507655 SEQ ID NO: 21 3658 human ANTH91 Heavy chain variable region HuMab 5E8 US8404820 SEQ ID NO: 2 3659 ANTH92 Heavy chain variable region HnMab 2D5 US8404820 SEQ ID NO: 8 3660 ANTH93 Heavy chain variable region HuMab 2H4 US8404820 SEQ ID NO: 12 3661 ANTH94 Heavy chain variable region HuMab 5D5- US8404820 SEQ ID NO: 16 3662 2E10 ANTH95 Heavy chain variable region 13E3 US8309P9P SEQ ID NO: 2 3663 ANTH96 Heavy chain variable region 3E1 US8309090 SEQ ID NO: 6 3667 ANTH97 Heavy chain variable region KCTC 10756BP US8268316 SEQ ID NO: 2 3665 ANTH98 Heavy chain variable region M18 scFv US7902344; US69I6474 SEQ ID 3666 NO: 23 ANTH99 Heavy chain variable region 21D9 MAb US7442373 SEQ ID NO: 2 3667 ANTH100 Heavy chain variable region 1C6 Mab US7442373 SEQ ID NO: 6 3668 ANTH101 Heavy chain variable region 4H7 Mab US7442373 SEQ ID NO: 10 3669 ANTH102 Heavy chain variable region 22G12 Mab US7442373 SEQ ID NO: 14 3670 ANTH103 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 20 3671 antibody 9-1 ANTH104 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 21 3672 antibody 7-1 ANTH105 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 22 3673 antibody 24-2 ANTH106 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 23 3674 antibody 21-4 ANTH107 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 24 3675 antibody 10-2 ANTH108 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 25 3676 antibody 22-1 ANTH109 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 26 3677 antibody 13-3 ANTH110 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 27 3678 antibody 8-3 ANTH111 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO 29 3679 antibody 6-1 ANTH112 Heavy chain variable region monoclonal WO1999055842 SEQ ID NO: 30 3680 antibody 3-1 ANTH113 Heavy chain variable region, EF12A US8961975 SEQ ID NO: 51 3681 Edema factor binding ANTH114 Heavy chain variable region, EF13D US8961975 SEQ ID NO: 33 3682 Edema factor binding ANTH115 Heavy chain variable region, EF14H US8961975 SEQ ID NO: 52 3683 Edema factor binding ANTH116 Heavy chain variable region, EF15A US8961975 SEQ ID NO: 53 3684 Edema factor binding ANTH117 Heavy chain variable region, LF9D US8961975 SEQ ID NO: 49 3685 Lethal factor ANTH118 Heavy chain variable region, LF10E US8961975 SEQ ID NO: 1 3686 Lethal factor ANTH119 Heavy chain, Antibody Obiltoxaximab 3687 against inhalational anthrax ANTH120 Kappa light chain US20040258699 SEQ ID NO: 19 3688 ANTH121 Kappa light chain US20040258699 SEQ ID NO: 20 3689 ANTH122 Kappa light chain US20040258699 SEQ ID NO: 21 3690 ANTH123 Kappa tight chain US20040258699 SEQ ID NO: 22 3691 ANTH124 Kappa light chain US20040258699 SEQ ID NO: 23 3692 ANTH125 Kappa light chain US20040258699 SEQ ID NO: 24 3693 ANTH126 Kappa light chain US20040258699 SEQ ID NO: 25 3694 ANTH127 Kappa light chain US20040258699 SEQ ID NO: 26 3695 ANTH128 Kappa tight chain US20040258699 SEQ ID NO: 39 3696 ANTH129 Kappa light chain US20040258699 SEQ ID NO: 40 3697 ANTH130 Kappa light chain US20040258699 SEQ ID NO: 41 3698 ANTH131 Kappa light chain US20040258699 SEQ ID NO: 42 3699 ANTH132 Kappa light chain US20040258699 SEQ ID NO: 43 3700 ANTH133 Kappa light chain US20040258699 SEQ ID NO: 44 3701 ANTH134 Kappa light chain US20040258699 SEQ ID NO: 45 3702 ANTH135 Kappa light chain US20040258699 SEQ ID NO: 46 3703 ANTH136 Kappa light chain US20040258699 SEQ ID NO: 47 3704 ANTH137 Kappa light chain US20040258699 SEQ ID NO: 48 3705 ANTH138 Kappa light chain US20040258699 SEQ ID NO: 49 3706 ANTH139 Kappa light chain US20040258699 SEQ ID NO: 50 3707 ANTH140 Kappa light chain US20040258699 SEQ ID NO: 51 3708 ANTH141 Kappa light chain US20040258699 SEQ ID NO: 52 3709 ANTH142 Kappa light chain US20040258699 SEQ ID NO: 53 3710 ANTH143 Kappa light chain US20040258699 SEQ ID NO: 54 3711 ANTH144 Kappa light chain US20040258699 SEQ ID NO: 55 3712 ANTH145 Kappa light chain US20040258699 SEQ ID NO: 56 3713 ANTH146 Kappa light chain US20040258699 SEQ ID NO: 57 3714 ANTH147 Kappa light chain US20040258699 SEQ ID NO: 58 3715 ANTH148 Kappa light chain US20040258699 SEQ ID NO: 59 3716 ANTH149 Kappa light chain US20040258699 SEQ ID NO: 60 3717 ANTH150 Kappa light chain US20040258699 SEQ ID NO: 61 3718 ANTH151 Lambda light chain US20040258699 SEQ ID NO: 27 3719 ANTH152 Lambda light chain US20040258699 SEQ ID NO: 28 3720 ANTH153 Lambda light chain US20040258699 SEQ ID NO: 29 3721 ANTH154 Lambda light chain US20040258699 SEQ ID NO: 30 3722 ANTH155 Lambda light chain US20040258699 SEQ ID NO: 31 3723 ANTH156 Lambda light chain US20040258699 SEQ ID NO: 32 3724 ANTH157 Lambda light chain US20040258699 SEQ ID NO: 33 3725 ANTH158 Lambda light chain US20040258699 SEQ ID NO: 34 3726 ANTH159 Lambda light chain US20040258699 SEQ ID NO: 35 3727 ANTH160 Lambda tight chain US20040258699 SEQ ID NO: 36 3728 ANTH161 Lambda light chain US20040258699 SEQ ID NO: 37 3729 ANTH162 Lambda light chain US20040258699 SEQ ID NO: 38 3730 ANTH163 Lambda light chain US20040258699 SEQ ID NO: 62 3731 ANTH164 Lambda light chain US20040258699 SEQ ID NO: 63 3732 ANTH165 Lambda light chain US20040258699 SEQ ID NO: 64 3733 ANTH166 Lambda light chain US20040258699 SEQ ID NO: 65 3734 ANTH167 Lambda light chain US20040258699 SEQ ID NO: 66 3735 ANTH168 Lambda light chain US20040258699 SEQ ID NO: 67 3736 ANTH169 Lambda light chain US20040258699 SEQ ID NO: 68 3737 ANTH170 Lambda light chain US20040258699 SEQ ID NO: 69 3738 ANTH171 Lambda light chain US20040258699 SEQ ID NO: 70 3739 ANTH172 Lambda light chain US20040258699 SEQ ID NO: 71 3740 ANTH173 Lambda light chain US20040258699 SEQ ID NO: 72 3741 ANTH174 Lambda light chain US20040258699 SEQ ID NO: 73 3742 ANTH175 Lambda light chain US20040258699 SEQ ID NO: 74 3743 ANTH178 Lambda light chain US20040258699 SEQ ID NO: 75 3744 ANTH177 Lambda light chain US20040258699 SEQ ID NO: 76 3745 ANTH178 Lambda light chain US20040258699 SEQ ID NO: 77 3746 ANTH179 Light chain US8617548 SEQ ID NO: 1 3747 ANTH180 Light chain IQNPA Lkappa US7658925 SEQ ID NO: 4 3748 ANTH181 Light chain IQNPA Lkappa US7658925 SEQ ID NO: 8 3749 ANTH182 Light chain 1A5 US20090022736 SEQ ID NO: 2 3750 ANTH183 Light chain 4A12 US20090022736 SEQ ID NO: 4 3751 ANTH184 Light chain 24B1 US20090022736 SEQ ID NO: 6 3752 ANTH185 Light chain 24G4 US20090022736 SEQ ID NO: 8 3753 ANTH186 Light chain ′32E12 US20090022736 SEQ ID NO: 10 3754 ANTH187 Light chain 33F4 US20090022736 SEQ ID NO: 12 3755 ANTH188 Light chain scFv 2LF EP2778173 SEQ ID NO: 6 3756 ANTH189 Light chain Obiltoxaximab 3757 ANTH190 Light chain region W1 US8685396 SEQ ID NO: 9 3758 ANTH191 Light chain region W2 US8685396 SEQ ID NO: 25 3759 ANTH192 Light chain region W5 USX685396 SEQ ID NO: 37 3760 ANTH193 Light chain region A63-6 US8685396 SEQ ID NO: 38 3761 ANTH194 Light chain region F3-6 US8685396 SEQ ID NO: 39 3762 ANTH195 Light chain region F5-1 US8685396 SEQ ID NO: 40 3763 ANTH196 Light chain variable region LF11H US8961975 SEQ ID NO: 25 3764 ANTH197 Light chain variable region LF9D US8961975 SEQ ID NO: 17 3765 ANTH198 Light chain variable region LF10E US8961975 SEQ ID NO: 9 3766 ANTH199 Light chain variable region 6.20 WO2015107307 SEQ ID NO: 2 3767 ANTH200 Light chain variable region 35PA83 WO200907186USEQ ID NO: 2 3768 ANTH201 Light chain variable region anti-γDPGA US8501182 SEQ ID NO: 2 3769 antibody ANTH202 Light chain variable region 4C US8501182 SEQ ID NO: 4 3770 ANTH203 Light chain variable region 11D US8501182 SEQ ID NO: 6 3771 ANTH204 Light chain variable region F20G75 WO2007131363 SEQ ID NO: 10 3772 ANTH205 Light chain variable region F20G76 WO2007131363 SEQ ID NO: 12 3773 ANTH206 Light chain variable region F20G77 WO2007131363 SEQ ID NO: 14 3774 ANTH207 Light chain variable region V2 variant US8507655 SEQ ID NO: 8 3775 ANTH208 Light chain variable region 6.20 variant US8507655 SEQ ID NO: 10 3776 ANTH209 Light chain variable region J24.15 variant US8507655 SEQ ID NO: 12 3777 ANTH210 Light chain variable region J24.7 variant US8507655 SEQ ID NO: 14 3778 ANTH211 Light chain variable region V2 variant human US8507655 SEQ ID NO: 16 3779 ANTH212 Light chain variable region 6.20 vaiiant US8507655 SEQ ID NO: 18 3780 human ANTH213 Light chain variable region J24.15 variant US8507655 SEQ ID NO: 20 3781 human ANTH214 Light chain variable region J24.7 variant US8507655 SEQ ID NO: 22 3782 human ANTH215 Light chain variable region HuMab 5E8 US8401820 SEQ ID NO: 4 3783 (Major) ANTH216 Light chain variable region HuMab 5E8 US8404820 SEQ ID NO: 6 3784 (Minor) ANTH217 Light chain variable region HuMab 2P5 US8404820 SEQ ID NO: 10 3785 ANTH218 Light chain variable region HuMab 2H4 US8404820 SEQ ID NO: 14 3786 ANTH219 Light chain variable region HuMab 5D5- US8404820 SEQ ID NO: 18 3787 2E10 ANTH220 Light chain variable region 13E3 US8309090 SEQ ID NO: 4 3788 ANTH221 Light chain variable region 3E1 US8309090 SEQ ID NO: 8 3789 ANTH222 Light chain variable region KCTC 10756BP US8268316 SEQ ID NO: 7 3790 ANTH223 Light chain variable region modified M18 US7902344; US6916474 SEQ ID 3791 sequence NO: 25 ANTH224 Light chain variable region 21D9 MAb US7442373 SEQ ID NO: 4 3792 ANTH225 Light chain variable region 1C6 Mab US7442373 SEQ ID NO: 8 3793 ANTH226 Light chain variable region 4H7 Mab US7442373 SEQ ID NO: 12 3794 ANTH227 Light chain variable region 22G12 Mab US7442373 SEQ ID NO: 16 3795 ANTH228 Light chain variable region ETI-204 US20120156196 SEQ ID NO: 2 3796 antibody against anthrax toxin, ANTH229 Light chain variable region, EF12A US8961975 SEQ ID NO: 54 3797 Edema factor ANTH230 Light chain variable region, EF13D US8961975 SEQ ID NO: 41 3798 Edema factor ANTH231 Light chain variable region, EF14H US8961973 SEQ ID NO: 55 3799 Edema factor ANTH232 Light chain variable region, EP15A US8961975 SEQ ID NO: 56 3800 Edema factor ANTH233 Scfv PWB2447 scFv US7601351; US7906119; 3801 US20110189197 SEQ ID NO 48 ANTH234 Scfv PWC2004 scFv US7601351; US7906119; 3802 US20110189197 SEQ ID NO: 49 ANTH235 Scfv PWD0283 scFv US7601351; US7906119; 3803 US20110189197 SEQ ID NO 50 ANTH236 Scfv PWP0323 scFv US7601351; US7906119; 3804 US20110189197 SEQ ID NO: 51 ANTH237 Scfv PWD0422 scFv US7601351; US7906119; 3805 US20110189197 SEQ ID NO: 52 ANTH238 Scfv PWD0587 scFv US7601351; US7906119; 3806 US20110189197 SEQ ID NO: 53 ANTH239 Scfv PWD0791 scFv US7601351; US7906119; 3807 US20110189197 SEQ ID NO: 54 ANTH240 Scfv PHP2222 scFv US7601351; US7906119; 3808 US20110189197 SEQ ID NO: 55 ANTH241 Scfv PHD2581 scFv US7601351; US7906119; 3809 US20110189197 SEQ ID NO: 56 ANTH242 Abthrax US20120136196 SEQ ID NO: 48 3810 ANTH243 Abthrax US20120156196 SEQ ID NO: 49 3811 ANTH244 WO2003063768 SEQ ID NO: 4 3812 ANTH245 WO2003063768 SEQ ID NO: 5 3813

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 16 against Botulinum Toxin.

TABLE 16 Antibodies against Botulinum Toxin SEQ Antibody Antibody ID No. Description Name Reference Information NO BOTT1 Heavy-chain-only US20130058962 SEQ ID NO: 56 3814 BOTT2 Heavy-chain-only US20130058962 SEQ ID NO: 57 3815 BOTT3 Heavy-chain-only US20130058962 SEQ ID NO: 58 3816 BOTT4 Heavy-chain only binding JDA-D12 WO2015100409 SEQ ID NO: 20 3817 agents specific to BoNT/A holotoxin BOTT5 Heavy-chain only binding JDQ-A5 WO2015100409 SEQ ID NO: 22 3818 agents specific to BoNT/A holotoxin BOTT6 Heavy-chain only binding JDQ-B5 WO2015100409 SEQ ID NO: 24 3819 agents specific to BoNT/A holotoxin BOTT7 Heavy-chain only binding JDQ-C2 WO2015100409 SEQ ID NO: 26 3820 agents specific to BoNT/A holotoxin BOTT8 Heavy-chain only binding JDQ-F 12 WO2015100409 SEQ ID NO: 28 3821 agents specific to BoNT/A holotoxin BOTT9 Heavy-chain only binding JDQ-G5 WO2015100409 SEQ ID NO: 30 3822 agents specific to BoNT/A holotoxin BOTT10 Heavy-chain only binding JDQ-H7 WO2015100409 SEQ ID NO: 32 3823 agents specific to BoNT/A holotoxin BOTT11 Heavy-chain only binding JEQ-A5 WO2015100409 SEQ ID NO: 34 3824 agents specific to BoNT/A holotoxin BOTT12 Heavy-chain only binding JEQ-H11 WO2015100409 SEQ ID NO: 36 3825 agents specific to BoNT/A holotoxin BOTT13 Heavy-chain only binding agent E-9 WO2015100409 SEQ ID NO: 38 3826 BOTT14 Heavy-chain only binding agent B2 WO2015100409 SEQ ID NO: 40 3827 BOTT15 Heavy-chain only binding agent C5 WO2015100409 SEQ ID NO: 42 3828 BOTT16 Heavy-chain only binding agent F9 WO2015100409 SEQ ID NO: 44 3829 BOTT17 Heavy-chain only binding agent heavy-chain only WO2015100409 SEQ ID NO: 46 3830 binding agent BOTT18 Heavy-chain only binding agent heavy-chain only WO2015100409 SEQ ID NO: 48 3831 with tag binding agent with tag BOTT19 Heavy-chain only binding agent heavy-chain only WO2015100409 SEQ ID NO: 50 3832 with tag binding agent with tag BOTT20 Heavy-chain only dimer heavy-chain only WO2015100409 SEQ ID NO: 52 3833 binding agent with two tags dimer binding agent with two tags BOTT21 Recombinant camelid heavy- H7 WO2015100409 SEQ ID NO: 56 3834 chain-only antibody BOTT22 Recombinant camelid heavy- B5 WO2015100409 SEQ ID NO: 57 3835 chain-only antibody BOTT23 Recombinant camelid heavy- WO2015100409 SEQ ID NO: 58 3836 chain-only antibody BOTT24 Scfv scFv#2 WO2015100409 SEQ ID NO: 2 3837 BOTT25 Scfv scFv#3 WO2015100409 SEQ ID NO: 4 3838 BOTT26 Scfv scFv#7 WO2015100409 SEQ ID NO: 6 3839 BOTT27 Scfv scFv#8 WO2015100409 SEQ ID NO: 8 3840 BOTT28 Scfv scFv#21 WO2015100409 SEQ ID NO: 10 3841 BOTT29 Scfv scFv#E WO2015100409 SEQ ID NO: 12 3842 BOTT30 Scfv scFv#7-2E WO2015100409 SEQ ID NO: 14 3843

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 17 against Shiga Toxin.

TABLE 17 Antibodies against Shiga Toxin SEQ Antibody Antibody ID No. Description Name Reference Information NO SHIG1 Camelid heavy-chain only JET-H12 WO2015100409 SEQ ID NO: 96 3844 SHIG2 Camelid heavy-chain only JFG-H6 WO2015100409 SEQ ID NO: 98 3845 SHIG3 Heavy chain US2014013548 SEQ ID NO: 44 3846 SHIG4 Heavy chain US2014013548 SEQ ID NO: 21 3847 SHIG5 Heavy chain of cαstx1 Shigamab US20120195891 SEQ ID NO: 1 3848 SHIG6 Heavy chain of cαstx1 Shigamab US20120195891 SEQ ID NO: 2 3849 SHIG7 Heavy chain of cαstx2 Shigamab US20120195891 SEQ ID NO: 3 3850 SHIG8 Heavy chain of cαstx2 Shigamab US20120195891 SEQ ID NO: 4 3851 SHIG9 Heavy chain single domain WO2014191904 SEQ ID NO: 7 3852 SHIG10 Heavy chain single domain WO2014191904 SEQ ID NO: 8 3853 SHIG11 Heavy chain single domain WO2014191904 SEQ ID NO: 9 3854 SHIG12 Heavy chain single domain WO2014191904 SEQ ID NO: 10 3855 SHIG13 Heavy chain single domain WO2014191904 SEQ ID NO: 11 3856 SHIG14 Heavy chain single domain WO2014191904 SEQ ID NO: 12 3857 SHIG15 Heavy chain single domain WO2014191904 SEQ ID NO: 13 3858 SHIG16 Heavy chain single domain WO2014191904 SEQ ID NO: 14 3859 SHIG17 Heavy chain single domain WO2014191904 SEQ ID NO: 15 3860 SHIG18 Heavy chain single domain WO2014191904 SEQ ID NO: 16 3861 SHIG19 Heavy chain single domain WO2014191904 SEQ ID NO: 17 3862 SHIG20 Heavy chain single domain WO2014191904 SEQ ID NO: 18 3863 SHIG21 Heavy chain single domain WO2014191904 SEQ ID NO: 19 3864 SHIG22 Heavy chain single domain WO2014191904 SEQ ID NO: 20 3865 SHIG23 Heavy chain single domain WO2014191904 SEQ ID NO: 21 3866 SHIG24 Heavy chain single domain WO2014191904 SEQ ID NO: 22 3867 SHIG25 Heavy chain single domain WO2014191904 SEQ ID NO: 23 3868 SHIG26 Heavy chain single domain WO2014191904 SEQ ID NO: 24 3869 SHIG27 Heavy chain single domain WO2014191904 SEQ ID NO: 25 3870 SHIG28 Heavy chain single domain WO2014191904 SEQ ID NO: 26 3871 SHIG29 Heavy chain single domain WO2014191904 SEQ ID NO: 27 3872 SHIG30 Heavy chain single domain WO2014191904 SEQ ID NO: 28 3873 SHIG31 Heavy chain single domain WO2014191904 SEQ ID NO: 29 3874 SHIG32 Heavy chain single domain WO2014191904 SEQ ID NO: 30 3875 SHIG33 Heavy chain single domain WO2014191904 SEQ ID NO: 31 3876 SHIG34 Heavy chain single domain WO2014191904 SEQ ID NO: 32 3877 SHIG35 Heavy chain single domain WO2014191904 SEQ ID NO: 33 3878 SHIG36 Heavy chain single domain WO2014191904 SEQ ID NO: 34 3879 SHIG37 Heavy chain single domain WO2014191904 SEQ ID NO: 35 3880 SHIG38 Heavy chain single domain WO2014191904 SEQ ID NO: 36 3881 SHIG39 Heavy chain single domain WO2014191904 SEQ ID NO: 37 3882 SHIG40 Heavy chain single domain WO2014191904 SEQ ID NO: 38 3883 SHIG41 Heavy chain single domain WO2014191904 SEQ ID NO: 39 3884 SHIG42 Heavy chain single domain WO2014191904 SEQ ID NO: 40 3885 SHIG43 Heavy chain single domain WO2014191904 SEQ ID NO: 41 3886 SHIG44 Heavy chain single domain WO2014191904 SEQ ID NO: 42 3887 SHIG45 Heavy chain single domain WO2014191904 SEQ ID NO: 43 3888 SHIG46 Heavy chain single domain WO2014191904 SEQ ID NO: 44 3889 SHIG47 Heavy chain single domain WO2014191904 SEQ ID NO: 45 3890 SHIG48 Heavy chain single domain WO2014191904 SEQ ID NO: 46 3891 SHIG49 Heavy chain single domain WO2014191904 SEQ ID NO: 47 3892 SHIG50 Heavy-chain-only US20130058962 SEQ ID NO: 77 3893 SHIG51 Heavy-chain-only US20130058962 SEQ ID NO: 78 3894 SHIG52 Heavy-chain-only US20130058962 SEQ ID NO: 79 3895 SHIG53 Heavy-chain-only US20130058962 SEQ ID NO: 80 3896 SHIG54 Heavy-chain-only US20130058962 SEQ ID NO: 81 3897 SHIG55 Heavy-chain-only US20130058962 SEQ ID NO: 82 3898 SHIG56 Heavy-chain-only US20130058962 SEQ ID NO: 83 3899 SHIG57 Heavy-chain-only US20130058962 SEQ ID NO: 84 3900 SHIG58 Heavy-chain-only US20130058962 SEQ ID NO: 85 3901 SHIG59 Heavy-chain-only US20130058962 SEQ ID NO: 86 3902 SHIG60 Light chain US2014013548 SEQ ID NO: 42 3903 SHIG61 Light chain US2014013548 SEQ ID NO: 19 3904 SHIG62 Recombinant camelid heavy- JET-A9 WO2015100409 SEQ ID NO: 77 3905 chain-only antibody, STX1 SHIG63 Recombinant camelid heavy- JGG-D4 WO2015100409 SEQ ID NO: 78 3906 chain-only antibody, STX1 SHIG64 Recombinant camelid heavy- JFD-A4 WO2015100409 SEQ ID NO: 84 3907 chain-only antibody, STX1, STX2 SHIG65 Recombinant camelid heavy- JFD-A5 WO2015100409 SEQ ID NO: 85 3908 chain-only antibody, STX1, STX2 SHIG66 Recombinant camelid heavy- JGG-G6 WO2015100409 SEQ ID NO: 86 3909 chain-only antibody, STX1, STX2 SHIG67 Recombinant camelid heavy- JEN-D10 WO2015100409 SEQ ID NO: 79 3910 chain-only antibody, STX2 SHIG68 Recombinant camelid heavy- JGH-G1 WO2015100409 SEQ ID NO: 80 3911 chain-only antibody, STX2 SHIG69 Recombinant camelid heavy- JEU-A6 WO2015100409 SEQ ID NO: 81 3912 chain-only antibody, STX2 SHIG70 Recombinant camelid heavy- JEU-D2 WO2015100409 SEQ ID NO: 82 3913 chain-only antibody, STX2 SHIG71 Recombinant camelid heavy- JGH-G9 WO2015100409 SEQ ID NO: 83 3914 chain-only antibody, STX2

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in US Pub. No. US20090280104, the contents of each of which are herein incorporated by reference in their entirety, against Shiga toxin

Tropical Diseases

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the tropical disease related payload antibody polypeptides listed in Tables 18-20.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 18 against Plasmodium falciparum causing Malaria.

TABLE 18 Antibodies against Plasmodium Falciparum causing Malaria SEQ Antibody Antibody ID No. Description Name Reference Information NO MALA1 Heavy chain immunoglobulin Wajanarogana, S. et al., Construction of a 3915 heavy chain human functional single-chain variable fragment variable region, (scFv) antibody recognizing the malaria parasite partial Plasmodium falciparum, Biotechnol. Appl. Biochem. 44 (PT 1), 55-61 (2006), NCBI Accession # AAX76832.1 (129aa) MALA2 Heavy chain anti-MSP1 Sowa, K. M. et al., Isolation of a monoclonal 3916 MAD20 block2 antibody from a malaria patient-derived phage ScFv Ig heavy display library recognizing the Block 2 region chain variable of Plasmodium falciparum merozoite surface region, partial protein-1, Mol. Biochem. Parasitol. 112 (1), 143-147 (2001), NCBI Accession #AAK08696.1 (119aa) MALA3 Heavy chain immunoglobulin Lundquist, R. et al., Human recombinant 3917 heavy chain antibodies against Plasmodium falciparum variable region, merozoite surface protein 3 cloned from partial peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties, Infect. Immun. 74 (6), 3222-3231, (2006), NCBI Accession # AAT09786.1 (113aa) MALA4 Heavy chain 2A10 anti- NCBI Accession # BAK41504.1 (118aa) 3918 variable region malaria antibody MALA5 Heavy chain U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 1 3919 MALA6 Heavy chain, U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 3 3920 Anti-ang-2 antibody MALA7 Heavy chain U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 5 3921 MALA8 Heavy chain US20150197562 SEQ ID NO: 14 3922 variable region MALA9 Heavy chain mAh 5D5 US20150158941 SEQ ID NO: 16 3923 variable region MALA10 Heavy chain US20140112930 SEQ ID NO: 18 3924 variable region MALA11 Heavy chain M071Xi0199 WO2014087007; SEQ ID NO: 182 3925 variable region MALA12 Heavy chain M071Xi2204 WO2014087007; SEQ ID NO: 186 3926 variable region MALA13 Heavy chain M071Xi0237 WO2014087007; SEQ ID NO: 190 3927 variable region MALA14 Heavy chain M071Xi2127 WO2014087007; SEQ ID NO: 194 3928 variable region MALA15 Heavy chain M071Xi0092 WO2014087007; SEQ ID NO: 198 3929 variable region MALA16 Heavy chain M071Xi2057 WO2014087007; SEQ ID NO: 202 3930 variable region MALA17 Heavy chain M070Xi3010 WO2014087007; SEQ ID NO: 206 3931 variable region MALA18 Heavy chain M071Xi0227 WO2014087007; SEQ ID NO: 210 3932 variable region MALA19 Heavy chain M071Xi0081 WO2014087007; SEQ ID NO: 214 3933 variable region MALA20 Heavy chain M071Xi0124 WO2014087007; SEQ ID NO: 218 3934 variable region MALA21 Heavy chain M036Xi0326 WO2014087007; SEQ ID NO: 222 3935 variable region MALA22 Heavy chain M070Xi3195 WO2014087007; SEQ ID NO: 226 3936 variable region MALA23 Heavy chain M070Xi3062 WO2014087007; SEQ ID NO: 230 3937 variable region MALA24 Heavy chain M071Xi2217 WO2014087007; SEQ ID NO: 234 3938 variable region MALA25 Heavy chain M036Xi0003 WO2014087007; SEQ ID NO: 238 3939 variable region MALA26 Heavy chain, Eba- R217 Chen et al., PLoS Pathol. 9 (5), E1003390 3940 175 (2013), NCBI Accession # 4QEX_I (215aa) MALA27 Heavy chain, Eba- R218 Chen et al., PLoS Pathol. 9 (5), E1003390 3941 175 (2013), NCBI Accession # 4K2U_I (233aa) MALA28 Light chain anti-MSP1 Sowa, K. M. et al., Isolation of a monoclonal 3942 MAD20 block2 antibody from a malaria patient-derived phage ScFv Ig heavy display library recognizing the Block 2 region chain variable of Plasmodium falciparum merozoite surface region, partial protein-1, Mol. Biochem. Parasitol. 112 (1), 143-147 (2001), NCBI Accession #AAK08697.1 (119aa) MALA29 Light chain anti-MSP1 Sowa, K. M. et al., Isolation of a monoclonal 3943 MAD20 block2 antibody from a malaria patient-derived phage ScFv Ig light display library recognizing the Block 2 region chain variable of Plasmodium falciparum merozoite surface region, partial protein-1, Mol. Biochem. Parasitol. 112 (1), 143-147 (2001), NCBI Accession #AAK08698.1 (110aa) MALA30 Light chain immunoglobulin Wajanarogana, S. et al., Construction of a 3944 light chain human functional single-chain variable fragment variable region, (scFv) antibody recognizing the malaria parasite partial Plasmodium falciparum, Biotechnol. Appl. Biochem. 44 (PT 1), 55-61 (2006) AAX76833.1 (107aa) MALA31 Kappa light chain immunoglobulin Lundquist, R. et al., Human recombinant 3945 kappa light antibodies against Plasmodium falciparum chain variable merozoite surface protein 3 cloned from region, partial peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties, Infect. Immun. 74 (6), 3222-3231, (2006), NCBI Accession # AAT09787.1 (113aa) MALA32 Light chain 2A10 anti- NCBI Accession # BAK41503.1 (108aa) 3946 variable region malaria antibody MALA33 Light chain U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 2 3947 MALA34 Light chain, Anti- U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 4 3948 ang-2 antibody MALA35 Light chain U.S. Pat. No. 7,811,569 to Dziegiel; SEQ ID NO: 6 3949 MALA36 Light chain US20150197562 SEQ ID NO: 15 3950 variable region MALA37 Light chain US20150197562 SEQ ID NO: 19 3951 variable region MALA38 Light chain mAb 5D5 US20150158941 SEQ ID NO: 14 3952 variable region MALA39 Light chain US20140112930 SEQ ID NO: 20 3953 variable region MALA40 Light chain M071Xi0199 WO2014087007; SEQ ID NO: 184 3954 variable region MALA41 Light chain M071Xi2204 WO2014087007; SEQ ID NO: 188 3955 variable region MALA42 Light chain M071Xi0237 WO2014087007; SEQ ID NO: 192 3956 variable region MALA43 Light chain M071Xi2127 WO2014087007; SEQ ID NO: 196 3957 variable region MALA44 Light chain M071Xi0092 WO2014087007; SEQ ID NO: 200 3958 variable region MALA45 Light chain M071Xi2057 WO2014087007; SEQ ID NO: 204 3959 variable region MALA46 Light chain M070Xi3010 WO2014087007; SEQ ID NO: 208 3960 variable region MALA47 Light chain M071Xi0227 WO2014087007; SEQ ID NO: 212 3961 variable region MALA48 Light chain M071Xi0081 WO2014087007; SEQ ID NO: 216 3962 variable region MALA49 Light chain M071Xi0124 WO2014087007; SEQ ID NO: 220 3963 variable region MALA50 Light chain M036Xi0326 WO2014087007; SEQ ID NO: 224 3964 variable region MALA51 Light chain M070Xi3195 WO2014087007; SEQ ID NO: 228 3965 variable region MALA52 Light chain M070Xi3062 WO2014087007; SEQ ID NO: 232 3966 variable region MALA53 Light chain M071Xi2217 WO2014087007; SEQ ID NO: 236 3967 variable region MALA54 Light chain M036Xi0003 WO2014087007; SEQ ID NO: 240 3968 variable region MALA55 Light chain, Eba- R217 Chen et al., PLoS Pathol. 9 (5), E1003390 3969 175 (2013), NCBI Accession # 4QEX_M (214aa) MALA56 Light chain, Eba- R218 Chen et al., PLoS Pathol. 9 (5), E1003390 3970 175 (2013), NCBI Accession # 4K2U_M (234aa) MALA57 Vivax apical F8.12.19 NCBI Accession # 2J4W_L (213aa) 3971 membrane antigen 1 monoclonal antibody, seqres

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 19 against Ebola and/or Margburg Viruses.

TABLE 19 Antibodies against Ebola and Marburg viruses SEQ Antibody Antibody ID No. Description Name Reference Information NO EBOL1 Chain A, Sudan Ebolavirus 16f6 Bale et al., Structural basis for 3972 Glycoprotein (Strain Boniface) differential neutralization of ebolaviruses; Viruses 4 (4), 447-470 (2012), NCBI Accession # 3VE0_B (212aa) EBOL2 Chain B, Sudan Ebolavirus 16f6 Bale et al., Structural basis for 3973 Glycoprotein (Strain Boniface) differential neutralization of ebolaviruses; Viruses 4 (4), 447-470 (2012), NCBI Accession # 3VE0_A (220aa) EBOL3 Ebola Virus Glycoprotein 13f6-1-2 Lee J. E. et al., Complex of a protective 3974 Fab antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain; J. Mol. Biol. 375 (1), 202-216 (2008), NCBI Accession # 2QHR_L (218aa) EBOL4 Ebola Virus Glycoprotein 13f6-1-2 Lee J. E. et al., Complex of a protective 3975 Fab antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain; J. Mol. Biol. 375 (1), 202-216 (2008), NCBI Accession # 2QHR_H (222aa) EBOL5 Fab heavy chain Envelope Mr78 Hashiguchi, T., et al., Cell 160 (5), 3976 Glycoprotein Gp1 904-912 (2015), NCBI Accession # 3X2D_P (226aa) EBOL6 Fab light chain, Envelope Mr78 Hashiguchi, T., et al., Cell 160 (5), 3977 Glycoprotein Gp1 904-912 (2015), NCBI Accession # 3X2D_O (213aa) EBOL7 Fusion protein, Zaire Ebola virus, US20140356354 SEQ ID NO: 2 3978 Mayinga strain glycoprotein EBOL8 Heavy chain Ebolavirus-Protective Olal, D., et al., Structure of an 3979 Antibody Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus; J. Virol. 86 (5), 2809-2816 (2012), NCBI Accession # 2Y6S_H (213aa) EBOL9 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 6 3980 Marburg) EBOL10 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 7 3981 Marburg) EBOL11 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 8 3982 Marburg) EBOL12 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 9 3983 Marburg) EBOL13 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 10 3984 Marburg) EBOL14 Heavy chain Filovirus (Ebola or US20140356354 SEQ ID NO: 11 3985 Marburg) EBOL15 Heavy chain variable region, Zaire WO2015127136 SEQ ID NO: 71 3986 ebolavirus (ZEBOV) glycoprotein EBOL16 Heavy chain variable region, Zaire WO2015127136 SEQ ID NO: 47 3987 ebolavirus (ZEBOV) glycoprotein EBOL17 Heavy chain variable region, Zaire WO2015127136 SEQ ID NO: 23 3988 ebolavirus (ZEBOV) glycoprotein EBOL18 Heavy chain variable region, Ebola 16H11 U.S. Pat. No. 9,097,713 SEQ ID NO: 2 3989 Sudan Boniface virus (ESB) glycoprotein (GP) EBOL19 Heavy chain variable region, Ebola 19B3 U.S. Pat. No. 9,097,713 SEQ ID NO: 4 3990 Sudan Boniface virus (ESB) glycoprotein (GP) EBOL20 Heavy chain variable region, Ebola 17F6 U.S. Pat. No. 9,097,713 SEQ ID NO: 6 3991 Sudan Boniface virus (ESB) glycoprotein (GP) EBOL21 Heavy chain variable region, Ebola 16F6 U.S. Pat. No. 9,097,713 SEQ ID NO: 8 3992 Sudan Boniface virus (ESB) glycoprotein (GP) EBOL22 Heavy chain variable region, Ebola EGP 6D8 U.S. Pat. No. 7,335,356 SEQ ID NO: 22 3993 virus GP 1-2 EBOL23 Heavy chain variable region, Ebola EGP13F6-1-2 U.S. Pat. No. 7,335,356 SEQ ID NO: 32 3994 virus GP EBOL24 Heavy chain variable region, Ebola EGP13C6-1-1 U.S. Pat. No. 7,335,356 SEQ ID NO: 12 3995 virus GP EBOL25 Heavy chain variable region, WO2015127140 SEQ ID NO: 14 3996 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL26 Heavy chain variable region, WO2015127140 SEQ ID NO: 38 3997 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL27 Heavy chain variable region, WO2015127140 SEQ ID NO: 62 3998 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL28 Heavy chain variable region, WO2015127140 SEQ ID NO: 86 3999 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL29 Heavy chain variable region, WO2015127140 SEQ ID NO: 110 4000 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL30 Heavy chain variable region, WO2015127140 SEQ ID NO: 134 4001 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL31 Heavy chain variable region, WO2015127140 SEQ ID NO: 158 4002 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL32 Heavy chain, Ebola virus Fab Kz52 Lee J. E. et al., Structure of the Ebola 4003 glycoprotein, virus glycoprotein bound to an antibody from a human survivor; Nature 454 (7201), 177-182 (2008), NCBI Accession # 3CSY_G (226aa) EBOL33 Light chain variable region, Ebola 16F6 U.S. Pat. No. 9,097,713 SEQ ID NO: 10 4004 Sudan Boniface virus (ESB) glycoprotein (GP) EBOL34 Light chain variable region, Ebola EGP 6D8 U.S. Pat. No. 7,335,356 SEQ ID NO: 27 4005 virus GP 1-2 EBOL35 Light chain variable region, Ebola EGP13F6-1-2 U.S. Pat. No. 7,335,356 SEQ ID NO: 37 4006 virus GP EBOL36 Light chain variable region, Ebola EGP13C6-1-1 U.S. Pat. No. 7,335,356 SEQ ID NO: 16 4007 virus GP EBOL37 Light chain variable region, WO2015127140 SEQ ID NO: 2 4008 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL38 Light chain variable region, WO2015127140 SEQ ID NO: 26 4009 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL39 Light chain variable region, WO2015127140 SEQ ID NO: 50 4010 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest vires or Reston virus glycoprotein EBOL40 Light chain variable region, WO2015127140 SEQ ID NO: 74 4011 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL41 Light chain variable region, WO2015127140 SEQ ID NO: 98 4012 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL42 Light chain variable region, WO2015127140 SEQ ID NO: 122 4013 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL43 Light chain variable region, WO2015127140 SEQ ID NO: 146 4014 Marburg virus, Ebola virus, Sudan virus, Bundibugyo virus, Tai Forest virus or Reston virus glycoprotein EBOL44 Light chain variable region, Zaire WO2015127136 SEQ ID NO: 59 4015 ebolavirus (ZEBOV) glycoprotein EBOL45 Light chain variable region, Zaire WO2015127136 SEQ ID NO: 35 4016 ebolavirus (ZEBOV) glycoprotein EBOL46 Light chain variable region, Zaire WO2015127136 SEQ ID NO: 11 4017 ebolavirus (ZEBOV) glycoprotein EBOL47 light chain, Ebola virus Fab Kz52 Lee J. E. et al., Structure of the Ebola 4018 glycoprotein virus glycoprotein bound to an antibody from a human survivor; Nature 454 (7201), 177-182 (2008), NCBI Accession # 3CSY_H (217aa) EBOL48 Light chain, Ebolavirus-Protective Olal, D., et al., Structure of an 4019 Antibody Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola Virus; J. Virol. 86 (5), 2809-2816 (2012), NCBI Accession # 2Y6S_L (217aa) EBOL49 Light chain, Filovirus (Ebola or US20140356354 SEQ ID NO: 12 4020 Marburg) EBOL50 Light chain, Filovirus (Ebola or US20140356354 SEQ ID NO: 13 4021 Marburg) EBOL51 Light chain, Filovirus (Ebola or US20140356354 SEQ ID NO: 14 4022 Marburg) EBOL52 Light chain, Filovirus (Ebola or US20140356354 SEQ ID NO: 15 4023 Marburg) EBOL53 Light chain, Filovirus (Ebola or US20140356354 SEQ ID NO: 16 4024 Marburg)

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in U.S. Pat. No. 7,335,356 and EP Pub. No. EP1539238, the contents of each of which are herein incorporated by reference in their entirety, against Ebola.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 20 against Mosquito-borne disease.

TABLE 20 Antibodies against Mosquito-borne diseases SEQ Antibody Antibody ID No. Description Name Reference Information NO MOSQ1 Gamma heavy chain, Thibodeaux, B. A. “Development of a human- 4025 partial, anti-Saint Louis murine chimeric immunoglobulin M antibody encephalitis virus for use in the serological detection of human envelope glycoprotein flavivirus antibodies”, Clin. Vaccine immunoglobulin Immunol. 16 (5), 679-685, 2009), NCBI Accession # ACI62179 MOSQ2 Gamma heavy chain, Thibodeaux, B. A. “Development of a human- 4026 partial, anti-Saint Louis murine chimeric immunoglobulin M antibody encephalitis virus for use in the serological detection of human envelope glycoprotein flavivirus antibodies”, Clin. Vaccine immunoglobulin Immunol. 16 (5), 679-685, 2009), NCBI Accession # ACI62180 MOSQ3 Heavy chain variable anti- US20080292644 SEQ ID NO: 69 4027 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ4 Heavy chain variable anti- US20080292644 SEQ ID NO: 70 4028 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ5 Heavy chain variable anti- US20080292644 SEQ ID NO: 71 4029 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ6 Heavy chain variable CN103864925 SEQ ID NO: 2 4030 region, Japanese encephalitis virus MOSQ7 Heavy chain variable Throsby, M. “Isolation and characterization 4031 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20480.1 MOSQ8 Heavy chain variable Throsby, M. “Isolation and characterization 4032 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20479.1 MOSQ9 Heavy chain variable Throsby, M. “Isolation and characterization 4033 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20478.1 MOSQ10 Heavy chain variable Throsby, M. “Isolation and characterization 4034 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20477.1 MOSQ11 Heavy chain variable Throsby, M. “Isolation and characterization 4035 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20476.1 MOSQ12 Heavy chain variable Throsby, M. “Isolation and characterization 4036 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20475.1 MOSQ13 Heavy chain variable Throsby, M. “Isolation and characterization 4037 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20474.1 MOSQ14 Heavy chain variable Throsby, M. “Isolation and characterization 4038 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20473.1 MOSQ15 Heavy chain variable Throsby, M. “Isolation and characterization 4039 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20472.1 MOSQ16 Heavy chain variable Throsby, M. “Isolation and characterization 4040 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006). NCBI Accession # ABF20471.1 MOSQ17 Heavy chain variable mAbl 1 WO2014144061 SEQ ID NO: 1 3359 region, WNV, Dengue, St. Louis encephalitis, yellow fever virus, Japanese encephalitis virus, Murray Valley encephalitis virus MOSQ18 Heavy chain, WNV CR4348 U.S. Pat. No. 8,911,738 SEQ ID NO: 30 4041 MOSQ19 Heavy chain, WNV CR4354 U.S. Pat. No. 8,911,738 SEQ ID NO: 32 4042 MOSQ20 Heavy chain, WNV CR4261 U.S. Pat. No. 8,911,738 SEQ ID NO: 60 4043 MOSQ21 Heavy chain, WNV CR4267 U.S. Pat. No. 8,911,738 SEQ ID NO: 62 4044 MOSQ22 Heavy chain, WNV CR4328 U.S. Pat. No. 8,911,738 SEQ ID NO: 64 4045 MOSQ23 Heavy chain, WNV CR4335 U.S. Pat. No. 8,911,738 SEQ ID NO: 66 4046 MOSQ24 Heavy chain, WNV CR4383 U.S. Pat. No. 8,911,738 SEQ ID NO: 68 4047 MOSQ25 Heavy chain, WNV CRM4354 U.S. Pat. No. 8,911,738 SEQ ID NO: 148 4048 MOSQ26 Heavy chain variable Antibody from U.S. Pat. No. 8,911,738 SEQ ID NO: 20 4049 region, WNV U.S. Pat. No. 8,911,738 MOSQ27 Heavy chain variable E16 heavy chain U.S. Pat. No. 7,572,456 SEQ ID NO: 21 4050 region, WNV version 1 MOSQ28 Heavy chain variable E16 heavy chain U.S. Pat. No. 7,572,456 SEQ ID NO: 22 4051 region, WNV version 2 MOSQ29 Heavy chain variable E16 heavy chain U.S. Pat. No. 7,572,456 SEQ ID NO: 23 4052 region, WNV version 3 MOSQ30 Heavy chain variable Antibody from U.S. Pat. No. 8,911,738 SEQ ID NO: 18 4053 region, WNV U.S. Pat. No. 8,911,738 MOSQ31 Heavy chain variable hu-E16/E16p U.S. Pat. No. 8,663,950 SEQ ID NO: 2 4054 region, WNV MOSQ32 Heavy chain variable hu-E16/E16p U.S. Pat. No. 8,663,950 SEQ ID NO: 3 4055 region, WNV MOSQ33 Heavy chain variable E16 U.S. Pat. No. 7,527,973 SEQ ID NO: 4 4056 region, WNV MOSQ34 Heavy chain variable E24 U.S. Pat. No. 7,527,973 SEQ ID NO: 8 4057 region, WNV MOSQ35 Heavy chain variable E34 U.S. Pat. No. 7,527,973 SEQ ID NO: 12 4058 region, WNV MOSQ36 Heavy chain variable 11 US20090130123 SEQ ID NO: 23 4059 region, WNV MOSQ37 Heavy chain variable 71 US20090130123 SEQ ID NO: 24 4060 region, WNV MOSQ38 Heavy chain variable 73 US20090130123 SEQ ID NO: 25 4061 region, WNV MOSQ39 Heavy chain variable 85 US20090130123 SEQ ID NO: 26 4062 region, WNV MOSQ40 Heavy chain variable 15 US20090130123 SEQ ID NO: 27 4063 region, WNV MOSQ41 Heavy chain variable 95 US20090130123 SEQ ID NO: 28 4064 region, WNV MOSQ42 Heavy chain variable 84 US20090130123 SEQ ID NO: 29 4065 region, WNV MOSQ43 Heavy chain variable 10 US20090130123 SEQ ID NO: 30 4066 region, WNV MOSQ44 Heavy chain variable 69 US20090130123 SEQ ID NO: 31 4067 region, WNV MOSQ45 Heavy chain variable 79 US20090130123 SEQ ID NO: 32 4068 region, WNV MOSQ46 Heavy chain variable 94 US20090130123 SEQ ID NO: 33 4069 region, WNV MOSQ47 Heavy chain variable 9FI2 WO2010093335 SEQ ID NO: 4 3333 region, WNV MOSQ48 Heavy chain variable Throsby, M. “Isolation and characterization 4070 region, partial sequence, of human monoclonal antibodies from WMV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20481.1 MOSQ49 Heavy chain translation, hu-E16/E16p U.S. Pat. No. 8,663,950 SEQ ID NO: 5 4071 WNV MOSQ50 Heavy chain variable anti-yellow fever Thibodeaux, B. A. “A humanized IgG but not 4072 region, Yellow fever virus vaccine IgM antibody is effective in prophylaxis and virus strain 17D E therapy of yellow fever infection in an glycoprotein AG129/17D-204 peripheral challenge mouse model” Antiviral Res. 94 (1), 1-8 (2012), NCBI Accession # ADO17683 MOSQ51 Light chain variable anti- US20080292644 SEQ ID NO: 66 4073 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ52 Light chain variable anti- US20080292644 SEQ ID NO: 67 4074 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ53 Light chain variable anti- US20080292644 SEQ ID NO: 68 4075 region, Japanese DLVR1/CLEC5A encephalitis virus MOSQ54 Light chain variable CN103864925 SEQ ID NO: 1 4076 region, Japanese encephalitis virus MOSQ55 Light chain variable mAbl 1 WO2014144061 SEQ ID NO: 3 3418 region, WNV, Dengue, St. Louis encephalitis, yellow fever virus, Japanese encephalitis virus, Murray Valley encephalitis virus MOSQ56 Light chain, WNV CR4348 U.S. Pat. No. 8,911,738 SEQ ID NO: 34 4077 MOSQ57 Light chain, WNV CR4354 U.S. Pat. No. 8,911,738 SEQ ID NO: 36 4078 MOSQ58 Light chain, WNV CR4261 U.S. Pat. No. 8,911,738 SEQ ID NO: 70 4079 MOSQ59 Light chain, WNV CR4267 U.S. Pat. No. 8,911,738 SEQ ID NO: 72 4080 MOSQ60 Light chain, WNV CR4328 U.S. Pat. No. 8,911,738 SEQ ID NO: 74 4081 MOSQ61 Light chain, WNV CR4335 U.S. Pat. No. 8,911,738 SEQ ID NO: 76 4082 MOSQ62 Light chain, WNV CR4383 U.S. Pat. No. 8,911,738 SEQ ID NO: 78 4083 MOSQ63 Light chain variable Antibody from U.S. Pat. No. 8,911,738 SEQ ID NO: 22 4084 region, WNV U.S. Pat. No. 8,911,738 MOSQ64 Light chain variable Antibody from U.S. Pat. No. 8,911,738 SEQ ID NO: 24 4085 region, WNV U.S. Pat. No. 8,911,738 MOSQ65 Light chain variable E16 U.S. Pat. No. 7,527,973 SEQ ID NO: 2 4086 region, WNV MOSQ66 Light chain variable E24 U.S. Pat. No. 7,527,973 SEQ ID NO: 6 4087 region, WNV MOSQ67 Light chain variable E34 U.S. Pat. No. 7,527,973 SEQ ID NO: 10 4088 region, WNV MOSQ68 Light chain variable E16 light chain U.S. Pat. No. 7,572,456 SEQ ID NO: 25 4089 region, WNV version 1 MOSQ69 Light chain variable E16 light chain U.S. Pat. No. 7,572,456 SEQ ID NO: 26 4090 region, WNV version 2 MOSQ70 Light chain variable 11 US20090130123 SEQ ID NO: 34 4091 region, WNV MOSQ71 Light chain variable 71 US20090130123 SEQ ID NO: 35 4092 region, WNV MOSQ72 Light chain variable 73 US20090130123 SEQ ID NO: 36 4093 region, WNV MOSQ73 Light chain variable 85 US20090130123 SEQ ID NO: 37 4094 region, WNV MOSQ74 Light chain variable 15 US20090130123 SEQ ID NO: 38 4095 region, WNV MOSQ75 Light chain variable 95 US20090130123 SEQ ID NO: 39 4096 region, WNV MOSQ76 Light chain variable 84 US20090130123 SEQ ID NO: 40 4097 region, WNV MOSQ77 Light chain variable 10 US20090130123 SEQ ID NO: 41 4098 region, WNV MOSQ78 Light chain variable US20090130123 SEQ ID NO: 42 4099 region, WNV MOSQ79 Light chain variable 79 US20090130123 SEQ ID NO: 43 4100 region, WNV MOSQ80 Light chain variable 94 US20090130123 SEQ ID NO: 44 4101 region, WNV MOSQ81 Light chain variable 9FI2 WO2010093335 SEQ ID NO: 6 3393 region, WNV MOSQ82 Light chain variable Throsby, M. “Isolation and characterization 4102 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20470.1 MOSQ83 Light chain variable Throsby, M. “Isolation and characterization 4103 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20469.1 MOSQ84 Light chain variable Throsby, M. “Isolation and characterization 4104 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20468.1 MOSQ85 Light chain variable Throsby, M. “Isolation and characterization 4105 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20467.1 MOSQ86 Light chain variable Throsby, M. “Isolation and characterization 4106 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20466.1 MOSQ87 Light chain variable Throsby, M. “Isolation and characterization 4107 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20465.1 MOSQ88 Light chain variable Throsby, M. “Isolation and characterization 4108 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20464.1 MOSQ89 Light chain variable Throsby, M. “Isolation and characterization 4109 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20463.1 MOSQ90 Light chain variable Throsby, M. “Isolation and characterization 4110 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20462.1 MOSQ91 Light chain variable Throsby, M. “Isolation and characterization 4111 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J, Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20461.1 MOSQ92 Light chain variable Throsby, M. “Isolation and characterization 4112 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20460.1 MOSQ93 Light chain variable Throsby, M. “Isolation and characterization 4113 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20459.1 MOSQ94 Light chain variable Throsby, M. “Isolation and characterization 4114 region, partial sequence, of human monoclonal antibodies from WNV individuals infected with west nile virus” J. Virol. 80 (14), 6982-6992 (2006), NCBI Accession # ABF20458.1 MOSQ95 Light chain translation, hu-E16/E16p U.S. Pat. No. 8,663,950 SEQ ID NO: 7 4115 WNV MOSQ96 Light chain variable anti-yellow fever Thibodeaux, B. A. “A humanized IgG but not 4116 region, Yellow fever virus vaccine IgM antibody is effective in prophylaxis and virus strain 17D E therapy of yellow fever infection in an glycoprotein AG129/17D-204 peripheral challenge mouse model” Antiviral Res. 94 (1), 1-8 (2012), NCBI Accession # ADO17684 MOSQ97 ScFv, WNV 9FI2 WO2010093335 SEQ ID NO: 8 3442 MOSQ98 Fc region, WNV, mAb-11 WO2014144061 SEQ ID NO: 5 4117 Dengue, St. Louis encephalitis, yellow fever virus, Japanese encephalitis virus, Murray Valley encephalitis virus MOSQ99 Fc region, WNV, mAb-11-LALA WO2014144061 SEQ ID NO: 6 4118 Dengue, St. Louis encephalitis, yellow fever virus, Japanese encephalitis virus, Murray Valley encephalitis virus MOSQ100 ScFv, WNV 11 US20090130123 SEQ ID NO: 12 4119 MOSQ101 ScFv, WNV 71 US20090130123 SEQ ID NO: 13 4120 MOSQ102 ScFv, WNV 73 US20090130123 SEQ ID NO: 14 4121 MOSQ103 ScFv, WNV 85 US20090130123 SEQ ID NO: 15 4122 MOSQ104 ScFv, WNV 15 US20090130123 SEQ ID NO: 16 4123 MOSQ105 ScFv, WNV 95 US20090130123 SEQ ID NO: 17 4124 MOSQ106 ScFv, WNV 84 US20090130123 SEQ ID NO: 18 4125 MOSQ107 ScFv, WNV 10 US20090130123 SEQ ID NO: 19 4126 MOSQ108 ScFv, WNV 69 US20090130123 SEQ ID NO: 20 4127 MOSQ109 ScFv, WNV 79 US20090130123 SEQ ID NO: 21 4128 MOSQ110 ScFv, WNV 94 US20090130123 SEQ ID NO: 22 4129 MOSQ111 ScFvs, WNV SC04-348 U.S. Pat. No. 8,911,738 SEQ ID NO: 26 4130 MOSQ112 ScFvs, WNV SC04-354 U.S. Pat. No. 8,911,738 SEQ ID NO: 28 4131 MOSQ113 ScFv, Yellow anti-yellow Daffis, S. et al. “Antibody responses against 4132 fever virus fever virus E wild-type yellow fever virus and the 17D protein scFv 7A vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants” Virology 337 (2), 262-272 (2005), NCBI Accession # AAT76799 MOSQ114 ScFv, Yellow anti-yellow Daffis, S. et al. “Antibody responses against 4133 fever virus fever virus E wild-type yellow fever virus and the 17D protein scFv vaccine strain: characterization with human R3(27) monoclonal antibody fragments and neutralization escape variants” Virology 337 (2), 262-272 (2005), NCBI Accession # AAT76800 MOSQ115 ScFv, Yellow anti-yellow Daffis, S. et al. “Antibody responses against 4134 fever virus fever virus E wild-type yellow fever virus and the 17D protein scFv 5A vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants” Virology 337 (2), 262-272 (2005), NCBI Accession # AAT76801 MOSQ116 ScFv, Yellow anti-yellow Daffis, S. et al. “Antibody responses against 4135 fever virus fever virus E wild-type yellow fever virus and the 17D protein scFv 1A vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants” Virology 337 (2), 262-272 (2005), NCBI Accession # AAT76802 MOSQ117 ScFv, Yellow anti-yellow Daffis, S. et al. “Antibody responses against 4136 fever virus fever virus E wild-type yellow fever virus and the 17D protein scFv 2A vaccine strain: characterization with human monoclonal antibody fragments and neutralization escape variants” Virology 337 (2), 262-272 (2005), NCBI Accession # AAT76803 MOSQ118 ScFv, Yellow anti-yellow Daffis, S. et al. “Antibody responses against 4137 fever virus fever virus E wild-type yellow fever virus and the 17D protein scFv vaccine strain: characterization with human R3(9) monoclonal antibody fragments and neutralization escape variants” Virology 337 (2), 262-272 (2005), NCBI Accession # AAT76804

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in U.S. Pat. No. 6,399,062 and US Pub. No. US20110171225, the contents of each of which are herein incorporated by reference in their entirety, against Malaria.

Infectious Diseases

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the infectious disease related payload anti body polypeptides listed in Tables 21-42.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 21 against Influenza virus

TABLE 21 Antibodies against Influenza virus SEQ Antibody Antibody ID No. Description Name Reference Information NO INFL1 Fab Fragment Heavy ch65 Whittle, J. R. et al., Broadly neutralizing 4138 chain human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin; Proc. Natl. Acad. Sci. U.S.A. 108 (34), 14216-14221 (2011), NCBI Accession #3SMS_H INFL2 Fab Heavy Chain Fab Cr6261 Lingwood, D., et al., Structural and 4139 (Somatic Heavy genetic basis for development of broadly Chain With neutralizing influenza antibodies; Nature Germline- 489 (7417), 566-570 (2012), NCBI Reverted Light Accession #4EVN_M (242aa) Chain) INFL3 Fab heavy chain Del2d1 Krause, J. C. et al., M Bio 2 (1), E00345- 4140 E00310 (2011), NCBI Accession #3QHF_H INFL4 Fab heavy chain Fld194 Fab Xiong, X. et al., Structures of complexes 4141 formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody; Proc. Natl. Acad. Sci. U.S.A. 112 (30), 9430-9435 (2015), NCBI Accession #5A3I_C (230aa) INFL5 Fab heavy chain H5.3 Winarski, K. L., Thornburg, N. J. et al., 4142 Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites “PNAS 2015 112 (30) 9346-9351”, NCBI Accession #4XNM_H INFL6 Fab Heavy chain 5j8 Hong, M. et al., Antibody Recognition of 4143 the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site; J. Virol. 87 (22), 12471-12480 (2013), NCBI Accession #4M5Z_H INFL7 Fab lambda heavy CR6261 Ekiert, D. C. et al., Antibody recognition 4144 chain of a highly conserved influenza virus epitope; Science 324 (5924), 246-251 (2009), NCBI Accession #3GBN_H INFL8 Fab lambda light CR6261 Ekiert, D. C. et al., Antibody recognition 4145 chain of a highly conserved influenza virus epitope; Science 324 (5924), 246-251 (2009), NCBI Accession #3GBN_L INFL9 Fab lambda light Fab Cr6261 Lingwood, D., et al., Structural and 4146 chain (Somatic Heavy genetic basis for development of broadly Chain With neutralizing influenza antibodies; Nature Germline- 489 (7417), 566-570 (2012), NCBI Reverted Light Accession #4EVN_N (217aa) Chain) INFL10 Fab light chain Del2d1 Krause, J. C. et al., M Bio 2 (1), E00345- 4147 E00310 (2011), NCBI Accession #3QHF_L INFL11 Fab Light Chain Fld194 Fab Xiong, X. et al., Structures of complexes 4148 formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody; Proc. Natl. Acad, Sci. U.S.A. 112 (30), 9430-9435 (2015), NCBI Accession #5A3I_D (219aa) INFL12 Fab, heavy chain F045-092 Lee, P. S. et al., Receptor mimicry by 4149 antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus; Nat Commun 5, 3614 (2014), NCBI Accession #4O5I_W INFL13 Fab, Light Chain F045-092 Lee, P. S. et al., Receptor mimicry by 4150 antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus; Nat Commun 5, 3614 (2014), NCBI Accession #4O5I_V INFL14 Fab, light chain H5.3 Winarski, K. L., Thornburg, N. J. et al., 4151 “Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites “PNAS 2015 112 (30) 9346-9351”, NCBI Accession #4XNM_L INFL15 Gamma heavy chain 8i10 U.S. Pat. No. 8,858,948 SEQ ID NO: 69 4152 variable INFL16 Gamma heavy chain 23K12 U.S. Pat. No. 8,858,948 SEQ ID NO: 100 4153 variable INFL17 Heavy chain CR6261, WO 2008028946 4154 Diridavumab, CR- 6261 INFL18 Heavy chain Firivumab, CT-P22 US20130004505 4155 INFL19 Heavy chain CT-P22 US20130004505 SEQ ID NO: 41; WO 4156 2011/111966 INFL20 Heavy chain Navivumab, WO2013048153, US20140234336 SEQ 4157 CT149 ID NO: 40 INFL21 Heavy chain AT10-004 US20150010566, WO2013081463 SEQ 4158 ID NO: 31 INFL22 Heavy chain AT10-003 US20150010566, WO2013081463 SEQ 4159 ID NO: 32 INFL23 Heavy chain AT10-002 US20150010566, WO2013081463 SEQ 4160 ID NO: 33 INFL24 Heavy chain AT10-001 US20150010566, WO2013081463 SEQ 4161 ID NO: 34 INFL25 Heavy chain AT10-005 US20150010566, WO2013081463 SEQ 4162 ID NO: 35 INFL26 Heavy chain CT104 WO2011111966, US20130004505 SEQ 4163 ID NO: 37 INFL27 Heavy chain CT120 WO2011111966, US20130004505 SEQ 4164 ID NO: 41 INFL28 Heavy chain CT123 WO2011111966, US20130004505 SEQ 4165 ID NO: 45 INFL29 Heavy chain 2A US20140011982 SEQ ID NO: 2 4166 INFL30 Heavy chain F005-126 WO2014049520, US20140086927 SEQ 4167 ID NO: 2 INFL31 Heavy chain BF1-1 WO2008156763 SEQ ID NO: 7 4168 INFL32 Heavy chain BF1-19 WO2008156763 SEQ ID NO: 11 4169 INFL33 Heavy chain BF1-10 WO2008156763 SEQ ID NO: 9 4170 INFL34 Heavy chain WO2010127252, U.S. Pat. No. 8,894,997 SEQ 4171 ID NO: 3 INFL35 Heavy chain A18 WO13170139 SEQ ID NO: 94 4172 INFL36 Heavy chain Ab A18 U.S. Pat. No. 7,788,200 SEQ ID NO: 15 4173 INFL37 Heavy chain Ab 014, Ab 028 U.S. Pat. No. 7,788,200 SEQ ID NO: 16 4174 INFL38 Heavy chain Ab 071 U.S. Pat. No. 7,788,200 SEQ ID NO: 162 4175 INFL39 Heavy chain Ab 072 U.S. Pat. No. 7,788,200 SEQ ID NO: 163 4176 INFL40 Heavy chain Ab 078, Ab 079, U.S. Pat. No. 7,788,200 SEQ ID NO: 164 4177 Ab 080, Ab 081 INFL41 Heavy chain Ab 001, Ab 009, U.S. Pat. No. 7,788,200 SEQ ID NO: 17 4178 Ab 017, Ab 160, Ab 186, Ab 187, Ab 188, Ab 189, Ab 190, Ab 191, Ab 192, Ab 193, Ab 202, Ab 211 INFL42 Heavy chain Ab 002, Ab 010, U.S. Pat. No. 7,788,200 SEQ ID NO: 18 4179 Ab 026, Ab 203, Ab 212 INFL43 Heavy chain Ab 003, Ab 011, U.S. Pat. No. 7,788,200 SEQ ID NO: 19 4180 Ab 027, Ab 194, Ab 195, Ab 196, Ab 197, Ab 198, Ab 199, Ab 200, Ab 204, Ab 213 INFL44 Heavy chain Ab 086 U.S. Pat. No. 7,788,200 SEQ ID NO: 20 4181 INFL45 Heavy chain Ab 154, Ab 155, U.S. Pat. No. 7,788,200 SEQ ID NO: 21 4182 Ab 157 INFL46 Heavy chain Ab 157, Ab 159 U.S. Pat. No. 7,788,200 SEQ ID NO: 22 4183 INFL47 Heavy chain Ab 210, Ab 219 U.S. Pat. No. 7,788,200 SEQ ID NO: 23 4184 INFL48 Heavy chain Ab A001, Ab U.S. Pat. No. 7,788,200 SEQ ID NO: 24 4185 A002, Ab A003, Ab A010, Ab A011, Ab 031, Ab 037 INFL49 Heavy chain Ab 004, Ab 005, U.S. Pat. No. 7,788,200 SEQ ID NO: 25 4186 Ab 006, Ab 012, Ab 013, Ab 032, Ab 038, Ab 043, Ab 044, Ab 045, Ab 046, Ab 047, Ab 048, Ab 049, Ab 050, Ab 051, Ab 052, Ab 067, Ab 068, Ab 069, Ab 070, Ab 073, Ab 074, Ab 075, Ab 076, Ab 077 INFL50 Heavy chain Ab 007, Ab 008, U.S. Pat. No. 7,788,200 SEQ ID NO: 26 4187 Ab A009, Ab A14, Ab 015, Ab 033, Ab 039 INFL51 Heavy chain Ab 016, Ab A017, U.S. Pat. No. 7,788,200 SEQ ID NO: 27 4188 Ab C18, Ab A019, Ab 034, Ab 040 INFL52 Heavy chain F005-126 WO2014049520 SEQ ID 2 4189 INFL53 Heavy chain 8f24 WO2012045001 SEQ ID 1 4190 INFL54 Heavy chain 3E22 WO2012045001 SEQ ID 5 4191 INFL55 Heavy chain 5117 WO2012045001 SEQ ID 9 4192 INFL56 Heavy chain WO2012045001 SEQ ID 13 4193 INFL57 Heavy chain WO2012045001 SEQ ID 29 4194 INFL58 Heavy chain WO2012045001 SEQ ID 33 4195 INFL59 Heavy chain WO2012045001 SEQ ID 17 4196 INFL60 Heavy chain 10A14 WO2012045001 SEQ ID 21 4197 INFL61 Heavy chain 8D4 WO2012045001 SEQ ID 25 4198 INFL62 Heavy chain 2B9 U.S. Pat. No. 9,115,201 SEQ ID NO: 6 4199 INFL63 Heavy chain mAB 7A7 US20150239960, US20140170163, 4200 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 6 INFL64 Heavy chain mAB 12D1 US20150239960, US20140170163, 4201 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 12 INFL65 Heavy chain mAB 66A6 US20150239960, US20140170163, 4202 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 16 INFL66 Heavy chain M1 D12 US20110033473, WO2009125395 SEQ 4203 ID NO: 17 INFL67 Heavy chain mAB1.12 WO2013030165 SEQ ID NO: 1 4204 INFL68 Heavy chain mAB3.1 WO2013030165 SEQ ID NO: 3 4205 INFL69 Heavy chain 5A7 WO2015120097 SEQ ID NO: 7 4206 INFL70 Heavy chain TRL053 WO2015120097 SEQ ID NO: 17 4207 INFL71 Heavy chain TRL579 WO2015120097 SEQ ID NO: 27 4208 INFL72 Heavy chain TRL784 WO2015120097 SEQ ID NO: 37 4209 INFL73 Heavy chain TRL794 WO2015120097 SEQ ID NO: 47 4210 INFL74 Heavy chain TRL798 WO2015120097 SEQ ID NO: 57 4211 INFL75 Heavy chain TRL799 WO2015120097 SEQ ID NO: 67 4212 INFL76 Heavy chain TRL809 WO2015120097 SEQ ID NO: 77 4213 INFL77 Heavy chain TRL811 WO2015120097 SEQ ID NO: 87 4214 INFL78 Heavy chain TRL812 WO2015120097 SEQ ID NO: 97 4215 INFL79 Heavy chain TRL813 WO2015120097 SEQ ID NO: 107 4216 INFL80 Heavy chain TRL823 WO2015120097 SEQ ID NO: 117 4217 INFL81 Heavy chain TRL832 WO2015120097 SEQ ID NO: 127 4218 INFL82 Heavy chain TRL833 WO2015120097 SEQ ID NO: 137 4219 INFL83 Heavy chain TRL834 WO2015120097 SEQ ID NO: 147 4220 INFL84 Heavy chain TRL835 WO2015120097 SEQ ID NO: 157 4221 INFL85 Heavy chain TRL835 WO2015120097 SEQ ID NO: 158 4222 INFL86 Heavy chain TRL837 WO2015120097 SEQ ID NO: 168 4223 INFL87 Heavy chain TRL839 WO2015120097 SEQ ID NO: 178 4224 INFL88 Heavy chain TRL841 WO2015120097 SEQ ID NO: 188 4225 INFL89 Heavy chain TRL842 WO2015120097 SEQ ID NO: 198 4226 INFL90 Heavy chain TRL845 WO2015120097 SEQ ID NO: 208 4227 INFL91 Heavy chain TRL846 WO2015120097 SEQ ID NO: 217 4228 INFL92 Heavy chain TRL847 WO2015120097 SEQ ID NO: 227 4229 INFL93 Heavy chain TRL848 WO2015120097 SEQ ID NO: 237 4230 INFL94 Heavy chain TRL849 WO2015120097 SEQ ID NO: 247 4231 INFL95 Heavy chain TRL851 WO2015120097 SEQ ID NO: 257 4232 INFL96 Heavy chain TRL854 WO2015120097 SEQ ID NO: 267 4233 INFL97 Heavy chain TRL856 WO2015120097 SEQ ID NO: 277 4234 INFL98 Heavy chain TRL858 WO2015120097 SEQ ID NO: 287 4235 INFL99 Heavy chain humM2e-hBiTE-1 WO2014140368 SEQ ID NO: 8 4236 INFL100 Heavy chain humM2e-hBiTE-2 WO2014140368 SEQ ID NO: 16 4237 INFL101 Heavy chain humM2e-hBiTE-3 WO2014140368 SEQ ID NO: 24 4238 INFL102 Heavy chain humM2e-hBiTE-4 WO2014140368 SEQ ID NO: 32 4239 INFL103 Heavy chain VH of humM2e- WO2014140368 SEQ ID NO: 40 4240 hBiTE-5 INFL104 Heavy chain humM2e-hBiTE-6 WO2014140368 SEQ ID NO: 48 4241 INFL105 Heavy chain humM2e-hBiTE-7 WO2014140368 SEQ ID NO: 56 4242 INFL106 Heavy chain humM2e-hBiTE-8 WO2014140368 SEQ ID NO: 64 4243 INFL107 Heavy chain humM2e-hBiTE-9 WO2014140368 SEQ ID NO: 72 4244 INFL108 Heavy chain murM2e-hBiTE WO2014140368 SEQ ID NO: 80 4245 INFL109 Heavy chain FLA5.10 U.S. Pat. No. 8,124,092 SEQ ID NO: 1 4246 INFL110 Heavy chain FLD21.140 U.S. Pat. No. 8,124,092 SEQ ID NO: 5 4247 INFL111 Heavy chain FLA3.14 U.S. Pat. No. 8,124,092 SEQ ID NO: 9 4248 INFL112 Heavy chain FLD20.19 U.S. Pat. No. 8,124,092 SEQ ID NO: 13 4249 INFL113 Heavy chain FLD84 U.S. Pat. No. 8,124,092 SEQ ID NO: 42 4250 INFL114 Heavy chain FLD93 U.S. Pat. No. 8,124,092 SEQ ID NO: 52 4251 INFL115 Heavy chain FLD122 U.S. Pat. No. 8,124,092 SEQ ID NO: 62 4252 INFL116 Heavy chain FLD127 U.S. Pat. No. 8,124,092 SEQ ID NO: 72 4253 INFL117 Heavy chain FLD129 U.S. Pat. No. 8,124,092 SEQ ID NO: 82 4254 INFL118 Heavy chain FLD132 U.S. Pat. No. 8,124,092 SEQ ID NO: 92 4255 INFL119 Heavy chain FLD194 U.S. Pat. No. 8,124,092 SEQ ID NO: 102 4256 INFL120 Heavy chain mAb2 WO2015112994 SEQ ID NO: 80 4257 INFL121 Heavy chain mAb3 WO2015112994 SEQ ID NO: 84 4258 INFL122 Heavy chain Tsibane, T. et al., Influenza Human 4259 Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses; PLoS Pathol. 8 (12), E1003067 (2012), NCBI Accession #4GXU_S INFL123 Heavy chain C05 Ekiert, D. C., et al., Cross-neutralization 4260 of influenza A viruses mediated by a single antibody loop; Nature 489 (7417), 526-532 (2012), NCBI Accession #4FNL_H (247aa) INFL124 Heavy chain CR8020 Ekiert, D. C., et al., A. highly conserved 4261 neutralizing epitope on group 2 influenza A viruses; Science 333 (6044), 843-850 (2011); WO2010130636, NCBI Accession #3SDY_H INFL125 Heavy chain CR8043 Friesen, R. H. et al., A common solution 4262 to group 2 influenza virus neutralization; Proc. Natl. Acad. Sci. U.S.A. 111 (1), 445-450 (2014), NCBI Accession #4NM8_H INFL126 Heavy chain CR8059 Dreyfus, C. et al., Highly conserved 4263 protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQK_H INFL127 Heavy chain CR8071 Dreyfus, C. et al., Highly conserved 4264 protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQJ_H (234aa) INFL128 Heavy chain CR9114 WO2013079473; WO2014191435; 4265 Dreyfus, C., Laursen, N. S. et al., Highly conserved protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQY_H (230aa) INFL129 Heavy chain Ch67 Schmidt, A. G., et al., Preconfiguration of 4266 the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody; Proc. Natl. Acad. Set. U.S.A. 110 (1), 264-269 (2013), NCBI Accession #4HKX_A (231aa) INFL130 Heavy chain Fab 26/9 Schulze-Gahmen, U. et al., J. Biol. 4267 Chem. 263 (32), 17100-17105 (1988); Churchill, M. E., et al., J. Mol. Biol. 241 (4), 534-556 (1994), NCBI Accession #1FRG_H INFL131 Heavy chain Fab 3.1 Wyrzucki, A. et al., Alternative 4268 Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a VH3-30-Encoded Heterosubtypic Antibody; J. Virol. 88 (12), 7083-7092 (2014), NCBI Accession #4PY8_I INFL132 Heavy chain Fab 2g1 Xu, R. et al., A recurring motif for 4269 antibody recognition of the receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013), NCBI Accession #4HG4_N (223aa) INFL133 Heavy chain Fab 8m2 Xu, R. et al., A recurring motif for 4270 antibody recognition of the receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013), NCBI Accession #4HFU_H (226aa) INFL134 Heavy chain Fab 8f8 Xu, R. et al., A recurring motif for 4271 antibody recognition of the receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013), NCBI Accession #4HF5_H (233aa) INFL135 Heavy chain Fab 2d1 Xu, R., et al., Structural basis of 4272 preexisting immunity to the 2009 H1N1 pandemic influenza virus; Science 328 (5976), 357-360 (2010), NCBI Accession #3LZF_H (230aa) INFL136 Heavy chain Fi6v3 Corti, D. et al., A neutralizing antibody 4273 selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins; Science 333 (6044), 850-856 (2011), NCBI Accession #3ZTJ_G INFL137 Heavy Chain Heavy chain Iba, Y., et al., Conserved Neutralizing 4274 3WHE_N Epitope at Globular Head of Hemagglutinin in H3N2 Influenza Viruses; J. Virol. (2014), NCBI Accession #3WHE_M (226aa) INFL138 Heavy chain 7A13 Krause et al. “Human Monoclonal 4275 Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses” J. Virol. 86 (11), 6334-6340 (2012), NCBI Accession #AFH78447 INFL139 Heavy chain 2D1 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4276 NO: 7 INFL140 Heavy chain 1F1 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4277 NO: 1 INFL141 Heavy chain WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4278 NO: 4 INFL142 Heavy chain 1I20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4279 NO: 5 INFL143 Heavy chain 4D20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4280 NO: 9 INFL144 Heavy chain WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4281 NO: 11 INFL145 Heavy chain US20140205614, US20100316654 SEQ 4282 ID NO: 21 INFL146 Heavy chain US20140205614, US20100316654 SEQ 4283 ID NO: 22 INFL147 Heavy chain US20140205614, US20100316654 SEQ 4284 ID NO: 23 INFL148 Heavy chain US20140205614, US20100316654 SEQ 4285 ID NO: 24 INFL149 Heavy chain US20140205614, US20100316654 SEQ 4286 ID NO: 25 INFL150 Heavy chain US20140205614, US20100316654 SEQ 4287 ID NO: 26 INFL151 Heavy chain US20140205614, US20100316654 SEQ 4288 ID NO: 27 INFL152 Heavy chain US20140205614, US20100316654 SEQ 4289 ID NO: 28 INFL153 Heavy chain US20140205614, US20100316654 SEQ 4290 ID NO: 29 INFL154 Heavy chain US20140205614, US20100316654 SEQ 4291 ID NO: 30 INFL155 Heavy chain US20140205614, US20100316654 SEQ 4292 ID NO: 31 INFL156 Heavy chain US20140205614, US20100316654 SEQ 4293 ID NO: 32 INFL157 Heavy chain US20140205614, US20100316654 SEQ 4294 ID NO: 33 INFL158 Heavy chain US20140205614, US20100316654 SEQ 4295 ID NO: 34 INFL159 Heavy chain US20140205614, US20100316654 SEQ 4296 ID NO: 35 INFL160 Heavy chain US20140205614, US20100316654 SEQ 4297 ID NO: 36 INFL161 Heavy chain US20140205614, US20100316654 SEQ 4298 ID NO: 37 INFL162 Heavy chain US20140205614, US20100316654 SEQ 4299 ID NO: 38 INFL163 Heavy chain US20140205614, US20100316654 SEQ 4300 ID NO: 39 INFL164 Heavy chain US20140205614, US20100316654 SEQ 4301 ID NO: 40 INFL165 Heavy chain US20140205614, US20100316654 SEQ 4302 ID NO: 41 INFL166 Heavy chain US20140205614, US20100316654 SEQ 4303 ID NO: 42 INFL167 Heavy chain US20140205614, US20100316654 SEQ 4304 ID NO: 43 INFL168 Heavy chain US20140205614, US20100316654 SEQ 4305 ID NO: 44 INFL169 Heavy chain US20140205614, US20100316654 SEQ 4306 ID NO: 45 INFL170 Heavy chain mAb1 WO2015112994 SEQ ID NO: 76 4307 INFL171 Heavy chain CR8033 Dreyfus, C., Laursen, N. S. et al., Highly 4308 conserved protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession # 4FQL_H INFL172 Heavy chain (Partial) monoclonal Burioni, R. et al., Monoclonal antibodies 4309 antibody PN- isolated from human B cells neutralize a SIA28 broad range of H1 subtype influenza A viruses including swine-origin Influenza virus(S-OIV); Virology (2010), NCBI Accession #ACX30936.1 (122aa) INFL173 Heavy chain (Partial) monoclonal Burioni, R, et al., Monoclonal antibodies 4310 antibody PN- isolated from human B cells neutralize a SIA49 broad range of H1 subtype influenza A viruses including swine-origin Influenza virus(S-OIV); Virology (2010), NCBI Accession #ACX30937.1 (127aa) INFL174 Heavy chain cdr1 Ab1A2 WO2015028478 SEQ ID 6 4311 INFL175 Heavy chain cdr2 Ab1A2 WO2015028478 SEQ ID 7 4312 INFL176 Heavy chain cdr3 Ab1A2 WO2015028478 SEQ ID 8 4313 INFL177 Heavy chain constant U.S. Pat. No. 8,992,929 SEQ ID NO. 22 4314 region, Human igg1 INFL178 Heavy chain Fab CT147 WO2013048153, US20140234336 SEQ 4315 ID NO: 38 INFL179 Heavy chain Fab CT164 WO2013048153, US20140234336 SEQ 4316 ID NO: 42 INFL180 Heavy chain Fab CT166 WO2013048153, US20140234336 SEQ 4317 ID NO: 44 INFL181 Heavy chain G2 h2B9 U.S. Pat. No. 9,115,201 SEQ ID NO: 7 4318 INFL182 Heavy chain G5 h2B10 U.S. Pat. No. 9,115,201 SEQ ID NO: 8 4319 INFL183 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 1 4320 (exemplary) US2013030234 INFL184 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 2 4321 (exemplary) US2013030234 INFL185 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 3 4322 (exemplary) US2013030234 INFL186 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 4 4323 (exemplary) US2013030234 INFL187 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 5 4324 (exemplary) US2013030234 INFL188 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 6 4325 (exemplary) US2013030234 INFL189 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 7 4326 (exemplary) US2013030234 INFL190 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 8 4327 (exemplary) US2013030234 INFL191 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 9 4328 (exemplary) US2013030234 INFL192 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 10 4329 (exemplary) US2013030234 INFL193 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 11 4330 (exemplary) US2013030234 INFL194 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 12 4331 (exemplary) US2013030234 INFL195 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 13 4332 (exemplary) US2013030234 INFL196 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 14 4333 (exemplary) US2013030234 INFL197 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 15 4334 (exemplary) US2013030234 INFL198 Heavy chain variable HC-VD from US2013030234 SEQ ID NO: 16 4335 (exemplary) US2013030234 INFL199 Heavy chain variable CR6141 US20150104459 SEQ ID NO: 199 4336 region INFL200 Heavy chain variable 39.18 B11 US20140161822 SEQ ID NO: 154 4337 region INFL201 Heavy chain variable 39.18 E12 US20140161822 SEQ ID NO: 158 4338 region INFL202 Heavy chain variable GG3 WO2014159960 SEQ ID NO: 17 4339 region INFL203 Heavy chain variable N547 U.S. Pat. No. 8,003,106 SEQ ID NO: 28 4340 region INFL204 Heavy chain variable L66 U.S. Pat. No. 8,003,106 SEQ ID NO: 30 4341 region INFL205 Heavy chain variable C40 U.S. Pat. No. 8,003,106 SEQ ID NO: 26 4342 region INFL206 Heavy chain variable 14C2 U.S. Pat. No. 8,080,244 SEQ ID NO: 6 4343 region INFL207 Heavy chain variable h14C2 U.S. Pat. No. 8,080,244 SEQ ID NO: 2 4344 region INFL208 Heavy chain variable 8G9 U.S. Pat. No. 8,603,467 SEQ ID NO: 2 4345 region INFL209 Heavy chain variable 13D4 U.S. Pat. No. 8,603,467 SEQ ID NO: 6 4346 region INFL210 Heavy chain variable 20A11 U.S. Pat. No. 8,603,467 SEQ ID NO: 10 4347 region INFL211 Heavy chain variable VN04-2-HuG1 US20100150941 SEQ ID NO: 5 4348 region INFL212 Heavy chain variable VN04-3-HuG1 US20100150941 SEQ ID NO: 7 4349 region INFL213 Heavy chain variable FI6 variant 1 U.S. Pat. No. 8,871,207 SEQ ID NO: 13 4350 region INFL214 Heavy chain variable FI6 variant 2 U.S. Pat. No. 8,871,207 SEQ ID NO: 33 4351 region INFL215 Heavy chain variable FI6 variant 3 U.S. Pat. No. 8,871,207 SEQ ID NO: 55 4352 region INFL216 Heavy chain variable FI6 variant 4, FI6 U.S. Pat. No. 8,871,207 SEQ ID NO: 59 4353 region variant 5 INFL217 Heavy chain variable FI28 variant 1 U.S. Pat. No. 8,871,207 SEQ ID NO: 29 4354 region INFL218 Heavy chain variable FI28 variant 2 U.S. Pat. No. 8,871,207 SEQ ID NO: 35 4355 region INFL219 Heavy chain variable 21B15 U.S. Pat. No. 8,858,948 SEQ ID NO: 44 4356 region INFL220 Heavy chain variable 3241_G23 U.S. Pat. No. 8,858,948 SEQ ID NO: 116 4357 region INFL221 Heavy chain variable 3244_I10 U.S. Pat. No. 8,858,948 SEQ ID NO: 120 4358 region INFL222 Heavy chain variable 3243_J07 U.S. Pat. No. 8,858,948 SEQ ID NO: 124 4359 region INFL223 Heavy chain variable 3259_J21 U.S. Pat. No. 8,858,948 SEQ ID NO: 128 4360 region INFL224 Heavy chain variable 3245_O19 U.S. Pat. No. 8,858,948 SEQ ID NO: 132 4361 region INFL225 Heavy chain variable 3244_H04 U.S. Pat. No. 8,858,948 SEQ ID NO: 136 4362 region INFL226 Heavy chain variable 3136_G05 U.S. Pat. No. 8,858,948 SEQ ID NO: 140 4363 region INFL227 Heavy chain variable 3252_C13 U.S. Pat. No. 8,858,948 SEQ ID NO: 144 4364 region INFL228 Heavy chain variable 3255_J06 U.S. Pat. No. 8,858,948 SEQ ID NO: 148 4365 region INFL229 Heavy chain variable 3420_I23 U.S. Pat. No. 8,858,948 SEQ ID NO: 152 4366 region INFL230 Heavy chain variable 3139_P23 U.S. Pat. No. 8,858,948 SEQ ID NO: 156 4367 region INFL231 Heavy chain variable 3139_P23 U.S. Pat. No. 8,858,948 SEQ ID NO: 158 4368 region INFL232 Heavy chain variable 3248_P18 U.S. Pat. No. 8,858,948 SEQ ID NO: 162 4369 region INFL233 Heavy chain variable 3253_P10 U.S. Pat. No. 8,858,948 SEQ ID NO: 166 4370 region INFL234 Heavy chain variable 3260_D19 U.S. Pat. No. 8,858,948 SEQ ID NO: 170 4371 region INFL235 Heavy chain variable 3362_B11 U.S. Pat. No. 8,858,948 SEQ ID NO: 172 4372 region INFL236 Heavy chain variable 3242_P05 U.S. Pat. No. 8,858,948 SEQ ID NO: 176 4373 region INFL237 Heavy chain variable 2K11 Krause, J. C. et al. “Epitope-specific 4374 region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16793 INFL238 Heavy chain variable 2O10 Krause, J. C. et al. “Epitope-specific 4375 region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16795 INFL239 Heavy chain variable 4K8 Krause, J. C. et al. “Epitope-specific 4376 region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16799 INFL240 Heavy chain variable 6D9 Krause, J. C. et al. “Epitope-specific 4377 region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16801 INFL241 Heavy chain variable 4D20 Yu, X. et al “Neutralizing antibodies 4378 region derived from the B cells of 1918 influenza pandemic survivors”, Nature 455 (7212), 532-536, NCBI Accession #ACI04579 INFL242 Heavy chain variable 2B12 Yu, X. et al “Neutralizing antibodies 4379 region derived from the B cells of 1918 influenza pandemic survivors”, Nature 455 (7212), 532-536, NCBI Accession #ABY48866 INFL243 Heavy chain variable 8D4 NCBI Accession #AFI57036 4380 region INFL244 Heavy chain variable 5B6 NCBI Accession #AFI57040 4381 region INFL245 Heavy chain variable A66 WO2009079259, US20110038935, 4382 region US20140011982 SEQ ID NO: 32 INFL246 Heavy chain variable D7 WO2009079259, US20110038935, 4383 region US20140011982 SEQ ID NO: 6 INFL247 Heavy chain variable D8, D80 WO2009079259, US20110038935, 4384 region US20140011982 SEQ ID NO: 12 INFL248 Heavy chain variable E88 WO2009079259, US20110038935, 4385 region US20140011982 SEQ ID NO: 36 INFL249 Heavy chain variable E90, F10 WO2009079259, US20110038935, 4386 region US20140011982 SEQ ID NO: 18 INFL250 Heavy chain variable F10 WO2009079259, US20110038935, 4387 region US20140011982 SEQ ID NO: 112 INFL251 Heavy chain variable G17 WO2009079259, US20110038935, 4388 region US20140011982 SEQ ID NO: 24 INFL252 Heavy chain variable H40 WO2009079259, US20110038935, 4389 region US20140011982 SEQ ID NO: 28 INFL253 Heavy chain variable CH65 WO2013020074, US20140302043 SEQ 4390 region ID NO: 14 INFL254 Heavy chain variable CH66 WO2013020074, US20140302043 SEQ 4391 region ID NO: 15 INFL255 Heavy chain variable CH67 WO2013020074, US20140302043 SEQ 4392 region ID NO: 16 INFL256 Heavy chain variable CL86OUCA WO2013020074, US20140302043 SEQ 4393 region ID NO: 13 INFL257 Heavy chain variable Antibody 1 WO2015051010 SEQ ID NO: 2 4394 region INFL258 Heavy chain variable Antibody 2 WO2015051010 SEQ ID NO: 12 4395 region INFL259 Heavy chain variable Antibody 3 WO2015051010 SEQ ID NO: 22 4396 region INFL260 Heavy chain variable Antibody 4 WO2015051010 SEQ ID NO: 32 4397 region INFL261 Heavy chain variable Antibody 5 WO2015051010 SEQ ID NO: 42 4398 region INFL262 Heavy chain variable Antibody 6 WO2015051010 SEQ ID NO: 52 4399 region INFL263 Heavy chain variable Antibody 7 WO2015051010 SEQ ID NO: 62 4400 region INFL264 Heavy chain variable Antibody 8 WO2015051010 SEQ ID NO: 72 4401 region INFL265 Heavy chain variable Antibody 9 WO2015051010 SEQ ID NO: 82 4402 region INFL266 Heavy chain variable Antibody 10 WO2015051010 SEQ ID NO: 92 4403 region INFL267 Heavy chain variable Antibody 11 WO2015051010 SEQ ID NO: 102 4404 region INFL268 Heavy chain variable Antibody 12 WO2015051010 SEQ ID NO: 112 4405 region INFL269 Heavy chain variable Antibody 13 WO2015051010 SEQ ID NO: 122 4406 region INFL270 Heavy chain variable Antibody 14 WO2015051010 SEQ ID NO: 132 4407 region INFL271 Heavy chain variable Antibody 15 WO201505I010 SEQ ID NO: 142 4408 region INFL272 Heavy chain variable Antibody 3-GL WO2015051010 SEQ ID NO: 152 4409 region INFL273 Heavy chain variable EM4C04 US20120282273 SEQ ID NO: 2 4410 region INFL274 Heavy chain variable 005-2G02 WO2013059524, US20140348851 SEQ 4411 region ID NO: 1 INFL275 Heavy chain variable 005-2G02 WO2013059524, US20140348851 SEQ 4412 region ID NO: 9 INFL276 Heavy chain variable 09-2A06 WO2013059524, US20140348851 SEQ 4413 region ID NO: 21 INFL277 Heavy chain variable 09-2A06 WO2013059524, US20140348851 SEQ 4414 region ID NO: 29 INFL278 Heavy chain variable 09-3A01 WO2013059524, US20140348851 SEQ 4415 region ID NO: 41 INFL279 Heavy chain variable 09-3A01 WO2013059524, US20140348851 SEQ 4416 region ID NO: 49 INFL280 Heavy chain variable 70-IF02 WO2012096994, US20140046039 SEQ 4417 region ID NO: 18 INFL281 Heavy chain variable US20120058124 SEQ ID NO: 10 4418 region INFL282 Heavy chain variable US20120058124 SEQ ID NO: 11 4419 region INFL283 Heavy chain variable US20120058124 SEQ ID NO: 12 4420 region INFL284 Heavy chain variable US20120058124 SEQ ID NO: 13 4421 region INFL285 Heavy chain variable US20120058124 SEQ ID NO: 14 4422 region INFL286 Heavy chain variable 81.39 US20140161822, US20140248286, 4423 region WO2014078268 SEQ ID NO: 111 INFL287 Heavy chain variable 81.39 US20140161822, US20140248286, 4424 region WO2014078268 SEQ ID NO: 115 INFL288 Heavy chain variable 39.29 US20140161822, US20140248286, 4425 region WO2014078268 SEQ ID NO: 134 INFL289 Heavy chain variable 39.29 US20140161822, US20140248286, 4426 region WO2014078268 SEQ ID NO: 138 INFL290 Heavy chain variable 39.29 US20140161822, US20140248286, 4427 region WO2014078268 SEQ ID NO: 142 INFL291 Heavy chain variable 39.29 US20140161822, US20140248286, 4428 region WO2014078268 SEQ ID NO: 148 INFL292 Heavy chain variable 36.89 US20140161822, US20140248286, 4429 region WO2014078268 SEQ ID NO: 160 INFL293 Heavy chain variable 9.01F3 US20140161822, US20140248286, 4430 region WO2014078268 SEQ ID NO: 164 INFL294 Heavy chain variable 23.06C2 US20140161822, US20140248286, 4431 region WO2014078268 SEQ ID NO: 168 INFL295 Heavy chain variable 39.29 US20140161822, US20140248286, 4432 region WO2014078268 SEQ ID NO: 234 INFL296 Heavy chain variable F16 Variant 5 WO2013011347, US20140271655, 4433 region US8871207 SEQ ID NO: 59 INFL297 Heavy chain variable F16 Variant 3 WO2013011347, US20140271655, 4434 region US8871207 SEQ ID NO: 55 INFL298 Heavy chain variable F16 Variant 2 WO2010010466 SEQ ID NO: 33 4435 region INFL299 Heavy chain variable FC41 WO2010010467 SEQ ID NO 60 4436 region INFL300 Heavy chain variable FE43 WO2010010467 SEQ ID NO 74 4437 region INFL301 Heavy chain variable FB75, FB110, WO2010010467 SEQ ID NO 121 4438 region FB177 INFL302 Heavy chain variable FE17 WO2010010467 SEQ ID NO 105 4439 region INFL303 Heavy chain variable FB79 WO2010010467 SEQ ID NO 131 4440 region INFL304 Heavy chain variable FC1C WO2010010467 SEQ ID NO 139 4441 region INFL305 Heavy chain variable FC6 WO2010010467 SEQ ID NO 45 4442 region INFL306 Heavy chain variable FE53 WO2010010467 SEQ ID NO 89 4443 region INFL307 Heavy chain variable 7A7 WO2010138564 SEQ ID NO: 6 4444 region INFL308 Heavy chain variable 12DI WO2010138564 SEQ ID NO: 12 4445 region INFL309 Heavy chain variable 66A6 WO2010138564 SEQ ID NO: 16 4446 region INFL310 Heavy chain variable B-1 U.S. Pat. No. 8,975,378, US20110319600, 4447 region WO2010073647 SEQ ID NO: 27 INFL311 Heavy chain variable D1 U.S. Pat. No. 8,975,378, US20110319600, 4448 region WO2010073647 SEQ ID NO: 29 INFL312 Heavy chain variable E-2 U.S. Pat. No. 8,975,378, US20110319600, 4449 region WO2010073647 SEQ ID NO: 31 INFL313 Heavy chain variable B-3 U.S. Pat. No. 8,975,378, US20110319600, 4450 region WO2010073647 SEQ ID NO: 33 INFL314 Heavy chain variable 5A7 WO2013114885, US20140377262 SEQ 4451 region ID NO: 33 INFL315 Heavy chain variable 3A2 WO2013114885, US20140377262 SEQ 4452 region ID NO: 37 INFL316 Heavy chain variable 10C4 WO2013114885, US20140377262 SEQ 4453 region ID NO: 41 INFL317 Heavy chain variable Fab49 WO2009144667, US20110076265 SEQ 4454 region ID NO: 1 INFL318 Heavy chain variable Fab28 IgG PN- WO2009115972, WO2011117848, 4455 region SIA28 US20110014187 SEQ ID NO: 1 INFL319 Heavy chain variable TCN-522 US20120207760, U.S. Pat. No. 8,916,160 SEQ ID 4456 region NO: 771; U.S. Pat. No. 8,900,590 SEQ ID NO: 32 INFL320 Heavy chain variable CR8019 WO2010130636 SEQ ID NO: 26 4457 region INFL321 Heavy chain variable CR8020 WO2010130636 SEQ ID NO: 30 4458 region INFL322 Heavy chain variable CR8021 WO2010130636 SEQ ID NO: 34 4459 region INFL323 Heavy chain variable CR8038 WO2010130636 SEQ ID NO: 38 4460 region INFL324 Heavy chain variable CR8039 WO2010130636 SEQ ID NO: 42 4461 region INFL325 Heavy chain variable CR8040 WO2010130636 SEQ ID NO: 46 4462 region INFL326 Heavy chain variable CR8041 WO2010130636 SEQ ID NO: 50 4463 region INFL327 Heavy chain variable CR8043 WO2010130636 SEQ ID NO: 54 4464 region INFL328 Heavy chain variable CR8049 WO2010130636 SEQ ID NO: 58 4465 region INFL329 Heavy chain variable CR8050 WO2010130636 SEQ ID NO: 61 4466 region INFL330 Heavy chain variable CR8052 WO2010130636 SEQ ID NO: 65 4467 region INFL331 Heavy chain variable CR8055 WO2010130636 SEQ ID NO: 69 4468 region INFL332 Heavy chain variable CR8057 WO2010130636 SEQ ID NO: 73 4469 region INFL333 Heavy chain variable CR8069 WO2010130636 SEQ ID NO: 77 4470 region INFL334 Heavy chain variable CR6255 US20090311265, U.S. Pat. No. 8,691,223, 4471 region U.S. Pat. No. 9,109,017, WO2008028946A SEQ ID NO: 59 INFL335 Heavy chain variable CR6257 US20090311265, U.S. Pat. No. 8,691,223, 4472 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 61 INFL336 Heavy chain variable CR6260 US20090311265, U.S. Pat. No. 8,691,223, 4473 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 63 INFL337 Heavy chain variable CR6261 US20090311265, U.S. Pat. No. 8,691,223, 4474 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 65 INFL338 Heavy chain variable CR6262 US20090311265, U.S. Pat. No. 8,691,223, 4475 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 67 INFL339 Heavy chain variable CR6268 US20090311265, U.S. Pat. No. 8,691,223, 4476 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 69 INFL340 Heavy chain variable CR6307 US20090311265, U.S. Pat. No. 8,691,223, 4477 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 71 INFL341 Heavy chain variable CR6310 US20090311265, U.S. Pat. No. 8,691,223, 4478 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 73 INFL342 Heavy chain variable CR6314 US20090311265, U.S. Pat. No. 8,691,223, 4479 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 75 INFL343 Heavy chain variable CR6323 US20090311265, U.S. Pat. No. 8,691,223, 4480 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 77 INFL344 Heavy chain variable CR6325 US20090311265, U.S. Pat. No. 8,691,223, 4481 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 79 INFL345 Heavy chain variable CR6331 US20090311265, U.S. Pat. No. 8,691,223, 4482 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 81 INFL346 Heavy chain variable CR6344 US20090311265, U.S. Pat. No. 8,691,223, 4483 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 83 INFL347 Heavy chain variable CR6141 US20090311265, U.S. Pat. No. 8,691,223, 4484 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 317 INFL348 Heavy chain variable CR6272 US20090311265, U.S. Pat. No. 8,691,223, 4485 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 321 INFL349 Heavy chain variable CR6296 US20090311265, U.S. Pat. No. 8,691,223, 4486 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 325 INFL350 Heavy chain variable CR6301 US20090311265, U.S. Pat. No. 8,691,223, 4487 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 329 INFL351 Heavy chain variable CR6327 US20090311265, U.S. Pat. No. 8,691,223, 4488 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 333 INFL352 Heavy chain variable CR6328 US20090311265, U.S. Pat. No. 8,691,223, 4489 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 337 INFL353 Heavy chain variable CR6329 US20090311265, U.S. Pat. No. 8,691,223, 4490 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 341 INFL354 Heavy chain variable CR6332 US20090311265, U.S. Pat. No. 8,691,223, 4491 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 345 INFL355 Heavy chain variable CR6334 US20090311265, U.S. Pat. No. 8,691,223, 4492 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 349 INFL356 Heavy chain variable CR6336 US20090311265, U.S. Pat. No. 8,691,223, 4493 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 353 INFL357 Heavy chain variable CR6339 US20090311265, U.S. Pat. No. 8,691,223, 4494 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 357 INFL358 Heavy chain variable CR6342 US20090311265, U.S. Pat. No. 8,691,223, 4495 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 361 INFL359 Heavy chain variable CR6343 US20090311265, U.S. Pat. No. 8,691,223, 4496 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 365 INFL360 Heavy chain variable CR9003 US20140120113 SEQ ID NO: 2 4497 region INFL361 Heavy chain variable CR9004 US20140120113 SEQ ID NO: 6 4498 region INFL362 Heavy chain variable CR9005 US20140120113 SEQ ID NO: 10 4499 region INFL363 Heavy chain variable CR9006 US20140120113 SEQ ID NO: 14 4500 region INFL364 Heavy chain variable CR9007 US20140120113 SEQ ID NO: 18 4501 region INFL365 Heavy chain variable CR9008 US20140120113 SEQ ID NO: 22 4502 region INFL366 Heavy chain variable CR9009 US20140120113 SEQ ID NO: 26 4503 region INFL367 Heavy chain variable CR9010 US20140120113 SEQ ID NO: 30 4504 region INFL368 Heavy chain variable CR9011 US20140120113 SEQ ID NO: 34 4505 region INFL369 Heavy chain variable CR9012 US20140120113 SEQ ID NO: 38 4506 region INFL370 Heavy chain variable CR9029 US20140120113 SEQ ID NO: 42 4507 region INFL371 Heavy chain variable CR9030 US20140120113 SEQ ID NO: 46 4508 region INFL372 Heavy chain variable CR9031 US20140120113 SEQ ID NO: 50 4509 region INFL373 Heavy chain variable CR9112 US20140120113 SEQ ID NO: 54 4510 region INFL374 Heavy chain variable CR9113 US20140120113 SEQ ID NO: 58 4511 region INFL375 Heavy chain variable CR9114 US20140120113 SEQ ID NO: 62 4512 region INFL376 Heavy chain variable CR8033 U.S. Pat. No. 8,852,595 SEQ ID NO: 71 4513 region INFL377 Heavy chain variable CR8059 U.S. Pat. No. 8,852,595 SEQ ID NO: 75 4514 region INFL378 Heavy chain variable CR8071 U.S. Pat. No. 8,852,595 SEQ ID NO: 78 4515 region INFL379 Heavy chain variable CR10051 U.S. Pat. No. 8,852,595 SEQ ID NO: 81 4516 region INFL380 Heavy chain variable CR10049 U.S. Pat. No. 8,852,595 SEQ ID NO: 85 4517 region INFL381 Heavy chain variable CR10023 U.S. Pat. No. 8,852,595 SEQ ID NO: 89 4518 region INFL382 Heavy chain variable CR10032 U.S. Pat. No. 8,852,595 SEQ ID NO: 93 4519 region INFL383 Heavy chain variable CR11035 U.S. Pat. No. 8,852,595 SEQ ID NO: 101 4520 region INFL384 Heavy chain variable CR11036 U.S. Pat. No. 8,852,595 SEQ ID NO: 105 4521 region INFL385 Heavy chain variable CR11038 U.S. Pat. No. 8,852,595 SEQ ID NO: 109 4522 region INFL386 Heavy chain variable CR11039 U.S. Pat. No. 8,852,595 SEQ ID NO: 113 4523 region INFL387 Heavy chain variable CR8031 U.S. Pat. No. 8,852,595 SEQ ID NO: 119 4524 region INFL388 Heavy chain variable CR8032 U.S. Pat. No. 8,852,595 SEQ ID NO: 123 4525 region INFL389 Heavy chain variable CR8034 U.S. Pat. No. 8,852,595 SEQ ID NO: 127 4526 region INFL390 Heavy chain variable CR8035 U.S. Pat. No. 8,852,595 SEQ ID NO: 131 4527 region INFL391 Heavy chain variable U.S. Pat. No. 8,992,929 SEQ ID NO: 4 4528 region INFL392 Heavy chain variable M2e U.S. Pat. No. 8,420,794 SEQ ID NO: 2 4529 region INFL393 Heavy chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 4530 region NO: 22 INFL394 Heavy chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 4531 region NO: 25 INFL395 Heavy chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 4532 region NO: 36 INFL396 Heavy chain variable 4A10 Krause, J. C. et al. “Epitope-specific 4533 region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16797 INFL397 Heavy chain variable anti-1918 influenza Yu, X., et al., Neutralizing antibodies 4534 region HA Ig derived front the B cells of 1918 influenza pandemic survivors; Nature 455 (7212), 532-536 (2008), NCBI Accession #ACI04579.1 (129aa) INFL398 Heavy chain variable TCN-522 US20150086555 SEQ ID NO: 33 4535 region (3212_I12) INFL399 Heavy chain variable TCN-521 US20150086555 SEQ ID NO: 21 4536 region (3280_D18) INFL400 Heavy chain variable TCN-523 US20150086555 SEQ ID NO: 45 4537 region (5248_A17) INFL401 Heavy chain variable TCN-563 US20150086555 SEQ ID NO: 57 4538 region (5237_B21) INFL402 Heavy chain variable TCN-526 US20150086555 SEQ ID NO: 69 4539 region (5084_C17) INFL403 Heavy chain variable TCN-527 US20150086555 SEQ ID NO: 81 4540 region (5086_C06) INFL404 Heavy chain variable TCN-528 US20150086555 SEQ ID NO: 93 4541 region (5087_P17) INFL405 Heavy chain variable TCN-529 US20150086555 SEQ ID NO: 105 4542 region (5297_H01) INFL406 Heavy chain variable TCN-530 US20150086555 SEQ ID NO: 117 4543 region (5248_H10) INFL407 Heavy chain variable TCN-531 US20150086555 SEQ ID NO: 129 4544 region (5091_H13) INFL408 Heavy chain variable TCN-532 US20150086555 SEQ ID NO: 141 4545 region (5262_H18) INFL409 Heavy chain variable TCN-533 US20150086555 SEQ ID NO: 153 4546 region (5256_A17a), TCN-564 (5256_A17b) INFL410 Heavy chain variable TCN-534 US20150086555 SEQ ID NO: 161 4547 region (5249_B02) INFL411 Heavy chain variable TCN-535 US20150086555 SEQ ID NO: 173 4548 region (5246_P19), TCN-558 (5248_H10b) INFL412 Heavy chain variable TCN-536 US20150086555 SEQ ID NO: 184 4549 region (5095_N01) INFL413 Heavy chain variable TCN-537 US20150086555 SEQ ID NO: 195 4550 region (3194_D21) INFL414 Heavy chain variable TCN-538 US20150086555 SEQ ID NO: 207 4551 region (3206_O17) INFL415 Heavy chain variable TCN-539 US20150086555 SEQ ID NO: 219 4552 region (5056_A08) INFL416 Heavy chain variable TCN-540 US20150086555 SEQ ID NO: 231 4553 region (5060_F05) INFL417 Heavy chain variable TCN-541 US20150086555 SEQ ID NO: 243 4554 region (5062_M11) INFL418 Heavy chain variable TCN-542 US20150086555 SEQ ID NO: 255 4555 region (5079_A16) INFL419 Heavy chain variable TCN-543 US20150086555 SEQ ID NO: 267 4556 region (5081_G23) INFL420 Heavy chain variable TCN-544 US20150086555 SEQ ID NO: 279 4557 region (5082_A19) INFL421 Heavy chain variable TCN-545 US20150086555 SEQ ID NO: 291 4558 region (5082_I15) INFL422 Heavy chain variable TCN-546 US20150086555 SEQ ID NO: 302 4559 region (5089_L08) INFL423 Heavy chain variable TCN-547 US20150086555 SEQ ID NO: 313 4560 region (5092_F11) INFL424 Heavy chain variable TCN-548 US20150086555 SEQ ID NO: 325 4561 region (5092_P01) INFL425 Heavy chain variable TCN-549 US20150086555 SEQ ID NO: 335 4562 region (5092_P04) INFL426 Heavy chain variable TCN-550 US20150086555 SEQ ID NO: 346 4563 region (5096_F06) INFL427 Heavy chain variable TCN-551 US20150086555 SEQ ID NO: 358 4564 region (5243_D01) INFL428 Heavy chain variable TCN-552 US20150086555 SEQ ID NO: 370 4565 region (5249_I23) INFL429 Heavy chain variable TCN-553 US20150086555 SEQ ID NO: 382 4566 region (5261_C18) INFL430 Heavy chain variable TCN-554 US20150086555 SEQ ID NO: 392 4567 region (5277_M05) INFL431 Heavy chain variable TCN-555 US20150086555 SEQ ID NO: 403 4568 region (5246_L16) INFL432 Heavy chain variable TCN-556 US20150086555 SEQ ID NO: 408 4569 region (5089_K12) INFL433 Heavy chain variable TCN-557 US20150086555 SEQ ID NO: 420 4570 region (5081_A04) INFL434 Heavy chain variable TCN-559 US20150086555 SEQ ID NO: 434 4571 region (5097_G08) INFL435 Heavy chain variable TCN-560 US20150086555 SEQ ID NO: 446 4572 region (5084_P10) INFL436 Heavy chain variable TCN-504 US20150086555 SEQ ID NO: 510 4573 region (3251_K17) INFL437 Heavy chain variable AB1 US20120093834, WO2009121004 SEQ 4574 region ID NO: 4 INFL438 Heavy chain variable AB2 US20120093834, WO2009121004 SEQ 4575 region ID NO: 45 INFL439 Heavy chain variable AB3 US20120093834, WO2009121004 SEQ 4576 region ID NO: 9 INFL440 Heavy chain variable AB4, AB5, AB6 US20120093834, WO2009121004 SEQ 4577 region ID NO: 61 INFL441 Heavy chain variable VN04-2 WO2008033105 SEQ ID NO: 5 4578 region INFL442 Heavy chain variable VN04-3 WO2008033105 SEQ ID NO: 7 4579 region INFL443 Heavy chain variable 1286-C05 WO2010132604, US20120128671 SEQ 4580 region ID NO: 1 INFL444 Heavy chain variable 1286-A11 WO2010132604, US20120128671 SEQ 4581 region ID NO: 2 INFL445 Heavy chain variable CR8001 WO2010130636 SEQ ID NO: 2 4582 region INFL446 Heavy chain variable CR8003 WO2010130636 SEQ ID NO: 6 4583 region INFL447 Heavy chain variable CR8015 WO2010130636 SEQ ID NO: 10 4584 region INFL448 Heavy chain variable CR8016 WO2010130636 SEQ ID NO: 14 4585 region INFL449 Heavy chain variable CR8017 WO2010130636 SEQ ID NO: 18 4586 region INFL450 Heavy chain variable CR8018 WO2010130636 SEQ ID NO: 22 4587 region INFL451 Heavy chain variable anti-1918 influenza Yu, X., et al., Neutralizing antibodies 4588 region (Partial) HA Ig derived from the B cells of 1918 influenza pandemic survivors; Nature 455 (7212), 532-536 (2008), NCBI Accession #ACI04581.1 (145aa) INFL452 Heavy chain variable 1A2 WO2015028478 SEQ ID NO: 2 4589 region mouse IgG INFL453 Heavy chain variable 7B8 WO2015028478 SEQ ID NO: 4 4590 region mouse IgG INFL454 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4591 region, partial antibody TCN-031 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23854.1 (120aa) INFL455 Heavy chain variable monoclonal Grandea, A. G. et al., Human, antibodies 4592 region, partial antibody TCN-032 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23853.1 (120aa) INFL456 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4593 region, partial antibody 3362_B11 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23869.1 (123aa) INFL457 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4594 region, partial antibody reveal a protective epitope that is highly 3260_D19 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23868.1 (118aa) INFL458 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4595 region, partial antibody 3253_P10 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23867.1 (121aa) INFL459 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4596 region, partial antibody 3248_P18 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23866.1 (120aa) INFL460 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4597 region, partial antibody 3139_P23 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23865.1 (119aa) INFL461 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4598 region, partial antibody 3420_I23 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23864.1 (121aa) INFL462 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4599 region, partial antibody 3255_J06 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23863.1 (119aa) INFL463 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4600 region, partial antibody 3252_C13 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession # ADK23862.1 (119aa) INFL464 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4601 region, partial antibody reveal a protective epitope that is highly 3136_G05 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23861.1 (120aa) INFL465 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4602 region, partial antibody reveal a protective epitope that is highly 3244_H04 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23860.1 (118aa) INFL466 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4603 region, partial antibody reveal a protective epitope that is highly 3245_O19 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23859.1 (118aa) INFL467 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4604 region, partial antibody 3259_J21 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23858.1 (120aa) INFL468 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4605 region, partial antibody 3243_J07 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23857.1 (121aa) INFL469 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4606 region, partial antibody 3244_I10 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession # ADK23856.1 (121aa) INFL470 Heavy chain variable monoclonal Grandea, A. G. et al., Human antibodies 4607 region, partial antibody reveal a protective epitope that is highly 3241_G23 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23855.1 (122aa) INFL471 Heavy chain variable Monoclonal Yasugi, M. et al., Emerging Antigenic 4608 region, partial antibody clone 5E4 Variants at the Antigenic Site Sb in Pandemic A(H1N1)2009 Influenza Virus in Japan Detected by a Human Monoclonal Antibody; PLoS ONE 8 (10), E77892 (2013), NCBI Accession #BAM76754.1 (141aa) INFL472 Heavy chain variable 100F4-HV Hu, H., et al., A Human Antibody 4609 region, partial Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses; J. Virol. 86 (6), 2978- 2989 (2012), NCBI Accession #AEL30603.1 (121aa) INFL473 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4610 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40460.1 (120aa) INFL474 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4611 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40459.1 (127aa) INFL475 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4612 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40458.1 (129aa) INFL476 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4613 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40457.1 (132aa) INFL477 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4614 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40456.1 (127aa) INFL478 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4615 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40455.1 (121aa) INFL479 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4616 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40454.1 (126aa) INFL480 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4617 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40453.1 (120aa) INFL481 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4618 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40452.1 (122aa) INFL482 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4619 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40451.1 (125aa) INFL483 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4620 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40450.1 (126aa) INFL484 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4621 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40449.1 (129aa) INFL485 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4622 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40448.1 (119aa) INFL486 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4623 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40447.1 (120aa) INFL487 Heavy chain variable anti-stem HA Pappas, L. et al., Rapid development of 4624 region, partial, Anti- immunoglobulin broadly influenza neutralizing antibodies stem HA through redundant mutations; Nature immunoglobulin (2014), NCBI Accession #AIN40446.1 (120aa) INFL488 Heavy chain, Human Fab 39.29 Nakamura, G. et al., An in vivo human- 4625 igg, plasmablast enrichment technique allows rapid identification of therapeutic influenza a antibodies; Cell Host Microbe 14 (1), 93-103 (2013), NCBI Accession #4KVN_H (227aa) INFL489 Heavy chain, Igg1 Fab H5m9 Zhu, X., et al., A Unique and Conserved 4626 Neutralization Epitope in H5N1 Influenza Viruses Identified by an Antibody against the A/Goose/Guangdong/1/96 Hemagglutinin; J. Virol. 87 (23), 12619- 12635 (2013), NCBI Accession #4MHH_H (222aa) INFL490 Immunoglobulin T2-6A Huang, K.-Y. A., et al., Focused antibody- 4627 heavy chain variable response to influenza linked to antigenic region, partial drift; J. Clin. Invest. (2015), NCBI Accession #AKF02484.1 (124aa) INFL491 Kappa light chain U.S. Pat. No. 8,992,929 SEQ ID NO. 24 4628 constant region, human INFL492 Kappa light chain 8D4 NCBI Accession #AFI57037 4629 variable INFL493 Kappa light chain 5B6 NCBI Accession #AFI57041 4630 variable INFL494 Kappa light chain 8i10 U.S. Pat. No. 8,858,948 SEQ ID NO: 56 4631 variable region INFL495 Kappa light chain 23K12 U.S. Pat. No. 8,858,948 SEQ ID NO: 91 4632 variable region INFL496 Kappa light chain 4K8 Krause, J. C. et al. “Epitope-specific 4633 variable region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16800 INFL497 Kappa light chain 6D9 Krause, J. C. et al. “Epitope-specific 4634 variable region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16802 INFL498 Kappa light chain 8G9 U.S. Pat. No. 8,603,467 SEQ ID NO: 4 4635 variable region INFL499 Kappa light chain 13D4 U.S. Pat. No. 8,603,467 SEQ ID NO: 8 4636 variable region INFL500 Kappa light chain 20A11 U.S. Pat. No. 8,603,467 SEQ ID NO: 12 4637 variable region INFL501 Kappa light chain EM4C04 US20120282273 SEQ ID NO: 1 4638 variable region INFL502 Kappa, light chain Fab H5m9 Zhu, X., et al., A Unique and Conserved 4639 Neutralization Epitope in H5N1 Influenza Viruses Identified by an Antibody against the A/Goose/Guangdong/1/96 Hemagglutinin; J. Virol. 87 (23), 12619- 12635 (2013), NCBI Accession # 4MHH_L(218aa) INFL503 Lambda light chain 7A13 Krause et al. “Human Monoclonal 4640 Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses” J. Virol. 86 (11), 6334-6340 (2012), NCBI Accession #AFH78448 INFL504 Lambda light chain 2K11 Krause, J. C. et al. “Epitope-specific 4641 variable human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16794 INFL505 Lambda light chain 2O10 Krause, J. C. et al. “Epitope-specific 4642 variable human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16796 INFL506 Lambda light chain Monoclonal Yasugi, M. et al., Emerging Antigenic 4643 variable region, antibody clone 5E4 Variants at the Antigenic Site Sb in partial Pandemic A(H1N1)2009 Influenza Virus in Japan Detected by a Human Monoclonal Antibody; PLoS ONE 8 (10), E77892 (2013), NCBI Accession #BAM76755.1 (126aa) INFL507 Lambda light chain T2-6A Huang, K.-Y. A., et al., Focused antibody 4644 variable region, response to influenza linked to antigenic partial, drift; J. Clin. Invest. (2015), NCBI Immunoglobulin Accession #AKF02488.1 (113aa) INFL508 Light chain CR6261, WO2008028946 4645 Diridavumab, CR- 6261 INFL509 Light chain Firivumab, CT-P22 US20130004505 4646 INFL510 Light chain Navivumab, WO2013048153, US20140234336 SEQ 4647 CT149 ID NO: 39 INFL511 Light chain AT10-004 US20150010566, WO2013081463 SEQ 4648 ID NO: 36 INFL512 Light chain AT10-003 US20150010566, WO2013081463 SEQ 4649 ID NO: 37 INFL513 Light chain AT10-002 US20150010566, WO2013081463 SEQ 4650 ID NO: 38 INFL514 Light chain AT10-001 US20150010566, WO2013081463 SEQ 4651 ID NO: 39 INFL515 Light chain AT10-005 US20150010566, WO2013081463 SEQ 4652 ID NO: 40 INFL516 Light chain CT104 WO2011111966, US20130004505 SEQ 4653 ID NO: 36 INFL517 Light chain CT120 WO2011111966, US20130004505 SEQ 4654 ID NO: 40 INFL518 Light chain CT123 WO2011111966, US20130004505 SEQ 4655 ID NO: 44 INFL519 Light chain 2A US20140011982 SEQ ID NO: 4 4656 INFL520 Light chain F005-126 WO2014049520, US20140086927 SEQ 4657 ID NO: 13 INFL521 Light chain BF1-1 WO2008156763 SEQ ID NO: 8 4658 INFL522 Light chain BF1-19 WO2008156763 SEQ ID NO: 12 4659 INFL523 Light chain BF1-10 WO2008156763 SEQ ID NO: 10 4660 INFL524 Light chain 2D1 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4661 NO: 8 INFL525 Light chain 1F1 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4662 NO: 2 INFL526 Light chain 4D20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 4663 NO: 10 INFL527 Light chain A18 WO13170139 SEQ ID NO: 95 4664 INFL528 Light chain Ab A18 U.S. Pat. No. 7,788,200 SEQ ID NO: 28 4665 INFL529 Light chain Ab 067 U.S. Pat. No. 7,788,200 SEQ ID NO: 153 4666 INFL530 Light chain Ab 068 U.S. Pat. No. 7,788,200 SEQ ID NO: 154 4667 INFL531 Light chain Ab 069, Ab 079 U.S. Pat. No. 7,788,200 SEQ ID NO: 155 4668 INFL532 Light chain Ab 070 U.S. Pat. No. 7,788,200 SEQ ID NO: 156 4669 INFL533 Light chain Ab 073 U.S. Pat. No. 7,788,200 SEQ ID NO: 165 4670 INFL534 Light chain Ab 074, Ab 080 U.S. Pat. No. 7,788,200 SEQ ID NO: 166 4671 INFL535 Light chain Ab 075 U.S. Pat. No. 7,788,200 SEQ ID NO: 167 4672 INFL536 Light chain Ab 076 U.S. Pat. No. 7,788,200 SEQ ID NO: 168 4673 INFL537 Light chain Ab 077, Ab 081 U.S. Pat. No. 7,788,200 SEQ ID NO: 169 4674 INFL538 Light chain Ab 014, Ab 154, U.S. Pat. No. 7,788,200 SEQ ID NO: 29 4675 Ab 157 INFL539 Light chain Ab 028, Ab 155 U.S. Pat. No. 7,788,200 SEQ ID NO: 30 4676 INFL540 Light chain Ab 001, Ab 002, U.S. Pat. No. 7,788,200 SEQ ID NO: 31 4677 Ab 003 INFL541 Light chain Ab 009, Ab 010, U.S. Pat. No. 7,788,200 SEQ ID NO: 32 4678 Ab 011 INFL542 Light chain Ab 017, Ab B18, U.S. Pat. No. 7,788,200 SEQ ID NO: 33 4679 Ab B18, Ab 019, Ab 019 INFL543 Light chain Ab 025, Ab 026, U.S. Pat. No. 7,788,200 SEQ ID NO: 34 4680 Ab 027, Ab 028 INFL544 Light chain Ab 159 U.S. Pat. No. 7,788,200 SEQ ID NO: 35 4681 INFL545 Light chain Ab 160 U.S. Pat. No. 7,788,200 SEQ ID NO: 36 4682 INFL546 Light chain Ab 186, Ab 194 U.S. Pat. No. 7,788,200 SEQ ID NO: 37 4683 INFL547 Light chain Ab 187, Ab 195 U.S. Pat. No. 7,788,200 SEQ ID NO: 38 4684 INFL548 Light chain Ab 188, Ab 196 U.S. Pat. No. 7,788,200 SEQ ID NO: 39 4685 INFL549 Light chain Ab 189, Ab 197 U.S. Pat. No. 7,788,200 SEQ ID NO: 40 4686 INFL550 Light chain Ab 190, Ab 198 U.S. Pat. No. 7,788,200 SEQ ID NO: 41 4687 INFL551 Light chain Ab 191, Ab 199 U.S. Pat. No. 7,788,200 SEQ ID NO: 42 4688 INFL552 Light chain Ab 192, Ab 200 U.S. Pat. No. 7,788,200 SEQ ID NO: 43 4689 INFL553 Light chain Ab 193 U.S. Pat. No. 7,788,200 SEQ ID NO: 44 4690 INFL554 Light chain Ab 202, Ab 203, U.S. Pat. No. 7,788,200 SEQ ID NO: 45 4691 Ab 204, Ab 210, Ab 031, Ab 032, Ab 033, Ab 034 INFL555 Light chain Ab 211, Ab 212, U.S. Pat. No. 7,788,200 SEQ ID NO: 46 4692 Ab 213, Ab 219, Ab 037, Ab 038, Ab 039, Ab 040 INFL556 Light chain Ab A001, Ab 004, U.S. Pat. No. 7,788,200 SEQ ID NO: 47 4693 Ab 007, Ab 016 INFL557 Light chain Ab A002, Ab 005, U.S. Pat. No. 7,788,200 SEQ ID NO: 48 4694 Ab 008, Ab A017 INFL558 Light chain Ab A003, Ab 006, U.S. Pat. No. 7,788,200 SEQ ID NO: 49 4695 Ab A009, Ab C18 INFL559 Light chain Ab A010, Ab 012, U.S. Pat. No. 7,788,200 SEQ ID NO: 50 4696 Ab A14, Ab A019 INFL560 Light chain Ab A011, Ab U.S. Pat. No. 7,788,200 SEQ ID NO: 51 4697 013m Ab 0135 INFL561 Light chain Ab 044, Ab 071, U.S. Pat. No. 7,788,200 SEQ ID NO: 52 4698 Ab 072, Ab 078 INFL562 Light chain Ab 051 U.S. Pat. No. 7,788,200 SEQ ID NO: 53 4699 INFL563 Light chain Ab 049 U.S. Pat. No. 7,788,200 SEQ ID NO: 54 4700 INFL564 Light chain Ab 047 U.S. Pat. No. 7,788,200 SEQ ID NO: 55 4701 INFL565 Light chain Ab 050 U.S. Pat. No. 7,788,200 SEQ ID NO: 56 4702 INFL566 Light chain Ab 045 U.S. Pat. No. 7,788,200 SEQ ID NO: 57 4703 INFL567 Light chain Ab 048 U.S. Pat. No. 7,788,200 SEQ ID NO: 58 4704 INFL568 Light chain Ab 046 U.S. Pat. No. 7,788,200 SEQ ID NO: 59 4705 INFL569 Light chain Ab 043 U.S. Pat. No. 7,788,200 SEQ ID NO: 60 4706 INFL570 Light chain Ab 052 U.S. Pat. No. 7,788,200 SEQ ID NO: 61 4707 INFL571 Light chain F005-126 WO2014049520 SEQ ID 13 4708 INFL572 Light chain 8f24 WO2012045001 SEQ ID 3 4709 INFL573 Light chain 3E22 WO2012045001 SEQ ID 7 4710 INFL574 Light chain 5117 WO2012045001 SEQ ID 11 4711 INFL575 Light chain WO2012045001 SEQ ID 15 4712 INFL576 Light chain WO2012045001 SEQ ID 31 4713 INFL577 Light chain WO2012045001 SEQ ID 35 4714 INFL578 Light chain WO2012045001 SEQ ID 19 4715 INFL579 Light chain 10A14 WO2012045001 SEQ ID 23 4716 INFL580 Light chain 8D4 WO2012045001 SEQ ID 27 4717 INFL581 Light chain 2B9 U.S. Pat. No. 9,115,201 SEQ ID NO: 5 4718 INFL582 Light chain mAB 7A7 US20150239960, US20140170163, 4719 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 7 INFL583 Light chain mAB 12D1 US20150239960, US20140170163, 4720 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 13 INFL584 Light chain mAB 66A6 US20150239960, US20140170163, 4721 U.S. Pat. No. 8,673,314, US20110027270, WO2010138564 SEQ ID NO: 17 INFL585 Light chain M1 D12 US20110033473, WO2009125395 SEQ 4722 ID NO: 15 INFL586 Light chain mAB1.12 WO2013030165 SEQ ID NO: 2 4723 INFL587 Light chain mAB3.1 WO2013030165 SEQ ID NO: 4 4724 INFL588 Light chain 5A7 WO2015120097 SEQ ID NO: 8 4725 INFL589 Light chain TRL053 WO2015120097 SEQ ID NO: 18 4726 INFL590 Light chain TRL579 WO2015120097 SEQ ID NO: 28 4727 INFL591 Light chain TRL784 WO2015120097 SEQ ID NO: 38 4728 INFL592 Light chain TRL794 WO2015120097 SEQ ID NO: 48 4729 INFL593 Light chain TRL798 WO2015120097 SEQ ID NO: 58 4730 INFL594 Light chain TRL799 WO2015120097 SEQ ID NO: 68 4731 INFL595 Light chain TRL809 WO2015120097 SEQ ID NO: 78 4732 INFL596 Light chain TRL811 WO2015120097 SEQ ID NO: 88 4733 INFL597 Light chain TRL812 WO2015120097 SEQ ID NO: 98 4734 INFL598 Light chain TRL813 WO2015120097 SEQ ID NO: 108 4735 INFL599 Light chain TRL823 WO2015120097 SEQ ID NO: 118 4736 INFL600 Light chain TRL832 WO2015120097 SEQ ID NO: 128 4737 INFL601 Light chain TRL833 WO2015120097 SEQ ID NO: 138 4738 INFL602 Light chain TRL834 WO2015120097 SEQ ID NO: 148 4739 INFL603 Light chain TRL837 WO2015120097 SEQ ID NO: 167 4740 INFL604 Light chain TRL839 WO2015120097 SEQ ID NO: 177 4741 INFL605 Light chain TRL841 WO2015120097 SEQ ID NO: 187 4742 INFL606 Light chain TRL842 WO2015120097 SEQ ID NO: 197 4743 INFL607 Light chain TRL845 WO2015120097 SEQ ID NO: 207 4744 INFL608 Light chain TRL846 WO2015120097 SEQ ID NO: 218 4745 INFL609 Light chain TRL847 WO2015120097 SEQ ID NO: 228 4746 INFL610 Light chain TRL848 WO2015120097 SEQ ID NO: 238 4747 INFL611 Light chain TRL849 WO2015120097 SEQ ID NO: 248 4748 INFL612 Light chain TRL851 WO2015120097 SEQ ID NO: 258 4749 INFL613 Light chain TRL854 WO2015120097 SEQ ID NO: 268 4750 INFL614 Light chain TRL856 WO2015120097 SEQ ID NO: 278 4751 INFL615 Light chain TRL858 WO2015120097 SEQ ID NO: 288 4752 INFL616 Light chain humM2e-hBiTE-1 WO2014140368 SEQ ID NO: 10 4753 INFL617 Light chain humM2e-hBiTE-2 WO2014140368 SEQ ID NO: 18 4754 INFL618 Light chain humM2e-hBiTE-3 WO2014140368 SEQ ID NO: 26 4755 INFL619 Light chain humM2e-hBiTE-4 WO2014140368 SEQ ID NO: 34 4756 INFL620 Light chain VH of humM2e- WO2014140368 SEQ ID NO: 42 4757 hBiTE-5 INFL621 Light chain humM2e-hBiTE-6 WO2014140368 SEQ ID NO: 50 4758 INFL622 Light chain humM2e-hBiTE-7 WO2014140368 SEQ ID NO: 58 4759 INFL623 Light chain humM2e-hBiTE-8 WO2014140368 SEQ ID NO: 66 4760 INFL624 Light chain humM2e-hBiTE-9 WO2014140368 SEQ ID NO: 74 4761 INFL625 Light chain murM2e-hBiTE WO2014140368 SEQ ID NO: 82 4762 INFL626 Light chain FLA5.10 U.S. Pat. No. 8,124,092 SEQ ID NO: 3 4763 INFL627 Light chain FLD21.140 U.S. Pat. No. 8,124,092 SEQ ID NO: 7 4764 INFL628 Light chain FLA3.14 U.S. Pat. No. 8,124,092 SEQ ID NO: 11 4765 INFL629 Light chain FLD20.19 U.S. Pat. No. 8,124,092 SEQ ID NO: 15 4766 INFL630 Light chain FLD84 U.S. Pat. No. 8,124,092 SEQ ID NO: 44 4767 INFL631 Light chain FLD93 U.S. Pat. No. 8,124,092 SEQ ID NO: 54 4768 INFL632 Light chain FLD122 U.S. Pat. No. 8,124,092 SEQ ID NO: 64 4769 INFL633 Light chain FLD127 U.S. Pat. No. 8,124,092 SEQ ID NO: 74 4770 INFL634 Light chain FLD129 U.S. Pat. No. 8,124,092 SEQ ID NO: 84 4771 INFL635 Light chain FLD132 U.S. Pat. No. 8,124,092 SEQ ID NO: 94 4772 INFL636 Light chain FLD194 U.S. Pat. No. 8,124,092 SEQ ID NO: 104 4773 INFL637 Light chain mAb1 WO2015112994 SEQ ID NO: 77 4774 INFL638 Light chain mAb2 WO2015112994 SEQ ID NO: 81 4775 INFL639 Light chain mAb3 WO2015112994 SEQ ID NO: 85 4776 INFL640 Light chain CT-P22 US20130004505 SEQ ID NO: 40; 4777 WO2011/111966 INFL641 Light chain C05 Ekiert, D. C., et al., Cross-neutralization 4778 of influenza A viruses mediated by a single antibody loop; Nature 489 (7417), 526-532 (2012), NCBI Accession #4FNL_L (214aa) INFL642 Light chain CR8020 Ekiert, D. C., et al., A highly conserved 4779 neutralizing epitope on group 2 influenza A viruses; Science 333 (6044), 843-850 (2011); WO2010130636, NCBI Accession #3SDY_L INFL643 Light chain CR8033 Dreyfus, C., Laursen, N. S. et al., Highly 4780 conserved protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession # 4FQL_L INFL644 Light chain CR8043 Friesen, R. H. et al., A common solution 4781 to group 2 influenza virus neutralization; Proc. Natl. Acad. Sci. U.S.A. 111 (1), 445-450 (2014), NCBI Accession #4NM8_L INFL645 Light chain CR8059 Dreyfus, C. et al., Highly conserved 4782 protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQK_L INFL646 Light chain CR8071 Dreyfus, C. et al., Highly conserved 4783 protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession # 4FQJ_L (216aa) INFL647 Light chain CR9114 WO2013079473; WO2014191435; 4784 Dreyfus, C., Laursen, N. S. et al., Highly conserved protective epitopes on influenza B viruses; Science 337 (6100), 1343-1348 (2012), NCBI Accession #4FQY_L(216aa) INFL648 Light chain Ch67 Schmidt, A. G., et al., Preconfiguration of 4785 the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody; Proc. Natl. Acad. Sci. U.S.A. 110 (1), 264-269 (2013), NCBI Accession #4HKX_B (214aa) INFL649 Light chain Fab 26/9 Schulze-Gahmen, U. et al., J. Biol. 4786 Chem. 263 (32), 17100-17105 (1988); Churchill, M. E., et al., J. Mol. Biol. 241 (4), 534-556 (1994), NCBI Accession #LFRG_L INFL650 Light chain Fab 3.1 Wyrzucki, A. et al., Alternative 4787 Recognition of the Conserved Stem Epitope in Influenza A Virus Hemagglutinin by a VH3-30-Encoded Heterosubtypic Antibody; J. Virol. 88 (12), 7083-7092 (2014), NCBI Accession #4PY8_J INFL651 Light chain Fab 2g1 Xu, R. et al., A recurring motif for 4788 antibody recognition of the receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013), NCBI Accession #4HG4_M (214aa) INFL652 Light chain Fab 8m2 Xu, R. et al., A recurring motif for 4789 antibody recognition of the receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013), NCBI Accession #4HFU_L (215aa) INFL653 Light chain Fab 8f8 Xu, R. et al., A recurring motif for 4790 antibody recognition of the receptor- binding site of influenza hemagglutinin; Nat. Struct. Mol. Biol. 20 (3), 363-370 (2013), NCBI Accession # 4HF5_L (218aa) INFL654 Light chain Fab 2d1 Xu, R., et al., Structural basis of 4791 preexisting immunity to the 2009 H1N1 pandemic influenza virus; Science 328 (5976), 357-360 (2010), NCBI Accession #3LZF_L (217aa) INFL655 Light chain Fi6v3 Corti, D. et al., A neutralizing antibody 4792 selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins; Science 333 (6044), 850-856 (2011), NCBI Accession #3ZTN_L INFL656 Light chain Light chain from Iba, Y., et al., Conserved Neutralizing 4793 3WHE_N Epitope at Globular Head of Hemagglutinin in H3N2 Influenza Viruses; J. Virol. (2014), NCBI Accession #3WHE_N (220aa) INFL657 Light chain monoclonal Burioni, R. et al., Monoclonal antibodies 4794 (partial) antibody PN- isolated from human B cells neutralize a SIA28 broad range of H1 subtype influenza A viruses including swine-origin Influenza virus(S-OIV); Virology (2010), NCBI Accession #ACX30939.1 (105aa) INFL658 Light chain monoclonal Burioni, R. et al., Monoclonal antibodies 4795 (partial) antibody PN- isolated from human B cells neutralize a SIA49 broad range of H1 subtype influenza A viruses including swine-origin Influenza virus(S-OIV); Virology (2010), NCBI Accession #ACX30938.1 (105aa) INFL659 Light chain; Fab 5j8 Hong, M. et al., Antibody Recognition of 4796 the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site; J. Virol. 87 (22), 12471-12480 (2013), NCBI Accession #4M5Z_L INFL660 Light chain CDR 1 Ab1A2 WO2015028478 SEQ ID 9 4797 INFL661 Light chain CDR 2 Ab1A2 WO2015028478 SEQ ID 10 4798 INFL662 Light chain CDR 3 Ab1A2 WO2015028478 SEQ ID 11 4799 INFL663 Light chain Fab CT147 WO2013048153, US20140234336 SEQ 4800 ID NO: 37 INFL664 Light chain Fab CT164 WO2013048153, US20140234336 SEQ 4801 ID NO: 41 INFL665 Light chain Fab CT166 WO2013048153, US20140234336 SEQ 4802 ID NO: 43 INFL666 Light chain Human Fab 39.29 Nakamura, G. et al., An in vivo human- 4803 igg plasmablast enrichment technique allows rapid identification of therapeutic influenza a antibodies; Cell Host Microbe 14 (1), 93-103 (2013), NCBI Accession #4KVN_L (215aa) INFL667 Light chain K3 h2B11 U.S. Pat. No. 9,115,201 SEQ ID NO: 9 4804 INFL668 Light chain K3 h2B12 U.S. Pat. No. 9,115,201 SEQ ID NO: 10 4805 INFL669 Light chain partial 4A10 Krause, J. C. et al. “Epitope-specific 4806 region human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence” J. Immunol. 187 (7), 3704-3711 (2011), NCBI Accession #AEO16798 INFL670 Light chain variable LC-VD from US2013030234 SEQ ID NO: 33 4807 (exemplary) US2013030234 INFL671 Light chain variable LC-VD from US2013030234 SEQ ID NO: 34 4808 (exemplary) US2013030234 INFL672 Light chain variable LC-VD from US2013030234 SEQ ID NO: 35 4809 (exemplary) US2013030234 INFL673 Light chain variable LC-VD from US2013030234 SEQ ID NO: 36 4810 (exemplary) US2013030234 INFL674 Light chain variable LC-VD from US2013030234 SEQ ID NO: 37 4811 (exemplary) US2013030234 INFL675 Light chain variable LC-VD from US2013030234 SEQ ID NO: 38 4812 (exemplary) US2013030234 INFL676 Light chain variable LC-VD from US2013030234 SEQ ID NO: 39 4813 (exemplary) US2013030234 INFL677 Light chain variable LC-VD from US2013030234 SEQ ID NO: 40 4814 (exemplary) US2013030234 INFL678 Light chain variable LC-VD from US2013030234 SEQ ID NO: 41 4815 (exemplary) US2013030234 INFL679 Light chain variable LC-VD from US2013030234 SEQ ID NO: 42 4816 (exemplary) US2013030234 INFL680 Light chain variable LC-VD from US2013030234 SEQ ID NO: 43 4817 (exemplary) US2013030234 INFL681 Light chain variable 39.18 B11 US20140161822 SEQ ID NO: 156 4818 region INFL682 Light chain variable GG3 WO2014159960 SEQ ID NO: 25 4819 region INFL683 Light chain variable N547 U.S. Pat. No. 8,003,106 SEQ ID NO: 29 4820 region INFL684 Light chain variable L66 U.S. Pat. No. 8,003,106 SEQ ID NO: 31 4821 region INFL685 Light chain variable C40 U.S. Pat. No. 8,003,106 SEQ ID NO: 27 4822 region INFL686 Light chain variable 14C2 U.S. Pat. No. 8,080,244 SEQ ID NO: 7 4823 region INFL687 Light chain variable h14C2 U.S. Pat. No. 8,080,244 SEQ ID NO: 1 4824 region INFL688 Light chain variable VN04-2-HuG1 US20100150941 SEQ ID NO: 6 4825 region INFL689 Light chain variable VN04-3-HuG1 US20100150941 SEQ ID NO: 8 4826 region INFL690 Light chain variable FI6 variant 1, FI6 U.S. Pat. No. 8,871,207 SEQ ID NO: 14 4827 region variant 2 INFL691 Light chain variable FI6 variant 3, FI6 U.S. Pat. No. 8,871,207 SEQ ID NO: 57 4828 region variant 4 INFL692 Light chain variable FI6 variant 5 U.S. Pat. No. 8,871,207 SEQ ID NO: 61 4829 region INFL693 Light chain variable FI28 vanant 1, U.S. Pat. No. 8,871,207 SEQ ID NO: 30 4830 region FI28 variant 2 INFL694 Light chain variable 21B15 U.S. Pat. No. 8,858,948 SEQ ID NO: 46 4831 region INFL695 Light chain variable 3241_G23 U.S. Pat. No. 8,858,948 SEQ ID NO: 118 4832 region INFL696 Light chain variable 3244_I10 U.S. Pat. No. 8,858,948 SEQ ID NO: 122 4833 region INFL697 Light chain variable 3243_J07 U.S. Pat. No. 8,858,948 SEQ ID NO: 126 4834 region INFL698 Light chain variable 3259_J21 U.S. Pat. No. 8,858,948 SEQ ID NO: 130 4835 region INFL699 Light chain variable 3245_O19 U.S. Pat. No. 8,858,948 SEQ ID NO: 134 4836 region INFL700 Light chain variable 3244_H04 U.S. Pat. No. 8,858,948 SEQ ID NO: 138 4837 region INFL701 Light chain variable 3136_G05 U.S. Pat. No. 8,858,948 SEQ ID NO: 142 4838 region INFL702 Light chain variable 3252_C13 U.S. Pat. No. 8,858,948 SEQ ID NO: 146 4839 region INFL703 Light chain variable 3255_J06 U.S. Pat. No. 8,858,948 SEQ ID NO: 150 4840 region INFL704 Light chain variable 3420_I23 U.S. Pat. No. 8,858,948 SEQ ID NO: 154 4841 region INFL705 Light chain variable 3248_P18 U.S. Pat. No. 8,858,948 SEQ ID NO: 160 4842 region INFL706 Light chain variable 3253_P10 U.S. Pat. No. 8,858,948 SEQ ID NO: 164 4843 region INFL707 Light chain variable 3260_D19 U.S. Pat. No. 8,858,948 SEQ ID NO: 168 4844 region INFL708 Light chain variable 3362_B11 U.S. Pat. No. 8,858,948 SEQ ID NO: 174 4845 region INFL709 Light chain variable 3242_P05 U.S. Pat. No. 8,858,948 SEQ ID NO: 178 4846 region INFL710 Light chain variable A66 WO2009079259, US20110038935, 4847 region US20140011982 SEQ ID NO: 34 INFL711 Light chain variable D7, H98 WO2009079259, US20110038935, 4848 region US20140011982 SEQ ID NO: 8 INFL712 Light chain variable D8 WO2009079259, US20110038935, 4849 region US20140011982 SEQ ID NO: 14 INFL713 Light chain variable D80 WO2009079259, US20110038935, 4850 region US20140011982 SEQ ID NO: 16 INFL714 Light chain variable E88 WO2009079259, US20110038935, 4851 region US20140011982 SEQ ID NO: 38 INFL715 Light chain variable E90 WO2009079259, US20110038935, 4852 region US20140011982 SEQ ID NO: 22 INFL716 Light chain variable F10 WO2009079259, US20110038935, 4853 region US20140011982 SEQ ID NO: 20 INFL717 Light chain variable G17 WO2009079259, US20110038935, 4854 region US20140011982 SEQ ID NO: 26 INFL718 Light chain variable H40 WO2009079259, US20110038935, 4855 region US20140011982 SEQ ID NO: 30 INFL719 Light chain variable H98 WO2009079259, US20110038935, 4856 region US20140011982 SEQ ID NO: 10 INFL720 Light chain variable CH65 WO2013020074, US20140302043 SEQ 4857 region ID NO: 10 INFL721 Light chain variable CH66 WO2013020074, US20140302043 SEQ 4858 region ID NO: 11 INFL722 Light chain variable CH67 WO2013020074, US20140302043 SEQ 4859 region ID NO: 12 INFL723 Light chain variable CL86OUCA WO2013020074, US20140302043 SEQ 4860 region ID NO: 9 INFL724 Light chain variable Antibody 1 WO2015051010 SEQ ID NO: 7 4861 region INFL725 Light chain variable Antibody 2 WO2015051010 SEQ ID NO: 17 4862 region INFL726 Light chain variable Antibody 3 WO2015051010 SEQ ID NO: 27 4863 region INFL727 Light chain variable Antibody 4 WO2015051010 SEQ ID NO: 37 4864 region INFL728 Light chain variable Antibody 5 WO2015051010 SEQ ID NO: 47 4865 region INFL729 Light chain variable Antibody 6 WO2015051010 SEQ ID NO: 57 4866 region INFL730 Light chain variable Antibody 7 WO2015051010 SEQ ID NO: 67 4867 region INFL731 Light chain variable Antibody 8 WO2015051010 SEQ ID NO: 77 4868 region INFL732 Light chain variable Antibody 9 WO2015051010 SEQ ID NO: 87 4869 region INFL733 Light chain variable Antibody 10 WO2015051010 SEQ ID NO: 97 4870 region INFL734 Light chain variable Antibody 11 WO2015051010 SEQ ID NO: 107 4871 region INFL735 Light chain variable Antibody 12 WO2015051010 SEQ ID NO: 117 4872 region INFL736 Light chain variable Antibody 13 WO2015051010 SEQ ID NO: 127 4873 region INFL737 Light chain variable Antibody 14 WO2015051010 SEQ ID NO: 137 4874 region INFL738 Light chain variable Antibody 15 WO2015051010 SEQ ID NO: 147 4875 region INFL739 Light chain variable Antibody 3-GL WO2015051010 SEQ ID NO: 157 4876 region INFL740 Light chain variable 005-2G02 WO2013059524, US20140348851 SEQ 4877 region ID NO: 11 INFL741 Light chain variable 005-2G02 WO2013059524, US20140348851 SEQ 4878 region ID NO: 19 INFL742 Light chain variable 09-2A06 WO2013059524, US20140348851 SEQ 4879 region ID NO: 31 INFL743 Light chain variable 09-2A06 WO2013059524, US20140348851 SEQ 4880 region ID NO: 39 INFL744 Light chain variable 09-3A01 WO2013059524, US20140348851 SEQ 4881 region ID NO: 51 INFL745 Light chain variable 09-3A01 WO2013059524, US20140348851 SEQ 4882 region ID NO: 59 INFL746 Light chain variable 70-IF02 WO2012096994, US20140046039 SEQ 4883 region ID NO: 21 INFL747 Light chain variable US20120058124 SEQ ID NO: 15 4884 region INFL748 Light chain variable US20120058124 SEQ ID NO: 16 4885 region INFL749 Light chain variable US20120058124 SEQ ID NO: 17 4886 region INFL750 Light chain variable US20120058124 SEQ ID NO: 18 4887 region INFL751 Light chain variable US20120058124 SEQ ID NO: 19 4888 region INFL752 Light chain variable US20120058124 SEQ ID NO: 20 4889 region INFL753 Light chain variable US20120058124 SEQ ID NO: 21 4890 region INFL754 Light chain variable US20120058124 SEQ ID NO: 22 4891 region INFL755 Light chain variable US20120058124 SEQ ID NO: 23 4892 region INFL756 Light chain variable US20120058124 SEQ ID NO: 24 4893 region INFL757 Light chain variable US20120058124 SEQ ID NO: 25 4894 region INFL758 Light chain variable US20120058124 SEQ ID NO: 26 4895 region INFL759 Light chain variable US20120058124 SEQ ID NO: 70 4896 region INFL760 Light chain variable 81.39 US20140161822, US20140248286, 4897 region WO2014078268 SEQ ID NO: 113 INFL761 Light chain variable 81.39 US20140161822, US20140248286, 4898 region WO2014078268 SEQ ID NO: 117 INFL762 Light chain variable 81.39 US20140161822, US20140248286, 4899 region WO2014078268 SEQ ID NO: 119 INFL763 Light chain variable 81.39 US20140161822, US20140248286, 4900 region WO2014078268 SEQ ID NO: 122 INFL764 Light chain variable 81.39 US20140161822, US20140248286, 4901 region WO2014078268 SEQ ID NO: 124 INFL765 Light chain variable 81.39 US20140161822, US20140248286, 4902 region WO2014078268 SEQ ID NO: 126 INFL766 Light chain variable 81.39 US20140161822, US20140248286, 4903 region WO2014078268 SEQ ID NO: 128 INFL767 Light chain variable 81.39 US20140161822, US20140248286, 4904 region WO2014078268 SEQ ID NO: 130 INFL768 Light chain variable 81.39 US20140161822, US20140248286, 4905 region WO2014078268 SEQ ID NO: 132 INFL769 Light chain variable 39.29 US20140161822, US20140248286, 4906 region WO2014078268 SEQ ID NO: 136 INFL770 Light chain variable 39.29 US20140161822, US20140248286, 4907 region WO2014078268 SEQ ID NO: 140 INFL771 Light chain variable 39.29 US20140161822, US20140248286, 4908 region WO2014078268 SEQ ID NO: 144 INFL772 Light chain variable 39.29 US20140161822, US20140248286, 4909 region WO2014078268 SEQ ID NO: 146 INFL773 Light chain variable 39.29 US20140161822, US20140248286, 4910 region WO2014078268 SEQ ID NO: 150 INFL774 Light chain variable 39.29 US20140161822, US20140248286, 4911 region WO2014078268 SEQ ID NO: 152 INFL775 Light chain variable 36.89 US20140161822, US20140248286, 4912 region WO2014078268 SEQ ID NO: 162 INFL776 Light chain variable 9.01F3 US20140161822, US20140248286, 4913 region WO2014078268 SEQ ID NO: 166 INFL777 Light chain variable 23.06C2 US20140161822, US20140248286, 4914 region WO2014078268 SEQ ID NO: 170 INFL778 Light chain variable 39.29 US20140161822, US20140248286, 4915 region WO2014078268 SEQ ID NO: 235 INFL779 Light chain variable F16 Variant 3 WO2013011347, US20140271655, 4916 region U.S. Pat. No. 8,871,207 SEQ ID NO: 57 INFL780 Light chain variable F16 Variant 5 WO2013011347, US20140271655, 4917 region U.S. Pat. No. 8,871,207 SEQ ID NO: 61 INFL781 Light chain variable FC41 WO2010010467 SEQ ID NO 61 4918 region INFL782 Light chain variable FE43 WO2010010467 SEQ ID NO 75 4919 region INFL783 Light chain variable FB75, FB110, WO2010010467 SEQ ID NO 122 4920 region FB177 INFL784 Light chain variable FB17 WO2010010467 SEQ ID NO 106 4921 region INFL785 Light chain variable FC6 WO2010010467 SEQ ID NO 46 4922 region INFL786 Light chain variable FE53 WO2010010467 SEQ ID NO 90 4923 region INFL787 Light chain variable 7A7 WO2010138564 SEQ ID NO: 7 4924 region INFL788 Light chain variable 12DI WO2010138564 SEQ ID NO: 13 4925 region INFL789 Light chain variable 66A6 WO2010138564 SEQ ID NO: 17 4926 region INFL790 Light chain variable B-1 U.S. Pat. No. 8,975,378, US20110319600, 4927 region WO2010073647 SEQ ID NO: 28 INFL791 Light chain variable D1 U.S. Pat. No. 8,975,378, US20110319600, 4928 region WO2010073647 SEQ ID NO: 30 INFL792 Light chain variable E-2 U.S. Pat. No. 8,975,378, US20110319600, 4929 region WO2010073647 SEQ ID NO: 32 INFL793 Light chain variable B-3 U.S. Pat. No. 8,975,378, US20110319600, 4930 region WO2010073647 SEQ ID NO: 34 INFL794 Light chain variable 5A7 WO2013114885, US20140377262 SEQ 4931 region ID NO: 35 INFL795 Light chain variable 3A2 WO2013114885, US20140377262 SEQ 4932 region ID NO: 39 INFL796 Light chain variable 10C4 WO2013114885, US20140377262 SEQ 4933 region ID NO: 43 INFL797 Light chain variable Fab49 WO2009144667, US20110076265 SEQ 4934 region ID NO: 2 INFL798 Light chain variable Fab28, IgG PN- WO2009115972, WO2011117848, 4935 region SIA28 US20110014187 SEQ ID NO: 2 INFL799 Light chain variable TCN-522 US20120207760, U.S. Pat. No. 8,916,160 SEQ ID 4936 region NO: 778; U.S. Pat. No. 8,900,590 SEQ ID NO: 33 INFL800 Light chain variable CR8018 WO2010130636 SEQ ID NO: 24 4937 region INFL801 Light chain variable CR8019 WO2010130636 SEQ ID NO: 28 4938 region INFL802 Light chain variable CR8020 WO2010130636 SEQ ID NO: 32 4939 region INFL803 Light chain variable CR8021 WO2010130636 SEQ ID NO: 36 4940 region INFL804 Light chain variable CR8038 WO2010130636 SEQ ID NO: 40 4941 region INFL805 Light chain variable CR8039 WO2010130636 SEQ ID NO: 44 4942 region INFL806 Light chain variable CR8040 WO2010130636 SEQ ID NO: 48 4943 region INFL807 Light chain variable CR8041 WO2010130636 SEQ ID NO: 52 4944 region INFL808 Light chain variable CR8043 WO2010130636 SEQ ID NO: 56 4945 region INFL809 Light chain variable CR8049 WO2010130636 SEQ ID NO: 59 4946 region INFL810 Light chain variable CR8050 WO2010130636 SEQ ID NO: 63 4947 region INFL811 Light chain variable CR8052 WO2010130636 SEQ ID NO: 67 4948 region INFL812 Light chain variable CR8055 WO2010130636 SEQ ID NO: 71 4949 region INFL813 Light chain variable CR8057 WO2010130636 SEQ ID NO: 75 4950 region INFL814 Light chain variable CR8069 WO2010130636 SEQ ID NO: 79 4951 region INFL815 Light chain variable CR6255 US20090311265, U.S. Pat. No. 8,691,223, 4952 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 85 INFL816 Light chain variable CR6257 US20090311265, U.S. Pat. No. 8,691,223, 4953 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 87 INFL817 Light chain variable CR6260 US20090311265, U.S. Pat. No. 8,691,223, 4954 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 89 INFL818 Light chain variable CR6261 US20090311265, U.S. Pat. No. 8,691,223, 4955 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 91 INFL819 Light chain variable CR6262 US20090311265, U.S. Pat. No. 8,691,223, 4956 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 93 INFL820 Light chain variable CR6268 US20090311265, U.S. Pat. No. 8,691,223, 4957 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 95 INFL821 Light chain variable CR6307 US20090311265, U.S. Pat. No. 8,691,223, 4958 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 97 INFL822 Light chain variable CR6310 US20090311265, U.S. Pat. No. 8,691,223, 4959 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 99 INFL823 Light chain variable CR6314 US20090311265, U.S. Pat. No. 8,691,223, 4960 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 101 INFL824 Light chain variable CR6323 US20090311265, U.S. Pat. No. 8,691,223, 4961 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 103 INFL825 Light chain variable CR6325 US20090311265, U.S. Pat. No. 8,691,223, 4962 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 105 INFL826 Light chain variable CR6331 US20090311265, U.S. Pat. No. 8,691,223, 4963 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 107 INFL827 Light chain variable CR6344 US20090311265, U.S. Pat. No. 8,691,223, 4964 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 109 INFL828 Light chain variable CR6141 US20090311265, U.S. Pat. No. 8,691,223, 4965 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 319 INFL829 Light chain variable CR6272 US20090311265, U.S. Pat. No. 8,691,223, 4966 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 323 INFL830 Light chain variable CR6296 US20090311265, U.S. Pat. No. 8,691,223, 4967 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 327 INFL831 Light chain variable CR6301 US20090311265, U.S. Pat. No. 8,691,223, 4968 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 331 INFL832 Light chain variable CR6327 US20090311265, U.S. Pat. No. 8,691,223, 4969 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 335 INFL833 Light chain variable CR6328 US20090311265, U.S. Pat. No. 8,691,223, 4970 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 339 INFL834 Light chain variable CR6329 US20090311265, U.S. Pat. No. 8,691,223, 4971 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 343 INFL835 Light chain variable CR6332 US20090311265, U.S. Pat. No. 8,691,223, 4972 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 347 INFL836 Light chain variable CR6334 US20090311265, U.S. Pat. No. 8,691,223, 4973 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 351 INFL837 Light chain variable CR6336 US20090311265, U.S. Pat. No. 8,691,223, 4974 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 355 INFL838 Light chain variable CR6339 US20090311265, U.S. Pat. No. 8,691,223, 4975 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 359 INFL839 Light chain variable CR6342 US20090311265, U.S. Pat. No. 8,691,223, 4976 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 363 INFL840 Light chain variable CR6343 US20090311265, U.S. Pat. No. 8,691,223, 4977 region U.S. Pat. No. 9,109,017, WO2008028946 SEQ ID NO: 367 INFL841 Light chain variable CR9003 US20140120113 SEQ ID NO: 4 4978 region INFL842 Light chain variable CR9004 US20140120113 SEQ ID NO: 8 4979 region INFL843 Light chain variable CR9005 US20140120113 SEQ ID NO: 12 4980 region INFL844 Light chain variable CR9006 US20140120113 SEQ ID NO: 16 4981 region INFL845 Light chain variable CR9007 US20140120113 SEQ ID NO: 20 4982 region INFL846 Light chain variable CR9008 US20140120113 SEQ ID NO: 24 4983 region INFL847 Light chain variable CR9009 US20140120113 SEQ ID NO: 28 4984 region INFL848 Light chain variable CR9010 US20140120113 SEQ ID NO: 32 4985 region INFL849 Light chain variable CR9011 US20140120113 SEQ ID NO: 36 4986 region INFL850 Light chain variable CR9012 US20140120113 SEQ ID NO: 40 4987 region INFL851 Light chain variable CR9029 US20140120113 SEQ ID NO: 44 4988 region INFL852 Light chain variable CR9030 US20140120113 SEQ ID NO: 48 4989 region INFL853 Light chain variable CR9031 US20140120113 SEQ ID NO: 52 4990 region INFL854 Light chain variable CR9112 US20140120113 SEQ ID NO: 56 4991 region INFL855 Light chain variable CR9113 US20140120113 SEQ ID NO: 60 4992 region INFL856 Light chain variable CR9114 US20140120113 SEQ ID NO: 64 4993 region INFL857 Light chain variable CR8033 U.S. Pat. No. 8,852,595 SEQ ID NO: 73 4994 region INFL858 Light chain variable CR8059 U.S. Pat. No. 8,852,595 SEQ ID NO: 77 4995 region INFL859 Light chain variable CR8071 U.S. Pat. No. 8,852,595 SEQ ID NO: 79 4996 region INFL860 Light chain variable CR10051 U.S. Pat. No. 8,852,595 SEQ ID NO: 83 4997 region INFL861 Light chain variable CR10049 U.S. Pat. No. 8,852,595 SEQ ID NO: 87 4998 region INFL862 Light chain variable CR10023 U.S. Pat. No. 8,852,595 SEQ ID NO: 91 4999 region INFL863 Light chain variable CR10032 U.S. Pat. No. 8,852,595 SEQ ID NO: 95 5000 region INFL864 Light chain variable CR11035 U.S. Pat. No. 8,852,595 SEQ ID NO: 103 5001 region INFL865 Light chain variable CR11036 U.S. Pat. No. 8,852,595 SEQ ID NO: 107 5002 region INFL866 Light chain variable CR11038 U.S. Pat. No. 8,852,595 SEQ ID NO: 111 5003 region INFL867 Light chain variable CR11039 U.S. Pat. No. 8,852,595 SEQ ID NO: 115 5004 region INFL868 Light chain variable CR8031 U.S. Pat. No. 8,852,595 SEQ ID NO: 121 5005 region INFL869 Light chain variable CR8032 U.S. Pat. No. 8,852,595 SEQ ID NO: 125 5006 region INFL870 Light chain variable CR8034 U.S. Pat. No. 8,852,595 SEQ ID NO: 129 5007 region INFL871 Light chain variable U.S. Pat. No. 8,992,929 SEQ ID NO: 2 5008 region INFL872 Light chain variable M2e U.S. Pat. No. 8,420,794 SEQ ID NO: 1 5009 region INFL873 Light chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 5010 region NO: 16 INFL874 Light chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 5011 region NO: 19 INFL875 Light chain variable U.S. Pat. No. 8,715,743, US20140275492 SEQ ID 5012 region NO: 32 INFL876 Light chain variable anti-1918 influenza Yu, X., et al., Neutralizing antibodies 5013 region HA Ig derived from the B cells of 1918 influenza pandemic survivors; Nature 455 (7212), 532-536 (2008), NCBI Accession #ACI04582.1 (121aa) INFL877 Light chain variable anti-1918 influenza Yu, X., et al., Neutralizing antibodies 5014 region HA Ig derived from the B cells of 1918 influenza pandemic survivors; Nature 455 (7212), 532-536 (2008), NCBI Accession #ACI04580.1 (118aa) INFL878 Light chain variable 4D20 Yu, X. et al “Neutralizing antibodies 5015 region derived from the B cells of 1918 influenza pandemic survivors”, Nature 455 (7212), 532-536, NCBI Accession #ACI04580 INFL879 Light chain variable 2B12 Yu, X. et al “Neutralizing antibodies 5016 region derived from the B cells of 1918 influenza pandemic survivors”, Nature 455 (7212), 532-536, NCBI Accession #ABY48869 INFL880 Light chain variable TCN-535 US20150086555 SEQ ID NO: 180 5017 region (5246_P19) INFL881 Light chain variable TCN-536 US20150086555 SEQ ID NO: 191 5018 region (5095_N01) INFL882 Light chain variable TCN-537 US20150086555 SEQ ID NO: 202 5019 region (3194_D21) INFL883 Light chain variable TCN-538 US20150086555 SEQ ID NO: 214 5020 region (3206_O17) INFL884 Light chain variable TCN-539 US20150086555 SEQ ID NO: 226 5021 region (5056_A08) INFL885 Light chain variable TCN-540 US20150086555 SEQ ID NO: 238 5022 region (5060_F05) INFL886 Light chain variable TCN-541 US20150086555 SEQ ID NO: 250 5023 region (5062_M11) INFL887 Light chain variable TCN-542 US20150086555 SEQ ID NO: 262 5024 region (5079_A16) INFL888 Light chain variable TCN-543 US20150086555 SEQ ID NO: 274 5025 region (5081_G23) INFL889 Light chain variable TCN-544 US20150086555 SEQ ID NO: 286 5026 region (5082_A19) INFL890 Light chain variable TCN-545 US20150086555 SEQ ID NO: 298 5027 region (5082_I15) INFL891 Light chain variable TCN-546 US20150086555 SEQ ID NO: 309 5028 region (5089_L08) INFL892 Light chain variable TCN-547 US20150086555 SEQ ID NO: 320 5029 region (5092_F11) INFL893 Light chain variable TCN-548 US20150086555 SEQ ID NO: 331 5030 region (5092_P01) INFL894 Light chain variable TCN-549 US20150086555 SEQ ID NO: 342 5031 region (5092_P04) INFL895 Light chain variable TCN-550 US20150086555 SEQ ID NO: 353 5032 region (5096_F06) INFL896 Light chain variable TCN-551 US20150086555 SEQ ID NO: 365 5033 region (5243_D01) INFL897 Light chain variable TCN-552 US20150086555 SEQ ID NO: 377 5034 region (5249_I23) INFL898 Light chain variable TCN-553 US20150086555 SEQ ID NO: 389 5035 region (5261_C18) INFL899 Light chain variable TCN-554 US20150086555 SEQ ID NO: 399 5036 region (5277_M05) INFL900 Light chain variable TCN-555 US20150086555 SEQ ID NO: 405 5037 region (5246_L16) INFL901 Light chain variable TCN-556 US20150086555 SEQ ID NO: 415 5038 region (5089_K12) INFL902 Light chain variable TCN-557 US20150086555 SEQ ID NO: 427 5039 region (5081_A04) INFL903 Light chain variable TCN-559 US20150086555 SEQ ID NO: 441 5040 region (5097_G08) INFL904 Light chain variable TCN-560 US20150086555 SEQ ID NO: 453 5041 region (5084_P10) INFL905 Light chain variable TCN-564 US20150086555 SEQ ID NO: 519 5042 region (5256_A17b) INFL906 Light chain variable CR8001 WO2010130636 SEQ ID NO: 4 5043 region INFL907 Light chain variable CR8003 WO2010130636 SEQ ID NO: 8 5044 region INFL908 Light chain variable CR8015 WO2010130636 SEQ ID NO: 12 5045 region INFL909 Light chain variable CR8016 WO2010130636 SEQ ID NO: 16 5046 region INFL910 Light chain variable CR8017 WO2010130636 SEQ ID NO: 20 5047 region INFL911 Light chain variable TCN-522 US20150086555 SEQ ID NO: 40 5048 region (3212_I12) INFL912 Light chain variable TCN-521 US20150086555 SEQ ID NO: 28 5049 region (3280_D18) INFL913 Light chain variable TCN-523 US20150086555 SEQ ID NO: 52 5050 region (5248_A17), TCN-533 (5256_A17a), TCN-534 (5249_B02) INFL914 Light chain variable TCN-563 US20150086555 SEQ ID NO: 64 5051 region (5237_B21) INFL915 Light chain variable TCN-526 US20150086555 SEQ ID NO: 76 5052 region (5084_C17) INFL916 Light chain variable TCN-527 US20150086555 SEQ ID NO: 88 5053 region (5086_C06) INFL917 Light chain variable TCN-528 US20150086555 SEQ ID NO: 100 5054 region (5087_P17) INFL918 Light chain variable TCN-529 US20150086555 SEQ ID NO: 112 5055 region (5297_H01) INFL919 Light chain variable TCN-530 US20150086555 SEQ ID NO: 124 5056 region (5248_H10), TCN-558 (5248_H10b) INFL920 Light chain variable TCN-531 US20150086555 SEQ ID NO: 136 5057 region (5091_H13) INFL921 Light chain variable TCN-532 US20150086555 SEQ ID NO: 148 5058 region (5262_H18) INFL922 Light chain variable TCN-534 US20150086555 SEQ ID NO: 168 5059 region (5249_B02) INFL923 Light chain variable TCN-504 US20150086555 SEQ ID NO: 524 5060 region (3251_K17) INFL924 Light chain variable AB1 US20120093834, WO2009121004 SEQ 5061 region ID NO: 71 INFL925 Light chain variable AB2 US20120093834, WO2009121004 SEQ 5062 region ID NO: 140 INFL926 Light chain variable AB3 US20120093834, WO2009121004 SEQ 5063 region ID NO: 81 INFL927 Light chain variable AB4 US20120093834, WO2009121004 SEQ 5064 region ID NO: 158 INFL928 Light chain variable AB5 US20120093834, WO2009121004 SEQ 5065 region ID NO: 159 INFL929 Light chain variable AB6 US20120093834, WO2009121004 SEQ 5066 region ID NO: 160 INFL930 Light chain variable VN04-2 WO2008033105 SEQ ID NO: 6 5067 region INFL931 Light chain variable VN04-3 WO2008033105 SEQ ID NO: 8 5068 region INFL932 Light chain variable 1286-C05 WO2010132604, US20120128671 SEQ 5069 region ID NO: 3 INFL933 Light chain variable 1286-C05 WO2010132604, US20120128671 SEQ 5070 region ID NO: 4 INFL934 Light chain variable 1286-C05 WO2010132604, US20120128671 SEQ 5071 region ID NO: 5 INFL935 Light chain variable 1286-A11 WO2010132604, US20120128671 SEQ 5072 region ID NO: 6 INFL936 Light chain variable IA2 WO2015028478 SEQ ID NO: 3 5073 region mouse IgG INFL937 Light chain variable 7B8 WO2015028478 SEQ ID NO: 5 5074 region mouse IgG INFL938 Light chain variable monoclonal U.S. Pat. No. 8,900,590, US2012039899, Grandea, 5075 region, partial antibody TCN-031 A. G. et al., Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Set. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23871.1 (106aa) INFL939 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5076 region, partial antibody TCN-032 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23870.1 (107aa) INFL940 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5077 region, partial antibody 3362_B11 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession # ADK23886.1 (107aa) INFL941 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5078 region, partial antibody reveal a protective epitope that is highly 3260_D19 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23885.1 (106aa) INFL942 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5079 region, partial antibody 3253_P10 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23884.1(107aa) INFL943 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5080 region, partial antibody 3248_P18 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23883.1 (106aa) INFL944 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5081 region, partial antibody 3139_P23 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23882.1(107aa) INFL945 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5082 region, partial antibody 3420_I23 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23881.1(108aa) INFL946 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5083 region, partial antibody 3255_J06 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23880.1(108aa) INFL947 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5084 region, partial antibody 3252_C13 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23879.1 (108aa) INFL948 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5085 region, partial antibody reveal a protective epitope that is highly 3136_G05 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23878.1 (108aa) INFL949 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5086 region, partial antibody reveal a protective epitope that is highly 3244_H04 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23877.1 (107aa) INFL950 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5087 region, partial antibody reveal a protective epitope that is highly 3245_O19 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23876.1 (107aa) INFL951 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5088 region, partial antibody 3259_J21 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23875.1 (107aa) INFL952 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5089 region, partial antibody 3243_J07 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23874.1 (108aa) INFL953 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5090 region, partial antibody 3244_I10 reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23873.1 (108aa) INFL954 Light chain variable monoclonal Grandea, A. G. et al., Human antibodies 5091 region, partial antibody reveal a protective epitope that is highly 3241_G23 conserved among human and nonhuman influenza A viruses; Proc. Natl. Acad. Sci. U.S.A. 107 (28), 12658-12663 (2010), NCBI Accession #ADK23872.1 (108aa) INFL955 Light chain variable 100F4-LV Hu, H., et al., A Human Antibody 5092 region, partial Recognizing a Conserved Epitope of H5 Hemagglutinin Broadly Neutralizes Highly Pathogenic Avian Influenza H5N1 Viruses; J. Virol. 86 (6), 2978- 2989 (2012), NCBI Accession #AEL30604.1 (112aa) INFL956 Light Chain, Fab ch65 Whittle, J. R. et al., Broadly neutralizing 5093 Fragment human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin; Proc. Natl. Acad. Sci. U.S.A. 108 (34), 14216-14221 (2011), NCBI Accession #3SM5_L INFL957 Light chain 1I20 WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 5094 NO: 6 INFL958 Light chain WO2010127252, U.S. Pat. No. 8,894,997 SEQ ID 5095 NO: 12 INFL959 Monoclonal antibody Neutralizing Wu, Y. et al., A potent broad-spectrum 5096 heavy chain Human protective human monoclonal antibody Monoclonal crosslinking two hemagglutinin Antibody With monomers of influenza A virus; Nat 1968 H3 Ha Commun 6, 7708 (2015), NCBI Accession #4UBD_C INFL960 Monoclonal antibody Neutralizing Wu, Y. et al., A potent broad-spectrum 5097 light chain Human protective human monoclonal antibody Monoclonal crosslinking two hemagglutinin Antibody With monomers of influenza A virus; Nat 1968 H3 Ha Commun 6, 7708 (2015), NCBI Accession #4UBD_D INFL961 Mutated heavy chain 8G9 mutated U.S. Pat. No. 8,603,467 SEQ ID NO: 42 5098 variable INFL962 Mutated heavy chain 13D4 mutated U.S. Pat. No. 8,603,467 SEQ ID NO: 46 5099 variable (VH-LV) INFL963 Mutated heavy chain 13D4 mutated U.S. Pat. No. 8,603,467 SEQ ID NO: 44 5100 variable (VH-SV) INFL964 Nanobody 202-C8 US20110182897, WO2009147248 SEQ 5101 ID NO: 138 INFL965 Nanobody 203-B12 US20110182897, WO2009147248 SEQ 5102 ID NO: 2439 INFL966 Nanobody 203-H9 US20110182897, WO2009147248 SEQ 5103 ID NO: 2445 INFL967 Scfv JM7_B-G7 WO2012072788 SEQ ID NO: 7 5104 INFL968 Scfv JM7_S-F8 WO2012072788 SEQ ID NO: 15 5105 INFL969 Scfv JM7JH-F1 WO2012072788 SEQ ID NO: 17 5106 INFL970 Scfv JM7_S-A9 WO2012072788 SEQ ID NO: 19 5107 INFL971 Scfv JM7_S-A10 WO2012072788 SEQ ID NO: 21 5108 INFL972 Scfv JM7_B-H WO2012072788 SEQ ID NO: 23 5109 INFL973 Scfv JM6_SC-H1 WO2012072788 SEQ ID NO: 25 5110 INFL974 Scfv jM6_SC_D3 WO2012072788 SEQ ID NO: 27 5111 INFL975 Scfv H2526 Schmidt, A. G. et al., Viral receptor- 5112 binding site antibodies with diverse germline origins; Cell 161 (5), 1026- 1034 (2015), NCBI Accession #4YJZ_L INFL976 Scfv fragment AVC4 WO2010040572A2 FIG. 6 5113 INFL977 Scfv fragment AVD1 WO2010040572A2 FIG. 8 5114 INFL978 Scfv fragment AVE2 WO2010040572A2 FIG. 10 5115 INFL979 Scfv fragment AVA6 WO2010040572A2 FIG. 12 5116 INFL980 Scfv fragment AVG4 WO2010040572A2 FIG. 14 5117 INFL981 Scfv heavy chain SC06-141 US20150104459 SEQ ID NO: 309 5118 variable region INFL982 Scfv heavy chain SC06-255 US20150104459 SEQ ID NO: 313 5119 variable region INFL983 Scfv heavy chain SC06-257 US20150104459 SEQ ID NO: 317 5120 variable region INFL984 Scfv heavy chain SC6-260 US20150104459 SEQ ID NO: 321 5121 variable region INFL985 Scfv heavy chain SC06-261 US20150104459 SEQ ID NO: 325 5122 variable region INFL986 Scfv heavy chain SC06-262 US20150104459 SEQ ID NO: 329 5123 variable region INFL987 Scfv heavy chain SC06-268 US20150104459 SEQ ID NO: 333 5124 variable region INFL988 Scfv heavy chain SC06-272 US20150104459 SEQ ID NO: 337 5125 variable region INFL989 Scfv heavy chain SC06-296 US20150104459 SEQ ID NO: 341 5126 variable region INFL990 Scfv heavy chain SC06-301 US20150104459 SEQ ID NO: 345 5127 variable region INFL991 Scfv heavy chain SC06-307 US20150104459 SEQ ID NO: 349 5128 variable region INFL992 Scfv heavy chain SC06-310 US20150104459 SEQ ID NO: 353 5129 variable region INFL993 Scfv heavy chain SC06-314 US20150104459 SEQ ID NO: 357 5130 variable region INFL994 Scfv heavy chain SC06-323 US20150104459 SEQ ID NO: 361 5131 variable region INFL995 Scfv heavy chain SC06-325 US20150104459 SEQ ID NO: 365 5132 variable region INFL996 Scfv heavy chain SC06-327 US20150104459 SEQ ID NO: 369 5133 variable region INFL997 Scfv heavy chain SC06-328 US20150104459 SEQ ID NO: 373 5134 variable region INFL998 Scfv heavy chain SC06-329 US20150104459 SEQ ID NO: 377 5135 variable region INFL999 Scfv heavy chain SC06-331 US20150104459 SEQ ID NO: 381 5136 variable region INFL1000 Scfv heavy chain SC06-332 US20150104459 SEQ ID NO: 385 5137 variable region INFL1001 Scfv heavy chain SC06-334 US20150104459 SEQ ID NO: 389 5138 variable region INFL1002 Scfv heavy chain SC06-336 US20150104459 SEQ ID NO: 393 5139 variable region INFL1003 Scfv heavy chain SC06-339 US20150104459 SEQ ID NO: 397 5140 variable region INFL1004 Scfv heavy chain SC06-342 US20150104459 SEQ ID NO: 401 5141 variable region INFL1005 Scfv heavy chain SC06-343 US20150104459 SEQ ID NO: 405 5142 variable region INFL1006 Scfv heavy chain SC06-344 US20150104459 SEQ ID NO: 409 5143 variable region INFL1007 Scfv heavy chain CR6255 US20150104459 SEQ ID NO: 417 5144 variable region INFL1008 Scfv heavy chain CR6257 US20150104459 SEQ ID NO: 423 5145 variable region INFL1009 Scfv heavy chain CR6260 US20150104459 SEQ ID NO: 429 5146 variable region INFL1010 Scfv heavy chain CR6261 US20150104459 SEQ ID NO: 435 5147 variable region INFL1011 Scfv heavy chain CR6262 US20150104459 SEQ ID NO: 441 5148 variable region INFL1012 Scfv heavy chain CR6268 US20150104459 SEQ ID NO: 447 5149 variable region INFL1013 Scfv heavy chain CR6272 US20150104459 SEQ ID NO: 453 5150 variable region INFL1014 Scfv heavy chain CR696 US20150104459 SEQ ID NO: 459 5151 variable region INFL1015 Scfv heavy chain CR6301 US20150104459 SEQ ID NO: 465 5152 variable region INFL1016 Scfv heavy chain CR6307 US20150104459 SEQ ID NO: 471 5153 variable region INFL1017 Scfv heavy chain CR6310 US20150104459 SEQ ID NO: 477 5154 variable region INFL1018 Scfv heavy chain CR6314 US20150104459 SEQ ID NO: 483 5155 variable region INFL1019 Scfv heavy chain CR6323 US20150104459 SEQ ID NO: 489 5156 variable region INFL1020 Scfv heavy chain CR6325 US20150104459 SEQ ID NO: 495 5157 variable region INFL1021 Scfv heavy chain CR6327 US20150104459 SEQ ID NO: 501 5158 variable region INFL1022 Scfv heavy chain CR6328 US20150104459 SEQ ID NO: 507 5159 variable region INFL1023 Scfv heavy chain CR6329 US20150104459 SEQ ID NO: 513 5160 variable region INFL1024 Scfv heavy chain CR6331 US20150104459 SEQ ID NO: 519 5161 variable region INFL1025 Scfv heavy chain CR6332 US20150104459 SEQ ID NO: 525 5162 variable region INFL1026 Scfv heavy chain CR6334 US20150104459 SEQ ID NO: 531 5163 variable region INFL1027 Scfv heavy chain CR6336 US20150104459 SEQ ID NO: 537 5164 variable region INFL1028 Scfv heavy chain CR6339 US20150104459 SEQ ID NO: 543 5165 variable region INFL1029 Scfv heavy chain CR6342 US20150104459 SEQ ID NO: 550 5166 variable region INFL1030 Scfv heavy chain CR6343 US20150104459 SEQ ID NO: 556 5167 variable region INFL1031 Scfv heavy chain CR6344 US20150104459 SEQ ID NO: 562 5168 variable region INFL1032 Scfv light chain SC06-141 US20150104459 SEQ ID NO: 310 5169 variable region INFL1033 Scfv light chain SC06-255 US20150104459 SEQ ID NO: 314 5170 variable region INFL1034 Scfv light chain SC06-257 US20150104459 SEQ ID NO: 318 5171 variable region INFL1035 Scfv light chain SC6-260 US20150104459 SEQ ID NO: 322 5172 variable region INFL1036 Scfv light chain SC06-261 US20150104459 SEQ ID NO: 326 5173 variable region INFL1037 Scfv light chain SC06-262 US20150104459 SEQ ID NO: 330 5174 variable region INFL1038 Scfv light chain SC06-268 US20150104459 SEQ ID NO: 334 5175 variable region INFL1039 Scfv light chain SC06-272 US20150104459 SEQ ID NO: 338 5176 variable region INFL1040 Scfv light chain SC06-296 US20150104459 SEQ ID NO: 342 5177 variable region INFL1041 Scfv light chain SC06-301 US20150104459 SEQ ID NO: 346 5178 variable region INFL1042 Scfv light chain SC06-307 US20150104459 SEQ ID NO: 350 5179 variable region INFL1043 Scfv light chain SC06-310 US20150104459 SEQ ID NO: 354 5180 variable region INFL1044 Scfv light chain SC06-314 US20150104459 SEQ ID NO: 358 5181 variable region INFL1045 Scfv light chain SC06-323 US20150104459 SEQ ID NO: 362 5182 variable region INFL1046 Scfv light chain SC06-325 US20150104459 SEQ ID NO: 366 5183 variable region INFL1047 Scfv light chain SC06-327 US20150104459 SEQ ID NO: 370 5184 variable region INFL1048 Scfv light chain SC06-328 US20150104459 SEQ ID NO: 374 5185 variable region INFL1049 Scfv light chain SC06-329 US20150104459 SEQ ID NO: 378 5186 variable region INFL1050 Scfv light chain SC06-331 US20150104459 SEQ ID NO: 382 5187 variable region INFL1051 Scfv light chain SC06-332 US20150104459 SEQ ID NO: 386 5188 variable region INFL1052 Scfv light chain SC06-334 US20150104459 SEQ ID NO: 390 5189 variable region INFL1053 Scfv light chain SC06-336 US20150104459 SEQ ID NO: 394 5190 variable region INFL1054 Scfv light chain SC06-339 US20150104459 SEQ ID NO: 398 5191 variable region INFL1055 Scfv light chain SC06-342 US20150104459 SEQ ID NO: 402 5192 variable region INFL1056 Scfv light chain SC06-343 US20150104459 SEQ ID NO: 406 5193 variable region INFL1057 Scfv light chain SC06-344 US20150104459 SEQ ID NO: 410 5194 variable region INFL1058 Scfv light chain CR6141 US20150104459 SEQ ID NO: 414 5195 variable region INFL1059 Scfv light chain CR6255 US20150104459 SEQ ID NO: 420 5196 variable region INFL1060 Scfv light chain CR6257 US20150104459 SEQ ID NO: 426 5197 variable region INFL1061 Scfv light chain CR6260 US20150104459 SEQ ID NO: 432 5198 variable region INFL1062 Scfv light chain CR6261 US20150104459 SEQ ID NO: 438 5199 variable region INFL1063 Scfv light chain CR6262 US20150104459 SEQ ID NO: 444 5200 variable region INFL1064 Scfv light chain CR6268 US20150104459 SEQ ID NO: 450 5201 variable region INFL1065 Scfv light chain CR6272 US20150104459 SEQ ID NO: 456 5202 variable region INFL1066 Scfv light chain CR696 US20150104459 SEQ ID NO: 462 5203 variable region INFL1067 Scfv light chain CR6301 US20150104459 SEQ ID NO: 468 5204 variable region INFL1068 Scfv light chain CR6307 US20150104459 SEQ ID NO: 474 5205 variable region INFL1069 Scfv light chain CR6310 US20150104459 SEQ ID NO: 480 5206 variable region INFL1070 Scfv light chain CR6314 US20150104459 SEQ ID NO: 486 5207 variable region INFL1071 Scfv light chain CR6323 US20150104459 SEQ ID NO: 492 5208 variable region INFL1072 Scfv light chain CR6325 US20150104459 SEQ ID NO: 498 5209 variable region INFL1073 Scfv light chain CR6327 US20150104459 SEQ ID NO: 504 5210 variable region INFL1074 Scfv light chain CR6328 US20150104459 SEQ ID NO: 510 5211 variable region INFL1075 Scfv light chain CR6329 US20150104459 SEQ ID NO: 516 5212 variable region INFL1076 Scfv light chain CR6331 US20150104459 SEQ ID NO: 522 5213 variable region INFL1077 Scfv light chain CR6332 US20150104459 SEQ ID NO: 528 5214 variable region INFL1078 Scfv light chain CR6334 US20150104459 SEQ ID NO: 534 5215 variable region INFL1079 Scfv light chain CR6336 US20150104459 SEQ ID NO: 540 5216 variable region INFL1080 Scfv light chain CR6339 US20150104459 SEQ ID NO: 547 5217 variable region INFL1081 Scfv light chain CR6342 US20150104459 SEQ ID NO: 553 5218 variable region INFL1082 Scfv light chain CR6343 US20150104459 SEQ ID NO: 559 5219 variable region INFL1083 Scfv light chain CR6344 US20150104459 SEQ ID NO: 565 5220 variable region INFL1084 Vhch antibody 641 I-9 Schmidt, A. G. et al., Viral receptor- 5221 binding site antibodies with diverse germline origins; Cell 161 (5), 1026- 1034 (2015), NCBI Accession #4YK4_Z INFL1085 Vlcl antibody 641 I-9 Schmidt, A. G. et al., Viral receptor- 5222 binding site antibodies with diverse germline origins; Cell 161 (5), 1026- 1034 (2015), NCBI Accession #4YK4_Y

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in U.S. Pat. Nos. 8,003,106 and 8,540,995. International Patent Publication No. WO2015028478, WO02012045001. US Publication No. US20150239960 and US20130251715, the contents of each of which are herein incorporated by reference in their entirety, against influenza.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 22 against Respiratory Syncytial Virus.

TABLE 22 Antibodies against Respiratory Syncytial Virus Antibody SEQ ID No. Description Antibody Name Reference Information NO RSV1 Heavy chain variable, F and G clone 888 US20110189171; 5223 Proteins US7879329SEQ ID NO: 43 RSV2 Heavy chain variable, F and G mAb 824 US20110189171; US7879329 5224 Proteins SEQ ID NO: 178 RSV3 Heavy chain variable, F and G clone 735 US20110189171; US7879329 5225 Proteins SEQ ID NO: 1 RSV4 Heavy chain variable, F and G clone 736 US20110189171; US7879329 5226 Proteins SEQ ID NO: 2 RSV5 Heavy chain variable, F and G clone 744 US20110189171; US7879329 5227 Proteins SEQ ID NO: 3 RSV6 Heavy chain variable, F and G clone 793 US20110189171; US7879329 5228 Proteins SEQ ID NO: 4 RSV7 Heavy chain variable, F and G clone 795 US20110189171; US7879329 5229 Proteins SEQ ID NO: 5 RSV8 Heavy chain variable, F and G clone 796 US2011018917; US7879329 5230 Proteins SEQ ID NO: 6 RSV9 Heavy chain variable, F and G clone 799 US20110189171; US7879329 5231 Proteins SEQ ID NO: 7 RSV10 Heavy chain variable, F and G clone 800 US20110189171; US7879329 5232 Proteins SEQ ID NO: 8 RSV11 Heavy chain variable, F and G clone 801 US20110189171; US7879329 5233 Proteins SEQ ID NO: 9 RSV12 Heavy chain variable, F and G clone 804 US20110189171; US7879329 5234 Proteins SEQ ID NO: 10 RSV13 Heavy chain variable, F and G clone 810 US20110189171; US7879329 5235 Proteins SEQ ID NO: 11 RSV14 Heavy chain variable, F and G clone 811 US20110189171; US7879329 5236 Proteins SEQ ID NO: 12 RSV15 Heavy chain variable, F and G clone 812 US20110189171; US7879329 5237 Proteins SEQ ID NO: 13 RSV16 Heavy chain variable, F and G clone 814 US20110189171; US7879329 5238 Proteins SEQ ID NO: 14 RSV17 Heavy chain variable, F and G clone 816 US20110189171; US7879329 5239 Proteins SEQ ID NO: 15 RSV18 Heavy chain variable, F and G clone 817 US20110189171; US7879329 5240 Proteins SEQ ID NO: 16 RSV19 Heavy chain variable, F and G clone 818 US20110189171; US7879329 5241 Proteins SEQ ID NO: 17 RSV20 Heavy chain variable, F and G clone 819 US20110189171; US7879329 5242 Proteins SEQ ID NO: 18 RSV21 Heavy chain variable, F and G clone 824 US20110189171; US7879329 5243 Proteins SEQ ID NO: 19 RSV22 Heavy chain variable, F and G clone 825 US20110189171; US7879329 5244 Proteins SEQ ID NO: 20 RSV23 Heavy chain variable, F and G clone 827 US20110189171; US7879329 5245 Proteins SEQ ID NO: 21 RSV24 Heavy chain variable, F and G clone 829 US20110189171; US7879329 5246 Proteins SEQ ID NO: 22 RSV25 Heavy chain variable, F and G clone 830 US20110189171; US7879329 5247 Proteins SEQ ID NO: 23 RSV26 Heavy chain variable, F and G clone 831 US20110189171; US7879329 5248 Proteins SEQ ID NO: 24 RSV27 Heavy chain variable, F and G clone 835 US20110189171; US7879329 5249 Proteins SEQ ID NO: 25 RSV28 Heavy chain variable, F and G clone 838 US20110189171; US7879329 5250 Proteins SEQ ID NO: 26 RSV29 Heavy chain variable, F and G clone 841 US20110189171; US7879329 5251 Proteins SEQ ID NO: 27 RSV30 Heavy chain variable, F and G clone 853 US20110189171; US7879329 5252 Proteins SEQ ID NO: 28 RSV31 Heavy chain variable, F and G clone 855 US20110189171; US7879329 5253 Proteins SEQ ID NO: 29 RSV32 Heavy chain variable, F and G clone 856 US20110189171; US7879329 5254 Proteins SEQ ID NO: 30 RSV33 Heavy chain variable, F and G clone 857 US20110189171; US7879329 5255 Proteins SEQ ID NO: 31 RSV34 Heavy chain variable, F and G clone 858 US20110189171; US7879329 5256 Proteins SEQ ID NO: 32 RSV35 Heavy chain variable, F and G clone 859 US20110189171; US7879329 5257 Proteins SEQ ID NO: 33 RSV36 Heavy chain variable, F and G clone 861 US20110189171; US7879329 5258 Proteins SEQ ID NO: 34 RSV37 Heavy chain variable, F and G clone 863 US20110189171; US7879329 5259 Proteins SEQ ID NO: 35 RSV38 Heavy chain variable, F and G clone 868 US20110189171; US7879329 5260 Proteins SEQ ID NO: 36 RSV39 Heavy chain variable, F and G clone 870 US20110189171; US7879329 5261 Proteins SEQ ID NO: 37 RSV40 Heavy chain variable, F and G clone 871 US20110189171; US7879329 5262 Proteins SEQ ID NO: 38 RSV41 Heavy chain variable, F and G clone 880 US20110189171; US7879329 5263 Proteins SEQ ID NO: 39 RSV42 Heavy chain variable, F and G clone 881 US20110189171; US7879329 5264 Proteins SEQ ID NO: 40 RSV43 Heavy chain variable, F and G clone 884 US20110189171; US7879329 5265 Proteins SEQ ID NO: 41 RSV44 Heavy chain variable, F and G clone 886 US20110189171; US7879329 5266 Proteins SEQ ID NO: 42 RSV45 Heavy chain variable, F and G clone 894 US20110189171; US7879329 5267 Proteins SEQ ID NO: 44 RSV46 heavy chain variable, F protein 3210 variant 1 WO2013140247 SEQ ID NO: 5268 of RSV, MPV, or PVM  13 RSV47 heavy chain variable, F protein 3210 variant 2, WO2013140247 SEQ ID NO: 5269 of RSV, MPV, or PVM 3210 variant 3,  17 3210 variant 6 RSV48 heavy chain variable, F protein 2430 variant 1 WO2013140247 SEQ ID NO: 5270 of RSV, MPV, or PVM  29 RSV49 heavy chain variable, F protein 2430 variant 2, WO2013140247 SEQ ID NO: 5271 of RSV, MPV, or PVM 2430 variant 5  33 RSV50 heavy chain variable, F protein 3210 variant 4, WO2013140247 SEQ ID NO: 5272 of RSV, MPV, or PVM 3210 variant 5  49 RSV51 heavy chain variable, F protein 2430 variant 3, WO2013140247 SEQ ID NO: 5273 of RSV, MPV, or PVM 2430 variant 4  59 RSV52 Heavy chain variable, CDR US20140093501 SEQ ID NO: 5274 Grafted, F Protein,  31 RSV53 Heavy chain, F Protein AM22 US8568726 SEQ ID NO: 16 5275 RSV54 Heavy chain, F Protein RSVF2-5 US8221759 SEQ ID NO: 1 5276 RSV55 Heavy chain, F Protein EP1259547; US8153133 SEQ 5277 ID NO: 4 RSV56 Heavy chain, F Protein MEDI- EP1259547; US8153133 SEQ 5278 493/Pavitizumab- ID NO: 2 N-VL (Brand name Synagis) RSV57 Heavy chain, F Protein EP1259547; US8153133 SEQ 5279 ID NO: 36 RSV58 Heavy chain, F Protein clone 18 EP1259547; US8153133 SEQ 5280 ID NO: 37 RSV59 Heavy chain, F Protein clone 19 EP1259547; US8153133 SEQ 5281 ID NO: 39 RSV60 Heavy chain, F Protein clone 20 EP1259547; US8153133 SEQ 5282 ID NO: 41 RSV61 Heavy chain, F Protein clone 21 EP1259547; US8153133 SEQ 5283 ID NO: 43 RSV62 Heavy chain, F Protein clone 22 EP1259547; US8153133 SEQ 5284 ID NO: 45 RSV63 Heavy chain, F Protein clone 23 EP1259547; US8153133 SEQ 5285 ID NO: 47 RSV64 Heavy chain, F Protein clone 24 EP1259547; US8153133 SEQ 5286 ID NO: 49 RSV65 Heavy chain, F Protein clone 25 EP1259547; US8153133 SEQ 5287 ID NO: 51 RSV66 Heavy chain, F Protein clone 26 EP1259547; US8153133 SEQ 5288 ID NO: 53 RSV67 Heavy chain variable region, F US20140093501 SEQ ID NO: 5289 Protein  17 RSV68 Heavy chain variable region, F MAb1308F US20140093501 SEQ ID NO: 5290 Protein  18 RSV69 Heavy chain variable region, F huCOR US20140093501 SEQ ID NO: 5291 Protein  30 RSV70 Heavy chain variable region, F MAb1129 US20140093501 SEQ ID NO: 5292 Protein  32 RSV71 Heavy chain variable region, F RSV G8 US7867497 SEQ ID NO: 2 5293 Protein RSV72 Heavy chain variable region, F Clone 1 US20120135006 SEQ ID NO: 5294 Protein  18 RSV73 Heavy chain variable region, F Clone 2 US20120135006 SEQ ID NO: 5295 Protein  20 RSV74 Heavy chain variable region, F Clone 3 US20120135006 SEQ ID NO: 5296 Protein  22 RSV75 Heavy chain variable region, F Clone 22 US20120135006 SEQ ID NO: 5297 Protein  24 RSV76 Heavy chain variable region, F Clone 23 US20120135006 SEQ ID NO: 5298 Protein  26 RSV77 Heavy chain variable region, F RSV13-9 WO2009088159 SEQ ID NO: 4 5299 Protein RSV78 HV3 heavy chain variable, F US20140093501 SEQ ID NO: 5300 Protein  16 RSV79 Constant heavy region, F B4HuVK EP636182; WO1993020210; 5301 protein SEQ ID NO: 6 RSV80 Constant heavy region, F B13/B14HuVK EP636182; WO1993020210; 5302 protein SEQ ID NO: 8 RSV81 Heavy chain, F protein 58c5 US20140044719 SEQ ID NO: 1 5303 RSV82 Heavy chain, F protein sc5 US20140044719 SEQ ID NO: 9 5304 RSV83 Heavy chain, F protein US20110027294 SEQ ID NO: 5305  74 RSV84 Heavy chain, F protein US20110027294 SEQ ID NO: 5306  75 RSV85 Heavy chain, F protein US20110027294 SEQ ID NO: 5307  76 RSV86 Heavy chain, F protein US20110027294 SEQ ID NO: 5308  77 RSV87 Heavy chain, F protein US20110027294 SEQ ID NO: 5309  78 RSV88 Heavy chain, F protein US20110027294 SEQ ID NO: 5310  79 RSV89 Heavy chain, F protein US20110027294 SEQ ID NO: 531,1  80 RSV90 Heavy chain, F protein Gλ-1 US20050175986 SEQ ID NO: 5 5312 RSV91 Heavy chain, F protein A construct US20050175986 SEQ ID NO: 7 5313 RSV92 Heavy chain, F protein B construct US200501,75986 SEQ ID NO: 8 5314 RSV93 Heavy chain, F protein hu19A US20050019758; 5315 WO1998019704 SEQ ID NO: 5 RSV94 Heavy chain, F protein hu19B US20050019758; 5316 WO1998019704 SEQ ID NO: 6 RSV95 Heavy chain, F protein hu19C US20050019758; 5317 WO1998019704 SEQ ID NO: 7 RSV96 Heavy chain, F protein hu19D US20050019758; 5318 WO1998019704 SEQ ID NO: 8 RSV97 Heavy chain, F protein B4HuVH EP636182; WO1993020210; 5319 SEQ ID NO: 5 RSV98 Heavy chain, F protein B13/B14HuVK EP636182; WO1993020210; 5320 SEQ ID NO: 7 RSV99 Heavy chain, F protein RSV19 EP636182; WO1993020210; 5321 SEQ ID NO: 10 RSV100 Heavy chain, F protein WO19922004381 5322 RSV101 Heavy chain, F protein WO19922004381 5323 RSV102 Heavy chain variable region, F P1212 US20140044719 SEQ ID NO: 5324 Protein  122 RSV103 Heavy chain variable region, F P12f4 US20140044719 SEQ ID NO: 5325 Protein  131 RSV104 Heavy chain variable region, F P11d4 US20140044719 SEQ ID NO: 5326 Protein  137 RSV105 Heavy chain variable region, F A1e9 US20140044719 SEQ ID NO: 5327 Protein  144 RSV106 Heavy chain variable region, F A12a6 US20140044719 SEQ ID NO: 5328 Protein  149 RSV107 Heavy chain variable region, F A13c4 US20140044719 SEQ ID NO: 5329 Protein  155 RSV108 Heavy chain variable region, F A17d4 US20140044719 SEQ ID NO: 5330 Protein  161 RSV109 Heavy chain variable region, F A4B4 US20140044719 SEQ ID NO: 5331 Protein  167 RSV110 Heavy chain variable region, F A8c7 US20140044719 SEQ ID NO: 5332 Protein  172 RSV111 Heavy chain variable region, F IX-493L1R US20140044719 SEQ ID NO: 5333 Protein  176 RSV112 Heavy chain variable region, F M3H9 US20140044719 SEQ ID NO: 5334 Protein  181 RSV113 Heavy chain variable region, F B21M US20110027294 SEQ ID NO: 5335 Protein  49 RSV114 Heavy chain variable region, F 101F US20110027294 SEQ ID NO: 4 5336 Protein RSV115 Heavy chain variable region, F HNK20 EP1720908; WO2005079479 5337 Protein SEQ ID NO: 1 RSV116 Heavy chain variable region, F P1212 US20140044719 SEQ ID NO: 5338 Protein  123 RSV117 Heavy chain variable region, F P12f4 US20140044719 SEQ ID NO: 5339 Protein  132 RSV118 Heavy chain variable region, F P11d4 US20140044719 SEQ ID NO: 5340 Protein  138 RSV119 Heavy chain variable region, F A1e9 US20140044719 SEQ ID NO: 5341 Protein  145 RSV120 Heavy chain variable region, F A12a6 US20140044719 SEQ ID NO: 5342 Protein  150 RSV121 Heavy chain variable region, F A13c4 US20140044719 SEQ ID NO: 5343 Protein  156 RSV122 Heavy chain variable region, F A17d4 US20140044719 SEQ ID NO: 5344 Protein  162 RSV123 Heavy chain variable region, F A4B4 US20140044719 SEQ ID NO: 5345 Protein  168 RSV124 Heavy chain variable region, F A8c7 US20140044719 SEQ ID NO: 5346 Protein  173 RSV125 Heavy chain variable region, F IX-493L1FR US20140044719 SEQ ID NO: 5347 Protein  177 RSV126 Heavy chain variable region, F H1 H3564P WO2014159822 SEQ ID NO: 2 5348 Protein RSV127 Heavy chain variable region, F H1 H3565P WO2014159822 SEQ ID NO: 5349 Protein  18 RSV128 Heavy chain variable region, F H1 H3566P WO2014159822 SEQ ID NO: 5350 Protein  34 RSV129 Heavy chain variable region, F H1 H3567P WO2014159822 SEQ ID NO: 5351 Protein  50 RSV130 Heavy chain variable region, F H1 H3581P WO2014159822 SEQ ID NO: 5352 Protein  66 RSV131 Heavy chain variable region, F H1 H3583P WO2014159822 SEQ ID NO: 5353 Protein  82 RSV132 Heavy chain variable region, F H1 H3589P WO2014159822 SEQ ID NO: 5354 Protein  98 RSV133 Heavy chain variable region, F H1 H3591 P WO2014159822 SEQ ID NO: 5355 Protein  114 RSV134 Heavy chain variable region, F H1 H3592P WO2014159822 SEQ ID NO: 5356 Protein  130 RSV135 Heavy chain variable region, F H1 H3597P WO2014159822 SEQ ID NO: 5357 Protein  146 RSV136 Heavy chain variable region, F H1 H3598P WO2014159822 SEQ ID NO: 5358 Protein  162 RSV137 Heavy chain variable region, F H1 H3603P WO2014159822 SEQ ID NO: 5359 Protein  178 RSV138 Heavy chain variable region, F H1 H3604P WO2014159822 SEQ ID NO: 5360 Protein  194 RSV139 Heavy chain variable region, F H1 H3605P WO2014159822 SEQ ID NO: 5361 Protein  210 RSV140 Heavy chain variable region, F H1 H3607P WO2014159822 SEQ ID NO: 5362 Protein  226 RSV141 Heavy chain variable region, F H1 H3608P2 WO2014159822 SEQ ID NO: 5363 Protein  242 RSV142 Heavy chain variable region, F H1 H3592P2 WO2014159822 SEQ ID NO: 5364 Protein  258 RSV143 Heavy chain variable region, F H1 H3592P3 WO2014159822 SEQ ID NO: 5365 Protein  274 RSV144 Heavy chain variable region, F H1 M3621 N WO2014159822 SEQ ID NO: 5366 Protein  290 RSV145 Heavy chain variable region, F H1 M3622N WO2014159822 SEQ ID NO: 5367 Protein  306 RSV146 Heavy chain variable region, F H1 M2634N WO2014159822 SEQ ID NO: 5368 Protein  322 RSV147 Heavy chain variable region, F H1 M3627N WO2014159822 SEQ ID NO: 5369 Protein  338 RSV148 Heavy chain variable region, F Clone No. 735 US20120009623 SEQ ID NO: 1 5370 Protein RSV149 Heavy chain variable region, F Clone No. 736 US20120009623 SEQ ID NO: 2 5371 Protein RSV150 Heavy chain variable region, F Clone No. 744 US20120009623 SEQ ID NO: 3 5372 Protein RSV151 Heavy chain variable region, F Clone No. 793 US20120009623 SEQ ID NO: 4 5373 Protein RSV152 Heavy chain variable region, F Clone No. 795 US21120009623 SEQ ID NO: 5 5374 Protein RSV153 Heavy chain variable region, F Clone No. 796 US20120009623 SEQ ID NO: 6 5375 Protein RSV154 Heavy chain variable region, F Clone No. 799 US20120009623 SEQ ID NO: 7 5376 Protein RSV155 Heavy chain variable region, F Clone No. 800 US20120009623 SEQ ID NO: 8 5377 Protein RSV156 Heavy chain variable region, F Clone No. 801 US20120009623 SEQ ID NO: 9 5378 Protein RSV157 Heavy chain variable region, F Clone No. 804 US20120009623 SEQ ID NO: 5379 Protein  10 RSV158 Heavy chain variable region, F Clone No. 810 US20120009623 SEQ ID NO: 5380 Protein  11 RSV159 Heavy chain variable region, F Clone No. 811 US20120009623 SEQ ID NO: 5381 Protein  12 RSV160 Heavy chain variable region, F Clone No. 812 US20120009623 SEQ ID NO: 5382 Protein  13 RSV161 Heavy chain variable region, F Clone No. 814 US20120009623 SEQ ID NO: 5383 Protein  14 RSV162 Heavy chain variable region, F Clone No. 816 US20120009623 SEQ ID NO: 5384 Protein  15 RSV163 Heavy chain variable region, F Clone No. 817 US20120009623 SEQ ID NO: 5385 Protein  16 RSV164 Heavy chain variable region, F Clone No. 818 US20120009613 SEQ ID NO: 5386 Protein  17 RSV165 Heavy chain variable region, F Clone No. 819 US20120009 23 SEQ ID NO: 5387 Protein  18 RSV166 Heavy chain variable region, F Clone No. 824 US20120009623 SEQ ID NO: 5388 Protein  19 RSV167 Heavy chain variable region, F Clone No. 825 US20120009623 SEQ ID NO: 5389 Protein  20 RSV168 Heavy chain variable region, F Clone No. 827 US20120009623 SEQ ID NO: 5390 Protein  21 RSV169 Heavy chain variable region, F Clone No. 829 US20120009623 SEQ ID NO: 5391 Protein  22 RSV170 Heavy chain variable region, F Clone No. 830 US20120009623 SEQ ID NO: 5392 Protein  23 RSV171 Heavy chain variable region, F Clone No. 831 US20120009623 SEQ ID NO: 5393 Protein  24 RSV172 Heavy chain variable region, F Clone No. 835 US20120009623 SEQ ID NO: 5394 Protein  25 RSV173 Heavy chain variable region, F Clone No. 838 US20120009623 SEQ ID NO: 5395 Protein  26 RSV174 Heavy chain variable region, F Clone No. 841 US20120009623 SEQ ID NO: 5396 Protein  27 RSV175 Heavy chain variable region, F Clone No. 853 US20120009623 SEQ ID NO: 5397 Protein  28 RSV176 Heavy chain variable region, F Clone No. 855 US20120009623 SEQ ID NO: 5398 Protein  29 RSV177 Heavy chain variable region, F Clone No. 856 US20120009623 SEQ ID NO: 5399 Protein  30 RSV178 Heavy chain variable region, F Clone No. 857 US20120009623 SEQ ID NO: 5400 Protein  31 RSV179 Heavy chain variable region, F Clone No. 858 US20120009623 SEQ ID NO: 5401 Protein  32 RSV180 Heavy chain variable region, F Clone No. 859 US20120009623 SEQ ID NO: 5402 Protein  33 RSV181 Heavy chain variable region, F Clone No. 861 US20120009623 SEQ ID NO: 5403 Protein  34 RSV182 Heavy chain variable region, F Clone No. 863 US20120009623 SEQ ID NO: 5404 Protein  35 RSV183 Heavy chain variable region, F Clone No. 868 US20120009623 SEQ ID NO: 5405 Protein  36 RSV184 Heavy chain variable region, F Clone No. 870 US20120009623 SEQ ID NO: 5406 Protein  37 RSV185 Heavy chain variable region, F Clone No. 871 US20120009623 SEQ ID NO: 5407 Protein  38 RSV186 Heavy chain variable region, F Clone No. 880 US20120009623 SEQ ID NO: 5408 Protein  39 RSV187 Heavy chain variable region, F Clone No. 881 US20120009623 SEQ ID NO: 5409 Protein  40 RSV188 Heavy chain variable region, F Clone No. 884 US20120009623 SEQ ID NO: 5410 Protein  41 RSV189 Heavy chain variable region, F Clone No. 886 US20120009623 SEQ ID NO: 5411 Protein  42 RSV190 Heavy chain variable region, F Clone No. 888 US20120009623 SEQ ID NO: 5412 Protein  43 RSV191 Heavy chain variable region, F Clone No. 894 US20120009623 SEQ ID NO: 5413 Protein  44 RSV192 Heavy chain variable region, F Gλ-1 US20050175986 SEQ ID NO: 4 5414 Protein RSV193 Super humanized heavy chain SHVh1 EP1720908; WO2005079479 5415 based on HNK20, F protein SEQ ID NO: 3 RSV194 Super humanized heavy chain SHVh2 EP1720908; WO2005079479 5416 based on HNK20, F protein SEQ ID NO: 4 RSV195 Super humanized heavy chain SHVh3 EP1720908; WO2005079479 5417 based on HNK20, F protein SEQ ID NO: 5 RSV196 Super humanized heavy chain SHVh4 EP1720908; WO2005079479 5418 based on HNK20, F protein SEQ ID NO: 6 RSV197 Super humanized heavy chain SHVh5 EP1720908; WO2005079479 5419 based on HNK20, F protein SEQ ID NO: 7 RSV198 Super humanized heavy chain SHVh6 EP1720908; WO2005079479 5420 based on HNK20, F protein SEQ ID NO: 8 RSV199 Super humanized heavy chain SHVh7 EP1720908; WO2005079479 5421 based on HNK20, F protein SEQ ID NO: 9 RSV200 Heavy chain variable region, F B4 EP636182; WO1993020210; 5422 Protein SEQ ID NO: 3 RSV201 Heavy chain variable region, F B13/14 EP636182; WO1993020210; 5423 Protein SEQ ID NO: 4 RSV202 Heavy chain variable region, F RF-1 EP854730; WO1996040252; 5424 Protein FIG. 7B RSV203 Heavy chain variable region, F RF-2 EP854730; WO1996040252; 5425 Protein FIG. 8B RSV204 Heavy chain, G Protein 1F12 US8273354 SEQ ID NO: 28 5426 RSV205 Heavy chain, G Protein 3G12 US8273354 SEQ ID NO: 29 5427 RSV206 Heavy chain, G Protein 1A5 US8273354 SEQ ID NO: 30 5428 RSV207 Heavy chain, G Protein 3D3 US8273354 SEQ ID NO: 31 5429 RSV208 Heavy chain, G Protein 1G1 US8273354 SEQ ID NO: 32 5430 RSV209 Heavy chain, G Protein 2B11 US8273354 SEQ ID NO: 33 5431 RSV210 Heavy chain, G Protein 5D8 US8273354 SEQ ID NO: 34 5432 RSV211 Heavy chain, G Protein 2D10 US8273354 SEQ ID NO: 35 5433 RSV212 Heavy chain, G Protein 3F9 US8273354 SEQ ID NO: 36 5434 RSV213 Heavy chain, G Protein 1D4 US8273354 SEQ ID NO: 37 5435 RSV214 Heavy chain, G Protein 1G8 US8273354 SEQ ID NO: 38 5436 RSV215 Heavy chain, G Protein 6A12 US8273354 SEQ ID NO: 39 5437 RSV216 Heavy chain, G Protein 10C6 US8273354 SEQ ID NO: 40 5438 RSV217 Heavy chain, G Protein Hu 131-2G US8273354 SEQ ID NO: 41 5439 RSV218 Heavy chain, G Protein AT46 US20150004155 SEQ ID NO: 5440  109 RSV219 Heavy chain, G Protein AT32 US20150004155 SEQ ID NO: 5441  110 RSV220 Heavy chain, G Protein AT33 US20150004155 SEQ ID NO: 5442  111 RSV221 Heavy chain, G Protein AT34 US20150004155 SEQ ID NO: 5443  112 RSV222 Heavy chain, G Protein AT735 US20150004155 SEQ ID NO: 5444  113 RSV223 Heavy chain, G Protein AT36 US20150004155 SEQ ID NO: 5445  114 RSV224 Heavy chain, G Protein AT737 US20150004155 SEQ ID NO: 5446  115 RSV225 Heavy chain, G Protein AT39 US20150004155 SEQ ID NO: 5447  116 RSV226 Heavy chain, G Protein AT40 US20150004155 SEQ ID NO: 5448  117 RSV227 Heavy chain, G Protein AT42 US2010004155 SEQ ID NO: 5449  118 RSV228 Heavy chain, G Protein AT43 US20150004155 SEQ ID NO: 5450  119 RSV229 Heavy chain, G Protein AT44 US20150004155 SEQ ID NO: 5451  120 RSV230 Heavy chain, G Protein AT45 US20150004155 SEQ ID NO: 5452  121 RSV231 Heavy chain, G Protein AT47 US20150004155 SEQ ID NO: 5453  122 RSV232 Heavy chain, G Protein AT49 US20150004155 SEQ ID NO: 5454  123 RSV233 Heavy chain, G Protein AT50 US20150004155 SEQ ID NO: 5455  124 RSV234 Heavy chain, G Protein AT51 US20150004155 SEQ ID NO: 5456  125 RSV235 Heavy chain variable region, G CB058.1 WO2014170257 SEQ ID NO: 5457 Protein  37 RSV236 Heavy chain variable region, G CB048.3 WO2014170257 SEQ ID NO: 5458 Protein  39 RSV237 Heavy chain variable region, G CB010.7 WO2014170257 SEQ ID NO: 5459 Protein  41 RSV238 Heavy chain variable region, G CB003.1 WO2014170257 SEQ ID NO: 5460 Protein  43 RSV239 Heavy chain variable region, G CB028.2 WO2014170257 SEQ ID NO: 5461 Protein  45 RSV240 Heavy chain variable region, G CB002.1 WO2014170257 SEQ ID NO: 5462 Protein  47 RSV241 Heavy chain variable region, G CB017.3L WO2014170258 SEQ ID NO: 5463 Protein  73 RSV242 Heavy chain variable region, G CB017.5L WO2014170258 SEQ ID NO: 5464 Protein  75 RSV243 Heavy chain variable region, G CB028.1 WO2014170258 SEQ ID NO: 5465 Protein  77 RSV244 Heavy chain variable region, G CB030.1 WO2014170258 SEQ ID NO: 5466 Protein  79 RSV245 Heavy chain variable region, G CB047.1 WO2014170258 SEQ ID NO: 5467 Protein  81 RSV246 Heavy chain variable region, G CB04712 WO2014170258 SEQ ID NO: 5468 Protein  83 RSV247 Heavy chain variable region, G CB065.1 WO2014170258 SEQ ID NO: 5469 Protein  85 RSV248 Heavy chain variable region, G CB071.1L WO2014170258 SEQ ID NO: 5470 Protein  87 RSV249 Heavy chain variable region, G CB072.1L WO2014170258 SEQ ID NO: 5471 Protein  89 RSV250 Heavy chain variable region, G CB073.1L WO2014170258 SEQ ID NO: 5472 Protein  91 RSV251 Heavy chain variable region, G CB076.2L WO2014170258 SEQ ID NO: 5473 Protein  93 RSV252 Heavy chain variable region, G CB079.1 WO2014170258 SEQ ID NO: 5474 Protein  95 RSV253 Heavy chain AM14 US20140377279 SEQ ID NO: 5475  78 RSV254 Heavy chain AM16 US20140377279 SEQ ID NO: 5476  85 RSV255 Heavy chain AM23 US20140377279 SEQ ID NO: 5477  92 RSV256 Heavy chain D25 US20140377279 SEQ ID NO: 7 5478 RSV257 Heavy chain AFFF US7635568 SEQ ID NO: 210 5479 RSV258 Heavy chain P12f2 US7635568 SEQ ID NO: 212 5480 RSV259 Heavy chain P12f4 US7635568 SEQ ID NO: 214 5481 RSV260 Heavy chain P11d4 US7635568 SEQ ID NO: 216 5482 RSV261 Heavy chain Ale9 US7635568 SEQ ID NO: 218 5483 RSV262 Heavy chain A12a6 US7635568 SEQ ID NO: 220 5484 RSV263 Heavy chain A13c4 US7635568 SEQ ID NO: 222 5485 RSV264 Heavy chain A17d4 US7635568 SEQ ID NO: 224 5486 RSV265 Heavy chain A4B4 US7635568 SEQ ID NO: 226 5487 RSV266 Heavy chain A8c7 US7635568 SEQ ID NO: 228 5488 RSV267 Heavy chain 1X-493L1FR US7635568 SEQ ID NO: 230 5489 RSV268 Heavy chain H3-3F4 US7635568 SEQ ID NO: 232 5490 RSV269 Heavy chain M3H9 US7635568 SEQ ID NO: 234 5491 RSV270 Heavy chain Y10H6 US7635568 SEQ ID NO: 236 5492 RSV271 Heavy chain DG US7635568 SEQ ID NO: 238 5493 RSV272 Heavy chain AFFF(1) US7635568 SEQ ID NO: 240 5494 RSV273 Heavy chain 6H8 US7635568 SEQ ID NO: 242 5495 RSV274 Heavy chain L1-7E5 US7635568 SEQ ID NO: 244 5496 RSV275 Heavy chain L2-15B10 US7635568 SEQ ID NO: 246 5497 RSV276 Heavy chain A13a11 US7635568 SEQ ID NO: 248 5498 RSV277 Heavy chain A1h5 US7635568 SEQ ID NO: 250 5499 RSV278 Heavy chain A4B4(1) US7635568 SEQ ID NO: 252 5500 RSV279 Heavy chain A4B4L1FR-S28R US7635568 SEQ ID NO: 254 5501 (MEDI-524, Motavizumab, Numax) RSV280 Heavy chain A4B4-F52S US7635568 SEQ ID NO: 256 5502 RSV281 Heavy chain US7364737 SEQ ID NO: 1 5503 RSV282 Heavy chain US7364737 SEQ ID NO: 2 5504 RSV283 Heavy chain variable region J variant WO2015108967 SEQ ID NO: 5505  12 RSV284 Heavy chainvariable region L variant WO2015108967 SEQ ID NO: 5506  13 RSV285 Heavy chain variable region LA variant WO2015108967 SEQ ID NO: 5507  14 RSV286 Heavy chain variable region 1G7 WO2015108967 SEQ ID NO: 5508  15 RSV287 Heavy chain variable region 1F5 WO2015108967 SEQ ID NO: 5509  16 RSV288 Heavy chain variable region 2D10 WO2015108967 SEQ ID NO: 5510  17 RSV289 Heavy chain variable region 1G7-GLM WO2015108967 SEQ ID NO: 5511  18 RSV290 Heavy chain variable region B12-1 WO2015108967 SEQ ID NO: 5512  19 RSV291 Heavy chain variable region E3-5 WO2015108967 SEQ ID NO: 5513  20 RSV292 Heavy chain variable region E9-2 WO2015108967 SEQ ID NO: 5514  21 RSV293 Heavy chain variable region 1X-493L1FR US7635568 SEQ ID NO: 7 5515 RSV294 Heavy chain variable region AFFF, AFFF(1) US7635568 SEQ ID NO: 9 5516 RSV295 Heavy chain variable region P12f2 US7635568 SEQ ID NO: 17 5517 RSV296 Heavy chain variable region P12f4 US7635568 SEQ ID NO: 24 5518 RSV297 Heavy chain variable region P11d4 US7635568 SEQ ID NO: 28 5519 RSV298 Heavy chain variable region Ale9, A1h5 US7635568 SEQ ID NO: 33 5520 RSV299 Heavy chain variable region A12a6 US7635568 SEQ ID NO: 36 5521 RSV300 Heavy chain variable region A13c4 US7635568 SEQ ID NO: 40 5522 RSV301 Heavy chain variable region A17d4 US7635568 SEQ ID NO: 44 5523 RSV302 Heavy chain variable region A4B4, A4B4(1), US7635568 SEQ ID NO: 48 5524 A4B4L1FR-S28R (MEDI-524, Motavizumab, Numax), A4B4- F52S RSV303 Heavy chain variable region A8c7 US7635568 SEQ ID NO: 51 5525 RSV304 Heavy chain variable region H3-3F4, M3H9, US7635568 SEQ ID NO: 55 5526 Y10H6 RSV305 Heavy chain variable region DG, 6H8, L1-7E5, US7635568 SEQ ID NO: 78 5527 L2-15B10 RSV306 Heavy chain variable region A13a11 US7635568 SEQ ID NO: 67 5528 RSV307 Heavy chain variable region US7364742 SEQ ID NO: 7 5529 RSV308 Heavy chain variable region US7364742 SEQ ID NO: 8 5530 RSV309 Heavy chain variable region D2E7 EP1807111; WO2006041970 5531 SEQ ID NO: 2 RSV310 Heavy chain variable region 2SD4 EP1807111; WO2006041970 5532 SEQ ID NO: 10 RSV311 Heavy chain, human Wen, X,, “Structure of the 5533 metapneumovirus fusion human metapneumovirus fusion protein with protein with neutralizing neutralizing antibody identifies antibody identifies a a pneumovirus antigenic site, pneumovirus antigenic site”, Nat. Struct. Mol. Biol. 19 (4), 461-463 (2012), NCBI Accession # 4DAG_H(220 aa) RSV312 Heavy chain variable, M2 1 8A4/G9-IgG US20140348858 SEQ ID NO: 3 5534 antigen RSV313 Heavy chain, Pre fusion RSV F HMB2435 WO2015010792 SEQ ID NO: 5535 protein  13 RSV314 Heavy chain, Pre fusion RSV F HMB2437 WO2015010792 SEQ ID NO: 5536 protein  29 RSV315 Heavy chain, Pre fusion RSV F HMB2416 WO2015010792 SEQ ID NO: 5537 protein  45 RSV316 Heavy chain, Pre fusion RSV F HMB2437 WO2015010792 SEQ ID NO: 5538 protein,  85 RSV317 Heavy chain, Pre fusion RSV F CR9501 WO2014202570 SEQ ID NO: 5539 protein  53 RSV318 Heavy chain, Pre fusion RSV F CR9502 WO2014202570 SEQ ID NO: 5540 protein  57 RSV319 Heavy chain 1, Pre fusion RSV HMB2432 WO2015010792 SEQ ID NO: 5541 F protein  61 RSV320 Heavy chain 2, Pre fusion RSV HMB2432 WO2015010792 SEQ ID NO: 5542 F protein  65 RSV321 Heavy chain FR LG, Pre HMB2435 WO2015010792 SEQ ID NO: 5543 fusion RSV F protein  75 RSV322 light chain, F and G Proteins clone 735 US20110189171; US7879329 5544 SEQ ID NO: 89 RSV323 light chain, F and G Proteins clone 736 US20110189171; US7879329 5545 SEQ ID NO: 90 RSV324 light chain, F and G Proteins clone 744 US20110189171; US7879329 5546 SEQ ID NO: 91 RSV325 light chain, F and G Proteins clone 793 US20110189171; US7879329 5547 SEQ ID NO: 92 RSV326 light chain, F and G Proteins clone 795 US20110189171; US7879329 5548 SEQ ID NO: 93 RSV327 light chain, F and G Proteins clone 796 US20110189171; US7879329 5549 SEQ ID NO: 94 RSV328 light chain, F and G Proteins clone 799 US20110189171; US7879329 5550 SEQ ID NO: 95 RSV329 light chain, F and G Proteins clone 800 US20110189171; US7879329 5551 SEQ ID NO: 96 RSV330 light chain, F and G Proteins clone 801 US20110189171; US7879329 5552 SEQ ID NO: 97 RSV331 light chain, F and G Proteins clone 804 US20110189171; US7879329 5553 SEQ ID NO: 98 RSV332 light chain, F and G Proteins clone 810 US20110189171; US7879329 5554 SEQ ID NO: 99 RSV333 light chain, F and G Proteins clone 811 US20110189171; US7879329 5555 SEQ ID NO: 100 RSV334 light chain, F and G Proteins clone 812 US20110189171; US7879329 5556 SEQ ID NO: 101 RSV335 light chain, F and G Proteins clone 814 US20110189171; US7879329 5557 SEQ ID NO: 102 RSV336 light chain, F and G Proteins clone 816 US20110189171; US7879329 5558 SEQ ID NO: 103 RSV337 light chain, F and G Proteins clone 817 US20110189171; US7879329 5559 SEQ ID NO: 104 RSV338 light chain, F and G Proteins clone 818 US20110189171; US7879329 5560 SEQ ID NO: 105 RSV339 light chain, F and G Proteins clone 819 US20110189171; US7879329 5561 SEQ ID NO: 106 RSV340 light chain, F and G Proteins clone 824 US20110189171; US7879329 5562 SEQ ID NO: 107 RSV341 light chain, F and G Proteins clone 825 US20110189171; US7879329 5563 SEQ ID NO: 108 RSV342 light chain, F and G Proteins clone 827 US20110189171; US7879329 5564 SEQ ID NO: 109 RSV343 light chain, F and G Proteins clone 829 US20110189171, US7879329 5565 SEQ ID NO: 110 RSV344 light chain, F and G Proteins clone 830 US20110189171; US7879329 5566 SEQ ID NO: 111 RSV345 light chain, F and G Proteins clone 831 US20110189171; US7879329 5567 SEQ ID NO: 112 RSV346 light chain, F and G Proteins clone 835 US20110189171; US7879329 5568 SEQ ID NO, 113 RSV347 light chain, F and G Proteins clone 838 US20110189171; US7879329 5569 SEQ ID NO: 114 RSV348 light chain, F and G Proteins clone 841 US20110189171; US7879329 5570 SEQ ID NO: 115 RSV349 light chain, F and G Proteins clone 853 US20110189171; US7879329 5571 SEQ ID NO: 116 RSV350 light chain, F and G Proteins clone 855 US20110189171; US7879329 5572 SEQ ID NO: 117 RSV351 light chain, F and G Proteins clone 856 US20110189171; US7879329 5573 SEQ ID NO: 118 RSV352 light chain, F and G Proteins clone 857 US20110189171; US7879329 5574 SEQ ID NO: 119 RSV353 light chain, F and G Proteins clone 858 US20110189171; US7879329 5575 SEQ ID NO: 120 RSV354 light chain, F and G Proteins clone 859 US20110189171; US7879329 5576 SEQ ID NO: 121 RSV355 light chain, F and G Proteins clone 861 US20110189171; US7879329 5577 SEQ ID NO: 122 RSV356 light chain, F and G Proteins clone 863 US20110189171; US7879329 5578 SEQ ID NO: 123 RSV357 light chain, F and G Proteins clone 868 US20110189171; US7879329 5579 SEQ ID NO: 124 RSV358 light chain, F and G Proteins clone 870 US20110189171; US7879329 5580 SEQ ID NO: 125 RSV359 light chain, F and G Proteins clone 871 US20110189171; US7879329 5581 SEQ ID NO: 126 RSV360 light chain, F and G Proteins clone 880 US20110189171; US7879329 5582 SEQ ID NO: 127 RSV361 light chain, F and G Proteins clone 881 US20110189171; US7879329 5383 SEQ ID NO: 128 RSV62 light chain, F and G Proteins clone 884 US20110189171; US7879329 5584 SEQ ID NO: 129 RSV363 light chain, F and G Proteins clone 886 US20110189171; US7879329 5585 SEQ ID NO: 130 RSV364 light chain, F and G Proteins clone 888 US20110189171; US7879329 5586 SEQ ID NO: 131 RSV365 light chain, F and G Proteins clone 894 US20110189171; US7879329 5587 SEQ ID NO: 132 RSV366 Light chain variable, F protein 3210 variant 1, WO2013140247 SEQ ID NO: 5588 of RSV, MPV, or PVM 3210 variant 2,  14 3210 variant 5 RSV367 Light chain variable, F protein 2430 variant 1, WO2013140247 SEQ ID NO: 5589 of RSV, MPV, or PVM 2430 variant 2,  30 2430 variant 4 RSV368 Light chain variable, F protein 3210 variant 3 WO2013140247 SEQ ID NO: 5590 of RSV, MPV, or PVM  37 RSV369 Light chain variable, F protein 3210 variant 4, WO20113140247 SEQ ID NO: 5591 of RSV, MPV, or PVM 3210 variant 6  50 RSV370 Light chain variable, F protein 2430 variant 3, WO2013140247 SEQ ID NO: 5592 of RSV, MPV, or PVM 2430 variant 5  60 RSV371 Light chain, F Protein clone 19 EP1259547; US8153133SEQ 5593 ID NO: 40 RSV372 Light chain variable region, US20140093501 SEQ ID NO: 5594 CDR Grafted, F Protein  20 RSV373 Light chain variable region, US20140093501 SEQ ID NO: 5595 CDR Grafted, F Protein  34 RSV374 Light chain, F Protein AM22 US8568726 SEQ ID NO: 32 5596 RSV375 Light chain, F Protein RSVF2-5 US8221759 SEQ ID NO: 9 5597 RSV376 Light chain, F Protein EP1259547; US8153133 SEQ 5598 ID NO: 3 RSV377 Light chain, F Protein MTDI- EP1259547; US8153133 SEQ 5599 493/Pavilizumab- ID NO: 1 N-VL (Brand name Synagis) RSV378 Light chain, F Protein EP1259547; US8153133 SEQ 5600 ID NO: 35 RSV379 Light chain, F Protein clone 18 EP1259547; US8153133 SEQ 5601 ID NO: 38 RSV380 Light chain, F Protein clone 20 ER1259547; US8153133 SEQ 5602 ID NO: 42 RSV381 Light chain, F Protein clone 21 EP1259547; US8153133 SEQ 5603 ID NO: 44 RSV382 Light chain, F Protein clone 22 ER1259547; US8153133 SEQ 5604 ID NO: 46 RSV383 Light chain, F Protein clone 23 EP1259547; US8153133 SEQ 5605 ID NO: 48 RSV384 Light chain, F Protein clone 24 ER1259547; US8153133 SEQ 5606 ID NO: 50 RSV385 Light chain, F Protein clone 25 EP1259547; US8153133 SEQ 5607 ID NO: 52 RSV386 Light chain, F Protein clone 26 ER1259547; US8153133 SEQ 5608 ID NO: 54 RSV387 Light chain variable region, F huK102 US20140093501 SEQ ID NO: 5609 Protein  19 RSV388 Light chain variable region, F huK102 US20140093501 SEQ ID NO: 5610 Protein  33 RSV389 Light chain variable region, F RSV G8 US7867497 SEQ ID NO: 4 5611 Protein RSV390 Light chain variable region, F Clone 1 US20120135006 SEQ ID NO: 5612 Protein  17 RSV391 Light chain variable region, F Clone 2 US20120135006 SEQ ID NO: 5613 Protein  19 RSV392 Light chain variable region, F Clone 3 US20120135006 SEQ ID NO: 5614 Protein  21 RSV393 Light chain variable region, F Clone 22 US20120135006 SEQ ID NO: 5615 Protein  23 RSV394 Light chain variable region, F Clone 23 US20120135006 SEQ ID NO: 5616 Protein  25 RSV395 Light chain variable region, F RSV13-9 WO2009088159 SEQ ID NO: 2 5617 Protein RSV396 Light chain variable region, F MAb1308F US20140093501 SEQ ID NO: 5618 Protein  21 RSV397 Light chain, F Protein 58c5 US20140044719 SEQ ID NO: 5 5619 RSV398 Light chain, F Protein sc5 US20140044719 SEQ ID NO: 5620  13 RSV399 Light chain, F Protein Clone No. 735 US20120009623 SEQ ID NO: 5621  89 RSV400 Light chain, F Protein Clone No. 736 US20120009623 SEQ ID NO: 5622  90 RSV401 Light chain, F Protein Clone No. 744 US20120009623 SEQ ID NO: 5623  91 RSV402 Light chain, F Protein Clone No. 793 US20120009623 SEQ ID NO: 5624  92 RSV403 Light chain, F Protein Clone No. 795 US20120009623 SEQ ID NO: 5625  93 RSV404 Light chain, F Protein Clone No. 796 US20120009623 SEQ ID NO: 5626  94 RSV405 Light chain, F Protein Clone No. 799 US20120009623 SEQ ID NO: 5627  95 RSV406 Light chain, F Protein Clone No. 800 US20120009623 SEQ ID NO: 5628  96 RSV407 Light chain, F Protein Clone No. 801 US20120009623 SEQ ID NO: 5629  97 RSV408 Light chain, F Protein Clone No. 804 US20120009623 SEQ ID NO: 5630  98 RSV409 Light chain, F Protein Clone No. 810 US2012000923 SEQ ID NO: 5631  99 RSV410 Light chain, F Protein Clone No. 811 US20120009623 SEQ ID NO: 5632  100 RSV411 Light chain, F Protein Clone No. 812 US20120009623 SEQ ID NO: 5633  101 RSV412 Light chain, F Protein Clone No. 814 US20120009623 SEQ ID NO: 5634  102 RSV413 Light chain, F Protein Clone No. 816 US20120009623 SEQ ID NO: 5635  103 RSV414 Light chain, F Protein Clone No. 817 US20120009623 SEQ ID NO: 5636  104 RSV415 Light chain, F Protein Clone No. 818 US20120009623 SEQ ID NO: 5637  105 RSV416 Light chain, F Protein Clone No. 819 US20120009623 SEQ ID NO: 5638  106 RSV417 Light chain, F Protein Clone No. 824 US20120009623 SEQ ID NO: 5639  107 RSV41,8 Light chain, F Protein Clone No. 825 US20120009623 SEQ ID NO: 5640  108 RSV419 Light chain, F Protein Clone No. 827 US20120009623 SEQ ID NO: 5641  109 RSV420 Light chain, F Protein Clone No. 829 US20120009623 SEQ ID NO: 5642  110 RSV421 Light chain, F Protein Clone No. 830 US20120009623 SEQ ID NO: 5643  111 RSV422 Light chain, F Protein Clone No. 831 US20120009623 SEQ ID NO: 5644  112 RSV23 Light chain, F Protein Clone No. 835 US20120009623 SEQ ID NO: 5645  113 RSV424 Light chain, F Protein Clone No. 838 US20120009623 SEQ ID NO: 5646  114 RSV42S Light chain, F Protein Clone No. 841 US20120009623 SEQ ID NO: 5647  115 RSV426 Light chain, F Protein Clone No. 853 US20120009623 SEQ ID NO: 5648  116 RSV427 Light chain, F Protein Clone No. 855 US20120009623 SEQ ID NO: 5649  117 RSV428 Light chain, F Protein Clone No. 856 US20120009623 SEQ ID NO: 5650  118 RSV429 Light chain, F Protein Clone No. 857 US20120009623 SEQ ID NO: 5651  119 RSV430 Light chain, F Protein Clone No. 858 US20120009623 SEQ ID NO: 5652  120 RSV431 Light chain, F Protein Clone No. 859 US20120009623 SEQ ID NO: 5653  121 RSV432 Light chain, F Protein Clone No. 861 US20120009623 SEQ ID NO: 5654  122 RSV433 Light chain, F Protein Clone No. 863 US20120009623 SEQ ID NO: 5655  123 RSV434 Light chain, F Protein Clone No. 868 US20120009623 SEQ ID NO: 5656  124 RSV435 Light chain, F Protein Clone No. 870 US20120009623 SEQ ID NO: 5657  125 RSV436 Light chain, F Protein Clone No. 871 US20120009623 SEQ ID NO: 5658  126 RSV437 Light chain, F Protein Clone No. 880 US2012000962 SEQ ID NO: 5659  127 RSV438 Light chain, F Protein Clone No. 881 US2012000923 SEQ ID NO: 5660  128 RSV439 Light chain, F Protein Clone No. 884 US20120009623 SEQ ID NO: 5661  129 RSV440 Light chain, F Protein Clone No. 886 US20120009623 SEQ ID NO: 5662  130 RSV441 Light chain, F Protein Clone No. 888 US20120009623 SEQ ID NO: 5663  131 RSV442 Light chain, F Protein Clone No. 894 US20120009623 SEQ ID NO: 5664  132 RSV443 Light chain, F Protein US20110027294 SEQ ID NO: 5665  63 RSV444 Light chain, F Protein US20110027294 SEQ ID NO: 5666  64 RSV445 Light chain, F Protein US20110027294 SEQ ID NO: 5667  65 RSV446 Light chain, F Protein US20110027294 SEQ ID NO: 5668  66 RSV447 Light chain, F Protein US20110027294 SEQ ID NO: 5669  67 RSV448 Light chain, F Protein US20110027294 SEQ ID NO: 5670  68 RSV449 Light chain, F Protein US20110027294 SEQ ID NO: 5671  69 RSV450 Light chain, F Protein US20110027294 SEQ ID NO: 5672  70 RSV451 Light chain, F Protein US20110027294 SEQ ID NO: 5673  71 RSV452 Light chain, F Protein US20110027294 SEQ ID NO: 5674  72 RSV453 Light chain, F Protein US20110027294 SEQ ID NO: 5675  73 RSV454 Light chain, F Protein US20110027294 SEQ ID NO: 5676  81 RSV455 Light chain, F Protein US20110027294 SEQ ID NO: 5677  82 RSV456 Light chain, F Protein US20110027294 SEQ ID NO: 5678  83 RSV457 Light chain, F Protein US20110027294 SEQ ID NO: 5679  84 RSV458 Light chain, F Protein US20110027294 SEQ ID NO: 5680  85 RSV459 Light chain, F Protein US20110027294 SEQ ID NO: 5681  86 RSV460 Light chain, F Protein US20110027294 SEQ ID NO: 5682  87 RSV461 Light chain, F Protein US20110027294 SEQ ID NO: 5683  88 RSV462 Light chain, F Protein US20110027294 SEQ ID NO: 5684  89 RSV463 Light chain, F Protein US20110027294 SEQ ID NO: 5685  90 RSV464 Light chain, F Protein US20110027294 SEQ ID NO: 5686  91 RSV465 Light chain, F Protein US20110027294 SEQ ID NO: 5687  92 RSV466 Light chain, F Protein US20110027294 SEQ ID NO: 5688  93 RSV467 Light chain, F Protein US20110027294 SEQ ID NO: 5689  94 RSV468 Light chain, F Protein US20110027294 SEQ ID NO: 5690  95 RSV469 Light chain, F Protein US20110027294 SEQ ID NO: 5691  96 RSV470 Light chain, F Protein US20110027294 SEQ ID NO: 5692  97 RSV471 Light chain, F Protein US20110027294 SEQ ID NO: 5693  98 RSV472 Light chain, F Protein US20110027294 SEQ ID NO: 5694   99 RSV473 Light chain, F Protein US20110027294 SEQ ID NO: 5695  100 RSV474 Light chain, F Protein US20110027294 SEQ ID NO: 5696  101 RSV475 Light chain, F Protein US20110027294 SEQ ID NO: 5697  102 RSV476 Light chain, F Protein US20110027294 SEQ ID NO: 5698  103 RSV477 Light chain, F Protein US20110027294 SEQ ID NO: 5699  104 RSV478 Light chain, F Protein US20110027294 SEQ ID NO: 5700  105 RSV479 Light chain, F Protein US20110027294 SEQ ID NO: 5701  106 RSV480 Light chain, F Protein US20110027294 SEQ ID NO: 5702  107 RSV481 Light chain, F Protein US20110027294 SEQ ID NO: 5703  108 RSV482 Light chain, F Protein US20110027294 SEQ ID NO: 5704  109 RSV483 Light chain, F Protein US20110027294 SEQ ID NO: 5705  110 RSV484 Light chain, F Protein US20110027294 SEQ ID NO: 5706  111 RSV485 Light chain, F Protein US20110027294 SEQ ID NO: 5707  112 RSV486 Light chain, F Protein Gλ-1A US20050175986 SEQ ID NO: 9 5708 RSV487 Light chain, F Protein A construct US20050175986 SEQ ID NO: 5709   11 RSV488 Light chain, F Protein B construct US20050175986 SEQ ID NO: 5710   12 RSV489 Light chain, F Protein hu19A US20050019758; 5711 WO1998019704 SEQ ID NO:   10 RSV490 Light chain, F Protein hu19B US20050019758; 5712 WO1998019704 SEQ ID NO:   11 RSV491 Light chain, F Protein hu19C US20050019758; 5713 WO1998019704 SEQ ID NO:   12 RSV492 Light chain, F Protein hu19D US20050019758; 5714 WO1998019704 SEQ ID NO:   13 RSV493 Light chain, F Protein RSV19 EP636182; WO1993020210; 5715 SEQ ID NO: 12 RSV494 Light chain, F Protein, WO19922004381 5716 RSV495 Light chain variable region, F P1212 US20140044719 SEQ ID NO: 5717 Protein  127 RSV496 Light chain variable region, F P12f4 US20140044719 SEQ ID NO: 5718 Protein  134 RSV497 Light chain variable region, F P11d4 US20140044719 SEQ ID NO: 5719 Protein  140 RSV498 Light chain variable region, F A1e9 US20140044719 SEQ ID NO: 5720 Protein  146 RSV499 Light chain variable region, F A12a6 US20140044719 SEQ ID NO: 5721 Protein  152 RSV500 Light chain variable region, F A13c4 US20140044719 SEQ ID NO: 5722 Protein  158 RSV501 Light chain variable region, F A17d4 US20140044719 SEQ ID NO: 5723 Protein  164 RSV502 Light chain variable region, F A4B4 US20140044719 SEQ ID NO: 5724 Protein  169 RSV503 Light chain variable region, F A8c7 US20140044719 SEQ ID NO: 5725 Protein  174 RSV504 Light chain variable region, F IX-493L1FR US20140044719 SEQ ID NO: 5726 Protein  178 RSV505 Light chain variable region, F M3H9 US20140044719 SEQ ID NO: 5727 Protein  180 RSV506 Light chain variable region, F B21M US20110027294 SEQ ID NO: 5728 Protein   51 RSV507 Light chain variable region, F 101F US20110027294 SEQ ID NO: 6 5729 Protein RSV508 Light chain variable region, F HNK20 EP1720908; WO2005079479 5730 Protein SEQ ID NO: 2 RSV509 Light chain variable region, F P1212 US20140044719 SEQ ID NO: 5731 Protein  128 RSV510 Light chain variable region, F P12f4 US20140044719 SEQ ID NO: 5732 Protein  135 RSV511 Light chain variable region, F P11d4 US20140044719 SEQ ID NO: 5733 Protein  141 RSV512 Light chain variable region, F A1e9 US20140044719 SEQ ID NO: 5734 Protein  147 RSV513 Light chain variable region, F A12a6 US20140044719 SEQ ID NO: 5735 Protein  153 RSV514 Light chain variable region, F A13c4 US20140044719 SEQ ID NO: 5736 Protein  159 RSV515 Light chain variable region, F A17d4 US20140044719 SEQ ID NO: 5737 Protein  165 RSV516 Light chain variable region, F A4B4 US20140044719 SEQ ID NO: 5738 Protein  170 RSV517 Light chain variable region, F A8c7 US20140044719 SEQ ID NO: 5739 Protein  175 RSV518 Light chain variable region, F IX-493L1FR US20140044719 SEQ ID NO: 5740 Protein  179 RSV519 Light chain variable region, F H1 H3564P WO2014159822 SEQ ID NO: 5741 Protein  10 RSV520 Light chain variable region, F H1 H3565P WO2014159822 SEQ ID NO: 5742 Protein  26 RSV521 Light chain variable region, F H1 H3566P WO2014159822 SEQ ID NO: 5743 Protein  42 RSV522 Light chain variable region, F H1 H3567P WO2014159822 SEQ ID NO: 5744 Protein  58 RSV523 Light chain variable region, F H1 H3581 P WO2014159822 SEQ ID NO: 5745 Protein  74 RSV524 Light chain variable region, F H1 H3583P WO2014159822 SEQ ID NO: 5746 Protein  90 RSV525 Light chain variable region, F H1 H3589P WO2014159822 SEQ ID NO: 5747 Protein  106 RSV526 Light chain variable region, F H1 H3591 P WO2014159822 SEQ ID NO: 5748 Protein  122 RSV527 Light chain variable region, F H1 H3592P WO2014159822 SEQ ID NO: 5749 Protein  138 RSV528 Light chain variable region, F H1 H3597P WO2014159822 SEQ ID NO: 5750 Protein  154 RSV529 Light chain variable region, F H1 H3598P WO2014159822 SEQ ID NO: 5751 Protein  170 RSV530 Light chain variable region, F H1 H3603P WO2014159822 SEQ ID NO: 5752 Protein  186 RSV531 Light chain variable region, F H1 H3604P WO2014159822 SEQ ID NO: 5753 Protein  202 RSV532 Light chain variable region, F H1 H3605P WO2014159822 SEQ ID NO: 5754 Protein  218 RSV533 Light chain variable region, F H1 H3607P WO2014159822 SEQ ID NO: 5755 Protein  234 RSV534 Light chain variable region, F H1 H3608P2 WO2014159822 SEQ ID NO: 5756 Protein  250 RSV535 Light chain variable region, F H1 H3592P2 WO2014159822 SEQ ID NO: 5757 Protein  266 RSV536 Light chain variable region, F H1 H3592P3 WO2014159822 SEQ ID NO: 5758 Protein  282 RSV537 Light chain variable region, F H1 M3621 N WO2014159822 SEQ ID NO: 5759 Protein  298 RSV538 Light chain variable region, F H1 M3622N WO2014159822 SEQ ID NO: 5760 Protein  314 RSV539 Light chain variable region, F H1 M2634N WO2014159822 SEQ ID NO: 5761 Protein  330 RSV540 Light chain variable region, F H1 M3627N WO2014159822 SEQ ID NO: 5762 Protein  346 RSV541 Light chain variable region, F Gλ-1 US20050175986 SEQ ID NO: 2 5763 Protein RSV542 Light chain variable region, F MAb1129 US20140093501 SEQ ID NO: 5764 Protein  35 RSV543 super humanized kappa light SHVl1 EP1720908; WO2005079479 5765 chain based on HNK20, F SEQ ID NO: 10 protein RSV544 super humanized kappa light SHVl2 EP1720908; WO2005079479 5766 chain based on HNK20, F SEQ ID NO: 11 protein RSV545 super humanized kappa light SHVl3 EP1720908; WO2005079479 5767 chain based on HNK20, F SEQ ID NO: 12 protein RSV546 super humanized kappa light SHVl4 EP1720908; WO2005079479 5768 chain based on HNK20, F SEQ ID NO: 13 protein RSV547 super humanized kappa light SHVl5 EP1720908; WO2005079479 5769 chain based on HNK20, F SEQ ID NO: 14 protein RSV548 super humanized kappa light SHVl6 EP1720908; WO2005079479 5770 chain based on HNK20, F SEQ ID NO: 15 protein RSV549 Light chain variable region, F B4 EP636182; WO1993020210; 5771 Protein SEQ ID NO: 1 RSV550 Light chain variable region, F B13/14 EP636182; WO1993020210; 5772 Protein SEQ ID NO: 2 RSV551 Light chain variable region, F RF-1 EP854730; WO1996040252; 5773 Protein FIG. 7A RSV552 Light chain variable region, F RF-2 EP854730; WO1996040252; 5774 Protein FIG. 8A RSV553 Light chain variable region CB058.1 WO2014170257 SEQ ID NO: 5775 Kappa, G protein  38 RSV554 Light chain variable region CB048.3 WO2014170257 SEQ ID NO: 5776 Kappa, G protein  40 RSV555 Light chain variable region CB010.7 WO2014170257 SEQ ID NO: 5777 Kappa, G protein  42 RSV556 Light chain variable region CB003.1 WO2014170257 SEQ ID NO: 5778 Kappa, G protein  44 RSV557 Light chain variable region CB028.2 WO2014170257 SEQ ID NO: 5779 Kappa, G protein  46 RSV558 Light chain variable region CB002.1 WO2014170257 SEQ ID NO: 5780 Kappa, G protein  48 RSV559 Light chain, G Protein 1F12 US8273354 SEQ ID NO: 42 5781 RSV560 Light chain, G Protein 3G12 US8273354 SEQ ID NO: 43 5782 RSV561 Light chain, G Protein 1A5 US8273354 SEQ ID NO: 44 5783 RSV562 Light chain, G Protein 3D3 US8273354 SEQ ID NO: 45 5784 RSV563 Light chain, G Protein 1G1 US8273354 SEQ ID NO: 46 5785 RSV564 Light chain, G Protein 2B11 US8273354 SEQ ID NO: 47 5786 RSV565 Light chain, G Protein 5D8 US8273354 SEQ ID NO: 48 5787 RSV566 Light chain, G Protein 2D10 US8273354 SEQ ID NO: 49 5788 RSV567 Light chain, G Protein 3F9 US8273354 SEQ ID NO: 50 5789 RSV568 Light chain, G Protein 1D4 US8273354 SEQ ID NO: 51 5790 RSV569 Light chain, G Protein 1G8 US8273354 SEQ ID NO: 52 5791 RSV570 Light chain, G Protein 6A12 US8273354 SEQ ID NO: 53 5792 RSV571 Light chain, G Protein 10C6 US8273354 SEQ ID NO: 54 5793 RSV572 Light chain, G Protein Hu 131-2G US8273354 SEQ ID NO: 55 5794 RSV573 Light chain, G Protein AT46 US20150004155 SEQ ID NO: 5795  127 RSV574 Light chain, G Protein AT32 US20150004155 SEQ ID NO: 5796  128 RSV575 Light chain, G Protein AT33 US20150004155 SEQ ID NO: 5797  129 RSV576 Light chain, G Protein AT34 US20150004155 SEQ ID NO: 5798  130 RSV577 Light chain, G Protein AT35 US20150004155 SEQ ID NO: 5799  131 RSV578 Light chain, G Protein AT36 US20150004155 SEQ ID NO: 5800  132 RSV579 Light chain, G Protein AT37 US20150004155 SEQ ID NO: 5801  133 RSV580 Light chain, G Protein AT39 US20150004155 SEQ ID NO: 5802  134 RSV581 Light chain, G Protein AT40 US20150004155 SEQ ID NO: 5803  135 RSV582 Light chain, G Protein AT42 US20150004155 SEQ ID NO: 5804  136 RSV583 Light chain, G Protein AT43 US20150004155 SEQ ID NO: 5805  137 RSV584 Light chain, G Protein AT44 US20150004155 SEQ ID NO: 5806  138 RSV585 Light chain, G Protein AT45 US20150004155 SEQ ID NO: 5807  139 RSV586 Light chain, G Protein AT47 US20150004155 SEQ ID NO: 5808  140 RSV587 Light chain, G Protein AT49 US20150004155 SEQ ID NO: 5809  141 RSV588 Light chain, G Protein AT50 US20150004155 SEQ ID NO: 5810  142 RSV589 Light chain, G Protein AT51 US20150004155 SEQ ID NO: 5811  143 RSV590 Light chain variable region, G CB017.3L WO2014170258 SEQ ID NO: 5812 Protein  74 RSV591 Light chain variable region, G CB017.5L WO2014170258 SEQ ID NO: 5813 Protein  76 RSV592 Light chain variable region, G CB028.1 WO2014170258 SEQ ID NO: 5814 Protein  78 RSV593 Light chain variable region, G CB030.1 WO2014170258 SEQ ID NO: 5815 Protein  80 RSV594 Light chain variable region, G CB047.1 WO2014170258 SEQ ID NO: 5816 Protein  82 RSV595 Light chain variable region, G CB047.2 WO2014170258 SEQ ID NO: 5817 Protein  84 RSV596 Light chain variable region, G CB065.1 WO2014170258 SEQ ID NO: 5818 Protein  86 RSV597 Light chain variable region, G CB071.1L WO2014170258 SEQ ID NO: 5819 Protein  88 RSV598 Light chain variable region, G CB072.1L WO2014170258 SEQ ID NO: 5820 Protein  90 RSV599 Light chain variable region, G CB073.1L WO2014170258 SEQ ID NO: 5821 Protein  92 RSV600 Light chain variable region, G CB076.2L WO2014170258 SEQ ID NO: 5822 Protein  94 RSV601 Light chain variable region, G CB079.1 WO2014170258 SEQ ID NO: 5823 Protein  96 RSV602 Light chain, human Wen,X., “Structure of the 5824 metapneumovirus fusion human metapueumovirus fusion protein with protein with neutralizing neutralizing antibody identifies antibody identifies a a pueumovirus antigenic site pneumovirus antigenic site”, Nat. Struct. Mol. Biol. 19 (4), 461-463 (2012), NCBI Accession # 4DAG_L(213 aa) RSV603 Light chain AM14 US20140377279 SEQ ID NO: 5825  79 RSV604 Light chain AM16 US20140377279 SEQ ID NO: 5826  86 RSV605 Light chain AM23 US20140377279 SEQ ID NO: 5827  93 RSV606 Light chain D25 US20140377279 SEQ ID NO: 8 5828 RSV607 Light chain AFFF US7635568 SEQ ID NO: 211 5829 RSV608 Light chain P12f2 US7635568 SEQ ID NO: 213 5830 RSV609 Light chain P12f4 US7635568 SEQ ID NO: 215 5831 RSV610 Light chain P11d4 US7635568 SEQ ID NO: 217 5832 RSV611 Light chain Ale9 US7635568 SEQ ID NO: 219 5833 RSV612 Light chain A12a6 US7635568 SEQ ID NO: 221 5834 RSV613 Light chain A13c4 US7635568 SEQ ID NO: 223 5835 RSV614 Light chain A17d4 US7635568 SEQ ID NO: 225 5836 RSV615 Light chain A4B4 US7635568 SEQ ID NO: 227 5837 RSV616 Light chain A8c7 US7635568 SEQ ID NO: 229 5838 RSV617 Light chain 1X-493-L1FR US7635568 SEQ ID NO: 231 5839 RSV618 Light chain H3-3F4, DG US7635568 SEQ ID NO: 233 5840 RSV619 Light chain M3H9 US7635568 SEQ ID NO: 235 5841 RSV620 Light chain Y10H6 US7635568 SEQ ID NO: 237 5842 RSV621 Light chain DG US7635568 SEQ ID NO: 239 5843 RSV622 Light chain AFFF(1) US7635568 SEQ ID NO: 241 5844 RSV623 Light chain 6H8 US7635568 SEQ ID NO: 243 5845 RSV624 Light chain L1-7E5 US7635568 SEQ ID NO: 245 5846 RSV625 Light chain L2-15B10 US7635568 SEQ ID NO: 247 5847 RSV626 Light chain A13a11 US7635568 SEQ ID NO: 249 5848 RSV627 Light chain A1h5 US7635568 SEQ ID NO: 251 5849 RSV628 Light chain A4B4(1) US7635568 SEQ ID NO: 253 5850 RSV629 Light chain A4B4L1FR-S28R US7635568 SEQ ID NO: 255 5851 RSV630 Light chain A4B4-F52S US7635568 SEQ ID NO: 257 5852 RSV631 Light chain variable region AFFF US7635568 SEQ ID NO: 13 5853 RSV632 Light chain variable region P12f2 US7635568 SEQ ID NO: 21 5854 RSV633 Light chain variable region P12f4 US7635568 SEQ ID NO: 26 5855 RSV634 Light chain variable region P11d4 US7635568 SEQ ID NO: 30 5856 RSV635 Light chain variable region Ale9 US7635568 SEQ ID NO: 34 5857 RSV636 Light chain variable region A12a6 US7635568 SEQ ID NO: 38 5858 RSV637 Light chain variable region A13c4 US7635568 SEQ ID NO: 42 5859 RSV638 Light chain variable region A17d4 US7635568 SEQ ID NO: 46 5860 RSV639 Light chain variable region A4B4 US7635568 SEQ ID NO: 49 5861 RSV640 Light chain variable region A8c7 US7635568 SEQ ID NO: 52 5862 RSV641 Light chain variable region 1X-493L1FR US7635568 SEQ ID NO: 54 5863 RSV642 Light chain variable region H3-3F4, DG US7635568 SEQ ID NO: 56 5864 RSV643 Light chain variable region M3H9 US7635568 SEQ ID NO: 70 5865 RSV644 Light chain variable region Y10H6 US7635568 SEQ ID NO: 58 5866 RSV645 Light chain variable region AFFF(1) US7635568 SEQ ID NO: 60 5867 RSV646 Light chain variable region 6H8 US7635568 SEQ ID NO: 62 5868 RSV647 Light chain variable region L1-7E5 US7635568 SEQ ID NO: 64 5869 RSV648 Light chain variable region L2-15B10 US7635568 SEQ ID NO: 65 5870 RSV649 Light chain variable region A13a11 US7635568 SEQ ID NO: 68 5871 RSV650 Light chain variable region A1h5 US7635568 SEQ ID NO: 71 5872 RSV651 Light chain variable region A4B4(1) US7635568 SEQ ID NO: 74 5873 RSV652 Light chain variable region A4B4L1FR-S28R US7635568 SEQ ID NO: 11 5874 RSV653 Light chain variable region A4B4-F52S US7635568 SEQ ID NO: 76 5875 RSV654 Light chain variable region 6H; 11H; 21H; US7364737 SEQ ID NO: 21 5876 22H; and 23H RSV655 Light chain variable region 13H and 19H US7364737 SEQ ID NO: 22 5877 RSV656 Light chain variable region 6L; 11L; 21L; and US7364737 SEQ ID NO: 23 5878 22L RSV657 Light chain variable region 23L US7364737 SEQ ID NO: 24 5879 RSV658 Light chain variable region 13L and 19L US7364737 SEQ ID NO: 25 5880 RSV659 Light chain variable region US7364742 SEQ ID NO: 9 5881 RSV660 Light chain variable region US7364742 SEQ ID NO: 10 5882 RSV661 Light chain variable region US7364742 SEQ ID NO: 11 5883 RSV662 Light chain variable region US7364742 SEQ ID NO: 12 5884 RSV663 Light chain variable region D2E7 EP1807111; WO2006041970 5885 SEQ ID NO: 1 RSV664 Light chain variable region 2SD4 EP1807111; WO2006041970 5886 SEQ ID NO: 9 RSV665 Light chain variable, M2 1 8A4/G9-IgG US20140348858 SEQ ID NO: 4 5887 antigen RSV666 Light chain, Pre fusion RSV F HMB2435 WO2015010792 SEQ ID NO: 5888 protein  14 RSV667 Light chain, Pre fusion RSV F HMB2437 WO2015010792 SEQ ID NO: 5889 protein  30 RSV668 Light chain, Pre fusion RSV F HMB2416 WO2015010792 SEQ ID NO: 5890 protein  46 RSV669 Light chain, Pre fusion RSV F HMB2437 WO2015010792 SEQ ID NO: 5891 protein  86 RSV670 Light chain, Pre fusion RSV F CR9501 WO2014202570 SEQ ID NO: 5892 protein  61 RSV671 Light chain, Pre fusion RSV F CR9502 WO2014202570 SEQ ID NO: 5893 protein  65 RSV672 Light chain 1, Pre fusion RSV HMB2432 WO2015010792 SEQ ID NO: 5894 F protein  62 RSV673 Light chain FR GL, Pre fusion HMB2432 WO2015010792 SEQ ID NO: 5895 RSV F protein  66 RSV674 Light chain 2, Pre fusion RSV HMB2435 WO2015010792 SEQ ID NO: 5896 F protein  76 RSV675 derived Ig variable region RSV19VH EP636182; WO1993020210; 5897 amino acid sequence, F protein SEQ ID NO: 13 RSV676 derived Ig variable region pHuRSV19VH EP636182; WO1993020210; 5898 amino acid sequence, F protein SEQ ID NO: 14 RSV677 derived Ig variable region pHuRSV19VHFNS EP636182; WO1993020210; 5899 amino acid sequence, F protein SEQ ID NO: 15 RSV678 derived Ig variable region pHuRSV19VHNIK EP636182; WO1993020210; 5900 amino acid sequence, F protein SEQ ID NO: 16 RSV679 derived Ig variable region pHuRSV19VK EP636182; WO1993020210; 5901 amino acid sequence, F protein SEQ ID NO: 17 RSV680 Nanobody binding to RSV F LG202A10 US20110182897 SEQ ID NO: 5902 protein  126 RSV681 Nanobody binding to RSV F LG202A12 US20110182897 SEQ ID NO: 5903 protein  127 RSV682 Nanobody binding to RSV F LG202A5 US20110182897 SEQ ID NO: 5904 protein  128 RSV683 Nanobody binding to RSV F LG202A9 US20110182897 SEQ ID NO: 5905 protein  129 RSV684 Nanobody binding to RSV F LG202B10 US20110182897 SEQ ID NO: 5906 protein  130 RSV685 Nanobody binding to RSV F LG202B7 US20110182897 SEQ ID NO: 5907 protein  131 RSV686 Nanobody binding to RSV F LG202B8 US20110182897 SEQ ID NO: 5908 protein  132 RSV687 Nanobody binding to RSV F LG202B9 US20110182897 SEQ ID NO: 5909 protein  133 RSV688 Nanobody binding to RSV F LG202C1 US20110182897 SEQ ID NO: 5910 protein  134 RSV689 Nanobody binding to RSV F LG202C11 US20110182897 SEQ ID NO: 5911 protein  135 RSV690 Nanobody binding to RSV F LG202C2 US20110182897 SEQ ID NO: 5912 protein  136 RSV691 Nanobody binding to RSV F LG202C7 US20110182897 SEQ ID NO: 5913 protein  137 RSV692 Nanobody binding to RSV F LG202C8 US20110182897 SEQ ID NO: 5914 protein  138 RSV693 Nanobody binding to RSV F LG202C9 US20110182897 SEQ ID NO: 5915 protein  139 RSV694 Nanobody binding to RSV F LG202D5 US20110182897 SEQ ID NO: 5916 protein  140 RSV695 Nanobody binding to RSV F LG202D7 US20110182897 SEQ ID NO: 5917 protein  141 RSV696 Nanobody binding to RSV F LG202D8 US20110182897 SEQ ID NO: 5918 protein  142 RSV697 Nanobody binding to RSV F LG202E11 US20110182897 SEQ ID NO: 5919 protein  143 RSV698 Nanobody binding to RSV F LG202E2 US20110182897 SEQ ID NO: 5920 protein  144 RSV699 Nanobody binding to RSV F LG202E5 US20110182897 SEQ ID NO: 5921 protein  145 RSV700 Nanobody binding to RSV F LG202E6 US20110182897 SEQ ID NO: 5922 protein  146 RSV701 Nanobody binding to RSV F LG202E7 US20110182897 SEQ ID NO: 5923 protein  147 RSV702 Nanobody binding to RSV F LG202F10 US20110182897 SEQ ID NO: 5924 protein  148 RSV703 Nanobody binding to RSV F LG202F12 US20110182897 SEQ ID NO: 5925 protein  149 RSV704 Nanobody binding to RSV F LG202F3 US20110182897 SEQ ID NO: 5926 protein  150 RSV705 Nanobody binding to RSV F LG202F4 US20110182897 SEQ ID NO: 5927 protein  151 RSV706 Nanobody binding to RSV F LG202F8 US20110182897 SEQ ID NO: 5928 protein  152 RSV707 Nanobody binding to RSV F LG202G11 US20110182897 SEQ ID NO: 5929 protein  153 RSV708 Nanobody binding to RSV F LG202G3 US20110182897 SEQ ID NO: 5930 protein  154 RSV709 Nanobody binding to RSV F LG202G8 US20110182897 SEQ ID NO: 5931 protein  155 RSV710 Nanobody binding to RSV F LG202H2 US20110182897 SEQ ID NO: 5932 protein  156 RSV711 Nanobody binding to RSV F LG202H8 US20110182897 SEQ ID NO: 5933 protein  157 RSV712 Nanobody binding to RSV F LG191B9 US20110182897 SEQ ID NO: 5934 protein  158 RSV713 Nanobody binding to RSV F LG191D3 US20110182897 SEQ ID NO: 5935 protein  159 RSV714 Nanobody binding to RSV F LG192A8 US20110182897 SEQ ID NO: 5936 protein  160 RSV715 Nanobody binding to RSV F LG192B1 US20110182897 SEQ ID NO: 5937 protein  161 RSV716 Nanobody binding to RSV F LG192C10 US20110182897 SEQ ID NO: 5938 protein  162 RSV717 Nanobody binding to RSV F LG192C4 US20110182897 SEQ ID NO: 5939 protein  163 RSV718 Nanobody binding to RSV F LG192C6 US20110182897 SEQ ID NO: 5940 protein  164 RSV719 Nanobody binding to RSV F LG192D3 US20110182897 SEQ ID NO: 5941 protein  165 RSV720 Nanobody binding to RSV F LG191E4 US20110182897 SEQ ID NO: 5942 protein  166 RSV721 Nanobody binding to RSV F LG192F2 US20110182897 SEQ ID NO: 5943 protein  167 RSV722 Nanobody binding to RSV F LG192H1 US20110182897 SEQ ID NO: 5944 protein  168 RSV723 Nanobody binding to RSV F LG192H2 US20110182897 SEQ ID NO: 5945 protein  169 RSV724 Nanobody binding to RSV F LG20610B US20110182897 SEQ ID NO: 5946 protein  170 RSV725 Nanobody binding to RSV F LG20610C US20110182897 SEQ ID NO: 5947 protein  171 RSV726 Nanobody binding to RSV F LG20610D US20110182897 SEQ ID NO: 5948 protein  172 RSV727 Nanobody binding to RSV F LG20610E US20110182897 SEQ ID NO: 5949 protein  173 RSV728 Nanobody binding to RSV F LG20610F US20110182897 SEQ ID NO: 5950 protein  174 RSV729 Nanobody binding to RSV F LG20611D US20110182897 SEQ ID NO: 5951 protein  175 RSV730 Nanobody binding to RSV F LG20611H US20110182897 SEQ ID NO: 5952 protein  176 RSV731 Nanobody binding to RSV F LG20612F US20110182897 SEQ ID NO: 5953 protein  177 RSV732 Nanobody binding to RSV F LG2062A US20110182897 SEQ ID NO: 5954 protein  178 RSV733 Nanobody binding to RSV F LG2062C US20110182897 SEQ ID NO: 5955 protein  179 RSV734 Nanobody binding to RSV F LG2062E US20110182897 SEQ ID NO: 5956 protein  180 RSV735 Nanobody binding to RSV F LG2062F US20110182897 SEQ ID NO: 5957 protein  181 RSV736 Nanobody binding to RSV F LG2062G US20110182897 SEQ ID NO: 5958 protein  182 RSV737 Nanobody binding to RSV F LG2062H US20110182897 SEQ ID NO: 5959 protein  183 RSV738 Nanobody binding to RSV F LG2063A US20110182897 SEQ ID NO: 5960 protein  184 RSV739 Nanobody binding to RSV F LG2063B US20110182897 SEQ ID NO: 5961 protein  185 RSV740 Nanobody binding to RSV F LG2063C US20110182897 SEQ ID NO: 5962 protein  186 RSV741 Nanobody binding to RSV F LG2063D US20110182897 SEQ ID NO: 5963 protein  187 RSV742 Nanobody binding to RSV F LG2063E US20110182897 SEQ ID NO: 5964 protein  188 RSV743 Nanobody binding to RSV F LG2063F US20110182897 SEQ ID NO: 5965 protein  189 RSV744 Nanobody binding to RSV F LG2064D US20110182897 SEQ ID NO: 5966 protein  190 RSV745 Nanobody binding to RSV F LG2064G US20110182897 SEQ ID NO: 5967 protein  191 RSV746 Nanobody binding to RSV F LG2065A US20110182897 SEQ ID NO: 5968 protein  192 RSV747 Nanobody binding to RSV F LG2065E US20110182897 SEQ ID NO: 5969 protein  193 RSV748 Nanobody binding to RSV F LG2066A US20110182897 SEQ ID NO: 5970 protein  194 RSV749 Nanobody binding to RSV F LG2066D US20110182897 SEQ ID NO: 5971 protein  195 RSV750 Nanobody binding to RSV F LG2067B US20110182897 SEQ ID NO: 5972 protein  196 RSV751 Nanobody binding to RSV F LG2067C US20110182897 SEQ ID NO: 5973 protein  197 RSV752 Nanobody binding to RSV F LG2067E US20110182897 SEQ ID NO: 5974 protein  198 RSV753 Nanobody binding to RSV F LG2067G US20110182897 SEQ ID NO: 5975 protein  199 RSV754 Nanobody binding to RSV F LG2067H US20110182897 SEQ ID NO: 5976 protein  200 RSV755 Nanobody binding to RSV F LG20711A US20110182897 SEQ ID NO: 5977 protein  201 RSV756 Nanobody binding to RSV F LG20711B US20110182897 SEQ ID NO: 5978 protein  202 RSV757 Nanobody binding to RSV F LG20711D US20110182897 SEQ ID NO: 5979 protein  203 RSV758 Nanobody binding to RSV F LG20711E US20110182897 SEQ ID NO: 5980 protein  204 RSV759 Nanobody binding to RSV F LG20711F US20110182897 SEQ ID NO: 5981 protein  205 RSV760 Nanobody binding to RSV F LG20711G US20110182897 SEQ ID NO: 5982 protein  206 RSV761 Nanobody binding to RSV F LG20711H US20110182897 SEQ ID NO: 5983 protein  207 RSV762 Nanobody binding to RSV F LG2071A US20110182897 SEQ ID NO: 5984 protein  208 RSV763 Nanobody binding to RSV F LG2071B US20110182897 SEQ ID NO: 5985 protein  209 RSV764 Nanobody binding to RSV F LG2071C US20110182897 SEQ ID NO: 5986 protein  210 RSV765 Nanobody binding to RSV F LG207D1 US20110182897 SEQ ID NO: 5987 protein  211 RSV766 Nanobody binding to RSV F LG2071E US20110182897 SEQ ID NO: 5988 protein  212 RSV767 Nanobody binding to RSV F LG2071F US20110182897 SEQ ID NO: 5989 protein  213 RSV768 Nanobody binding to RSV F LG2074A US20110182897 SEQ ID NO: 5990 protein  214 RSV769 Nanobody binding to RSV F LG2074B US20110182897 SEQ ID NO: 5991 protein  215 RSV770 Nanobody binding to RSV F LG2074D US20110182897 SEQ ID NO: 5992 protein  216 RSV771 Nanobody binding to RSV F LG2074H US20110182897 SEQ ID NO: 5993 protein  217 RSV772 Nanobody binding to RSV F LG2075A US20110182897 SEQ ID NO: 5994 protein  218 RSV773 Nanobody binding to RSV F LG2075B US20110182897 SEQ ID NO: 5995 protein  219 RSV774 Nanobody binding to RSV F LG2075C US20110182897 SEQ ID NO: 5996 protein  220 RSV775 Nanobody binding to RSV F LG2075D US20110182897 SEQ ID NO: 5997 protein  221 RSV776 Nanobody binding to RSV F LG2075E US20110182897 SEQ ID NO: 5998 protein  222 RSV777 Nanobody binding to RSV F LG2076A US20110182897 SEQ ID NO: 5999 protein  223 RSV778 Nanobody binding to RSV F LG2076B US20110182897 SEQ ID NO: 6000 protein  224 RSV779 Nanobody binding to RSV F LG2076C US20110182897 SEQ ID NO: 6001 protein  225 RSV780 Nanobody binding to RSV F LG2076D US20110182897 SEQ ID NO: 6002 protein  226 RSV781 Nanobody binding to RSV F LG2076E US20110182897 SEQ ID NO: 6003 protein  227 RSV782 Nanobody binding to RSV F LG2076F US20110182897 SEQ ID NO: 6004 protein  228 RSV783 Nanobody binding to RSV F LG2079A US20110182897 SEQ ID NO: 6005 protein  229 RSV784 Nanobody binding to RSV F LG2079B US20110182897 SEQ ID NO: 6006 protein  230 RSV785 Nanobody binding to RSV F LG2079C US20110182897 SEQ ID NO: 6007 protein  231 RSV786 Nanobody binding to RSV F LG2079D US20110182897 SEQ ID NO: 6008 protein  232 RSV787 Nanobody binding to RSV F LG2079E US20110182897 SEQ ID NO: 6009 protein  233 RSV788 Nanobody binding to RSV F LG2079F US20110182897 SEQ ID NO: 6010 protein  234 RSV789 Nanobody binding to RSV F LG2079G US20110182897 SEQ ID NO: 6011 protein  235 RSV790 Nanobody binding to RSV F LG2079H US20110182897 SEQ ID NO: 6012 protein  236 RSV791 Nanobody binding to RSV F LG213B7 US20110182897 SEQ ID NO: 6013 protein  237 RSV792 Nanobody binding to RSV F LG213D6 US20110182897 SEQ ID NO: 6014 protein  238 RSV793 Nanobody binding to RSV F LG213D7 US20110182897 SEQ ID NO: 6015 protein  239 RSV794 Nanobody binding to RSV F LG213E6 US20110182897 SEQ ID NO: 6016 protein  240 RSV795 Nanobody binding to RSV F LG213H7 US20110182897 SEQ ID NO: 6017 protein  241 RSV796 Nanobody binding to RSV F LG214A8 US20110182897 SEQ ID NO: 6018 protein  242 RSV797 Nanobody binding to RSV F LG214C10 US20110182897 SEQ ID NO: 6019 protein  243 RSV798 Nanobody binding to RSV F LG214D10 US20110182897 SEQ ID NO: 6020 protein  244 RSV799 Nanobody binding to RSV F LG214E8 US20110182897 SEQ ID NO: 6021 protein  245 RSV800 Nanobody binding to RSV F LG214F8 US20110182897 SEQ ID NO: 6022 protein  246 RSV801 Nanobody binding to RSV F LG214H10 US20110182897 SEQ ID NO: 6023 protein  247 RSV802 Nanobody binding to RSV F RSVPMP5C1 US20110182897 SEQ ID NO: 6024 protein  248 RSV803 Nanobody binding to RSV F RSVPMP8A1 US20110182897 SEQ ID NO: 6025 protein  249 RSV804 Nanobody binding to RSV F RSVPMP8G1 US20110182897 SEQ ID NO: 6026 protein  250 RSV805 Nanobody binding to RSV F RSVPMP25B3 US20110182897 SEQ ID NO: 6027 protein  251 RSV806 Nanobody binding to RSV F RSVPMP8C8 US20110182897 SEQ ID NO: 6028 protein  252 RSV807 Nanobody binding to RSV F RSVPMP5A6 US20110182897 SEQ ID NO: 6029 protein  253 RSV808 Nanobody binding to RSV F RSVPMP8E11 US20110182897 SEQ ID NO: 6030 protein  254 RSV809 Nanobody binding to RSV F RSVPMP8F11 US20110182897 SEQ ID NO: 6031 protein  255 RSV810 Nanobody binding to RSV F RSVPMP13F11 US20110182897 SEQ ID NO: 6032 protein  256 RSV811 Nanobody binding to RSV F RSVPMP15B8 US20110182897 SEQ ID NO: 6033 protein  257 RSV812 Nanobody binding to RSV F RSVPMP15G11 US20110182897 SEQ ID NO: 6034 protein  258 RSV813 Nanobody binding to RSV F RSVPMP17C10 US20110182897 SEQ ID NO: 6035 protein  259 RSV814 Nanobody binding to RSV F RSVPMP21E7 US20110182897 SEQ ID NO: 6036 protein  260 RSV815 Nanobody binding to RSV F RSVPMP21F8 US20110182897 SEQ ID NO: 6037 protein  261 RSV816 Nanobody binding to RSV F RSVPMP5A2 US20110182897 SEQ ID NO: 6038 protein  262 RSV817 Nanobody binding to RSV F RSVPMP5B2 US20110182897 SEQ ID NO: 6039 protein  263 RSV818 Nanobody binding to RSV F RSVPMP5C3 US20110182897 SEQ ID NO: 6040 protein  264 RSV819 Nanobody binding to RSV F RSVPMP5D2 US20110182897 SEQ ID NO: 6041 protein  265 RSV820 Nanobody binding to RSV F RSVPMP5E2 US20110182897 SEQ ID NO: 6042 protein  266 RSV821 Nanobody binding to RSV F RSVPMP5F3 US20110182897 SEQ ID NO: 6043 protein  267 RSV822 Nanobody binding to RSV F RSVPMP5G3 US20110182897 SEQ ID NO: 6044 protein  268 RSV823 Nanobody binding to RSV F RSVPMP5H2 US20110182897 SEQ ID NO: 6045 protein  269 RSV824 Nanobody binding to RSV F RSVPMP5H3 US20110182897 SEQ ID NO: 6046 protein  270 RSV825 Nanobody binding to RSV F RSVPMP8C1 US20110182897 SEQ ID NO: 6047 protein  271 RSV826 Nanobody binding to RSV F RSVPMP8F2 US20110182897 SEQ ID NO: 6048 protein  272 RSV827 Nanobody binding to RSV F RSVPMP8G4 US20110182897 SEQ ID NO: 6049 protein  273 RSV828 Nanobody binding to RSV F RSVPMP13A1 US20110182897 SEQ ID NO: 6050 protein  274 RSV829 Nanobody binding to RSV F RSVPMP13A4 US20110182897 SEQ ID NO: 6051 protein  275 RSV830 Nanobody binding to RSV F RSVPMP13B1 US20110182897 SEQ ID NO: 6052 protein  276 RSV831 Nanobody binding to RSV F RSVPMP13B2 US20110182897 SEQ ID NO: 6053 protein  277 RSV832 Nanobody binding to RSV F RSVPMP13C1 US20110182897 SEQ ID NO: 6054 protein  278 RSV833 Nanobody binding to RSV F RSVPMP13C3 US20110182897 SEQ ID NO: 6055 protein  279 RSV834 Nanobody binding to RSV F RSVPMP13D6 US20110182897 SEQ ID NO: 6056 protein  280 RSV835 Nanobody binding to RSV F RSVPMP13E2 US20110182897 SEQ ID NO: 6057 protein  281 RSV836 Nanobody binding to RSV F RSVPMP13E3 US20110182897 SEQ ID NO: 6058 protein  282 RSV837 Nanobody binding to RSV F RSVPMP15A5 US20110182897 SEQ ID NO: 6059 protein  283 RSV838 Nanobody binding to RSV F RSVPMP15A6 US20110182897 SEQ ID NO: 6060 protein  284 RSV839 Nanobody binding to RSV F RSVPMP15B2 US20110182897 SEQ ID NO: 6061 protein  285 RSV840 Nanobody binding to RSV F RSVPMP15B3 US20110182897 SEQ ID NO: 6062 protein  286 RSV841 Nanobody binding to RSV F RSVPMP15E5 US20110182897 SEQ ID NO: 6063 protein  287 RSV842 Nanobody binding to RSV F RSVPMP17C2 US20110182897 SEQ ID NO: 6064 protein  288 RSV843 Nanobody binding to RSV F RSVPMP17D4 US20110182897 SEQ ID NO: 6065 protein  289 RSV844 Nanobody binding to RSV F RSVPMP17G4 US20110182897 SEQ ID NO: 6066 protein  290 RSV845 Nanobody binding to RSV F RSVPMP19B2 US20110182897 SEQ ID NO: 6067 protein  291 RSV846 Nanobody binding to RSV F RSVPMP25A4 US20110182897 SEQ ID NO: 6068 protein  292 RSV847 Nanobody binding to RSV F RSVPMP25A9 US20110182897 SEQ ID NO: 6069 protein  293 RSV848 Nanobody binding to RSV F RSVPMP25B5 US20110182897 SEQ ID NO: 6070 protein  294 RSV849 Nanobody binding to RSV F RSVPMP25G2 US20110182897 SEQ ID NO: 6071 protein  295 RSV850 Nanobody binding to RSV F RSVPMP25H5 US20110182897 SEQ ID NO: 6072 protein  296 RSV851 Nanobody binding to RSV F RSVPMP25E11 US20110182897 SEQ ID NO: 6073 protein  297 RSV852 Nanobody binding to RSV F RSVPMP8G3 US20110182897 SEQ ID NO: 6074 protein  298 RSV853 Nanobody binding to RSV F RSVPMP13B5 US20110182897 SEQ ID NO: 6075 protein  299 RSV854 Nanobody binding to RSV F RSVPMP15F2 US20110182897 SEQ ID NO: 6076 protein  300 RSV855 Nanobody binding to RSV F RSVPMP19E2 US20110182897 SEQ ID NO: 6077 protein  301 RSV856 Nanobody binding to RSV F RSVPMP25D1 US20110182897 SEQ ID NO: 6078 protein  302 RSV857 Nanobody binding to RSV F RSVPMP5A1 US20110182897 SEQ ID NO: 6079 protein  303 RSV858 Nanobody binding to RSV F RSVPMP5G2 US20110182897 SEQ ID NO: 6080 protein  304 RSV859 Nanobody binding to RSV F RSVPMP5H1 US20110182897 SEQ ID NO: 6081 protein  305 RSV860 Nanobody binding to RSV F RSVPMP6B1 US20110182897 SEQ ID NO: 6082 protein  306 RSV861 Nanobody binding to RSV F RSVPMP8H2 US20110182897 SEQ ID NO: 6083 protein  307 RSV862 Nanobody binding to RSV F RSVPMP8H3 US20110182897 SEQ ID NO: 6084 protein  308 RSV863 Nanobody binding to RSV F RSVPMP13A3 US20110182897 SEQ ID NO: 6085 protein  309 RSV864 Nanobody binding to RSV F RSVPMP13C5 US20110182897 SEQ ID NO: 6086 protein  310 RSV865 Nanobody binding to RSV F RSVPMP13H1 US20110182897 SEQ ID NO: 6087 protein  311 RSV866 Nanobody binding to RSV F RSVPMP13H2 US20110182897 SEQ ID NO: 6088 protein  312 RSV867 Nanobody binding to RSV F RSVPMP15E6 US20110182897 SEQ ID NO: 6089 protein  313 RSV868 Nanobody binding to RSV F RSVPMP17A3 US20110182897 SEQ ID NO: 6090 protein  314 RSV869 Nanobody binding to RSV F RSVPMP25G8 US20110182897 SEQ ID NO: 6091 protein  315 RSV870 Nanobody binding to RSV F RSVPMP6D1 US20110182897 SEQ ID NO: 6092 protein  316 RSV871 Nanobody binding to RSV F RSVPMP8D5 US20110182897 SEQ ID NO: 6093 protein  317 RSV872 Nanobody binding to RSV F RSVPMP13B4 US20110182897 SEQ ID NO: 6094 protein  318 RSV873 Nanobody binding to RSV F RSVPMP13B6 US20110182897 SEQ ID NO: 6095 protein  319 RSV874 Nanobody binding to RSV F RSVPMP13E6 US20110182897 SEQ ID NO: 6096 protein  320 RSV875 Nanobody binding to RSV F RSVPMP13F4 US20110182897 SEQ ID NO: 6097 protein  321 RSV876 Nanobody binding to RSV F RSVPMP15H3 US20110182897 SEQ ID NO: 6098 protein  322 RSV877 Nanobody binding to RSV F RSVPMP17E5 US20110182897 SEQ ID NO: 6099 protein  323 RSV878 Nanobody binding to RSV F RSVPMP19D3 US20110182897 SEQ ID NO: 6100 protein  324 RSV879 Nanobody binding to RSV F RSVPMP19F3 US20110182897 SEQ ID NO: 6101 protein  325 RSV880 Nanobody binding to RSV F RSVPMP25C4 US20110182897 SEQ ID NO: 6102 protein  326 RSV881 Nanobody binding to RSV F RSVPMP25E3 US20110182897 SEQ ID NO: 6103 protein  327 RSV882 Nanobody binding to RSV F RSVPMP5G4 US20110182897 SEQ ID NO: 6104 protein  328 RSV883 Nanobody binding to RSV F RSVPMP6G5 US20110182897 SEQ ID NO: 6105 protein  329 RSV884 Nanobody binding to RSV F RSVPMP8E6 US20110182897 SEQ ID NO: 6106 protein  330 RSV885 Nanobody binding to RSV F RSVPMP13A10 US20110182897 SEQ ID NO: 6107 protein  331 RSV886 Nanobody binding to RSV F RSVPMP21H10 US20110182897 SEQ ID NO: 6108 protein  332 RSV887 Nanobody binding to RSV F RSVPMP5A8 US20110182897 SEQ ID NO: 6109 protein  333 RSV888 Nanobody binding to RSV F RSVPMP5A10 US20110182897 SEQ ID NO: 6110 protein  334 RSV889 Nanobody binding to RSV F RSVPMPHA6 US20110182897 SEQ ID NO: 6111 protein  335 RSV890 Nanobody binding to RSV F RSVPMP16A6 US20110182897 SEQ ID NO: 6112 protein  336 RSV891 Nanobody binding to RSV F RSVPMP22D6 US20110182897 SEQ ID NO: 6113 protein  337 RSV892 Nanobody binding to RSV F RSVPMP8E2 US20110182897 SEQ ID NO: 6114 protein  338 RSV893 Nanobody binding to RSV F RSVPMP8C6 US20110182897 SEQ ID NO: 6115 protein  339 RSV894 Nanobody binding to RSV F RSVPMP5C6 US20110182897 SEQ ID NO: 6116 protein  340 RSV895 Nanobody binding to RSV F RSVPMP6D4 US20110182897 SEQ ID NO: 6117 protein  341 RSV896 Nanobody binding to RSV F RSVPMP8B10 US20110182897 SEQ ID NO: 6118 protein  342 RSV897 Nanobody binding to RSV F RSVPMP8E10 US20110182897 SEQ ID NO: 6119 protein  343 RSV898 Nanobody binding to RSV F RSVPMP15A7 US20110182897 SEQ ID NO: 6120 protein  344 RSV899 Nanobody binding to RSV F RSVPMP15E10 US20110182897 SEQ ID NO: 6121 protein  345 RSV900 Nanobody binding to RSV F RSVPMP13C7 US20110182897 SEQ ID NO: 6122 protein  346 RSV901 Nanobody binding to RSV F RSVPMP15A9 US20110182897 SEQ ID NO: 6123 protein  347 RSV902 Nanobody binding to RSV F RSVPMP15F11 US20110182897 SEQ ID NO: 6124 protein  348 RSV903 Nanobody binding to RSV F RSVPMP15A1 US20110182897 SEQ ID NO: 6125 protein  349 RSV904 Nanobody binding to RSV F RSVPMP6H2 US20110182897 SEQ ID NO: 6126 protein  350 RSV905 Nanobody binding to RSV F RSVPMP17A9 US20110182897 SEQ ID NO: 6127 protein  351 RSV906 Nanobody binding to RSV F RSVPMP7G1 US20110182897 SEQ ID NO: 6128 protein  352 RSV907 Nanobody binding to RSV F RSVPMP5A9 US20110182897 SEQ ID NO: 6129 protein  353 RSV908 Nanobody binding to RSV F RSVPMP7B2 US20110182897 SEQ ID NO: 6130 protein  354 RSV909 Nanobody binding to RSV F RSVPMP22A4 US20110182897 SEQ ID NO: 6131 protein  355 RSV910 Nanobody binding to RSV F RSVPMP22E10 US20110182897 SEQ ID NO: 6132 protein  356 RSV911 Nanobody binding to RSV F RSVPMP22H4 US20110182897 SEQ ID NO: 6133 protein  357 RSV912 Nanobody binding to RSV F RSVPMP15C5 US20110182897 SEQ ID NO: 6134 protein  358 RSV913 Nanobody binding to RSV F RSVNC39 US20110182897 SEQ ID NO: 6135 protein  359 RSV914 Nanobody binding to RSV F RSVPMP7B9 US20110182897 SEQ ID NO: 6136 protein  360 RSV915 Nanobody binding to RSV F RSVPMP15E11 US20110182897 SEQ ID NO: 6137 protein  361 RSV916 Nanobody binding to RSV F RSVPMP7E7 US20110182897 SEQ ID NO: 6138 protein  362 RSV917 Nanobody binding to RSV F RSVPMP14H3 US20110182897 SEQ ID NO: 6139 protein  363 RSV918 Nanobody binding to RSV F RSVPMP24D6 US20110182897 SEQ ID NO: 6140 protein  364 RSV919 Nanobody binding to RSV F RSVPMP23E5 US20110182897 SEQ ID NO: 6141 protein  365 RSV920 Nanobody binding to RSV F RSVPMP8A6 US20110182897 SEQ ID NO: 6142 protein  366 RSV921 Nanobody binding to RSV F RSVPMP14E2 US20110182897 SEQ ID NO: 6143 protein  367 RSV922 Nanobody binding to RSV F RSVPMP25F3 US20110182897 SEQ ID NO: 6144 protein  368 RSV923 Nanobody binding to RSV F RSVPMP19A6 US20110182897 SEQ ID NO: 6145 protein  369 RSV924 Nanobody binding to RSV F RSVPMP23G1 US20110182897 SEQ ID NO: 6146 protein  370 RSV925 Nanobody binding to RSV F RSVPMP15H8 US20110182897 SEQ ID NO: 6147 protein  371 RSV926 Nanobody binding to RSV F RSVNC41 US20110182897 SEQ ID NO: 6148 protein  372 RSV927 Nanobody binding to RSV F RSVPMP6A8 US20110182897 SEQ ID NO: 6149 protein  373 RSV928 Nanobody binding to RSV F RSVPMP25H9 US20110182897 SEQ ID NO: 6150 protein  374 RSV929 Nanobody binding to RSV F RSVPMP8B11 US20110182897 SEQ ID NO: 6151 protein  375 RSV930 Nanobody binding to RSV F RSVPMP17E1 US20110182897 SEQ ID NO: 6152 protein  376 RSV931 Nanobody binding to RSV F RSVPMP21A4 US20110182897 SEQ ID NO: 6153 protein  377 RSV932 Nanobody binding to RSV F RSVPMP25A11 US20110182897 SEQ ID NO: 6154 protein  378 RSV933 Nanobody binding to RSV F RSVPMP25C8 US20110182897 SEQ ID NO: 6155 protein  379 RSV934 Nanobody binding to RSV F RSVNC23 US20110182897 SEQ ID NO: 6156 protein  380 RSV935 Nanobody binding to RSV F RSVPMP20A11 US20110182897 SEQ ID NO: 6157 protein  381 RSV936 Nanobody binding to RSV F RSVPMP20A9 US20110182897 SEQ ID NO: 6158 protein  382 RSV937 Nanobody binding to RSV F RSVPMP1F7 US20110182897 SEQ ID NO: 6159 protein  383 RSV938 Nanobody binding to RSV F RSVPMP20D6 US20110182897 SEQ ID NO: 6160 protein  384 RSV939 Nanobody binding to RSV F RSVPMP1F1 US20110182897 SEQ ID NO: 6161 protein  385 RSV940 Nanobody binding to RSV F RSVPMP3D3 US20110182897 SEQ ID NO: 6162 protein  386 RSV941 Nanobody binding to RSV F RSVPMP3E6 US20110182897 SEQ ID NO: 6163 protein  387 RSV942 Nanobody binding to RSV F RSVPMP1C8 US20110182897 SEQ ID NO: 6164 protein  388 RSV943 Nanobody binding to RSV F RSVPMP1A2 US20110182897 SEQ ID NO: 6165 protein  389 RSV944 Nanobody binding to RSV F RSVPMP1C5 US20110182897 SEQ ID NO: 6166 protein  390 RSV945 Nanobody binding to RSV F RSVPMP20G5 US20110182897 SEQ ID NO: 6167 protein  391 RSV946 Nanobody binding to RSV F RSVPMP4D8 US20110182897 SEQ ID NO: 6168 protein  392 RSV947 Nanobody binding to RSV F RSVPMP20B6 US20110182897 SEQ ID NO: 6169 protein  393 RSV948 Nanobody binding to RSV F RSVPMP1D11 US20110182897 SEQ ID NO: 6170 protein  394 RSV949 Nanobody binding to RSV F RSVPMP20A8 US20110182897 SEQ ID NO: 6171 protein  395 RSV950 Nanobody binding to RSV F RSVPMP20E7 US20110182897 SEQ ID NO: 6172 protein  396 RSV951 Nanobody binding to RSV F RSVPMP20G8 US20110182897 SEQ ID NO: 6173 protein  397 RSV952 Nanobody binding to RSV F RSVPMP2D3 US20110182897 SEQ ID NO: 6174 protein  398 RSV953 Nanobody binding to RSV F RSVPMP2G5 US20110182897 SEQ ID NO: 6175 protein  399 RSV954 Nanobody binding to RSV F RSVPMP2A6 US20110182897 SEQ ID NO: 6176 protein  400 RSV955 Nanobody binding to RSV F RSVPMP3A2 US20110182897 SEQ ID NO: 6177 protein  401 RSV956 Nanobody binding to RSV F RSVPMP4A8 US20110182897 SEQ ID NO: 6178 protein  402 RSV957 Nanobody binding to RSV F RSVPMP4F9 US20110182897 SEQ ID NO: 6179 protein  403 RSV958 Nanobody binding to RSV F RSVPMP1A6 US20110182897 SEQ ID NO: 6180 protein  404 RSV959 Nanobody binding to RSV F RSVPMP3C2 US20110182897 SEQ ID NO: 6181 protein  405 RSV960 Nanobody binding to RSV F RSVPMP4H9 US20110182897 SEQ ID NO: 6182 protein  406 RSV961 Nanobody binding to RSV F RSVPMP4B10 US20110182897 SEQ ID NO: 6183 protein  407 RSV962 Nanobody binding to RSV F 203B1 US20110182897 SEQ ID NO: 6184 protein 2431 RSV963 Nanobody binding to RSV F 203B2 US20110182897 SEQ ID NO: 6185 protein 2432 RSV964 Nanobody binding to RSV F 203G1 US20110182897 SEQ ID NO: 6186 protein 2433 RSV965 Nanobody binding to RSV F 203H1 US20110182897 SEQ ID NO: 6187 protein 2434 RSV966 Nanobody binding to RSV F 202E4 US20110182897 SEQ ID NO: 6188 protein 2435 RSV967 Nanobody binding to RSV F 189E2 US20110182897 SEQ ID NO: 6189 protein 2436 RSV968 Nanobody binding to RSV F 203A12 US20110182897 SEQ ID NO: 6190 protein 2437 RSV969 Nanobody binding to RSV F 203A9 US20110182897 SEQ ID NO: 6191 protein 2438 RSV970 Nanobody binding to RSV F 203B12 US20110182897 SEQ ID NO: 6192 protein 2439 RSV971 Nanobody binding to RSV F 203D2 US20110182897 SEQ ID NO: 6193 protein 2440 RSV972 Nanobody binding to RSV F 203D9 US20110182897 SEQ ID NO: 6194 protein 2441 RSV973 Nanobody binding to RSV F 203G3 US20110182897 SEQ ID NO: 6195 protein 2442 RSV974 Nanobody binding to RSV F 203G9 US20110182897 SEQ ID NO: 6196 protein 2443 RSV975 Nanobody binding to RSV F 203G10 US20110182897 SEQ ID NO: 6197 protein 2444 RSV976 Nanobody binding to RSV F 203H9 US20110182897 SEQ ID NO: 6198 protein 2445 RSV977 Nanobody binding to RSV F 203H10 US20110182897 SEQ ID NO: 6199 protein 2446 RSV978 Nanobody binding to RSV F 202E4 US20110182897 SEQ ID NO: 6200 protein 2447 RSV979 Nanobody binding to RSV F 189E2 US20110182897 SEQ ID NO: 6201 protein 2448 RSV980 Nanobody binding to RSV F PRSVPMP20C3 US20110182897 SEQ ID NO: 6202 protein 2574 RSV981 Nanobody binding to RSV F PRSVPMP20C5 US20110182897 SEQ ID NO: 6203 protein 2575 RSV982 Nanobody binding to RSV F PRSVPMP20B2 US20110182897 SEQ ID NO: 6204 protein 2576 RSV983 Nanobody binding to RSV F PRSVPMP20C1 US20110182897 SEQ ID NO: 6205 protein 2577 RSV984 Nanobody binding to RSV F PRSVPMP1G8 US20110182897 SEQ ID NO: 6206 protein 2578 RSV985 Nanobody binding to RSV F PRSVNMP1A4 US20110182897 SEQ ID NO: 6207 protein 2579 RSV986 Nanobody binding to RSV F PRSVPMP13E12 US20110182897 SEQ ID NO: 6208 protein 2580 RSV987 Nanobody binding to RSV F PRSVPMP5C6 US20110182897 SEQ ID NO: 6209 protein 2581 RSV988 Nanobody binding to RSV F LG203E7 US20110182897 SEQ ID NO: 6210 protein 2682 RSV989 Nanobody binding to RSV F LG203G8 US20110182897 SEQ ID NO: 6211 protein 2683 RSV990 Nanobody binding to RSV F LG211A10 US20110182897 SEQ ID NO: 6212 protein 2684 RSV991 Nanobody binding to RSV F LG211A8 US20110182897 SEQ ID NO: 6213 protein 2685 RSV992 Nanobody binding to RSV F LG211B10 US20110182897 SEQ ID NO: 6214 protein 2686 RSV993 Nanobody binding to RSV F LG211B8 US20110182897 SEQ ID NO: 6215 protein 2687 RSV994 Nanobody binding to RSV F LG211C12 US20110182897 SEQ ID NO: 6216 protein 2688 RSV995 Nanobody binding to RSV F LG211C8 US20110182897 SEQ ID NO: 6217 protein 2689 RSV996 Nanobody binding to RSV F LG211D10 US20110182897 SEQ ID NO: 6218 protein 2690 RSV997 Nanobody binding to RSV F LG211D8 US20110182897 SEQ ID NO: 6219 protein 2691 RSV998 Nanobody binding to RSV F LG211E10 US20110182897 SEQ ID NO: 6220 protein 2692 RSV999 Nanobody binding to RSV F LG211E12 US20110182897 SEQ ID NO: 6221 protein 2693 RSV1000 Nanobody binding to RSV F LG211E8 US20110182897 SEQ ID NO: 6222 protein 2694 RSV1001 Nanobody binding to RSV F LG211H8 US20110182897 SEQ ID NO: 6223 protein 2695 RSV1002 Nanobody binding to RSV F LG212A10 US20110182897SEQ ID NO: 6224 protein 2696 RSV1003 Nanobody binding to RSV F LG212A12 US20110182897 SEQ ID NO: 6225 protein 2697 RSV1004 Nanobody binding to RSV F LG212A2 US20110182897 SEQ ID NO: 6226 protein 2698 RSV1005 Nanobody binding to RSV F LG212A8 US20110182897 SEQ ID NO: 6227 protein 2699 RSV1006 Nanobody binding to RSV F LG212B12 US20110182897 SEQ ID NO: 6228 protein 2700 RSV1007 Nanobody binding to RSV F LG212B2 US20110182897 SEQ ID NO: 6229 protein 2701 RSV1008 Nanobody binding to RSV F LG212C12 US20110182897 SEQ ID NO: 6230 protein 2702 RSV1009 Nanobody binding to RSV F LG212D10 US20110182897 SEQ ID NO: 6231 protein 2703 RSV1010 Nanobody binding to RSV F LG212D12 US20110182897 SEQ ID NO: 6232 protein 2704 RSV1011 Nanobody binding to RSV F L0212D2 US20110182897 SEQ ID NO: 6233 protein 2705 RSV1012 Nanobody binding to RSV F LG212E10 US20110182897 SEQ ID NO: 6234 protein 2706 RSV1013 Nanobody binding to RSV F LG212E12 US20110182897 SEQ ID NO: 6235 protein 2707 RSV1014 Nanobody binding to RSV F LG212E6 US20110182897 SEQ ID NO: 6236 protein 2708 RSV1015 Nanobody binding to RSV F LG212F10 US20110182897 SEQ ID NO: 6237 protein 2709 RSV1016 Nanobody binding to RSV F LG212F12 US20110182897 SEQ ID NO: 6238 protein 2710 RSV1017 Nanobody binding to RSV F LG212F6 US20110182897 SEQ ID NO: 6239 protein 2711 RSV1018 Nanobody binding to RSV F LG212F8 US20110182897 SEQ ID NO: 6240 protein 2712 RSV1019 Nanobody binding to RSV F LG212G10 US20110182897 SEQ ID NO: 6241 protein 2713 RSV1020 Nanobody binding to RSV F LG212G2 US20110182897 SEQ ID NO: 6242 protein 2714 RSV1021 Nanobody binding to RSV F LG212H10 US20110182897 SEQ ID NO: 6243 protein 2715 RSV1022 Nanobody binding to RSV F LG212H2 US20110182897 SEQ ID NO: 6244 protein 2716 RSVI023 Nanobody binding to RSV F LG212H8 US20110182897 SEQ ID NO: 6245 protein 2717 RSV1024 Nanobody binding to RSV F IV121 US20110182897 SEQ ID NO: 6246 protein 3064 RSV1025 Nanobody binding to RSV F IV122 US20110182897 SEQ ID NO: 6247 protein 3065 RSV1026 Nanobody binding to RSV F IV123 US20110182897 SEQ ID NO: 6248 protein 3066 RSV1027 Nanobody binding to RSV F IV126 US20110182897 SEQ ID NO: 6249 protein 3067 RSV1028 Nanobody binding to RSV F IV127 US20110182897 SEQ ID NO: 6250 protein 3068 RSV1029 Nanobody binding to RSV F IV131 US20110182897 SEQ ID NO: 6251 protein 3069 RSV1030 Nanobody binding to RSV F IV132 US20110182897 SEQ ID NO: 6252 protein 3070 RSV1031 Nanobody binding to RSV F IV133 US20110182897 SEQ ID NO: 6253 protein 3071 RSV1032 Nanobody binding to RSV F IV134 US20110182897 SEQ ID NO: 6254 protein 3072 RSV1033 Nanobody binding to RSV F IV135 US20110182897 SEQ ID NO: 6255 protein 3073 RSV1034 Nanobody binding to RSV F IV136 US20110182897 SEQ ID NO: 6256 protein 3074 RSV1035 Nanobody binding to RSV F IV140 US20110182897 SEQ ID NO: 6257 protein 3075 RSV1036 Nanobody binding to RSV F IV144 US20110182897 SEQ ID NO: 6258 protein 3076 RSV1037 Nanobody binding to RSV F IV156 US20110182897 SEQ ID NO: 6259 protein 3077 RSV1038 Nanobody binding to RSV F IV157 US20110182897 SEQ ID NO: 6260 protein 3078 RSV1039 Nanobody binding to RSV F IV160 US20110182897 SEQ ID NO: 6261 protein 3079 RSV1040 Nanobody binding to RSV F IV124 US20110182897 SEQ ID NO: 6262 protein 3080 RSV1041 Nanobody binding to RSV F IV125 US20110182897 SEQ ID NO: 6263 protein 3081 RSV1042 Nanobody binding to RSV F IV145 US20110182897 SEQ ID NO: 6264 protein 3082 RSV1043 Nanobody binding to RSV F IV146 US20110182897 SEQ ID NO: 6265 protein 3083 RSV1044 Nanobody binding to RSV F IV147 US20110182897 SEQ ID NO: 6266 protein 3084 RSV1045 Nanobody binding to RSV F IV151 US20110182897 SEQ ID NO: 6267 protein 3085 RSV1046 Nanobody binding to RSV F IV153 US20110182897 SEQ ID NO: 6268 protein 3086 RSV1047 Nanobody binding to RSV F IV154 US20110182897 SEQ ID NO: 6269 protein 3087 RSV1048 Nanobody binding to RSV F IV155 US20110182897 SEQ ID NO: 6270 protein 3088 RSV1049 Nanobody binding to RSV F IV1 US20110182897 SEQ ID NO: 6271 protein 3089 RSV1050 Nanobody binding to RSV F IV2 US20110182897 SEQ ID NO: 6272 protein 3090 RSV1051 Nanobody binding to RSV F IV3 US20110182897 SEQ ID NO: 6273 protein 3091 RSV1052 Nanobody binding to RSV F IV4 US20110182897 SEQ ID NO: 6274 protein 3092 RSV1053 Nanobody binding to RSV F IV6 US20110182897 SEQ ID NO: 6275 protein 3093 RSV1054 Nanobody binding to RSV F IV7 US20110182897 SEQ ID NO: 6276 protein 3094 RSV1055 Nanobody binding to RSV F IV9 US20110182897 SEQ ID NO: 6277 protein 3095 RSV1056 Nanobody binding to RSV F IV10 US20110182897 SEQ ID NO: 6278 protein 3096 RSV1057 Nanobody binding to RSV F IV11 US20110182897 SEQ ID NO: 6279 protein 3097 RSV1058 Nanobody binding to RSV F IV12 US20110182897 SEQ ID NO: 6280 protein 3098 RSV1059 Nanobody binding to RSV F IV16 US20110182897 SEQ ID NO: 6281 protein 3099 RSV1060 Nanobody binding to RSV F IV24 US20110182897 SEQ ID NO: 6282 protein 3100 RSV1061 Nanobody binding to RSV F IV26 US20110182897 SEQ ID NO: 6283 protein 3101 RSV1062 Nanobody binding to RSV F IV30 US20110182897 SEQ ID NO: 6284 protein 3102 RSV1063 Nanobody binding to RSV F IV34 US20110182897 SEQ ID NO: 6285 protein 3103 RSV1064 Nanobody binding to RSV F IV14 US20110182897 SEQ ID NO: 6286 protein 3104 RSV1065 Nanobody binding to RSV F IV15 US20110182897 SEQ ID NO: 6287 protein 3105 RSV1066 Nanobody binding to RSV F IV17 US20110182897 SEQ ID NO: 6288 protein 3106 RSV1067 Nanobody binding to RSV F IV18 US20110182897 SEQ ID NO: 6289 protein 3107 RSV1068 Nanobody binding to RSV F IV29 US20110182897 SEQ ID NO: 6290 protein 3108 RSV1069 Nanobody binding to RSV F IV31 US20110182897 SEQ ID NO: 6291 protein 3109 RSV1070 Nanobody binding to RSV F IV33 US20110182897 SEQ ID NO: 6292 protein 3110 RSV1071 Nanobody binding to RSV F IV35 US20110182897 SEQ ID NO: 6293 protein 3111 RSV1072 Nanobody binding to RSV F IV36 US20110182897 SEQ ID NO: 6294 protein 3112 RSV1073 Nanobody binding to RSV F IV40 US20110182897 SEQ ID NO: 6295 protein 3113 RSV1074 Nanobody binding to RSV F IV42 US20110182897 SEQ ID NO: 6296 protein 3114 RSV1075 Nanobody binding to RSV F IV8 US20110182897 SEQ ID NO: 6297 protein 3115 RSV1076 Nanobody binding to RSV F IV21 US20110182897 SEQ ID NO: 6298 protein 3116 RSV1077 Nanobody binding to RSV F IV23 US20110182897 SEQ ID NO: 6299 protein 3117 RSV1078 Nanobody binding to RSV F IV45 US20110182897 SEQ ID NO: 6300 protein 3118 RSV1079 Nanobody binding to RSV F IV47 US20110182897 SEQ ID NO: 6301 protein 3119 RSV1080 Nanobody binding to RSV F IV48 US20110182897 SEQ ID NO: 6302 protein 3120 RSV1081 Nanobody binding to RSV F IV50 US20110182897 SEQ ID NO: 6303 protein 3121 RSV1082 Nanobody binding to RSV F IV22 US20110182897 SEQ ID NO: 6304 protein 3122 RSV1083 Nanobody binding to RSV F IV37 US20110182897 SEQ ID NO: 6305 protein 3123 RSV1084 Nanobody binding to RSV F IV38 US20110182897 SEQ ID NO: 6306 protein 3124 RSV1085 Nanobody binding to RSV F IV5 US20110182897 SEQ ID NO: 6307 protein 3125 RSV1086 Nanobody binding to RSV F IV27 US20110182897 SEQ ID NO: 6308 protein 3126 RSV1087 Nanobody binding to RSV F IV25 US20110182897 SEQ ID NO: 6309 protein 3127 RSV1088 Nanobody binding to RSV F IV28 US20110182897 SEQ ID NO: 6310 protein 3128

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in US Publication No. US20140363427, and International Publication No. WO2004083373, the contents of each of which are herein incorporated by reference in their entirety, against RSV F or RSV G protein.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 23 against Hepatitis B, Hepatitis C and/or Hepatitis D.

TABLE 23 Antibodies against Hepatitis B, C, D viruses SEQ Antibody Antibody ID No. Description Name Reference Information NO HEPBD1 Anti-preS1 Park, S.G., et al., Hepatitis B virus- 6311 immunoglobulin, neutralizing anti-pre-S1 human antibody HBV Ab fragments from large naive antibody phage library; Antiviral Res. 68 (3), 109-115 (2005); NCBI Accession # AAW82034.1 (107aa) HEPBD2 Anti-preS1 Park, S.G., et al., Hepatitis B virus- 6312 immunoglobulin, neutralizing anti-pre-S1 human antibody HBV Ab fragments from large naive antibody phage library; Antiviral Res. 68 (3), 109-115 (2005); NCBI Accession # AAW82035.1 (132aa) HEPBD3 Anti-preS1 Park, S.G., et al., Hepatitis B virus- 6313 immunoglobulin, neutralizing anti-pre-S1 human antibody HBV Ab fragments from large naive antibody phage library; Antiviral Res. 68(3), 109-115 (2005); NCBI Accession # AAW82033.1(111aa) HEPBD4 Anti-preS1 Park, S.G., et al., Hepatitis B virus- 6314 immunoglobulin, neutralizing anti-pre-S1 human antibody HBV Ab fragments from large naive antibody phage library; Antiviral Res. 68(3), 109-115 (2005); NCBI Accession # AAW82032.1 (142aa) HEPBD5 HCV Ab Hu5b3.v3 Pantua, H., et al., Glycan shifting on 6315 hepatitis C virus(HCV) e2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914 (2013) NCBI Accession # 4HS8_H(228aa) HEPBD6 HCV Ab Igh526 Kong L., et al., Structure of Hepatitis C 6316 Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526; J. Mol. Biol. 427 (16), 2617-2628 (2015) NCBI Accession # 4N0Y_H(231aa) HEPBD7 Heavy chain partial, Esposito, G., et al., Recombinant human 6317 HCV Ab antibodies specific for hepatitis C virus proteins; Arch. Virol. 142 (3), 601-610 (1997) NCBI Accession # CAA54914 (122aa) HEPBD8 Heavy chain variable EP0521348 6318 gene, Chimeric HBV Ab HEPBD9 Heavy chain variable Keck, Z.Y., et al., Human monoclonal 6319 region partial, HCV antibody to hepatitis C virUSE1 Ab glycoprotein that blocks virus attachment and viral infectivity; J. Virol. 78 (13), 7257-7263 (2004) NCBI Accession # AAS47839 (142aa) HEPBD10 Heavy chain variable E183/A2 US20120308580 SEQ ID NO: 33; WO 6320 region, HBV Ab 2011062562; CN102781961, EP2501723 HEPBD11 Heavy chain variable US20100260712 SEQ ID NO: 1; 6321 region, HBV Ab WO2009069917 HEPBD12 Heavy chain variable WO2015107126 SEQ ID NO: 2 6322 region, HBV Ab HEPBD13 Heavy chain variable HB48-33, US8840895 SEQ ID NO: 1 6323 region, HBV Ab HB48-35, HB48-59 HEPBD14 Heavy chain variable HFW141 US7435414 SEQ ID NO: 35; 6324 region, HBV Ab US20060014937; WO2005100400; CN1980956 HEPBD15 Heavy chain variable US7112664 SEQ ID NO: 8; US6680053, 6325 region, HBV Ab US6924368, US20020061581, US20040191259, US20050249753, WO2001092529 HEPBD16 Heavy chain variable Ab17.1.4 1 USRE39586 SEQ ID NO: 4; US6146629; 6326 region, HBV Ab WO1997047653 HEPBD17 Heavy chain variable Ab 19.79.5 USRE40831 SEQ ID NO: 4 6327 region, HBV Ab HEPBD18 Heavy chain variable US20150232537 SEQ ID NO: 7; 6328 region, HB V Ab WO2014048910; CA2884388; CN104662041A; EP2900692 HEPBD19 Heavy chain variable WO2013165972 SEQ ID NO: 45 6329 region, HBV Ab HEPBD20 Heavy chain variable WO2013165972 SEQ ID NO: 54 6330 region, HBV Ab HEPBD21 Heavy chain variable WO2013165972 SEQ ID NO: 63 6331 region, HBV Ab HEPBD22 Heavy chain variable WO2013165972 SEQ ID NO: 72 6332 region, HBV Ab HEPBD23 Heavy chain variable WO2013165972 SEQ ID NO: 81 6333 region, HBV Ab HEPBD24 Heavy chain variable WO2013165972 SEQ ID NO: 90 6334 region, HBV Ab HEPBD25 Heavy chain variable WO2013165972 SEQ ID NO: 99 6335 region, HBV Ab HEPBD26 Heavy chain variable WO2013165972 SEQ ID NO: 108 6336 region, HBV Ab HEPBD27 Heavy chain variable WO2013165972 SEQ ID NO: 117 6337 region, HBV Ab HEPBD28 Heavy chain variable WO2013165972 SEQ ID NO: 126 6338 region, HBV Ab HEPBD29 Heavy chain variable WO2013165972 SEQ ID NO: 135 6339 region, HBV Ab HEPBD30 Heavy chain variable WO2013165972 SEQ ID NO: 144 6340 region, HBV Ab HEPBD31 Heavy chain variable WO2013165972 SEQ ID NO: 153 6341 region, HBV Ab HEPBD32 Heavy chain variable WO2013165972 SEQ ID NO: 162 6342 region, HBV Ab HEPBD33 Heavy chain variable WO2013165972 SEQ ID NO: 171 6343 region, HBV Ab HEPBD34 Heavy chain variable WO2013165972 SEQ ID NO: 180 6344 region, HBV Ab HEPBD35 Heavy chain variable WO2013165972 SEQ ID NO: 189 6345 region, HBV Ab HEPBD36 Heavy chain variable WO2013165972 SEQ ID NO: 198 6346 region, HBV Ab HEPBD37 Heavy chain variable WO2013165972 SEQ ID NO: 207 6347 region, HBV Ab HEPBD38 Heavy chain variable WO2013165972 SEQ ID NO: 405 6348 region, HBV Ab HEPBD39 Heavy chain variable WO2013165972 SEQ ID NO: 409 6349 region, HBV Ab HEPBD40 Heavy chain variable WO2013165972 SEQ ID NO: 412 6350 region, HBV Ab HEPBD41 Heavy chain variable WO2013165972 SEQ ID NO: 418 6351 region, HBV Ab HEPBD42 Heavy chain variable WO2013165972 SEQ ID NO: 421 6352 region, HBV Ab HEPBD43 Heavy chain variable WO2009069916 SEQ ID NO: 1 6353 region, HBV Ab HEPBD44 Heavy chain variable PE1-1 WO1994011495 6354 region, HBV Ab HEPBD45 Heavy chain variable ZM1-1 WO1994011495 6355 region, HBV Ab HEPBD46 Heavy chain variable ZM1-2 WO1994011495 6356 region, HBV Ab HEPBD47 Heavy chain variable MD3-4 WO1994011495 6357 region, HBV Ab HEPBD48 Heavy chain variable A2E2 CN102757492 SEQ ID NO: 2 6358 region, HBV Ab HEPBD49 Heavy chain variable C9G9 CN102757492 SEQ ID NO: 6 6359 region, HBV Ab HEPBD50 Heavy chain variable CN104530228 SEQ ID NO: 3 6360 region, HBV Ab HEPBD51 Heavy chain variable CN104530228 SEQ ID NO: 4 6361 region, HBV Ab HEPBD52 Heavy chain variable Ab19 US8580256 SEQ ID NO: 2 6362 region, HBV Ab HEPBD53 Heavy chain variable Ab17 US8580256 SEQ ID NO: 4 6363 region, HBV Ab HEPBD54 Heavy chain variable KR127 US8420353 SEQ ID NO: 28 6364 region, HBV Ab HEPBD55 Heavy chain variable DP7 US8420353 SEQ ID NO: 32 6365 region, HBV Ab HEPBD56 Heavy chain variable HZ1 US8420353 SEQ ID NO: 36 6366 region, HBV Ab HEPBD57 Heavy chain variable MBL-HCV1 US8551484 SEQ ID NO: 1 6367 region, HCV Ab (Antibody produced by clone 83-128) HEPBD58 Heavy chain variable MBL-HCV1 US8551484 SEQ ID NO: 3 6368 region, HCV Ab (Antibody produced by clone 95-2) HEPBD59 Heavy chain variable MBL-HCV1 US8551484 SEQ ID NO: 5 6369 region, HCV Ab (Antibody produced by clone 95-14) HEPBD60 Heavy chain variable Clone 13 US7250166 SEQ ID NO: 1 6370 region, HCV Ab HEPBD61 Heavy chain variable Clone 98 US7250166 SEQ ID NO: 3 6371 region, HCV Ab HEPBD62 Heavy chain variable Clone 1:4 US7250166 SEQ ID NO: 5 6372 region, HCV Ab HEPBD63 Heavy chain variable Clone 1:8 US7250166 SEQ ID NO: 7 6373 region, HCV Ab HEPBD64 Heavy chain variable Clone 1:9 US7250166 SEQ ID NO: 9 6374 region, HCV Ab HEPBD65 Heavy chain variable Clone 1:10 US7250166 SEQ ID NO: 11 6375 region, HCV Ab HEPBD66 Heavy chain variable Clone 4:6 US7250166 SEQ ID NO: 13 6376 region, HCV Ab HEPBD67 Heavy chain variable Clone 6a:5 US7250166 SEQ ID NO: 15 6377 region, HCV Ab HEPBD68 Heavy chain variable Clone2a:2 US7250166 SEQ ID NO: 17 6378 region, HCV Ab HEPBD69 Heavy chain variable Clone 2a:4 US7250166 SEQ ID NO: 19 6379 region, HCV Ab HEPBD70 Heavy chain variable Clone 2a:5 US7250166 SEQ ID NO: 21 6380 region, HCV Ab HEPBD71 Heavy chain variable Clone 2a:13 US7250166 SEQ ID NO: 23 6381 region, HCV Ab HEPBD72 Heavy chain variable Clone 2a:14 US7250166 SEQ ID NO: 25 6382 region, HCV Ab HEPBD73 Heavy chain variable Clone 2a:23 US7250166 SEQ ID NO: 27 6383 region, HCV Ab HEPBD74 Heavy chain variable Clone 2a:23 US7250166 SEQ ID NO: 29 6384 region, HCV Ab HEPBD75 Heavy chain variable Clone 2a:25 US7250166 SEQ ID NO: 31 6385 region, HCV Ab HEPBD76 Heavy chain variable Clone 2a:30 US7250166 SEQ ID NO: 33 6386 region, HCV Ab HEPBD77 Heavy chain variable Clone 2a:32 US7250166 SEQ ID NO: 35 6387 region, HCV Ab HEPBD78 Heavy chain variable Clone 2a:33 US7250166 SEQ ID NO: 37 6388 region, HCV Ab HEPBD79 Heavy chain variable Clone 2a:37 US7250166 SEQ ID NO: 39 6389 region, HCV Ab HEPBD80 Heavy chain variable Clone 2a:40 US7250166 SEQ ID NO: 41 6390 region, HCV Ab HEPBD81 Heavy chain variable Clone 2b:1 US7250166 SEQ ID NO: 43 6391 region, HCV Ab HEPBD82 Heavy chain variable Clone 2b:3 US7250166 SEQ ID NO: 45 6392 region, HCV Ab HEPBD83 Heavy chain variable Clone 2b:4 US7250166 SEQ ID NO: 47 6393 region, HCV Ab HEPBD84 Heavy chain variable Clone 2b:5 US7250166 SEQ ID NO: 49 6394 region, HCV Ab HEPBD85 Heavy chain variable Clone 2b:7 US7250166 SEQ ID NO: 51 6395 region, HCV Ab HEPBD86 Heavy chain variable Clone 2b:9 US7250166 SEQ ID NO: 53 6396 region, HCV Ab HEPBD87 Heavy chain variable Clone 2b:10 US7250166 SEQ ID NO: 55 6397 region, HCV Ab HEPHD88 Heavy chain variable anti-NS3 Fab US7314919 SEQ ID NO: 1 6398 region, HCV Ab HEPBD89 Heavy chain variable Antibody US8551484 SEQ ID NO: 32 6399 region, HCV Ab produced by clone 95-14 HEPBD90 Heavy chain variable Antibody US8551484 SEQ ID NO: 33 6400 region, HCV Ab produced by clone 95-38 HEPBD91 Heavy chain variable Antibody US8551484 SEQ ID NO: 34 6401 region, HCV Ab produced by clone 95-25 HEPBD92 Heavy chain variable Antibody US8551484 SEQ ID NO: 35 6402 region, HCV Ab produced by clone 95.42 HEPBD93 Heavy chain variable Antibody US8551484 SEQ ID NO: 36 6403 region, HCV Ab produced by clone 95-43 HEPBD94 Heavy chain variable Antibody US8551484 SEQ ID NO: 37 6404 region, HCV Ab produced by clone 95-49 HEPBD95 Heavy chain variable Antibody US8551484 SEQ ID NO: 38 6405 region, HCV Ab produced by clone 95-54 HEPBD96 Heavy chain variable Antibody US8551484 SEQ ID NO: 39 6406 region, HCV Ab produced by clone 95-58 HEPBD97 Heavy chain variable Antibody US8551484 SEQ ID NO: 40 6407 region, HCV Ab produced by clone 95-62 HEPBD98 Heavy chain variable HC-84.1 US20130084301 SEQ ID NO: 55 6408 region, HCV Ab HEPBD99 Heavy chain variable HC-84.20 US20130084301 SEQ ID NO: 56 6409 region, HCV Ab HEPBD100 Heavy chain variable HC-84.21 US20130084301 SEQ ID NO: 57 6410 region, HCV Ab HEPBD101 Heavy chain variable HC-84.22 US20130084301 SEQ ID NO: 58 6411 region, HCV Ab HEPBD102 Heavy chain variable HC-23 US20130084301 SEQ ID NO: 59 6412 region, HCV Ab HEPBD103 Heavy chain variable HC-84.24 US20130084301 SEQ ID NO: 60 6413 region, HCV Ab HEPBD104 Heavy chain variable HC-84.25 US20130084301 SEQ ID NO: 61 6414 region, HCV Ab HEPBD105 Heavy chain variable HC-84.26 US20130084301 SEQ ID NO: 62 6415 region, HCV Ab HEPBD106 Heavy chain variable HC-84.27. US20130084301 SEQ ID NO: 63 6416 region, HCV Ab HEPBD107 Heavy chain variable AOT3 US20120009196 SEQ ID NO: 1 6417 region, HCV Ab HEPBD108 Heavy chain variable C11-3 US20120009196 SEQ ID NO: 3 6418 region, HCV Ab HEPBD109 Heavy chain variable C11-7 US20120009196 SEQ ID NO: 5 6419 region, HCV Ab HEPBDI10 Heavy chain variable C11-9 US20120009196 SEQ ID NO: 7 6420 region, HCV Ab HEPBD111 Heavy chain variable C11-14 US20120009196 SEQ ID NO: 9 6421 region, HCV Ab HEPBD112 Heavy chain variable WO2014065822 SEQ ID NO: 3 6422 region, HCV Ab HEPBD113 Heavy chain variable WO2014065822 SEQ ID NO: 7 6423 region, HCV Ab HEPBD114 Heavy chain variable mPA-29 WO2007143701 SEQ ID NO: 2 6424 region, HCV Ab HEPBD115 Heavy chain variable Hc33.1 Li Y. et al., Structural basis for penetration 6425 region, HCV Ab of the glycan shield of hepatitis C virUSe2 glycoprotein by a broadly neutralizing human antibody; J. Biol. Chem. 290 (16), 10117-10125 (2015) NCBI Accession # 4XVJ_H (141aa) HEPBD116 Heavy chain variable Martin, F., et al., Affinity selection of a 6426 region, HCV Ab camelized V(H) domain antibody inhibitor of hepatitis C virUSNS3 protease; Protein Eng. 10(5), 607-614 (1997NCBI Accession # 1OL0_B (121aa) HEPBD117 Heavy chain variable US20150118242 SEQ ID NO: 2 6427 region, HCV Ab HEPBD118 Heavy chain variable US20150166637 SEQ ID NO: 1, 6428 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD119 Heavy chain variable US20150166637 SEQ ID NO: 2; 6429 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD120 Heavy chain variable US20150166637 SEQ ID NO: 3; 6430 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD121 Heavy chain variable US20150166637 SEQ ID NO: 4; 6431 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD122 Heavy chain variable US20150166637 SEQ ID NO: 5; 6432 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD123 Heavy chain variable c18/A2 US20120308580 SEQ ID NO: 2; WO 6433 region, Monoclonal 2011062562; CN102781961, EP2501723 HBV antibody HEPBD124 Heavy chain variable US20110097270 SEQ ID NO: 1 6434 region, Neutralizing monoclonal HBV antibody HEPBD125 Heavy chain, full US20150232537 SEQ ID NO: 9; 6435 HBV Ab WO2014048910; CA2884388; CN104662041A; EP2900692 HEPBD126 Heavy chain, HBV Ab HBFab21 CN103588874 SEQ ID NO: 2 6436 HEPBD127 Heavy chain, HCV Ab Fab clone 1:5 US6747136 SEQ ID NO: 1 6437 HEPBD128 Heavy chain, HCV Ab Fab clone 1:7 US6747136 SEQ ID NO: 2 6438 HEPBD129 Heavy chain, ACV Ab Fab clone 1:11 US6747136 SEQ ID NO: 3 6439 HEPBD130 Heavy chain, HCV Ab Fab clone L3 US6747136 SEQ ID NO: 4 6440 HEPBD131 Heavy chain, HCV Ab Fab clone L1 US6747136 SEQ ID NO: 5 6441 HEPBD132 Heavy chain, HCV Ab Fab clone A8 US6747136 SEQ ID NO: 6 6442 HEPBD133 Heavy chain, HCV Ab Fab clone A12 US6747136 SEQ ID NO: 7 6443 HEPBD134 Heavy chain, HCV Ab HCV-AB 68 US7241445 SEQ ID NO: 3 6444 HEPBD135 Heavy chain, HCV Ab e8 US7727529 SEQ ID NO: 1 6445 HEPBD136 Heavy chain, HCV Ab e10 US7727529 SEQ ID NO: 3 6446 HEPBD137 Heavy chain, HCV Ab e20 US7727529 SEQ ID NO: 5 6447 HEPBD138 Heavy chain, HCV Ab e137 US7727529 SEQ ID NO: 7 6448 HEPBD139 Heavy chain, HCV Ab e301 US7727529 SEQ ID NO: 9 6449 HEPBD140 Heavy chain, HCV Ab e509 US7727529 SEQ ID NO: 11 6450 HEPBD141 Heavy chain, HCV Ab 5D2 US20090104207 SEQ ID NO: 7 6451 HEPBD142 Heavy chain, HCV Ab Mab V WO2013186752 SEQ ID NO: 3 6452 HEPBD143 Heavy chain, HCV Ab Mab VI WO2013186752 SEQ ID NO: 5 6453 HEPBD144 Heavy chain, HCV Ab WO2007143701 SEQ ID NO: 12 6454 HEPBD145 Heavy chain, HCV Ab HuPA29VH#1 WO2007143701 SEQ ID NO: 15 6455 HEPBD146 Heavy chain, HCV Ab HuPA29VH#2 WO2007143701 SEQ ID NO: 16 6456 HEPBD147 Heavy chain, HCV Ab HuPA29VH#3 WO2007143701 SEQ ID NO: 17 6457 HEPBD148 Heavy chain, HCV Ab PA29 WO2007143701 SEQ ID NO: 28 6458 HEPBD149 Heavy chain, HCV Ab Ap33 Kong, L., et al., Structure of Hepatitis C 6459 Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33; J. Virol. 86 (23), 13085-13088 (2012) NCBI Accession # 4G6A _H (224aa) HEPBD50 Heavy chain, HCV Ab Single Chain Fv Gilmartin, A.A., et al., Protein Eng. Des. 6460 Fragment 1:7 Sel. 25 (2), 59-66 (2012) NCBI Accession # 3U6R_A(149aa) HEPBD151 Heavy Chain, HCV Ar3c Kong, L., etal., Hepatitis C virUSE2 6461 Fab envelope glycoprotein core structure; Science 342 (6162), 1090-1094 (2013) NCBI Accession # 4MWF_A (233aa) HEPBD152 Heavy Chain, HCV Mrct10.v362 Pantua, H., et al., Glycan shifting on 6462 Fab hepatitis C virus (HCV) e2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914 (2013) NCBI Accession # HS6_H (226aa) HEPBD153 Heavy Chain, Hcv1 Hcv1, P2(1) Kong, L., et al., Structural basis of 6463 HCV Ab Form hepatitis C virus neutralization by broadly neutralizing antibody HCV1; Proc. Natl. Acad. Sci. U.S.A. 109 (24), 9499-9504 (2012) NCBI Accession # 4DGV_H (226aa) HEPBD154 Heavy Chain, Hcv1 Hcv1, C2 Form Kong, L., etal., Structural basis of 6464 HCV Ab hepatitis C virus neutralization by broadly neutralizing antibody HCV1; Proc. Natl. Acad. Sci. U.S.A. 109 (24), 9499-9504 (2012) NCBI Accession # 4DGY_H (226aa) HEPBD155 Heavy gamma chain P18-9E US8592559 SEQ ID NO: 13 6465 variable, HCV Ab HEPBD156 Heavy-chain-only, VHH D03 WO2014053634 SEQ ID NO: 4 6466 HCV Ab HEPBD157 Heavy-chain-only, VHH C09 WO2014053634 SEQ ID NO: 5 6467 HCV Ab HEPBD158 Heavy-chain-only, B1 1 WO2014053634 SEQ ID NO: 6 6468 HCV Ab HEPBD159 Heavy-chain-only, D04 WO2014053634 SEQ ID NO: 7 6469 HCV Ab HEPBD160 Light chain full, HBV US20150232537 SEQ ID NO: 10; 6470 Ab WO2014048910; CA2884388; CN104662041A; EP2900692 HEPBD161 Light chain kappa, Esposito, C., et al., Recombinant human 6471 partial, HCV Ab antibodies specific for hepatitis C virus proteins; Arch. Virol. 142 (3), 601-610 (1997) NCBI Accession # CAA54913.1(110aa) HEPBD162 Light chain variable c18/A2 US20120308580 SEQ ID NO: 1; WO 6472 domain, monoclonal 2011062562; CN102781961, EP2501723 HBV antibody HEPBD163 Light chain variable US20110097270 SEQ ID NO: 9 6473 domain, neutralizing monoclonal HBV antibody, HEPBD164 Light chain variable EP0521348 6474 gene, Chimeric HBV Ab HEPBD165 Light chain variable E183/A2 US20120308580 SEQ ID NO: 32; WO 6475 region, HBV Ab 2011062562; CN102781961, EP2501723 HEPBD166 Light chain variable HB48-33 US8840895 SEQ ID NO: 2 6476 region, HBV Ab HEPBD167 Light chain variable HB48-35 US8840895 SEQ ID NO: 3 6477 region, HBV Ab HEPBD168 Light chain variable HB48-59 US8840895 SEQ ID NO: 4 6478 region, HBV Ab HEPBD169 Light chain variable LFW22-31 US7435414 SEQ ID NO: 36; 6479 region, HBV Ab US20060014937; WO2005100400; CN1980956 HEPBD170 Light chain variable LFW22-312 US7435414 SEQ ID NO: 37; 6480 region, HBV Ab US20060014937; WO2005100400; CN1980956 HEPBD171 Light chain variable WO2013165972 SEQ ID NO: 216 6481 region, HBV Ab HEPBD172 Light chain variable WO2013165972 SEQ ID NO: 225 6482 region, HBV Ab HEPBD173 Light chain variable WO2013165972 SEQ ID NO: 234 6483 region, HBV Ab HEPBD174 Light chain variable WO2013165972 SEQ ID NO: 243 6484 region, HBV Ab HEPBD175 Light chain variable WO2013165972 SEQ ID NO: 252 6485 region, HBV Ab HEPBD176 Light chain variable WO2013165972 SEQ ID NO: 261 6486 region, HBV Ab HEPBD177 Light chain variable WO2013165972 SEQ ID NO: 270 6487 region, HBV Ab HEPBD178 Light chain variable WO2013165972 SEQ ID NO: 279 6488 region, HBV Ab HEPBD179 Light chain variable WO2013165972 SEQ ID NO: 288 6489 region, HBV Ab HEPBD180 Light chain variable WO2013165972 SEQ ID NO: 297 6490 region, HBV Ab HEPBD181 Light chain variable WO2013165972 SEQ ID NO: 306 6491 region, HBV Ab HEPBD182 Light chain variable WO2013165972 SEQ ID NO: 315 6492 region, HBV Ab HEPBD183 Light chain variable WO2013165972 SEQ ID NO: 324 6493 region, HBV Ab HEPBD184 Light chain variable WO2013165972 SEQ ID NO: 333 6494 region, HBV Ab HEPBD185 Light chain variable WO2013165972 SEQ ID NO: 342 and 351 6495 region, HBV Ab HEPBD186 Light chain variable WO2013165972 SEQ ID NO: 360 6496 region, HBV Ab HEPBD187 Light chain variable WO2013165972 SEQ ID NO: 369 6497 region, HBV Ab HEPBD188 Light chain variable WO2013165972 SEQ ID NO: 378 6498 region, HBV Ab HEPBD189 Light chain variable WO2013165972 SEQ ID NO: 387 6499 region, HBV Ab HEPBD190 Light chain variable WO2013165972 SEQ ID NO: 396 6500 region, HBV Ab HEPBD191 Light chain variable WO2009069916 SEQ ID NO: 2 6501 region, HBV Ab HEPBD192 Light chain variable PE1-1 WO1994011495 6502 region, HBV Ab HEPBD193 Light chain variable ZM1-1 WO1994011495 6503 region, HBV Ab HEPBD194 Light chain variable ZM1-2 WO1994011495 6504 region, HB V Ab HEPBD195 Light chain variable MD3 -4 WO1994011495 6505 region, HBV Ab HEPBD196 Light chain variable A2E2 CN102757492 SEQ ID NO: 4 6506 region, HBV Ab HEPBD197 Light chain variable C9G9 CN102757492 SEQ ID NO: 8 6507 region, HBV Ab HEPBD198 Light chain variable CN104530228 SEQ ID NO: 1 6508 region, HBV Ab HEPBD199 Light chain variable CN104530228 SEQ ID NO: 2 6509 region, HBV Ab HEPBD200 Light chain variable Ab19 US8580256 SEQ ID NO: 1 6510 region, HBV Ab HEPBD201 Light chain variable Ab17 US8580256 SEQ ID NO: 3 6511 region, HBV Ab HEPBD202 Light chain variable KR127 US8420353 SEQ ID NO: 4 6512 region, HBV Ab HEPBD203 Light chain variable KR127 US8420353 SEQ ID NO: 2 6513 region, HBV Ab HEPBD204 Light chain variable KR127 US8420353 SEQ ID NO: 30 6514 region, HBV Ab HEPBD205 Light chain variable DPK12 US8420353 SEQ ID NO: 34 6515 region, HBV Ab HEPBD206 Light chain variable HZI US8420353 SEQ ID NO: 38 6516 region, HBV Ab HEPBD207 Light chain variable US7112664 SEQ ID NO: 7; US6680053, 6517 region, HBV Ab US6924368, US20020061581, US20040191259, US20050249753, WO2001092529 HEPBD208 Light chain variable Ab17.1.4 1 USRE39586 SEQ ID NO: 2; US6146629; 6518 region, HBV Ab WO1997047653 HEPBD209 Light chain variable Ab 19.79.5 USRE40831 SEQ ID NO: 2 6519 region, HBV Ab HEPBD210 Light chain variable US20150232537 SEQ ID NO: 8; 6520 region, HBV Ab WO2014048910; CA2884388; CN104662041A; EP2900692 HEPBD211 Light chain variable US20100260712 SEQ ID NO: 2; 6521 region, HBV Ab WO2009069917 HEPBD212 Light chain variable WO2015107126 SEQ ID NO: 4 6522 region, HBV Ab HEPBD213 Light chain variable MBL-HCV1 US8551484 SEQ ID NO: 2 6523 region, HCV Ab (Antibody produced by clone 83-128) HEPBD214 Light chain variable MBL-HCV1 US8551484 SEQ ID NO: 4 6524 region, HCV Ab (Antibody produced by clone 95-2) HEPBD215 Light chain variable MBL-HV1 US8551484 SEQ ID NO: 6 6525 region, HCV Ab (Antibody produced by clone 073-1) HEPBD216 Light chain variable Clone 13 US7250166 SEQ ID NO: 2 6526 region, HCV Ab HEPBD217 Light chain variable Clone 98 US7250166 SEQ ID NO: 4 6527 region, HCV Ab HEPBD218 Light chain variable Clone 1:4 US7250166 SEQ ID NO: 6 6528 region, HCV Ab HEPBD219 Light chain variable Clone 1:8 US7250166 SEQ ID NO: 8 6529 region, HCV Ab HEPBD220 Light chain variable Clone 1:9 US7250166 SEQ ID NO: 10 6530 region, HCV Ab HEPBD221 Light chain variable Clone 1:10 US7250166 SEQ ID NO: 12 6531 region, HCV Ab HEPBD222 Light chain variable Clone 4:6 US7250166 SEQ ID NO: 14 6532 region, HCV Ab HEPBD223 Light chain variable Clone 6a:5 US7250166 SEQ ID NO: 16 6533 region, HCV Ab HEPBD224 Light chain variable Clone 2a:2 US7250166 SEQ ID NO: 18 6534 region, HCV Ab HEPBD225 Light chain variable Clone 2a:4 US7250166 SEQ ID NO: 20 6535 region, HCV Ab HEPBD226 Light chain variable Clone 2a:5 US7250166 SEQ ID NO: 22 6536 region, HCV Ab HEPBD227 Light chain variable Clone 2a:13 US7250166 SEQ ID NO: 24 6537 region, HCV Ab HEPBD228 Light chain variable Clone 2a:14 US7250166 SEQ ID NO: 26 6538 region, HCV Ab HEPBD229 Light chain variable Clone 2a:23 US7250166 SEQ ID NO: 28 6539 region, HCV Ab HEPBD230 Light chain variable Clone 2a:23 US7250166 SEQ ID NO: 30 6540 region, HCV Ab HEPBD231 Light chain variable Clone 2a:25 US7250166 SEQ ID NO: 32 6541 region, HCV Ab HEPBD232 Light chain variable Clone 2a:30 US7250166 SEQ ID NO: 34 6542 region, HCV Ab HEPBD233 Light chain variable Clone 2a:32 US7250166 SEQ ID NO: 36 6543 region, HCV Ab HEPBD234 Light chain variable Clone 2a:33 US7250166 SEQ ID NO: 38 6544 region, HCV Ab HEPBD235 light chain variable Clone 2a:37 US7250166 SEQ ID NO: 40 6545 region, HCV Ab HEPBD236 Light chain variable Clone 2a:40 US7250166 SEQ ID NO: 42 6546 region, HCV Ab HEPBD237 Light chain variable Clone 2b:1 US7250166 SEQ ID NO: 44 6547 region, HCV Ab HEPBD238 Light chain variable Clone 2b:3 US7250166 SEQ ID NO: 46 6548 region, HCV Ab HEPBD239 Light chain variable Clone 2b:4 US7250166 SEQ ID NO: 48 6549 region, HCV Ab HEPBD240 Light chain variable Clone 2b:5 US7250166 SEQ ID NO: 50 6550 region, HCV Ab HEPBD241 Light chain variable Clone 2b:7 US7250166 SEQ ID NO: 52 6551 region, HCV Ab HEPBD242 Light chain variable Clone 2b:9 US7250166 SEQ ID NO: 54 6552 region, HCV Ab HEPBD243 Light chain variable Clone 2b:10 US7250166 SEQ ID NO: 56 6553 region, HCV Ab HEPBD244 Light chain variable anti-NS3 Fab US7314919 SEQ ID NO: 6 6554 region, HCV Ab HEPBD245 Light chain variable US7507408 SEQ ID NO: 2 6555 region, HCV Ab HEPBD246 Light chain variable US7507408 SEQ ID NO: 4 6556 region, HCV Ab HEPBD247 Light chain variable US7507408 SEQ ID NO: 6 6557 region, HCV Ab HEPBD248 Light chain variable Antibody US8551484 SEQ ID NO: 44 6558 region, HCV Ab produced by clone 95-14 HEPBD249 Light chain variable Antibody US8551484 SEQ ID NO: 53 6559 region, HCV Ab produced by clone 95-38 HEPBD250 Light chain variable HC-84.1 US20130084301 SEQ ID NO: 64 6560 region, HCV Ab HEPBD251 Light chain variable HC-84.20 US20130084301 SEQ ID NO: 65 6561 region, HCV Ab HEPBD252 Light chain variable HC-84.21 US20130084301 SEQ ID NO: 66 6562 region, HCV Ab HEPBD253 Light chain variable HC-84.22 US20130084301 SEQ ID NO: 67 6563 region, HCV Ab HEPBD254 Light chain variable HC-23 US20130084301 SEQ ID NO: 68 6564 region, HCV Ab HEPBD255 Light chain variable HC-84.24 US20130084301 SEQ ID NO: 69 6565 region, HCV Ab HEPBD256 Light chain variable HC-84.25 US20130084301 SEQ ID NO: 70 6566 region, HCV Ab HEPBD257 Light chain variable HC-84,26 US20130084301 SEQ ID NO: 71 6567 region, HCV Ab HEPBD258 Light chain variable HC-84.27. US20130084301 SEQ ID NO. 72 6568 region, HCV Ab HEPBD259 Light chain variable AOT3 US20120009196 SEQ ID NO: 2 6569 region, HCV Ab HEPBD260 Light chain variable C11-3 US20120009196 SEQ ID NO: 4 6570 region, HCV Ab HEPBD261 Light chain variable C11-7 US20120009196 SEQ ID NO: 6 6571 region, HCV Ab HEPBD262 Light chainvariable C11-9 US20120009196 SEQ ID NO: 8 6572 region, HCV Ab HEPBD263 Light chain variable C11-14 US20120009196 SEQ ID NO: 10 6573 region, HCV Ab HEPBD264 Light chain variable WO2014065822 SEQ ID NO: 5 6574 region, HCV Ab HEPBD265 Light chain variable WO2014065822 SEQ ID NO: 9 6575 region, HCV Ab HEPBD266 Light chain variable Antibody light WO2007143701 SEQ ID NO: 1 6576 region, HCV Ab chain from WO2007143701 HEPBD267 Light chain variable Hc33.1 Li Y. et al., Structural basis for penetration 6577 region, HCV Ab of the glycan shield of hepatitis C virUSe2 glycoprotein by a broadly neutralizing human antibody; J. Biol. Chem. 290 (16), 10117-10125 (2015) NCBI Accession # 4XVJ_L (115aa) HEPBD268 Light chain variable US20150118242 SEQ ID NO: 3 6578 region, HCV Ab HEPBD269 Light chain variable US20150166637 SEQ ID NO: 6; 6579 region, Human HVB WO2014010890; CA2878155, antibody that binds to CN104487090; EP2858674 the surface antigen (HBsAg) HEPBD270 Light chain variable US20150166637 SEQ ID NO: 7; 6580 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD271 Light chain variable US20150166637 SEQ ID NO: 8; 6581 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD272 Light chain variable US20150166637 SEQ ID NO: 9; 6582 region, Human HBV WO2014010890; CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD273 Light chain variable US20150166637 SEQ ID NO: 10; 6583 region, Human HBV WO2014010890, CA2878155, antibody that binds to CN104487090, EP2858674 the surface antigen (HBsAg) HEPBD274 Light chain variable Keck, Z.Y., et al., Human monoclonal 6584 region, partial, HCV antibody to hepatitis C virUSE1 Ab glycoprotein that blocks virus attachment and viral infectivity; J. Virol. 78(13), 7257-7263 (2004) NCBI Accession # AAS47840 (147aa) HEPBD275 Light chain, HCV Ab Hu5b3.v3 Pantua, B., et al., Glycan shifting on 6585 hepatitis C virus (HCV) e2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914 (2013) NCBI Accession # 4HS8_L (218aa) HEPBD276 Light chain, HCV Ab Ap33 Kong, L., et al., Structure of Hepatitis C 6586 Virus Envelope Glycoprotein E2 Antigenic Site 412 to 423 in Complex with Antibody AP33; J. Virol. 86 (23), 13085-13088 (2012) NCBI Accession # 4G6A_L (218aa) HEPBD277 Light chain, HBV Ab HBFab21 CN103588874 SEQ ID NO: 1 6587 HEPBD278 Light chain, HBV Ab Fab clone 1:5 US6747136 SEQ ID NO: 8 6588 HEPBD279 Light chain, HCV Ab Fab clone 1:7 US6747136 SEQ ID NO: 9 6589 HEPBD280 Light chain, HCV Ab Fab clone 1:11 US6747136 SEQ ID NO: 10 6590 HEPBD281 Light chain, HCV Ab Fab clone L3 US6747136 SEQ ID NO: 11 6591 HEPBD282 Light chain, HCV Ab Fab clone L1 US6747136 SEQ ID NO: 12 6592 HEPBD283 Light chain, HCV Ab Fab clone A8 US6747136 SEQ ID NO: 13 6593 HEPBD284 Light chain, HCV Ab Fab clone A12 US6747136 SEQ ID NO: 14 6594 HEPBD285 Light chain, HCV Ab HCV#1 US6924362 SEQ ID NO: 1 6595 HEPBD286 Light chain, HCV Ab HCV#4 US6924362 SEQ ID NO: 2 6596 HEPBD287 Light chain, HCV Ab HCV#7 US6924362 SEQ ID NO: 3 6597 HEPBD288 Light chain, HEV Ab HCV#12 US6924362 SEQ ID NO: 4 6598 HEPBD289 Light chain, HCV Ab HGV#13 US6924362 SEQ ID NO: 5 6599 HEPBD290 Light chain, HCV Ab HCV-AB 68 US7241445 SEQ ID NO: 4 6600 HEPBD291 Light chain, HCV Ab e8 US7727529 SEQ ID NO: 2 6601 HEPBD292 Light chain, HCV Ab e10 US7727529 SEQ ID NO: 4 6602 HEPBD293 Light chain, HEV Ab e20 US7727529 SEQ ID NO: 6 6603 HEPBD294 Light chain, HCV Ab e137 US7727529 SEQ ID NO: 8 6604 HEPBD295 Light chain, HCV Ab e301 US7727529 SEQ ID NO: 10 6605 HEPBD296 Light chain, HCV Ab e509 US7727529 SEQ ID NO: 12 6606 HEPBD297 Light chain, HCV Ab 5D2 US20090104207 SEQ ID NO: 8 6607 HEPBD298 Light chain, HCV Ab MabV WO2013186752 SEQ ID NO: 4 6608 HEPBD299 Light chain, HCV Ab Mab VI WO2013186752 SEQ ID NO: 6 6609 HEPBD300 Light chain, HCV Ab WO2007143701 SEQ ID NO: 11 6610 HEPBD301 Light chain, HCV Ab HuPA29VH#1 WO2007143701 SEQ ID NO: 18 6611 HEPBD302 Light chain, HCV Ab HuPA29VH#2 WO2007143701 SEQ ID NO: 19 6612 HEPBD303 Light chain, HCV Ab PA29 WO2007143701 SEQ ID NO: 29 6613 HEPBD304 Light chain, HCV Ab Single Chain Fv Gilmartin, A.A., et al., Protein Eng. Des. 6614 Fragment 1:7 Sel. 25 (2), 59-66 (2012) NCBI Accession # 3U6R_B (143aa) HEPBD305 Light chain, HCV Ab Igh526 Kong L., et al., Structure of Hepatitis C 6615 Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody 1GH526; J. Mol. Biol. 427 (16), 2617-2628 (2015) NCBI Accession # 4N0Y_L (218aa) HEPBD306 Light chain, HCV Fab Ar3c Kong, L., et al., Hepatitis C virUSE2 6616 envelope glycoprotein core structure; Science 342 (6162), 1090-1094 (2013) NCBI Accession # 4MWF_B (214aa) HEPBD307 Light chain, HCV Fab Mrct10.v362 Pantua, H., et al., Glycan shifting on 6617 hepatitis C virus (HCV) e2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies; J. Mol. Biol. 425 (11), 1899-1914 (2013) NCBI Accession # 4HS6_L (218aa) HEPBD308 Light chain, Hcv1 Hcv1, C2 Form Kong, L., et al., Structural basis of 6618 HCV Ab hepatitis C virus neutralization by broadly neutralizing antibody HCV1; Proc. Natl. Acad. Sci, U.S.A. 109 (24), 9499-9504 (2012) NCBI Accession # 4DGY_L (213aa) HEPBD309 Light chain, Hcv1 Hcv1, P2(1) Kong, L., et al., Structural basis of 6619 HCV Ab Form hepatitis C virus neutralization by broadly neutralizing antibody HCV1; Proc. Natl. Acad. Sci, U.S.A. 109 (24), 9499-9504 (2012) NCBI Accession # 4DGV_L (213aa) HEPBD310 Light kappa chain P18-9E US8592559 SEQ ID NO: 14 6620 variable, HCV Ab HEPBD311 PEGylated anti-E2 WO2006028634 SEQ ID NO: 1 6621 heavy chain, HCV Ab HEPBD312 PEGylated anti-E2 WO2006028634 SEQ ID NO: 2 6622 heavy chain, HCV Ab HEPBD313 PEGylated anti-E2 WO2006028634 SEQ ID NO: 3 6623 heavy chain, HCV Ab HEPBD314 PEGylated anti-E2 WO2006028634 SEQ ID NO: 4 6624 heavy chain, HCV Ab HEPBD315 PEGylated anti-E2 WO2006028634 SEQ ID NO: 8 6625 heavy chain, HCV Ab HEPBD316 single chain, HBV Ab US6562599 SEQ ID NO: 4 6626 HEPBD317 single chain, HBV Ab US6562599 SEQ ID NO: 6 6627

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in U.S. Pat. Nos. 7,241,445, and 8,858,947, the contents of each of which are herein incorporated by reference in their entirety, against HCV.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in US Publication No. US20150072885 and US20110046354, U.S. Pat. No. 5,204,095, European Publication No. EP0232921, EP0038642, and EP0186371, and International Publication No. WO1994011495, the contents of each of which are herein incorporated by reference in their entirety, against HBV.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in U.S. Pat. No. 6,020,195, the contents of which are herein incorporated by reference in their entirety, against HGV (hepatitis G virus).

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 24 against Herpes Virus.

TABLE 24 Antibodies against Herpesvirus SEQ Antibody Antibody ID No. Description Name Reference Information NO HERP1 Chain A, HSV E317 Fab Lee, C. et al., “Structural basis for the 6628 antibody neutralization of herpes simplex virus” Acta Crystallogr. D Biol. Crystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession # 3W9D_A HERP2 Chain B, HSV E317 Fab Lee, C. et al., “Structural basis for the 6629 antibody neutralization of herpes simplex virus” Acta Crystallogr. D Biol. Clystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession # 3W9D_B HERP3 Chain C, HSV E317 Fab Lee, C. et al., “Structural basis for the 6630 antibody neutralization of herpes simplex virus” Acta Crystatlogr. D Biol. Crystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession # 3W9D_C HERP4 Chain D, HSV E317 Fab Lee, C. et al., “Structural basis for the 6631 antibody neutralization of herpes simplex virus” Acta Crystallogr. D Biol. Clystallogr. 69 (PT 10), 1935-1945 (2013), NCBI Accession # 3W9D_D HERP5 Chimeric anti- Tanner, J.E., “Peptides Designed To Spatially 6632 EBVs Depict the Epstein-Barr Virus Major Virion gp350 antibody Glycoprotein gp350 Neutralization Epitope Elicit Antibodies That Block Virus- Neutralizing Antibody 72A1 Interaction with the Native gp350 Molecule””, J. Virol. 89 (9), 4932-4911(2015), NCBI Accession #AJR20276 HERP6 Chimeric anti- Tanner, J.E., “Peptides Designed To Spatially 6633 EBVs Depict the Epstein-Barr Virus Major Virion gp350 antibody Glycoprotein gp350 Neutralization Epitope Elicit Antibodies That Block Virus- Neutralizing Antibody 72A1 Interaction with the Native gp350 Molecule””, J. Virol. 89 (9), 4932-4941 (2015), NCBI Accession #AJR20275 HERP7 CMV AE11F/3-20L1 Lantto, J. et al., Binding characteristics 6634 determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus, Virology 305 (1), 201-209 (2003), NCBI Accession # AAN87569.1 (256 aa) HERP8 Fv, EBV G5 Fang, C.Y., “Modulation of Epstein-Barr virus 6635 latent membrane protein 1 activity by intrabodies”, Intervirology 50 (4), 254-263 (2007), NCBI Accession #ABA55015 HERP9 Fv, EBV A4 Fang, C.Y., “Modulation of Epstein-Barr virus 6636 latent membrane protein 1 activity by intrabodies”, Intervirology 50(4), 254-263 (2007), NCBI Accession #ABA55014 HERP10 Fv, EBV B8 Fang, CY., “Modulation of Epstein-Barr virus 6637 latent membrane protein 1 activity by intrabodies”, Intervirology 50 (4), 254-263 (2007), NCBI Accession #ABA55013 HERP11 Fv, EBV F5 Fang, C.Y., “Modulation of Epstein-Barr virus 6638 latent membrane protein 1 activity by intrabodies”, Intervirology 50(4), 254-263 (2007), NCBI Accession #ABA55012 HERP12 Fv, EBV E2 Fang, C.Y., “Modulation of Epstein-Barr virus 6639 latent membrane protein 1 activity by intrabodies”, Intervirology 50 (4), 254-263 (2007), NCBI Accession #ABA55011 HERP13 Fv, EBV H3 Fang, C,Y., “Modulation of Epstein-Barr virus 6640 latent membrane protein 1 activity by intrabodies”, Intervirology 50 (4), 254-263 (2007), NCBI Accession #ABA55010 HERP14 Heavy chain, DDF-VZV1 US20100074906 SEQ ID NO: 20 6641 FLAGhis tagged sequence, VZV HERP15 Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to 6642 variable domain, glycoprotein D neutralizes infectivity and clone 11, HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 ( 1), 355-359 (1994), NCBI Accession # AAB29447 HERP16 Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to 6643 variable domain, glycoprotein D neutralizes infectivity and clone 13, HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 ( 1), 355-359 (1994), NCBI Accession # AAB29449 HERP17 Heavy chain ACHDV2 Burioni, R, et al, “Recombinant human Fab to 6644 variable domain, glycoprotein D neutralizes infectivity and clone 15, HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 ( 1), 355-359 (1994), NCBI Accession # AAB29456 HERP18 Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to 6645 variable domain, glycoprotein D neutralizes infectivity and clone 15, HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 (1), 355-359 (1994,) NCBI Accession # AAB29450 HERP19 Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to 6646 variable domain, glycoprotein D neutralizes infectivity and clone 18, HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 (1), 355-359 (1994,) NCBI Accession # AAB29448 HERP20 Heavy chain ACHDV1 Burioni, R. et al. “Recombinant human Fab to 6647 variable domain, glycoprotein D neutralizes infectivity and clone 2, HSV prevents cell-to-cell transmission of herpes simplex viruses 1 and 2 in vitro”, Proc. Natl. Acad. Sci. U.S.A. 91 (1), 355-359 (1994), NCBI Accession # AAB29455 HERP21 Heavy chain 1F7 US8202518 SEQ ID NO: 5 6648 variable region, CMV HERP22 Heavy chain Humanized 57.4 WO2014200898 SEQ ID NO: 633 6649 variable region, CMV HERP23 Heavy chain Humanized 57.4 WO2014200898 SEQ ID NO: 634 6650 variable region, CMV HERP24 Heavy chain Humanized 58.5 WO2014200898 SEQ ID NO: 637 6651 variable region, CMV HERP25 Heavy chain Humanized 58.5 WO2014200898 SEQ ID NO: 638 6652 variable region, CMV HERP26 Heavy chain Humanized WO2014200898 SEQ ID NO: 641 6653 variable region, 272.7 CMV HERP27 Heavy chain Humanized WO2014200898 SEQ ID NO: 644 6654 variable region, 276.10 CMV HERP28 Heavy chain Humanized WO2014200898 SEQ ID NO: 645 6655 variable region, 276.10 CMV HERP29 Heavy chain Sm5-1 Li, B., Construction and characterization of a 6656 variable region, high-affinity humanized SMS-1 monoclonal CMV antibody, Biochem. Biophys. Res. Commun. 357 (4), 951-956 (2007), NCBI Accession # ABI22831.1 HERP30 Heavy chain Schoppel, K. et al., Antibodies specific for the 6657 variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) of human cytomegalovirus bind to different substructures, Virology 216 (1), 133- 145 (1996), NCBI Accession # AAB26953.1 (163 aa) HERP1 Heavy chain Schoppel, K. et al., Antibodies specific for the 6658 variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) of human cytomegalovirus bind to different substructures, Virology 216 (1), 133- 145 (1996), NCBI Accession # AAB26952.1 (161 aa) HERP32 Heavy chain Schoppel, K. et al., Antibodies specific for the 6659 variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) of human cytomegalovirus bind to different substructures, Virology 216 (1), 133- 145 (1996), NCBI Accession # AAB26951.1 (158 aa) HERP33 Heavy chain Potzsch, S., B Cell Repertoire Analysis 6660 variable region, Identifies New Antigenic Domains on CMV Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies, NCBI Accession # AEF33814.1 HERP34 Heavy chain 1F11 US9149524 SEQ ID NO: 7 6661 variable region, CMV, a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A HERP35 Heavy chain 2F4 US9149524 SEQ ID NO: 17 6662 variable region, CMV, a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A HERP36 Heavy chain 5A2 US9149524 SEQ ID NO: 39 6663 variable region, CMV, a complex of human cytomegalovirus (hCMV) proteins UL130 and UL131A HERP37 Heavy chain EV2038 US8492529 SEQ ID NO: 10 6664 variable region, CMV, AD1 region of HMV glycoprotein gB HERP38 Heavy chain US20150064174 SEQ ID 1 6665 variable region, EBV HERP39 Heavy chain US20150064174 SEQ ID 2 6666 variable region, EBV HERP40 Heavy chain HCMV16 WO1994009136, FIG. 1 6667 variable region, gH glycoprotein of HCMV HERP41 Heavy chain Nejatollahi, F. and Bagheri, V., “Isolation of 6668 variable region, neutralizing human specific single-chain HSV antibodies against Herpes Simplex Virus type 1 glycoproiein D”, unpublished, NCBI Accession # AGO59015 HERP42 Heavy chain E317 US8431118 SEQ ID NO: 1; US8252906 6669 variable region, HSV 1&2 HERP43 Heavy chain E425 US8431118 SEQ ID NO: 3; US8252906 6670 variable region, HSV 1&2 HERP44 Heavy chain Y571 US8431118 SEQ ID NO: 41; US8252906 6671 variable region, HSV 1&2 HERP45 Heavy chain US5506132 SEQ ID NO: 4 6672 variable region, VZV HERP46 Heavy chain DDF-VZV2 US20100074906 SEQ ID NO: 26 6673 variable region, VZV HERP47 Heavy chain EV2038 US8492529 SEQ ID NO: 6 6674 without a signal sequence, CMV, AD1 region of HCMV glycoprote in gB HERP48 Heavy chain, 8f9 McLean, G.R. et al., Recognition of human 6675 CMV cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response, J. Immunol. 174 (8), 4768-4778 (2005), NCBI Accession # CAE54374.1 HERP49 Heavy chain, Mab 109 Simpson, J.A. et al., Neutralizing monoclonal 6676 CMV antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24505.1 (119 aa) HERP50 Heavy chain, Mab 115 Simpson, J.A. et al., Neutralizing monoclonal 6677 CMV antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationaly distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24504.1 (117 aa) HERP51 Heavy chain, Mab 33 Simpson, J.A. et al., Neutralizing monoclonal 6678 CMV antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24503.1 (120 aa) HERP52 Heavy chain, Mab 5 Simpson, J.A. et at, Neutralizing monoclonal 6679 CMV antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationaly distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24502.1 (120 aa) HERP53 Heavy chain, 6G4 WO2010007463 SEQ ID NO: 7 6680 CMV, a combination of the hCMV proteins UL128, UL130 and UL131A HERP54 Heavy chain, US20140093526 SEQ ID 12 6681 HHV-6 HERP55 Heavy chain, FabHS V 8. US6156313 SEQ ID NO: 2 6682 HSV 1&2 HERP56 Heavy chain, 64-683 US5646041 SEQ ID NO: 2; EP876478 6683 HSV 1&2 HERP57 Heavy chain, H005157 US20140302062 SEQ ID NO: 3 6684 HSV 1&2 HERP58 Heavy chain, H005158 US20140302062 SEQ ID NO: 4 6685 HSV 1&2 HERP59 Heavy chain, H005159 US20140302062 SEQ ID NO: 5 6686 HSV 1&2 HERP60 Heavy chain, H005160 US20140302062 SEQ ID NO: 6 6687 HSV 1&2 HERP61 Heavy chain, H005188 US20140302062 SEQ ID NO: 7 6688 HSV 1&2 HERP62 Heavy chain, H005190 US20140302062 SEQ ID NO: 8 6689 HSV 1&2 HERP63 Heavy chain, H005192 US20140302062 SEQ ID NO: 9 6690 HSV 1&2 HERP64 Light chain HCMV16 WO1994009136, FIG. 2 6691 variable region, gH glycoprotein of HCMV HERP65 Light chain DDF-VZV1 US20100074906 SEQ ID NO: 22 6692 recombinant, VZV HERP66 Light chain 1F7 US8202518 SEQ ID NO: 10 6693 variable region, CMV HERP67 Light chain Humanized 57.4 WO2014200898 SEQ ID NO: 631 6694 variable region, CMV HERP68 Light chain Humanized 57.4 WO2014200898 SEQ ID NO: 632 6695 variable region, CMV HERP69 Light chain Humanized 58.5 WO2014200898 SEQ ID NO: 635 6696 variable region, CMV HERP70 Light chain Humanized 58.5 WO2014200898 SEQ ID NO: 636 6697 variable region, CMV HERP71 Light chain Humanized WO2014200898 SEQ ID NO: 639 6698 variable region, 272.7 CMV HERP72 Light chain Humanized WO2014200898 SEQ ID NO: 640 6699 variable region, 272.7 CMV HERP73 Light chain Humanized WO2014200898 SEQ ID NO: 642 6700 variable region, 276.10 CMV HERP74 Light chain Humanized WO2014200898 SEQ ID NO: 643 6701 variable region, 276.10 CMV HERP75 Light chain Sm5-1 Li, B., Construction and characterization of a 6702 variable region, high-affinity humanized SM5-1 monoclonal CMV antibody, Biochem. Biophys. Res. Commun. 357 (4), 951-956 (2007), NCBI Accession # AB122832.1 HERP76 Light chain 8f9 Schoppel, K. et al., Antibodies specific for the 6703 variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) of human cytomegalovirus bind to different substructures, Virology 216 (1), 133- 145 (1996), NCBI Accession # AAB26956.1 (146 aa) HERP77 Light chain Schoppel, K. et al., Antibodies specific for the 6704 variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) of human cytomegalovirus bind to different substructures, Virology 216 (1), 133- 145 (1996), NCBI Accession # AAB26955.1 (141 aa) HERP78 Light chain Schoppel, K. et al., Antibodies specific for the 6705 variable region, antigenic domain 1 of glycoprotein B CMV (gpUL55) of human cytomegalovirus bind to different substructures, Virology 216 (1), 133- 45 (1996), NCBI Accession # AAB26954.1 (152 aa) HERP79 Light chain Potzsch, S., B Cell Repertoire Analysis 6706 variable region, Identifies New Antigenic Domains on CMV Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies, NCBI Accession # AEF33824.1 HERP80 Light chain 1F11 US9149524 SEQ ID NO: 8 6707 variable region, CMV, a combination of the hCMV proteins UL128, UL130 and UL131A HERP81 Light chain 2F4 US9149524 SEQ ID NO: 18 6708 variable region, CMV, a combination of the hCMV proteins UL128, ULL30 and UL131A HERP82 Light chain 5A2 US9149524 SEQ ID NO: 40 6709 variable region, CMV, a combination of the hCMV proteins IUL128, UL130 and UL131A HERP83 Light chain EV2038 US8492529 SEQ ID NO. 12 6710 variable region, CMV, AD1 region of HCMV glycoprotein gB HERP84 Light chain US20150064174 SEQ ID 3 6711 variable region, EBV HERP85 Light chain US20150064174 SEQ ID 4 6712 variable region, EBV HERP86 Light chain Nejatollahi, F. and Bagheri, V., “Isolation of 6713 variable region, neutralizing human specific single-chain HSV antibodies against Herpes Simplex Virus type 1 glycoprotein D”, unpublished”, NCBI Accession # AGO59016 HERP87 Light chain E317 US8431118 SEQ ID NO: 2; US8252906 6714 variable region, HSV 1&2 HERP88 Light chain E425 US8431118 SEQ ID NO: 4; US8252906 6715 variable region, HSV 1&2 HERP89 Light chain Y571 US8431118 SEQ ID NO: 42; US8252906 6716 variable region, HSV 1&2 HERP90 Light chain US5506132 SEQ ID NO: 2 6717 variable region, VZV HERP91 Light chain DDF-VZV2 US20100074906 SEQ ID NO: 24 6718 variable region, VZV HERP92 Light chain EV2038 US8492529 SEQ ID NO: 8 6719 without a signal sequence, CMV, AD1 region of HCMV glycoprotein gB HERP93 Light chain, CMV 8f9 McLean, G.R. et al., Recognition of human 6720 cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response, J. Immunol. 174 (8), 4768-4778 (2005), NCBI Accession # CAE54366.1 HERP94 Light chain, CMV Mab 109 Simpson, J.A. et al., Neutralizing monoclonal 6721 antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # A AB24501.1 (111 aa) HERP95 Light chain, CMV Mab 115 Simpson, J.A. et al., Neutralizing monoclonal 6722 antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationaly distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24500.1 (107 aa) HERP96 Light chain, CMV Mab 33 Simpson, J.A. et al., Neutralizing monoclonal 6723 antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24499.1 (107 aa) HERP97 Light chain, CMV Mab 5 Simpson, J.A. et al., Neutralizing monoclonal 6724 antibodies that distinguish three antigenic sites on human cytomegalovirus glycoprotein H have conformationally distinct binding sites, J. Virol. 67 (1), 489-496 (1993), NCBI Accession # AAB24498.1 (107 aa) HERP98 Light chain, 6G4 WO2010007463 SEQ ID NO: 8 6725 CMV, a combination of the hCMV proteins UL128, UL130 and UL131A HERP99 Light chain, US20140093526 SEQ ID 10 6726 HHV-6 HERP100 Light chain, HSV 64-683 US5646041 SEQ ID NO: 4; EP876478 6727 1&2 HERP101 Light chain, HSV K003927 US20140302062 SEQ ID NO: 10 6728 1&2 HERP102 Light chain, HSV K003928 US20140302062 SEQ ID NO: 11 6729 1&2 HERP103 Light chain, HSV K003929 US20140302062 SEQ ID NO: 12 6730 1&2 HERP104 Light chain, HSV K003930 US20140302062 SEQ ID NO: 13 6731 1&2 HERP105 Light chain, HSV K003946 US20140302062 SEQ ID NO: 14 6732 1&2 HERP106 Light chain, HSV K003948 US20140302062 SEQ ID NO: 15 6733 1&2 HERP107 Light chain, HSV K003949 US20140302062 SEQ ID NO: 16 6734 1&2 HERP108 Light chain, HSV L00184-4 US20140302062 SEQ ID NO: 17 6735 1&2 HERP109 Single chain Fv Lantto, J. et al., Non-germ-line encoded 6736 antibody, residues are critical for effective antibody glycoprotein B recognition of a poorly immunogenic recombinant, neutralization epitope on glycoprotein B of CMV human cytomegalovirus, Eur. J. Immunol. 32 (6), 1659-1669 (2002), NCBI Accession # AAM92769.1 (255 aa)

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in International Publication No. WO2010109874, and WO1997026329, the contents of each of which are herein incorporated by reference in their entirety, against HSV.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in International Publication No. WO1995031546, the contents of which are herein incorporated by reference in their entirety, against VZV.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody poly peptides listed in Table 25 against Coronavirus.

TABLE 25 Antibodies against Coronaviruses SEQ Antibody Antibody Reference ID No. Description Name Information NO CORV1 Heavy chain partial sequence, Liu, J., unpublished, NCBI 6737 Human anti-SARS antibody, Ig Accession # BAE94186.1(228aa) CORV2 Heavy chain partial sequence H12 AAX19356.1(127aa) 6738 Human SARS neutralization antibody, Ig CORV3 Heavy chain variable partial Leung et at., PLoS Med. 3 (7), 6739 sequence, Human neutralizing E237 (2006), NCBI Accession # SARS antibody ABA54614.1(113aa) CORV4 Heavy chain variable region, M396 Prabakaran etal., J. Biol. Chem. 6740 Human anti-SARS antibody 281 (23), 15829-15836 (2006), NCBI Accession # 2G75_D (213aa) CORV5 Heavy chain variable region, Prabakaran etal., J. Biol. Chem. 6741 Human neutralizing SARS 281 (23), 15829-15836 (2006), antibody NCBI Accession # 2DD8_L (213aa) CORV6 Heavy chain variable region, CN103864924 SEQ ID NO: 1 6742 Humanized neutralizing murine monoclonal MERS CORV7 Heavy chain variable region, CN104447986 SEQ ID NO: 1 6743 MERs CORV8 Heavy chain variable region, US7750123 SEQ ID NO: 12; 6744 Neutralizing antibody (binds to WO2005060520; CN1914226; the spike protein (5) of SARS- US20050249739 cov) CORV9 Heavy chain variable region, s110.4 US20110159001 SEQ ID NO: 62; 6745 SARS antibody WO2009128963; EP2242768; CN102015767 CORV10 Heavy chain variable region, s124.5 US20110159001 SEQ ID NO: 66; 6746 SARS antibody WO2009128963; EP2242768; CN102015767 CORV11 Heavy chain variable region, s215.17 US20110159001 SEQ ID NO: 70; 6747 SARS antibody WO2009128963; EP2242768; CN102015767 CORV12 Heavy chain variable region, s218.9 US20110159001 SEQ ID NO: 74; 6748 SARS antibody WO2009128963; EP2242768; CN102015767 CORV13 Heavy chain variable region, s223.4 US20110159001 SEQ ID NO: 78; 6749 SARS antibody WO2009128963; EP2242768; CN102015767 CORV14 Heavy chain variable region, s22512 US20110159001 SEQ ID NO: 82; 6750 SARS antibody WO2009128963; EP2242768; CN102015767 CORV15 Heavy chain variable region, s231.19 US20110159001 SEQ ID NO: 86; 6751 SARS antibody WO2009128963; EP2242768; CN102015767 CORV16 Heavy chain variable region, s230.14 + 15 US20110159001 SEQ ID NO: 90; 6752 SARS antibody WO2009128963; EP2242768; CN102015767 CORV17 Heavy chain variable region, s227. 14 US20110159001 SEQ ID NO: 94; 6753 SARS antibody WO2009128963; EP2242768; CN102015767 CORV18 Heavy chain variable region, s109.8 US20110159001 SEQ ID NO: 98; 6754 SARS antibody WO2009128963; EP2242768; CN102015767 CORV19 Heavy chain variable region, Fab58 CN1513874 6755 SARS antibody CORV20 Heavy chain variable region, Fab59 CN1513874 6756 SARS antibody CORV21 Heavy chain variable region, 3C7 US7728110 SEQ ID NO: 60; 6757 SARS human monoclonal WO2008060331; EP2035454A2, antibody US20080248043 CORV22 Heavy chain variable region, F26G18 US7622112 SEQ ID NO: 5; 6758 SARS human monoclonal WO2005054469; antibody US20080248043; US20080081047 CORV23 Heavy chain variable region A, WO2006095180 SEQ ID NO: 24 6759 humanized antibody binding to S2 domain of SARS CORV24 Heavy chain Humanized CN103864924 SEQ ID NO: 3 6760 neutralizing murine monoclonal MERS CORV25 Heavy chain, MERS m336 WO2015057942 SEQ ID NO: 1 6761 CORV26 Heavy chain, MERS m337 WO2015057942 SEQ ID NO: 9 6762 CORV27 Fleavy chain, MERS m338 WO2015057942 SEQ ID NO: 16 6763 CORV28 Heavy chain, MERS 2e 6 CN104447986 SEQ ID NO: 3 6764 CORV29 Heavy chain, MERS M336 Ying et al., Nat Commun 6, 8223 6765 (2015), NCBI Accession # 4XAK_H(252aa) CORV30 Human anti-SARS antibody Leung et al., PLoS Med. 3 (7), 6766 E237 (2006), NCBI Accession # ABA54613.1(117aa) CORV31 Human monoclonal MERS Mers-27 CN104628848 SEQ ID NO: 1 6767 CORV32 Human monoclonal MERS Mers-27 CN104628848 SEQ ID NO. 3 6768 CORV33 Human monoclonal MERS Mers-4 CN104628849 SEQ ID NO: 1 6769 CORV34 Human monoclonal MERS Mers-4 CN104628849 SEQ ID NO: 3 6770 CORV35 Kappa light chain partial H12 AX19355.1(108aa) 6771 sequence, human SARS neutralization antibody, Ig CORV36 Light chain partial sequence, Liu, J., unpublished, NCBI 6772 Human anti-SARS antibody, Ig Accession # BAE94187.1(219aa) CORV37 Light chain variable domain, CN104447986 SEQ ID NO: 2 6773 MERS CORV38 Light chain variable partial 80R Hwang et al., J. Biol. Chem. 281 6774 sequence, Human neutralizing (45), 34610-34616 (2006), NCBI SARS antibody Accession # 2GHW_D (247aa) CORV39 Light chain variable region, A WO2006095180 SEQ ID NO: 25 6775 humanized antibody binding to S2 domain of SARS CORV40 Light chain variable region, M396 Prabakaran et al., J. Biol. Chem. 6776 human anti-SARS antibody 281 (23), 15829-15836 (2006), NCBI Accession # 2G75_C (245aa) CORV41 Light chain variable region, Prabakaran et al., J. Biol. Chem. 6777 Human neutralizing SARS 281 (23), 15829-15836 (2006), antibody NCBI Accession # 2DD8_H(245aa) CORV42 Light chain variable region, CN103864924 SEQ ID NO: 2 6778 Humanized neutralizing murine monoclonal MERS CORV43 Light chain variable region, US7750123 SEQ ID NO: 20; 6779 neutralizing antibody (binds to WO2005060520; CN1914226; the spike protein (S) of SARS- US20050249739 cov) CORV44 Light chain variable region, s110.4 US20110159001 SEQ ID NO: 64; 6780 SARS antibody WO2009128963; EP2242768; CN102015767 CORV45 Light chain variable region, s124.5 US20110159001 SEQ ID NO: 68; 6781 SARS antibody WO2009128963; EP2242768; CN102015767 CORV46 Light chain variable region, s215.17 US20110159001 SEQ ID NO: 72; 6782 SARS antibody WO2009128963; EP2242768; CN102015767 CORV47 Light chain variable region, s218.9 US20110159001 SEQ ID NO: 76; 6783 SARS antibody WO2009128963; EP2242768; CN102015767 CORV48 Light chain variable region, s223.4 US20110159001 SEQ ID NO: 80; 6784 SARS antibody WO2009128963; EP2242768; CN102015767 CORV49 Light chain variable region, s225.1.2 US20110159001 SEQ ID NO: 84; 6785 SARS antibody WO2009128963; EP2242768; CN102015767 CORV50 Light chain variable region, s231.19 US20110159001 SEQ ID NO: 88; 6786 SARS antibody WO2009128963; EP2242768; CN102015767 CORV51 Light chain variable region, s230.14 + 15 US20110159001 SEQ ID NO: 92; 6787 SARS antibody WO2009128963; EP2242768; CN102015767 CORV52 Light chain variable region, s227.14 US20110159001 SEQ ID NO: 96; 6788 SARS antibody WO2009128963; EP2242768; CN102015767 CORV53 Light chain variable region, s109.8 US20110159001 SEQ ID NO: 6789 SARS antibody 101; WO2009128963; EP2242768; CN102015767 CORV54 Light chain variable region, Fab58 CN1513874 6790 SARS antibody CORV55 Light chain variable region, Fab59 CN1513874 6791 SARS antibody CORN56 Light chain variable region, 3C7 US7728110 SEQ ID NO: 58; 6792 SARS human monoclonal WO2008060331; EP2035454A2, antibody US20080248043 CORV57 Light chain variable region, F26G18 US7622112 SEQ ID NO: 14; 6793 SARS human monoclonal WO2005054469; antibody US20080248043; US20080081047 CORV58 Light chain, Humanized CN103864924 SEQ ID NO: 4 6794 neutralizing murine monoclonal MERS CORV59 Light chain, MERS m336 WO2015057942 SEQ ID NO: 2 6795 CORV60 Light chain, MERS m337 WO2015057942 SEQ ID NO: 10 6796 CORV61 Light chain, MERS m338 WO2015057942 SEQ ID NO: 17 6797 CORV62 Light chain, MERS 2E 6 CN104447986 SEQ ID NO: 4 6798 CORV63 Light chain, MERS M336 Ying et al., Nat Commun 6, 8223 6799 (2015), NCBI Accession # 4XAK_L (214aa) CORV64 Variable heavy chain-constant 4C2Fab CN103864924 SEQ ID NO: 7 6800 heavy chain 1, Humanized neutralizing murine monoclonal MERS CORV65 Variable light chain-constant 4C2Fab CN103864924 SEQ ID NO: 9 6801 light chain 1, Humanized neutralizing murine monoclonal MERS

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in U.S. Pat. No. 7,629,443, US Publication No US20080254440, Chinese Publication No. CN103613666. CN1570638, CN101522208, CN1673231, CN1590409, CN1557838, and CN1488645, the contents of each of which are herein incorporated by reference in their entirety, against SARS.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 26 against John Cunningham Virus.

TABLE 26 Antibodies against John Cunningham Virus Anti- SEQ body Antibody Reference ID No. Description Name Information NO JCV1 Heavy chain 14G8 US20150056188 6802 SEQ ID NO: 1 JCV2 Heavy chain 16H5 US20150056188 6803 SEQ ID NO: 5 JCV3 Heavy chain 18C9 US20150056188 6804 SEQ ID NO: 9 JCV4 Heavy chain 34C6 US20150056188 6805 SEQ ID NO: 13 JCV5 Heavy chain 18C9 N55S US20150056188 6806 SEQ ID NO: 16 JCV6 Heavy chain 18C9 N55Q US20150056188 6807 SEQ ID NO: 18 JCV7 Heavy chain 18C9 N55D US20150056188 6808 SEQ ID NO: 20 JCV8 Heavy chain 18C9 N55H US20150056188 6809 SEQ ID NO: 22 JCV9 Heavy chain 18C9 N55T US20150056188 6810 SEQ ID NO: 24 JCV10 Heavy chain 18C9 N55A US20150056188 6811 SEQ ID NO: 26 JCV11 Heavy chain 18C9 N55L US20150056188 6812 SEQ ID NO: 28 JCV12 Heavy chain 18C9 N55X US20150056188 6813 SEQ ID NO: 30 JCV13 Heavy chain 18C9 G56A US20150056188 6814 SEQ ID NO: 32 JCV14 Heavy chain 18C9 G56V US20150056188 6815 SEQ ID NO: 34 JCV15 Heavy chain 18C9 G56P US20150056188 6816 SEQ ID NO: 36 JCV16 Heavy chain 18C9 G56X US20150056188 6817 SEQ ID NO: 38 JCV17 Heavy chain 399-h (C35A US20150050271 6818 V50A) SEQ ID NO: 20 JCV18 Heavy chain Antibody from US20150050271 6819 US20150050271 SEQ ID NO: 66 JCV19 Heavy chain H0 US20150050271 6820 SEQ ID NO: 51 JCV20 Heavy chain H1 US20150050271 6821 SEQ ID NO: 52 JCV21 Heavy chain H3 US20150050271 6822 SEQ ID NO: 54 JCV22 Heavy chain H4 US20150050271 6823 SEQ ID NO: 55 JCV23 Heavy chain H5 US20150050271 6824 SEQ ID NO: 56 JCV24 Heavy chain H6 US20150050271 6825 SEQ ID NO: 57 JCV25 Heavy chain H7 US20150050271 6826 SEQ ID NO: 58 JCV26 Heavy chain H8 US20150050271 6827 SEQ ID NO: 59 JCV27 Heavy chain H9 US20150050271 6828 SEQ ID NO: 60 JCV28 Heavy chain L0 US20150050271 6829 SEQ ID NO: 48 JCV29 Heavy chain jcv411_vh US20150050271 6830 SEQ ID NO: 43 JCV30 Heavy chain IGHV3-30-3x01 US20150050271 6831 SEQ ID NO: 44 JCV31 Heavy chain H0 US20150050271 6832 SEQ ID NO: 19 JCV32 Heavy chain H0 V50G US20150050271 6833 SEQ ID NO: 21 JCV33 Heavy chain H1 US20150050271 6834 SEQ ID NO: 22 JCV34 Heavy chain H2 US20150050271 6835 SEQ ID NO: 23 JCV35 Heavy chain H3 US20150050271 6836 SEQ ID NO: 24 JCV36 Heavy chain H4 US20150050271 6837 SEQ ID NO: 25 JCV37 Heavy chain H5 US20150050271 6838 SEQ ID NO: 26 JCV38 Heavy chain H6 US20150050271 6839 SEQ ID NO: 27 JCV39 Heavy chain H7 US20150050271 6840 SEQ ID NO: 28 JCV40 Heavy chain H8 US20150050271 6841 SEQ ID NO: 29 JCV41 Heavy chain H9 US20150050271 6842 SEQ ID NO: 30 JCV42 Heavy chain GRE1 US20150191530 6843 variable SEQ ID NO: 1 region JCV43 Heavy chain R399 US20150050271 6844 variable SEQ ID NO: 6 region JCV44 Light chain 14G8 US20150056188 6845 SEQ ID NO: 3 JCV45 Light chain 16H5 US20150056188 6846 SEQ ID NO: 7 JCV46 Light chain 18C9 US20150056188 6847 SEQ ID NO: 11 JCV47 Light chain 34C6 US20150056188 6848 SEQ ID NO: 14 JCV48 Light chain 18C9 C96L US20150056188 6849 SEQ ID NO: 40 JCV49 Light chain 18C9 C96S US20150056188 6850 SEQ ID NO: 42 JCV50 Light chain 18C9 C96A US20150056188 6851 SEQ ID NO: 44 JCV51 Light chain 18C9 C96X US20150056188 6852 SEQ ID NO: 46 JCV52 Light chain 399-1 (N31G), US20150050271 6853 L SEQ ID NO: 15 JCV53 Light chain Antibody from US20150050271 6854 US20150050271 SEQ ID NO: 67 JCV54 Light chain H2 US20150050271 6855 SEQ ID NO: 53 JCV55 Light chain L1 US20150050271 6856 SEQ ID NO: 49 JCV56 Light chain L2 US20150050271 6857 SEQ ID NO: 50 JCV57 Light chain 1GKV1D-13x01 US20150050271 6858 SEQ ID NO: 39 JCV58 Light chain L0 US20150050271 6859 SEQ ID NO: 11 JCV59 Light chain L1 US20150050271 6860 SEQ ID NO: 12 JCV60 Light chain L2 US20150050271 6861 SEQ ID NO: 13 JCV61 Light chain L2 N31A US20150050271 6862 SEQ ID NO: 14 JCV62 Heavy chain GRE1 US20150191530 6863 variable SEQ ID NO: 2 region JCV63 Heavy chain R399 US20150050271 6864 variable SEQ ID NO: 1 region JCV64 Heavy chain R411.jcv411_vh US20150050271 6865 variable SEQ ID NO: 38 region

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 27 against Poxvirus.

TABLE 27 Antibodies against Poxvirus Antibody Antibody Reference SEQ ID No. Description Name Information NO POXV1 Heavy chain B5R binding US8623370 6866 variable region, antibody SEQ ID NO: 2 B5R envelope protein POXV2 Heavy chain B5R binding US8623370 6867 variable region, antibody SEQ ID NO: 6 B5R envelope protein POXV3 Heavy chain B5R binding US8623370 6868 variable region, antibody SEQ ID NO: B5R envelope 10 protein POXV4 Heavy chain B5R binding US8623370 6869 variable region, antibody SEQ ID NO: B5R envelope 14 protein POXV5 Heavy chain, H3L binding US20140186370 6870 H3L envelope antibody SEQ ID protein NO: 14 POXV6 Light chain variable B5R binding US8623370 6871 region, B5R antibody SEQ ID NO: 4 envelope protein POXV7 Light chain variable B5R binding US8623370 6872 region, B5R antibody SEQ ID NO: 8 envelope protein POXV8 Light chain variable B5R binding US8623370 6873 region, B5R SEQ ID NO: envelope protein antibody 12 POXV9 Light chain variable B5R binding US8623370 6874 region, B5R SEQ ID NO: envelope protein antibody 16 POXV10 Light chain, H3L binding US20140186370 6875 H3L envelope antibody SEQ ID protein NO: 16

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 28 against Enterovirus 71.

TABLE 28 Antibodies against Enterovirus 71 SEQ Antibody Reference ID No. Description Antibody Name Information NO ENTV1 Heavy chain CN102718864A 6876 variable region SEQ ID NO: 2 ENTV2 Heavy chain E18 WO2015092668 6877 variable region SEQ ID NO: 1 ENTV3 Heavy chain E19 WO2015092668 6878 variable region SEQ ID NO: 3 ENTV4 Heavy chain E20 WO2015092668 6879 variable region SEQ ID NO: 5 ENTV5 Heavy chain E19 humanized WO2015092668 6880 variable region VH1 SEQ ID NO: 19 ENTV6 Heavy chain E19 humanized WO2015092668 6881 variable region VH2 SEQ ID NO: 20 ENTV7 Heavy chain E19 humanized WO2015092668 6882 variable region VH3 SEQ ID NO: 21 ENTV8 Heavy chain E19 humanized WO2015092668 6883 variable region VH4 SEQ ID NO: 22 ENTV9 Light chain CN102718864A 6884 variable region SEQ ID NO: 1 ENTV10 Light chain E18 WO2015092668 6885 variable region SEQ ID NO: 2 ENTV11 Light chain E19 WO2015092668 6886 variable region SEQ ID NO: 4 ENTV12 Light chain E20 WO2015092668 6887 variable region SEQ ID NO: 6 ENTV13 Light chain E18 VL2 WO2015092668 6888 variable region SEQ ID NO: 15 ENTV14 Light chain E19 humanized WO2015092668 6889 variable region VL1 SEQ ID NO: 16 ENTV15 Light chain E19 humanized WO2015092668 6890 variable region VL2 SEQ ID NO: 17 ENTV16 Light chain E19 humanized WO2015092668 6891 variable region VL3 SEQ ID NO: 18

In one embodiment, the payload region of the AA particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in Chinese Publication No. CN104357400, the contents of which are herein incorporated by reference in their entirety, against EV71.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants encoding MAB979, fragments or variants thereof for treating a disease and/or disorder or preventing a disease and/or disorder. As a non-limiting example, the disease and/or disorder is EV71.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 29 against Rubella Virus.

TABLE 29 Antibodies against Rubella Virus Antibody Antibody SEQ ID No. Description Name Reference Information NO RUBV1 Heavy chain DDF-RuV1 US20100143376 6892 variable region SEQ ID NO: 2 RUBV2 Heavy chain DDF-RuV2 US20100143376 6893 variable region SEQ ID NO: 9 RUBV3 Light chain DDF-RuV1 US20100143376 6894 variable region SEQ ID NO: 7 RUBV4 Light chain DDF-RuV2 US20100143376 6895 variable region SEQ ID NO: 14

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 30 against Human Papilloma Virus.

TABLE 30 Antibodies against Human Papilloma Virus Antibody SEQ No. Description Reference Information ID NO HPV1 Heavy chain WO2015096269 SEQ ID NO: 1 6896 variable region HPV2 Light chain WO2015096269 SEQ ID NO: 2 6897 variable region

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in US Publication No. US20130337438, the contents of which are herein incorporated by reference in their entirety, against HBV.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the broadly neutralizing payload antibody polypeptides listed in Table 31 against viruses.

TABLE 31 Broadly Neutralizing Antibodies for Viruses Anti- SEQ body Antibody Reference ID No. Description Name Information NO VIR1 Heavy chain variable 3G4 US7611704 6898 region, hepatitis, influenza, SEQ ID HIV, herpes, NO: 2 paramyxovirus, poxvirus, rhabdovirus or arenavirus VIR2 Heavy chain variable 3G4 US7611704 6899 region, hepatitis, influenza, SEQ ID HIV, herpes, NO: 4 paramyxovirus, poxvirus, rhabdovirus or arenavirus VIR3 Heavy chain variable 679 US7429381 6900 region, HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 4 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, light chain variable region, Dengue, rubella, measles, adenovirus, human T-cell leukemias, Epstein- Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue VIR4 Heavy chain variable Mu-9V US7429381 6901 region, HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 10 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T- cell leukemias, Epstein-Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue, light chain variable region VIR5 Heavy chain variable humanized US7429381 6902 region, HIV, herpes, Mu-9 SEQ ID cytomegalovirus, rabies, NO: 14 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T- cell leukemias, Epstein-Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue, light chain variable region VIR6 Heavy chain variable Fab-2 US20120269801 6903 region, Human Clone3 SEQ cytomegalovirus, HCMV, ID NO: 6 human T-cell leukemia virus type 1, HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirus saimiri virus, influenza virus, and vaccinia virus VIR7 Heavy chain variable Fab-3 US20120269801 6904 region, Human Clone 7 SEQ cytomegalovirus, HCMV, ID NO: 10 human T-cell leukemia virus type 1, HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirus saimiri virus, influenza virus, and vaccinia virus VIR8 Light chain variable Mu-9V US7429381 6905 region, HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 8 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T- cell leukemias, Epstein-Bair, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue, light chain variable region VIR9 Light chain variable humanized US7429381 6906 region, HIV, herpes, Mu-9 SEQ ID cytomegalovirus, rabies, NO: 12 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T- cell leukemias, Epstein-Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue, light chain variable region VIR10 Light chain variable 679 US7429381 6907 region, HIV, herpes, SEQ ID cytomegalovirus, rabies, NO: 2 influenza, hepatitis B, Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T- cell leukemias, Epstein-Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue VIR11 Light chain variable Fab-3 US20120269801 6908 region, Human Clone 7 SEQ cytomegalovirus, HCMV, ID NO: 8 human T-cell leukemia virus type 1, HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirus saimiri virus, influenza virus, and vaccinia virus VIR12 Light chain variable, Fab-2 US20120269801 6909 Human cytomegalovirus, Clone3 SEQ HCMV, human T-cell ID NO: 4 leukemia virus type 1, HIV-1, simian immunodeficiency virus, Ebola virus, Herpesvirus saimiri virus, influenza virus, and vaccinia virus, region VIR13 ScFv, hepatitis, influenza, 3A2 US7611704 6910 HIV, herpes, SEQ ID paramyxovirus, poxvirus, NO: 6 rhabdovirus or arenavirus VIR14 ScFv, HIV, herpes, 679 US7429381 6911 cytomegalovirus, rabies, SEQ ID influenza, hepatitis B, NO: 6 Sendai, feline leukemia, Reo, polio, human serum parvo-like, simian 40, respiratory syncytial, mouse mammary tumor, Varicella-Zoster, Dengue, rubella, measles, adenovirus, human T-cell leukemias, Epstein- Barr, murine leukemia, mumps, vesicular stomatitis, Sindbis, lymphocytic choriomeningitis, wart and blue tongue

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 32 against Pseudomonas aeruginosa

TABLE 32 Antibodies against Pseudomonas Aeruginosa Anti- SEQ body Reference ID No. Description Antibody Name Information NO PSEU1 Bivalent 260 (1E11- US20150044215 6912 nanobody 40GS-2B10) SEQ ID NO: 118 PSEU2 Bivalent 272 (11B09- US20150044215 6913 nanobody 40GS- SEQ ID NO: 119 10C05) PSEU3 Bivalent 308 (6B05- US20150044215 6914 nanobody 40GS-1E11) SEQ ID NO: 120 PSEU4 Bivalent 264 (1E11- US20150044215 6915 nanobody 40GS-2B02) SEQ ID NO: 121 PSEU5 Bivalent 302 (5H01- US20150044215 6916 nanobody 40GS-7C10) SEQ ID NO: 122 PSEU6 Bivalent 234 (7C10- US20150044215 6917 nanobody 40GS-5H01) SEQ ID NO: 123 PSEU7 Bivalent 064 (13F07- US20150044215 6918 nanobody 40GS-7C10) SEQ ID NO: 124 PSEU8 Bivalent 275 (2G09- US20150044215 6919 nanobody 40GC-5H10) SEQ ID NO: 125 PSEU9 Bivalent 083 (7C10- US20150044215 6920 nanobody 40GS-11B09) SEQ ID NO: 126 PSEU10 Bivalent 087 (1E11- US20150044215 6921 nanobody 40GS-7C10) SEQ ID NO: 127 PSEU11 Bivalent 269 (6B05- US20150044215 6922 nanobody 40GS-13F07) SEQ ID NO: 128 PSEU12 Bivalent 256 (13F07- US20150044215 6923 nanobody 40GS-5H01) SEQ ID NO: 129 PSEU13 Bivalent 277 (5H01- US20150044215 6924 nanobody 40GS-11B09) SEQ ID NO: 130 PSEU14 Bivalent 257 (13F07- US20150044215 6925 nanobody 40GS-2B10) SEQ ID NO: 131 PSEU15 Bivalent 285 (13F07- US20150044215 6926 nanobody 40GS-2B02) SEQ ID NO: 132 PSEU16 Bivalent 115 (11B09- US20150044215 6927 nanobody 40GS-13F07) SEQ ID NO: 133 PSEU17 Bivalent 258 (13F07- US20150044215 6928 nanobody 40GS-14E10) SEQ ID NO: 134 PSEU18 Bivalent 283 (7E09- US20150044215 6929 nanobody 40G5-6B05) SEQ ID NO: 135 PSEU19 Bivalent 271 (7C10- US20150044215 6930 nanobody 40GS-14E10) SEQ ID NO: 136 PSEU20 Bivalent 259 (1E11- US20150044215 6931 nanobody 40GS-5H01) SEQ ID NO: 137 PSEU21 Bivalent 319 (13F07- US20150044215 6932 nanobody 40GS-6B05) SEQ ID NO: 138 PSEU22 Bivalent 335 (5H01- US20150044215 6933 nanobody 40G5-1E11) SEQ ID NO: 139 PSEU23 Bivalent 261 (5H01- US20150044215 6934 nanobody 40GS-2B10) SEQ ID NO: 140 PSEU24 Bivalent 262 (7E09- US20150044215 6935 nanobody 40GS-7C10) SEQ ID NO: 141 PSEU25 Constant US20150044215 6936 heavy chain SEQ ID NO: 148 PSEU26 Constant US20150044215 6937 light chain SEQ ID NO: 149 PSEU27 Heavy chain Panobacumab US8197816 6938 SEQ ID NO: 8 PSEU28 Heavy chain US20130156696 6939 SEQ ID NO: 2 PSEU29 Heavy chain US7494653 6940 SEQ ID NO: 2 PSEU30 Heavy chain KB0001 US8044181 6941 variable SEQ ID NO: 3 region PSEU31 Heavy chain KB0001 US8044181 6942 variable SEQ ID NO: 5 region PSEU32 Heavy chain KB0001 US8044181 6943 variable SEQ ID NO: 7 region PSEU33 Heavy chain KB0001 US8044181 6944 variable SEQ ID NO: 9 region PSEU34 Heavy chain KB0001 US8044181 6945 variable SEQ ID NO: 11 region PSEU35 Heavy chain 1F3 US9085611 6946 variable SEQ ID NO: 11 region PSEU36 Heavy chain 2A4 US9085611 6947 variable SEQ ID NO: 13 region PSEU37 Heavy chain US9085611 6948 variable SEQ ID NO: 27 region PSEU38 Heavy chain mAbs LST-001 US8653242 6949 variable SEQ ID NO: 29 region PSEU39 Heavy chain rnAbs LST-002 US8653242 6950 variable SEQ ID NO: 49 region PSEU40 Heavy chain mAbs LST-005 US8653242 6951 variable SEQ ID NO: 52 region PSEU41 Heavy chain rnAbs LST-006 US8653242 6952 variable SEQ ID NO: 54 region PSEU42 Heavy chain mAbs LST-007 US8653242 6953 variable SEQ ID NO: 13 region PSEU43 Heavy chain mAbs LST-008 US8653242 6954 variable SEQ ID NO: 15 region PSEU44 Heavy chain 310BO6 US7597893 6955 variable SEQ ID NO: 8 region PSEU45 Heavy chain Cam-003 US20140227285 6956 variable SEQ ID NO: 1 region PSEU46 Heavy chain Cam-004 US20140227285 6957 variable SEQ ID NO: 3 region PSEU47 Heavy chain Cam-005 US20140227285 6958 variable SEQ ID NO: 4 region PSEU48 Heavy chain WapR-001 US20140227285 6959 variable SEQ ID NO: 5 region PSEU49 Heavy chain WapR-002 US20140227285 6960 variable SEQ ID NO: 7 region PSEU50 Heavy chain WapR-003 US20140227285 6961 variable SEQ ID NO: 9 region PSEU51 Heavy chain WapR-004 US20140227285 6962 variable SEQ ID NO: 11 region PSEU52 Heavy chain WapR-007 US20140227285 6963 variable SEQ ID NO: 13 region PSEU53 Heavy chain WapR-016 US20140227285 6964 variable SEQ ID NO: 15 region PSEU54 Heavy chain 1584 US20130045207 6965 variable SEQ ID NO: 8 region PSEU55 Heavy chain 1573 US20130045207 6966 variable SEQ ID NO: 16 region PSEU56 Heavy chain 1572 US20130045207 6967 variable SEQ ID NO: 24 region PSEU57 Heavy chain 1587 US20130045207 6968 variable SEQ ID NO: 32 region PSEU58 Heavy chain 3099 US20130022604 6969 variable SEQ ID NO: 8 region PSEU59 Heavy chain 2745 US20130022604 6970 variable SEQ ID NO: 16 region PSEU60 Heavy chain 2459 US20130022604 6971 variable SEQ ID NO: 24 region PSEU61 Heavy chain 2316 US20130022606 6972 variable SEQ ID NO: 8 region PSEU62 Heavy chain 1838 US20130022606 6973 variable SEQ ID NO: 16 region PSEU63 Heavy chain 2314 US20130022606 6974 variable SEQ ID NO: 24 region PSEU64 Heavy chain 2326 US20130022606 6975 variable SEQ ID NO: 32 region PSEU65 Heavy chain 2328 US20130022606 6976 variable SEQ ID NO: 40 region PSEU66 Heavy chain 2438 US20130022606 6977 variable SEQ ID NO: 48 region PSEU67 Heavy chain 1774 US20130004500 6978 variable SEQ ID NO: 8 region PSEU68 Heavy chain 1660 US20130004500 6979 variable SEQ ID NO: 16 region PSEU69 Heavy chain 1923 US20130004500 6980 variable SEQ ID NO: 24 region PSEU70 Heavy chain 1656 US20130004499 6981 variable SEQ ID NO: 8 region PSEU71 Heavy chain 1640 US20130004499 6982 variable SEQ ID NO: 16 region PSEU72 Heavy chain 2459 US20130004499 6983 variable SEQ ID NO: 24 region PSEU73 Heavy chain US20120114657 6984 variable SEQ ID NO: 8 region PSEU74 Heavy chain Anti-It-2 US20110177087 6985 variable SEQ ID NO: 13 region PSEU75 Heavy chain Anti-It-3 US20110177087 6986 variable SEQ ID NO: 14 region PSEU76 Heavy chain Anti-It-4 US20110177087 6987 variable SEQ ID NO: 15 region PSEU77 Heavy chain Anti-It-5 US20110177087 6988 variable SEQ ID NO: 16 region PSEU78 Heavy chain Anti-It-6 US20110177087 6989 variable SEQ ID NO: 17 region PSEU79 Heavy chain Anti-170003 US20110177087 6990 variable SEQ ID NO: 18 region PSEU80 Heavy chain Anti-170006 US20110177087 6991 variable SEQ ID NO: 19 region PSEU81 Heavy chain Anti-Pa01 US20110177087 6992 variable SEQ ID NO: 20 region PSEU82 Heavy chain Anti-IATS016 US20110177087 6993 variable SEQ ID NO: 21 region PSEU83 Heavy chain US20090191186 6994 variable SEQ ID NO: 1 region PSEU84 Heavy chain US20090191186 6995 variable SEQ ID NO: 11 region PSEU85 Heavy chain US20090191186 6996 variable SEQ ID NO: 3 region PSEU86 Heavy chain US20090191186 6997 variable SEQ ID NO: 7 region PSEU87 Heavy chain US20090191186 6998 variable SEQ ID NO: 9 region PSEU88 Heavy chain US20090191186 6999 variable SEQ ID NO: 5 region PSEU89 Heavy chain US20090191186 7000 variable SEQ ID NO: 13 region PSEU90 Heavy chain US20090191186 7001 variable SEQ ID NO: 21 region PSEU91 Heavy chain US20090191186 7002 variable SEQ ID NO: 17 region PSEU92 Heavy chain US20090191186 7003 variable SEQ ID NO: 26 region PSEU93 Heavy chain US20090191186 7004 variable SEQ ID NO: 25 region PSEU94 Heavy chain US20090191186 7005 variable SEQ ID NO: 23 region PSEU95 Heavy chain US20090191186 7006 variable SEQ ID NO: 29 region PSEU96 Heavy chain US20090191186 7007 variable SEQ ID NO: 35 region PSEU97 Heavy chain V2L2 WO2014074528 7008 variable SEQ ID NO: 216 region PSEU98 Heavy chain V2L2-MD WO2014074528 7009 variable SEQ ID NO: 255 region PSEU99 Heavy chain V2L2-MD WO2O14074528 7010 variable and V2L2- SEQ ID NO: 256 region GL PSEU100 Heavy chain V2L2-GL WO2014074528 7011 variable SEQ ID NO: 257 region PSEU101 Heavy chain 2409 WO2013024905 7012 variable SEQ ID NO: 16 region PSEU102 Heavy chain 2453 WO2013024905 7013 variable SEQ ID NO: 24 region PSEU103 Heavy chain S20 US7972845 7014 variable SEQ ID NO: 2 region PSEU104 Heavy chain Fab 13.37 US20150044215 7015 variable SEQ ID NO: 142 region PSEU105 Heavy chain Fab 26.24 US20150044215 7016 variable SEQ ID NO: 144 region PSEU106 Heavy chain Fab 35.36 US20150044215 7017 variable SEQ ID NO: 146 region PSEU107 Heavy chain KB0001 US8044181 7018 variable SEQ ID NO: 1 region PSEU108 Heavy Horn., M.P. et al. 7019 chain, LPS “Preclinical In serotype Vitro and In Vivo IATS-O11. characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS- O11”, Antimicrob. Agents Chemother. 54 (6), 2338- 2344 (2010) PSEU109 J chain Panobacumab 7020 PSEU110 Light chain Panobacumab US8197816 7021 SEQ ID NO: 7 PSEU111 Light chain US20130156696 7022 SEQ ID NO: 4 PSEU112 Light chain US7494653 7023 SEQ ID NO: 4 PSEU113 Light chain 1F3 US9085611 7024 variable SEQ ID NO: 2 region PSEU114 Light chain 2A4 US9085611 7025 variable SEQ ID NO: 4 region PSEU115 Light chain US9085611 7026 variable SEQ ID NO: 28 region PSEU116 Light chain mAbS LST-001 US8653242 7027 variable SEQ ID NO: 18 region PSEU117 Light chain mAbs LST-006 US8653242 7028 variable SEQ ID NO: 53 region PSEU118 Light chain mAbs LST-008 US8653242 7029 variable SEQ ID NO: 14 region PSEU119 Light chain mAbs LST-008 US8653242 7030 variable SEQ ID NO: 16 region PSEU120 Light chain 310BO6 US7597893 7031 variable SEQ ID NO: 7 region PSEU121 Light chain Cam-003, US20140227285 7032 variable Cam-004, SEQ ID NO: 2 region Cam-005 PSEU122 Light chain WapR-001 US20140227285 7033 variable SEQ ID NO: 6 region PSEU123 Light chain WapR-002 US20140227285 7034 variable SEQ ID NO: 8 region PSEU124 Light chain WapR-003 US20140227285 7035 variable SEQ ID NO: 10 region PSEU125 Light chain WapR-004, US20140227285 7036 variable WapR- SEQ ID NO: 12 region 004-RAD PSEU126 Light chain WapR-007 US20140227285 7037 variable SEQ ID NO: 14 region PSEU127 Light chain WapR-016 US20140227285 7038 variable SEQ ID NO: 16 region PSEU128 Light chain 1584 US20130045207 7039 variable SEQ ID NO: 7 region PSEU129 Light chain 1573 US20130045207 7040 variable SEQ ID NO: 5 region PSEU130 Light chain 1572 US20130045207 7041 variable SEQ ID NO: 23 region PSEU131 Light chain 1587 US20130045207 7042 variable SEQ ID NO: 31 region PSEU132 Light chain 3099 US20130022604 7043 variable SEQ ID NO: 7 region PSEU133 Light chain 2745 US20130022604 7044 variable SEQ ID NO: 15 region PSEU134 Light chain 2459 US20130022604 7045 variable SEQ ID NO: 23 region PSEU135 Light chain 2316 US20130022606 7046 variable SEQ ID NO: 7 region PSEU136 Light chain 1838 US20130022606 7047 variable SEQ ID NO: 15 region PSEU137 Light chain 2314 US20130022606 7048 variable SEQ ID NO: 23 region PSEU138 Light chain 2326 US20130022606 7049 variable SEQ ID NO: 31 region PSEU139 Light chain 2328 US20130022606 7050 variable SEQ ID NO: 39 region PSEU140 Light chain 2438 US20130022606 7051 variable SEQ ID NO: 47 region PSEU141 Light chain 1774 US20130004500 7052 variable SEQ ID NO: 7 region PSEU142 Light chain 1660 US20130004500 7053 variable SEQ ID NO: 15 region PSEU143 Light chain 1923 US20130004500 7054 variable SEQ ID NO: 23 region PSEU144 Light chain 1656 US20130004499 7055 variable SEQ ID NO: 7 region PSEU145 Light chain 1640 US20130004499 7056 variable SEQ ID NO: 5 region PSEU146 Light chain 2459 US20130004499 7057 variable SEQ ID NO: 23 region PSEU147 Light chain US20120114657 7058 variable SEQ ID NO: 7 region PSEU148 Light chain Anti-It-2 US20110177087 7059 variable SEQ ID NO: 22 region PSEU149 Light chain Anti-It-3 US20110177087 7060 variable SEQ ID NO: 23 region PSEU150 Light chain Anti-It-4 US20110177087 7061 variable SEQ ID NO: 24 region PSEU151 Light chain Anti-It-5 US20110177087 7062 variable SEQ ID NO: 25 region PSEU152 Light chain Anti-It-6 US20110177087 7063 variable SEQ ID NO: 26 region PSEU153 Light chain Anti-170003 US20110177087 7064 variable SEQ ID NO: 27 region PSEU154 Light chain Anti-170006 US20110177087 7065 variable SEQ ID NO: 28 region PSEU155 Light chain Anti-Pa01 US20110177087 7066 variable SEQ ID NO: 29 region PSEU156 Light chain Anti- US20110177087 7067 variable IATS016 SEQ ID NO: 30 region PSEU157 Light chain US20090191186 7068 variable SEQ ID NO: 2 region PSEU158 Light chain US20090191186 7069 variable SEQ ID NO: 12 region PSEU159 Light chain US20090191186 7070 variable SEQ ID NO: 8 region PSEU160 Light chain US20090191186 7071 variable SEQ ID NO: 10 region PSEU161 Light chain US20090191186 7072 variable SEQ ID NO: 6 region PSEU162 Light chain US20090191186 7073 variable SEQ ID NO: 37 region PSEU163 Light chain US20090191186 7074 variable SEQ ID NO: 18 region PSEU164 Light chain US20090191186 7075 variable SEQ ID NO: 24 region PSEU165 Light chain US20090191186 7076 variable SEQ ID NO: 20 region PSEU166 Light chain US20090191186 7077 variable SEQ ID NO: 36 region PSEU167 Light chain US20090191186 7078 variable SEQ ID NO: 28 region PSEU168 Light chain US20090191186 7079 variable SEQ ID NO: 30 region PSEU169 Light chain US20090191186 7080 variable SEQ ID NO: 34 region PSEU170 Light chain US20090191186 7081 variable SEQ ID NO: 32 region PSEU171 Light chain V2L2 WO2014074528 7082 variable SEQ ID NO: 217 region PSEU172 Light chain 2409 WO2013024905 7083 variable SEQ ID NO: 15 region PSEU173 Light chain 2453 WO2013024905 7084 variable SEQ ID NO: 23 region PSEU174 Light chain S20 US7972845 7085 variable SEQ ID NO: 4 region PSEU175 Light chain Fab 13.37 US20150044215 7086 variable SEQ ID NO: 143 region PSEU176 Light chain Fab 26.24 US20150044215 7087 variable SEQ ID NO: 45 region PSEU177 Light chain Fab 35.36 US20150044215 7088 variable SEQ ID NO: 147 region PSEU178 Light chain mAbs US8653242 7089 variable LST-002 SEQ ID NO: 32 region majority PSEU179 Light chain mAbs US8653242 7090 variable LST-006 SEQ ID NO: 55 region majority PSEU180 Light chain mAbs US8653242 7091 variable LST-002 SEQ ID NO: 51 region minority PSEU181 Light chain mAbs LST-007 US8653242 7092 variable SEQ ID NO: 56 region minority PSEU182 Light chain, Horn, M.P. et al. 7093 Anti-P. “Preclinical In Aeuginosa LPS Vitro and in Vivo serotype characterization IATS-O11, of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11”, Antimicrob. Agents Chemother. 54 (6), 2338- 2344 (2010) PSEU183 Light kappa KB0001 US8044181 7094 chain SEQ ID NO: 10 variable region PSEU184 Light kappa KB0001 US8044181 7095 chain SEQ ID NO: 2 variable region PSEU185 Light kappa KB0001 US8044181 7096 chain SEQ ID NO: 4 variable region PSEU186 Light kappa KB0001 US8044181 7097 chain SEQ ID NO: 6 variable region PSEU187 Light kappa KB0001 US8044181 7098 chain SEQ ID NO: 8 variable region PSEU188 Monovalent 5H01 US20150044215 7099 nanobody SEQ ID NO: 1 PSEU189 Monovalent 7C10 US20150044215 7100 nanobody SEQ ID NO: 2 PSEU190 Monovalent 1E11 US20150044215 7101 nanobody SEQ ID NO: 3 PSEU191 Monovalent 2B02 US20150044215 7102 nanobody SEQ ID NO: 4 PSEU192 Monovalent 2B10 US20150044215 7103 nanobody SEQ ID NO: 5 PSEU193 Monovalent 2G09 US20150044215 7104 nanobody SEQ ID NO: 6 PSEU194 Monovalent 6B05 US20150044215 7105 nanobody SEQ ID NO: 7 PSEU195 Monovalent 10C05 US20150044215 7106 nanobody SEQ ID NO: 8 PSEU196 Monovalent 11B09 US20150044215 7107 nanobody SEQ ID NO: 9 PSEU197 Monovalent 14E10 US20150044215 7108 nanobody SEQ ID NO: 10 PSEU198 Monovalent 7E09 US20150044215 7109 nanobody SEQ ID NO: 11 PSEU199 Monovalent 13F07 US20150044215 7110 nanobody SEQ ID NO: 12 PSEU200 Monovalent 3B11 US20150044215 7111 nanobody SEQ ID NO: 13 PSEU201 Monovalent 4C03 US20150044215 7112 nanobody SEQ ID NO: 14 PSEU202 Monovalent 4G10 US20150044215 7113 nanobody SEQ ID NO: 15 PSEU203 Monovalent 12B02 US20150044215 7114 nanobody SEQ ID NO: 16 PSEU204 Monovalent 14B10 US20150044215 7115 nanobody SEQ ID NO: 17 PSEU205 Monovalent 3E10 US20150044215 7116 nanobody SEQ ID NO: 18 PSEU206 Monovalent 5E02 US20150044215 7117 nanobody SEQ ID NO: 19 PSEU207 Scfv-Fc W4-M1 WO2014074528 7118 SEQ ID NO: 78 PSEU208 Scfv-Fc W4-M5 WO2014074528 7119 SEQ ID NO: 79 PSEU209 Scfv-Fc W4-M6 WO2014074528 7120 SEQ ID NO: 80 PSEU210 Scfv-Fc W4-M7 WO2014074528 7121 SEQ ID NO: 81 PSEU211 Scfv-Fc W4-M8 WO2014074528 7122 SEQ ID NO: 82 PSEU212 Scfv-Fc W4-M9 WO2014074528 7123 SEQ ID NO: 83 PSEU213 Scfv-Fc W4-M11 WO2014074528 7124 SEQ ID NO: 84 PSEU214 Scfv-Fc W4-M12 WO2014074528 7125 SEQ ID NO: 85 PSEU215 Scfv-Fc W4-M14 WO2014074528 7126 SEQ ID NO: 86 PSEU216 Scfv-Fc W4-M15 WO2014074528 7127 SEQ ID NO: 87 PSEU217 Scfv-Fc W4-M16 WO2014074528 7128 SEQ ID NO: 88 PSEU218 Scfv-Fc W4-M17 WO2014074528 7129 SEQ ID NO: 89 PSEU219 Scfv-Fc W4-M19 WO2014074528 7130 SEQ ID NO: 90 PSEU220 Scfv-Fc W4-M20 WO2014074528 7131 SEQ ID NO: 91 PSEU221 Sefv-Fc W4-M4 WO2014074528 7132 SEQ ID NO: 92 PSEU222 Scfv-Fc W4-M10 WO2014074528 7133 SEQ ID NO: 93 PSEU223 Scfv-Fc W4-HC1-LCP WO2014074528 7134 SEQ ID NO: 94 PSEU224 Scfv-Fc W4-HC1-LC7 WO2014074528 7135 SEQ ID NO: 95 PSEU225 Scfv-Fc W4-HC2-LC7 WO2014074528 7136 SEQ ID NO: 96 PSEU226 Scfv-Fc W4-HC3-LCP WO2014074528 7137 SEQ ID NO: 97 PSEU227 Scfv-Fc W4-HC4-LCP WO2014074528 7138 SEQ ID NO: 98 PSEU228 Scfv-Fc W4-HC5-LCP WO2014074528 7139 SEQ ID NO: 99 PSEU229 Scfv-Fc W4-HC5-LC7 WO2014074528 7140 SEQ ID NO: 100 PSEU230 Scfv-Fc W4-HC7-LCP WO2014074528 7141 SEQ ID NO: 101 PSEU231 Scfv-Fc W4-VH1-VL8 WO2014074528 7142 SEQ ID NO: 102 PSEU232 Scfv-Fc W4-VH2-VLP WO2014074528 7143 SEQ ID NO: 103 PSEU233 Scfv-Fc W4-VH2-VL8 WO2014074528 7144 SEQ ID NO: 104 PSEU234 Scfv-Fc W4-VH3-VL7 WO2014074528 7145 SEQ ID NO: 105 PSEU235 Scfv-Fc W4-VH3-VL8 WO2014074528 7146 SEQ ID NO: 106 PSEU236 Scfv-Fc W4-VH5-VL8 WO2014074528 7147 SEQ ID NO: 107 PSEU237 Scfv-Fc W4-VH6-VL7 WO2014074528 7148 SEQ ID NO: 108 PSEU238 Scfv-Fc W4-VH6-VL8 WO2014074528 7149 SEQ ID NO: 109 PSEU239 Scfv-Fc W4-VH6-VLP WO2014074528 7150 SEQ ID NO: 110 PSEU240 Scfv-Fc W4-VH7-VLP WO2014074528 7151 SEQ ID NO: 111 PSEU241 Scfv-Fc W4-VH7-VL7 WO2014074528 7152 SEQ ID NO: 112 PSEU242 Scfv-Fc W4-VH7-VL8 WO2014074528 7153 SEQ ID NO: 113 PSEU243 Scfv-Fc W4-VH9-VLP WO2014074528 7154 SEQ ID NO: 114 PSEU244 Scfv-Fc W4-VH10-VLP WO2014074528 7155 SEQ ID NO: 115 PSEU245 Scfv-Fc W4-VH11-VLP WO2014074528 7156 SEQ ID NO: 116 PSEU246 Scfv-Fc W4-VH12-VLP WO2014074528 7157 SEQ ID NO: 117 PSEU247 Scfv-Fc W4-VH15-VLP WO2014074528 7158 SEQ ID NO: 118 PSEU248 Scfv-Fc W4-VH16-VLP WO2014074528 7159 SEQ ID NO: 119 PSEU249 Scfv-Fc W4-VH20-VLP WO2014074528 7160 SEQ ID NO: 120 PSEU250 Scfv-Fc W4-VH31-VLP WO2014074528 7161 SEQ ID NO: 121 PSEU251 Scfv-Fc W4-VH37-VLP WO2014074528 7162 SEQ ID NO: 122 PSEU252 Scfv-Fc W4-VH41-VLP WO2014074528 7163 SEQ ID NO: 123 PSEU253 Scfv-Fc W4-VH42-VLP WO2014074528 7164 SEQ ID NO: 124 PSEU254 Scfv-Fc W4-VH35-VLP WO2014074528 7165 SEQ ID NO: 125 PSEU255 Scfv-Fc W4-VH36-VLP WO2014074528 7166 SEQ ID NO: 126 PSEU256 Scfv-Fc W4-VH52-VLP WO2014074528 7167 SEQ ID NO: 127 PSEU257 Scfv-Fc W4-VH53-VLP WO2014074528 7168 SEQ ID NO: 128 PSEU258 Scfv-Fc W4-VH54-VLP WO2014074528 7169 SEQ ID NO: 129 PSEU259 Scfv-Fc W4-VH55-VLP WO2014074528 7170 SEQ ID NO: 130 PSEU260 Scfv-Fc W4-VH56-VLP WO2014074528 7171 SEQ ID NO: 131 PSEU261 Scfv-Fc W4-VH57-VLP WO2014074528 7172 SEQ ID NO: 132 PSEU262 Scfv-Fc W4-VH58-VLP WO2014074528 7173 SEQ ID NO: 133 PSEU263 Scfv-Fc W4-VH60-VLP WO2014074528 7174 SEQ ID NO: 134 PSEU264 Scfv-Fc W4-VH61-VLP WO2014074528 7175 SEQ ID NO: 135 PSEU265 Scfv-Fc W4-VH62-VLP WO2014074528 7176 SEQ ID NO: 136 PSEU266 Scfv-Fc W4-VH63-VLP WO2014074528 7177 SEQ ID NO: 137 PSEU267 Scfv-Fc W4-VH64-VLP WO2014074528 7178 SEQ ID NO: 138 PSEU268 Scfv-Fc W4-VH65-VLP WO2014074528 7179 SEQ ID NO: 139 PSEU269 Scfv-Fc W4-VH66-VLP WO2014074528 7180 SEQ ID NO: 140 PSEU270 Scfv-Fc W4-VH67-VLP WO2014074528 7181 SEQ ID NO: 141 PSEU271 Scfv-Fc W4-VH69-VLP WO2014074528 7182 SEQ ID NO: 142 PSEU272 Scfv-Fc W4-VH70-VLP WO2014074528 7183 SEQ ID NO: 143 PSEU273 Scfv-Fc W4-VH72-VLP WO2014074528 7184 SEQ ID NO: 144 PSEU274 Scfv-Fc W4-VH79-VLP WO2014074528 7185 SEQ ID NO: 145 PSEU275 Scfv-Fc W4-VH80-VLP WO2014074528 7186 SEQ ID NO: 146 PSEU276 Scfv-Fc W4-M9 WO2014074528 7187 SEQ ID NO: 152 PSEU277 Scfv-Fc Psl0170 WO2014074528 7188 SEQ ID NO: 245 PSEU278 Scfv-Fc Psl0304 WO2014074528 7189 SEQ ID NO: 246 PSEU279 Scfv-Fc Psl0348 WO2014074528 7190 SEQ ID NO: 247 PSEU280 Scfv-Fc Psl0573 WO2014074528 7191 SEQ ID NO: 248 PSEU281 Scfv-Fc Psl0574 WO2014074528 7192 SEQ ID NO: 249 PSEU282 Scfv-Fc Psl0582 WO2014074528 7193 SEQ ID NO: 250 PSEU283 Scfv-Fc Psl0584 WO2014074528 7194 SEQ ID NO: 251 PSEU284 Scfv-Fc Psl0585 WO2014074528 7195 SEQ ID NO: 252 PSEU285 Scfv-Fc Psl0589 WO2014074528 7196 SEQ ID NO: 253

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 33 against Streptococcus bacteria.

TABLE 33 Antibodies against Streptococcus bacteria Anti- SEQ body Antibody Reference ID No. Description Name Information NO STRP1 Heavy chair US7625561 7197 variable region, SEQ ID NO: 5 Diabody for Streptococcus STRP2 Heavy chain US7625561 7198 variable region, SEQ ID NO: 3 Diabody for Streptococcus STRP3 Heavy chain US7625561 7199 variable region, SEQ ID NO: 7 Diabody for Streptococcus STRP4 Heavy chain DP-54 Lucas, A.H. 7200 variable region, “Combinatorial partial, library Streptococcus cloning of human pneumoniae antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48823 STRP5 Heavy chain DP-35 Lucas, A.H. 7201 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pueumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F,” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48825 STRP6 Heavy chain DP-47 Lucas, A.H. 7202 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48827 S'I7RP7 Heavy chain DP-47 Lucas, A.H. 7203 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001,) NCBI Accession # AAD48828 S'IRP8 Heavy chain LSG-6 1 Lucas, A.H. 7204 variable “Combinatorial region, library partial, cloning of hurnan Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48830 STRP9 Heavy chain LSG6.1 Lucas, A.H. 7205 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48832 STRP10 Heavy chain DP-47 Lucas, A.H. 7206 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48835 STRP11 Heavy chain humanized US7429381 6902 variable region, Mu-9 SEQ ID NO: 14 Streptococcus agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B. Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis. STRP12 Heavy chain Anti-PsaA US20070003561 7207 variable region. 7-1G9 SEQ ID NO: 16 Streptococcus pneumoniae STRP13 Heavy chain Anti-PsaA US20070003561 7208 variable region, 1-15E5 SEQ ID NO: 32 Streptococcus pneumoniae STRP14 Heavy chain Anti-PsaA US20070003561 7209 variable region, 9A7 SEQ ID NO: 48 Streptococcus pneumoniae STRP15 Heavy chain 23f Fab Bryson, S., 7210 variable region, 023.102, “Multitasking Streptococcus chain B immimoglobulin pneumoniae V-Genes And Somatic Div Cdr3 Loops Generate Binding Sites For Chemically Di Antigens From Bacterial And. Viral Pathogens” Unpublished″, NCBI Accession # 4HIE B STRP16 Heavy chain 5.12.14 US5686070 7211 variable region, SEQ ID NO: 22 Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosa SIRP17 Heavy chain 6G4.2.5 US5686070 7212 variable region, SEQ ID NO: 50 Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosa STRP18 Heavy chain chimeric US5686070 7213 variable region, 6G4.2.5 SEQ ID NO: 58 Streptococcus pneumoniae Escherichia coli, or Pseudomonas aeruginosa STRP19 Heavy chain, Mab6679 US7429381 6900 Streptococcus SEQ ID NO: 4 agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema palliduni Lyrae disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis. STRP20 Light chain US7625561 7214 variable region, SEQ ID NO: 6 Diabody for Streptococcus STRP21 Light chain US7625561 7215 variable region, SEQ ID NO: 8 Diabody for Streptococcus STRP22 Light chain US7625561 7216 variable region, SEQ ID NO: 4 Diabody for Streptococcus STRP23 Light chain A2 Lucas, A.H. 7217 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48824 STRP24 Light chain 133 Lucas, A.H. 7218 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48822 STRP25 Light chain A23 Lucas, A.H. 7219 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48826 STRP26 Light chain L2 Lucas, A.H. 7220 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48829 STRP27 Light chain DPL5 Lucas, A.H. 7221 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48831 STRP28 Light chain DPL5 Lucas, A.H. 7222 variable “Combinatorial region, library partial, cloning of human Streptococcus antibodies to pneumoniae Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48833 STRP29 Light chain L2 Lucas, A.H. 7223 variable region, “Combinatorial partial, library Streptococcus cloning of human pneumoniae antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23F” Infect. Immun. 69 (2), 853-864 (2001), NCBI Accession # AAD48834 STRP30 Light chain Anti-PsaA US20070003561 7224 variable region, 7-1G9 SEQ ID NO: 8 Streptococcus pneumoniae STRP31 Light chain Anti-PsaA US20070003561 7225 variable region, 1-15E5 SEQ ID NO: 24 Streptococcus pneumoniae STRP32 Light chain Anti-pSaA US20070003561 7226 variable region, 9A7 SEQ ID NO: 40 Streptococcus pneumoniae STRP33 Light chain 5.12.14 US5686070 7227 variable region, SEQ ID NO: 20 Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosa STRP34 Light chain 6G4.2.5 US5686070 7228 variable region, SEQ ID NO: 48 Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosa STRP35 Light chain chimeric US5686070 7229 variable region, 6G4.2.5 SEQ ID NO: 56 Streptococcus pneumoniae, Escherichia coli, or Pseudomonas aeruginosa STRP36 Light chain, Mab679 US7429381 6907 Streptococcus SEQ ID NO: 2 agalactiae, Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis STRP37 scFv, Streptococcus Mab679 US7429381 6911 agalactiae, SEQ ID NO: 6 Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis STRP38 scFv, Streptococcus Mu-9V US7429381 6905 agalactiae, SEQ ID NO: 8 Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis STRP39 scFv, Streptococcus Mu-9V US7429381 6901 agalactiae, SEQ ID NO: 10 Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis STRP40 scFv, Streptococcus humanized US7429381 6906 agalactiae, Mu-9 SEQ ID NO: 12 Legionella pneumophilia, Streptococcus pyogenes, Escherichia coli, Neisseria gonorrhoeae, Neisseria meningitidis, Pneumococcus, Hemophilis influenzae B, Treponema pallidum, Lyme disease spirochetes, Pseudomonas aeruginosa, Mycobacterium leprae, Brucella abortus and Mycobacterium tuberculosis

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in US Pub No. US20040198960 and US20130195876, the contents of each of which are herein incorporated by reference in their entirety, against Streptococcus pneumoniae infection.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants encoding Afelimomab, fragments or variants thereof for treating a disease and/or disorder or preventing a disease and/or disorder. As a non-limiting example, the disease and/or disorder is sepsis.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants encoding Nebacumab, fragments or variants thereof for treating a disease and/or disorder or preventing a disease and/or disorder. As a non-limiting example, the disease and/or disorder is sepsis.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 34 against Staphylococcal bacteria and related bacteria.

TABLE 34 Antibodies against Staphylococcal bacteria and related bacteria SEQ Antibody Antibody ID No. Description Name Reference Information NO STPH1 Heavy chain variable region, S. aureus U.S. Pat. No. 8,609,102 7230 SEQ ID NO: 2 STPH2 Heavy chain variable region, S. aureus U.S. Pat. No. 8,609,102 7231 SEQ ID NO: 6 STPH3 Heavy chain variable region, S. aureus SAR279356 U.S. Pat. No. 7,786,255 7232 or S. epidermidis, E. coli, Yersinia SEQ ID NO: 1 pestis (Y. pestis), Y. entercolitica, Xanthomnonas axonopodis (X. axonopodis), Pseudonmonas fuorescerns (P. fluorescens), Actinobacillus actinomycetemcomitans (A. actinomycetemcomitans), A. pleuropneumoniae, Ralstonia solanacearum (R. solanacearum), Bordetella pertussis (B. pertussis), B. parapertussis or B. bronchiseptica STPH4 Heavy chain variable region, S. aureus SAR279356 US20110002932 SEQ ID 7233 or S. epidermidis, E. coli, Yersinia NO: 1 pestis (Y. pestis), Y. entercolitica, Xanthomnonas axonopodis (X. axonopodis), Pseudonmonas fuorescerns (P. fluorescens), Actinobacillus actinomycetemcomitans (A. actinomycetemcomitans), A. pleuropneumoniae, Ralstonia solanacearum (R. solanacearum), Bordetella pertussis (B. pertussis), B. parapertussis or B. bronchiseptica STPH5 Heavy chain variable region, S. 108-1 U.S. Pat. No. 8,475,798 7234 epidermidis SEQ ID NO: 18 STPH6 Heavy chain variable region, S. 108-36 U.S. Pat. No. 8,475,798 7235 epidermidis SEQ ID NO: 22 STPH7 Heavy chain variable region, S. 110-15 U.S. Pat. No. 8,475,798 7236 epidermidis SEQ ID NO: 26 STPH8 Heavy chain variable region, S. 108-1VH- U.S. Pat. No. 8,475,798 7237 epidermidis Hu SEQ ID NO: 28 STPH9 Heavy chain variable region, S. 108-36VH- U.S. Pat. No. 8,475,798 7238 epidermidis Hu SEQ ID NO: 30 STPH10 Heavy chain variable region, S. 110-15VH- U.S. Pat. No. 8,475,798 7239 epidermidis Hu SEQ ID NO: 32 STPH11 Heavy chain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7240 Staphylococcal sepsis SEQ ID NO: 87 STPH12 Heavy chain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7241 Staphylococcal sepsis SEQ ID NO: 12 STPH13 Heavy chain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7242 Staphylococcal sepsis SEQ ID NO: 17 STPH14 Heavy chain variable region, F628 U.S. Pat. No. 8,912,314 7243 Staphylococci such as S. aureus and S. SEQ ID NO: 3 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH15 Heavy chain variable region, F630 U.S. Pat. No. 8,912,314 7244 Staphylococci such as S. aureus and S. SEQ ID NO: 5 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH16 Heavy chain variable region, F598 U.S. Pat. No. 8,912,314 7245 Staphylococci such as S. aureus and S. SEQ ID NO: 55 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH17 Heavy chain variable region, F628 U.S. Pat. No. 8,912,314 7246 Staphylococci such as S. aureus and S. SEQ ID NO: 58 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH18 Heavy chain variable region, F598 U.S. Pat. No. 8,912,314 7247 Staphylococci such as S. aureus and S. SEQ ID NO: 1 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH19 Heavy chain variable region, 108-3BVH- U.S. Pat. No. 8,475,798 7248 Staphylococcus epidermidis Hu SEQ ID NO: 34 STPH20 Heavy chain, MRSA, MSSA 2B2 U.S. Pat. No. 8,735,554 7249 SEQ ID NO: 3 STPH21 Heavy chain, MRSA, MSSA 2G7 U.S. Pat. No. 8,735,554 7250 SEQ ID NO: 5 STPH22 Heavy chain, MRSA, MSSA 3B12 U.S. Pat. No. 8,735,554 7251 SEQ ID NO: 7 STPH23 Heavy chain, S. aureus DF1.1 U.S. Pat. No. 8,715,673 7252 SEQ ID NO: 2 STPH24 Heavy chain, S. aureus DF1 U.S. Pat. No. 8,715,673 7253 SEQ ID NO: 4 STPH25 Heavy chain, S. aureus DF2 U.S. Pat. No. 8,715,673 7254 SEQ ID NO: 35 STPH26 Heavy chain, S. aureus DF3 U.S. Pat. No. 8,715,673 7255 SEQ ID NO: 36 STPH27 Heavy chain, S. aureus DF4 U.S. Pat. No. 8,715,673 7256 SEQ ID NO: 37 STPH28 Heavy chain, S. aureus DF5 U.S. Pat. No. 8,715,673 7257 SEQ ID NO: 38 STPH29 Heavy chain, S. aureus DF6 U.S. Pat. No. 8,715,673 7258 SEQ ID NO: 39 STPH30 Heavy chain, S. aureus DF7 U.S. Pat. No. 8,715,673 7259 SEQ ID NO: 40 STPH31 Heavy chain, S. aureus DF8 U.S. Pat. No. 8,715,673 7260 SEQ ID NO: 41 STPH32 Heavy chain, S. aureus DF9 U.S. Pat. No. 8,715,673 7261 SEQ ID NO: 42 STPH33 Heavy chain, S. aureus DF10 U.S. Pat. No. 8,715,673 7262 SEQ ID NO: 43 STPH34 Heavy chain, S. aureus DF11 U.S. Pat. No. 8,715,673 7263 SEQ ID NO: 44 STPH35 Heavy chain, S. aureus DF12 U.S. Pat. No. 8,715,673 7264 SEQ ID NO: 45 STPH36 Heavy chain, S. aureus DF13 U.S. Pat. No. 8,715,673 7265 SEQ ID NO: 46 STPH37 Heavy chain, S. aureus DF14 U.S. Pat. No. 8,715,673 7266 SEQ ID NO: 47 STPH38 Heavy chain, S. aureus DF15 U.S. Pat. No. 8,715,673 7267 SEQ ID NO: 48 STPH39 Heavy chain, S. aureus DF16 U.S. Pat. No. 8,715,673 7268 SEQ ID NO: 49 STPH40 Heavy chain, S. aureus DF17 U.S. Pat. No. 8,715,673 7269 SEQ ID NO: 50 STPH41 Heavy chain, S. aureus DF18 U.S. Pat. No. 8,715,673 7270 SEQ ID NO: 51 STPH42 Heavy chain, S. aureus DF19 U.S. Pat. No. 8,715,673 7271 SEQ ID NO: 52 STPH43 Heavy chain, S. aureus DF20 U.S. Pat. No. 8,715,673 7272 SEQ ID NO: 53 STPH44 Heavy chain, S. aureus and S. CR2430 U.S. Pat. No. 8,460,666 7273 epidermidis SEQ ID NO: 26 STPH45 Heavy chain, S. aureus and S. CR5132 U.S. Pat. No. 8,460,666 7274 epidermidis SEQ ID NO: 28 STPH46 Heavy chain, S. aureus and S. CR5133 U.S. Pat. No. 8,460,666 7275 epidermidis SEQ ID NO: 30 STPH47 Heavy chain, S. aureus and S. CR6166 U.S. Pat. No. 8,460,666 7276 epidermidis SEQ ID NO: 117 STPH48 Heavy chain, S. aureus and S. CR6171 U.S. Pat. No. 8,460,666 7277 epidermidis SEQ ID NO: 119 STPH49 Heavy chain, S. aureus and S. CR6176 U.S. Pat. No. 8,460,666 7278 epidermidis SEQ ID NO: 121 STPH50 Heavy chain, S. aureus and S. CR6187 U.S. Pat. No. 8,460,666 7279 epidermidis SEQ ID NO: 123 STPH51 Heavy chain, S. aureus and S. CR6193 U.S. Pat. No. 8,460,666 7280 epidermidis SEQ ID NO: 125 STPH52 Heavy chain, S. aureus and S. CR6249 U.S. Pat. No. 8,460,666 7281 epidermidis SEQ ID NO: 127 STPH53 Heavy chain, S. aureus and S. CR6273 U.S. Pat. No. 8,460,666 7282 epidermidis SEQ ID NO: 129 STPH54 Heavy chain, S. aureus and S. CR6389 U.S. Pat. No. 8,460,666 7283 epidermidis SEQ ID NO: 131 STPH55 Heavy chain, S. aureus and S. CR6403 U.S. Pat. No. 8,460,666 7284 epidermidis SEQ ID NO: 133 STPH56 Heavy chain, S. aureus and S. CR6406 U.S. Pat. No. 8,460,666 7285 epidermidis SEQ ID NO: 135 STPH57 Heavy chain, S. aureus and S. CR6410 U.S. Pat. No. 8,460,666 7286 epidermidis SEQ ID NO: 137 STPH58 Heavy chain, S. aureus and S. CR6446 U.S. Pat. No. 8,460,666 7287 epidermidis SEQ ID NO: 139 STPH59 Heavy chain, S. aureus and S. CR6450 U.S. Pat. No. 8,460,666 7288 epidermidis SEQ ID NO: 141 STPH60 Heavy chain, S. aureus and S. CR6452 U.S. Pat. No. 8,460,666 7289 epidermidis SEQ ID NO: 143 STPH61 Heavy chain, S. aureus and S. CR6453 U.S. Pat. No. 8,460,666 7290 epidermidis SEQ ID NO: 145 STPH62 Heavy chain, S. aureus and S. CR6464 U.S. Pat. No. 8,460,666 7291 epidermidis SEQ ID NO: 147 STPH63 Heavy chain, S. aureus and S. CR6471 U.S. Pat. No. 8,460,666 7292 epidermidis SEQ ID NO: 149 STPH64 Heavy chain, S. aureus and S. CR6516 U.S. Pat. No. 8,460,666 7293 epidermidis SEQ ID NO: 151 STPH65 Heavy chain, S. aureus and S. CR6517 U.S. Pat. No. 8,460,666 7294 epidermidis SEQ ID NO: 153 STPH66 Heavy chain, S. aureus and S. CR6526 U.S. Pat. No. 8,460,666 7295 epidermidis SEQ ID NO: 155 STPH67 Heavy chain, S. aureus and S. CR6528 U.S. Pat. No. 8,460,666 7296 epidermidis SEQ ID NO: 157 STPH68 Heavy chain, S. aureus and S. CR6531 U.S. Pat. No. 8,460,666 7297 epidermidis SEQ ID NO: 159 STPH69 Heavy chain, S. aureus and S. CR6533 U.S. Pat. No. 8,460,666 7298 epidermidis SEQ ID NO: 161 STPH70 Heavy chain, S. aureus and S. CR6536 U.S. Pat. No. 8,460,666 7299 epidermidis SEQ ID NO: 163 STPH71 Heavy chain, S. aureus and S. CR6537 U.S. Pat. No. 8,460,666 7300 epidermidis SEQ ID NO: 165 STPH72 Heavy chain, S. aureus and S. CR6538 U.S. Pat. No. 8,460,666 7301 epidermidis SEQ ID NO: 167 STPH73 Heavy chain, S. aureus and S. CR6540 U.S. Pat. No. 8,460,666 7302 epidermidis SEQ ID NO: 169 STPH74 Heavy chain, S. aureus and S. CR6544 U.S. Pat. No. 8,460,666 7303 epidermidis SEQ ID NO: 171 STPH75 Heavy chain, S. aureus and S. CR6566 U.S. Pat. No. 8,460,666 7304 epidermidis SEQ ID NO: 173 STPH76 Heavy chain, S. aureus and S. CR6625 U.S. Pat. No. 8,460,666 7305 epidermidis SEQ ID NO: 175 STPH77 Heavy chain, S. aureus, Enterococcus CR5140 U.S. Pat. No. 8,628,776 7306 SEQ ID NO: 395 STPH78 Heavy chain, S. aureus, Enterococcus CR5159 U.S. Pat. No. 8,628,776 7307 SEQ ID NO: 82 STPH79 Heavy chain, S. aureus, Enterococcus CR5179 U.S. Pat. No. 8,628,776 7308 SEQ ID NO: 399 STPH80 Heavy chain, S. aureus, Enterococcus CR6016 U.S. Pat. No. 8,628,776 7309 SEQ ID NO: 88 STPH81 Heavy chain, S. aureus, Enterococcus CR6049 U.S. Pat. No. 8,628,776 7310 SEQ ID NO: 92 STPH82 Heavy chain, S. aureus. Enterococcus CR6071 U.S. Pat. No. 8,628,776 7311 SEQ ID NO: 94 STPH83 Heavy chain, S. aureus, Enterococcus CR6078 U.S. Pat. No. 8,628,776 7312 SEQ ID NO: 96 STPH84 Heavy chain, S. aureus, Enterococcus CR6086 U.S. Pat. No. 8,628,776 7313 SEQ ID NO: 407 STPH85 Heavy chain, S. aureus, Enterococcus CR6089 U.S. Pat. No. 8,628,776 7314 SEQ ID NO: 213 STPH86 Heavy chain, S. aureus, Enterococcus CR6191 UU.S. Pat. No. 8,628,776 7315 SEQ ID NO: 411 STPH87 Heavy chain, S. aureus, Enterococcus CR6198 U.S. Pat. No. 8,628,776 7316 SEQ ID NO: 415 STPH88 Heavy chain, S. aureus, Enterococcus CR6242 U.S. Pat. No. 8,628,776 7317 SEQ ID NO: 417 STPH89 Heavy chain, S. aureus, Enterococcus CR6252 U.S. Pat. No. 8,628,776 7318 SEQ ID NO: 100 STPH90 Heavy chain, S. aureus, Enterococcus CR6389 0U.S. Pat. No. 8,628,776 7319 SEQ ID NO: 423 STPH91 Heavy chain, S. aureus, Enterococcus CR6402 U.S. Pat. No. 8,628,776 7320 SEQ ID NO: 427 STPH92 Heavy chain, S. aureus, Enterococcus CR6415 U.S. Pat. No. 8,628,776 7321 SEQ ID NO: 431 STPH93 Heavy chain, S. aureus, Enterococcus CR6429 U.S. Pat. No. 8,628,776 7322 SEQ ID NO: 435 STPH94 Heavy chain, S. aureus, Enterococcus CR5140 U.S. Pat. No. 8,628,776 7323 SEQ ID NO: 439 STPH95 Heavy chain, S. aureus, Enterococcus CR5159 U.S. Pat. No. 8,628,776 7324 SEQ ID NO: 102 STPH96 Heavy chain, S. aureus, Enterococcus CR5179 U.S. Pat. No. 8,628,776 7325 SEQ ID NO: 443 STPH97 Heavy chain, S. aureus, Enterococcus CR6016 U.S. Pat. No. 8,628,776 7326 SEQ ID NO: 108 STPH98 Heavy chain, S. aureus, Enterococcus CR6049 U.S. Pat. No. 8,628,776 7327 SEQ ID NO: 112 STPH99 Heavy chain, S. aureus, Enterococcus CR6071 U.S. Pat. No. 8,628,776 7328 SEQ ID NO: 114 STPH100 Heavy chain, S. aureus, Enterococcus CR6078 U.S. Pat. No. 8,628,776 7329 SEQ ID NO: 116 STPH101 Heavy chain, S. aureus, Enterococcus CR6086 U.S. Pat. No. 8,628,776 7330 SEQ ID NO: 451 STPH102 Heavy chain, S. aureus, Enterococcus CR6089 U.S. Pat. No. 8,628,776 7331 SEQ ID NO: 217 STPH103 Heavy chain, S. aureus, Enterococcus CR6191 U.S. Pat. No. 8,628,776 7332 SEQ ID NO: 455 STPH104 Heavy chain, S. aureus, Enterococcus CR6198 U.S. Pat. No. 8,628,776 7333 SEQ ID NO: 459 STPH105 Heavy chain, S. aureus, Enterococcus CR6242 U.S. Pat. No. 8,628,776 7334 SEQ ID NO: 461 STPH106 Heavy chain, S. aureus, Enterococcus CR6252 U.S. Pat. No. 8,628,776 7335 SEQ ID NO: 120 STPH107 Heavy chain, S. aureus, Enterococcus CR6389 U.S. Pat. No. 8,628,776 7336 SEQ ID NO: 467 STPH108 Heavy chain, S. aureus, Enterococcus CR6402 U.S. Pat. No. 8,628,776 7337 SEQ ID NO: 471 STPH109 Heavy chain, S. aureus, Enterococcus CR6415 U.S. Pat. No. 8,628,776 7338 SEQ ID NO: 475 STPH110 Heavy chain, S. aureus, Enterococcus CR6429 U.S. Pat. No. 8,628,776 7339 SEQ ID NO: 479 STPH111 Heavy chain, S. aureus, S. epidermidis, F1 antibody U.S. Pat. No. 8,617,556 7340 S. caprae, S. saprophyticus, S. capitis, or variant SEQ ID NO: 7 methicillin-resistant S. aureus (MRSA) STPH112 Heavy chain, S. aureus, S. epidermidis, F1 antibody U.S. Pat. No. 8,617,556 7341 S. caprae, S. saprophyticus, S. capitis, or variant SEQ ID NO: 9 methicillin-resistant S. aureus (MRSA) STPH113 Heavy chain, S. aureus, S. epidermidis, rF1 U.S. Pat. No. 8,617,556 7342 S. caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 55 methicillin-resistant S. aureus (MRSA) STPH114 Heavy chain, S. aureus, S. epidermidis, rF1 A114C U.S. Pat. No. 8,617,556 7343 S. caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 56 methicillin-resistant S. aureus (MRSA) STPH115 Heavy chain, S. aureus, S. epidermidis, rF1 U.S. Pat. No. 8,617,556 7344 S. caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 63 methicillin-resistant S. aureus (MRSA) STPH116 Heavy chain, S. aureus, S. epidermidis, rF1 A114C U.S. Pat. No. 8,617,556 7345 S. caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 62 methicillin-resistant S. aureus (MRSA) STPH117 Light chain U.S. Pat. No. 8,609,102 7346 SEQ ID NO: 4 STPH118 Light chain variable region, S. aureus U.S. Pat. No. 8,609,102 7347 SEQ ID NO: 8 STPH119 Light chain variable region, S. aureus or SAR279356 U.S. Pat. No. 7,786,255 7348 S. epidermidis, E. coli, Yersinia SEQ ID NO: 2 pestis (Y. pestis), Y. entercolitica, Xanthomnonas axonopodis (X. axonopodis), Pseudonmonas fuorescerns (P. fluorescens), Actinobacillus actinomycetemcomitans (A. actinomycetemcomitans), A. pleuropneumoniae, Ralstonia solanacearum (R. solanacearum), Bordetella pertussis (B. pertussis), B. parapertussis or B. bronchiseptica STPH120 Light chain variable region, S. aureus or SAR279356 US20110002932 SEQ ID 7349 S. epidermidis, E. coli, Yersinia NO: 2 pestis (Y. pestis), Y. entercolitica, Xanthomnonas axonopodis (X. axonopodis), Pseudonmonas fuorescerns (P. fluorescens), Actinobacillus actinomycetemcomitans (A. actinomycetemcomitans), A. pleuropneumoniae, Ralstonia solanacearum (R. solanacearum), Bordetella pertussis (B. pertussis), B. parapertussis or B. bronchiseptica STPH121 Light chain variable region, S. 108-1 U.S. Pat. No. 8,475,798 7350 epidermidis SEQ ID NO: 16 STPH122 Light chain variable region, S. 108-36 U.S. Pat. No. 8,475,798 7351 epidermidis SEQ ID NO: 20 STPH123 Light chain variable region, S. 110-15 U.S. Pat. No. 8,475,798 7352 epidermidis SEQ ID NO: 24 STPH124 Light chain variable region, S. 108-1VL- U.S. Pat. No. 8,475,798 7353 epidermidis Hu SEQ ID NO: 27 STPH125 Light chain variable region, S. 108-36VL- U.S. Pat. No. 8,475,798 7354 epidermidis Hu SEQ ID NO: 29 STPH126 Light chain variable region, S. 110-15VL- U.S. Pat. No. 8,475,798 7355 epidermidis Hu SEQ ID NO: 31 STPH127 Light chain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7356 Staphylococcal sepsis SEQ ID NO: 89 STPH128 Light chain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7357 Staphylococcal sepsis SEQ ID NO: 10 STPH129 Light chain variable region, Pagibaximab U.S. Pat. No. 8,372,958 7358 Staphylococcal sepsis SEQ ID NO: 16 STPH130 Light chain variable region, F598 U.S. Pat. No. 8,912,314 7359 Staphylococci such as S. aureus and S. SEQ ID NO: 2 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH131 Light chain variable region, F628 U.S. Pat. No. 8,912,314 7360 Staphylococci such as S. aureus and S. SEQ ID NO: 4 epidermidis, E. coli such as E. coli strains O157: H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH132 Light chain variable region, F630 U.S. Pat. No. 8,912,314 7361 Staphylococci such as S. aureus and S. SEQ ID NO: 6 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH133 Light chain variable region, F598 U.S. Pat. No. 8,912,314 7362 Staphylococci such as S. aureus and S. SEQ ID NO: 57 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH134 Light chain variable region, F630 U.S. Pat. No. 8,912,314 7363 Staphylococci such as S. aureus and S. SEQ ID NO: 60 epidermidis, E. coli such as E. coli strains O157:H7 and CFT073, Yersinia pestis, Yersinia entercolitica, Xanthomonas axonopodis, Pseudomonas fluorescens (all of which are sequenced species with complete pgaABCD loci), and Actinobacillus actinomycetemcomitans (AA), Actinobacillus pleuropneumoniae (Ap), Ralstonia solanacearum (e.g., megaplasmid form), Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica STPH135 Light chain, MRSA, MSSA 2B2 U.S. Pat. No. 8,735,554 7364 SEQ ID NO: 2 STPH136 Light chain. MRSA, MSSA 2G7 U.S. Pat. No. 8,735,554 7365 SEQ ID NO: 4 STPH137 Light chain, MRSA, MSSA 3B12 U.S. Pat. No. 8,735,554 7366 SEQ ID NO: 6 STPH138 Light chain, S. aureus DFLI U.S. Pat. No. 8,715,673 7367 SEQ ID NO: 1 STPH139 Light chain, S. aureus DF1-DF20 U.S. Pat. No. 8,715,673 7368 SEQ ID NO: 3 STPH140 Light chain, S. aureus and S. epidermidis CR2430 U.S. Pat. No. 8,460,666 7369 SEQ ID NO: 32 STPH141 Light chain, S. aureus and S. epidermidis CR5132 U.S. Pat. No. 8,460,666 7370 SEQ ID NO: 34 STPH142 Light chain, S. aureus and S. epidermidis CR5133 U.S. Pat. No. 8,460,666 7371 SEQ ID NO: 36 STPH143 Light chain, S. aureus and S. epidermidis CR6166 U.S. Pat. No. 8,460,666 7372 SEQ ID NO: 177 STPH144 Light chain, S. aureus and S. epidermidis CR6171 U.S. Pat. No. 8,460,666 7373 SEQ ID NO: 179 STPH145 Light chain, S. aureus and S. epidermidis CR6176 U.S. Pat. No. 8,460,666 7374 SEQ ID NO: 181 STPH146 Light chain, S. aureus and S. epidermidis CR6187 U.S. Pat. No. 8,460,666 7375 SEQ ID NO: 183 STPH147 Light chain, S. aureus and S. epidermidis CR6193 U.S. Pat. No. 8,460,666 7376 SEQ ID NO: 185 STPH148 Light chain, S. aureus and S. epidermidis CR6249 U.S. Pat. No. 8,460,666 7377 SEQ ID NO: 187 STPH149 Light chain, S. aureus and S. epidermidis CR6273 U.S. Pat. No. 8,460,666 7378 SEQ ID NO: 189 STPH150 Light chain, S. aureus and S. epidermidis CR6389 U.S. Pat. No. 8,460,666 7379 SEQ ID NO: 191 STPH151 Light chain, S. aureus and S. epidermidis CR6403 U.S. Pat. No. 8,460,666 7380 SEQ ID NO: 193 STPH152 Light chain, S. aureus and S. epidermidis CR6406 U.S. Pat. No. 8,460,666 7381 SEQ ID NO: 195 STPH153 Light chain, S. aureus and S. epidermidis CR6410 U.S. Pat. No. 8,460,666 7382 SEQ ID NO: 197 STPH154 Light chain, S. aureus and S. epidermidis CR6446 U.S. Pat. No. 8,460,666 7383 SEQ ID NO: 199 STPH155 Light chain, S. aureus and S. epidermidis CR6450 U.S. Pat. No. 8,460,666 7384 SEQ ID NO: 201 STPH156 Light chain, S. aureus and S. epidermidis CR6452 U.S. Pat. No. 8,460,666 7385 SEQ ID NO: 203 STPH157 Light chain, S. aureus and S. epidermidis CR6453 U.S. Pat. No. 8,460,666 7386 SEQ ID NO: 205 STPH158 Light chain, S. aureus and S. epidermidis CR6464 U.S. Pat. No. 8,460,666 7387 SEQ ID NO: 207 STPH159 Light chain, S. aureus and S. epidermidis CR6471 U.S. Pat. No. 8,460,666 7388 SEQ ID NO: 209 STPH160 Light chain, S. aureus and S. epidermidis CR6516 U.S. Pat. No. 8,460,666 7389 SEQ ID NO: 211 STPH161 Light chain, S. aureus and S. epidermidis CR6517 U.S. Pat. No. 8,460,666 7390 SEQ ID NO: 213 STPH162 Light chain, S. aureus and S. epidermidis CR6526 U.S. Pat. No. 8,460,666 7391 SEQ ID NO: 215 STPH163 Light chain, S. aureus and S. epidermidis CR6528 U.S. Pat. No. 8,460,666 7392 SEQ ID NO: 217 STPH164 Light chain, S. aureus and S. epidermidis CR6531 U.S. Pat. No. 8,460,666 7393 SEQ ID NO: 219 STPH165 Light chain, S. aureus and S. epidermidis CR6533 U.S. Pat. No. 8,460,666 7394 SEQ ID NO: 221 STPH166 Light chain, S. aureus and S. epidermidis CR6536 U.S. Pat. No. 8,460,666 7395 SEQ ID NO: 223 STPH167 Light chain, S. aureus and S. epidermidis CR6537 U.S. Pat. No. 8,460,666 7396 SEQ ID NO: 225 STPH168 Light chain, S. aureus and S. epidermidis CR6538 U.S. Pat. No. 8,460,666 7397 SEQ ID NO: 227 STPH169 Light chain, S. aureus and S. epidermidis CR6540 U.S. Pat. No. 8,460,666 7398 SEQ ID NO: 229 STPH170 Light chain, S. aureus and S. epidermidis CR6544 U.S. Pat. No. 8,460,666 7399 SEQ ID NO: 231 STPH171 Light chain, S. aureus and S. epidermidis CR6566 U.S. Pat. No. 8,460,666 7400 SEQ ID NO: 233 STPH172 Light chain, S. aureus and S. epidermidis CR6625 U.S. Pat. No. 8,460,666 7401 SEQ ID NO: 235 STPH173 Light chain, S. aureus, Enterococcus CR6157 U.S. Pat. No. 8,628,776 7402 SEQ ID NO: 397 STPH174 Light chain, S. aureus, Enterococcus CR5166 U.S. Pat. No. 8,628,776 7403 SEQ ID NO: 84 STPH175 Light chain, S. aureus, Enterococcus CR5187 U.S. Pat. No. 8,628,776 7404 SEQ ID NO: 86 STPH176 Light chain, S. aureus, Enterococcus CR6043 U.S. Pat. No. 8,628,776 7405 SEQ ID NO: 90 STPH177 Light chain, S. aureus, Enterococcus CR6050 U.S. Pat. No. 8,628,776 7406 SEQ ID NO: 401 STPH178 Light chain, S. aureus, Enterococcus CR6077 U.S. Pat. No. 8,628,776 7407 SEQ ID NO: 403 STPH179 Light chain, S. aureus, Enterococcus CR6079 U.S. Pat. No. 8,628,776 7408 SEQ ID NO: 405 STPH180 Light chain, S. aureus, Enterococcus CR6087 U.S. Pat. No. 8,628,776 7409 SEQ ID NO: 211 STPH181 Light chain, S. aureus, Enterococcus CR6092 U.S. Pat. No. 8,628,776 7410 SEQ ID NO: 409 STPH182 Light chain, S. aureus, Enterococcus CR6195 U.S. Pat. No. 8,628,776 7411 SEQ ID NO: 413 STPH183 Light chain, S. aureus, Enterococcus CR6241 U.S. Pat. No. 8,628,776 7412 SEQ ID NO: 98 STPH184 Light chain, S. aureus, Enterococcus CR6246 U.S. Pat. No. 8,628,776 7413 SEQ ID NO: 419 STPH185 Light chain, S. aureus, Enterococcus CR6388 U.S. Pat. No. 8,628,776 7414 SEQ ID NO: 421 STPH186 Light chain, S. aureus, Enterococcus CR6396 U.S. Pat. No. 8,628,776 7415 SEQ ID NO: 425 STPH187 Light chain, S. aureus, Enterococcus CR6409 U.S. Pat. No. 8,628,776 7416 SEQ ID NO: 429 STPH188 Light chain, S. aureus, Enterococcus CR6421 U.S. Pat. No. 8,628,776 7417 SEQ ID NO: 433 STPH189 Light chain, S. aureus, Enterococcus CR6432 U.S. Pat. No. 8,628,776 7418 SEQ ID NO: 437 STPH190 Light chain, S. aureus, Enterococcus CR5157 U.S. Pat. No. 8,628,776 7419 SEQ ID NO: 441 STPH191 Light chain, S. aureus, Enterococcus CR5166 U.S. Pat. No. 8,628,776 7420 SEQ ID NO: 104 STPH192 Light chain, S. aureus, Enterococcus CR5187 U.S. Pat. No. 8,628,776 7421 SEQ ID NO: 106 STPH193 Light chain, S. aureus, Enterococcus CR6043 U.S. Pat. No. 8,628,776 7422 SEQ ID NO: 110 STPH194 Light chain, S. aureus, Enterococcus CR6050 U.S. Pat. No. 8,628,776 7423 SEQ ID NO: 445 STPH195 Light chain, S. aureus, Enterococcus CR6077 U.S. Pat. No. 8,628,776 7424 SEQ ID NO: 447 STPH196 Light chain, S. aureus, Enterococcus CR6079 U.S. Pat. No. 8,628,776 7425 SEQ ID NO: 449 STPH197 Light chain, S. aureus, Enterococcus CR6087 U.S. Pat. No. 8,628,776 7426 SEQ ID NO: 215 STPH198 Light chain, S. aureus, Enterococcus CR6092 U.S. Pat. No. 8,628,776 7427 SEQ ID NO: 453 STPH199 Light chain, S. aureus, Enterococcus CR6195 U.S. Pat. No. 8,628,776 7428 SEQ ID NO: 457 STPH200 Light chain, S. aureus, Enterococcus CR6241 U.S. Pat. No. 8,628,776 7429 SEQ ID NO: 118 STPH201 Light chain, S. aureus, Enterococcus CR6246 U.S. Pat. No. 8,628,776 7430 SEQ ID NO: 463 STPH202 Light chain, S. aureus, Enterococcus CR6388 U.S. Pat. No. 8,628,776 7431 SEQ ID NO: 465 STPH203 Light chain, S. aureus, Enterococcus CR6396 U.S. Pat. No. 8,628,776 7432 SEQ ID NO: 469 STPH204 Light chain, S. aureus, Enterococcus CR6409 U.S. Pat. No. 8,628,776 7433 SEQ ID NO: 473 STPH205 Light chain, S. aureus, Enterococcus CR6421 U.S. Pat. No. 8,628,776 7434 SEQ ID NO: 477 STPH206 Light chain, S. aureus, Enterococcus CR6432 U.S. Pat. No. 8,628,776 7435 SEQ ID NO: 481 STPH207 Light chain, S. aureus, S. epidermidis, S. F1 antibody U.S. Pat. No. 8,617,556 7436 caprae, S. saprophyticus, S. capitis, or variant SEQ ID NO: 8 methicillin-resistant S. aureus (MRSA) STPH208 Light chain, S. aureus, S. epidermidis, S. F1 antibody U.S. Pat. No. 8,617,556 7437 caprae, S. saprophyticus, S. capitis, or variant SEQ ID NO: 10 methicillin-resistant S. aureus (MRSA) STPH209 Light chain, S. aureus, S. epidermidis, S. F1 antibody U.S. Pat. No. 8,617,556 7438 caprae, S. saprophyticus, S. capitis, or variant SEQ ID NO: 11 methicillin-resistant S. aureus (MRSA) STPH210 Light chain, S. aureus, S. epidermidis, S. rF1 U.S. Pat. No. 8,617,556 7439 caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 57 methicillin-resistant S. aureus (MRSA) STPH211 Light chain, S. aureus, S. epidermidis, S. rF1 V205C U.S. Pat. No. 8,617,556 7440 caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 58 methicillin-resistant S. aureus (MRSA) STPH212 Light chain, S. aureus, S. epidermidis, S. rF1 U.S. Pat. No. 8,617,556 7441 caprae, S. saprophyticus, S. capitis, or SEQ ID NO: 64 methicillin-resistant S. aureus (MRSA) STPH213 ScFv, S. aureus and S. epidermidis SC02-430 U.S. Pat. No. 8,460,666 7442 SEQ ID NO: 20 STPH214 ScFv, S. aureus and S. epidermidis SC05-132 U.S. Pat. No. 8,460,666 7443 SEQ ID NO: 22 STPH215 ScFv, S. aureus and S. epidermidis SC05-133 U.S. Pat. No. 8,460,666 7444 SEQ ID NO: 24 STPH216 ScFv, S. aureus, Enterococcus SC05-140 U.S. Pat. No. 8,628,776 7445 SEQ ID NO: 351 STPH217 ScFv, S. aureus, Enterococcus SC05-157 U.S. Pat. No. 8,628,776 7446 SEQ ID NO: 353 STPH218 ScFv, S. aureus, Enterococcus SC05-159 U.S. Pat. No. 8,628,776 7447 SEQ ID NO: 62 STPH219 ScFv, S. aureus, Enterococcus SC05-166 U.S. Pat. No. 8,628,776 7448 SEQ ID NO: 64 STPH220 ScFv, S. aureus, Enterococcus SC05-179 U.S. Pat. No. 8,628,776 7449 SEQ ID NO: 355 STPH221 ScFv, S. aureus, Enterococcus SC05-187 U.S. Pat. No. 8,628,776 7450 SEQ ID NO: 66 STPH222 ScFv, S. aureus, Enterococcus SC06-016 U.S. Pat. No. 8,628,776 7451 SEQ ID NO: 68 STPH223 ScFv, S. aureus, Enterococcus SC06-043 U.S. Pat. No. 8,628,776 7452 SEQ ID NO: 70 STPH224 ScFv, S. aureus, Enterococcus SC06-049 U.S. Pat. No. 8,628,776 7453 SEQ ID NO: 72 STPH225 ScFv, S. aureus, Enterococcus SC06-050 U.S. Pat. No. 8,628,776 7454 SEQ ID NO: 357 STPH226 ScFv, S. aureus, Enterococcus SC06-071 U.S. Pat. No. 8,628,776 7455 SEQ ID NO: 74 STPH227 ScFv, S. aureus, Enterococcus SC06-077 U.S. Pat. No. 8,628,776 7456 SEQ ID NO: 359 STPH228 ScFv, S. aureus, Enterococcus SC06-078 U.S. Pat. No. 8,628,776 7457 SEQ ID NO: 76 STPH229 ScFv, S. aureus, Enterococcus SC06-079 U.S. Pat. No. 8,628,776 7458 SEQ ID NO: 361 STPH230 ScFv, S. aureus, Enterococcus SC06-086 U.S. Pat. No. 8,628,776 7459 SEQ ID NO: 363 STPH231 ScFv, S. aureus, Enterococcus SC06-087 U.S. Pat. No. 8,628,776 7460 SEQ ID NO: 207 STPH232 ScFv, S. aureus, Enterococcus SC06-089 U.S. Pat. No. 8,628,776 7461 SEQ ID NO: 209 STPH233 ScFv, S. aureus, Enterococcus SC06-092 U.S. Pat. No. 8,628,776 7462 SEQ ID NO: 365 STPH234 ScFv, S. aureus, Enterococcus SC06-091 U.S. Pat. No. 8,628,776 7463 SEQ ID NO: 367 STPH235 ScFv, S. aureus, Enterococcus SC06-195 U.S. Pat. No. 8,628,776 7464 SEQ ID NO: 369 STPH236 ScFv, S. aureus, Enterococcus SC06-198 U.S. Pat. No. 8,628,776 7465 SEQ ID NO: 371 STPH237 ScFv, S. aureus, Enterococcus SC06-241 U.S. Pat. No. 8,628,776 7466 SEQ ID NO: 78 STPH238 ScFv, S. aureus, Enterococcus SC06-242 U.S. Pat. No. 8,628,776 7467 SEQ ID NO: 373 STPH239 ScFv, S. aureus, Enterococcus SC06-246 U.S. Pat. No. 8,628,776 7468 SEQ ID NO: 375 STPH240 ScFv, S. aureus, Enterococcus SC06-252 U.S. Pat. No. 8,628,776 7469 SEQ ID NO: 80 STPH241 ScFv, S. aureus, Enterococcus SC06-388 U.S. Pat. No. 8,628,776 7470 SEQ ID NO: 377 STPH242 ScFv, S. aureus, Enterococcus SC06-389 U.S. Pat. No. 8,628,776 7471 SEQ ID NO: 379 STPH243 ScFv, S. aureus, Enterococcus SC06-396 U.S. Pat. No. 8,628,776 7472 SEQ ID NO: 381 STPH244 ScFv, S. aureus, Enterococcus SC06-402 U.S. Pat. No. 8,628,776 7473 SEQ ID NO: 383 STPH245 ScFv, S. aureus, Enterococcus SC06-409 U.S. Pat. No. 8,628,776 7474 SEQ ID NO: 385 STPH246 ScFv, S. aureus, Enterococcus SC06-415 U.S. Pat. No. 8,628,776 7475 SEQ ID NO: 387 STPH247 ScFv, S. aureus, Enterococcus SC06-421 U.S. Pat. No. 8,628,776 7476 SEQ ID NO: 389 STPH248 ScFv, S. aureus, Enterococcus SC06-429 U.S. Pat. No. 8,628,776 7477 SEQ ID NO: 391 STPH249 ScFv, S. aureus, Enterococcus SC06-432 U.S. Pat. No. 8,628,776 7478 SEQ ID NO: 393

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in International Publication No. WO2000071585, WO2013162751, WO2015089502, WO2015088346 (e.g., SEQ ID NO: 17), US Pub No. US20030224000, US20080014202, US20140037650, US20140170134, U.S. Pat. No. 8,460,666, the contents of each of which are herein incorporated by reference in their entirety, against Staphylococcus infection.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 35 against Clostridium tetani.

TABLE 35 Antibodies against Clostridium Tetani SEQ Antibody Antibody ID No. Description Name Reference Information NO CTET1 Heavy chain Sims, G. P. “Tetanus toxoid specific antibody heavy chain 7479 partial V-gene sequence”, Unpublished, CNBI Accession # AAC69189.1 CTET2 Heavy chain F5-20 Sims, G. P. “Tetanus toxoid specific antibody heavy chain 7480 variable region V-gene sequence”, Unpublished, CNBI Accession # AAB50736.1 CTET3 Heavy chain Larrick, J. W., “Therapeutic human antibodies derived 7481 variable region from PCR amplification of B-cell variable regions”, Immunol. Rev. 130, 69-85 (1992), CNBI Accession # AAB25318.1 CTET4 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7482 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36976.1 CTET5 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7483 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36975.1 CTET6 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7484 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36974.1 CTET7 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7485 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36973.1 CTET8 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7486 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36972.1 CTET9 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7487 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36971.1 CTET10 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7488 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36970.1 CTET11 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7489 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36969.1 CTET12 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7490 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36968.1 CTET13 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7491 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol, Biol, immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36967.1 CTET14 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7492 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36966.1 CTET15 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7493 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36965.1 CTET16 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7494 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36964.1 CTET17 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7495 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36963.1 CTET18 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7496 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36962.1 CTET19 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7497 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36961.1 CTET20 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7498 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36960.1 CTET21 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7499 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36958.1 CTET22 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7500 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36959.1 CTET23 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7501 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36957.1 CTET24 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7502 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36956.1 CTET25 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7503 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36955.1 CTET26 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7504 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36954.1 CTET27 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7505 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36953.1 CTET28 Heavy chain de Kruif, J, et al., “Human immunoglobulin repertoires 7506 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36952.1 CTET29 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7507 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36951.1 CTET30 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7508 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36950.1 CTET31 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7509 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36949.1 CTET32 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7510 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36948.1 CTET33 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7511 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36947.1 CTET34 Heavy chain de Kruif, J, et al., “Human immunoglobulin repertoires 7512 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36946.1 CTET35 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7513 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36924.1 CTET36 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7514 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36925.1 CTET37 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7515 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36926.1 CTET38 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7516 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36927.1 CTET39 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7517 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36928.1 CTET40 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7518 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J, Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36929.1 CTET41 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7519 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36930.1 CTET42 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7520 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36931.1 CTET43 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7521 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36932.1 CTET44 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7522 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36933.1 CTET45 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7523 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36934.1 CTET46 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7524 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36935.1 CTET47 Heavy chain de Kruif, J. et al., “Human immunoglobulin repertoires 7525 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36936.1 CTET48 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7526 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36937.1 CTET49 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7527 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36938.1 CTET50 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7528 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36939.1 CTET51 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7529 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36940.1 CTET52 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7530 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36941.1 CTET53 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7531 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36943.1 CTET54 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7532 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36942.1 CTET55 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7533 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36944.1 CTET56 Heavy chain e Kruif, J. et al., “Human immunoglobulin repertoires 7534 variable region, against tetanus toxoid contain a large and diverse fraction Human of high-affinity promiscuous V(H) genes”, J. Mol. Biol. immunoglobulin 387 (3), 548-558 (2009), CNBI Accession # ACL36945.1 CTET57 Light chain Larrick, J. W.. “Therapeutic human antibodies derived 7535 variable region from PCR amplification of B-cell variable regions”, Immunol. Rev. 130, 69-85 (1992), CNBI Accession # AAB25319.1

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 36 against Bordetella pertussis and/or Bordetella parapertussis.

TABLE 36 Antibodies against Bordetella Pertussis and Bordetella Parapertussis SEQ Antibody Antibody ID No. Description Name Reference information NO BORT1 Heavy chain 42.1 1.D4 WO2014160098 SEQ ID NO: 47 7536 BORT2 Heavy chain 42.12.G2 WO2014160098 SEQ ID NO: 51 7537 BORT3 Heavy chain 42.12.A12 WO2014160098 SEQ ID NO: 55 7538 BORT4 Heavy chain 42.12.A9 WO2014160098 SEQ ID NO: 59 7539 BORT5 Heavy chain 42.18.E12 WO2014160098 SEQ ID NO: 63 7540 BORT6 Heavy chain 55.12.A8 WO2014160098 SEQ ID NO: 67 7541 BORT7 Heavy chain 55.15.H5 WO2014160098 SEQ ID NO: 71 7542 BORT8 Heavy chain 55.17.D8 WO2014160098 SEQ ID NO: 75 7543 BORT9 Heavy chain 55.22.E7 WO2014160098 SEQ ID NO: 79 7544 BORT10 Light chain 42,1 1.D4 WO2014160098 SEQ ID NO: 49 7545 BORT11 Light chain 42.12.G2 WO2014160098 SEQ ID NO: 53 7546 BORT12 Light chain 42.12.A12 WO2014160098 SEQ ID NO: 57 7547 BORT13 Light chain 42.12.A9 WO2014160098 SEQ ID NO: 61 7548 BORT14 Light chain 42.18.E12 WO2014160098 SEQ ID NO: 65 7549 BORT15 Light chain 55.12.A8 WO2014160098 SEQ ID NO: 69 7550 BORT16 Light chain 55.15.H5 WO2014160098 SEQ ID NO: 73 7551 BORT17 Light chain 55.17.D8 WO2014160098 SEQ ID NO: 77 7552 BORT18 Light chain 55.22.E7 WO2014160098 SEQ ID NO: 81 7553 BORT19 Single chain variable Hussein, A. H. et al. “Construction and 7554 fragment antibody type characterization of single-chain variable 1 a1, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13478.1 BORT20 Single chain variable Hussein, A. H. et al. “Construction and 7555 fragment antibody type characterization of single-chain variable 18 a18, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13483.1 BORT21 Single chain variable Hussein, A. H, el al. “Construction and 7556 fragment antibody type characterization of single-chain variable 2 a2, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13479.1 BORT22 Single chain variable Hussein, A. H. et al. “Construction and 7557 fragment antibody type characterization of single-chain variable 4 b4, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13480.1 BORT23 Single chain variable Hussein, A. H. et al. “Construction and 7558 fragment antibody type characterization of single-chain variable 5 c5, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13481.1 BORT24 Single chain variable Hussein, A. H. et al. “Construction and 7559 fragment antibody type characterization of single-chain variable 6 d6, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13482.1 BORT25 Single chain variable Hussein, A. H. et al. “Construction and 7560 fragment antibody type characterization of single-chain variable 7 e, single chain fragment antibodies directed against the variable region Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin” Infect. Immun. 75 (11), 5476-5482 (2007), NCBI Accession # ABB13484.1

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 37 against Mycobacteria

TABLE 37 Antibodies against Mycobacteria SEQ Antibody Antibody ID No, Description Name Reference Information NO MYCO1 Autod2 Single-chain variable Berger et al., Microbes Infect, 9 7561 fragment antibody, Tb antibody, anti- (8), 963-970 (2007), NCBI neutrophil cytoplasmic antibodies Accession # ABI81486.1 cross-react with mycobacterium avium subsp. Paratuberculosis antigens MYCO2 autoh1 single-chain variable fragment Berger et al., Microbes Infect. 9 7562 antibody, Tb antibody, anti-neutrophil (8), 963-970 (2007), NCBI cytoplasmic antibodies cross-react Accession # ABI81485.1 with mycobacterium avium subsp. Paratuberculosis antigens, MYCO3 Heavy chain constant region, moG2a/ US20130309237 SEQ ID NO: 7563 Mycobacteria moG2afull 10 MYCO4 Heavy chain constant region, hG1mG2a US20130309237 SEQ ID NO: 7564 Mycobacteria 11 MYCO5 Heavy chain constant region, hG3mG2a US20130309237 SEQ ID NO: 7565 Mycobacteria 12 MYCO6 Heavy chain constant region, huG1full US20130309237 SEQ ID NO: 7566 Mycobacteria 13 MYCO7 Heavy chain constant region, huG3full US20130309237 SEQ ID NO: 7567 Mycobacteria 14 MYCO8 Heavy chain variable region, 2F12 IgGs US20130309237 SEQ ID NO: 7568 Mycobacteria 15 MYCO9 Heavy chain variable region, 2F12 IgGs US20130309237 SEQ ID NO: 7569 Mycobacteria 18 MYCO10 Heavy chain variable region, partial 16a1 Al-sayyed et al., Tuberculosis 7570 sequence, Tb antibody, mouse (Edinb) 87 (6), 489-497 (2007), monoclonal mpt51 NCBI Accession # ABS20005.1 MYCO11 Light chain constant region, HuCK US20130309237 SEQ ID NO: 7571 Mycobacteria 16 MYCO12 Light chain variable region, MoCK US20130309237 SEQ ID NO: 7572 Mycobacteria 17 MYCO13 Light chain variable region, partial 16a1 Al-sayyed el al., Tuberculosis 7573 sequence, Tb antibody, mouse (Edinb) 87 (6), 489-497 (2007), monoclonal mpt51 NCBI Accession # ABS20006.1 MYC014 Scfv, Tb antibody, an engineered US20060229438 SEQ ID NO: 3 7574 single chain antibody MYC015 Scfv, Tb antibody, an engineered US20060229438 SEQ ID NO: 4 7575 single chain antibody MYC016 Scfv, Tb antibody, an engineered US20060229438 SEQ ID NO: 2 7576 single chain antibody

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 38 against Francisella tularensis.

TABLE 38 Antibodies against Francisella Tularensis SEQ Antibody Antibody ID No. Description Name Reference Information NO FRAN1 Chain H Ab-52 Rynkiewicz, M. J. et al., “Structural Analysis of a Protective 7577 Epitope of the Francisella tularensis O-Polysaccharide”, Biochemistry- 51 (28), 5684-5694 (2012), NCBI Accession # 3UJT_H FRAN2 Chain H N62 Lu, Z., et al., “The binding sites of monoclonal antibodies to 7578 the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide”, Immunology 140 (3), 374-389 (2013), NCBI Accession # 4KPH_H FRAN3 Chain H Ab64 Lu, Z. et al., “B-cell epitopes in GroEL of Francisella 7579 tularensis”, PLoS ONE 9 (6), E99847 (2014), NCBI Accession # 4PB9_H FRAN4 Chain H Ab53 Lu, Z, et al., “B-cell epitopes in GroEL of Francisella 7580 tularensis”, PLoS ONE 9 (6), E99847 (2014), NCBI Accession # 4PB0_H FRAN5 Chain H N203 Lu, Z. et al., “Functional and Structural Characterization of 7581 Francisella tularensis O-Antigen Antibodies at the Low End of Antigen Reactivity”, Monoclonal Antib Immunodiagn Immunother 33 (4), 235-245 (2014), NCBI Accession # 4OTX_H FRAN6 Chain I Ab-52 Rynkiewicz, M. J., et al., “Structural Analysis of a Protective 7582 Epitope of the Francisella tularensis O-Polysaccharide”, Biochemistry 51 (28), 5684-5694 (2012), NCBI Accession # 3UJT_I FRAN7 Chain I N62 Lu, Z., et al., “The binding sites of monoclonal antibodies to 7583 the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide”, Immunology 140 (3), 374-389 (2013), NCBI Accession # 4KPH_I FRAN8 Chain I N203 Lu, Z. et al., “Functional and Structural Characterization of 7584 Francisella tularensis O-Antigen Antibodies at the Low End of Antigen Reactivity”, Monoclonal Antib Immunodiagn Immunother 33 (4), 235-245 (2014), NCBI Accession # 4OTX_I FRAN9 Chain L Ab-52 Rynkiewicz, M. J., et al., “Structural Analysis of a Protective 7585 Epitope of the Francisella tularensis O-Polysaccharide”, Biochemistry 51 (28), 5684-5694 (2012), NCBI Accession # 3UJT_L FRAN10 Chain L N62 Lu, Z., et al., “The binding sites of monoclonal antibodies to 7586 the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide”, Immunology 140 (3), 374-389 (2013), NCBI Accession # 4KPH_L FRAN11 Chain L Ab64 Lu, Z. et al., “B-cell epitopes in GroEL of Francisella 7587 tularensis”, PLoS ONE 9 (6), E99847 (2014), NCBI Accession # 4PB9_L FRAN12 Chain L Ab53 Lu, Z. et al., “B-cell epitopes in GroEL of Francisella 7588 tularensis”, PLoS ONE 9 (6), E99847 (2014), NCBI Accession # 4PB0_L FRAN13 Chain L N203 Lu, Z, et al., “Functional and Structural Characterization of 7589 Francisella tularensis O-Antigen Antibodies at the Low End of Antigen Reactivity”, Monoclonal Antib Immunodiagn Immunother 33 (4), 235-245 (2014), NCBI Accession # 4OTX_L FRAN14 Chain M Ab-52 Rynkiewicz, M. J. et al., “Structural Analysis of a Protective 7590 Epitope of the Francisella tularensis O-Polysaccharide”, Biochemistry 51 (28), 5684-5694 (2012), NCBI Accession # 3UJT_M FRAN15 Chain M N62 Lu, Z., et al., “The binding sites of monoclonal antibodies to 7591 the non-reducing end of Francisella tularensis O-antigen accommodate mainly the terminal saccharide”, Immunology 140 (3), 374-389 (2013), NCBI Accession # 4KPH_M FRAN16 Chain M N203 Lu, Z, et al., “Functional and Structural Characterization of 7592 Francisella tularensis O-Antigen Antibodies at the Low End of Antigen Reactivity”, Monoclonal Antib Immunodiagn Immunother 33 (4), 235-245 (2014), NCBI Accession # 4OTX_M

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 39 against Bacteria.

TABLE 39 Antibodies against Bacteria SEQ Antibody ID No. Description Antibody Name Reference Information NO BACI1 Heavy chain variable US20080038266 SEQ ID NO: 1 7593 region, Enterococcus faecium, Enterococcus faecalis, Clostridium difficile BACI2 Heavy chain variable Naid60 US20060073139 SEQ ID NO: 5 7594 region, Neisseria meningitidis, BACI3 Heavy chain, Neisseria Fernandez de Cossio, M. E., et al. 7595 meningitidis, “Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis”, J. Infect. Dis. 166 (6), 1322-1328 (1992), AAB18935 BACI4 Heavy chain, Neisseria Fernandez de Cossio, M. E., et al. 7596 meningitidis, “Human monoclonal antibodies against an epitope on the class 5c outer membrane protein common to many pathogenic strains of Neisseria meningitidis”, J. Infect. Dis. 166 (6), 1322-1328 (1992), AAB18934 BACI5 Heavy chain, Septic Edobacomab, 7597 shock, meningococcal E5, XMMEN- septic shock 0E5 BACI6 Ig kappa chain V-I Goni, F. and Frangione, B., “Amino acid 7598 region WEA, sequence of the Fv region of a human Klebsiella bacteria monoclonal IgM (protein WEA) with antibody activity against 3,4-pyruvylated galactose in Klebsiella polysaccharides K30 and K33”, Proc. Natl. Acad. Sci. U.S.A. 80 (15), 4837-4841 (1983). P01610 BACI7 Ig kappa chain V-I Goni, F. and Frangione, B., “Amino acid 7599 region WEA, sequence of the Fv region of a human Klebsiella bacteria monoclonal IgM (protein WEA) with antibody activity against 3,4-pyruvylated galactose in Klebsiella polysaccharides K30 and K33”, Proc. Natl. Acad. Sci. U.S.A. 80 (15), 4837-4841 (1983), P01763 BACI8 Light chain variable US20080038266 SEQ ID NO: 16 7600 region, Enterococcus faecium, Enterococcus faecalis, Clostridium difficile BACI9 Light chain variable Naid60 US20060073139 SEQ ID NO: 6 7601 region, Neisseria meningitidis BACI10 Light chain, Septic Edobacomab, 7602 shock, meningococcal E5, XMMEN- septic shock, 0E5 BACI11 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7603 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ABI97022.1 BACI12 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7604 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ABI97023.1 BACI13 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7605 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ABI97021.1 BACI14 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7606 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ABI97018.1 BACI15 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7607 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ABI97024.1 BACI16 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7608 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ACZ65033.1 BACI17 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7609 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ACZ65032.1 BACI18 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7610 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ACZ65031.1 BACI19 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7611 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ACZ65030.1 BACI20 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain. Fv 7612 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ACZ65029.1 BACI21 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7613 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ACZ65028.1 BAC122 scFv antibody, Anti- Zou, N,, et al. “Human Single-Chain Fv 7614 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # AB197020.1 BACI23 scFv antibody, Anti- Zou, N., et al. “Human Single-Chain Fv 7615 Burkholderia mallei Antibodies against Burkholderia mallei and Burkholderia pseudomallei”, unpublished, NCBI Accession # ABI97019.1 BACI24 Single chain variable, CB515 LaRocca, T. J., et al. “Bactericidal action 7616 Borrelia, of a complement-independent relapsing fever Borrelia resides in its variable region”, J. Immunol. 180 (9), 6222-6228 (2008), NCBI Accession # ABV22509

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants encoding Doxorubicin, fragments or variants thereof for treating a disease and/or disorder or preventing a disease and/or disorder. As a non-limiting example, the disease and/or disorder is bacterial infection.

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 40 against Toxoplasma gondii.

TABLE 40 Antibodies against Toxoplasma gondii Antibody SEQ ID No. Description Antibody Name Reference Information NO TOXO1 4f11e12 Fab Heavy Chain Variable Graille, M. et al., J. Mol. Biol. 354 7617 Region, Surface antigen 1 (2), 447-458 (2005), NCBI Accession (SAG1) # 1YNT_D (218aa) TOXO2 4f11e12 Fab Light Chain Variable Graille, M. et al., J. Mol, Biol. 354 7618 Region, Surface antigen 1 (2), 447-458 (2005), NCBI Accession (SAG1) # 1YNT_C (213aa)

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 41 against Candida Yeast

TABLE 41 Antibodies against Candida Yeast Antibody SEQ ID No. Description Antibody Name NO CAND1 Efungumab Candida 7619

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences encoding one or more of the payload antibody polypeptides listed in Table 42.

TABLE 42 HIV Antibodies SEQ Antibody Antibody ID No. Description Name Reference Information NO HIV1 4e10 Antibody 4e10antibody NCBI Accession # 4OB5_H (127aa) 7620 Germline Precursor 7 Heavy Chain Fv HIV2 4e10 Antibody 4e10antibody NCBI Accession # 4OB5_L (114aa) 7621 Germline Precursor 7 Light Chain Fv HIV3 Antigen Binding Ch103 Liao et al., Co-evolution of a broadly 7622 Fragment Of Heavy neutralizing HIV-1 antibody and founder virus; Chain Nature 496 (7446), 469-476 (2013), NCBI Accession # 4JAM_H (226aa) HIV4 Antigen Binding Ch103 Liao et al., Co-evolution of a broadly 7623 Fragment Of Light neutralizing HIV-1 antibody and founder virus; Chain Nature 496 (7446), 469-476 (2013), NCBI Accession # 4JAM_L (209aa) HIV5 Fab Fragment, Heavy N12-i15 NCBI Accession # 3QEH_G (232aa) 7624 Chain HIV6 Fab Fragment, Light N12-i15 NCBI Accession # 3QEH_H (218aa) 7625 Chain HIV7 Fab Heavy Chain 35o22 Huang et al., Broad and potent HIV-1 7626 neutralization by a human antibody that binds the gp41-gp120 interface; Nature 515 (7525), 138-142 (2014), NCBI Accession # 4TOY_H (243 aa) HIV8 Fab Heavy Chain 8anc195 Scharf, L., et al., Cell Rep 7 (3), 785-795 7627 (2014), NCBI Accession # 4P9H_H (244aa) HIV9 Fab Heavy Chain B13 Chen L. et al., Science 326 (5956), 1123-1127 7628 (2009), NCBI Accession # 3IDY_B (231aa) HIV10 Fab Heavy Chain Ch58 Liao et al., vaccine Induction of Antibodies 7629 against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable region 1 and 2; Immunity 38 (1), 176-186 (2013), NCBI Accession # 4HQQ_H (231aa) HIV11 Fab Heavy Chain Ch59 Liao et al., vaccine Induction of Antibodies 7630 against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable region 1 and 2; Immunity 38 (1), 176-186 (2013), NCBI Accession # 4HPY_H (225aa) HIV12 Fab Heavy Chain E51 Huang C et al., Proc. Natl, Acad. Sci. U.S.A. 7631 101 (9), 2706-2711 (2004), NCBI Accession # 1RZF_H (235aa) HIV13 Fab Heavy Chain N26-i1 Fab NCBI Accession # 4FZE_H(232aa) 7632 HIV14 Fab Heavy Chain Pgt145 McLellan, J. S. et al., Structure of HIV-1 gp120 7633 V1 V2 domain with broadly neutralizing antibody PG9; Nature 480 (7377), 336-343 (2011), NCBI Accession # 3U1S_H (267aa) HIV15 Fab Heavy Chain Of A32 Fab NCBI Accession # 3TNM_A (231aa) 7634 Human Anti-hiv-1 Env Antibody A32 HIV16 Fab Heavy Chain Of C11 Fab NCBI Accession # 4FZ8_H (237aa) 7635 Human Anti-hiv-1 Env Antibody C11 HIV17 Fab Light Chain 35o22 Huang et al., Broad and potent HIV-1 7636 neutralization by a human antibody that binds the gp41-gp120 interface; Nature 515 (7525), 138-142 (2014), NCBI Accession # 4TOY_L (216aa) HIV18 Fab Light Chain 8anc195 Scharf, L., et al., Cell Rep 7 (3), 785-795 7637 (2014), NCBI Accession # 4P9H_L (215aa) HIV19 Fab Light Chain B13 Chen L. et al., Science 326 (5956), 1123-1127 7638 (2009), NCBI Accession # 3IDY_C (215aa) HIV20 Fab Light Chain Ch58 Liao et al., vaccine Induction of Antibodies 7639 against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable region 1 and 2; Immunity 38 (1), 176-186 (2013), NCBI Accession # 4HQQ_L (216aa) HIV21 Fab Light Chain Ch59 Liao et al., vaccine Induction of Antibodies 7640 against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable region 1 and 2; Immunity 38 (1), 176-186 (2013), NCBI Accession # 4HPY_L (215aa) HIV22 Fab Light Chain E51 Huang C et al., Proc. Natl. Acad. Sci. U.S.A. 7641 101 (9), 2706-2711 (2004), NCBI Accession # 1RZF_L (213aa) HIV23 Fab Light Chain Monoclonal Bartesaghi, A. et al., Perfusion structure of 7642 Antibody trimeric HIV-1 envelope glycoprotein Vrc03 determined by cryo-electron microscopy; Nat. Struct. Mol. Biol. 20 (12), 1352-1357 (2013), NCBI Accession # 4CC8_L (209aa) HIV24 Fab Light Chain N26-i1 Fab NCBI Accession# 4FZE_L (212aa) 7643 HIV25 Fab Light Chain Pgt145 McLellan, J. S. et al., Structure of HIV-1 gp120 7644 V1 V2 domain with broadly neutralizing antibody PG9; Nature 480 (7377), 336-343 (2011), NCBI Accession # 3U1S_L (239aa) HIV26 Fab Light Chain Of A32 Fab NCBI Accession # 3TNM_B (216aa) 7645 Human Anti-hiv-1 Env Antibody A32 HIV27 Fab Light Chain Of C11 Fab NCBI Accession # 4FZ8_L (218aa) 7646 Human Anti-hiv-1 Env Antibody C11 HIV28 Fab Region Of The Fab 2558 Gorny et al., PLoS ONE 6 (12), E27780 (2011), 7647 Heavy Chain NCBI Accession # 3UJI_H (223aa) HIV29 Fab Region Of The Fab 4025 Gorny et al., PLoS ONE 6 (12), E27780 (2011), 7648 Heavy Chain NCBI Accession # 3UJJ_H (230aa) HIV30 Fab, Heavy Chain 3bnc60 Scheid, J. F., et al,. Science 333 (6049), 1633- 7649 1637 (2011), NCBI Accession # 3RPI_A (229aa) HIV31 Fab, Heavy Chain 48d Huang C C et al., Proc. Natl. Acad. Sci. U.S.A. 7650 101 (9), 2706-2711 (2004), NCBI Accession # 1R27_H (219aa) HIV32 Fab, Heavy Chain 4e10Fab Bird et al., Nat. Struct. Mol. Biol. (2014), NCBI 7651 Accession # 4NGH_H (228aa) HIV33 Fab, Heavy Chain Ch58-ua Nicely et al. Ebiomedicine 2 (2015), NCBI 7652 Accession # 4RIS_H (230aa) HIV34 Fab, Heavy chain Mab 2909 Spurrier, B., et al., Structure 19 (5), 691-699 7653 (2011), NCBI Accession # 3Q6F_J (233aa) HIV35 Fab, Heavy Chain Monoclonal Bartesaghi, A. et al., Perfusion structure of 7654 Antibody trimeric HIV-1 envelope glycoprotein Vrc03 determined by cryo-electron microscopy; Nat. Struct. Mol. Biol. 20 (12), 1352-1357 (2013), NCBI Accession # 4CC8_I (233aa) HIV36 Fab, light chain 3bnc60 Scheid, J. F., et al., Science 333 (6049), 1633- 7655 1637 (2011), NCBI Accession # 3RPI_B (206aa) HIV37 Fab, Light Chain 48d Huang C C et al., Proc. Natl. Acad. Sci. U.S.A. 7656 101 (9), 2706-2711. (2004), NCBI Accession # 1RZ7_L (212aa) HIV38 Fab, Light Chain 4e10Fab Bird et al., Nat. Struct. Mol. Biol. (2014), NCBI 7657 Accession # 4NGH_L (215aa) HIV39 Fab, Light Chain Ch58-ua Nicely et al. Ebiomedicine 2 (2015), NCBI 7658 Accession # 4RIS_L (216aa) HIV40 Fab, light Chain Mab 2909 Spurrier, B., et al., Structure 19 (5), 691-699 7659 (2011), NCBI Accession # 3Q6F_K (213aa) HIV41 Gamma heavy chain 1443_C16 U.S. Pat. No. 9,051,362 SEQ ID NO: 12 7660 HIV42 Gamma heavy chain 1471 M23 U.S. Pat. No. 9,051,362 SEQ ID NO: 139 7661 HIV43 Gamma heavy chain 1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 59 7662 HIV44 Gamma heavy chain 1503_H05 U.S. Pat. No. 9,051,362 SEQ ID NO: 53 7663 HIV45 Gamma heavy chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 48 7664 variable region HIV46 Gamma heavy chain 1456_P20 U.S. Pat. No. 9,051,362 SEQ ID NO: 33 7665 variable region HIV47 Gamma heavy chain 1460_G14 U.S. Pat. No. 9,051,362 SEQ ID NO: 35 7666 variable region HIV48 Gamma heavy chain 1470_M23 U.S. Pat. No. 9,051,362 SEQ ID NO: 140 7667 variable region HIV49 Gamma heavy chain 1480_I08 U.S. Pat. No. 9,051,362 SEQ ID NO: 31 7668 variable region HIV50 Gamma heavy chain 1480_I08 U.S. Pat. No. 9,051,362 SEQ ID NO: 65 7669 variable region HIV51 Gamma heavy chain 1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 60 7670 variable region HIV52 Gamma heavy chain 1495_C14 U.S. Pat. No. 9,051,362 SEQ ID NO: 37 7671 variable region HIV53 Gamma heavy chain 1503_H05 U.S. Pat. No. 9,051,362 SEQ ID NO: 54 7672 variable region HIV54 Gamma heavy chain 1496_C09 U.S. Pat. No. 9,051,362 SEQ ID NO: 39 7673 variable region HIV55 Gamma heavy chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 47 7674 HIV56 Gamma heavy chain 1460_G14 U.S. Pat. No. 9,051,362 SEQ ID NO: 20 7675 HIV57 Gamma heavy chain 1495_C14 U.S. Pat. No. 9,051,362 SEQ ID NO: 24 7676 HIV58 Gamma heavy chain 1496_C09 U.S. Pat. No. 9,051,362 SEQ ID NO: 28 7677 HIV59 Gamma heavy 1456_P20 U.S. Pat. No. 9,051,362 SEQ ID NO: 16 7678 HIV60 Gp41-specific US20140348785 SEQ ID NO: 11 7679 antibody, heavy chain HIV61 Gp41-specific US20140348785 SEQ ID NO: 146 7680 antibody, heavy chain consensus HIV62 Gp41-specific US20140348785 SEQ ID NO: 187 7681 antibody, heavy chain consensus variable region HIV63 Gp41-specific US20140348785 SEQ ID NO: 188 7682 antibody, heavy chain consensus variable region HIV64 Gp41-specific US20140348785 SEQ ID NO: 153 7683 antibody, heavy chain variable region HIV65 Gp41-specific US20140348785 SEQ ID NO: 154 7684 antibody, heavy chain variable region HIV66 Gp41-specific US20140348785 SEQ ID NO: 155 7685 antibody, heavy chain variable region HIV67 Gp41-specific US20140348785 SEQ ID NO: 156 7686 antibody, heavy chain variable region HIV68 Gp41-specific US20140348785 SEQ ID NO: 157 7687 antibody, heavy chain variable region HIV69 Gp41-specific US20140348785 SEQ ID NO: 158 7688 antibody, heavy chain variable region HIV70 Gp41-specific US20140348785 SEQ ID NO: 159 7689 antibody, heavy chain variable region HIV71 Gp41-specific US20140348785 SEQ ID NO: 160 7690 antibody, heavy chain variable region HIV72 Gp41-specific US20140348785 SEQ ID NO: 161 7691 antibody, heavy chain variable region HIV73 Gp41-specific US20140348785 SEQ ID NO: 162 7692 antibody, heavy chain variable region HIV74 Gp41 -specific US20140348785 SEQ ID NO: 163 7693 antibody, heavy chain variable region HIV75 Gp41-specific US20140348785 SEQ ID NO: 189 7694 antibody, heavy chain variable region HIV76 Gp41-specific US20140348785 SEQ ID NO: 190 7695 antibody, heavy chain variable region HIV77 Gp41-specific US20140348785 SEQ ID NO: 191 7696 antibody, heavy chain variable region HIV78 Gp41-specific US20140348785 SEQ ID NO: 192 7697 antibody, heavy chain variable region HIV79 Gp41-specific US20140348785 SEQ ID NO: 200 7698 antibody, heavy chain variable region HIV80 Gp41-specific US20140348785 SEQ ID NO: 201 7699 antibody, heavy chain variable region HIV81 Gp41-specific US20140348785 SEQ ID NO: 202 7700 antibody, heavy chain variable region HIV82 Gp41-specific US20140348785 SEQ ID NO: 203 7701 antibody, heavy chain variable region HIV83 Gp41-specific US20140348785 SEQ ID NO: 204 7702 antibody, heavy chain variable region HIV84 Gp41-specific US20140348785 SEQ ID NO: 205 7703 antibody, heavy chain variable region HIV85 Gp41-specific US20140348785 SEQ ID NO: 206 7704 antibody, heavy chain variable region HIV86 Gp41-specific US20140348785 SEQ ID NO: 207 7705 antibody, heavy chain variable region HIV87 Gp41-specific US20140348785 SEQ ID NO: 208 7706 antibody, heavy chain variable region HIV88 Gp41-specific US20140348785 SEQ ID NO: 209 7707 antibody, heavy chain variable region HIV89 Gp41-specific US20140348785 SEQ ID NO: 12 7708 antibody, light chain variable region HIV90 Gp41-specific US20140348785 SEQ ID NO: 164 7709 antibody, light chain variable region HIV91 Gp41-specific US20140348785 SEQ ID NO: 165 7710 antibody, light chain variable region HIV92 Gp41-specific US20140348785 SEQ ID NO: 166 7711 antibody, light chain variable region HIV93 Gp41-specific US20140348785 SEQ ID NO: 167 7712 antibody, light chain variable region HIV94 Gp41-specific US20140348785 SEQ ID NO: 168 7713 antibody, light chain variable region HIV95 Gp41-specific US20140348785 SEQ ID NO: 169 7714 antibody, light chain variable region HIV96 Gp41-specific US20140348785 SEQ ID NO: 170 7715 antibody, light chain variable region HIV97 Gp41-specific US20140348785 SEQ ID NO: 171 7716 antibody, light chain variable region HIV98 Gp41-specific US20140348785 SEQ ID NO: 172 7717 antibody, light chain variable region HIV99 Gp41-specific US20140348785 SEQ ID NO: 173 7718 antibody, light chain variable region HIV100 Gp41-specific US20140348785 SEQ ID NO: 174 7719 antibody, light chain variable region HIV101 Gp41-specific US20140348785 SEQ ID NO: 175 7720 antibody, light chain variable region HIV102 Gp41-specific US20140348785 SEQ ID NO: 176 7721 antibody, light chain variable region HIV103 Gp41-specific US20140348785 SEQ ID NO: 177 7722 antibody, light chain variable region HIV104 Gp41-specific US20140348785 SEQ ID NO: 178 7723 antibody, light chain variable region HIV105 Gp41-specific US20140348785 SEQ ID NO: 179 7724 antibody, light chain variable region HIV106 Gp41-specific US20140348785 SEQ ID NO: 180 7725 antibody, light chain variable region HIV107 Gp41-specific US20140348785 SEQ ID NO: 181 7726 antibody, light chain variable region HIV108 Gp41-specific US20140348785 SEQ ID NO: 182 7727 antibody, light chain variable region HIV109 Gp41-specific US20140348785 SEQ ID NO: 183 7728 antibody, light chain variable region HIV110 Gp41-specific US20140348785 SEQ ID NO: 184 7729 antibody, light chain variable region HIV111 Gp41-specific US20140348785 SEQ ID NO: 185 7730 antibody, light chain variable region HIV112 Gp41-specific US20140348785 SEQ ID NO: 186 7731 antibody, light chain variable region HIV113 Gp41-specific US20140348785 SEQ ID NO: 197 7732 antibody, light chain variable region HIV114 Gp41-specific US20140348785 SEQ ID NO: 198 7733 antibody, light chain variable region HIV115 Gp41-specific US20140348785 SEQ ID NO: 199 7734 antibody, light chain variable region HIV116 Heavy chain Vrc06b Wu, X., et al., Maturation and Diversity of the 7735 VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNZ_E (234aa) HIV117 Heavy Chain 2424 Kumar, R., et al., Functional and Structural 7736 Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL; J. Virol. 89 (17), 9090-9102 (2015), NCBI Accession # 4XML_H(223aa) HIV118 Heavy chain 5827 US20140205607 Table S13 7737 HIV119 Heavy chain 7863 US20140205607 Table S13 7738 HIV120 Heavy Chain 8062 Gustchina, E., PLoS ONE 8 (11), E78187 7739 (2013), NCBI Accession # 4KHX_H(245aa) HIV121 Heavy chain 18761 US20140205607 Table S13 7740 HIV122 Heavy chain 19891 US20140205607 Table S13 7741 HIV123 Heavy chain 22425 US20140205607 Table S13 7742 HIV124 Heavy chain 28241 US20140205607 Table S13 7743 HIV125 Heavy chain 61272 US20140205607 Table S13 7744 HIV126 Heavy chain 61822 US20140205607 Table S13 7745 HIV127 Heavy chain 65030 US20140205607 Table S13 7746 HIV128 Heavy chain 70085 US20140205607 Table S13 7747 HIV129 Heavy chain 70542 US20140205607 Table S13 7748 HIV130 Heavy chain 80585 US20140205607 Table S13 7749 HIV131 Heavy chain 87722 US20140205607 Table S13 7750 HIV132 Heavy chain 96362 US20140205607 Table S13 7751 HIV133 Heavy chain 103787 US20140205607 Table S13 7752 HIV134 Heavy chain 146940 US20140205607 Table S13 7753 HIV135 Heavy chain 153849 US20140205607 Table S13 7754 HIV136 Heavy chain 1.00E+09 US20140348785 SEQ ID NO: 1 7755 HIV137 Heavy chain 104625_2 US20140205607 Table S14 7756 HIV138 Heavy chain 105239_4 US20140205607 Table S14 7757 HIV139 Heavy chain 10731_1 US20140205607 Table S14 7758 HIV140 Heavy Chain 10e8 Huang J et al., Nature 491 (7424), 406-412 7759 (monoclonal) (2012), NCBI Accession # 4G6F_B (236aa) HIV141 Heavy chain 120119_4 US20140205607 Table S14 7760 HIV142 Heavy chain 121325_4 US20140205607 Table S14 7761 HIV143 Heavy chain 12467_3 US20140205607 Table S14 7762 HIV144 Heavy chain 124918_2 US20140205607 Table S14 7763 HIV145 Heavy chain 127586_4 US20140205607 Table S14 7764 HIV146 Heavy chain 12A10HC US20140328862 SEQ ID NO: 147 7765 HIV147 Heavy chain 12A12HC US20140328862 SEQ ID NO: 148 7766 HIV148 Heavy chain 12A13HC US20140328862 SEQ ID NO: 149 7767 HIV149 Heavy chain 12A16HC US20140328862 SEQ ID NO: 150 7768 HIV150 Heavy chain 12A17HC US20140328862 SEQ ID NO: 151 7769 HIV151 Heavy chain 12A1HC US20140328862 SEQ ID NO: 152 7770 HIV152 Heavy chain 12A20HC US20140328862 SEQ ID NO: 153 7771 HIV153 Heavy Chain 12a21 NCBI Accession # 4JPW_H (225aa) 7772 HIV154 Heavy chain 12A21HC US20140328862 SEQ ID NO: 154 7773 HIV155 Heavy chain I2A22HC US20140328862 SEQ ID NO: 155 7774 HIV156 Heavy chain 12A23HC US20140328862 SEQ ID NO: 156 7775 HIV157 Heavy chain 12A27HC US20140328862 SEQ ID NO: 157 7776 HIV158 Heavy chain 12A2HC US20140328862 SEQ ID NO: 158 7777 HIV159 Heavy chain 12A30HC US20140328862 SEQ ID NO: 159 7778 HIV160 Heavy chain 12A37HC US20140328862 SEQ ID NO: 160 7779 HIV161 Heavy chain 12A46HC US20140328862 SEQ ID NO: 161 7780 HIV162 Heavy chain 12A4HC US20140328862 SEQ ID NO: 162 7781 HIV163 Heavy chain 12A55HC US20140328862 SEQ ID NO: 163 7782 HIV164 Heavy chain 12A56HC US20140328862 SEQ ID NO: 164 7783 HIV165 Heavy chain 12A6HC US20140328862 SEQ ID NO: 165 7784 HIV166 Heavy chain 12A7HC US20140328862 SEQ ID NO: 166 7785 HIV167 Heavy chain 12A9HC US20140328862 SEQ ID NO: 167 7786 HIV168 Heavy chain 132797_4 US20140205607 Table S14 7787 HIV169 Heavy chain 135083_3 US20140205607 Table S14 7788 HIV170 Heavy chain 13826_2 US20140205607 Table S14 7789 HIV171 Heavy chain 143251_3 US20140205607 Table S14 7790 HIV172 Heavy chain 149590_4 US20140205607 Table S14 7791 HIV173 Heavy chain 149768_4 US20140205607 Table S14 7792 HIV174 Heavy chain 151901_4 US20140205607 Table S14 7793 HIV175 Heavy chain 156858_3 US20140205607 Table S14 7794 HIV176 Heavy chain 164202_3 US20140205607 Table S14 7795 HIV177 Heavy chain 164922_3 US20140205607 Table S14 7796 HIV178 Heavy chain 165478_2 US20140205607 Table S14 7797 HIV179 Heavy chain 166726_3 US20140205607 Table S14 7798 HIV180 Heavy chain 167612_4 US20140205607 Table S14 7799 HIV181 Heavy chain 168509_2 US20140205607 Table S14 7800 HIV182 Heavy chain 169094_4 US20140205607 Table S14 7801 HIV183 Heavy chain 17720_4 US20140205607 Table S14 7802 HIV184 Heavy chain 178037_3 US20140205607 Table S14 7803 HIV185 Heavy chain 179400_4 US20140205607 Table S14 7804 HIV186 Heavy chain 179500_4 US20140205607 Table S14 7805 HIV187 Heavy chain 179888_3 US20140205607 Table S14 7806 HIV188 Heavy Chain 17b Kwong, P. D., et al., structure of an HIV gp120 7807 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody; Nature 393 (6686), 648-659 (1998), NCBI Accession# 1G9M_H (229aa) HIV189 Heavy chain 18278_1 US20140205607 Table S14 7808 HIV190 Heavy chain 184939_4 US20140205607 Table S14 7809 HIV191 Heavy chain 185961_4 US20140205607 Table S14 7810 HIV192 Heavy chain 186066_4 US20140205607 Table S14 7811 HIV193 Heavy chain 186275_2 US20140205607 Table S14 7812 HIV194 Heavy chain 186640_2 US20140205607 Table S14 7813 HIV195 Heavy chain 190244_4 US20140205607 Table S14 7814 HIV196 Heavy chain 193526_4 US20140205607 Table S14 7815 HIV197 Heavy chain 193896_4 US20140205607 Table S14 7816 HIV198 Heavy chain 195462_4 US20140205607 Table S14 7817 HIV199 Heavy chain 196147_4 US20140205607 Table S14 7818 HIV200 Heavy chain 196283_4 US20140205607 Table S14 7819 HIV201 Heavy Chain 1b2530 Zhou T el al., Structural Repertoire of HIV-1- 7820 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YFL_H (227aa) HIV202 Heavy chain 1F7 U.S. Pat. No. 6,057,421A FIG. 8 7821 HIV203 Heavy chain 1NC9 WO2012154312 SEQ ID NO: 2471 7822 HIV204 Heavy Chain 2.2C Acharya, P., et al., Structural Definition of an 7823 Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV- 1 Infection; J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4R4N_H (220aa) HIV205 Heavy chain 24972_4 US20140205607 Table S14 7824 HIV206 Heavy chain 28936_1 US20140205607 Table S14 7825 HIV207 Heavy chain 2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 5 7826 HIV208 Heavy chain 2F5 F100BW U.S. Pat. No. 8,637,036B2 SEQ ID NO: 7 7827 HIV209 Heavy chain 2F5 L100AW U.S. Pat. No. 8,637,036B2 SEQ ID NO: 6 7828 HIV210 Heavy chain 2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 9 7829 L100AW- V100DW HIV211 Heavy chain 2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 8 7830 V100DW HIV212 Heavy chain 30263_2 US20140205607 Table S14 7831 HIV213 Heavy chain 3040HC WO2015117008 SEQ ID NO: 14 7832 HIV214 Heavy chain 3044HC WO20S5117008 SEQ ID NO: 17 7833 HIV215 Heavy chain 31458_3 US20140205607 Table S14 7834 HIV216 Heavy chain 3430HC WO2015117008 SEQ ID NO: 15 7835 HIV217 Heavy chain 3484HC WO2015117008 SEQ ID NO: 16 7836 HIV218 Heavy chain 3630HC WO2015117008 SEQ ID NO: 18 7837 HIV219 Heavy chain 3A124HC US20140328862 SEQ ID NO: 261 7838 HIV220 Heavy chain 3A125HC US20140328862 SEQ ID NO: 262 7839 HIV221 Heavy chain 3A140HC US20140328862 SEQ ID NO: 263 7840 HIV222 Heavy chain 3A144HC US20140328862 SEQ ID NO: 264 7841 HIV223 Heavy chain 3A160HC US20140328862 SEQ ID NO: 265 7842 HIV224 Heavy chain 3A18HC US20140328862 SEQ ID NO: 266 7843 HIV225 Heavy chain 3A204HC US20140328862 SEQ ID NO: 267 7844 HIV226 Heavy chain 3A228HC US20140328862 SEQ ID NO: 268 7845 HIV227 Heavy chain 3A233HC US20140328862 SEQ ID NO: 269 7846 HIV228 Heavy chain 3A244HC US20140328862 SEQ ID NO: 270 7847 HIV229 Heavy chain 3A255HC US20140328862 SEQ ID NO: 271 7848 HIV230 Heavy chain 3A296HC US20140328862 SEQ ID NO: 272 7849 HIV231 Heavy chain 3A334HC US20140328862 SEQ ID NO: 273 7850 HIV232 Heavy chain 3A366HC US20140328862 SEQ ID NO: 274 7851 HIV233 Heavy chain 3A381HC US20140328862 SEQ ID NO: 275 7852 HIV234 Heavy chain 3A384HC US20140328862 SEQ ID NO: 276 7853 HIV235 Heavy chain 3A419HC US20140328862 SEQ ID NO: 277 7854 HIV236 Heavy chain 3a426hc US20140328862 SEQ ID NO: 343 7855 HIV237 Heavy chain 3A461HC US20140328862 SEQ ID NO: 278 7856 HIV238 Heavy chain 3A474HC US20140328862 SEQ ID NO: 279 7857 HIV239 Heavy chain 3a515hc US20140328862 SEQ ID NO: 344 7858 HIV240 Heavy chain 3A518HC US20140328862 SEQ ID NO: 280 7859 HIV241 Heavy chain 3A539HC US20140328862 SEQ ID NO: 281 7860 HIV242 Heavy chain 3A576HC US20140328862 SEQ ID NO: 282 7861 HIV243 Heavy chain 3A613HC US20140328862 SEQ ID NO: 283 7862 HIV244 Heavy chain 3A64HC US20140328862 SEQ ID NO: 284 7863 HIV245 Heavy chain 3A650HC US20140328862 SEQ ID NO: 285 7864 HIV246 Heavy chain 3A67HC US20140328862 SEQ ID NO: 286 7865 HIV247 Heavy chain 3A779HC US20140328862 SEQ ID NO: 287 7866 HIV248 Heavy chain 3A816HC US20140328862 SEQ ID NO: 288 7867 HIV249 Heavy chain 3A869HC US20140328862 SEQ ID NO: 289 7868 HIV250 Heavy chain 3A93HC US20140328862 SEQ ID NO: 290 7869 HIV251 Heavy chain 3A966HC US20140328862 SEQ ID NO: 291 7870 HIV252 Heavy chain 3A978HC US20140328862 SEQ ID NO: 292 7871 HIV253 Heavy chain 3ANC32HC US20140328862 SEQ ID NO: 346 7872 HIV254 Heavy chain 3ANC3HC US20140328862 SEQ ID NO: 293 7873 HIV255 Heavy chain 3ANC3HC US20140328862 SEQ ID NO: 347 7874 HIV256 Heavy chain 3ANC41HC US20140328862 SEQ ID NO: 348 7875 HIV257 Heavy chain 3ANC42HC US20140328862 SEQ ID NO: 294 7876 HIV258 Heavy chain 3ANC42HC US20140328862 SEQ ID NO: 349 7877 HIV259 Heavy chain 3ANC66HC US20140328862 SEQ ID NO: 295 7878 HIV260 Heavy chain 3ANC66HC US20140328862 SEQ ID NO: 350 7879 HIV261 Heavy chain 3ANC70HC US20140328862 SEQ ID NO: 351 7880 HIV262 Heavy chain 3ANC75HC US20140328862 SEQ ID NO: 352 7881 HIV263 Heavy chain 3ANC79HC US20140328862 SEQ ID NO: 296 7882 HIV264 Heavy chain 3ANC79HC US20140328862 SEQ ID NO: 353 7883 HIV265 Heavy chain 3ANC87HC US20140328862 SEQ ID NO: 354 7884 HIV266 Heavy chain 3ANC8HC US20140328862 SEQ ID NO: 355 7885 HIV267 Heavy chain 3ANC96HC US20140328862 SEQ ID NO: 356 7886 HIV268 Heavy chain 3B106HC US20140328862 SEQ ID NO: 357 7887 HIV269 Heavy chain 3B10HC US20140328862 SEQ ID NO: 297 7888 HIV270 Heavy chain 3B120HC US20140328862 SEQ ID NO: 298 7889 HIV271 Heavy chain 3B126HC US20140328862 SEQ ID NO: 299 7890 HIV272 Heavy chain 3B129HC US20140328862 SEQ ID NO: 300 7891 HIV273 Heavy chain 3B142HC US20140328862 SEQ ID NO: 301 7892 HIV274 Heavy chain 3B154HC US20140328862 SEQ ID NO: 302 7893 HIV275 Heavy chain 3B165HC US20140328862 SEQ ID NO: 303 7894 HIV276 Heavy chain 3B16HC US20140328862 SEQ ID NO: 358 7895 HIV277 Heavy chain 3B171HC US20140328862 SEQ ID NO: 304 7896 HIV278 Heavy chain 3B17HC US20140328862 SEQ ID NO: 305 7897 HIV279 Heavy chain 3B180HC US20140328862 SEQ ID NO: 359 7898 HIV280 Heavy chain 3B183HC US20140328862 SEQ ID NO: 360 7899 HIV281 Heavy chain 3B186HC US20140328862 SEQ ID NO: 306 7900 HIV282 Heavy chain 3B191HC US20140328862 SEQ ID NO: 361 7901 HIV283 Heavy chain 3B193HC US20140328862 SEQ ID NO: 307 7902 HIV284 Heavy chain 3B21HC US20140328862 SEQ ID NO: 362 7903 HIV285 Heavy chain 3B22HC US20140328862 SEQ ID NO: 308 7904 HIV286 Heavy chain 3B27HC US20140328862 SEQ ID NO: 309 7905 HIV287 Heavy chain 3B29HC US20140328862 SEQ ID NO: 310 7906 HIV288 Heavy chain 3B2HC US20140328862 SEQ ID NO: 311 7907 HIV289 Heavy chain 3B31HC US20140328862 SEQ ID NO: 312 7908 HIV290 Heavy chain 3B33HC US20140328862 SEQ ID NO: 313 7909 HIV291 Heavy chain 3B40HC US20140328862 SEQ ID NO: 314 7910 HIV292 Heavy chain 3B41HC US20140328862 SEQ ID NO: 315 7911 HIV293 Heavy chain 3B44HC US20140328862 SEQ ID NO: 316 7912 HIV294 Heavy chain 3B45HC US20140328862 SEQ ID NO: 317 7913 HIV295 Heavy chain 3b46HC US20140328862 SEQ ID NO: 345 7914 HIV296 Heavy chain 3B48HC US20140328862 SEQ ID NO: 318 7915 HIV297 Heavy chain 3B50HC US20140328862 SEQ ID NO: 319 7916 HIV298 Heavy chain 3B51HC US20140328862 SEQ ID NO: 320 7917 HIV299 Heavy chain 3B56HC US20140328862 SEQ ID NO: 321 7918 HIV300 Heavy chain 3B57HC US20140328862 SEQ ID NO: 322 7919 HIV301 Heavy chain 3B5HC US20140328862 SEQ ID NO: 323 7920 HIV302 Heavy chain 3B61HC US20140328862 SEQ ID NO: 324 7921 HIV303 Heavy chain 3B6HC US20140328862 SEQ ID NO: 325 7922 HIV304 Heavy chain 3B77HC US20140328862 SEQ ID NO: 326 7923 HIV305 Heavy chain 3B79HC US20140328862 SEQ ID NO: 327 7924 HIV306 Heavy chain 3B84HC US20140328862 SEQ ID NO: 328 7925 HIV307 Heavy chain 3B86HC US20140328862 SEQ ID NO: 329 7926 HIV308 Heavy chain 3B8HC US20140328862 SEQ ID NO: 330 7927 HIV309 Heavy chain 3B93HC US20140328862 SEQ ID NO: 331 7928 HIV310 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 363 7929 HIV311 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 364 7930 HIV312 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 365 7931 HIV313 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 366 7932 HIV314 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 367 7933 HIV315 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 368 7934 HIV316 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 369 7935 HIV317 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 370 7936 HIV318 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 371 7937 HIV319 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 372 7938 HIV320 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 373 7939 HIV321 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 374 7940 HIV322 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 375 7941 HIV323 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 376 7942 HIV324 Heavy chain 3BBM60 US20140328862 SEQ ID NO: 377 7943 HIV325 Heavy chain 3BNC101HC US20140328862 SEQ ID NO: 332 7944 HIV326 Heavy chain 3BNC101HC US20140328862 SEQ ID NO: 378 7945 HIV327 Heavy chain 3BNC102HC US20140328862 SEQ ID NO: 379 7946 HIV328 Heavy chain 3BNC104HC US20140328862 SEQ ID NO: 380 7947 HIV329 Heavy chain 3BNC105HC US20140328862 SEQ ID NO: 381 7948 HIV330 Heavy chain 3BNC106HC US20140328862 SEQ ID NO: 382 7949 HIV331 Heavy chain 3BNC107HC US20140328862 SEQ ID NO: 383 7950 HIV332 Heavy chain 3BNC108HC US20140328862 SEQ ID NO: 384 7951 HIV333 Heavy chain 3BNC10HC US20140328862 SEQ ID NO: 385 7952 HIV334 Heavy chain 3BNC114HC US20140328862 SEQ ID NO: 386 7953 HIV335 Heavy Chain 3bnc117 Zhou T et al., Immunity 39 (2), 245-258 (2013), 7954 NCBI Accession # 4LSV_H (226aa) HIV336 Heavy chain 3BNC117HC US20140328862 SEQ ID NO: 387 7955 HIV337 Heavy chain 3BNC124HC US20140328862 SEQ ID NO: 333 7956 HIV338 Heavy chain 3BNC126HC US20140328862 SEQ ID NO: 388 7957 HIV339 Heavy chain 3BNC127HC US20140328862 SEQ ID NO: 389 7958 HIV340 Heavy chain 3BNC130HC US20140328862 SEQ ID NO: 334 7959 HIV341 Heavy chain 3BNC134HC US20140328862 SEQ ID NO: 390 7960 HIV342 Heavy chain 3BNC140HC US20140328862 SEQ ID NO: 391 7961 HIV343 Heavy chain 3BNC141HC US20140328862 SEQ ID NO: 392 7962 HIV344 Heavy chain 3BNC142HC US20140328862 SEQ ID NO: 393 7963 HIV345 Heavy chain 3BNC148HC US20140328862 SEQ ID NO: 394 7964 HIV346 Heavy chain 3BNC149HC US20140328862 SEQ ID NO: 335 7965 HIV347 Heavy chain 3BNC149HC US20140328862 SEQ ID NO: 395 7966 HIV348 Heavy chain 3BNC151HC US20140328862 SEQ ID NO: 396 7967 HIV349 Heavy chain 3BNC153HC US20140328862 SEQ ID NO: 397 7968 HIV350 Heavy chain 3BNC156HC US20140328862 SEQ ID NO: 398 7969 HIV351 Heavy chain 3BNC158HC US20140328862 SEQ ID NO: 399 7970 HIV352 Heavy chain 3BNC159HC US20140328862 SEQ ID NO: 400 7971 HIV353 Heavy chain 3BNC15HC US20140328862 SEQ ID NO: 401 7972 HIV354 Heavy chain 3BNC173HC US20140328862 SEQ ID NO: 402 7973 HIV355 Heavy chain 3BNC175HC US20140328862 SEQ ID NO: 403 7974 HIV356 Heavy chain 3BNC176HC US20140328862 SEQ ID NO: 404 7975 HIV357 Heavy chain 3BNC177HC US20140328862 SEQ ID NO: 336 7976 HIV358 Heavy chain 3BNC17HC US20140328862 SEQ ID NO: 337 7977 HIV359 Heavy chain 3BNC181HC US20140328862 SEQ ID NO: 405 7978 HIV360 Heavy chain 3BNC186HC US20140328862 SEQ ID NO: 406 7979 HIV361 Heavy chain 3BNC18HC US20140328862 SEQ ID NO: 407 7980 HIV362 Heavy chain 3BNC193HC US20140328862 SEQ ID NO: 408 7981 HIV363 Heavy chain 3BNC196HC US20140328862 SEQ ID NO: 409 7982 HIV364 Heavy chain 3BNC20HC US20140328862 SEQ ID NO: 410 7983 HIV365 Heavy chain 3BNC29HC US20140328862 SEQ ID NO: 411 7984 HIV366 Heavy chain 3BNC31HC US20140328862 SEQ ID NO: 412 7985 HIV367 Heavy chain 3BNC33HC US20140328862 SEQ ID NO: 413 7986 HIV368 Heavy chain 3BNC42HC US20140328862 SEQ ID NO: 414 7987 HIV369 Heavy chain 3BNC44HC US20140328862 SEQ ID NO: 415 7988 HIV370 Heavy chain 3BNC45HC US20140328862 SEQ ID NO: 416 7989 HIV371 Heavy chain 3BNC48HC US20140328862 SEQ ID NO: 338 7990 HIV372 Heavy chain 3BNC53HC US20140328862 SEQ ID NO: 417 7991 HIV373 Heavy chain 3BNC54HC US20140328862 SEQ ID NO: 418 7992 HIV374 Heavy chain 3BNC55HC US20140328862 SEQ ID NO: 419 7993 HIV375 Heavy chain 3BNC58HC US20140328862 SEQ ID NO: 339 7994 HIV376 Heavy chain 3BNC59HC US20140328862 SEQ ID NO: 420 7995 HIV377 Heavy chain 3BNC60HC US20140328862 SEQ ID NO: 421 7996 HIV378 Heavy chain 3BNC62HC US20140328862 SEQ ID NO: 422 7997 HIV379 Heavy chain 3BNC64HC US20140328862 SEQ ID NO: 423 7998 HIV380 Heavy chain 3BNC65HC US20140328862 SEQ ID NO: 424 7999 HIV381 Heavy chain 3BNC66HC US20140328862 SEQ ID NO: 425 8000 HIV382 Heavy chain 3BNC6HC US20140328862 SEQ ID NO: 426 8001 HIV383 Heavy chain 3BNC72HC US20140328862 SEQ ID NO: 427 8002 HIV384 Heavy chain 3BNC75HC US20140328862 SEQ ID NO: 428 8003 HIV385 Heavy chain 3BNC78HC US20140328862 SEQ ID NO: 340 8004 HIV386 Heavy chain 3BNC79HC US20140328862 SEQ ID NO: 429 8005 HIV387 Heavy chain 3BNC81HC US20140328862 SEQ ID NO: 430 8006 HIV388 Heavy chain 3BNC82HC US20140328862 SEQ ID NO: 341 8007 HIV389 Heavy chain 3BNC84HC US20140328862 SEQ ID NO: 431 8008 HIV390 Heavy chain 3BNC86HC US20140328862 SEQ ID NO: 432 8009 HIV391 Heavy chain 3BNC87HC US20140328862 SEQ ID NO: 433 8010 HIV392 Heavy chain 3BNC89HC US20140328862 SEQ ID NO: 434 8011 HIV393 Heavy chain 3BNC8HC US20140328862 SEQ ID NO: 342 8012 HIV394 Heavy chain 3BNC91HC US20140328862 SEQ ID NO: 435 8013 HIV395 Heavy chain 3BNC92HC US20140328862 SEQ ID NO: 436 8014 HIV396 Heavy chain 3BNC94HC US20140328862 SEQ ID NO: 437 8015 HIV397 Heavy chain 3BNC95HC US20140328862 SEQ ID NO: 438 8016 HIV398 Heavy Chain 412d Huang et al., Science 317 (5846), 1930-1934 8017 (2007), NCBI Accession # 2QAD_H (231aa) HIV399 Heavy chain 43243_3 US20140205607 Table S14 8018 HIV400 Heavy chain 43359_2 US20140205607 Table S14 8019 HIV401 Heavy chain 43555_1 US20140205607 Table S14 8020 HIV402 Heavy chain 43567_2 US20140205607 Table S14 8021 HIV403 Heavy Chain 44-vrc13.01 Zhou T et al., Structural Repertoire of HIV-1- 8022 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDJ_A(238aa) HIV404 Heavy chain 45-46m2 Diskin, R., et al., Restricting HIV-1 pathways 8023 for escape using rationally designed anti-HIV-1 antibodies; J. Exp. Med. 210 (6), 1235-1249 (2013), NCBI Accession # 4JKP_H (229aa) HIV405 Heavy chain 46260_1 US20140205607 Table S14 8024 HIV406 Heavy chain 47890_1 US20140205607 Table S14 8025 HIV407 Heavy Chain 4e10 Fv Finton, K. A., et al., PLoS Pathol. 9 (9), 8026 E1003639 (2013), NCBI Accession # 4LLV_A (129aa) HIV408 Heavy chain 53821_1 US20140205607 Table S14 8027 HIV409 Heavy chain 57729_2 US20140205607 Table S14 8028 HIV410 Heavy chain 61048_1 US20140205607 Table S14 8029 HIV411 Heavy chain 69713_1 US20140205607 Table S14 8030 HIV412 Heavy chain 70679_1 US20140205607 Table S14 8031 HIV413 Heavy chain 71632_2 US20140205607 Table S14 8032 HIV414 Heavy chain 74400_3 US20140205607 Table S14 8033 HIV415 Heavy chain 74511_1 US20140205607 Table S14 8034 HIV416 Heavy chain 76927_2 US20140205607 Table S14 8035 HIV417 Heavy Chain 7b2 Santra, S., et al., PLoS Pathol. 11 (8), 8036 E1005042 (2015), NCBI Accession # 4YDV_H (252aa) HIV418 Heavy chain 7H6 US20140348785 SEQ ID NO: 3 8037 HIV419 Heavy chain 7N16 US20140348785 SEQ ID NO: 5 8038 HIV420 Heavy chain 8460_4 US20140205607 Table S14 8039 HIV421 Heavy chain 86277_2 US20140205607 Table S14 8040 HIV422 Heavy chain 86343_1 US20140205607 Table S14 8041 HIV423 Heavy chain 86984_2 US20140205607 Table S14 8042 HIV424 Heavy chain 89680_4 US20140205607 Table S14 8043 HIV425 Heavy chain 8A253HC US20140328862 SEQ ID NO: 5 8044 HIV426 Heavy chain 8A275HC US20140328862 SEQ ID NO: 6 8045 HIV427 Heavy chain 8ABM11 US20140328862 SEQ ID NO: 7 8046 HIV428 Heavy chain 8ABM12 US20140328862 SEQ ID NO: 8 8047 HIV429 Heavy chain 8ABM13 US20140328862 SEQ ID NO: 9 8048 HIV430 Heavy chain 8ABM14 US20140328862 SEQ ID NO: 10 8049 HIV431 Heavy chain 8ABM20 US20140328862 SEQ ID NO: 11 8050 HIV432 Heavy chain 8ABM24 US20140328862 SEQ ID NO: 12 8051 HIV433 Heavy chain 8ABM26 US20140328862 SEQ ID NO: 13 8052 HIV434 Heavy chain 8ABM27 US20140328862 SEQ ID NO: 14 8053 HIV435 Heavy chain 8ANC103HC US20140328862 SEQ ID NO: 36 8054 HIV436 Heavy chain 8ANC105HC US20140328862 SEQ ID NO: 15 8055 HIV437 Heavy chain 8ANC106HC US20140328862 SEQ ID NO: 37 8056 HIV438 Heavy chain 8ANC107HC US20140328862 SEQ ID NO: 38 8057 HIV439 Heavy chain 8ANC108HC US20140328862 SEQ ID NO: 39 8058 HIV440 Heavy chain 8ANC109HC US20140328862 SEQ ID NO: 40 8059 HIV441 Heavy chain 8ANC10HC US20140328862 SEQ ID NO: 41 8060 HIV442 Heavy chain 8ANC111HC US20140328862 SEQ ID NO: 42 8061 HIV443 Heavy chain 8ANC112HC US20140328862 SEQ ID NO: 43 8062 HIV444 Heavy chain 8ANC113HC US20140328862 SEQ ID NO: 44 8063 HIV445 Heavy chain 8ANC114HC US20140328862 SEQ ID NO: 45 8064 HIV446 Heavy chain 8ANC115HC US20140328862 SEQ ID NO: 46 8065 HIV447 Heavy chain 8ANC116HC US20140328862 SEQ ID NO: 16 8066 HIV448 Heavy chain 8ANC117HC US20140328862 SEQ ID NO: 47 8067 HIV449 Heavy chain 8ANC11HC US20140328862 SEQ ID NO: 48 8068 HIV450 Heavy chain 8ANC121HC US20140328862 SEQ ID NO: 49 8069 HIV451 Heavy chain 8ANC126HC US20140328862 SEQ ID NO: 50 8070 HIV452 Heavy chain 8ANC127HC US20140328862 SEQ ID NO: 17 8071 HIV453 Heavy chain 8ANC130HC US20140328862 SEQ ID NO: 51 8072 HIV454 Heavy Chain 8anc131 Zhou T et al., Structural Repertoire of HIV-1- 8073 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4RWY_H (227aa) HIV455 Heavy chain 8ANC131HC US20140328862 SEQ ID NO: 18 8074 HIV456 Heavy chain 8ANC132HC US20140328862 SEQ ID NO: 52 8075 HIV457 Heavy chain 8ANC133HC US20140328862 SEQ ID NO: 53 8076 HIV458 Heavy Chain 8anc134 Zhou T et al., Structural Repertoire of HIV-1- 8077 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4RX4_H (229aa) HIV459 Heavy chain 8ANC134HC US20140328862 SEQ ID NO: 19 8078 HIV460 Heavy chain 8ANC136HC US20140328862 SEQ ID NO: 54 8079 HIV461 Heavy chain 8ANC137HC US20140328862 SEQ ID NO: 55 8080 HIV462 Heavy chain 8ANC139HC US20140328862 SEQ ID NO: 56 8081 HIV463 Heavy chain 8ANC13HC US20140328862 SEQ ID NO: 20 8082 HIV464 Heavy chain 8ANC140HC US20140328862 SEQ ID NO: 57 8083 HIV465 Heavy chain 8ANC142HC US20140328862 SEQ ID NO: 58 8084 HIV466 Heavy chain 8ANC143HC US20140328862 SEQ ID NO: 59 8085 HIV467 Heavy chain 8ANC144HC US20140328862 SEQ ID NO: 60 8086 HIV468 Heavy chain 8ANC145HC US20140328862 SEQ ID NO: 61 8087 HIV469 Heavy chain 8ANC146HC US20140328862 SEQ ID NO: 62 8088 HIV470 Heavy chain 8ANC147HC US20140328862 SEQ ID NO: 63 8089 HIV471 Heavy chain 8ANC148HC US20140328862 SEQ ID NO: 64 8090 HIV472 Heavy chain 8ANC149HC US20140328862 SEQ ID NO: 65 8091 HIV473 Heavy chain 8ANC14HC US20140328862 SEQ ID NO: 66 8092 HIV474 Heavy chain 8ANC150HC US20140328862 SEQ ID NO: 67 8093 HIV475 Heavy chain 8ANC151HC US20140328862 SEQ ID NO: 68 8094 HIV476 Heavy chain 8ANC153HC US20140328862 SEQ ID NO: 69 8095 HIV477 Heavy chain 8ANC154HC US20140328862 SEQ ID NO: 70 8096 HIV478 Heavy chain 8ANC155HC US20140328862 SEQ ID NO: 71 8097 HIV479 Heavy chain 8ANC156HC US20140328862 SEQ ID NO: 72 8098 HIV480 Heavy chain 8ANC157HC US20140328862 SEQ ID NO: 73 8099 HIV481 Heavy chain 8ANC158HC US20140328862 SEQ ID NO: 74 8100 HIV482 Heavy chain 8ANC160HC US20140328862 SEQ ID NO: 75 8101 HIV483 Heavy chain 8ANC161HC US20140328862 SEQ ID NO: 76 8102 HIV484 Heavy chain 8ANC162HC US20140328862 SEQ ID NO: 77 8103 HIV485 Heavy chain 8ANC163HC US20140328862 SEQ ID NO: 78 8104 HIV486 Heavy chain 8ANC164HC US20140328862 SEQ ID NO: 79 8105 HIV487 Heavy chain 8ANC165HC US20140328862 SEQ ID NO: 80 8106 HIV488 Heavy chain 8ANC166HC US20140328862 SEQ ID NO: 81 8107 HIV489 Heavy chain 8ANC168HC US20140328862 SEQ ID NO: 82 8108 HIV490 Heavy chain 8ANC169HC US20140328862 SEQ ID NO: 83 8109 HIV491 Heavy chain 8ANC16HC US20140328862 SEQ ID NO: 84 8110 HIV492 Heavy chain 8ANC171HC US20140328862 SEQ ID NO: 21 8111 HIV493 Heavy chain 8ANC173HC US20140328862 SEQ ID NO: 85 8112 HIV494 Heavy chain 8ANC174HC US20140328862 SEQ ID NO: 86 8113 HIV495 Heavy chain 8ANC175HC US20140328862 SEQ ID NO: 87 8114 HIV496 Heavy chain 8ANC176HC US20140328862 SEQ ID NO: 88 8115 HIV497 Heavy chain 8ANC177HC US20140328862 SEQ ID NO: 89 8116 HIV498 Heavy chain 8ANC178HC US20140328862 SEQ ID NO: 90 8117 HIV499 Heavy chain 8ANC179HC US20140328862 SEQ ID NO: 91 8118 HIV500 Heavy chain 8ANC17HC US20140328862 SEQ ID NO: 92 8119 HIV501 Heavy chain 8ANC18 US20140328862 SEQ ID NO: 22 8120 HIV502 Heavy chain 8ANC180HC US20140328862 SEQ ID NO: 93 8121 HIV503 Heavy chain 8ANC181HC US20140328862 SEQ ID NO: 94 8122 HIV504 Heavy chain 8ANC182HC US20140328862 SEQ ID NO: 23 8123 HIV505 Heavy chain 8ANC184HC US20140328862 SEQ ID NO: 95 8124 HIV506 Heavy chain 8ANC185HC US20140328862 SEQ ID NO: 96 8125 HIV507 Heavy chain 8ANC186HC US20140328862 SEQ ID NO: 97 8126 HIV508 Heavy chain 8ANC187HC US20140328862 SEQ ID NO: 98 8127 HIV509 Heavy chain 8ANC188HC US20140328862 SEQ ID NO: 99 8128 HIV510 Heavy chain 8ANC191HC US20140328862 SEQ ID NO: 100 8129 HIV511 Heavy chain 8ANC192HC US20140328862 SEQ ID NO: 24 8130 HIV512 Heavy chain 8ANC193HC US20140328862 SEQ ID NO: 101 8131 HIV513 Heavy chain 8ANC194HC US20140328862 SEQ ID NO: 102 8132 HIV514 Heavy chain 8ANC195HC US20140328862 SEQ ID NO: 103 8133 HIV515 Heavy chain 8ANC196HC US20140328862 SEQ ID NO: 104 8134 HIV516 Heavy chain 8ANC20HC US20140328862 SEQ ID NO: 105 8135 HIV517 Heavy chain 8ANC21HC US20140328862 SEQ ID NO: 106 8136 HIV518 Heavy chain 8ANC22HC US20140328862 SEQ ID NO: 25 8137 HIV519 Heavy chain 8ANC24HC US20140328862 SEQ ID NO: 107 8138 HIV520 Heavy chain 8ANC25HC US20140328862 SEQ ID NO: 108 8139 HIV521 Heavy chain 8ANC26HC US20140328862 SEQ ID NO: 26 8140 HIV522 Heavy chain 8ANC27HC US20140328862 SEQ ID NO: 109 8141 HIV523 Heavy chain 8ANC2HC US20140328862 SEQ ID NO: 27 8142 HIV524 Heavy chain 8ANC30HC US20140328862 SEQ ID NO: 28 8143 HIV525 Heavy chain 8ANC31HC US20140328862 SEQ ID NO: 110 8144 HIV526 Heavy chain 8ANC33HC US20140328862 SEQ ID NO: 111 8145 HIV527 Heavy chain 8ANC34HC US20140328862 SEQ ID NO: 112 8146 HIV528 Heavy chain 8ANC36HC US20140328862 SEQ ID NO: 113 8147 HIV529 Heavy chain 8ANC37HC US20140328862 SEQ ID NO: 29 8148 HIV530 Heavy chain 8ANC38HC US20140328862 SEQ ID NO: 114 8149 HIV531 Heavy chain 8ANC39HC US20140328862 SEQ ID NO: 115 8150 HIV532 Heavy chain 8ANC3HC US20140328862 SEQ ID NO: 116 8151 HIV533 Heavy chain 8ANC40HC US20140328862 SEQ ID NO: 30 8152 HIV534 Heavy chain 8ANC41HC US20140328862 SEQ ID NO: 31 8153 HIV535 Heavy chain 8ANC43HC US20140328862 SEQ ID NO: 117 8154 HIV536 Heavy chain 8ANC45HC US20140328862 SEQ ID NO: 32 8155 HIV537 Heavy chain 8ANC46HC US20140328862 SEQ ID NO: 118 8156 HIV538 Heavy chain 8ANC48HC US20140328862 SEQ ID NO: 119 8157 HIV539 Heavy chain 8ANC49HC US20140328862 SEQ ID NO: 120 8158 HIV540 Heavy chain 8ANC50HC US20140328862 SEQ ID NO: 33 8159 HIV541 Heavy chain 8ANC51HC US20140328862 SEQ ID NO: 121 8160 HIV542 Heavy chain 8ANC53HC US20140328862 SEQ ID NO: 34 8161 HIV543 Heavy chain 8ANC57HC US20140328862 SEQ ID NO: 122 8162 HIV544 Heavy chain 8ANC58HC US20140328862 SEQ ID NO: 123 8163 HIV545 Heavy chain 8ANC5HC US20140328862 SEQ ID NO: 124 8164 HIV546 Heavy chain 8ANC60HC US20140328862 SEQ ID NO: 125 8165 HIV547 Heavy chain 8ANC63HC US20140328862 SEQ ID NO: 126 8166 HIV548 Heavy chain 8ANC65HC US20140328862 SEQ ID NO: 127 8167 HIV549 Heavy chain 8ANC67HC US20140328862 SEQ ID NO: 128 8168 HIV550 Heavy chain 8ANC69HC US20140328862 SEQ ID NO: 129 8169 HIV551 Heavy chain 8ANC6HC US20140328862 SEQ ID NO: 130 8170 HIV552 Heavy chain 8ANC70HC US20140328862 SEQ ID NO: 131 8171 HIV553 Heavy chain 8ANC71HC US20140328862 SEQ ID NO: 132 8172 HIV554 Heavy chain 8ANC72HC US20140328862 SEQ ID NO: 133 8173 HIV555 Heavy chain 8ANC74HC US20140328862 SEQ ID NO: 134 8174 HIV556 Heavy chain 8ANC75HC US20140328862 SEQ ID NO: 135 8175 HIV557 Heavy chain 8ANC76HC US20140328862 SEQ ID NO: 136 8176 HIV558 Heavy chain 8ANC78HC US20140328862 SEQ ID NO: 137 8177 HIV559 Heavy chain 8ANC79HC US20140328862 SEQ ID NO: 138 8178 HIV560 Heavy chain 8ANC7HC US20140328862 SEQ ID NO: 139 8179 HIV561 Heavy chain 8ANC80HC US20140328862 SEQ ID NO: 140 8180 HIV562 Heavy chain 8ANC82HC US20140328862 SEQ ID NO: 141 8181 HIV563 Heavy chain 8ANC83HC US20140328862 SEQ ID NO: 142 8182 HIV564 Heavy chain 8ANC88HC US20140328862 SEQ ID NO: 35 8183 HIV565 Heavy chain 8ANC91HC US20140328862 SEQ ID NO: 143 8184 HIV566 Heavy chain 8ANC92HC US20140328862 SEQ ID NO: 144 8185 HIV567 Heavy chain 8ANC93HC US20140328862 SEQ ID NO: 145 8186 HIV568 Heavy chain 8ANC9HC US20140328862 SEQ ID NO: 146 8187 HIV569 Heavy chain 94565_1 US20140205607 Table S14 8188 HIV570 Heavy chain 95589_2 US20140205607 Table S14 8189 HIV571 Heavy chain 96298_1 US20140205607 Table S14 8190 HIV572 Heavy chain 9815_2 US20140205607 Table S14 8191 HIV573 Heavy chain 99473_3 US20140205607 Table S14 8192 HIV574 Heavy chain 99989_1 US20140205607 Table S14 8193 HIV575 Heavy chain Antibody US20140328862 SEQ ID NO: 439 8194 HIV576 Heavy chain Anti-HcG Fotinou C. et al “Structure of an Fab fragment 8195 against a C-terminal peptide of hCG at 2.0 A resolution” J. Biol. Chem. 273 (35), 22515- 22518 (1998); NCBI Accession # 1SBS_H HIV577 Heavy Chain B12 Zhou T et al., Structural definition of a 8196 conserved neutralization epitope on HIV-1 gp120; Nature 445 (7129), 732-737 (2007), NCBI Accession # 2NY7_H (230aa) HIV578 Heavy Chain C38-vrc16.01 Zhou T et al., Structural Repertoire of HIV-1- 8197 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDK_H (234aa) HIV579 Heavy Chain C38-vrc18.02 Zhou T et al., Structural Repertoire of HIV-1- 8198 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDL_H (226aa) HIV580 Heavy chain CAP256- WO2015128846 SEQ ID NO: 13 8199 VRC26.01 HIV581 Heavy chain CAP256- WO2015128846 SEQ ID NO: 17 8200 VRC26.02 HIV582 Heavy chain CAP256- WO2015128846 SEQ ID NO: 21 8201 VRC26.03 HIV583 Heavy chain CAP256- WO2015128846 SEQ ID NO: 25 8202 VRC26.04 HIV584 Heavy chain CAP256- WO2015128846 SEQ ID NO: 29 8203 VRC26.05 HIV585 Heavy chain CAP256- WO2015128846 SEQ ID NO: 33 8204 VRC26.06 HIV586 Heavy chain CAP256- WO2015128846 SEQ ID NO: 37 8205 VRC26.07 HIV587 Heavy chain CAP256- WO2015128846 SEQ ID NO: 41 8206 VRC26.08 HIV588 Heavy chain CAP256- WO2015128846 SEQ ID NO: 45 8207 VRC26.09 HIV589 Heavy chain CAP256- WO2015128846 SEQ ID NO: 49 8208 VRC26.10 HIV590 Heavy chain CAP256- WO2015128846 SEQ ID NO: 53 8209 VRC26.11 HIV591 Heavy chain CAP256- WO2015128846 SEQ ID NO: 57 8210 VRC26.12 HIV592 Heavy chain CAP256- WO2015128846 SEQ ID NO: 170 8211 VRC26.25 HIV593 Heavy chain CAP256- WO2015128846 SEQ ID NO: 178 8212 VRC26.26 HIV594 Heavy chain CAP256- WO2015128846 SEQ ID NO: 186 8213 VRC26.27 HIV595 Heavy chain CAP256- WO2015128846 SEQ ID NO: 5 8214 VRC26-I1 HIV596 Heavy chain CAP256- WO2015128846 SEQ ID NO: 9 8215 VRC26-I2. HIV597 Heavy chain CAP256- WO2015128846 SEQ ID NO: 1 8216 VRC26- UCA. HIV598 Heavy chain construct WO2015013390 SEQ ID NO: 3 8217 #2816, #2859 HIV599 Heavy chain construct WO2015013390 SEQ ID NO: 4 8218 #2817 HIV600 Heavy chain construct WO2015013390 SEQ ID NO: 8 8219 #2858, #2860 HIV601 Heavy Chain Fab 2219 Stanfield, R. L., et al., J. Virol. 80 (12), 6093- 8220 6105 (2006), NCBI Accession # 2B0S_H (226aa) HIV602 Heavy Chain Fab 2g12 Doores. K. J., et al., J. Virol. 84 (20), 10690- 8221 10699 (2010), NCBI Accession # 3OAU_H (225aa) HIV603 Heavy Chain Fab 2g12 Stanfield, R. L. et al., Crystal structure of the 8222 HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose; Glycobiology 25 (4), 412-419 (2015), NCBI Accession # 4RBP_H (224aa) HIV604 Heavy Chain Fab F425- Bell et al., J. Mol. Biol. 375 (4), 969-978 8223 b4e8 (2008), NCBI Accession # 2QSC_H (222aa) HIV605 Heavy chain fusion protein US20080038280 SEQ ID NO: 5 8224 of A32 and m9 HIV606 Heavy chain g20 WO2015117008 SEQ ID NO: 4 8225 HIV607 Heavy chain g22 WO2015117008 SEQ ID NO: 7 8226 HIV608 Heavy chain g23 WO2015117008 SEQ ID NO: 2 8227 HIV609 Heavy chain g3 WO2015117008 SEQ ID NO: 13 8228 HIV610 Heavy chain g4 WO2015117008 SEQ ID NO: 9 8229 HIV611 Heavy chain g44 WO2015117008 SEQ ID NO: 11 8230 HIV612 Heavy chain g46 WO2015117008 SEQ ID NO: 10 8231 HIV613 Heavy chain G4D US20130195881 SEQ ID NO: 9 8232 HIV614 Heavy chain G4H US20130195881 SEQ ID NO: 8 8233 HIV615 Heavy chain g50 WO2015117008 SEQ ID NO: 12 8234 HIV616 Heavy chain g52 WO2015117008 SEQ ID NO: 1 8235 HIV617 Heavy chain g59 WO2015117008 SEQ ID NO: 5 8236 HIV618 Heavy chain g62 WO2015117008 SEQ ID NO: 6 8237 HIV619 Heavy chain g8 WO2015117008 SEQ ID NO: 3 8238 HIV620 Heavy chain gl5 WO2015117008 SEQ ID NO: 8 8239 HIV621 Heavy chain gVRC- WO2013090644 SEQ ID NO: 45 8240 H5(d74)/VR C-PG04LC HIV622 Heavy chain gVRCOH12(D74)/ WO2013090644 SEQ ID NO: 46 8241 VRC- PG04LC HIV623 Heavy Chain I2 (unbound) Fera, D. et al., Affinity maturation in an HIV 8242 From Ch103 broadly neutralizing B-cell lineage through Lineage reorientation of variable domains; Proc. Natl. Acad. Sci. U.S.A. 111 (28), 10275-10280 (2014), NCBI Accession # 4QHN_A (232aa) HIV624 Heavy chain IGHV3- US20140348785 SEQ ID NO: 7 8243 15*05 HIV625 Heavy chain LSSB2055HC US20140328862 SEQ ID NO: 229 8244 HIV626 Heavy chain LSSB2066HC US20140328862 SEQ ID NO: 230 8245 HIV627 Heavy chain LSSB2068HC US20140328862 SEQ ID NO: 231 8246 HIV628 Heavy chain LSSB2080HC US20140328862 SEQ ID NO: 232 8247 HIV629 Heavy chain LSSB2133HC US20140328862 SEQ ID NO: 233 8248 HIV630 Heavy chain LSSB2182HC US20140328862 SEQ ID NO: 234 8249 HIV631 Heavy chain LSSB218HC US20140328862 SEQ ID NO: 235 8250 HIV632 Heavy chain LSSB2277HC US20140328862 SEQ ID NO: 236 8251 HIV633 Heavy chain LSSB2288HC US20140328862 SEQ ID NO: 237 8252 HIV634 Heavy chain LSSB2339HC US20140328862 SEQ ID NO: 168 8253 HIV635 Heavy chain LSSB2351HC US20140328862 SEQ ID NO: 169 8254 HIV636 Heavy chain LSSB2361HC US20140328862 SEQ ID NO: 170 8255 HIV637 Heavy chain LSSB2364HC US20140328862 SEQ ID NO: 171 8256 HIV638 Heavy chain LSSB2367HC US20140328862 SEQ ID NO: 172 8257 HIV639 Heavy chain LSSB2416HC US20140328862 SEQ ID NO: 173 8258 HIV640 Heavy chain LSSB2434HC US20140328862 SEQ ID NO: 174 8259 HIV641 Heavy chain LSSB2483HC US20140328862 SEQ ID NO: 175 8260 HIV642 Heavy chain LSSB2490HC US20140328862 SEQ ID NO: 176 8261 HIV643 Heavy chain LSSB2503HC US20140328862 SEQ ID NO: 177 8262 HIV644 Heavy chain LSSB2525HC US20140328862 SEQ ID NO: 178 8263 HIV645 Heavy chain LSSB2530HC US20140328862 SEQ ID NO: 179 8264 HIV646 Heavy chain LSSB2538HC US20140328862 SEQ ID NO: 180 8265 HIV647 Heavy chain LSSB2554HC US20140328862 SEQ ID NO: 181 8266 HIV648 Heavy chain LSSB2573HC US20140328862 SEQ ID NO: 182 8267 HIV649 Heavy chain LSSB2578HC US20140328862 SEQ ID NO: 183 8268 HIV650 Heavy chain LSSB2586HC US20140328862 SEQ ID NO: 184 8269 HIV651 Heavy chain LSSB2609HC US20140328862 SEQ ID NO: 185 8270 HIV652 Heavy chain LSSB2612HC US20140328862 SEQ ID NO: 186 8271 HIV653 Heavy chain LSSB2630HC US20140328862 SEQ ID NO: 187 8272 HIV654 Heavy chain LSSB2640HC US20S40328862 SEQ ID NO: 188 8273 HIV655 Heavy chain LSSB2644HC US20140328862 SEQ ID NO: 189 8274 HIV656 Heavy chain LSSB2665HC US20S40328862 SEQ ID NO: 190 8275 HIV657 Heavy chain LSSB2666HC US20140328862 SEQ ID NO: 191 8276 HIV658 Heavy chain LSSB2669HC US20S40328862 SEQ ID NO: 192 8277 HIV659 Heavy chain LSSB2680HC US20140328862 SEQ ID NO: 193 8278 HIV660 Heavy chain LSSB2683HC US20S40328862 SEQ ID NO: 194 8279 HIV661 Heavy chain LSSB331HC US20140328862 SEQ ID NO: 238 8280 HIV662 Heavy chain LSSB344HC US20140328862 SEQ ID NO: 195 8281 HIV663 Heavy chain LSSNEC101HC US20140328862 SEQ ID NO: 239 8282 HIV664 Heavy chain LSSNEC106HC US20140328862 SEQ ID NO: 240 8283 HIV665 Heavy chain LSSNEC107HC US20140328862 SEQ ID NO: 196 8284 HIV666 Heavy chain LSSNEC108HC US20140328862 SEQ ID NO: 197 8285 HIV667 Heavy chain LSSNEC109HC US20140328862 SEQ ID NO: 198 8286 HIV668 Heavy chain LSSNEC110HC US20140328862 SEQ ID NO: 199 8287 HIV669 Heavy chain LSSNEC112HC US20140328862 SEQ ID NO: 241 8288 HIV670 Heavy chain LSSNEC115HC US20140328862 SEQ ID NO: 242 8289 HIV671 Heavy chain LSSNEC116HC US20140328862 SEQ ID NO: 200 8290 HIV672 Heavy chain LSSNEC117HC US20140328862 SEQ ID NO: 201 8291 HIV673 Heavy chain LSSNEC118HC US20140328862 SEQ ID NO: 202 8292 HIV674 Heavy chain LSSNEC11HC US20140328862 SEQ ID NO: 203 8293 HIV675 Heavy chain LSSNEC122HC US20140328862 SEQ ID NO: 204 8294 HIV676 Heavy chain LSSNEC123HC US20140328862 SEQ ID NO: 205 8295 HIV677 Heavy chain LSSNEC124HC US20140328862 SEQ ID NO: 243 8296 HIV678 Heavy chain LSSNEC125HC US20140328862 SEQ ID NO: 244 8297 HIV679 Heavy chain LSSNEC126HC US20140328862 SEQ ID NO: 245 8298 HIV680 Heavy chain LSSNEC127HC US20140328862 SEQ ID NO: 206 8299 HIV681 Heavy chain LSSNEC14HC US20140328862 SEQ ID NO: 246 8300 HIV682 Heavy chain LSSNEC16HC US20140328862 SEQ ID NO: 247 8301 HIV683 Heavy chain LSSNEC18HC US20140328862 SEQ ID NO: 207 8302 HIV684 Heavy chain LSSNEC21HC US20140328862 SEQ ID NO: 248 8303 HIV685 Heavy chain LSSNEC24HC US20140328862 SEQ ID NO: 208 8304 HIV686 Heavy chain LSSNEC29HC US20140328862 SEQ ID NO: 209 8305 HIV687 Heavy chain LSSNEC2HC US20140328862 SEQ ID NO: 210 8306 HIV688 Heavy chain LSSNEC30HC US20140328862 SEQ ID NO: 249 8307 HIV689 Heavy chain LSSNEC33HC US20140328862 SEQ ID NO: 211 8308 HIV690 Heavy chain LSSNEC34HC US20140328862 SEQ ID NO: 212 8309 HIV691 Heavy chain LSSNEC3HC US20140328862 SEQ ID NO: 213 8310 HIV692 Heavy chain LSSNEC46HC US20140328862 SEQ ID NO: 214 8311 HIV693 Heavy chain LSSNEC48HC US20140328862 SEQ ID NO: 215 8312 HIV694 Heavy chain LSSNEC49HC US20140328862 SEQ ID NO: 250 8313 HIV695 Heavy chain LSSNEC52HC US20140328862 SEQ ID NO: 216 8314 HIV696 Heavy chain LSSNEC54HC US20140328862 SEQ ID NO: 251 8315 HIV697 Heavy chain LSSNEC55HC US20140328862 SEQ ID NO: 252 8316 HIV698 Heavy chain LSSNEC56HC US20140328862 SEQ ID NO: 217 8317 HIV699 Heavy chain LSSNEC57HC US20140328862 SEQ ID NO: 253 8318 HIV700 Heavy chain LSSNEC5HC US20140328862 SEQ ID NO: 254 8319 HIV701 Heavy chain LSSNEC60HC US20140328862 SEQ ID NO: 218 8320 HIV702 Heavy chain LSSNEC66HC US20140328862 SEQ ID NO: 219 8321 HIV703 Heavy chain LSSNEC67HC US20140328862 SEQ ID NO: 255 8322 HIV704 Heavy chain LSSNEC70HC US20140328862 SEQ ID NO: 220 8323 HIV705 Heavy chain LSSNEC72HC US20140328862 SEQ ID NO: 221 8324 HIV706 Heavy chain LSSNEC74HC US20140328862 SEQ ID NO: 256 8325 HIV707 Heavy chain LSSNEC77HC US20140328862 SEQ ID NO: 257 8326 HIV708 Heavy chain LSSNEC7HC US20140328862 SEQ ID NO: 222 8327 HIV709 Heavy chain LSSNEC82HC US20140328862 SEQ ID NO: 223 8328 HIV710 Heavy chain LSSNEC85HC US20140328862 SEQ ID NO: 258 8329 HIV711 Heavy chain LSSNEC89HC US20140328862 SEQ ID NO: 224 8330 HIV712 Heavy chain LSSNEC8HC US20140328862 SEQ ID NO: 225 8331 HIV713 Heavy chain LSSNEC91HC US20140328862 SEQ ID NO: 259 8332 HIV714 Heavy chain LSSNEC92HC US20140328862 SEQ ID NO: 260 8333 HIV715 Heavy chain LSSNEC94HC US20140328862 SEQ ID NO: 226 8334 HIV716 Heavy chain LSSNEC95HC US20140328862 SEQ ID NO: 227 8335 HIV717 Heavy chain LSSNEC9HC US20140328862 SEQ ID NO: 228 8336 HIV718 Heavy chain m12_Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 3 8337 HIV719 Heavy chain m14-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 1 8338 HIV720 Heavy chain m16-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 4 8339 HIV721 Heavy chain m18 Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 2 8340 HIV722 Heavy Chain M66 Ofek, G., et al., Structural Basis for HIV-1 8341 Neutralization by 2F5-Like Antibodies m66 and m66.6; J. Virol. 88 (5), 2426-2441 (2014), NCBI Accession # 4NRY_L (220aa) HIV723 Heavy Chain M66.6 Ofek, G., et al., Structural Basis for HIV-1 8342 Neutralization by 2F5-Like Antibodies m66 and m66.6; J. Virol. 88 (5), 2426-2441 (2014), NCBI Accession # 4NRZ_H (234aa) HIV724 Heavy Chain Mab 2158 Spurrier, B., et al., Functional Implications of 8343 the Binding Mode of a Human Conformation- Dependent V2 Monoclonal Antibody against HIV; J. Virol, 88 (8), 4100-4112 (2014), NCBI Accession # 4OAW_D (236aa) HIV725 Heavy chain MV1 US20130195881 SEQ ID NO: 10 8344 HIV726 Heavy Chain Pg16 Fab Pancera, M., et al., Nat. Struct. Mol. Biol. 20 8345 (7), 804-813 (2013), NCBI Accession # 4DQO_H (246aa) HIV727 Heavy Chain Pg9 Willis, J. R., et al., J. Clin. Invest. 125 (6), 2523- 8346 2531 (2015), NCBI Accession # 4YAQ_H(248aa) HIV728 Heavy Chain Pgt121-Gl Mouquet H et al., Complex-type N-glycan 8347 Fab recognition by potent broadly neutralizing HIV antibodies; Proc Natl Acad Sci USA. 2012 Nov. 20; 109(47): E3268-77, NCBI Accession # 4FQQ_B (244aa) HIV729 Heavy Chain Pgt122 Julien, J. P., et al., PLoS Pathol. 9 (5), 8348 E1003342 (2013), NCBI Accession # 4JY5_H (235aa) HIV730 Heavy Chain Pgt123 Julien, J. P., et al., PLoS Pathol. 9 (5), 8349 E1003342 (2013), NCBI Accession # 4JY6_B (235aa) HIV731 Heavy Chain Pgt124 Garces, F., et al., Structural Evolution of 8350 Glycan Recognition by a Family of Potent HIV Antibodies; Cell 159 (1), 69-79 (2014), NCBI Accession # 4R26_H (236aa) HIV732 Heavy Chain Pgt130 Doores, K. J., et al., J. Virol. 89 (2), 1105-1118 8351 (2015), NCBI Accession # 4RNR_A (233aa) HIV733 Heavy Chain Pgt135 Grover et al., Science 343 (6171), 656-661 8352 (2014), NCBI Accession # 4NZR_H (234aa) HIV734 Heavy chain S19 US20110059015 SEQ ID NO: 6 8353 HIV735 Heavy chain S20 US20110059015 SEQ ID NO: 8 8354 HIV736 Heavy chain S8 US20110059015 SEQ ID NO: 4 8355 HIV737 Heavy Chain Vrc- Pg04 Wu, X., et al., Focused evolution of HIV-1 8356 neutralizing antibodies revealed by structures and deep sequencing; Science 333 (6049), 1593-1602 (2011)”, NCBI Accession # 3SE9_H (228aa) HIV738 Heavy chain VRC01 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 1 8357 HIV739 Heavy chain VRC01HC/VRCO3LC WO2013090644 SEQ ID NO: 2 8358 HIV740 Heavy chain VRC02 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 3 8359 HIV741 Heavy chain VRC03 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 27 8360 HIV742 Heavy chain VRC03HC- WO2013090644 SEQ ID NO: 32 8361 VRC01LC HIV743 Heavy chain VRC07 US20140322163 SEQ ID NO: 258 8362 G54H, S58N HIV744 Heavy chain VRC07 I37V, US20140322163 SEQ ID NO: 260 8363 G54H, S58N, T93A HIV745 Heavy chain VRC07 I37V, US20140322163 SEQ ID NO: 259 8364 G54H, T93A HIV746 Heavy Chain Vrc08c Wu, X., et al., Maturation and Diversity of the 8365 VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNY_H (235aa) HIV747 Heavy Chain Vrc23 Georgiev, I. S., et al., Delineating antibody 8366 recognition in polyclonal sera from patterns of HIV-1 isolate neutralization; Science 340 (6133), 751-756 (2013), NCBI Accession # 4J6R_H (224aa) HIV748 Heavy chain VRC-CH30 WO2013090644 SEQ ID NO: 22 8367 HIV749 Heavy Chain Vrc-ch31 Zhou T et al., Immunity 39 (2), 245-258 (2013), 8368 NCBI Accession # 4LSP_H (236aa) HIV750 Heavy chain VRC-CH32 Wu X. et al, “Focused evolution of HIV-1 8369 neutralizing antibodies revealed by structures and deep sequencing” Science 333 (6049), 1593-1602 (2011), NCBI Accession # AEM62724 HIV751 Heavy chain VRC-CH33 WO2013090644 SEQ ID NO: 28 8370 HIV752 Heavy chain VRC-CH34 WO2013090644 SEQ ID NO: 30 8371 HIV753 Heavy chain VRCO7 US20140322163 SEQ ID NO: 33 8372 G54H HIV754 Heavy chain VRC-PG04 Wu X. et al, “Focused evolution of HIV-1 8373 neutralizing antibodies revealed by structures and deep sequencing” Science 333 (6049), 1593-1602 (2011), NCBI Accession # AEM62752 HIV755 Heavy chain VRC-PG04b WO2013090644 SEQ ID NO: 44 8374 HIV756 Heavy Chain Vrc-pg20 Zhou T et al., Immunity 39 (2), 245-258 (2013), 8375 NCBI Accession # 4LSU_H (227aa) HIV757 Heavy chain X5 U.S. Pat. No. 7,378,093B2 SEQ ID NO: 3 8376 HIV758 Heavy chain X5 U.S. Pat. No. 8,110,192B2 SEQ ID NO: 5 8377 HIV759 Heavy chain X5 variant U.S. Pat. No. 7,378,093B2 SEQ ID NO: 11 8378 HIV760 Heavy Chain Z13e1 Stanfield, R. L., et al, J. Mol. Biol. 414 (3). 460- 8379 476 (2011), NCBI Accession # 3Q1S_H(230aa) HIV761 Heavy Chain Z258- Zhou. T et al., Structural Repertoire of HIV-1- 8380 vrc27.01 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDI_H(227aa) HIV762 Heavy Chain NCBI Accession # 1N0X_K (230aa) 8381 HIV763 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 142 8382 HIV764 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 143 8383 HIV765 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 144 8384 HIV766 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 145 8385 HIV767 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 146 8386 HIV768 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 66 8387 HIV769 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 67 8388 HIV770 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 68 8389 HIV771 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 70 8390 HIV772 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 72 8391 HIV773 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 73 8392 HIV774 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 74 8393 HIV775 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 75 8394 HIV776 Heavy chain U.S. Pat. No. 5,804,440A SEQ ID NO: 78 8395 HIV777 Heavy chain WO2014063059 SEQ ID NO: 10 8396 HIV778 Heavy chain WO2014063059 SEQ ID NO: 12 8397 HIV779 Heavy chain WO2014063059 SEQ ID NO: 130 8398 HIV780 Heavy chain WO2014063059 SEQ ID NO: 14 8399 HIV781 Heavy chain WO2014063059 SEQ ID NO: 16 8400 HIV782 Heavy chain WO2014063059 SEQ ID NO: 18 8401 HIV783 Heavy chain WO2014063059 SEQ ID NO: 20 8402 HIV784 Heavy chain WO2014063059 SEQ ID NO: 22 8403 HIV785 Heavy chain WO2014063059 SEQ ID NO: 24 8404 HIV786 Heavy chain WO2014063059 SEQ ID NO: 4 8405 HIV787 Heavy chain WO2014063059 SEQ ID NO: 6 8406 HIV788 Heavy chain WO2014063059 SEQ ID NO: 8 8407 HIV789 Heavy chain WO2014063059 SEQ ID NO: 2 8408 consensus HIV790 Heavy chain constant G4D US20130195881 SEQ ID NO: 6 8409 region HIV791 Heavy chain constant G4H US20130195881 SEQ ID NO: 5 8410 region HIV792 Heavy chain constant MV1 US20130195881 SEQ ID NO: 7 8411 region HIV793 Heavy chain constant TNX-355, US20130195881 SEQ ID NO: 4 8412 region Idalizumab HIV794 Heavy Chain Fab Ch04 McLellan, J. S., et al. Nature 480 (7377), 336- 8413 343 (2011), NCBI Accession # 3U46_A (238aa) HIV795 Heavy Chain Of 21C Diskin, R., et al, Nat. Struct. Mol. Biol. 17 (5), 8414 Anti-HIV Fab From 608-613 (2010), NCBI Accession # 3LMJ_H Human 21c Antibody (231aa) HIV796 Heavy Chain Of 830a Pan et al, J. Virol. 89 (15), 8003-8010 (2015), 8415 Anti-hiv-1 Gp120 NCBI Accession # 4YWG_H (226aa) V1v2 Antibody 830a HIV797 Heavy chain partial 412D Huang C. et al “Structural basis of tyrosine 8416 sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120” Proc. Natl. Acad. Sci. U.S.A. 101 (9), 2706-2711 (2004), NCBI Accession # AAR88379 HIV798 Heavy chain variable 0.5γ(1C10) U.S. Pat. No. 8,722,861B2 SEQ ID NO: 1 8417 region HIV799 Heavy chain variable 0.5δ (3D6) U.S. Pat. No. 8,722,861B2 SEQ ID NO: 5 8418 region HIV800 Heavy chain variable 10J4 mAb WO2015103549 SEQ ID NO: 3 8419 region HIV801 Heavy chain variable 10M6 mAb WO2015103549 SEQ ID NO: 5 8420 region HIV802 Heavy chain variable 13110 mAb WO2015103549 SEQ ID NO: 7 8421 region HIV803 Heavy chain variable 2N5mAb WO2015103549 SEQ ID NO: 9 8422 region HIV804 Heavy chain variable 35022 mAb WO2015103549 SEQ ID NO: 1 8423 region HIV805 Heavy chain variable 42F9 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 7 8424 region HIV806 Heavy chain variable 4835_F12 US20140205612 SEQ ID NO: 404 8425 region (PGT-124) HIV807 Heavy chain variable 4838_L06 US20140205612 SEQ ID NO: 66 8426 region (PGT-121) HIV808 Heavy chain variable 4858_P08 US20140205612 SEQ ID NO: 167 8427 region (PGT-123) HIV809 Heavy chain variable 4869-K15 US20140205612 SEQ ID NO: 419 8428 region (PGT-133) HIV810 Heavy chain variable 4873_E03 US20140205612 SEQ ID NO: 62 8429 region (PGT-121) HIV811 Heavy chain variable 4876_M06 US20140205612 SEQ ID NO: 434 8430 region (PGT-134) HIV812 Heavy chain variable 4877_D15 US20140205612 SEQ ID NO: 155 8431 region (PGT-122) HIV813 Heavy chain variable 4964_G22 US20140205612 SEQ ID NO: 275 8432 region (PGT-141), 4993_K13 (PGT-141) HIV814 Heavy chain variable 4970_K22 US20140205612 SEQ ID NO: 306 8433 region (PGT-144) HIV815 Heavy chain variable 4980_N08 US20140205612 SEQ ID NO: 297 8434 region (PGT-143) HIV816 Heavy chain variable 4995_E20 US20140205612 SEQ ID NO: 291 8435 region (PGT-142) HIV817 Heavy chain variable 4995_P16 US20140205612 SEQ ID NO: 400 8436 region (PGT-145) HIV818 Heavy chain variable 49G2 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 9 8437 region HIV819 Heavy chain variable 4O20mAb WO2015103549 SEQ ID NO: 11 8438 region HIV820 Heavy chain variable 5114_A19 US20140205612 SEQ ID NO: 333 8439 region (PGT-128) HIV821 Heavy chain variable 5120_N10 US20140205612 SEQ ID NO: 462 8440 region (PGT-139) HIV822 Heavy chain variable 5131_A17 US20140205612 SEQ ID NO: 443 8441 region (PGT-132) HIV823 Heavy chain variable 5136_H01 US20140205612 SEQ ID NO: 345 8442 region (PGT-131) HIV824 Heavy chain variable 5138_G07 US20140205612 SEQ ID NO: 453 8443 region (PGT-138) HIV825 Heavy chain variable 5141_B17 US20140205612 SEQ ID NO: 199 8444 region (PGT-126) HIV826 Heavy chain variable 5145_B14 US20140205612 SEQ ID NO: 318 8445 region (PGT-127) HIV827 Heavy chain variable 5147_N06 US20140205612 SEQ ID NO: 215 8446 region (PGT-130) HIV828 Heavy chain variable 5329_C19 US20140205612 SEQ ID NO: 248 8447 region (PGT-136), 5366_P21 (PGT-136) HIV829 Heavy chain variable 5343_B08 US20140205612 SEQ ID NO: 231 8448 region (PGT-135), 5344_E16 (PGT-135) HIV830 Heavy chain variable 5345_I01 US20140205612 SEQ ID NO: 362 8449 region (PGT-137) HIV831 Heavy chain variable 5G2 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 3 8450 region HIV832 Heavy chain variable 6808_B09 US20140205612 SEQ ID NO: 546 8451 region (PGT-156) HIV833 Heavy chain variable 6831_A21 US20140205612 SEQ ID NO: 473 8452 region (PGT-151) HIV834 Heavy chain variable 6843_G20 US20140205612 SEQ ID NO: 516 8453 region (PGT-154) HIV835 Heavy chain variable 6881_N05 US20140205612 SEQ ID NO: 572 8454 region (PGT-158). HIV836 Heavy chain variable 6889_117 US20140205612 SEQ ID NO: 489 8455 region (PGT-152) HIV837 Heavy chain variable 6891_F06 US20140205612 SEQ ID NO: 501 8456 region (PGT-153) HIV838 Heavy chain variable 6892_C23 US20140205612 SEQ ID NO: 559 8457 region (PGT-157) HIV839 Heavy chain variable 6892_D19 US20140205612 SEQ ID NO: 531 8458 region (PGT-155) HIV840 Heavy chain variable 7B9mAb WO2015103549 SEQ ID NO: 13 8459 region HIV841 Heavy chain variable 7K3mAb WO2015103549 SEQ ID NO: 15 8460 region HIV842 Heavy chain variable B4 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 2 8461 region HIV843 Heavy chain variable B4DIVHv.1 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 5 8462 region HIV844 Heavy chain variable B4DIVHv.2 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 6 8463 region HIV845 Heavy chain variable B4DTVHv.3 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 7 8464 region HIV846 Heavy chain variable B4DIVHv.4 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 8 8465 region HIV847 Heavy chain variable bI2 IgA2 WO2014040024 SEQ ID NO: 29 8466 region antibody HIV848 Heavy chain variable CHμ39.1 U.S. Pat. No. 5,773,247 SEQ ID NO: 10 8467 region HIV849 Heavy chain variable CHμ5.5 U.S. Pat. No. 5,773,247 SEQ ID NO: 14 8468 region HIV850 Heavy chain variable F425-Alg8 WO2014040024 SEQ ID NO: 9 8469 region antibody HIV851 Heavy chain variable Fab 43 US20090191216 SEQ ID NO: 8 8470 region HIV852 Heavy chain variable HGN194 US20110212106 SEQ ID NO: 45 8471 region HIV853 Heavy chain variable HJ16 US20110212106 SEQ ID NO: 13 8472 region HIV854 Heavy chain variable HK20 US20110212106 SEQ ID NO: 29 8473 region HIV855 Heavy chain variable IgA antibody WO2014040024 SEQ ID NO: 11 8474 region HIV856 Heavy chain variable L1719A11 US20150158934 SEQ ID NO: 175 8475 region HIV857 Heavy chain variable L1719A12 US20150158934 SEQ ID NO: 176 8476 region HIV858 Heavy chain variable L1719A9 US20150158934 SEQ ID NO: 174 8477 region HIV859 Heavy chain variable L1719B12 US20150158934 SEQ ID NO: 177 8478 region HIV860 Heavy chain variable L1719C1 US20150158934 SEQ ID NO: 178 8479 region HIV861 Heavy chain variable L1719D10 US20150158934 SEQ ID NO: 179 8480 region HIV862 Heavy chain variable L1719E1 US20150158934 SEQ ID NO: 180 8481 region HIV863 Heavy chain variable L1719E11 US20150158934 SEQ ID NO: 181 8482 region HIV864 Heavy chain variable L1719E12 US20150158934 SEQ ID NO: 182 8483 region HIV865 Heavy chain variable L1719F11 US20150158934 SEQ ID NO: 183 8484 region HIV866 Heavy chain variable L1719H10 US20150158934 SEQ ID NO: 185 8485 region HIV867 Heavy chain variable L1719H9 US20150158934 SEQ ID NO: 184 8486 region HIV868 Heavy chain variable L1720C1 US20150158934 SEQ ID NO: 186 8487 region HIV869 Heavy chain variable L1720E4 US20150158934 SEQ ID NO: 187 8488 region HIV870 Heavy chain variable L1721A3 US20150158934 SEQ ID NO: 188 8489 region HIV871 Heavy chain variable L1721A5 US20150158934 SEQ ID NO: 189 8490 region HIV872 Heavy chain variable L1721A8 US20150158934 SEQ ID NO: 190 8491 region HIV873 Heavy chain variable L1721H4 US20150158934 SEQ ID NO: 191 8492 region HIV874 Heavy chain variable L1723A10 US20150158934 SEQ ID NO: 193 8493 region HIV875 Heavy chain variable L1723A11 US20150158934 SEQ ID NO: 194 8494 region HIV876 Heavy chain variable L1723A9 US20150158934 SEQ ID NO: 192 8495 region HIV877 Heavy chain variable L1723E5 US20150158934 SEQ ID NO: 195 8496 region HIV878 Heavy chain variable L2319G11 US20150158934 SEQ ID NO: 197 8497 region HIV879 Heavy chain variable L2319G7 US20150158934 SEQ ID NO: 196 8498 region HIV880 Heavy chain variable L2319H7 US20150158934 SEQ ID NO: 198 8499 region HIV881 Heavy chain variable L2320E9 US20150158934 SEQ ID NO: 199 8500 region HIV882 Heavy chain variable L2320F9 US20150158934 SEQ ID NO: 200 8501 region HIV883 Heavy chain variable L2321B7 US20150158934 SEQ ID NO: 201 8502 region HIV884 Heavy chain variable L2321H6 US20150158934 SEQ ID NO: 202 8503 region HIV885 Heavy chain variable L81C11 US20150158934 SEQ ID NO: 15 8504 region HIV886 Heavy chain variable L81C9 US20150158934 SEQ ID NO: 30 8505 region HIV887 Heavy chain variable L81D9 US20150158934 SEQ ID NO: 10 8506 region HIV888 Heavy chain variable L81E1 US20150158934 SEQ ID NO: 18 8507 region HIV889 Heavy chain variable L81E7 US20150158934 SEQ ID NO: 16 8508 region HIV890 Heavy chain variable L81F1 US20150158934 SEQ ID NO: 19 8509 region HIV891 Heavy chain variable L81G7 US20150158934 SEQ ID NO: 13 8510 region HIV892 Heavy chain variable L81H1 US20150158934 SEQ ID NO: 98 8511 region HIV893 Heavy chain variable L81H2 US20150158934 SEQ ID NO: 23 8512 region HIV894 Heavy chain variable L81H7 US20150158934 SEQ ID NO: 11 8513 region HIV895 Heavy chain variable L81H9 US20150158934 SEQ ID NO: 28 8514 region HIV896 Heavy chain variable L82B12A US20150158934 SEQ ID NO: 105 8515 region HIV897 Heavy chain variable L82B1A US20150158934 SEQ ID NO: 99 8516 region HIV898 Heavy chain variable L82B1D US20150158934 SEQ ID NO: 100 8517 region HIV899 Heavy chain variable L82B2A US20150158934 SEQ ID NO: 101 8518 region HIV900 Heavy chain variable L82B3F US20150158934 SEQ ID NO: 102 8519 region HIV901 Heavy chain variable L82B4A US20150158934 SEQ ID NO: 103 8520 region HIV902 Heavy chain variable L82B4E US20150158934 SEQ ID NO: 104 8521 region HIV903 Heavy chain variable L82B4F US20150158934 SEQ ID NO: 21 8522 region HIV904 Heavy chain variable L832G6 US20150158934 SEQ ID NO: 113 8523 region HIV905 Heavy chain variable L833E1 US20150158934 SEQ ID NO: 72 8524 region HIV906 Heavy chain variable L833F5 US20150158934 SEQ ID NO: 17 8525 region HIV907 Heavy chain variable L833H1 US20150158934 SEQ ID NO: 114 8526 region HIV908 Heavy chain variable L833H3 US20150158934 SEQ ID NO: 115 8527 region HIV909 Heavy chain variable L88B10B US20150158934 SEQ ID NO: 27 8528 region HIV910 Heavy chain variable L88B11B US20150158934 SEQ ID NO: 12 8529 region HIV911 Heavy chain variable L88B12G US20150158934 SEQ ID NO: 29 8530 region HIV912 Heavy chain variable L88B1D US20150158934 SEQ ID NO: 20 8531 region HIV913 Heavy chain variable L88B2A US20150158934 SEQ ID NO: 106 8532 region HIV914 Heavy chain variable L88FA2 US20150158934 SEQ ID NO: 26 8533 region HIV915 Heavy chain variable L88FA3 US20150158934 SEQ ID NO: 107 8534 region HIV916 Heavy chain variable L88FA5 US20150158934 SEQ ID NO: 108 8535 region HIV917 Heavy chain variable L88FB1 US20150158934 SEQ ID NO: 25 8536 region HIV918 Heavy chain variable L88FC11 US20150158934 SEQ ID NO: 22 8537 region HIV919 Heavy chain variable L88FD12 US20150158934 SEQ ID NO: 24 8538 region HIV920 Heavy chain variable L89B12D US20150158934 SEQ ID NO: 112 8539 region HIV921 Heavy chain variable L89B1D US20150158934 SEQ ID NO: 109 8540 region HIV922 Heavy chain variable L89B2C US20150158934 SEQ ID NO: 110 8541 region HIV923 Heavy chain variable L89B3E US20150158934 SEQ ID NO: 14 8542 region HIV924 Heavy chain variable L89B6B US20150158934 SEQ ID NO: 111 8543 region HIV925 Heavy chain variable L8Cb15 US20150158934 SEQ ID NO: 116 8544 region HIV926 Heavy chain variable L8Cj3 US20150158934 SEQ ID NO: 73 8545 region HIV927 Heavy chain variable L8Fe2 US20150158934 SEQ ID NO: 117 8546 region HIV928 Heavy chain variable L8Fg12 US20150158934 SEQ ID NO: 118 8547 region HIV929 Heavy chain variable L8Fj19 US20150158934 SEQ ID NO: 119 8548 region HIV930 Heavy chain variable L8Fo17 US20150158934 SEQ ID NO: 120 8549 region HIV931 Heavy chain variable L8Fp6 US20150158934 SEQ ID NO: 121 8550 region HIV932 Heavy chain variable L8Hi20 US20150158934 SEQ ID NO: 122 8551 region HIV933 Heavy chain variable L911B11E US20150158934 SEQ ID NO: 140 8552 region HIV934 Heavy chain variable L911B12B US20150158934 SEQ ID NO: 71 8553 region HIV935 Heavy chain variable L911B1E US20150158934 SEQ ID NO: 137 8554 region HIV936 Heavy chain variable L911B1G US20150158934 SEQ ID NO: 65 8555 region HIV937 Heavy chain variable L911B2E US20150158934 SEQ ID NO: 138 8556 region HIV938 Heavy chain variable L911B3D US20150158934 SEQ ID NO: 75 8557 region HIV939 Heavy chain variable L911B9A US20150158934 SEQ ID NO: 139 8558 region HIV940 Heavy chain variable L911F12B US20150158934 SEQ ID NO: 142 8559 region HIV941 Heavy chain variable L911F1B US20150158934 SEQ ID NO: 141 8560 region HIV942 Heavy chain variable L911F1F US20150158934 SEQ ID NO: 77 8561 region HIV943 Heavy chain variable L911F4C US20150158934 SEQ ID NO: 33 8562 region HIV944 Heavy chain variable L91A1 US20150158934 SEQ ID NO: 123 8563 region HIV945 Heavy chain variable L91B5 US20150158934 SEQ ID NO: 37 8564 region HIV946 Heavy chain variable L91B5, 4A7 US20150158934 SEQ ID NO: 97 8565 region HIV947 Heavy chain variable L91B5, A12 US20150158934 SEQ ID NO: 92 8566 region HIV948 Heavy chain variable L91B5, A4 US20150158934 SEQ ID NO: 90 8567 region HIV949 Heavy chain variable L91B5, A7 US20150158934 SEQ ID NO: 91 8568 region HIV950 Heavy chain variable L91B5, B2 US20150158934 SEQ ID NO: 93 8569 region HIV951 Heavy chain variable L91B5, D4 US20150158934 SEQ ID NO: 94 8570 region HIV952 Heavy chain variable L91B5, F11 US20150158934 SEQ ID NO: 96 8571 region HIV953 Heavy chain variable L91B5, F4 US20150158934 SEQ ID NO: 95 8572 region HIV954 Heavy chain variable L91C2 US20150158934 SEQ ID NO: 61 8573 region HIV955 Heavy chain variable L91E1 US20150158934 SEQ ID NO: 45 8574 region HIV956 Heavy chain variable L91E2 US20150158934 SEQ ID NO: 124 8575 region HIV957 Heavy chain variable L91F10 US20150158934 SEQ ID NO: 69 8576 region HIV958 Heavy chain variable L91G2 US20150158934 SEQ ID NO: 64 8577 region HIV959 Heavy chain variable L91H3 US20150158934 SEQ ID NO: 128 8578 region HIV960 Heavy chain variable L91H9 US20150158934 SEQ ID NO: 41 8579 region HIV961 Heavy chain variable L922B2 US20150158934 SEQ ID NO: 143 8580 region HIV962 Heavy chain variable L922B4 US20150158934 SEQ ID NO: 144 8581 region HIV963 Heavy chain variable L922E1 US20150158934 SEQ ID NO: 145 8582 region HIV964 Heavy chain variable L922E2 US20150158934 SEQ ID NO: 53 8583 region HIV965 Heavy chain variable L923A1 US20150158934 SEQ ID NO: 146 8584 region HIV966 Heavy chain variable L923A4 US20150158934 SEQ ID NO: 32 8585 region HIV967 Heavy chain variable L92A11 US20150158934 SEQ ID NO: 125 8586 region HIV968 Heavy chain variable L92C7 US20150158934 SEQ ID NO: 62 8587 region HIV969 Heavy chain variable L92D4 US20150158934 SEQ ID NO: 126 8588 region HIV970 Heavy chain variable L92E6 US20150158934 SEQ ID NO: 63 8589 region HIV971 Heavy chain variable L92E7 US20150158934 SEQ ID NO: 74 8590 region HIV972 Heavy chain variable L92E7, A1 US20150158934 SEQ ID NO: 85 8591 region HIV973 Heavy chain variable L92E7, A2 US20150158934 SEQ ID NO: 86 8592 region HIV974 Heavy chain variable L92E7, A3 US20150158934 SEQ ID NO: 87 8593 region HIV975 Heavy chain variable L92E7, A4 US20150158934 SEQ ID NO: 80 8594 region HIV976 Heavy chain variable L92E7, A4 US20150158934 SEQ ID NO: 88 8595 region HIV977 Heavy chain variable L92E7, A5 US20150158934 SEQ ID NO: 89 8596 region HIV978 Heavy chain variable L92E7, B5 US20150158934 SEQ ID NO: 78 8597 region HIV979 Heavy chain variable L92E7. C US20150158934 SEQ ID NO: 79 8598 region HIV980 Heavy chain variable L92E7, C3 US20150158934 SEQ ID NO: 82 8599 region HIV981 Heavy chain variable L92E7, D3 US20150158934 SEQ ID NO: 83 8600 region HIV982 Heavy chain variable L92E7, E1 US20150158934 SEQ ID NO: 84 8601 region HIV983 Heavy chain variable L92E7, G4 US20150158934 SEQ ID NO: 81 8602 region HIV984 Heavy chain variable L932A9 US20150158934 SEQ ID NO: 58 8603 region HIV985 Heavy chain variable L932E10 US20150158934 SEQ ID NO: 35 8604 region HIV986 Heavy chain variable L932E8 US20150158934 SEQ ID NO: 147 8605 region HIV987 Heavy chain variable L932G9 US20150158934 SEQ ID NO: 34 8606 region HIV988 Heavy chain variable L933D10 US20150158934 SEQ ID NO: 50 8607 region HIV989 Heavy chain variable L93B3 US20150158934 SEQ ID NO: 70 8608 region HIV990 Heavy chain variable L93B4 US20150158934 SEQ ID NO: 127 8609 region HIV991 Heavy chain variable L93C3 US20150158934 SEQ ID NO: 51 8610 region HIV992 Heavy chain variable L93C6 US20150158934 SEQ ID NO: 67 8611 region HIV993 Heavy chain variable L93D3 US20150158934 SEQ ID NO: 129 8612 region HIV994 Heavy chain variable L93D4 US20150158934 SEQ ID NO: 43 8613 region HIV995 Heavy chain variable L93D9 US20150158934 SEQ ID NO: 130 8614 region HIV996 Heavy chain variable L93E3 US20150158934 SEQ ID NO: 55 8615 region HIV997 Heavy chain variable L93E6 US20150158934 SEQ ID NO: 131 8616 region HIV998 Heavy chain variable L93F12 US20150158934 SEQ ID NO: 133 8617 region HIV999 Heavy chain variable L93F2 US20150158934 SEQ ID NO: 132 8618 region HIV1000 Heavy chain variable L93F2 US20150158934 SEQ ID NO: 59 8619 region HIV1001 Heavy chain variable L93H6 US20150158934 SEQ ID NO: 38 8620 region HIV1002 Heavy chain variable L93H9 US20150158934 SEQ ID NO: 134 8621 region HIV1003 Heavy chain variable L94A12 US20150158934 SEQ ID NO: 46 8622 region HIV1004 Heavy chain variable L94C2 US20150158934 SEQ ID NO: 31 8623 region HIV1005 Heavy chain variable L94D12 US20150158934 SEQ ID NO: 42 8624 region HIV1006 Heavy chain variable L94D4 US20150158934 SEQ ID NO: 47 8625 region HIV1007 Heavy chain variable L94E3 US20150158934 SEQ ID NO: 39 8626 region HIV1008 Heavy chain variable L94E4 US20150158934 SEQ ID NO: 54 8627 region HIV1009 Heavy chain variable L94E5 US20150158934 SEQ ID NO: 57 8628 region HIV1010 Heavy chain variable L94H1 US20150158934 SEQ ID NO: 36 8629 region HIV1011 Heavy chain variable L94H2 US20150158934 SEQ ID NO: 40 8630 region HIV1012 Heavy chain variable L94H5 US20150158934 SEQ ID NO: 48 8631 region HIV1013 Heavy chain variable L94H7 US20150158934 SEQ ID NO: 135 8632 region HIV1014 Heavy chain variable L95B10D US20150158934 SEQ ID NO: 136 8633 region HIV1015 Heavy chain variable L95B12A US20150158934 SEQ ID NO: 68 8634 region HIV1016 Heavy chain variable L95B12E US20150158934 SEQ ID NO: 66 8635 region HIV1017 Heavy chain variable L95B8A US20150158934 SEQ ID NO: 60 8636 region HIV1018 Heavy chain variable L98FB10 US20150158934 SEQ ID NO: 76 8637 region HIV1019 Heavy chain variable L9Ab16 US20150158934 SEQ ID NO: 148 8638 region HIV1020 Heavy chain variable L9Ab19 US20150158934 SEQ ID NO: 149 8639 region HIV1021 Heavy chain variable L9Ad13 US20150158934 SEQ ID NO: 151 8640 region HIV1022 Heavy chain variable L9Ad14 US20150158934 SEQ ID NO: 152 8641 region HIV1023 Heavy chain variable L9Ad3 US20150158934 SEQ ID NO: 150 8642 region HIV1024 Heavy chain variable L9Aj2 US20150158934 SEQ ID NO: 153 8643 region HIV1025 Heavy chain variable L9An7 US20150158934 SEQ ID NO: 154 8644 region HIV1026 Heavy chain variable L9Ao15 US20150158934 SEQ ID NO: 155 8645 region HIV1027 Heavy chain variable L9Ap11 US20150158934 SEQ ID NO: 156 8646 region HIV1028 Heavy chain variable L9Bb3 US20150158934 SEQ ID NO: 157 8647 region HIV1029 Heavy chain variable L9Bc6 US20150158934 SEQ ID NO: 158 8648 region HIV1030 Heavy chain variable L9Bd8 US20150158934 SEQ ID NO: 159 8649 region HIV1031 Heavy chain variable L9Bd9 US20150158934 SEQ ID NO: 160 8650 region HIV1032 Heavy chain variable L9Be11 US20150158934 SEQ ID NO: 161 8651 region HIV1033 Heavy chain variable L9Bf11 US20150158934 SEQ ID NO: 49 8652 region HIV1034 Heavy chain variable L9Bf19 US20150158934 SEQ ID NO: 162 8653 region HIV1035 Heavy chain variable L9Bj13 US20150158934 SEQ ID NO: 163 8654 region HIV1036 Heavy chain variable L9Bm10 US20150158934 SEQ ID NO: 164 8655 region HIV1037 Heavy chain variable L9Bm16 US20150158934 SEQ ID NO: 56 8656 region HIV1038 Heavy chain variable L9Bp16 US20150158934 SEQ ID NO: 165 8657 region HIV1039 Heavy chain variable L9Bp5 US20150158934 SEQ ID NO: 44 8658 region HIV1040 Heavy chain variable L9Ca12 US20150158934 SEQ ID NO: 166 8659 region HIV1041 Heavy chain variable L9Ca13 US20150158934 SEQ ID NO: 167 8660 region HIV1042 Heavy chain variable L9Cd12 US20150158934 SEQ ID NO: 168 8661 region HIV1043 Heavy chain variable L9Cf15 US20150158934 SEQ ID NO: 169 8662 region HIV1044 Heavy chain variable L9Cl22 US20150158934 SEQ ID NO: 52 8663 region HIV1045 Heavy chain variable L9Cm18 US20150158934 SEQ ID NO: 170 8664 region HIV1046 Heavy chain variable L9Co22 US20150158934 SEQ ID NO: 171 8665 region HIV1047 Heavy chain variable L9Cp5 US20150158934 SEQ ID NO: 172 8666 region HIV1048 Heavy chain variable L9Cpl3 US20150158934 SEQ ID NO: 173 8667 region HIV1049 Heavy chain variable Makandal US20100111990 SEQ ID NO: 4 8668 region monoclonal antibody (Mmab) HIV1050 Heavy chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 17 8669 region HIV1051 Heavy chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 27 8670 region HuVH HIV1052 Heavy chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 29 8671 region HuVK HIV1053 Heavy chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 31 8672 region HuVKF HIV1054 Heavy chain variable PGT125 Walker L. M. et al “Broad neutralization 8673 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14393 HIV1055 Heavy chain variable PGT126 Walker L. M. et al “Broad neutralization 8674 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14394 HIV1056 Heavy chain variable PGT131 Walker L. M. et al “Broad neutralization 8675 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14389 HIV1057 Heavy chain variable PGT136 Walker L. M. et al “Broad neutralization 8676 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365),466-470 (2011), NCBI Accession # AEN14400 HIV1058 Heavy chain variable PGT137 Walker L. M. et al “Broad neutralization 8677 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14401 HIV1059 Heavy chain variable PGT141 Walker L. M. et al “Broad neutralization 8678 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14402 HIV1060 Heavy chain variable PGT142 Walker L. M. et al “Broad neutralization 8679 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14368 HIV1061 Heavy chain variable PGT143 Walker L. M. et al “Broad neutralization 8680 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14404 HIV1062 Heavy chain variable PGT144 Walker L. M. et al “Broad neutralization 8681 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14405 HIV1063 Heavy chain variable PGT151 Falkowska, E. et al “Broadly Neutralizing HIV 8682 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC3535 HIV1064 Heavy chain variable PGT152 Falkowska, E. et al “Broadly Neutralizing HIV 8683 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32536 HIV1065 Heavy chain variable PGT153 Falkowska, E. et al “Broadly Neutralizing HIV 8684 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32537 HIV1066 Heavy chain variable PGT154 Falkowska, E. et al “Broadly Neutralizing HIV 8685 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32521 HIV1067 Heavy chain variable PGT155 Falkowska, E. et al “Broadly Neutralizing HIV 8686 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32539 HIV1068 Heavy chain variable PGT156 Falkowska, E. et al “Broadly Neutralizing HIV 8687 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32540 HIV1069 Heavy chain variable PGT157 Falkowska, E. et al “Broadly Neutralizing HIV 8688 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32541 HIV1070 Heavy chain variable PGT158 Falkowska, E. et al “Broadly Neutralizing HIV 8689 region Antibodies Define a Glycan-Dependent Epitope on the Perfusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32542 HIV1071 Heavy chain variable rF105 WO1993012232 SEQ ID NO: 4 8690 region HIV1072 Heavy chain variable ScFvX5- U.S. Pat. No. 7,378,093B2 SEQ ID NO: 14 8691 region CD4 HIV1073 Heavy chain variable TNX-355, US20130195881 SEQ ID NO: 3 8692 region Idalizumab HIV1074 Heavy chain variable VCR14 US20150044137 SEQ ID NO: 13 8693 region HIV1075 Heavy chain variable VCR14b US20150044137 SEQ ID NO: 14 8694 region HIV1076 Heavy chain variable VCR14c US20150044137 SEQ ID NO: 15 8695 region HIV1077 Heavy chain variable VCR16 US20150044137 SEQ ID NO: 29 8696 region HIV1078 Heavy chain variable VCR16b US20150044137 SEQ ID NO: 30 8697 region HIV1079 Heavy chain variable VCR16c US20150044137 SEQ ID NO: 31 8698 region HIV1080 Heavy chain variable VCR16d US20150044137 SEQ ID NO: 32 8699 region HIV1081 Heavy chain variable VLP_A14 US20150158934 SEQ ID NO: 203 8700 region HIV1082 Heavy chain variable VLP_B9 US20150158934 SEQ ID NO: 204 8701 region HIV1083 Heavy chain variable VLP3_B21 US20150158934 SEQ ID NO: 205 8702 region HIV1084 Heavy chain variable VRC13 US20150044137 SEQ ID NO: 5 8703 region HIV1085 Heavy chain variable VRC13b US20150044137 SEQ ID NO: 6 8704 region HIV1086 Heavy chain variable VRC13c US20150044137 SEQ ID NO: 7 8705 region HIV1087 Heavy chain variable VRC13d US20150044137 SEQ ID NO: 8 8706 region HIV1088 Heavy chain variable VRC13e US20150044137 SEQ ID NO: 9 8707 region HIV1089 Heavy chain variable VRC13f US20150044137 SEQ ID NO: 10 8708 region HIV1090 Heavy chain variable VRC13g US20150044137 SEQ ID NO: 11 8709 region HIV1091 Heavy chain variable VRC13h US20150044137 SEQ ID NO: 12 8710 region HIV1092 Heavy chain variable VRC15 US20150044137 SEQ ID NO: 16 8711 region HIV1093 Heavy chain variable US20150004190 SEQ ID NO: 56 8712 region HIV1094 Heavy chain variable P7 NCBI Accession # AAB41043.1 (136aa) 8713 region, partial HIV1095 Heavy Chain, Fab Ch04 McLellan, J. S. et al., Structure of HIV-1 gp120 8714 V1 V2 domain with broadly neutralizing antibody PG9; Nature 480 (7377), 336-343 (2011), NCBI Accession # 3TCL_A (237aa) HIV1096 Heavy Chain, Fab N5-i5 Acharya, P., et al., Structural Definition of an 8715 Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV- 1 infection; J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4H8W_H (226aa) HIV1097 Heavy Chain, Fab N60-i3 Gohain, N., et al., Cocrystal Structures of 8716 Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody- Dependent Effector Function against HIV-1; J. Virol. 89 (17), 8840-8854 (2015), NCBI Accession # 4RFO_H (229aa) HIV1098 Heavy Chain, Ig Nih45-46 Fab Diskin, R., et al., Science 334 (6060), 1289- 8717 Gamma-1 Chain C 1293 (2011), NCBI Accession # 3U7Y_H Region (229aa) HIV1099 Heavy Chain, Ig Pgt127 Pejchal, R., et al., Science 334 (6059), 1097- 8718 Gamma-1 Chain C 1103 (2011), NCBI Accession # Region 3TWC_H(239aa) HIV1100 Heavy Chain, Ig Pgt128 Pejchal, R., et al., Science 334 (6059), 1097- 8719 Gamma-1 Chain C 1103 (2011), NCBI Accession # Region 3TV3_H(239aa) HIV1101 HIV, heavy chain Suvizumab 8720 HIV1102 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 43 8721 antibody, heavy chain antibody HIV1103 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 44 8722 antibody, heavy chain antibody HIV1104 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 45 8723 antibody, heavy chain antibody HIV1105 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 46 8724 antibody, heavy chain antibody HIV1106 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 47 8725 antibody, heavy chain antibody HIV1107 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 48 8726 antibody, heavy chain antibody HIV1108 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 49 8727 antibody, heavy chain antibody HIV1109 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 57 8728 antibody, heavy chain antibody HIV1110 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 58 8729 antibody, heavy chain antibody HIV1111 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 59 8730 antibody, heavy chain antibody HIV1112 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 60 8731 antibody, heavy chain antibody HIV1113 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 61 8732 antibody, heavy chain antibody HIV1114 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 62 8733 antibody, heavy chain antibody HIV1115 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 63 8734 antibody, heavy chain antibody HIV1116 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 64 8735 antibody, heavy chain antibody HIV1117 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 73 8736 antibody, heavy chain antibody HIV1118 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 74 8737 antibody, heavy chain antibody HIV1119 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 75 8738 antibody, heavy chain antibody HIV1120 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 76 8739 antibody, heavy chain antibody HIV1121 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 77 8740 antibody, heavy chain antibody HIV1122 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 78 8741 antibody, heavy chain antibody HIV1123 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 50 8742 antibody, light chain antibody HIV1124 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 51 8743 antibody, light chain antibody HIV1125 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 52 8744 antibody, light chain antibody HIV1126 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 53 8745 antibody, light chain antibody HIV1127 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 54 8746 antibody, light chain antibody HIV1128 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 55 8747 antibody, light chain antibody HIV1129 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 56 8748 antibody, light chain antibody HIV1130 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 65 8749 antibody, light chain antibody HIV1131 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 66 8750 antibody, light chain antibody HIV1132 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 67 8751 antibody, light chain antibody HIV1133 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 68 8752 antibody, light chain antibody HIV1134 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 69 8753 antibody, light chain antibody HIV1135 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 70 8754 antibody, light chain antibody HIV1136 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 71 8755 antibody, light chain antibody HIV1137 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 72 8756 antibody, light chain antibody HIV1138 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 79 8757 antibody, light chain antibody HIV1139 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 80 8758 antibody, light chain antibody HIV1140 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 81 8759 antibody, light chain antibody HIV1141 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 82 8760 antibody, light chain antibody HIV1142 HIV1 gp120 HIV1 gp120 WO2001000678 SEQ ID NO: 83 8761 antibody, light chain antibody HIV1143 Kappa light chain 1460_G14 U.S. Pat. No. 9,051,362 SEQ ID NO: 22 8762 HIV1144 Kappa light chain 1456_P20 U.S. Pat. No. 9,051,362 SEQ ID NO: 34 8763 variable region HIV1145 Kappa light chain 1460_G14 U.S. Pat. No. 9,051,362 SEQ ID NO: 36 8764 variable region HIV1146 Kappa light chain 1456_P20 U.S. Pat. No. 9,051,362 SEQ ID NO: 18 8765 HIV1147 Lambda light chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 50 8766 HIV1148 Lambda light chain 1469 M23 U.S. Pat. No. 9,051,362 SEQ ID NO: 142 8767 HIV1149 Lambda light chain 1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 14 8768 HIV1150 Lambda light chain 1495_C14 U.S. Pat. No. 9,051,362 SEQ ID NO: 26 8769 HIV1151 Lambda light chain 1489_I13 U.S. Pat. No. 9,051,362 SEQ ID NO: 32 8770 variable region HIV1152 Lambda light chain 1495_C14 U.S. Pat. No. 9,051,362 SEQ ID NO: 38 8771 variable region HIV1153 Lambda light chain 1496_C09 U.S. Pat. No. 9,051,362 SEQ ID NO: 40 8772 variable region HIV1154 Lambda light chain 1456_A12 U.S. Pat. No. 9,051,362 SEQ ID NO: 51 8773 variable region HIV1155 Lambda light chain 1503_H05 U.S. Pat. No. 9,051,362 SEQ ID NO: 56 8774 variable region HIV1156 Lambda light chain 1496_C09 U.S. Pat. No. 9,051,362 SEQ ID NO: 30 8775 HIV1157 Light chain 2424 Kumar, R., et al., Functional and Structural 8776 Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL; J. Virol. 89 (17), 9090-9102 (2015), NCBI Accession # 4XML_L(215aa) HIV1158 Light chain 8062 Gustchina, E., PLoS ONE 8 (11), E78187 8777 (2013), NCBI Accession # 4KHX_L(213aa) HIV1159 Light chain 1.00E+09 US20140348785 SEQ ID NO: 2 8778 HIV1160 Light Chain 10e8 Huang J et al., Nature 491 (7424), 406-412 8779 (monoclonal) (2012), NCBI Accession # 4G6F_D (215aa) HIV1161 Light chain 12a12kc US20140328862 SEQ ID NO: 453 8780 HIV1162 Light chain 12a13kc US20140328862 SEQ ID NO: 454 8781 HIV1163 Light chain 12a16kc US20140328862 SEQ ID NO: 455 8782 HIV1164 Light chain 12a1kc US20140328862 SEQ ID NO: 456 8783 HIV1165 Light chain 12a20kc US20140328862 SEQ ID NO: 457 8784 HIV1166 Light chain 12a21 NCBI Accession # 4JPW_L (210aa) 8785 HIV1167 Light chain 12a21kc US20140328862 SEQ ID NO: 458 8786 HIV1168 Light chain 12a22kc US20140328862 SEQ ID NO: 459 8787 HIV1169 Light chain 12a23kc US20140328862 SEQ ID NO: 460 8788 HIV1170 Light chain 12a27kc US20140328862 SEQ ID NO: 461 8789 HIV1171 Light chain 12a46kc US20140328862 SEQ ID NO: 462 8790 HIV1172 Light chain 12a55kc US20140328862 SEQ ID NO: 463 8791 HIV1173 Light chain 12a56kc US20140328862 SEQ ID NO: 464 8792 HIV1174 Light chain 12a6kc US20140328862 SEQ ID NO: 465 8793 HIV1175 Light chain 12a7kc US20140328862 SEQ ID NO: 466 8794 HIV1176 Light chain 17b Kwong, P. D., et al., structure of an HIV gp120 8795 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody; Nature 393 (6686). 648-659 (1998), NCBI Accession # 1G9M_L(214aa) HIV1177 Light chain 1b2530 Zhou T et al., Structural Repertoire of HIV-1- 8796 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YFL_L (215aa) HIV1178 Light chain 1F7 U.S. Pat. No. 6,057,421A FIG. 8 8797 HIV1179 Light chain 1NC9 WO2012154312 SEQ ID NO: 2472 8798 HIV1180 Light chain 2.2C Acharya, P., et al., Structural Definition of an 8799 Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV- 1 Infection; J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4R4N_L (210aa) HIV1181 Light chain 2F5 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 10 8800 HIV1182 Light chain 3040LC WO2015117008 SEQ ID NO: 29 8801 HIV1183 Light chain 3044LC WO2015117008 SEQ ID NO: 32 8802 HIV1184 Light chain 3430LC WO2015117008 SEQ ID NO: 30 8803 HIV1185 Light chain 3484LC WO2015117008 SEQ ID NO: 31 8804 HIV1186 Light chain 3630LC WO2015117008 SEQ ID NO: 33 8805 HIV1187 Light chain 3A124KC US20140328862 SEQ ID NO: 506 8806 HIV1188 Light chain 3A125KC US20140328862 SEQ ID NO: 507 8807 HIV1189 Light chain 3A140LC US20140328862 SEQ ID NO: 508 8808 HIV1190 Light chain 3A144KC US20140328862 SEQ ID NO: 509 8809 HIV1191 Light chain 3A160KC US20140328862 SEQ ID NO: 510 8810 HIV1192 Light chain 3A18KC US20140328862 SEQ ID NO: 511 8811 HIV1193 Light chain 3A204KC US20140328862 SEQ ID NO: 512 8812 HIV1194 Light chain 3A228KC US20140328862 SEQ ID NO: 513 8813 HIV1195 Light chain 3A233LC US20140328862 SEQ ID NO: 514 8814 HIV1196 Light chain 3A244LC US20140328862 SEQ ID NO: 515 8815 HIV1197 Light chain 3A255LC US20140328862 SEQ ID NO: 516 8816 HIV1198 Light chain 3A296KC US20140328862 SEQ ID NO: 517 8817 HIV1199 Light chain 3A334LC US20140328862 SEQ ID NO: 518 8818 HIV1200 Light chain 3A366KC US20140328862 SEQ ID NO: 519 8819 HIV1201 Light chain 3A384KC US20140328862 SEQ ID NO: 520 8820 HIV1202 Light chain 3A419KC US20140328862 SEQ ID NO: 521 8821 HIV1203 Light chain 3a426kc US20140328862 SEQ ID NO: 535 8822 HIV1204 Light chain 3A461KC US20140328862 SEQ ID NO: 522 8823 HIV1205 Light chain 3A474KC US20140328862 SEQ ID NO: 523 8824 HIV1206 Light chain 3a515kc US20140328862 SEQ ID NO: 536 8825 HIV1207 Light chain 3A518KC US20140328862 SEQ ID NO: 524 8826 HIV1208 Light chain 3A539LC US20140328862 SEQ ID NO: 525 8827 HIV1209 Light chain 3A576LC US20140328862 SEQ ID NO: 526 8828 HIV1210 Light chain 3A613LC US20140328862 SEQ ID NO: 527 8829 HIV1211 Light chain 3A64KC US20140328862 SEQ ID NO: 528 8830 HIV1212 Light chain 3A650KC US20140328862 SEQ ID NO: 529 8831 HIV1213 Light chain 3A67KC US20140328862 SEQ ID NO: 530 8832 HIV1214 Light chain 3A779KC US20140328862 SEQ ID NO: 531 8833 HIV1215 Light chain 3A816KC US20140328862 SEQ ID NO: 532 8834 HIV1216 Light chain 3A869KC US20140328862 SEQ ID NO: 533 8835 HIV1217 Light chain 3A93LC US20140328862 SEQ ID NO: 534 8836 HIV1218 Light chain 3anc3kc US20140328862 SEQ ID NO: 547 8837 HIV1219 Light chain 3b106kc US20140328862 SEQ ID NO: 548 8838 HIV1220 Light chain 3b129kc US20140328862 SEQ ID NO: 537 8839 HIV1221 Light chain 3b16kc US20140328862 SEQ ID NO: 549 8840 HIV1222 Light chain 3b171lc US20140328862 SEQ ID NO: 538 8841 HIV1223 Light chain 3b180kc US20140328862 SEQ ID NO: 550 8842 HIV1224 Light chain 3b183kc US20140328862 SEQ ID NO: 551 8843 HIV1225 Light chain 3b191kc US20140328862 SEQ ID NO: 552 8844 HIV1226 Light chain 3b21kc US20140328862 SEQ ID NO: 553 8845 HIV1227 Light chain 3b27kc US20140328862 SEQ ID NO: 539 8846 HIV1228 Light chain 3b41kc US20140328862 SEQ ID NO: 540 8847 HIV1229 Light chain 3b46kc US20140328862 SEQ ID NO: 542 8848 HIV1230 Light chain 3b57lc US20140328862 SEQ ID NO: 543 8849 HIV1231 Light chain 3b5kc US20140328862 SEQ ID NO: 541 8850 HIV1232 Light chain 3b8kc US20140328862 SEQ ID NO: 544 8851 HIV1233 Light chain 3bnc102kc US20140328862 SEQ ID NO: 554 8852 HIV1234 Light chain 3bnc104kc US20140328862 SEQ ID NO: 555 8853 HIV1235 Light chain 3bnc105kc US20140328862 SEQ ID NO: 556 8854 HIV1236 Light chain 3bnc107kc US20140328862 SEQ ID NO: 557 8855 HIV1237 Light chain 3bnc108kc US20140328862 SEQ ID NO: 558 8856 HIV1238 Light chain 3bnc117 Zhou T et al., Immunity 39 (2), 245-258 (2013), 8857 NCBI Accession # 4LSV_L(206aa) HIV1239 Light chain 3bnc117kc US20140328862 SEQ ID NO: 559 8858 HIV1240 Light chain 3bnc134kc US20140328862 SEQ ID NO: 560 8859 HIV1241 Light chain 3bnc142kc US20140328862 SEQ ID NO: 561 8860 HIV1242 Light chain 3bnc151kc US20140328862 SEQ ID NO: 562 8861 HIV1243 Light chain 3bnc153kc US20140328862 SEQ ID NO: 563 8862 HIV1244 Light chain 3bnc156kc US20140328862 SEQ ID NO: 564 8863 HIV1245 Light chain 3bnc158kc US20140328862 SEQ ID NO: 565 8864 HIV1246 Light chain 3bnc159kc US20140328862 SEQ ID NO: 566 8865 HIV1247 Light chain 3bnc15kc US20140328862 SEQ ID NO: 567 8866 HIV1248 Light chain 3bnc176kc US20140328862 SEQ ID NO: 568 8867 HIV1249 Light chain 3bnc193kc US20140328862 SEQ ID NO: 569 8868 HIV1250 Light chain 3bnc196kc US20140328862 SEQ ID NO: 570 8869 HIV1251 Light chain 3bnc31kc US20140328862 SEQ ID NO: 571 8870 HIV1252 Light chain 3bnc42kc US20140328862 SEQ ID NO: 572 8871 HIV1253 Light chain 3bnc53kc US20140328862 SEQ ID NO: 573 8872 HIV1254 Light chain 3BNC55KC US20140328862 SEQ ID NO: 545 8873 HIV1255 Light chain 3BNC60KC US20140328862 SEQ ID NO: 546 8874 HIV1256 Light chain 3bnc62kc US20140328862 SEQ ID NO: 574 8875 HIV1257 Light chain 3bnc65kc US20140328862 SEQ ID NO: 575 8876 HIV1258 Light chain 3bnc66kc US20140328862 SEQ ID NO: 576 8877 HIV1259 Light chain 3bnc75kc US20140328862 SEQ ID NO: 577 8878 HIV1260 Light chain 3bnc79kc US20140328862 SEQ ID NO: 578 8879 HIV1261 Light chain 3bnc81kc US20140328862 SEQ ID NO: 579 8880 HIV1262 Light chain 3bnc84kc US20140328862 SEQ ID NO: 580 8881 HIV1263 Light chain 3bnc87kc US20140328862 SEQ ID NO: 581 8882 HIV1264 Light chain 3bnc89kc US20140328862 SEQ ID NO: 582 8883 HIV1265 Light chain 3bnc91kc US20140328862 SEQ ID NO: 583 8884 HIV1266 Light chain 3bnc95kc US20140328862 SEQ ID NO: 584 8885 HIV1267 Light chain 412d Huang et al., Science 317 (5846), 1930-1934 8886 (2007), NCBI Accession # 2QAD_G (214aa) HIV1268 Light Chain 44-vrc13.01 Zhon T et al., Structural Repertoire of HIV-1- 8887 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDJ_B (206aa) HIV1269 Light chain 45-46m2 Diskin, R., et al., Restricting HIV-1 pathways 8888 for escape using rationally designed anti-HIV-1 antibodies; J. Exp. Med. 210 (6), 1235-1249 (2013), NCBI Accession # 4JKP_L (210aa) HIV1270 Light chain 4835_F12 US20140205612 SEQ ID NO: 413 8889 (PGT-124) HIV1271 Light chain 4838_L06 US20140205612 SEQ ID NO: 148 8890 (PGT-121) HIV1272 Light chain 4858_P08 US20140205612 SEQ ID NO: 176 8891 (PGT-123) HIV1273 Light chain 4869-K15 US20140205612 SEQ ID NO: 428 8892 (PGT-133) HIV1274 Light chain 4873_E03 US20140205612 SEQ ID NO: 147 8893 (PGT-121) HIV1275 Light chain 4876_M06 US20140205612 SEQ ID NO: 439 8894 (PGT-134) HIV1276 Light chain 4877_D15 US20140205612 SEQ ID NO: 160 8895 (PGT-122) HIV1277 Light chain 4964_G22 US20140205612 SEQ ID NO: 284 8896 (PGT-141), 4993_K13 (PGT-141), 4995_E20 (PGT-142) HIV1278 Light chain 4970_K22 US20140205612 SEQ ID NO: 312 8897 (PGT-144) HIV1279 Light chain 4980_N08 US20140205612 SEQ ID NO: 301 8898 (PGT-143) HIV1280 Light chain 4995_P16 US20140205612 SEQ ID NO: 385 8899 (PGT-145) HIV1281 Light chain 4e10 Fv Finton, K. A., et al., PLoS Pathol. 9 (9), 8900 E1003639 (2013), NCBI Accession # 4LLV_B (112aa) HIV1282 Light chain 5114_A19 US20140205612 SEQ ID NO: 392 8901 (PGT-128) HIV1283 Light chain 5120_N10 US20140205612 SEQ ID NO: 469 8902 (PGT-139) HIV1284 Light chain 5131_A17 US20140205612 SEQ ID NO: 488 8903 (PGT-132) HIV1285 Light chain 5136_H01 US20140205612 SEQ ID NO: 355 8904 (PGT-131) HIV1286 Light chain 5138_G07 US20140205612 SEQ ID NO: 483 8905 (PGT-138) HIV1287 Light chain 5141_B17 US20140205612 SEQ ID NO: 208 8906 (PGT-126) HIV1288 Light chain 5145_B14 US20140205612 SEQ ID NO: 329 8907 (PGT-127) HIV1289 Light chain 5147_N06 US20140205612 SEQ ID NO: 244 8908 (PGT-130) HIV1290 Light chain 5329_C19 US20140205612 SEQ ID NO: 257 8909 (PGT-136), 5366_P21 (PGT-136) HIV1291 Light chain 5343_B08 US20140205612 SEQ ID NO: 240 8910 (PGT-135), 5344_E16 (PGT-135) HIV1292 Light chain 5345_I01 US20140205612 SEQ ID NO: 396 8911 (PGT-137) HIV1293 Light chain 6808_B09 US20140205612 SEQ ID NO: 553 8912 (PGT-156) HIV1294 Light chain 6831_A21 US20140205612 SEQ ID NO: 482 8913 (PGT-151) HIV1295 Light chain 6843_G20 US20140205612 SEQ ID NO: 524 8914 (PGT-154) HIV1296 Light chain 6881_N05 US20140205612 SEQ ID NO: 578 8915 (PGT-158). HIV1297 Light chain 6889_I17 US20140205612 SEQ ID NO: 496 8916 (PGT-152) HIV1298 Light chain 6891_F06 US20140205612 SEQ ID NO: 510 8917 (PGT-153) HIV1299 Light chain 6892_C23 US20140205612 SEQ ID NO: 565 8918 (PGT-157) HIV1300 Light chain 6892_D19 US20140205612 SEQ ID NO: 539 8919 (PGT-155) HIV1301 Light chain 7H6 US20140348785 SEQ ID NO: 4 8920 HIV1302 Light chain 7N16 US20140348785 SEQ ID NO: 6 8921 HIV1303 Light chain 8anc131 Zhou T et al. Structural Repertoire of HIV-1- 8922 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4RWY_L (213aa) HIV1304 Light chain 8ANC131KC US20140328862 SEQ ID NO: 440 8923 HIV1305 Light chain 8anc134 Zhou T et al, Structural Repertoire of HIV-1- 8924 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4RX4_L (213aa) HIV1306 Light chain 8ANC134KC US20140328862 SEQ ID NO: 441 8925 HIV1307 Light chain 8ANC13KC US20140328862 SEQ ID NO: 442 8926 HIV1308 Light chain 8ANC14KC US20140328862 SEQ ID NO: 448 8927 HIV1309 Light chain 8ANC16KC US20140328862 SEQ ID NO: 449 8928 HIV1310 Light chain 8anc182kc US20140328862 SEQ ID NO: 446 8929 HIV1311 Light chain 8anc192kc US20140328862 SEQ ID NO: 447 8930 HIV1312 Light chain 8ANC195KC US20140328862 SEQ ID NO: 450 8931 HIV1313 Light chain 8ANC24KC US20140328862 SEQ ID NO: 451 8932 HIV1314 Light chain 8ANC45KC US20140328862 SEQ ID NO: 443 8933 HIV1315 Light chain 8ANC50KC US20140328862 SEQ ID NO: 444 8934 HIV1316 Light chain 8ANC5KC US20140328862 SEQ ID NO: 452 8935 HIV1317 Light chain 8ANC88KC US20140328862 SEQ ID NO: 445 8936 HIV1318 Light chain Anti-HcG Fotinou C. et al “Structure of an Fab fragment 8937 against a C-terminal peptide of hCG at 2.0 A resolution” J. Biol. Chem. 273 (35), 22515- 22518 (1998); NCBI Accession # 1SBS_L HIV1319 Light chain B12 Zhou T et al., Structural definition of a 8938 conserved neutralization epitope on HIV-1 gp120; Nature 445 (7129), 732-737 (2007), NCBI Accession # 2NY7_L (215aa) HIV1320 Light Chain C38-vrc16.01 Zhou T et al., Structural Repertoire of HIV-1- 8939 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDK_L (214aa) HIV1321 Light chain C38-vrc18.02 Zhou T et al., Structural Repertoire of HIV-1- 8940 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDL_L (211aa) HIV1322 Light chain CAP256- WO2015128846 SEQ ID NO: 14 8941 VRC26.01 HIV1323 Light chain CAP256- WO2015128846 SEQ ID NO: 18 8942 VRC26.02 HIV1324 Light chain CAP256- WO2015128846 SEQ ID NO: 22 8943 VRC26.03 HIV1325 Light chain CAP256- WO2015128846 SEQ ID NO: 26 8944 VRC26.04 HIV1326 Light chain CAP256- WO2015128846 SEQ ID NO: 30 8945 VRC26.05 HIV1327 Light chain CAP256- WO2015128846 SEQ ID NO: 34 8946 VRC26.06 HIV1328 Light chain CAP256- WO2015128846 SEQ ID NO: 38 8947 VRC26.07 HIV1329 Light chain CAP256- WO2015128846 SEQ ID NO: 42 8948 VRC26.08 HIV1330 Light chain CAP256- WO2015128846 SEQ ID NO: 46 8949 VRC26.09 HIV1331 Light chain CAP256- WO2015128846 SEQ ID NO: 50 8950 VRC26.10 HIV1332 Light chain CAP256- WO2015128846 SEQ ID NO: 54 8951 VRC26.11 HIV1333 Light chain CAP256- WO2015128846 SEQ ID NO: 58 8952 VRC26.12 HIV1334 Light chain CAP256- WO2015128846 SEQ ID NO: 171 8953 VRC26.25 HIV1335 Light chain CAP256- WO2015128846 SEQ ID NO: 179 8954 VRC26.26 HIV1336 Light chain CAP256- WO2015128846 SEQ ID NO: 187 8955 VRC26.27 HIV1337 Light chain CAP256- WO2015128846 SEQ ID NO: 6 8956 VRC26-I1 HIV1338 Light chain CAP256- WO2015128846 SEQ ID NO: 10 8957 VRC26-I2 HIV1339 Light chain CAP256- WO2015128846 SEQ ID NO: 2 8958 VRC26- UCA. HIV1340 Light chain construct WO2015013390 SEQ ID NO: 5 8959 #2816, #2861 HIV1341 Light chain construct WO2015013390 SEQ ID NO: 6 8960 #2817, #2860 HIV1342 Light chain construct WO2015013390 SEQ ID NO: 7 8961 #2858, #2859, #2861 HIV1343 Light chain Fab 2219 Stanfield, R. L., et al., J. Virol. 80 (12), 6093- 8962 6105 (2006), NCBI Accession # 2B0S_L (215aa) HIV1344 Light chain Fab 2g12 Doores, K. J., et al., J. Virol. 84 (20), 10690- 8963 10699 (2010), NCBI Accession # 3OAU_L(212a) HIV1345 Light chain Fab 2g12 Stanfield, R. L. et al., Crystal structure of the 8964 HIV neutralizing antibody 2G12, in complex with a bacterial oligosaccharide analog of mammalian oligomannose; Glycobiology 25 (4), 412-419 (2015), NCBI Accession # 4RBP_L (213aa) HIV1346 Light chain Fab F425- Bell et al., J. Mol. Biol. 375 (4), 969-978 8965 b4e8 (2008), NCBI Accession # 2QSC_L (215aa) HIV1347 Light chain G4D US20130195881 SEQ ID NO: 39 8966 HIV1348 Light chain G4H US20130195881 SEQ ID NO: 38 8967 HIV1349 Light chain gVRC-H5(d74)/ WO2013090644 SEQ ID NO: 19 8968 VRC-PG04LC, gVRCOH12(D74)/ VRC-PG04LC HIV1350 Light chain 12 (unbound) Fera, D. et al., Affinity maturation in an HIV 8969 From Ch103 broadly neutralizing B-cell lineage through Lineage reorientation of variable domains; Proc. Natl. Acad. Sci. U.S.A. 111 (28), 10275-10280 (2014), NCBI Accession # 4QHN_B (213aa) HIV1351 Light chain IGLV3- US20140348785 SEQ ID NO: 8 8970 19*01 HIV1352 Light chain k3 WO2015117008 SEQ ID NO: 19 8971 HIV1353 Light chain k5 WO2015117008 SEQ ID NO: 20 8972 HIV1354 Light chain k53 WO2015117008 SEQ ID NO: 24 8973 HIV1355 Light chain k59 WO2015117008 SEQ ID NO: 21 8974 HIV1356 Light chain k61 WO2015117008 SEQ ID NO: 25 8975 HIV1357 Light chain k62 WO2015117008 SEQ ID NO: 22 8976 HIV1358 Light chain k81 WO2015117008 SEQ ID NO: 28 8977 HIV1359 Light chain kl 1 WO2015117008 SEQ ID NO: 26 8978 HIV1360 Light chain kl8 WO2015117008 SEQ ID NO: 23 8979 HIV1361 Light chain kl9 WO2015117008 SEQ ID NO: 27 8980 HIV1362 Light chain LSSB2066KC US20140328862 SEQ ID NO: 501 8981 HIV1363 Light chain LSSB2080KC US20140328862 SEQ ID NO: 502 8982 HIV1364 Light chain LSSB2133KC US20140328862 SEQ ID NO: 503 8983 HIV1365 Light chain LSSB2182KC US20140328862 SEQ ID NO: 504 8984 HIV1366 Light chain LSSB2339LC US20140328862 SEQ ID NO: 467 8985 HIV1367 Light chain LSSB2351LC US20140328862 SEQ ID NO: 468 8986 HIV1368 Light chain LSSB2364LC US20140328862 SEQ ID NO: 469 8987 HIV1369 Light chain LSSB2367LC US20140328862 SEQ ID NO: 470 8988 HIV1370 Light chain LSSB2490LC US20140328862 SEQ ID NO: 471 8989 HIV1371 Light chain LSSB2530LC US20140328862 SEQ ID NO: 472 8990 HIV1372 Light chain LSSB2554LC US20140328862 SEQ ID NO: 473 8991 HIV1373 Light chain LSSB2586LC US20140328862 SEQ ID NO: 474 8992 HIV1374 Light chain LSSB2612LC US20140328862 SEQ ID NO: 475 8993 HIV1375 Light chain LSSB2640LC US20140328862 SEQ ID NO: 476 8994 HIV1376 Light chain LSSB2644LC US20140328862 SEQ ID NO: 477 8995 HIV1377 Light chain LSSB2666LC US20140328862 SEQ ID NO: 478 8996 HIV1378 Light chain LSSB2680LC US20140328862 SEQ ID NO: 479 8997 HIV1379 Light chain LSSB2683LC US20140328862 SEQ ID NO: 480 8998 HIV1380 Light chain LSSB331KC US20140328862 SEQ ID NO: 505 8999 HIV1381 Light chain LSSB344LC US20140328862 SEQ ID NO: 481 9000 HIV1382 Light chain LSSNEC107LC US20140328862 SEQ ID NO: 482 9001 HIV1383 Light chain LSSNEC108LC US20140328862 SEQ ID NO: 483 9002 HIV1384 Light chain LSSNEC117LC US20140328862 SEQ ID NO: 484 9003 HIV1385 Light chain LSSNEC118LC US20140328862 SEQ ID NO: 485 9004 HIV1386 Light chain LSSNEC122LC US20140328862 SEQ ID NO: 486 9005 HIV1387 Light chain LSSNEC24LC US20140328862 SEQ ID NO: 487 9006 HIV1388 Light chain LSSNEC2LC US20140328862 SEQ ID NO: 488 9007 HIV1389 Light chain LSSNEC33LC US20140328862 SEQ ID NO: 489 9008 HIV1390 Light chain LSSNEC46LC US20140328862 SEQ ID NO: 490 9009 HIV1391 Light chain LSSNEC48LC US20140328862 SEQ ID NO: 491 9010 HIV1392 Light chain LSSNEC52LC US20140328862 SEQ ID NO: 492 9011 HIV1393 Light chain LSSNEC56LC US20140328862 SEQ ID NO: 493 9012 HIV1394 Light chain LSSNEC60LC US20140328862 SEQ ID NO: 494 9013 HIV1395 Light chain LSSNEC70LC US20140328862 SEQ ID NO: 495 9014 HIV1396 Light chain LSSNEC72LC US20140328862 SEQ ID NO: 496 9015 HIV1397 Light chain LSSNEC7LC US20140328862 SEQ ID NO: 497 9016 HIV1398 Light chain LSSNEC89LC US20140328862 SEQ ID NO: 498 9017 HIV1399 Light chain LSSNEC94LC US20140328862 SEQ ID NO: 499 9018 HIV1400 Light chain LSSNEC9LC US20140328862 SEQ ID NO: 500 9019 HIV1401 Light chain m12-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 7 9020 HIV1402 Light chain m14-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 5 9021 HIV1403 Light chain m16-Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 8 9022 HIV1404 Light chain m18 Fd-aa U.S. Pat. No. 7,803,913B2 SEQ ID NO: 6 9023 HIV1405 Light chain M66 Ofek, G., et al., Structural Basis for HIV-1 9024 Neutralization by 2F5-Like Antibodies m66 and m66.6; J. Virol. 88 (5), 2426-2441 (2014), NCBI Accession # 4NRY_H (235aa) HIV1406 Light chain M66.6 Ofek, G., et al., Structural Basis for HIV-1 9025 Neutralization by 2F5-Like Antibodies m66 and m66.6; J. Virol. 88 (5), 2426-2441 (2014), NCBI Accession # 4NRZ_L (213aa) HIV1407 Light Chain Mab 2158 Spurrier, B., et al., Functional Implications of 9026 the Binding Mode of a Human Conformation- Dependent V2 Monoclonal Antibody against HIV; J. Virol, 88 (8), 4100-4112 (2014), NCBI Accession # 4OAW_C (214aa) HIV1408 Light chain MV1 US20130195881 SEQ ID NO: 40 9027 HIV1409 Light chain Pg16 Fab Pancera, M., et al., Nat. Struct. Mol. Biol. 20 9028 (7), 804-813 (2013), NCBI Accession # 4DQO_L (216aa) HIV1410 Light chain Pg9 Willis, J. R., et al., J. Clin. Invest. 125 (6), 2523- 9029 2531 (2015), NCBI Accession # 4YAQ_L (216aa) HIV1411 Light chain Pgt121-Gl Mouquet H et al., Complex-type N-glycan 9030 Fab recognition by potent broadly neutralizing HIV antibodies; Proc Natl Acad Sci USA. 2012 Nov. 20; 109(47): E3268-77, NCBI Accession # 4FQQ_A (215aa) HIV1412 Light chain Pgt122 Julien, J. P., et al., PLoS Pathol. 9 (5), 9031 E1003342 (2013)”, NCBI Accession # 4JY5_L (211aa) HIV1413 Light chain Pgt123 Julien, J. P., et al., PLoS Pathol. 9 (5), 9032 E1003342 (2013)”, NCBI Accession # 4JY6_A (211aa) HIV1414 Light chain Pgt124 Garces, F., et al., Structural Evolution of 9033 Glycan Recognition by a Family of Potent HIV Antibodies; Cell 159 (1), 69-79 (2014), NCBI Accession # 4R26_L (214aa) HIV1415 Light chain Pgt130 Doores, K. J., et al., J. Virol. 89 (2), 1105-1118 9034 (2015), NCBI Accession # 4RNR_B (216aa) HIV1416 Light chain Pgt135 Grover et al., Science 343 (6171), 656-661 9035 (2014), NCBI Accession # 4NZR_L (214aa) HIV1417 Light chain S8, S19, S20 US20110059015 SEQ ID NO: 2 9036 HIV1418 light chain Suvizumab 9037 HIV1419 Light Chain Vrc- Pg04 Wu, X., et al., Focused evolution of HIV-1 9038 neutralizing antibodies revealed by structures and deep sequencing; Science 333 (6049), 1593-1602 (2011)”, NCBI Accession # 3SE9_L (208aa) HIV1420 Light chain VRC01 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 2 9039 HIV1421 Light chain VRC01 US2014 0322163 SEQ ID NO: 53 9040 E1/12 deletion HIV1422 Light chain VRC01 US2014 0322163 SEQ ID NO: 222 9041 E1/I2del F97D HIV1423 Light chain VRC01 US2014 0322163 SEQ ID NO: 225 9042 E1/I2del F97H HIV1424 Light chain VRC01 US2014 0322163 SEQ ID NO: 223 9043 E1/I2del F97K HIV1425 Light chain VRC01 US2014 0322163 SEQ ID NO: 224 9044 E1/I2del F97S HIV1426 Light chain VRC01 US2014 0322163 SEQ ID NO: 219 9045 E1/I2del V3E HIV1427 Light chain VRC01 US2014 0322163 SEQ ID NO: 227 9046 E1/I2del V3E, F97H HIV1428 Light chain VRC01 US2014 0322163 SEQ ID NO: 226 9047 E1/I2del V3E, F97S HIV1429 Light chain VRC01 US2014 0322163 SEQ ID NO: 220 9048 E1/I2del V3K HIV1430 Light chain VRC01 US2014 0322163 SEQ ID NO: 221 9049 E1/I2del V3S HIV1431 Light chain VRC01HC/ WO2013090644 SEQ ID NO: 31 9050 VRC03LC HIV1432 Light chain VRC01hpL02 US2014 0322163 SEQ ID NO: 50 9051 HIV1433 Light chain VRC01hpL02 US2014 0322163 SEQ ID NO: 232 9052 E1/I2- deletion, V3S HIV1434 Light chain VRC01hpL03 US2014 0322163 SEQ ID NO: 228 9053 HIV1435 Light chain VRC01hpL04 US2014 0322163 SEQ ID NO: 229 9054 HIV1436 Light chain VRC01hpL05 US2014 0322163 SEQ ID NO: 230 9055 HIV1437 Light chain VRC01hpL06 US2014 0322163 SEQ ID NO: 231 9056 HIV1438 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 233 9057 03 E1/I2- deletion, V3S HIV1439 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 237 9058 04 E1/I2- deletion, V3E HIV1440 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 234 9059 04 E1/I2- deletion, V3S HIV1441 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 235 9060 05 E1/12 deletion, V3S HIV1442 Light chain VRC01LhpL US2014 0322163 SEQ ID NO: 236 9061 06 E1/I2- deletion, V3S HIV1443 Light chain VRC02 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 4 9062 HIV1444 Light chain VRC03 U.S. Pat. No. 8,637,036B2 SEQ ID NO: 28 9063 HIV1445 Light chain VRC03HC- WO2013090644 SEQ ID NO: 1 9064 VRC01LC HIV1446 Light chain Vrc06b Wu, X., et al., Maturation and Diversity of the 9065 VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNZ_F (209aa) HIV1447 Light chain Vrc08c Wu, X., et al., Maturation and Diversity of the 9066 VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection; Cell 161 (3), 470-485 (2015), NCBI Accession # 4XNY_L (211aa) HIV1448 Light chain Vrc23 Georgiev, I. S., et al., Delineating antibody 9067 recognition in polyclonal sera from patterns of HIV-1 isolate neutralization; Science 340 (6133), 751-756 (2013), NCBI Accession # 4J6R_L (210aa) HIV1449 Light chain VRC-CH30 WO2013090644 SEQ ID NO: 21 9068 HIV1450 Light chain Vrc-ch31 Zhou T et al., Immunity 39 (2), 245-258 (2013), 9069 NCBI Accession # 4LSP_L (210aa) HIV1451 Light chain VRC-CH32 Wu X. et al., “Focused evolution of HIV-1 9070 neutralizing antibodies revealed by structures and deep sequencing” Science 333 (6049), 1593-1602 (2011), NCBI Accession # AEM62727 HIV1452 Light chain VRC-CH33 WO2013090644 SEQ ID NO: 27 9071 HIV1453 Light chain VRC-CH34 WO2013090644 SEQ ID NO: 29 9072 HIV1454 Light chain VRC-PG04 Wu X. et al,“Focused evolution of HIV-1 9073 neutralizing antibodies revealed by structures and deep sequencing” Science 333 (6049), 1593-1602 (2011), NCBI Accession # AEM62754 HIV1455 Light chain VRC-PG04b WO2013090644 SEQ ID NO: 43 9074 HIV1456 Light chain Vrc-pg20 Zhou T et al., immunity 39 (2), 245-258 (2013), 9075 NCBI Accession # 4LSU_L (204aa) HIV1457 Light chain X5 U.S. Pat. No. 7,378,093B2 SEQ ID NO: 2 9076 HIV1458 Light chain X5 U.S. Pat. No. 8,110,192B2 SEQ ID NO: 4 9077 HIV1459 Light chain Z13e1 Stanfield. R. L., et al, J. Mol. Biol. 414 (3), 460- 9078 476 (2011), NCBI Accession # 3Q1S_L (212aa) HIV1460 Light Chain Z258- Zhon T et al., Structural Repertoire of HIV-1- 9079 vrc27.01 Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors; Cell 161 (6), 1280- 1292 (2015), NCBI Accession # 4YDI_L (210aa) HIV1461 Light chain NCBI Accession # 1N0X_M (215aa) 9080 HIV1462 Light chain Okada, N., et al., Human IgM Monoclonal 9081 Antibodies Reactive with HIV-1-Infected Cells Generated Using a Trans-Chromosome Mouse; Microbiol. Immunol. 49 (5), 447-459 (2005), NCBI Accession # AAS01772.1(236aa) HIV1463 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 101 9082 HIV1464 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 102 9083 HIV1465 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 103 9084 HIV1466 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 104 9085 HIV1467 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 105 9086 HIV1468 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 107 9087 HIV1469 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 110 9088 HIV1470 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 115 9089 HIV1471 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 118 9090 HIV1472 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 121 9091 HIV1473 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 122 9092 HIV1474 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 124 9093 HIV1475 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 132 9094 HIV1476 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 147 9095 HIV1477 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 148 9096 HIV1478 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 149 9097 HIV1479 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 150 9098 HIV1480 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 151 9099 HIV1481 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 95 9100 HIV1482 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 96 9101 HIV1483 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 97 9102 HIV1484 Light chain U.S. Pat. No. 5,804,440A SEQ ID NO: 98 9103 HIV1485 Light chain WO2014063059 SEQ ID NO: 11 9104 HIV1486 Light chain WO2014063059 SEQ ID NO: 129 9105 HIV1487 Light chain WO2014063059 SEQ ID NO: 13 9106 HIV1488 Light chain WO2014063059 SEQ ID NO: 15 9107 HIV1489 Light chain WO2014063059 SEQ ID NO: 17 9108 HIV1490 Light chain WO2014063059 SEQ ID NO: 19 9109 HIV1491 Light chain WO2014063059 SEQ ID NO: 21 9110 HIV1492 Light chain WO2014063059 SEQ ID NO: 23 9111 HIV1493 Light chain WO2014063059 SEQ ID NO: 3 9112 HIV1494 Light chain WO2014063059 SEQ ID NO: 5 9113 HIV1495 Light chain WO2014063059 SEQ ID NO: 7 9114 HIV1496 Light chain WO2014063059 SEQ ID NO: 9 9115 HIV1497 Light chain WO2014063059 SEQ ID NO: 1 9116 consensus HIV1498 Light chain constant TNX-355, US20130195881 SEQ ID NO: 2 9117 region Idalizumab HIV1499 Light Chain Fab Ch02 McLellan, J. S., et al., Nature 480 (7377), 336- 9118 343 (2011), NCBI Accession # 3U46_B (215aa) HIV1500 Light Chain Of Anti- 21C Diskin, R., et al., Nat. Struct. Mol. Biol. 17 (5), 9119 HIV Fab From 608-613 (2010), NCBI Accession # 3LMJ_L Human 21c Antibody (217aa) HIV1501 Light Chain Of Anti- 830a Pan et al., J. Virol. 89 (15), 8003-8010 (2015), 9120 hiv-1 Gp120 V1v2 NCBI Accession # 4YWG_L (216aa) Antibody 830a HIV1502 Light Chain Of Anti- Fab 2558 Gorny et al., PLoS ONE 6 (12), E27780 (2011), 9121 hiv-1 V3 Monoclonal NCBI Accession # 3UJI_L (209aa) Antibody HIV1503 Light Chain Of Anti- Fab 4025 Gorny et al., PLoS ONE 6 (12), E27780 (2011), 9122 hiv-1 V3 Monoclonal NCBI Accession # 3UJJ_L (213aa) Antibody HIV1504 Light chain partial 412D Huang C. et al “Structural basis of tyrosine 9123 sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120” Proc. Natl. Acad. Sci. U.S.A. 101 (9), 2706-2711 (2004), NCBI Accession # AAR88380 HIV1505 Light chain partial 694/98D Li L. et al, “A broad range of mutations in HIV- 9124 1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site”, Mol. Immunol. 66 (2), 364-374 (2015); NCBI Accession # AKH36512 HIV1506 Light chain variable 0.5γ (1C10) U.S. Pat. No. 8,722,861B2 SEQ ID NO: 2 9125 region HIV1507 Light chain variable 0.5γ (3D6) U.S. Pat. No. 8,722,861B2 SEQ ID NO: 6 9126 region HIV1508 Light chain variable 10J4 mAb WO2015103549 SEQ ID NO: 4 9127 region HIV1509 Light chain variable 10M6 mAb WO2015103549 SEQ ID NO: 6 9128 region HIV1510 Light chain variable 13110 mAb WO2015103549 SEQ ID NO: 8 9129 region HIV1511 Light chain variable 2N5mAb WO2015103549 SEQ ID NO: 10 9130 region HIV1512 Light chain variable 35022 mAb WO2015103549 SEQ ID NO: 2 9131 region HIV1513 Light chain variable 42F9 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 8 9132 region HIV1514 Light chain variable 49G2 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 10 9133 region HIV1515 Light chain variable 4O20mAb WO2015103549 SEQ ID NO: 12 9134 region HIV1516 Light chain variable 5G2 U.S. Pat. No. 8,722,861B2 SEQ ID NO: 4 9135 region HIV1517 Light chain variable 7B9mAb WO2015103549 SEQ ID NO: 14 9136 region HIV1518 Light chain variable 7K3mAb WO2015103549 SEQ ID NO: 16 9137 region HIV1519 Light chain variable B4 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 4 9138 region HIV1520 Light chain variable B4DIVKv.1 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 9 9139 region HIV1521 Light chain variable B4DIVKv.2 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 10 9140 region HIV1522 Light chain variable B4DIVKv.3 U.S. Pat. No. 7,872,110B2 SEQ ID NO: 11 9141 region HIV1523 Light chain variable bl2 IgA2 WO2014040024 SEQ ID NO: 30 9142 region antibody HIV1524 Light chain variable CHμ39.1 U.S. Pat. No. 5,773,247 SEQ ID NO: 12 9143 region HIV1525 Light chain variable CHμ5.5 U.S. Pat. No. 5,773,247 SEQ ID NO: 16 9144 region HIV1526 Light chain variable F425-Alg8 WO2014040024 SEQ ID NO: 13 9145 region antibody HIV1527 Light chain variable Fab 43 US20090191216 SEQ ID NO: 9 9146 region HIV1528 Light chain variable HGN194 US20110212106 SEQ ID NO: 46 9147 region HIV1529 Light chain variable HJ16 US20110212106 SEQ ID NO: 14 9148 region HIV1530 Light chain variable HK20 US20110212106 SEQ ID NO: 30 9149 region HIV1531 Light chain variable IgA antibody WO2014040024 SEQ ID NO: 15 9150 region HIV1532 Light chain variable Makandal US20100111990 SEQ ID NO: 3 9151 region monoclonal antibody (Mmab) HIV1533 Light chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 18 9152 region HIV1534 Light chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 28 9153 region HuVH HIV1535 Light chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 30 9154 region HuVK HIV1536 Light chain variable NM-01 U.S. Pat. No. 5,665,569 SEQ ID NO: 32 9155 region HuVKF HIV1537 Light chain variable PGT125 Walker L. M. et al “Broad neutralization 9156 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14410 HIV1538 Light chain variable PGT126 Walker L. M. et al “Broad neutralization 9157 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14411 HIV1539 Light chain variable PGT131 Walker L. M. et al “Broad neutralization 9158 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AENT4415 HIV1540 Light chain variable PGT136 Walker L. M. et al “Broad neutralization 9159 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14417 HIV1541 Light chain variable PGT137 Walker L. M. et al “Broad neutralization 9160 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14418 HIV1542 Light chain variable PGT141 Walker L. M. et al “Broad neutralization 9161 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession# AEN14419 HIV1543 Light chain variable PGT142 Walker L.M. et al “Broad neutralization 9162 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (20 1 I), NCBI Accessiots # AEN14385 HIV1544 Light chain variable PGT143 Walker L.M. et al “Broad neutralization 9163 region coverage of HIV by multiple liighly potent antibodies”. Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14421 HIV1545 Light chain variable PGT144 Walker L.M. et al “Broad neutralization 9164 region coverage of HIV by multiple highly potent antibodies”, Nature 477 (7365), 466-470 (2011), NCBI Accession # AEN14422 HIV1546 Light chain variable PGT151 Falkowska, E. et al “Broadly Neutralizing HIV 9165 region Antibodies Define a Gly can-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32543 HIV1547 Light chain variable PGT152 Falkowska, E. et al “Broadly Neutralizing HIV 9166 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32544 HIV1548 Light chain variable PGT153 Falkowska, E. et al “Broadly Neutralizing HIV 9167 region Antibodies Define a Glycan-Dependent Epitope on the Profusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (>). 657-668 (2014), NCBI Accession # AIC32545 HIV1549 Light chain variable PGT154 Falkowska, E. et al “Broadly Neutralizing HIV 9168 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32529 HIV1550 Light chain variable PGT155 Falkowska, E. et al “Broadly Neutralizing HIV 9169 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32547 HIV1551 Light chain variable PGT156 Falkowska, E. et al “Broadly Neutralizing HIV 9170 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32548 HIV1552 Light chain variable PGT157 Falkowska, E. et al “Broadly Neutralizing HIV 9171 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32549 HIV1553 Light chain variable PGTI58 Falkowska, E. et al “Broadly Neutralizing HIV 9172 region Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers” Immunity 40 (5), 657-668 (2014), NCBI Accession # AIC32550 HIV1554 Light chain variable rF105 WO1993012232 SEQ ID NO: 3 9173 region HIV1555 Light chain variable ScFvX5-CD4 U.S. Pat. No. 7,378,093B2 SEQ ID NO: 15 9174 region HIV1556 Light chain variable TNX-355, US20130195881 SEQ ID NO: 1 9175 region Idalizumab HIV1557 Light chain variable VCR14 US20150044137 SEQ ID NO: 25 9176 region HIV1558 Light chain variable VCR14b US20150044137 SEQ ID NO: 26 9177 region HIV1559 Light chain variable VCR14c US20150044137 SEQ ID NO: 27 9178 region HIV1560 Light chain variable VCR16 US20150044137 SEQ ID NO: 33 9179 region HIV1561 Light chain variable VCR16b US20150044137 SEQ ID NO: 34 9180 region HIV1562 Light chain variable VCR16c US20150044137 SEQ ID NO: 35 9181 region HIV1563 Light chain variable VCR16d US20150044137 SEQ ID NO: 36 9182 region HIV1564 Light chain variable VRC13 US20150044137 SEQ ID NO: 17 9183 region HIV1565 Light chain variable VRC13b US20150044137 SEQ ID NO: 18 9184 region HIV1566 Light chain variable VRC13c US20150044137 SEQ ID NO: 19 9185 region HIV1567 Light chain variable VRC13d US20150044137 SEQ ID NO: 20 9186 region HIV1568 Light chain variable VRC13e US20150044137 SEQ ID NO: 21 9187 region HIV1569 Light chain variable VRC13f US20150044137 SEQ ID NO: 22 9188 region HIV1570 Light chain variable VRC13g US20150044137 SEQ ID NO: 23 9189 region HIV1571 Light chain variable VRC13h US20150044137 SEQ ID NO: 24 9190 region HIV1572 Light chain variable VRC15 US20150044137 SEQ ID NO: 28 9191 region HIV1573 Light chain variable US20150004190 SEQ ID NO: 57 9192 region HIV1574 Light Chain, Fab Ch04 McLellan, J. S. et al., Structure of HIV-1 gp120 9193 V1 V2 domain with broadly neutralizing antibody PC9; Nature 480 (7377), 336-343 (2011), NCBI Accession # 3TCL_B (215aa) HIV1575 Light Chain, Fab N5-i5 Acharya, P., et al., Structural Definition of an 9194 Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV- 1 Infection; J. Virol. 88 (21), 12895-12906 (2014), NCBI Accession # 4H8W_L (217aa) HIV1576 Light Chain, Ig Nih45-46 Fab Diskin, R., et al., Science 334 (6060), 1289- 9195 Kappa Chain C 1293 (2011), NCBI Accession # 3U7Y_L Region (210aa) HIV1577 Light Chain, Ig Pgt127 Pejchal, R., et al., Science 334 (6059), 1097- 9196 Lambda-2 Chain C 1103 (2011), NCBI Accession # region 3TWC_L(211aa) HIV1578 Light Chain, Ig 7b2 Santra, S., et al., PLoS Pathol. 11 (8), 9197 Kappa Chain C E1005042 (2015), NCBI Accession # 4YDV_L Region (265aa) HIV1579 Light Chain; Fab N60-i3 Gohain, N., et al., Cocrystal Structures of 9198 Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Invoked in Effective Antibody- Dependent Effector Function against HIV-1; J. Virol. 89 (17), 8840-8854 (2015), NCBI Accession # 4RFO_L (221aa) HIV1580 Light Chain; Ig Pgt128 Pejchal, R., et al., Science 334 (6059), 1097- 9199 Lambda-2 Chain C 1103 (2011), NCBI Accession # 3TV3_L region (211aa) HIV1581 Scfv B11 U.S. Pat. No. 7,744,887B2 SEQ ID NO: 8 9200 HIV1582 Scfv U.S. Pat. No. 8,110,192B2 SEQ ID NO: 1 9201 HIV1583 Scfv U.S. Pat. No. 8,110,192B2 SEQ ID NO: 2 9202 HIV1584 Scfv U.S. Pat. No. 8,110,192B2 SEQ ID NO: 3 9203 HIV1585 Scfv (SEQRES) 3b3 variant Clark et al., Protein Sci. 18 (12), 2429-2441 9204 (2009), NCBI Accession # 3JUY_A (256aa) HIV1586 Scfv D5 U.S. Pat. No. 7,744,887B2 SEQ ID NO: 2 9205 HIV1587 Scfv-cd4 fusion U.S. Pat. No. 8,110,192B2 SEQ ID NO: 8 9206 protein HIV1588 447-52d Dhillon, A. K., et al., Acta Crystallogr. D Biol. 9207 Crystallogr. D64 (PT 7), 792-802 (2008), NCBI Accession # 3C2A_1(231aa) HIV1589 447-52d Dhillon, A. K., et al., Acta Crystallogr, D Biol. 9208 Crystallogr. D64 (PT 7), 792-802 (2008), NCBI Accession # 3C2A_M (216aa) HIV1590 F105 Wilkinson, R. A., et al., J. Virol. 79 (20), 13060- 9209 13069 (2005), NCBI Accession # 1U6A_H (224aa) HIV1591 F105 Wilkinson, R. A., et al., J. Virol. 79 (20), 13060- 9210 13069 (2005), NCBI Accession # 1U6A_L (215aa) HIV1592 Fab 8062 Frisch, C., et al., PLoS Pathol. 6 (11), 9211 E1001182 (2010), NCBI Accession # 3MAC_H (245aa) HIV1593 Fab 8062 Frisch, C., et al., PLoS Pathol. 6 (11), 9212 E1001182 (2010), NCBI Accession # 3MAC_L (213aa) HIV1594 Fab 8066 Frisch, C., et al., PLoS Pathol. 6 (11), 9213 E1001182 (2010), NCBI Accession # 3MA9_H (245aa) HIV1595 Fab 8066 Frisch, C., et al., PLoS Pathol. 6 (11), 9214 E1001182 (2010), NCBI Accession # 3MA9_L (213aa) HIV1596 Fab′2F5 U.S. Pat. No. 6,482,928 SEQ ID NO: 6 9215 fragment HIV1597 Fab′2F5 U.S. Pat. No. 6,482,928 SEQ ID NO: 7 9216 fragment HIV1598 M18 Fab Prabakaran, P., et al., J. Mol. Biol. 357 (1), 82- 9217 99 (2006), NCBI Accession # 2AJ3_D (228aa) HIV1599 M18 Fab Prabakaran, P., et al., J. Mol. Biol. 357 (1), 82- 9218 99 (2006), NCBI Accession # 2AJ3_E (213aa) HIV1600 Pg16 Pancera, M. et al., J. Virol. 84 (16), 8098-8110 9219 (2010), NCBI Accession # 3MME_A (238aa) HIV1601 Pg16 Paneera, M, et al., J. Virol. 84 (16), 8098-8110 9220 (2010), NCBI Accession # 3MME_B (216aa)

In one embodiment, the payload region of the AAV particle comprises one or more nucleic acid sequences, fragment or variants thereof or encodes one or more polypeptides, fragments or variants thereof described in European Patent Publication No. EP327000, EP478689, EP554401, EP581353 and EP711439, US Publication No US20110104163, US20110212106, US20130215726 and US20130251726, U.S. Pat. Nos. 5,266,479, 5,804,440, 6,657,050, 8,637,036, and 9,090,675, and International Publication No. WO2012154312, WO2013163427, WO2014043386, WO2015048462, WO2015048610, WO2015048770 the contents of each of which are herein incorporated by reference in their entirety, against HIV.

Disease Specific Epitopes, Innate Defense Regulator Peptides, Cyclic Peptides

In one embodiment, the viral genomes of the AAV particles may comprise nucleic acids which have been engineered to enable expression of antibodies binding to disease-specific epitopes of proteins. Such antibodies may be used to diagnose, prevent, and/or treat the corresponding medical conditions by targeting epitopes of the protein presented by or accessible on native or non-native forms (e.g., misfolded forms of native proteins) of the target Such epitopes may be specific to diseases involved with misfolding of a protein due to pathologic condition and resulting in misfolded aggregates. The disease-specific proteins are considered to be toxic to neurons and to have a role in neuronal cell death and dysfunction in neurodegenerative diseases including, but not limited to. Alzheimer's disease (AD), armyotrophic lateral sclerosis (ALS), Parkinson's disease, dementia by Lew body (DLB), and prion diseases. e.g. Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), kuru, and fatal farnilial insomnia (FFI).

In one embodiment, the encoded disease-specific epitopes may include epitopes on SOD1 that are revealed as SOD1 (Superoxide dismutase [Cu—Zn]) dissociates from its homodimeric, normal state. The SOD epitopes may be selectively presented or accessible in non-native SOD1 forms including misfolded SOD1 monomer, misfolded SOD1 dimer, and the epitopes selectively presented or accessible in SOD1 aggregates. Such epitopes may be specific to neurodegenerative diseases including, but not limited to, armyotrophic lateral sclerosis (ALS), Alzheimer's (AD). Parkinson's (PD), and Lewr body diseases (LBD).

In one embodiment, the expressed antibodies may bind to epitopes presented by or accessible on non-native forms of SOD1, such as those presented by SEQ ID NO: 2, 3, 5, 6, and 7 of U.S. Pat. No. 7,977,314 (the contents of which are herein incorporated by reference in its entirety), or presented by or accessible on monomeric forms of SOD1, such as those presented by SEQ ID NOs: 1 and 4 of U.S. Pat. No. 7,977,314, the contents of which are herein incorporated by reference in their entirety. In one embodiment, the expressed antibodies may comprise isolated peptides corresponding to such epitopes, such as those presented in SEQ ID NOs: 1-8 or SEQ ID NOs-8-16, or epitopes presented by SEQ ID NOs: 34-63, 65-79 of U.S. Pat. No. 7,977,314, the contents of which are herein incorporated by reference in their entirety.

In one embodiment, the encoded disease-specific epitopes may be specific to diseases associated with prion protein (PrP), familial amyloid polyneuropathy or senile systemic amyloidosis or a disease related by the presence of misfolded transthyretine (TTR); renal accumulation of 1(2 microglobulin amyloid deposits or a disease related by the presence of misfolded D12 microglobulin, amyotrophic lateral sclerosis (ALS) or a disease related by the presence of misfolded SOD1; leukemias or myelomas or a disease related by the presence of misfolded cluster of differentiation 38 (CD38); colon cancer metastasis and or a disease related by the presence of misfolded cluster of differentiation (CD44); tumors associated with tumor necrosis factor receptor (TNFR); cancers including cervical, head and neck, endometrial, lung and breast carcinomas, pleural mesotheliomas, malignant melanomas, Hodgkin lymphomas, anaplastic large cell non-Hodgkin lymphomas, or a disease related by the presence of misfolded Notch homolog 1 (NOTCH1) e.g. acute myeloid leukemias and B-cell chronic lymphoid leukemias; cancer in which Fas receptor (FasR) is implicated, cancers and related disorders in which misfolded epidermal growth factor (EGFR) is implicated; and/or other related diseases, disorders and conditions.

In one embodiment, the encoded disease specific epitopes may include epitopes that are revealed as the proteins misfold. In one embodiment, the expressed antibodies may bind to predicted epitopes of human PrP, such as those presented by SEQ ID NOs: 1-10 of US Patent Publication No. US20100233176; bovine PrP, such as those presented by SEQ ID NOs: 11-15 of US Patent Publication No. US20100233176. TTR, such as those presented by SEQ ID NOs: 16-22 of US Patent Publication No US20100233176; beta-2 microglobulin, such as those presented by SEQ ID NOs: 23-26 of US Patent Publication No. US20100233176; SOD1, such as those presented by SEQ ID NOs: 27-40 of US Patent Publication No. US201100233176; CD38, such as those presented by SEQ ID NOs: 41-45 of US Patent Publication No. US20100233176; CD44, such as those presented by 46-50 of US Patent Publication No. US20100233176; TNFR, such as those presented by 51-55 of US Patent Publication No. US20100233176; notch protein, such as those presented in SEQ ID NOs: 56-60 of US Patent Publication No US201100233176; FasR, such as those presented by SEQ ID NOs: 61-65 of US Patent Publication No. US20100233176 and EGFR, such as those presented by SEQ ID NOs: 66-80 of US Patent Publication No. US20100233176; the contents of which are herein incorporated by reference in their entirety.

In one embodiment, the expressed antibodies may comprise peptides corresponding to such epitopes. In one embodiment, the expressed antibodies may comprise prion-specific peptides, such as those presented by SEQ ID NOs: 81-88 of US Patent Publication No. US20100233176, the contents of which are herein incorporated by reference in their entirety, and variations thereof.

In one embodiment, the encoded disease-specific epitopes may be specific to prion diseases, including transmissible spongiform encephalopathies (TSEs) or other prion diseases. In one embodiment, the expressed antibodies may bind to predicted epitopes of PrP, such as those presented by SEQ ID NOs: 24, 26, 28, 30, 32, 34, 36, 39-43, of US Patent Publication No. US20150004185, the contents of which are herein incorporated by reference in their entirety. In one embodiment, the expressed antibodies may comprise prion-specific peptides or peptide fusions, such as those presented by SEQ ID NOs: 12-23, 25, 27, 29, 31, 33, 35, 37, 38, 43, and 44-48 of US Patent Publication No. US20150004185, the contents of which are herein incorporated by reference in their entirety.

In one embodiment, the expressed antibodies may comprise prion peptides binding to prion specific abnormal isoform of the prion protein, such as those presented by SEQ ID NOs: 2-10 of US Patent Publication No. US20040072236, the contents of which are herein incorporated by reference in their entirety.

In one embodiment, the viral genomes of the AAV particles may comprise nucleic acids which have been engineered to express innate defense regulator (IDR) peptides. IDRs are immunomodulatory peptides that act directly on cells to effect an innate immune response. Such IDRs may be used to treat neurodegenerative diseases associated with neuroinflammation, e.g. amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Friedreich's ataxia. Huntington's disease, Lewr body disease, Parkinson's disease, spinal muscular atrophy, and multiple sclerosis (MS) and other neurodegenerative diseases. In one embodiment. IDRs may be those presented by SEQ ID NOS: 1-969, and 973-1264 of International Publication No. WO2013034982, the contents of which are herein incorporated by reference in their entirety, or analogs, derivatives, amidated variations and conservative variations thereof.

In one embodiment, the viral genomes of the AAV particles may comprise nucleic acids which have been engineered to express antibodies binding to an epitope of the Tropomyosin receptor kinase (TrkC) receptor. Such antibodies may comprise a peptide, such as one presented by SEQ ID NO: 1 of U.S. Pat. No. 9,200,080, the contents of which are herein incorporated by reference in their entirety.

In some embodiments, the viral genomes of the AAV particles may comprise nucleic acids which have been engineered to express cyclic peptides with an amino acid sequence SNK, Non-limiting examples of other cyclic peptides include SEQ ID NO: 1-7 of U.S. Pat. No. 9,216,217, the contents of which are herein incorporated by reference in their entirety. The method of preparing the antibodies may include hyperimmune preparation method, as described in U.S. Pat. No. 9,216,217, the contents of which are herein incorporated by reference in their entirety.

Prions

In one embodiment, the viral genomes of the AAV particles may comprise a nucleic acid sequence encoding antibodies comprising prion peptides comprising prion epitopes, and fusions and repeats thereof, such as those presented by SEQ ID NOs: 8-32, 35, and 36 of U.S. Pat. No. 9,056,918, the contents of which are herein incorporated by reference in their entirety.

In one embodiment, the viral genomes of the AAV particles may comprise a nucleic acid sequence encoding prion binding proteins (PrPBP). In one embodiment, the PrPBPs are cadherins, such as those presented by SEQ ID NOs: 1 and 2 of International Publication WO 1997/045746, the contents of which are herein incorporated by reference in their entirety. In one embodiment, the PrPBPs are cadherins, such as those presented by SEQ ID NOs: 2 and 7-9 of International Publication No. WO2001000235, the contents of which are herein incorporated by reference in their entirety.

The Nature of the Polypeptides and Variants

Antibodies encoded by payload regions of the viral genomes of the invention may be translated as a whole polypeptide, a plurality of polypeptides or fragments of polypeptides, which independently may be encoded by one or more nucleic acids, fragments of nucleic acids or variants of any of the aforementioned. As used herein, “polypeptide” means a polymer of amino acid residues (natural or unnatural) linked together most often by peptide bonds. The term, as used herein, refers to proteins, polypeptides, and peptides of any size, structure, or function. In some instances, the polypeptide encoded is smaller than about 50 amino acids and the polypeptide is then termed a peptide. If the polypeptide is a peptide, it will be at least about 2, 3, 4, or at least 5 amino acid residues long. Thus, polypeptides include gene products, naturally occurring polypeptides, synthetic polypeptides, homologs, orthologs, paralogs, fragments and other equivalents, variants, and analogs of the foregoing. A polypeptide may be a single molecule or may be a multi-molecular complex such as a dimer, trimer or tetramer. They may also comprise single chain or multichain polypeptides and may be associated or linked. The term polypeptide may also apply to amino acid polymers in which one or more amino acid residues are an artificial chemical analogue of a corresponding naturally occurring amino acid.

The term “polypeptide variant” refers to molecules which differ in their amino acid sequence from a native or reference sequence. The amino acid sequence variants may possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence, as compared to a native or reference sequence Ordinarily, variants will possess at least about 50% identity (homology) to a native or reference sequence, and preferably, they will be at least about 80%, more preferably at least about 90% identical (homologous) to a native or reference sequence.

In some embodiments “variant mimics” are provided. As used herein, the term “variant mimic” is one which contains one or more amino acids which would mimic an activated sequence. For example, glutamate may serve as a mimic for phosphoro-threonine and/or phosphoro-serine. Alternatively, variant mimics may result in deactivation or in an inactivated product containing the mimic, e.g., phenylalanine may act as an inactivating substitution for tyrosine; or alanine may act as an inactivating substitution for serine.

The term “amino acid sequence variant” refers to molecules with some differences in their amino acid sequences as compared to a native or starting sequence. The amino acid sequence variants may possess substitutions, deletions, and/or insertions at certain positions within the amino acid sequence. “Native” or “starting” sequence should not be confused with a wild type sequence. As used herein, a native or starting sequence is a relative term referring to an original molecule against which a comparison may be made. “Native” or “starting” sequences or molecules may represent the wild-type (that sequence found in nature) but do not have to be the wild-type sequence.

Ordinarily, variants will possess at least about 70% homology to a native sequence, and preferably, they will be at least about 80%, more preferably at least about 90% homologous to a native sequence. “Homology” as it applies to amino acid sequences is defined as the percentage of residues in the candidate amino acid sequence that are identical with the residues in the amino acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology. Methods and computer programs for the alignment are well known in the art. It is understood that homology depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation.

By “homologs” as it applies to amino acid sequences is meant the corresponding sequence of other species having substantial identity to a second sequence of a second species.

“Analogs” is meant to include polypeptide variants which differ by one or more amino acid alterations, e.g., substitutions, additions or deletions of amino acid residues that still maintain the properties of the parent polypeptide.

Sequence tags or amino acids, such as one or more lysines, can be added to the peptide sequences of the invention (e.g., at the N-terminal or C-terminal ends). Sequence tags can be used for peptide purification or localization. Lysines can be used to increase peptide solubility or to allow for biotinylation. Alternatively, amino acid residues located at the carboxy and amino terminal regions of the amino acid sequence of a peptide or protein may optionally be deleted providing for truncated sequences. Certain amino acids (e.g., C-terminal or N-terminal residues) may alternatively be deleted depending on the use of the sequence, as for example, expression of the sequence as part of a larger sequence which is soluble, or linked to a solid support.

“Substitutional variants” when referring to proteins are those that have at least one amino acid residue in a native or starting sequence removed and a different amino acid inserted in its place at the same position. The substitutions may be single, where only one amino acid in the molecule has been substituted, or they may be multiple, where two or more amino acids have been substituted in the same molecule.

As used herein the term “conservative amino acid substitution” refers to the substitution of an amino acid that is normally present in the sequence with a different amino acid of similar size, charge, or polarity. Examples of conservative substitutions include the substitution of a non-polar (hydrophobic) residue such as isoleucine, valine and leucine for another non-polar residue. Likewise, examples of conservative substitutions include the substitution of one polar (hydrophilic) residue for another such as between arginine and lysine, between glutamine and asparagine, and between glycine and serine. Additionally, the substitution of a basic residue such as lysine, arginine or histidine for another, or the substitution of one acidic residue such as aspartic acid or glutamic acid for another acidic residue are additional examples of conservative substitutions. Examples of non-conservative substitutions include the substitution of a non-polar (hydrophobic) amino acid residue such as isoleucine, valine, leucine, alanine, methionine for a polar (hydrophilic) residue such as cysteine, glutanane, glutamic acid or lysine and/or a polar residue for a non-polar residue.

“Insertional variants” when referring to proteins are those with one or more amino acids inserted immediately adjacent to an amino acid at a particular position in a native or starting sequence. “Immediately adjacent” to an amino acid means connected to either the alpha-carboxy or alpha-amino functional group of the amino acid.

“Deletional variants” when referring to proteins, are those with one or more amino acids in the native or starting amino acid sequence removed. Ordinarily, deletional variants will have one or more amino acids deleted in a particular region of the molecule.

As used herein, the term “derivative” is used synonymously with the term “variant” and refers to a molecule that has been modified or changed in any way relative to a reference molecule or starting molecule. In some embodiments, derivatives include native or starting proteins that have been modified with an organic proteinaceous or non-proteinaceous derivatizing agent, and post-translational modifications. Covalent modifications are traditionally introduced by reacting targeted amino acid residues of the protein with an organic derivatizing agent that is capable of reacting with selected side-chains or terminal residues, or by harnessing mechanisms of post-translational modifications that function in selected recombinant host cells. The resultant covalent derivatives are useful in programs directed at identifying residues important for biological activity, for immunoassays, or for the preparation of anti-protein antibodies for immunoaffinity purification of the recombinant glycoprotein. Such modifications are within the ordinary skill in the art and are performed without undue experimentation.

Certain post-translational modifications are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deaminated to the corresponding glutamyl and aspartyl residues. Alternatively, these residues are deaminated under mildly acidic conditions. Either form of these residues may be present in the proteins used in accordance with the present invention.

Other post-translational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the alpha-amino groups of lysine, arginine, and histidine side chains (T. E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)).

“Features” when referring to proteins are defined as distinct amino acid sequence-based components of a molecule. Features of the proteins of the present invention include surface manifestations, local conformational shape, folds, loops, half-loops, domains, half-domains, sites, termini or any combination thereof.

As used herein when referring to proteins the term “surface manifestation” refers to a polypeptide based component of a protein appearing on an outermost surface.

As used herein when referring to proteins the term “local conformational shape” means a polypeptide based structural manifestation of a protein which is located within a definable space of the protein.

As used herein when referring to proteins the term “fold” means the resultant conformation of an amino acid sequence upon energy minimization. A fold may occur at the secondary or tertiary level of the folding process. Examples of secondary level folds include beta sheets and alpha helices Examples of tertiary folds include domains and regions formed due to aggregation or separation of energetic forces. Regions formed in this way include hydrophobic and hydrophilic pockets, and the like.

As used herein the term “turn” as it relates to protein conformation means a bend which alters the direction of the backbone of a peptide or polypeptide and may involve one, two, three or more amino acid residues.

As used herein when referring to proteins the term “loop” refers to a structural feature of a peptide or polypeptide which reverses the direction of the backbone of a peptide or polypeptide and comprises four or more amino acid residues. Oliva et al. have identified at least 5 classes of protein loops (J. Mol Biol 266 (4): 814-830: 1997).

As used herein when referring to proteins the term “half-loop” refers to a portion of an identified loop having at least half the number of amino acid residues as the loop from which it is derived. It is understood that loops may not always contain an even number of amino acid residues. Therefore, in those cases where a loop contains or is identified to comprise an odd number of amino acids, a half-loop of the odd-numbered loop will comprise the whole number portion or next whole number portion of the loop (number of amino acids of the loop/2+/−0.5 amino acids). For example, a loop identified as a 7 amino acid loop could produce half-loops of 3 amino acids or 4 amino acids (7/2=3.5+/−0.5 being 3 or 4).

As used herein when referring to proteins the term “domain” refers to a motif of a polypeptide having one or more identifiable structural or functional characteristics or properties (e.g., binding capacity, serving as a site for protein-protein interactions).

As used herein when referring to proteins the term “half-domain” means portion of an identified domain having at least half the number of amino acid residues as the domain from which it is derived. It is understood that domains may not always contain an even number of amino acid residues. Therefore, in those cases where a domain contains or is identified to comprise an odd number of amino acids, a half-domain of the odd-numbered domain will comprise the whole number portion or next whole number portion of the domain (number of amino acids of the domain/2+/−0.5 amino acids). For example, a domain identified as a 7 amino acid domain could produce half-domains of 3 amino acids or 4 amino acids (7/2=3.5+/−0.5 being 3 or 4). It is also understood that sub-domains may be identified within domains or half-domains, these subdomains possessing less than all of the structural or functional properties identified in the domains or half domains from which they were derived. It is also understood that the amino acids that comprise any of the domain types herein need not be contiguous along the backbone of the poly peptide (i.e., nonadjacent amino acids may fold structurally to produce a domain, half-domain or subdomain).

As used herein when referring to proteins the terms “site” as it pertains to amino acid based embodiments is used synonymous with “amino acid residue” and “amino acid side chain”. A site represents a position within a peptide or polypeptide that may be modified, manipulated, altered, derivatized or varied within the polypeptide based molecules of the present invention.

As used herein the terms “termini or terminus” when referring to proteins refers to an extremity of a peptide or polypeptide. Such extremity is not limited only to the first or final site of the peptide or polypeptide but may include additional amino acids in the terminal regions. The polypeptide based molecules of the present invention may be characterized as having both an N-terminus (terminated by an amino acid with a free amino group (NH2)) and a C-terminus (terminated by an amino acid with a free carboxyl group (COOH)). Proteins of the invention are in some cases made up of multiple polypeptide chains brought together by disulfide bonds or by non-covalent forces (multimers, oligomers). These sorts of proteins will have multiple N- and C-termini. Alternatively, the termini of the polypeptides may be modified such that they begin or end, as the case may be, with a non-polypeptide based moiety such as an organic conjugate.

Once any of the features have been identified or defined as a component of a molecule of the invention, any of several manipulations and/or modifications of these features may be performed by moving, swapping, inverting, deleting, randomizing or duplicating. Furthermore, it is understood that manipulation of features may result in the same outcome as a modification to the molecules of the invention. For example, a manipulation which involves deleting a domain would result in the alteration of the length of a molecule just as modification of a nucleic acid to encode less than a full-length molecule would.

Modifications and manipulations can be accomplished by methods known in the art such as site directed mutagenesis. The resulting modified molecules may then be tested for activity using in vitro or in vivo assays such as those described herein or any other suitable screening assay known in the art.

AAV Production

The present invention provides methods for the generation of parvoviral particles, e.g. AAV particles, by viral genome replication in a viral replication cell.

In accordance with the invention, the viral genome comprising a payload region encoding an antibody, an antibody-based composition or fragment thereof, will be incorporated into the AAV particle produced in the viral replication cell. Methods of making AAV particles are well known in the art and are described in e.g., U.S. Pat. Nos. 6,204,059, 5,756,283, 6,258,595, 6,261,551, 6,270,996, 6,281,10, 6,365,394, 6,475,769, 6,482,634, 6,4859,669, 6,943,01, 6,953,690, 7,022,519, 7,238,526, 7,291,498 and 7,491,508, 5,064,764, 6,194,191, 6,566,118, 8,137,948, or International Publication Nos. WO1996039530, WO1998010088, WO999014354, WO1999015685, WO1999047691, WO2000055342, WO2000075353 and WO2001023597; Methods In Molecular Biology, ed. Richard, Humana Press, N J (1995); O'Reilly et al., Baculovirus Expression Vectors, A Laboratory Manual. Oxford Univ. Press (1994); Samulski et al., J. Vir. 63:3822-8 (1989); Kajigaya et al., Proc. Nat'l. Acad. Sci. USA 88: 4646-50 (1991); Ruffing et al., J. Vir. 66:6922-30 (1992); Kimbauer et al., Vir. 219:37-44 (1996); Zhao et al., Vir. 272:382-93 (2000); the contents of each of which are herein incorporated by reference in their entirety. In one embodiment, the AAV particles are made using the methods described in WO2015191508, the contents of which are herein incorporated by reference in their entirety.

Viral replication cells commonly used for production of recombinant AAV viral vectors include but are not limited to 293 cells, COS cells. HeLa cells, KB cells, and other mammalian cell lines as described in U.S. Pat. Nos. 6,156,303, 5,387,484, 5,741,683, 5,691,176, and 5,688,676; U.S. patent publication No. 2002/0081721, and International Patent Publication Nos. WO 00/47757, WO 00/24916, and WO 96/17947, the contents of each of which are herein incorporated by reference in their entireties.

In some embodiments, the present invention provides a method for producing an AAV particle having enhanced (increased, improved) transduction efficiency comprising the steps of: 1) co-transfecting competent bacterial cells with a bacmid vector and either a viral construct vector and/or AAV payload construct vector, 2) isolating the resultant viral construct expression vector and AAV payload construct expression vector and separately transfecting viral replication cells, 3) isolating and purifying resultant payload and viral construct particles comprising viral construct expression vector or AAV payload construct expression vector, 4) co-infecting a viral replication cell with both the AAV payload and viral construct particles comprising viral construct expression vector or AAV payload construct expression vector, and 5) harvesting and purifying the AAV particle comprising a viral genome.

In some embodiments, the present invention provides a method for producing an AAV particle comprising the steps of 1) simultaneously co-transfecting mammalian cells, such as, but not limited to HEK293 cells, with a pay load region, a construct expressing rep and cap genes and a helper construct, 2) harvesting and purifying the AAV particle comprising a viral genome.

In some embodiments, the viral genome of the AAV particle of the invention optionally encodes a selectable marker. The selectable marker may comprise a cell-surface marker, such as any protein expressed on the surface of the cell including, but not limited to receptors. CD markers, lectins, integrins, or truncated versions thereof.

In some embodiments, selectable marker reporter genes as described in International application No WO 96/23810, Heirn et al, Current Biology 2:178-182 (1996); Heim et al., Proc. Natl. Acad. Sci. USA (1995); or Heim et al., Science 373:663-664 (1995); WO 96/30540, the contents of each of which are incorporated herein by reference in their entireties).

II. Formulation and Delivery

Pharmaceutical Compositions

According to the present invention the AAV particles may be prepared as pharmaceutical compositions. It will be understood that such compositions necessarily comprise one or more active ingredients and, most often, a pharmaceutically acceptable excipient.

Relative amounts of the active ingredient (e.g. AAV particle), a pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.

In some embodiments, the AAV particle pharmaceutical compositions described herein may comprise at least one pa load. As a non-limiting example, the pharmaceutical compositions may contain an AAV particle with 1, 2, 3, 4 or 5 payloads. In one embodiment, the pharmaceutical composition may contain a nucleic acid encoding a payload construct encoding proteins selected from antibodies and/or antibody-based compositions.

Although the descriptions of pharmaceutical compositions provided herein are principally directed to pharmaceutical compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to any other animal, e.g., to non-human animals, e.g. non-human mammals. Modification of pharmaceutical compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the pharmaceutical compositions is contemplated include, but are not limited to, humans and/or other primates; mammals, including commercially relevant mammals such as cattle, pigs, horses, sheep, cats, dogs, mice, rats, birds, including commercially relevant birds such as poultry, chickens, ducks, geese, and/or turkeys.

In some embodiments, compositions are administered to humans, human patients or subjects.

Formulations

The AAV particles of the invention can be formulated using one or more excipients to: (1) increase stability; (2) increase cell transfection or transduction; (3) permit the sustained or delayed expression of the payload; (4) alter the biodistribution (e.g., target the viral particle to specific tissues or cell types); (5) increase the translation of encoded protein; (6) alter the release profile of encoded protein and/or (7) allow for regulatable expression of the payload.

Formulations of the present invention can include, without limitation, saline, liposomes, lipid nanoparticles, polymers, peptides, proteins, cells transfected with viral vectors (e.g., for transfer or transplantation into a subject) and combinations thereof.

Formulations of the pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. As used herein the term “pharmaceutical composition” refers to compositions comprising at least one active ingredient and optionally one or more pharmaceutically acceptable excipients.

In general, such preparatory methods include the step of associating the active ingredient with an excipient and/or one or more other accessory ingredients. As used herein, the phrase “active ingredient” generally refers either to an AAV particle carrying a payload region encoding the polypeptides of the invention or to the antibody or antibody-based composition encoded by a viral genome of by an AAV particle as described herein.

Formulations of the AAV particles and pharmaceutical compositions described herein may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include the step of bringing the active ingredient into association with an excipient and/or one or more other accessor ingredients, and then, if necessary and/or desirable, dividing, shaping and/or packaging the product into a desired single- or multi-dose unit.

A pharmaceutical composition in accordance with the present disclosure may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a “unit dose” refers to a discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.

In one embodiment, the AAV particles of the invention may be formulated in PBS with 0.001% of pluronic acid (F-68) at a pH of about 7.0.

Relative amounts of the active ingredient (e.g. AAV particle), the pharmaceutically acceptable excipient, and/or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure may vary, depending upon the identity, size, and/or condition of the subject being treated and further depending upon the route by which the composition is to be administered. For example, the composition may comprise between 0.1% and 99% (w/w) of the active ingredient. By way of example, the composition may comprise between 0.1% and 100%, e.g., between 0.5 and 50%, between 1-30%, between 5-80%, at least 80% (w/w) active ingredient.

In some embodiments, the AAV formulations described herein may contain sufficient AAV particles for expression of at least one expressed functional antibody or antibody-based composition. As a non-limiting example, the AAV particles may contain viral genomes encoding 1, 2, 3, 4 or 5 functional antibodies.

According to the present invention AAV particles may be formulated for CNS delivery. Agents that cross the brain blood barrier may be used. For example, some cell penetrating peptides that can target molecules to the brain blood barrier endothelium may be used for formulation (e.g., Mathupala, Expert Opin Ther Pat., 2009, 19, 137-140; the content of which is incorporated herein by reference in its entirety).

Excipients and Diluents

The AAV particles of the invention can be formulated using one or more excipients or diluents to (1) increase stability; (2) increase cell transfection or transduction; (3) permit the sustained or delayed release; (4) alter the biodistribution (e.g. target the viral particle to specific tissues or cell types); (5) increase the translation of encoded protein in vivo; (6) alter the release profile of encoded protein in vivo and/or (7) allow for regulatable expression of the polypeptides of the invention.

In some embodiments, a pharmaceutically acceptable excipient may be at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use for humans and for veterinary use. In some embodiments, an excipient may be approved by United States Food and Drug Administration. In some embodiments, an excipient may be of pharmaceutical grade. In some embodiments, an excipient may meet the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.

Excipients, as used herein, include, but are not limited to, any and all solvents, dispersion media, diluents, or other liquid vehicles, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, and the like, as suited to the particular dosage form desired. Various excipients for formulating pharmaceutical compositions and techniques for preparing the composition are known in the art (see Remington: The Science and Practice of Pharmacy, 21st Edition, A R Gennaro. Lippincott, Williams & Wilkins, Baltimore, Md., 2006; incorporated herein by reference in its entirety). The use of a conventional excipient medium may be contemplated within the scope of the present disclosure, except insofar as any conventional excipient medium may be incompatible with a substance or its derivatives, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutical composition.

Exemplary diluents include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, etc., and/or combinations thereof.

Inactive Ingredients

In some embodiments, AAV particle formulations may comprise at least one inactive ingredient. As used herein, the term “inactive ingredient” refers to one or more agents that do not contribute to the activity of the active ingredient of the pharmaceutical composition included in formulations. In some embodiments, all, none or some of the inactive ingredients which may be used in the formulations of the present invention may be approved by the US Food and Drug Administration (FDA).

In one embodiment, the AAV particle pharmaceutical compositions comprise at least one inactive ingredient such as, but not limited to, 1,2,6-Hexanetriol; 1,2-Dimyristoyl-Sn-Glycero-3-(Phospho-S-(1-Glycerol)); 1,2-Dilmyristoyl-Sn-Glycero-3-Phospho choline; 1,2-Dioleoyl-Sn-Glycero-3-Phosphocholine; 1,2-Dialmitoyl-Sn-Glycero-3-(Phospho-Rac-(1-Glycerol)); 1,2-Distearyl-Sn-Glycero-3-(Phospho-Rac-(1-Glycerol)); 1,2-Distearoyl-Sn-Glycero-3-Phosphocholine; 1-O-Tolylbiguanide; 2-Ethyl-1,6-Hexanediol; Acetic Acid; Acetic Acid, Glacial; Acetic Anhydride; Acetone, Acetone Sodium Bisulfite; Acetylated Lanolin Alcohols; Acetylated Monoglycerides; Acetylcysteine; Acetyltryptophan. DL-; Acrylates Copolymer; Acrylic Acid-Isooctyl Acrylate Copolymer; Acrylic Adhesive 788; Activated Charcoal; Adcote 72A103; Adhesive Tape; Adipic Acid; Aerotex Resin 3730; Alanine; Albumin Aggregated; Albumin Colloidal, Albumin Human, Alcohol, Alcohol, Dehydrated; Alcohol, Denatured; Alcohol; Diluted; Alfadex; Alginic Acid; Alkyl Ammonium Sulfonic Acid Betaine; Alkyl Aryl Sodium Sulfonate; Allantoin; Allyl .Alpha-Ionone; Almond Oil; Alpha-Terpineol; Alpha-Tocopherol; Alpha-Tocopherol Acetate; Dl-; Alpha-Tocopherol; Dl-; Aluminum Acetate; Aluminum Chlorhydroxy Allantoinate; Aluminum Hydroxide; Aluminum Hydroxide-Sucrose; Hydrated; Aluminum Hydroxide Gel; Aluminum Hydroxide Gel F 500; Aluminum Hydroxide Gel F 5000; Aluminum Monostearate; Aluminum Oxide; Aluminum Polyester; Aluminum Silicate; Aluminum Starch Octenylsuccinate; Aluminum Stearate; Aluminum Subacetate; Aluminum Sulfate Anhydrous; Amerchol C; Amerchol-Cab; Aminomethylpropanol; Ammonia; Ammonia Solution; Ammonia Solution; Strong; Ammonium Acetate; Ammonium Hydroxide; Ammonium Lauryl Sulfate; Ammonium Nonoxynol-4 Sulfate; Ammonium Salt Of C-12-C-15 Linear Primary Alcohol Ethoxylate; Ammonium Sulfate; Ammonyx; Amphoteric-2; Amphoteric-9; Anethole; Anhydrous Citric Acid; Anhydrous Dextrose; Anhydrous Lactose; Anhydrous Trisodium Citrate; Aniseed Oil; Anoxid Sbn; Antifoam; Antipyrine; Apaflurane; Apricot Kernel Oil Peg-6 Esters; Aquaphor; Arginine; Arlacel; Ascorbic Acid; Ascorbyl Palmitate; Aspartic Acid; Balsam Peru; Barium Sulfate; Beeswax; Beeswax; Synthetic; Beheneth-10; Bentonite; Benzalkonium Chloride; Benzenesulfonic Acid; Benzethonium Chloride; Benzododecinium Bromide; Benzoic Acid; Benzyl Alcohol; Benzyl Benzoate; Benzyl Chloride; Betadex; Bibapcitide; Bismuth Subgallate; Boric Acid; Brocrinat; Butane; Butyl Alcohol; Butyl Ester Of Vinyl Methyl Ether/Maleic Anhydride Copolymer (125000) Mw); Butyl Stearate; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Butylene Glycol; Butylparaben; Butyric Acid; C20-40 Pareth-24; Caffeine; Calcium; Calcium Carbonate; Calcium Chloride; Calcium Gluceptate; Calcium Hydroxide; Calcium Lactate; Calcobutrol; Caldiamide Sodium; Caloxetate Trisodium; Calteridol Calcium; Canada Balsam; Caprylic/Capric Triglyceride; Caprylic/Capric/Stearic Triglyceride; Captan; Captisol; Caramel; Carbomer 1342; Carbomer 1382; Carbomer 934; Carbomer 934p; Carbomer 940; Carbomer 941; Carbomer 980; Carbomer 981; Carbomer Homopolymer Type B (Allyl Pentaerythrtol Crosslinked); Carbomer Homopolymer Type C (Allyl Pentaerythritol Crosslinked); Carbon Dioxide; Carboxy Vinyl Copolymer; Carboxymethylcellulose; Carboxymethylcellulose Sodium; Carboxypolymethylene; Carrageenan; Carrageenan Salt; Castor Oil; Cedar Leaf Oil; Cellulose; Cellulose; Microcrystalline; Cerasynt-Se; Ceresin; Ceteareth-12; Ceteareth-15; Ceteareth-30; Cetearyl Alcohol/Ceteareth-20; Cetearyl Ethylhexanoate; Ceteth-10; Ceteth-2; Ceteth-20; Ceteth-23; Cetostearyl Alcohol; Cetrimonium Chloride; Cetyl Alcohol; Cetyl Esters Wax; Cetyl Palmitate; Cetylpyridinium Chloride; Chlorobutanol; Chlorobutanol H-Hhemihydrate; Chlorobutanol; Anhydrous; Chlorocresol; Chloroxylenol; Cholesterol; Choleth; Choleth-24; Citrate; Citric Acid; Citric Acid Monohydrate; Citric Acid, Hydrous. Cocamide Ether Sulfate; Cocamine Oxide; Coco Betaine; Coco Diethanolamide; Coco Monoethanolamide, Cocoa Butter; Coco-Glycerides; Coconut Oil; Coconut Oil; Hydrogenated; Coconut Oil/Palm Kernel Oil Glycerides, Hydrogenated; Cocoyl Caprylocaprate; Cola Nitida Seed Extract; Collagen; Coloring Suspension, Corn Oil. Cottonseed Oil; Cream Base; Creatine; Creatinine; Cresol; Croscarmellose Sodium; Crospovidone; Cupric Sulfate, Cupric Sulfate Anhydrous; Cyclomethicone; Cyclomethicone/Dimethicone Copolyol; Cysteine; Cysteine Hydrochloride; Cysteine Hydrochloride Anhydrous; Cysteine, D1-; D&C Red No. 28; D&C Red No. 33; D&C Red No. 36; D&C Red No. 39, D&C Yellow No. 10; Dalfampridine; Daubert 1-5 Pestr (Matte) 164z; Decyl Methyl Sulfoxide; Dehydag Wax Sx; Dehydroacetic Acid; Dehymuls E; Denatonium Benzoate; Deoxycholic Acid; Dextran; Dextran 40; Dextrin; Dextrose; Dextrose Monohydrate, Dextrose Solution; Diatrizoic Acid; Diazolidinyl Urea; Dichlorobenzl Alcohol; Dichlorodifluoromethane; Dichlorotetrafluoroethane; Diethanolamine, Diethyl Pyrocarbonate; Diethyl Sebacate; Diethylene Glycol Monoethyl Ether; Diethylhexyl Phthalate; Dihydroxyaluminum Aminoacetate; Diisopropanolamine; Diisopropyl Adipate; Diisopropyl Dilinoleate, Dimethicone 350; Dimethicone Copolyol; Dimethicone Mdx4-4210; Dimethicone Medical Fluid 360; Dimethyl Isosorbide; Dimethyl Sulfoxide; Dimethylaminoethyl Methacrylate-Butyl Methacrylate—Methyl Methacrylate Copolymer; Dimethyldioctadecylammonium Bentonite; Dimethylsiloxane/Methylvinylsiloxane Copolymer; Dinoseb Ammonium Salt; Dipalmitoylphosphatidylglycerol, Dl-; Dipropylene Glycol; Disodium Cocoamphodiacetate; Disodium Laureth Sulfosuccinate; Disodium Lauryl Sulfosuccinate; Disodium Sulfosalicylate; Disofenin; Divinylbenzene Styrene Copolymer; Dmdm Hydantoin; Docosanol; Docusate Sodium, Duro-Tak 280-2516; Duro-Tak 387-2516; Duro-Tak 80-1196, Duro-Tak 87-2070; Duro-Tak 87-2194; Duro-Tak 87-2287; Duro-Tak 87-2296; Duro-Tak 87-2888; Duro-Tak 87-2979; Edetate Calcium Disodium; Edetate Disodium; Edetate Disodium Anhydrous; Edetate Sodium; Edetic Acid; Egg Phospholipids, Entsufon; Entsufon Sodium; Epilactose; Epitetracycline Hydrochloride; Essence Bouquet 9200; Ethanolamine Hydrochloride, Ethyl Acetate; Ethyl Oleate; Ethylcelluloses; Ethylene Glycol; Ethylene Vinyl Acetate Copolymer; Ethylenediamrne; Ethylenediamrne Dihydrochloride. Ethylene-Propylene Copolymer; Ethylene-Vinyl Acetate Copolymer (28% Vinyl Acetate), Ethylene-Vinyl Acetate Copolymer (9% Vinylacetate); Ethylhexyl Hydroxystearate; Ethylparaben; Eucalyptol; Exametazime; Fat, Edible; Fat, Hard; Fatty Acid Esters; Fatty Acid Pentaerythriol Ester; Fatty Acids; Fatty Alcohol Citrate; Fatty Alcohols; Fd&C Blue No. 1; Fd&C Green No. 3; Fd&C Red No. 4; Fd&C Red No. 40; Fd&C Yellow No. 10 (Delisted); Fd&C Yellow No 5; Fd&C Yellow No 6; Ferric Chloride; Ferric Oxide; Flavor 89-186; Flavor 89-259. Flavor Df-119; Flavor Df-1530; Flavor Enhancer; Flavor Fig 827118; Flavor Raspberry Pfc-8407; Flavor Rhodia Pharmaceutical No. Rf 451; Fluorochlorohydrocarbons; Formaldehyde; Formaldehyde Solution; Fractionated Coconut Oil; Fragrance 3949-5; Fragrance 520a; Fragrance 6.007; Fragrance 91-122; Fragrance 9128-Y; Fragrance 93498g; Fragrance Balsam Pine No. 5124. Fragrance Bouquet 10328; Fragrance Chemoderm 6401-B; Fragrance Chemoderm 6411, Fragrance Cream No. 73457, Fragrance Cs-28197; Fragrance Felton 066m; Fragrance Firmenich 47373; Fragrance Givaudan Ess 9090/1c; Fragrance H-6540; Fragrance Herbal 10396, Fragrance Nj-1085; Fragrance PO Fl-147. Fragrance Pa 52805; Fragrance Pera Derm D, Fragrance Rbd-9819; Fragrance Shaw Mudge U-7776; Fragrance Tf 044078; Fragrance Ungerer Honeysuckle K 2771; Fragrance Ungerer N5195; Fructose; Gadolinium Oxide; Galactose; Gamma Cyclodextrin; Gelatin; Gelatin, Crosslinked; Gelfoam Sponge; Gellan Gum (Low Acyl); Gelva 737; Gentisic Acid; Gentisic Acid Ethanolamide, Gluceptate Sodium; Gluceptate Sodium Dihydrate; Gluconolactone, Glucuronic Acid; Glutamic Acid; D1-; Glutathione; Glycerin; Glycerol Ester Of Hydrogenated Rosin; Glyceryl Citrate; Glyceryl Isostearate, Glyceryl Laurate; Glyceryl Monostearate; Glyceryl Oleate; Glyceryl Oleate/Propylene Glycol; Glyceryl Palmitate; Glyceryl Ricinoleate; Glyceryl Stearate; Glyceryl Stearate-Laureth-23; Glyceryl Stearate/Peg Stearate; Glyceryl Stearate/Peg-100 Stearate; Glyceryl Stearate/Peg-40 Stearate; Glyceryl Stearate-Stearamidoethyl Diethylamine; Glyceryl Trioleate; Glycine; Glycine Hydrochloride; Glycol Distearate; Glycol Stearate; Guanidine Hydrochloride; Guar Gum; Hair Conditioner (18n195-1m); Heptane, Hetastarch; Hexylene Glycol; High Density Polyethylene; Histidine; Human Albumin Microspheres; Hyaluronate Sodium; Hydrocarbon; Hydrocarbon Gel, Plasticized; Hydrochloric Acid; Hydrochloric Acid, Diluted; Hydrocortisone; Hydrogel Polymer; Hydrogen Peroxide; Hydrogenated Castor Oil; Hydrogenated Palm Oil; Hydrogenated Palm/Palm Kernel Oil Peg-6 Esters; Hydrogenated Polybutene 635-690; Hydroxide Ion; Hydroxyethyl Cellulose; Hydroxyethylpiperazine Ethane Sulfonic Acid; Hydroxymethyl Cellulose; Hydroxyoctacosanyl Hydroxystearate; Hydroxypropyl Cellulose; Hydroxypropyl Methylcellulose 2906; Hydroxypropyl-Beta-cyclodextrn; Hypromellose 2208 (15000 Mpa S); Hypromellose 2910 (1500 Mpa·S); Hypromellose; Imidurea; Iodine; Iodoxamic Acid; Iofetamine Hydrochloride; Irish Moss Extract; Isobutane; Isoceteth-20; Isoleucine; Isooctyl Acrylate; Isopropyl Alcohol; Isopropyl Isostearate; Isopropyl Myristate; Isopropyl Myristate-Myristyl Alcohol; Isopropyl Palmatate; Isopropyl Stearate; Isostearic Acid; Isostearyl Alcohol; Isotonic Sodium Chloride Solution; Jelene, Kaolin; Kathon Cg; Kathon Cg II, Lactate; Lactic Acid; Lactic Acid. Dl-; Lactic Acid. L-; Lactobionic Acid; Lactose; Lactose Monohydrate; Lactose, Hydrous, Laneth; Lanolin, Lanolin Alcohol-Mineral Oil; Lanolin Alcohols; Lanolin Anhydrous; Lanolin Cholesterols; Lanolin Nonionic Derivatives; Lanolin, Ethoxylated; Lanolin, Hydrogenated, Lauralkonium Chloride; Lauramine Oxide; Laurdimonium Hydrolyzed Animal Collagen; Laureth Sulfate; Laureth-2; Laureth-23; Laureth-4; Lauric Diethanolamide; Lauric Myristic Diethanolamide; Lauroyl Sarcosine; Lauryl Lactate; Lauryl Sulfate; Lavandula Angustifolia Flowering Top; Lecithin; Lecithin Unbleached; Lecithin, Egg; Lecithin, Hydrogenated; Lecithin, Hydrogenated Soy; Lecithin, Soybean; Lemon Oil; Leucine; Levulinic Acid; Lidofenin; Light Mineral Oil; Light Mineral Oil (85 Ssu); Limonene, (+/−)-; Lipocol Sc-15; Lysine. Lysine Acetate; Lysine Monohydrate, Magnesium Aluminum Silicate, Magnesium Aluminum Silicate Hydrate; Magnesium Chloride; Magnesium Nitrate; Magnesium Stearate; Maleic Acid; Mannitol; Maprofix; Mebrofenin; Medical Adhesive Modified S-15; Medical Antiform A-F Emulsion. Medronate Disodium; Medronic Acid. Meglumine; Menthol; Metacresol; Metaphosphoric Acid; Methanesulfonic Acid, Methionine; Methyl Alcohol; Methyl Gluceth-10; Methyl Gluceth-20; Methyl Gluceth-20 Sesquistearate; Methyl Glucose Sesquistearate; Methyl Laurate; Methyl Pyrrolidone; Methyl Salicylate; Methyl Stearate; Methylboronic Acid; Methylcellulose (4000 Mpa·S); Methylcelluloses; Methylchloroisothiazolinone; Methylene Blue, Methylisothiazolinone; Methylparaben; Microcrystalline Wax; Mineral Oil; Mono and Diglyceride; Monostearyl Citrate; Monothioglycerol; Multisterol Extract; Myristyl Alcohol; Myristyl Lactate; Myristyl-.Gamma.-Picolinium Chloride, N-(Carbamoyl-Methoxy Peg-40)-1,2-Distearoyl-Cephalin Sodium; N,N-Dimethylacetamide; Niacinamide, Nioxime; Nitric Acid; Nitrogen; Nonoxynol Iodine; Nonoxynol-15; Nonoxynol-9; Norflurane; Oatmeal; Octadecene-1/Maleic Acid Copolymer; Octanoic Acid; Octisalate; Octoxynol-1; Octoxynol-40, Octoxynol-9. Octyldodecanol, Octylphenol Polymethylene, Oleic Acid; Oleth-10/Oleth-5; Oleth-2; Oleth-20; Oleyl Alcohol; Oleyl Oleate; Olive Oil; Oxidronate Disodium; Oxyquinoline; Palm Kernel Oil; Palmitamine Oxide; Parabens; Paraffin; Paraffin, White Soft; Parfum Creme 45/3; Peanut Oil; Peanut Oil, Refined. Pectin; Peg 6-32 Stearate/Glycol Stearate; Peg Vegetable Oil; Peg-100 Stearate; Peg-12 Glyceryl Laurate; Peg-120 Glyceryl Stearate; Peg-120 Methyl Glucose Dioleate; Peg-15 Cocanmine; Peg-150 Distearate; Peg-2 Stearate; Peg-20 Sorbitan Isostearate; Peg-22 Methyl Ether/Dodecyl Glycol Copolymer; Peg-25 Propylene Glycol Stearate; Peg-4 Dilaurate; Peg-4 Laurate, Peg-40 Castor Oil; Peg-40 Sorbitan Diisostearate; Peg-45/Dodecyl Glycol Copolymer; Peg-5 Oleate; Peg-50 Stearate; Peg-54 Hydrogenated Castor Oil; Peg-6 Isostearate; Peg-60 Castor Oil; Peg-60 Hydrogenated Castor Oil; Peg-7 Methyl Ether; Peg-75 Lanolin; Peg-8 Laurate; Peg-8 Stearate, Pegoxol 7 Stearate; Pentadecalactone; Pentaerythrtol Cocoate; Pentasodium Pentetate, Pentetate Calcium Trisodium, Pentetic Acid, Peppermint Oil; Perflutren; Perfume 25677; Perfume Bouquet, Perfume E-1991; Perfume Gd 5604; Perfume Tana 90/42 Scba; Perfume W-1952-1, Petrolatum, Petrolatum; White; Petroleum Distillates; Phenol; Phenol; Liquefied; Phenonip; Phenoxyethanol; Phenylalanine; Phenylethyl Alcohol; Phenylmercuric Acetate; Phenylmercuric Nitrate; Phosphatidyl Glycerol; Egg; Phospholipid; Phospholipid, Egg; Phospholipon 90g; Phosphoric Acid, Pine Needle Oil (Pinus Sylvestris); Piperazine Hexahydrate; Plastibase-50w; Polacrilin; Polidronium Chloride, Poloxamer 124; Poloxamer 181; Poloxamer 182; Poloxamer 188; Poloxamer 237; Poloxamer 407; Poly(Bis(P-Carboxyphenoxy)Propane Anhydride); Sebacic Acid; Poly(Dimethylsiloxane/Methylvinylsiloxane/Methylhydrogensiloxane) Dimethylvinyl Or Dimethylhydroxy Or Trimethyl Endblocked; Poly(Dl-Lactic-Co-Glycolic Acid), (50:50; Poly(Dl-Lactic-Co-Glycolic Acid), Ethyl Ester Terminated; (50:50; Polyacrylic Acid (250000 Mw); Polybutene (1400 Mw); Polycarbophil; Polyester; Polyester Pol amine Copolymer; Polyester Rayon, Polyethylene Glycol 1000; Polyethylene Glycol 1450; Polyethylene Glycol 1500); Polyethylene Glycol 1540; Polyethylene Glycol 200; Polyethylene Glycol 300; Polyethylene Glycol 300-1600, Polyethylene Glycol 3350; Polyethylene Glycol 400; Polyethylene Glycol 4000; Polyethylene Glycol 540; Polyethylene Glycol 600; Polyethylene Glycol 6000; Polyethylene Glycol 8000; Polyethylene Glycol 900; Polyethylene High Density Containing Ferric Oxide Black (<1%); Polyethylene Low Density Containing Barium Sulfate (20-24%); Polyethylene T; Polyethylene Terephthalates; Polyglactin; Polyglyceryl-3 Oleate; Polyglyceryl-4 Oleate, Ppolyhydroxyethyl Methacrylate, Polyisobutylene, Polyisobutylene (1100000 Mw); Polyisobutylene (35000 Mw); Polyisobutylene 178-236; Polyisobutylene 241-294; Polyisobutylene 35-39; Polyisobutylene Low Molecular Weight; Polyisobutylene Medium Molecular Weight; Polyisobutylene/Polybutene Adhesive; Polylactide; Polyols, Polyoxyethylene Polyoxypropylene 1800; Polyoxyethylene Alcohols; Polyoxyethylene Fatty Acid Esters; Polyoxyethylene Propylene; Polyoxyl 20 Cetostearyl Ether; Polyoxyl 35 Castor Oil; Polyoxyl 40 Hydrogenated Castor Oil; Polyoxyl 40 Stearate; Polyoxyl 400 Stearate; Polyoxyl 6 And Polyoxyl 32 Palmitostearate; Polyoxyl Distearate; Polyoxyl Glyceryl Stearate, Polyoxyl Lanolin; Polyoxyl Palmitate; Polyoxyl Stearate; Polypropylene; Polypropylene Glycol; Polyquarternium-10; Polyquarternium-7 (70/30 Acrylamide/Dadmac; Polysiloxane; Polysorbate 20; Polysorbate 40; Polysorbate 60, Polysorbate 65, Polysorbate 80; Polyurethane; Polyvinyl Acetate, Polyvinyl Alcohol; Polyvinyl Chloride; Polyvinyl Chloride-Polyvinyl Acetate Copolymer; Polyvinylpyridine; Poppy Seed Oil; Potash; Potassium Acetate; Potassium Alum; Potassium Bicarbonate; Potassium Bisulfate; Potassium Chloride; Potassium Citrate; Potassium Hydroxide; Potassium Metabisulfite; Potassium Phosphate, Dibasic; Potassium Phosphate, Monobasic; Potassium Soap; Potassium Sorbate; Povidone Acrylate Copolymer; Povidone Hydrogel; Povidone K17; Povidone K25; Povidone K29/32, Povidone K30, Povidone K90; Povidone K90f; Povidone/Eicosene Copolymer; Povidones; Ppg-12/Smdi Copolymer; Ppg-15 Stearyl Ether; Ppg-20 Methyl Glucose Ether Distearate; Ppg-26 Oleate; Product Wat; Proline; Promulgen D; Promulgen G; Propane; Propellant A-46; Propyl Gallate; Propylene Carbonate; Propylene Glycol; Propylene Glycol Diacetate; Propylene Glycol Dicaprylate, Propylene Glycol Monolaurate; Propylene Glycol Monopalmitostearate; Propylene Glycol Palmitostearate; Propylene Glycol Ricinoleate; Propylene Glycol/Diazolidinyl Urea/Methylparaben/Propylparben; Propylparaben; Protamine Sulfate; Protein Hydrolysate, Pvm/Ma Copolymer; Quaternium-15; Quaternium-15 Cis-Form; Quaternium-52; Ra-2397; Ra-3011; Saccharin; Saccharin Sodium; Saccharin Sodium Anhydrous; Safflower Oil; Sd Alcohol 3a; Sd Alcohol 40; Sd Alcohol 40-2; Sd Alcohol 40b, Sepineo P600; Serine; Sesame Oil; Shea Butter, Silastic Brand Medical Grade Tubing; Silastic Medical Adhesive, Silicone Type A; Silica, Dental; Silicon; Silicon Dioxide; Silicon Dioxide, Colloidal; Silicone; Silicone Adhesive 4102; Silicone Adhesive 4502, Silicone Adhesive Bio-Psa Q7-4201; Silicone Adhesive Bio-Psa Q7-4301; Silicone Emulsion, Silicone/Polyester Film Strip; Simethicone; Simethicone Emulsion; Sipon Ls 20np; Soda Ash; Sodium Acetate; Sodium Acetate Anhydrous; Sodium Alkyl Sulfate; Sodium Ascorbate; Sodium Benzoate; Sodium Bicarbonate; Sodium Bisulfate; Sodium Bisulfite; Sodium Borate; Sodium Borate Decahydrate; Sodium Carbonate; Sodium Carbonate Decahydrate, Sodium Carbonate Monohydrate; Sodium Cetostearyl Sulfate, Sodium Chlorate, Sodium Chloride; Sodium Chloride Injection; Sodium Chloride Injection, Bacteriostatic; Sodium Cholesteryl Sulfate, Sodium Citrate; Sodium Cocoyl Sarcosinate; Sodium Desoxycholate; Sodium Dithionite; Sodium Dodecylbenzenesulfonate; Sodium Formaldehyde Sulfoxylate; Sodium Gluconate; Sodium Hydroxide; Sodium Hypochlorite; Sodium Iodide; Sodium Lactate; Sodium Lactate, L-; Sodium Laureth-2 Sulfate; Sodium Laureth-3 Sulfate; Sodium Laureth-5 Sulfate; Sodium Lauroyl Sarcosinate, Sodium Lauryl Sulfate; Sodium Lauryl Sulfoacetate; Sodium Metabisulfite; Sodium Nitrate; Sodium Phosphate; Sodium Phosphate Dihydrate; Sodium Phosphate, Dibasic; Sodium Phosphate, Dibasic, Anhydrous; Sodium Phosphate, Dibasic; Dihydrate; Sodium Phosphate, Dibasic, Dodecahydrate; Sodium Phosphate, Dibasic, Heptahydrate; Sodium Phosphate, Monobasic; Sodium Phosphate; Monobasic; Anhydrous, Sodium Phosphate, Monobasic; Dihydrate; Sodium Phosphate, Monobasic; Monohydrate; Sodium Polyacrylate (2500000 Mw); Sodium Pyrophosphate; Sodium Pyrrolidone Carboxylate; Sodium Starch Glycolate; Sodium Succinate Hexahydrate; Sodium Sulfate; Sodium Sulfate Anhydrous; Sodium Sulfate Decahydrate; Sodium Sulfite; Sodium Sulfosuccinated Undecyclenic Monoalkylolamide; Sodium Tartrate; Sodium Thioglycolate; Sodium Thiomalate, Sodium Thiosulfate; Sodium Thiosulfate Anhydrous; Sodium Trimetaphosphate, Sodium Xylenesulfonate; Somay 44; Sorbic Acid; Sorbitan; Sorbitan Isostearate; Sorbitan Monolaurate; Sorbitan Monooleate; Sorbitan Monopalmitate; Sorbitan Monostearate; Sorbitan Sesquioleate; Sorbitan Trioleate; Sorbitan Tristearate; Sorbitol; Sorbitol Solution, Soybean Flour; Soybean Oil; Spearmint Oil, Spermaceti; Squalane; Stabilized Oxychloro Complex; Stannous 2-Ethylhexanoate; Stannous Chloride; Stannous Chloride Anhydrous; Stannous Fluoride; Stannous Tartrate; Starch; Starch 1500; Pregelatinized; Starch, Corn; Stearalkoniun Chloride; Stearalkonium Hectorite/Propylene Carbonate; Stearamidoethyl Diethylamine; Steareth-10, Steareth-100; Steareth-2; Steareth-20; Steareth-21; Steareth-40; Stearic Acid; Stearic Diethanolamide; Stearoxytrimethylsilane; Steartrimonium Hydrolyzed Animal Collagen; Stearyl Alcohol; Sterile Water For Inhalation; Styrene/Isoprene/Styrene Block Copolymer; Succimer; Succinic Acid; Sucralose; Sucrose; Sucrose Distearate; Sucrose Polyesters; Sulfacetamide Sodium; Sulfobutylether .Beta.-Cyclodextrin; Sulfur Dioxide; Sulfuric Acid; Sulfurous Acid; Surfactol Qs; Tagatose, D-; Talc; Tall Oil; Tallow Glycerides; Tartaric Acid; Tartaric Acid; Dl-; Tenox; Tenox-2, Tert-Butyl Alcohol; Tert-Butyl Hydroperoxide; Tert-Butvlhydroquinone; Tetrakis(2-Methoxyisobutylisocyanide)Copper(I) Tetrafluoroborate; Tetrapropyl Orthosilicate; Tetrofosmin; Theophylline; Thimerosal; Threonine; Thymol; Tin; Titanium Dioxide; Tocopherol; Tocophersolan; Total parenteral nutrition, lipid emulsion; Triacetin; Tricaprylin; Trichloromonofluoromethane; Trideceth-10; Triethanolamine Lauryl Sulfate, Trifluoroacetic Acid; Triglycerides, Medium Chain; Trihydroxystearin; Trilaneth-4 Phosphate; Trilaureth-4 Phosphate, Trisodium Citrate Dihydrate; Trisodium Hedta; Triton 720; Triton X-200; Trolamine; Tromantadine; Tromethamine (TRIS); Typtophan; Tyloxapol; Tyrosine; Undecylenic Acid; Union 76 Amsco-Res 6038; Urea; Valine; Vegetable Oil; Vegetable Oil Glyceride, Hydrogenated; Vegetable Oil, Hydrogenated; Versetamide; Viscarin; Viscose/Cotton; Vitamin E; Wax, Emulsifying; Wecobee Fs; White Ceresin Wax; White Wax; Xanthan Gum; Zinc; Zinc Acetate; Zinc Carbonate; Zinc Chloride; and Zinc Oxide.

Pharmaceutical composition formulations of AAV particles disclosed herein may include cations or anions. In one embodiment, the formulations include metal cations such as, but not limited to, Zn2+, Ca2+, Cu2+, Mn2+, Mg+ and combinations thereof. As a non-limiting example, formulations may include polymers and complexes with a metal cation (See e.g., U.S. Pat. Nos. 6,265,389 and 6,555,525, each of which is herein incorporated by reference in its entirety).

Formulations of the invention may also include one or more pharmaceutically acceptable salts. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form (e.g., by reacting the free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, acetic acid, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzene sulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.

Solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof. Examples of suitable solvents are ethanol, water (for example, mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N,N′-dimethylformamide (DMF), N,N′-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, and the like. When water is the solvent, the solvate is referred to as a “hydrate”

III. Administration and Dosing

Administration

The AAV particles of the present invention may be administered by any delivery route which results in a therapeutically effective outcome. These include, but are not limited to, enteral (into the intestine), gastroenteral, epidural (into the dura mater), oral (by way of the mouth), transdermal, intracerebral (into the cerebrum), intracerebroventricular (into the cerebral ventricles), epicutaneous (application onto the skin), intradermal. (into the skin itself), subcutaneous (under the skin), nasal administration (through the nose), intravenous (into a vein), intravenous bolus, intravenous drip, intra-arterial (into an artery), intramuscular (into a muscle), intracardiac (into the heart), intraosseous infusion (into the bone marrow), intrathecal (into the spinal canal), intraparenchymal (into brain tissue), Intraperitoneal. (infusion or injection into the peritoneum), Intravesical infusion, intravitreal, (through the eye), intracavernous injection (into a pathologic cavity) intracavitary (into the base of the penis), intravaginal administration, intrauterine, extra-amniotic administration, transdermal (diffusion through the intact skin for systemic distribution), transmucosal (diffusion through a mucous membrane), transvaginal, insufflation (snorting), sublingual, sublabial, enema, eye drops (onto the conjunctiva), or in ear drops, auricular (in or by way of the ear), buccal (directed toward the cheek), conjunctival, cutaneous, dental (to a tooth or teeth), electro-osmosis, endocervical, endosinusial, endotracheal, extracorporeal, hemodialysis, infiltration, interstitial, intra-abdominal, intra-amniotic, intra-articular, intrabiliary, intrabronchial, intrabursal, intracartilaginous (within a cartilage), intracaudal (within the cauda equine), intracisternal (within the cisterna magna cerebellomedularis), intracorneal (within the cornea), dental intracornal, intracoronary (within the coronary arteries), intracorporus cavernosum (within the dilatable spaces of the corporus cavernosa of the penis), intradiscal (within a disc), intraductal (within a duct of a gland), intraduodenal (within the duodenum), intradural (within or beneath the dura), intraepidermal (to the epidermis), intraesophageal (to the esophagus), intragastric (within the stomach), intragingival (within the gingivae), intraileal (within the distal portion of the small intestine), intralesional (within or introduced directly to a localized lesion), intraluminal (within a lumen of a tube), intralymphatic (within the lymph), intramedullary (within the marrow cavity of a bone), intrameningeal (within the meninges), intramyocardial (within the myocardium), intraocular (within the eye), intraovarian (within the ovary), intrapericardial (within the pericardium), intrapleural (within the pleura), intraprostatic (within the prostate gland), intrapulmonary (within the lungs or its bronchi), intrasinal (within the nasal or periorbital sinuses), intraspinal (within the vertebral column), intrasynovial (within the synovial cavity of a joint), intratendinous (within a tendon), intratesticular (within the testicle), intrathecal (within the cerebrospinal fluid at any level of the cerebrospinal axis), intrathoracic (within the thorax), intratubular (within the tubules of an organ), intratumor (within a tumor), intratympanic (within the aurus media), intravascular (within a vessel or vessels), intraventricular (within a ventricle), iontophoresis (by means of electric current where ions of soluble salts migrate into the tissues of the body), irrigation (to bathe or flush open wounds or body cavities), laryngeal (directly upon the larynx), nasogastric (through the nose and into the stomach), occlusive dressing technique (topical route administration which is then covered by a dressing which occludes the area), ophthalmic (to the external eye), oropharyngeal (directly to the mouth and pharynx), parenteral, percutaneous, periarticular, peridural, perineural, periodontal, rectal, respiratory (within the respiratory tract by inhaling orally or nasally for local or systemic effect), retrobulbar (behind the pons or behind the eyeball), soft tissue, subarachnoid, subconjunctival, submucosal, topical, transplacental (through or across the placenta), transtracheal (through the wall of the trachea), transtympanic (across or through the tympanic cavity), ureteral (to the ureter), urethral (to the urethra), vaginal, caudal block, diagnostic, nerve block, biliary perfusion, cardiac perfusion, photopheresis and spinal.

In some embodiments, compositions may be administered in a way which allows them to cross the blood-brain barrier, vascular barrier, or other epithelial barrier. The AAV particles of the present invention may be administered in any suitable form, either as a liquid solution or suspension, as a solid form suitable for liquid solution or suspension in a liquid solution. The AAV particles may be formulated with any appropriate and pharmaceutically acceptable excipient.

In one embodiment, the AAV particles of the present invention may be delivered to a subject, in a single route administration.

In one embodiment, the AAV particles of the present invention may be delivered to a subject via a multi-site route of administration. A subject may be administered at 2, 3, 4, 5 or more than 5 sites.

In one embodiment, a subject may be administered the AAV particles of the present invention using a bolus infusion.

In one embodiment, a subject may be administered the AAV particles of the present invention using sustained delivery over a period of minutes, hours or days. The infusion rate may be changed depending on the subject, distribution, formulation or another delivery parameter.

In one embodiment, the AAV particles of the present invention may be delivered by intramuscular delivery route. (See, e.g., U.S. Pat. No. 6,506,379, the content of which is incorporated herein by reference in its entirety). Non-limiting examples of intramuscular administration include an intravenous injection or a subcutaneous injection.

In one embodiment, the AAV particles of the present invention may be delivered by oral administration. Non-limiting examples of oral administration include a digestive tract administration and a buccal administration.

In one embodiment, the AAV particles of the present invention may be delivered by intraocular delivery route A non-limiting example of intraocular administration include an intravitreal injection.

In one embodiment, the AAV particles of the present invention may be delivered by intranasal delivery route. Non-limiting examples of intranasal delivery include administration of nasal drops or nasal sprays.

In some embodiments, the AAV particles that may be administered to a subject by peripheral injections. Non-limiting examples of peripheral injections include intraperitoneal, intramuscular, intravenous, conjunctival or joint injection. It was disclosed in the art that the peripheral administration of AAV vectors can be transported to the central nervous system, for example, to the motor neurons (e.g., U.S. Patent Publication Nos. 20100240739; and 20100130594; the content of each of which is incorporated herein by reference in their entirety).

In one embodiment, the AAV particles may be delivered by injection into the CSF pathway. Non-limiting examples of delivery to the CSF pathway include intrathecal and intracerebroventricular administration.

In one embodiment, the AAV particles may be delivered by systemic delivery. As a non-limiting example, the systemic delivery may be by intravascular administration.

In one embodiment, the AAV particles of the present invention may be administered to a subject by intracranial delivers' (See, e.g., U.S. Pat. No. 8,119,611; the content of which is incorporated herein by reference in its entirety).

In one embodiment, the AAV particles of the present invention may be administered to a subject by intraparenchymal administration.

In one embodiment, the AAV particles of the present invention may be administered to a subject by intramuscular administration.

In one embodiment, the AAV particles of the present invention are administered to a subject and transduce muscle of a subject. As a non-limiting example, the AAV particles are administered by intramuscular administration.

In one embodiment, the AAV particles of the present invention may be administered to a subject by intravenous administration.

In one embodiment, the AAV particles of the present invention may be administered to a subject by subcutaneous administration.

In one embodiment, the AAV particles of the present invention may be administered to a subject by topical administration.

In one embodiment, the AAV particles may be delivered by direct injection into the brain. As a non-limiting example, the brain delivery may be by intrastriatal administration.

In one embodiment, the AAV particles may be delivered by more than one route of administration. As non-limiting examples of combination administrations, AAV particles may be delivered by intrathecal and intracerebroventricular, or by intravenous and intraparenchymal administration.

Parenteral and Injectable Administration

In some embodiments, pharmaceutical compositions, AAV particles of the present invention may be administered parenterally. Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral compositions can include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents. In certain embodiments for parenteral administration, compositions are mixed with solubilizing agents such as CREMOPHOR®, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof. In other embodiments, surfactants are included such as hydroxypropylcellulose.

Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing agents, wetting agents, and/or suspending agents. Sterile injectable preparations may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P, and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil can be employed including synthetic mono- or diglycerides Fatty acids such as oleic acid can be used in the preparation of injectables.

Injectable formulations may be sterilized, for example, by filtration through a bacterial-retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

In order to prolong the effect of active ingredients, it is often desirable to slow the absorption of active ingredients from subcutaneous or intramuscular injections. This may be accomplished by the use of liquid suspensions of crystalline or amorphous material with poor water solubility. The rate of absorption of active ingredients depends upon the rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.

Rectal and Vaginal Administration

In some embodiments, pharmaceutical compositions, AAV particles of the present invention may be administered rectally and/or vaginally Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing compositions with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.

Oral Administration

In some embodiments, pharmaceutical compositions, AAV particles of the present invention may be administered orally. Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, an active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient such as sodium citrate or dicalcium phosphate and/or fillers or extenders (e.g. starches, lactose, sucrose, glucose, mannitol, and silicic acid), binders (e.g. carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia), humectants (e.g. glycerol), disintegrating agents (e.g. agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarding agents (e.g. paraffin), absorption accelerators (e.g. quaternary ammonium compounds), wetting agents (e.g. cetyl alcohol and glycerol monostearate), absorbents (e.g. kaolin and bentonite clay), and lubricants (e.g. talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate), and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.

Topical or Transdermal Administration

As described herein, pharmaceutical compositions, AAV particles of the present invention may be formulated for administration topically. The skin may be an ideal target site for delivery as it is readily accessible. Three routes are commonly considered to deliver pharmaceutical compositions, AAV particles of the present invention to the skin: (i) topical application (e.g. for local/regional treatment and/or cosmetic applications); (ii) intradermal injection (e.g. for local/regional treatment and/or cosmetic applications), and (iii) systemic delivery (e.g. for treatment of dermatologic diseases that affect both cutaneous and extracutaneous regions). Pharmaceutical compositions, AAV particles of the present invention can be delivered to the skin by several different approaches known in the art.

In some embodiments, the invention provides for a variety of dressings (e.g., wound dressings) or bandages (e.g., adhesive bandages) for conveniently and/or effectively carrying out methods of the present invention. Typically dressing or bandages may comprise sufficient amounts of pharmaceutical compositions, AAV particles of the present invention described herein to allow users to perform multiple treatments.

Dosage forms for topical and/or transdermal administration may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants and/or patches. Generally, active ingredients are admixed under sterile conditions with pharmaceutically acceptable excipients and/or any needed preservatives and/or buffers. Additionally, the present invention contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of pharmaceutical compositions, AAV particles of the present invention to the body. Such dosage forms may be prepared, for example, by dissolving and/or dispensing pharmaceutical compositions, AAV particles in the proper medium. Alternatively, or additionally, rates may be controlled by either providing rate controlling membranes and/or by dispersing pharmaceutical compositions, AAV particles in a polymer matrix and/or gel.

Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions.

Topically-administrable formulations may, for example, comprise from about 1% to about 10% (w/w) active ingredient, although the concentration of active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.

Depot Administration

As described herein, in some embodiments, pharmaceutical compositions, AAV particles of the present invention are formulated in depots for extended release. Generally, specific organs or tissues (“target tissues”) are targeted for administration.

In some aspects of the invention, pharmaceutical compositions, AAV particles of the present invention are spatially retained within or proximal to target tissues. Provided are methods of providing pharmaceutical compositions, AAV particles, to target tissues of mammalian subjects by contacting target tissues (which comprise one or more target cells) with pharmaceutical compositions, AAV particles, under conditions such that they are substantially retained in target tissues, meaning that at least 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99, 99.9, 99.99 or greater than 99.99% of the composition is retained in the target tissues. Advantageously, retention is determined by measuring the amount of pharmaceutical compositions, AAV particles, that enter one or more target cells. For example, at least 1%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.9%, 99.99% or greater than 99.99% of pharmaceutical compositions, AAV particles, administered to subjects are present intracellularly at a period of time following administration. For example, intramuscular injection to mammalian subjects may be performed using aqueous compositions comprising pharmaceutical compositions, AAV particles of the present invention and one or more transfection reagents, and retention is determined by measuring the amount of pharmaceutical compositions, AAV particles, present in muscle cells.

Certain aspects of the invention are directed to methods of providing pharmaceutical compositions, AAV particles of the present invention to a target tissues of mammalian subjects, by contacting target tissues (comprising one or more target cells) with pharmaceutical compositions, AAV particles under conditions such that they are substantially retained in such target tissues. Pharmaceutical compositions, AAV particles comprise enough active ingredient such that the effect of interest is produced in at least one target cell. In some embodiments, pharmaceutical compositions, AAV particles generally comprise one or more cell penetration agents, although “naked” formulations (such as without cell penetration agents or other agents) are also contemplated, with or without pharmaceutically acceptable carriers.

Pulmonary Administration

In some embodiments, pharmaceutical compositions, AAV particles of the present invention may be prepared, packaged, and/or sold in formulations suitable for pulmonary administration. In some embodiments, such administration is via the buccal cavity. In some embodiments, formulations may comprise dry particles comprising active ingredients. In such embodiments, dry particles may have a diameter in the range from about 0.5 nm to about 7 nm or from about 1 nm to about 6 nm. In some embodiments, formulations may be in the form of dry powders for administration using devices comprising dry powder reservoirs to which streams of propellant may be directed to disperse such powder. In some embodiments, self-propelling solvent/powder dispensing containers may be used. In such embodiments, active ingredients may be dissolved and/or suspended in low-boiling propellant in sealed containers. Such powders may comprise particles wherein at least 98% of the particles by weight have diameters greater than 0.5 nm and at least 95% of the particles by number have diameters less than 7 nm. Alternatively, at least 95% of the particles by weight have a diameter greater than 1 nm and at least 90% of the particles by number have a diameter less than 6 nm. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.

Low boiling propellants generally include liquid propellants having a boiling point of below 65° F. at atmospheric pressure. Generally, propellants may constitute 50% to 99.9% (w/w) of the composition, and active ingredient may constitute 0.1% to 20% (w/w) of the composition. Propellants may further comprise additional ingredients such as liquid non-ionic and/or solid anionic surfactant and/or solid diluent (which may have particle sizes of the same order as particles comprising active ingredients).

Pharmaceutical compositions formulated for pulmonary delivery may provide active ingredients in the form of droplets of solution and/or suspension. Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising active ingredients, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. Droplets provided by this route of administration may have an average diameter in the range from about 0.1 nm to about 200 nm.

Intranasal, Nasal and Buccal Administration

In some embodiments, pharmaceutical compositions, AAV particles of the present invention may be administered nasally and/or intranasal. In some embodiments, formulations described herein useful for pulmonary delivery may also be useful for intranasal deliver. In some embodiments, formulations for intranasal administration comprise a coarse powder comprising the active ingredient and having an average particle from about 0.2 μm to 500 μm. Such formulations are administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nose.

Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (w/w) and as much as 100% (w/w) of active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (w/w) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise powders and/or an aerosolized and/or atomized solutions and/or suspensions comprising active ingredients. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may comprise average particle and/or droplet sizes in the range of from about 0.1 nm to about 200 nm, and may further comprise one or more of any additional ingredients described herein

Ophthalmic or Otic Administration

In some embodiments, pharmaceutical compositions, AAV particles of the present invention may be prepared, packaged, and/or sold in formulations suitable for ophthalmic and/or otic administration. Such formulations may, for example, be in the form of eye and/or ear drops including, for example, a 0.1/1.0% (w/w) solution and/or suspension of the active ingredient in aqueous and/or oily liquid excipients. Such drops may further comprise buffering agents, salts, and/or one or more other of any additional ingredients described herein. Other ophthalmically-administrable formulations which are useful include those which comprise active ingredients in microcrystalline form and/or in liposomal preparations. Subretinal inserts may also be used as forms of administration.

Delivery to Cells

The present disclosure provides a method of delivering to a cell or tissue any of the above-described AAV particles, comprising contacting the cell or tissue with said AAV particle or contacting the cell or tissue with a formulation comprising said AAV particle, or contacting the cell or tissue with any of the described compositions, including pharmaceutical compositions. The method of delivering the AAV particle to a cell or tissue can be accomplished in vitro, ex vivo, or in vivo.

Delivery to Subjects

The present disclosure additionally provides a method of delivering to a subject, including a mammalian subject, any of the above-described AAV particles comprising administering to the subject said AAV particle, or administering to the subject a formulation comprising said AAV particle, or administering to the subject any of the described compositions, including pharmaceutical compositions.

Dose and Regimen

The present invention provides methods of administering AAV particles in accordance with the invention to a subject in need thereof. The pharmaceutical, diagnostic, or prophylactic AAV particles and compositions of the present invention may be administered to a subject using any amount and any route of administration effective for preventing, treating, managing, or diagnosing diseases, disorders and/or conditions. The exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease, the particular composition, its mode of administration, its mode of activity, and the like. The subject may be a human, a mammal, or an animal. Compositions in accordance with the invention are typically formulated in unit dosage form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of the compositions of the present invention may be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective, prophylactically effective, or appropriate diagnostic dose level for any particular individual will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific payload employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific AAV particle employed; the duration of the treatment; drugs used in combination or coincidental with the specific AAV particle employed; and like factors well known in the medical arts.

In certain embodiments, AAV particle pharmaceutical compositions in accordance with the present invention may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 100 mg/kg, from about 0.001 mg/kg to about 0.05 mg/kg, from about 0.005 mg/kg to about 0.05 mg/kg, from about 0.001 mg/kg to about 0.005 mg/kg, from about 0.05 mg/kg to about 0.5 mg/kg, from about 0.01 mg/kg to about 50 mg/kg, from about 0.1 mg/kg to about 40 mg/kg, from about 0.5 mg/kg to about 30 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, or from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic, diagnostic, or prophylactic, effect. It will be understood that the above dosing concentrations may be converted to vg or viral genomes per kg or into total viral genomes administered by one of skill in the art.

In certain embodiments, AAV particle pharmaceutical compositions in accordance with the present disclosure may be administered at about 10 to about 600 μl/site, 50 to about 500 μl/site, 100 to about 400 μl/site, 120 to about 300 μl/site, 140 to about 200 μl/site, about 160 μl/site. As non-limiting examples, AAV particles may be administered at 50 μl/site and/or 150 μl/site.

The desired dosage of the AAV particles of the present invention may be delivered only once, three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). When multiple administrations are employed, split dosing regimens such as those described herein may be used. As used herein, a “split dose” is the division of “single unit dose” or total daily dose into two or more doses, e.g., two or more administrations of the “single unit dose”. As used herein, a “single unit dose” is a dose of any therapeutic administered in one dose/at one time/single route/single point of contact, i.e., single administration event.

The desired dosage of the AAV particles of the present invention may be administered as a “pulse dose” or as a “continuous flow” As used herein, a “pulse dose” is a series of single unit doses of any therapeutic administered with a set frequency over a period of time. As used herein, a “continuous flow” is a dose of therapeutic administered continuously for a period of time in a single route/single point of contact, i.e., continuous administration event. A total daily dose, an amount given or prescribed in 24 hour period, may be administered by any of these methods, or as a combination of these methods, or by any other methods suitable for a pharmaceutical administration.

In one embodiment, delivery of the AAV particles of the present invention to a subject provides neutralizing activity to a subject. The neutralizing activity can be for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 1 year, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 20 months, 21 months, 22 months, 23 months, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years or more than 10 years.

In one embodiment, delivery, of the AAV particles of the present invention results in minimal serious adverse events (SAEs) as a result of the delivery of the AAV particles.

In one embodiment, delivery of AAV particles to cells of the central nervous system (e.g., parenchyma) may comprise a total dose between about 1×10⁶ VG and about 1×10¹⁶ VG, In some embodiments, delivery may comprise a total dose of about 1×10⁶, 2×10⁶, 3×10⁶, 4×10⁶, 5×10⁶, 6×10⁶, 7×10⁶, 8×10⁶, 9×10⁶, 1×10⁷, 2×10⁷, 3×10⁷, 4×10⁷, 5×10⁷, 6×10⁷, 7×10⁷, 8×10⁷, 9×10⁷, 1×10⁸, 2×10⁸, 3×10⁸, 4×10⁸, 5×10⁸, 6×10⁸, 7×10⁸, 8×10⁸, 9×10⁸, 1×10⁹, 2×10⁹, 3×10⁹, 4×10⁹, 5×10⁹, 6×10⁹, 7×10⁹, 8×10⁹, 9×10⁹, 1×10¹⁰, 1.9×10¹⁰, 2×10¹⁰, 3×10¹⁰, 3.73×10¹⁰, 4×10¹⁰, 5×10¹⁰, 6×10¹⁰, 7×10¹⁰, 8×10¹⁰, 9×10¹⁰, 1×10¹¹, 2×10¹¹, 2.5×10¹¹, 3×10¹¹, 4×10¹¹, 5×10¹¹, 6×10¹¹, 7×10¹¹, 8×10¹¹, 9×10¹¹, 1×10¹², 2×10¹², 3×10¹², 4×10¹², 5×10¹², 6×10¹², 7×10¹², 8×10¹², 9×10¹², 1×10¹³, 2×10¹³, 3×10¹³, 4×10¹³, 4×10¹³, 6×10¹³, 7×10¹³, 8×10¹³, 9×10¹³, 1×10¹⁴, 2×10¹⁴, 3×10¹⁴, 4×10¹⁴, 5×10¹⁴, 6×10¹⁴, 7×10¹⁴, 8×10¹⁴, 9×10¹⁴, 1×10¹⁵, 2×10¹⁵, 3×10¹⁵, 4×10¹⁵, 5×10¹⁵, 6×10¹⁵, 7×10¹⁵, 8×10¹⁵, 9×10¹⁵, or 1×10¹⁶ VG. As a non-limiting example, the total dose is 1×10¹³ VG. As another non-limiting example, the total dose is 2.1×10¹² VG.

In one embodiment, delivery of AAV particles to cells of the central nervous system (e.g., parenchyma) may comprise a composition concentration between about 1×10⁶ VG/mL and about 1×10¹⁶ VG/mL. In some embodiments, delivery may comprise a composition concentration of about 1×10⁶, 2×10⁶, 3×10⁶, 4×10⁶, 5×10⁶, 6×10⁶, 7×10⁶, 8×10⁶, 9×10⁶, 1×10⁷, 2×10⁷, 3×10⁷, 4×10⁷, 5×10⁷, 6×10⁷, 7×10⁷, 8×10⁷, 9×10⁷, 1×10⁸, 2×10⁸, 3×10⁸, 4×10⁸, 5×10⁸, 6×10⁸, 7×10⁸, 8×10⁸, 9×10⁸, 1×10⁹, 2×10⁹, 3×10⁹, 4×10⁹, 5×10⁹, 6×10⁹, 7×10⁹, 8×10⁹, 9×10⁹, 1×10¹⁰, 2×10¹⁰, 3×10¹⁰, 4×10¹⁰, 5×10¹⁰, 6×10¹⁰, 7×10¹⁰, 8×10¹⁰, 9×10¹⁰, 1×10¹¹, 2×10¹¹, 3×10¹¹, 4×10¹¹, 5×10¹¹, 6×10¹¹, 7×10¹¹, 8×10¹¹, 9×10¹¹, 1×10¹², 2×10¹², 3×10¹², 4×10¹², 5×10¹², 6×10¹², 7×10¹², 8×10¹², 9×10¹², 1×10¹³, 2×10¹³, 3×10¹³, 4×10¹³, 5×10¹³, 6×10¹³, 7×10¹³, 8×10¹³, 9×10¹³, 1×10¹⁴, 2×10¹⁴, 3×10¹⁴, 4×10¹⁴, 5×10¹⁴, 6×10¹⁴, 7×10¹⁴, 8×10¹⁴, 9×10¹⁴, 1×10¹⁵, 2×10¹⁵, 3×10¹⁵, 4×10¹⁵, 5×10¹⁵, 6×10¹⁵, 7×10¹⁵, 8×10¹⁵, 9×10¹⁵, or 1×10¹⁶ VG/mL. In one embodiment, the delivery comprises a composition concentration of 1×10¹³ VG/mL. In one embodiment, the delivery comprises a composition concentration of 2.1×10¹² VG/mL.

Combinations

The AAV particles may be used in combination with one or more other therapeutic, prophylactic, research or diagnostic agents. By “in combination with,” it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the present invention. Compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In some embodiments, the present disclosure encompasses the delivery of pharmaceutical, prophylactic, research, or diagnostic compositions in combination with agents that may improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.

Measurement of Expression

Expression of payloads from viral genomes may be determined using various methods known in the art such as, but not limited to immunochemistry (e.g., IHC), in situ hybridization (ISH), enzyme-linked immunosorbant assay (ELISA), affinity ELISA, ELISPOT, flow cytometry, immunocytology, surface plasmon resonance analysis, kinetic exclusion assay, liquid chromatography-mass spectrometry (LCMS), high-performance liquid chromatography (HPLC). BCA assay, immunoelectrophoresis. Western blot, SDS-PAGE, protein immunoprecipitation, and/or PCR,

Bioavalability

The AAV particles, when formulated into a composition with a delivery agent as described herein, can exhibit an increase in bioavailability as compared to a composition lacking a delivery agent as described herein. As used herein, the term “bioavailability” refers to the systemic availability of a given amount of AAV particle or expressed payload administered to a mammal. Bioavailability can be assessed by measuring the area under the curve (AUC) or the maximum serum or plasma concentration (C_(max)) of the composition following. AUC is a determination of the area under the curve plotting the serum or plasma concentration of a compound (e.g., AAV particles or expressed payloads) along the ordinate (Y-axis) against time along the abscissa (X-axis). Generally, the AUC for a particular compound can be calculated using methods known to those of ordinary skill in the art and as described in G. S. Banker, Modern Pharmaceutics, Drugs and the Pharmaceutical Sciences, v. 72, Marcel Dekker, New York, Inc., 1996, the contents of which are herein incorporated by reference in its entirety.

The C_(max) value is the maximum concentration of the AAV particle or expressed payload achieved in the serum or plasma of a mammal following administration of the AAV particle to the mammal. The C_(max) value of can be measured using methods known to those of ordinary skill in the art. The phrases “increasing bioavailability” or “improving the pharmacokinetics,” as used herein mean that the systemic availability of a first AAV particle or expressed payload, measured as AUC, C_(max), or C_(min) in a mammal is greater, when co-administered with a delivery agent as described herein, than when such co-administration does not take place. In some embodiments, the bioavailability can increase by at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%.

Therapeutic Window

As used herein “therapeutic window” refers to the range of plasma concentrations, or the range of levels of therapeutically active substance at the site of action, with a high probability of eliciting a therapeutic effect. In some embodiments, the therapeutic window of the AAV particle as described herein can increase by at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100%.

Volume of Distribution

As used herein, the term “volume of distribution” refers to the fluid volume that would be required to contain the total amount of the drug in the body at the same concentration as in the blood or plasma: V_(dist) equals the amount of drug in the body/concentration of drug in blood or plasma. For example, for a 10 mg dose and a plasma concentration of 10 mg/L, the volume of distribution would be 1 liter. The volume of distribution reflects the extent to which the drug is present in the extravascular tissue. A large volume of distribution reflects the tendency of a compound to bind to the tissue components compared with plasma protein binding. In a clinical setting, V_(dist) can be used to determine a loading dose to achieve a steady state concentration. In some embodiments, the volume of distribution of the AAV particles as described herein can decrease at least about 2%, at least about 5%, at least about 10%, at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%.

Biological Effect

In one embodiment, the biological effect of the AAV particles delivered to the animals may be categorized by analyzing the payload expression in the animals. The payload expression may be determined from analyzing a biological sample collected from a mammal administered the AAV particles of the present invention. For example, a protein expression of 50-200 pg/ml for the protein encoded by the AAV particles delivered to the mammal may be seen as a therapeutically effective amount of protein in the mammal.

IV. Methods and Uses of the Compositions of the Invention

The present disclosure provides a method for treating a disease, disorder and/or condition in a mammalian subject, including a human subject, comprising administering to the subject any of the AAV particles described herein or administering to the subject any of the described compositions, including pharmaceutical compositions, described herein.

In one embodiment, the AAV particles of the present invention are administered to a subject prophylactically.

In one embodiment, the AAV particles of the present invention are administered to a subject having at least one of the diseases described herein.

In one embodiment, the AAV particles of the present invention are administered to a subject to treat a disease or disorder described herein. The subject may have the disease or disorder or may be at-risk to developing the disease or disorder.

In one embodiment, the AAV particles of the present invention are part of an active immunization strategy to protect against diseases and disorders. In an active immunization strategy, a vaccine or AAV particles are administered to a subject to prevent an infectious disease by activating the subject's production of antibodies that can fight off invading bacteria or viruses.

In one embodiment, the AAV particles of the present invention are part of a passive immunization strategy. In a passive immunization strategy, antibodies against a particular infectious agent are given directly to the subject.

Diseases and Toxins

Various infectious diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As used herein, the term “infectious disease” refers to any disorders caused by organisms such as bacteria, viruses, fungi or parasites. As a non-limiting example, the infectious disease may be Acute bacterial rhinosinusitis, 14-day measles. Acne, Acrodermatitis chronica atrophicans (ACA)-(late skin manifestation of latent Lyme disease), Acute hemorrhagic conjunctivitis, Acute hemorrhagic cystitis, Acute rhinosinusitis, Adult T-cell Leukemia-Lymphoma (ATLL), African Sleeping Sickness, AIDS (Acquired Immunodeficiency Syndrome), Alveolar hydatid, Amebiasis, Amebic meningoencephalitis, Anaplasmosis, Anthrax, Arboviral or parainfectious, Ascariasis—(Roundworm infections), Aseptic meningitis, Athlete's foot (Tinea pedis), Australian tick typhus, Avian Influenza, Babesiosis, Bacillary angiomatosis, Bacterial meningitis, Bacterial vaginosis, Balanitis, Balantidiasis, Bang's disease, Barmah Forest virus infection, Bartonellosis (Verruga peruana; Carrion's disease; Oroya fever), Bat Lyssavirus Infection, Bay sore (Chiclero's ulcer), Baylisascaris infection (Racoon roundworm infection), Beaver fever, Beef tapeworm, Bejel (endemic syphilis), Biphasic meningoencephalitis, Black Bane, Black death, Black piedra, Blackwater Fever, Blastomycosis, Blennorrhea of the newborn, Blepharitis, Boils, Bomholm disease (pleurodynia), Borrelia miyamotoi Disease, Botulism, Boutonneuse fever, Brazilian purpuric fever, Break Bone fever, Brill, Bronchiolitis, Bronchitis, Brucellosis (Bang's disease), Bubonic plague, Bullous impetigo, Burkholderia mallei (Glanders), Burkholderia pseudomallei (Melioidosis), Buruli ulcers (also Mycoburuli ulcers), Busse Busse-Buschke disease (Cryptococcosis), California group encephalitis, Campylobacteriosis, Candidiasis, Canefield fever (Canicola fever; 7-day fever; Weil's disease; leptospirosis; canefield fever), Canicola fever, Capillanasis, Carate, Carbapenem-resistant Enterobacteriaceae (CRE), Carbuncle, Carrion's disease, Cat Scratch fever, Cave disease, Central Asian hemorrhagic fever, Central European tick, Cervical cancer, Chagas disease, Chancroid (Soft chancre), Chicago disease, Chickenpox (Varicella), Chiclero's ulcer, Chikungunya fever, Chlarmydial infection, Cholera, Chromoblastomycosis, Ciguatera, Clap, Clonorchiasis (Liver fluke infection), Clostridium difficile Infection, Clostridium perfringens (Epsilon Toxin), Coccidioidonycosis fungal infection (Valley fever; desert rheumatism), Coenurosis, Colorado tick fever, Condyloma accuminata, Condyloma accununata (Warts), Condyloma lata, Congo fever, Congo hemorrhagic fever virus, Conjunctivitis, cowpox, Crabs, Crimean, Croup, Cryptococcosis, Cryptosporidiosis (Crypto), Cutaneous Larval Migrans, Cyclosporiasis, Cystic hydatid, Cysticercosis, Cystatis, Czechoslovak tick, D68 (EV-D68), Dacryocytitis, Dandy fever, Darling's Disease, Deer fly fever, Dengue fever (1, 2, 3 and 4), Desert rheumatism, Devil's grip, Diphasic milk fever, Diphtheria, Disseminated Intravascular Coagulation, Dog tapeworm, Donovanosis, Donovanosis (Granuloma inguinale), Dracontiasis, Dracunculosis, Duke's disease, Dum Dum Disease, Durand-Nicholas-Favre disease, Dwarf tapeworm, E, Coli infection (E. Coli), Eastern equine encephalitis, Ebola Hemorrhagic Fever (Ebola virus disease EVD), Ectothrix, Ehrlichiosis (Sennetsu fever), Encephalitis, Endemic Relapsing fever, Endemic syphilis, Endophthalmitis, Endothrix, Enterobiasis (Pinworm infection), Enterotoxin-B Poisoning (Staph Food Poisoning), Enterovirus Infection, Epidemic Keratoconjunctivitis, Epidemic Relapsing fever, Epidemic typhus, Epiglottitis, Erysipelis, Ervsipeloid (Erysipelothricosis), Erythema chronicum migrans, Erythema infectiosum, Erythema marginatum, Enrthema multiforme, Erythema nodosum, Erythema nodosum leprosum Erythrasma, Espundia, Euniycotic mycetoma, European blastomycosis, Exanthem subitumn (Sixth disease), Eyeworm, Far Eastern tick, Fascioliasis, Fievre boutonneuse (Tick typhus), Fifth Disease (erythema infectiosum), Filatow-Dukes' Disease (Scalded Skin Syndrome; Ritter's Disease), Fish tapeworm, Fitz-Hugh-Curtis syndrome—Perihepatitis, Flinders Island Spotted Fever, Flu (Influenza), Folliculitis, Four Corners Disease, Four Corners Disease (Human Pulmonary Syndrome (HPS)), Frambesia, Francis disease, Furunculosis, Gas gangrene, Gastroenteritis, Genital Herpes, Genital Warts, German measles, Gerstmann-Straussler-Scheinker (GSS), Giardiasis, Gilchrist's disease, Gingivitis, Gingivostomatitis, Glanders, Glandular fever (infectious mononucleosis), Gnathostomiasis, Gonococcal Infection (Gonorrhea), Gonorrhea, Granuloma inguinale (Donovanosis), Guinea Worm, Haemophilus Influenza disease, Hamburger disease, Hansen's disease—leprosy, Hantaan disease, Hantaan-Korean hemorrhagic fever, Hantavirus Pulmonary Syndrome, Hantavirus Pulmonary Syndrome (HPS), Hard chancre, Hard measles, Haverhill fever—Rat bite fever, Head and Body Lice, Heartland fever, Helicobacterosis, Hemolytic Uremic Syndrome (HUS), Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Herpangina, Herpes—genital, Herpes labialis, Herpes—neonatal, Hidradenitis, Histoplasmosis, Histoplasmosis infection (Histoplasmosis), His-Werner disease, HIV infection, Hookworm infections, Hordeola, Hordeola (Stye), HTLV, HTLV-associated myelopathy (HAM), Human granulocytic ehrlichiosis, Human monocytic ehrlichiosis, Human Papillomavirus (HPV), Human Pulmonary Syndrome, Hydatid cyst, Hydrophobia, Impetigo, Including congenital (German Measles), Inclusion conjunctivitis, Inclusion conjunctivitis+Swimming Pool conjunctivitis—Pannus, Infantile diarrhea, Infectious Mononucleosis, Infectious myocarditis, Infectious pericarditis, Influenza, Isosporiasis, Israeli spotted fever, Japanese Encephalitis, Jock itch, Jorge Lobo disease—Iobomycosis, Jungle yellow fever, Junin Argentinian hemorrhagic fever, Kala Azar, Kaposi's sarcoma, Keloidal blastomycosis, Keratoconjunctivitis, Kuru, Kyasanur forest disease, LaCrosse encephalitis, Lassa hemorrhagic fevter, Legionellosis (Legionnaires Disease), Legionnaires pneumonia, Lemierre's Syndrome (Postanginal septicemia), Lemming fever, Leprosy, Leptospirosis (Nanukayami fever: Well's disease), Listeriosis (Listeria), Liver fluke infection, Lobo's mycosis, Lockjaw, Loiasis, Louping Ill, Ludwig's angina, Lung fluke infection, Lung fluke infection (Paragonimiasis), Lyme disease, Lymphogranuloma venereum infection (LGV), Machupo Bolivian hemorrhagic fever, Madura foot, Mal del pinto, Malaria, Malignant pustule, Malta fever, Marburg hemorrhagic fever, Masters disease, Maternal Sepsis (Puerperal fever), Measles, Mediterannean spotted fever, Melioidosis (Whitmore's disease), Meningitis, Meningococcal Disease, MERS, Milker's nodule, Molluscum contagiosum, Moniliasis, monkeypox, Mononucleosis, Mononucleosis-like syndrome, Montezuma's Revenge, Morbillih, MRSA (methicillin-resistant Staphylococcus aureus) infection, Mucormycosis-Zygonmycosis, Multiple Organ Dysfunction Syndrome or MODS, Multiple-system atrophy (MSA), Mumps, Murine typhus, Murray Valley Encephalitis (MVE), Mycoburuli ulcers, Mycoburuli ulcers-Buruli ulcers, Mycotic vulvovaginitis, Myositis, Nanukavami fever, Necrotizing fasciitis, Necrotizing fasciitis—Type 1, Necrotizing fasciitis—Type 2, Negishi, New world spotted fever, Nocardiosis, Nongonococcal urethritis, Non-Polio (Non-Polio Enterovirus), Norovirus infection, North American blastonmycosis, North Asian tick typhus, Norwalk virus infection, Norwegian itch, O'Hara disease, Omsk hemorrhagic fever, Onchocerciasis, Onychomycosis, Opisthorchiasis, Opthalmia neonatorium, Oral hairy leukoplakia, Orf, Oriental Sore, Oriental Spotted Fever, Omithosis (Parrot fever; Psittacosis), Oroya fever, Otitis externa, Otitis media, Pannus, Paracoccidioidomycosis, Paragonimiasis, Paralytic Shellfish Poisoning (Paralytic Shellfish Poisoning), Paronychia (Whitlow), Parotitis, PCP pneumonia, Pediculosis, Peliosis hepatica, Pelvic Inflammatory Disease, Pertussis (also called Whooping cough), Phaeohyphomycosis, Pharyngoconjunctival fever, Piedra (White Piedra), Piedra(Black Piedra), Pigbel, Pink eye conjunctivitis, Pinta, Pinworm infection, Pitted Keratolysis, Pityriasis versicolor (Tinea versicolor), Plague; Bubonic, Pleurodynia, Pneumococcal Disease, Pneumocystosis, Pneumonia, Pneumonic (Plague), Polio or Poliominvelitis, Polycystic hydatid, Pontiac fever, Pork tapeworm, Posada-Wemicke disease, Postanginal septicemia, Powassan, Progressive multifocal leukencephalopathy, Progressive Rubella Panencephalitis, Prostatitis, Pseudomembranous colitis, Psittacosis, Puerperal fever, Pustular Rash diseases (Small pox), Pyelonephritis, Pylephlebitis, Q-Fever, Quinsy, Quintana fever (5-day fever), Rabbit fever, Rabies, Racoon roundworm infection, Rat bite fever, Rat tapeworm, Reiter Syndrome, Relapsing fever, Respiratory syncytial virus (RSV) infection, Rheumatic fever, Rhodotorulosis, Ricin Poisoning, Rickettsialpox, Rickettsiosis, Rift Valley Fever, Ringworm, Ritter's Disease, River Blindness, Rocky Mountain spotted fever, Rose Handler's disease (Sporotrichosis), Rose rash of infants, Roseola, Ross River fever, Rotavirus infection, Roundworm infections, Rubella, Rubeola, Russian spring, Salmonellosis gastroenteritis, San Joaquin Valley fever, Sao Paulo Encephalitis, Sao Paulo fever, SARS, Scabies Infestation (Scabies) (Norwegian itch), Scalded Skin Syndrome, Scarlet fever (Scarlatina), Schistosomiasis, Scombroid, Scrub typhus, Sennetsu fever, Sepsis (Septic shock), Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome (SARS), Shiga Toxigenic Escherichia coli (STEC/VTEC), Shigellosis gastroenteritis (Shigella), Shinbone fever, Shingles, Shipping fever, Siberian tick typhus, Sinusitis, Sixth disease, Slapped cheek disease, Sleeping sickness, Smallpox (Variola), Snail Fever, Soft chancre, Southern tick associated rash illness, Sparganosis, Spelunker's disease, Sporadic typhus, Sporotrichosis, Spotted fever, Spring, St, Louis encephalitis, Staphylococcal Food Poisoning, Staphylococcal Infection, Strep, throat, Streptococcal Disease, Streptococcal Toxic-Shock Syndrome, Strongyloiciasis, Stye, Subacute Sclerosing Panencephalitis, Subacute Sclerosing Panencephalitis (SSPE), Sudden Acute Respiratory Syndrome, Sudden Rash, Swimmer's ear, Swimmer's Itch, Swimming Pool conjunctivitis, Sylvatic yellow fever, Syphilis, Systemic Inflammatory Response Syndrome (SIRS), Tabes dorsalis (tertiary syphilis), Taeniasis, Taiga encephalitis, Tanner's disease, Tapeworm infections, Temporal lobe encephalitis, Temporal lobe encephalitis, tetani (Lock Jaw), Tetanus Infection, Threadwonn infections, Thrush, Tick, Tick typhus, Tinea barbae, Tinea capitis, Tinea corporis, Tinea cruris, Tinea manuum, Tinea nigra, Tinea pedis, Tinea unguiunm, Tinea versicolor, Torulopsosis, Torulosis, Toxic Shock Syndrome, Toxoplasmosis, transmissible spongioform (CJD), Traveler's diarrhea, Trench fever 5, Trichinellosis, Trichomoniasis, Trichomycosis axillaris, Trichuriasis, Tropical Spastic Paraparesis (TSP), Trypanosomiasis, Tuberculosis (TB), Tuberculousis, Tularemia, Typhoid Fever, Typhus fever, Ulcus molle, Undulant fever, Urban yellow fever, Urethritis, Vaginitis, Vaginosis, Vancomycin Intermediate (VISA), Vancomycin Resistant (VRSA), Varicella, Venezuelan Equune encephalitis, Verruga peruana, Vibrio cholerae (Cholera), Vibriosis (Vibrio), Vincent's disease or Trench mouth, Viral conjunctivitis, Viral Meningitis, Viral meningoencephalitis, Viral rash, Visceral Larval Migrans, Vornito negro, Vulvovaginitis, Warts, Waterhouse, Weil's disease, West Nile Fever, Western equine encephalitis, Whipple's disease, Whipworm infection, White Piedra, Whitlow, Whitmore's disease, Winter diarrhea, Wolhynia fever, Wool sorters' disease, Yaws, Yellow Fever, Yersinosis, Yersinosis (Yersinia), Zahorsky's disease, Zika virus disease, Zoster, Zygornmcosis, John Cunningham Virus (JCV), Human immunodeficiency virus (HIV), Influenza virus, Hepatitis B, Hepatitis C, Hepatitis D, Respiratory syncytial virus (RSV), Herpes simplex virus 1 and 2, Human Cytomegalovirus, Epstein-Barr virus, Varicella zoster virus, Coronaviruses, Poxviruses, Enterovirus 71, Rubella virus, Human papilloma virus, Streptococcus pneumoniae, Streptococcus viridans, Staphylococcus aureus (S. aureus), Methicillin-resistant Staphylococcus aureus (MRSA), Vancomycin-intermediate Staphylococcus aureus (VISA), Vancomycin-resistant Staphylococus aureus (VRSA), Staphylococcus epidermidis (S. epidermidis), Clostridium teltani, Bordetella pertussis, Bordetelia paratussis, Mycobacterium, Francisella yularensis, Toxoplasma gondii, Candida ((C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei and C. lusiltaniae) and/or any other infectious diseases, disorders or syndromes.

Various toxins may be treated with the pharmaceutical compositions, AAV particles, of the present invention. Non-limited examples of toxins include Ricin, Bacillus anthracis, Shiga toxin and Shiga-like toxin, Botulinum toxins.

Various tropical diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. Non-limited examples of tropical diseases include Chikungunya fever. Dengue fever. Chagas disease, Rabies, Malaria. Ebola virus, Marburg virus, West Nile Virus, Yellow Fever, Japanese encephalitis virus. St Louis encephalitis virus.

Various foodborne illnesses and gastroenteritis may be treated with pharmaceutical compositions, AAV particles, of the present invention. Non-limited examples of foodborne illnesses and gastroenteritis include Rotavirus, Norwalk virus (Norovirus), Campylobacter jejuni, Clostridium difficile, Entamoeba histolytica, Helicobacter pylori, Enterotoxin B of Staphylococcus aureus, H-lepatitis A virus (HAV), Hepatitis E. Listeria monocytogenes, Salmonella, Clostridium perfringens, and Salmonella.

Various infectious agents may be treated with pharmaceutical compositions, AAV particles, of the present invention. Non-limited examples of infectious agents include adenoviruses. Anaplasma phagocytophilium, Ascaris lumbricoides, Bacillus anthracis, Bacillus cereus, Bacteroides sp, Barmah Forest virus, Bartonella bacilliformis, Bartonella henselae, Bartonella quintana, beta-toxin of Clostridium perifingens, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Borrelia miyamotoi, Borrelia recurrentis, Borreha sp., Botulinum toxin, Brucella sp., Burkholderia pseudomallei, California encephalitis virus, Campylobacter, Candida albicans, chikungunya virus, Chlamydia psittaci, Chlamydia trachomatis, Clonorchts sinensis, Clostridium difficile bacteria, Clostridium tetani, Colorado tick fever virus, Corynebacterium diphtheriae, Corynebacterium minutissimum, Coxiella burneii, coxsackie A, coxsackie B, Crimean-Congo hemorrhagic fever virus, cytomegalovirus, dengue virus, Eastern Equine encephalitis virus, Ebola viruses, echovirus, Ehrlichia chaffeensis, Ehrlichia equi, Ehrlichia sp., Entamoeba histolytica, Enterobacter sp., Enterococcus feacalis, Enterovirus 71, Epstein-Barr virus (EBV), Erysipelothrix rhusioplathiae, Escherichia coli, Flavivirus, Fusobacterium necrophorum, Gardnerella vaginalis, Group B streptococcus, Haemophilus aegyptius, Haemophilus ducreyi, Haemophilus influenzae, hantavirus, Helicobacter pylori, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, herpes simplex virus 1 and 2, human herpes virus 6, human herpes Virus 8, human immunodeficiency virus 1 and 2, human T-cell leukemia viruses 1 and 11, influenza viruses (A, B, C), Jamestown Canyon virus, Japanese encephalitis antigenic, Japanese encephalitis virus, John Cunningham virus, juninvirus, Kaposi's Sarcoma-associated Herpes Virus (KSHV), Klebsiella granulomatis, Klebsiella sp., Kyasanur Forest Disease virus, La Crosse virus, Lassavirus, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, lymphocytic choriomeningitis virus, lyssavirus, Machupovirus, Marburg virus, measles virus, MERS coronavirus (MERS-CoV), Micrococcus sedentarius, Mobiliuncus sp., Molluscipeoxvirus, Moraxella catarrhalis, Morbilli-Ruheola virus, Mumpsvirus, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma genitalium, Mycoplasma sp. Nairovirus, Neisseria gonorrhoeae, Neisseria menigitidis, Nocardia, Norwalk virus, norovirus, Onmsk hemorrhagic fever virus, papilloma virus, parainfluenza viruses 1-3, parapoxvirus, parvovirus B19, Peptostreptococccus sp., Plasmodium sp., polioviruses types 1, 11, and III, Proteus sp., Pseudomonas aeruginosa, Pseudomonas pseudomallei, Pseudomonas sp., rabies virus, respiratory syncytial virus, ricin toxin, Rickettsia australis, Rickettsia conori, Rickettsia honei, Rickettsia prowazekii, Ross River Virus, rotavirus, rubellavirus, Saint Louis encephalitis, Salmonella typhi, Sarcoptes scabiei, SARS-associated coronavirus (SARS-CoV), Serratia sp., Shiga toxin and Shiga-like toxin, Shigella sp., Sin Nombre Virus, Snowshoe hare virus, Staphylococcus aureus, Staphylococcus epidermidis, Streptobacillus moniliformis, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus agalacticae, Streptococcus group A-H, Streptococcus pneumoniae, Streptcoccus pyogenes, Treponema pallidum subsp. Pallidum, Treponema pallidum var. carateum, Treponema pallidum var. endemicum, Tropheryma whippelii, Ureaplasma urealytcum, Varicella-Zoster virus, variola virus, Vibrio cholerae, West Nile virus, yellow fever virus, Yersinia enterocolitica, Yersinia pestis, and Zika virus.

Various rare diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As used herein, the term “rare disease” refers to any disease that affects a small percentage of the population. As a non-limiting example, the rare disease may be Acrocephalosyndactylia, Acrodermatitis, Addison Disease, Adie Syndrome, Alagille Syndrome, Amylose, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Angiolymphoid Hyperplasia with Eosinophilia, Arnold-Chiari Malformation, Arthritis, Juvenile Rheumatoid, Asperger Syndrome, Bardet-Biedl Syndrome, Barrett Esophagus, Beckwith-Wiedemann Syndrome, Behcet Syndrome, Bloom Syndrome, Bowen's Disease, Brachial Plexus Neuropathies, Brown-Sequard Syndrome, Budd-Chiari Syndrome, Burkitt Lymphoma, Carcinoma 256, Walker, Caroli Disease, Charcot-Marie-Tooth Disease, Chediak-Hiigashi Syndrome, Chiari-Frommel Syndrome, Chondrodysplasia Punctata, Colonic Pseudo-Obstruction, Colorectal Neoplasms, Hereditary Nonpolyposis, Craniofacial Dysostosis, Creutzfeldt-Jakob Syndrome, Crohn Disease, Cushing Syndrome, Cystic Fibrosis, Dandy-Walker Syndrome, De Lange Syndrome, Dementia, Vascular, Dermatitis Herpetiformis, DiGeorge Syndrome, Diffuse Cerebral Sclerosis of Schilder, Duane Retraction Syndrome, Dupuytren Contracture, Ebstein Anomaly, Eisenmenger Complex, Ellis-Van Creveld Syndrome, Encephalitis, Enchondromatosis, Epidermal Necrolysis, Toxic, Facial Hemiatrophy, Factor XII Deficiency, Fanconi Anemia, Felty's Syndrome, Fibrous Dyvsplasia, Polvostotic, Fox-Fordyce Disease, Friedreich Ataxia, Fusobacterium, Gardner Syndrome, Gaucher Disease, Gerstmann Syndrome, Giant Lymph Node Hyperplasia, Glycogen Storage Disease Type I, Glycogen Storage Disease Type II, Glycogen Storage Disease Type IV, Glycogen Storage Disease Type V, Glycogen Storage Disease Type VII, Goldenhar Syndrome, Guillain-Barre Syndrome, Hallermann's Syndrome, Hamartoma Syndrome, Multiple, Hartnup Disease, Hepatolenticular Degeneration, Hepatolenticular Degeneration, Hereditary Sensory and Motor Neuropathy, Hirschsprung Disease, Histiocytic Necrotizing Lymphadenitis, Histiocytosis, Langerhans-Cell, Hodgkin Disease, Homer Syndrome, Huntington Disease, Hyperaldosteronism, Hyperhidrosis, Hyperostosis, Diffuse Idiopathic Skeletal, Hypopituitarism, Inappropriate ADH Syndrome, Intestinal Polyps, Isaacs Syndrome, Kartagener Syndrome, Keams-Sayre Syndrome, Klippel-Feil Syndrome, Klippel-Trenaunay-Weber Syndrome, Kluver-Bucy Syndrome, Korsakoff Syndrome, Lafora Disease, Lambert-Eaton Myasthenic Syndrome, Landau-Kleffner Syndrome, Langer-Giedion Syndrome, Leigh Disease, Lesch-Nyhan Syndrome, Leukodystrophy, Globoid Cell, Li-Fraumeni Syndrome, Long QT Syndrome, Machado-Joseph Disease, Mallory-Weiss Syndrome, Marek Disease, Marfan Syndrome, Meckel Diverticulum, Meige Syndrome, Melkersson-Rosenthal Syndrome, Meniere Disease, Mikulicz' Disease, Miller Fisher Syndrome, Mobius Syndrome, Moyamoya Disease, Mucocutaneous Lymph Node Syndrome, Mucopoly saccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis III, Mucopolysaccharidosis IV, Mucopolysaccharidosis VI, Multiple Endocrine Neoplasia Type 1, Munchausen Syndrome by Proxy, Muscular Atrophy, Spinal, Narcolepsy, Neuroaxonal Dystrophies, Neuromyelitis Optica, Neuronal Ceroid-Lipofuscinoses, Niemann-Pick Diseases, Noonan Syndrome, Optic Atrophies, Hereditary, Osteitis Deformans, Osteochondritis, Osteochondrodysplasias, Osteolysis, Essential, Paget Disease Extramammary, Paget's Disease, Mammary, Panuuculitis, Nodular Nonsuppurative, Papillon-Lefevre Disease, Paralysis, Pelizaeus-Merzbacher Disease, Pemphigus, Benign Familial, Penile Induration, Pericarditis, Constrictive, Peroxisomal Disorders, Peutz-Jeghers Syndrome, Pick Disease of the Brain, Pierre Robin Syndrome, Pigmentation Disorders, Pityriasis Lichenoides, Polycystic Ovary Syndrome, Polyendocrinopathies, Autoimmune, Prader-Willi Syndrome, Pupil Disorders, Rett Syndrome, Reye Syndrome, Rubinstein-Taybi Syndrome, Sandhoff Disease, Sarcoma, Ewing's, Schnitzler Syndrome, Sjogren's Syndrome, Sjogren-Larsson Syndrome, Smith-Lemli-Opitz Syndrome, Spinal Muscular Atrophies of Childhood, Sturge-Weber Syndrome, Sweating, Gustatory, Takayasu Arteritis, Tangier Disease, Tay-Sachs Disease, Thromboangiitis Obliterans, Thyroiditis, Autoimmune, Tietze's Syndrome, Togaviridae Infections, Tolosa-Hunt Syndrome, Tourette Syndrome, Uveomeningoencephalitic Syndrome, Waardenburg's Syndrome, Wegener Granulomatosis, Weil Disease, Werner Syndrome, Williams Syndrome, Wilms Tumor, Wolff-Parkinson-White Syndrome, Wolfram Syndrome, Wolman Disease, Zellweger Syndrome, Zollinger-Ellison Syndrome, and von Willebrand Diseases.

Various autoimmune diseases and autoimmune-related diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As used herein, the term “autoimmune disease” refers to a disease in which the body produces antibodies that attack its own tissues. As a non-limiting example, the autoimmune disease may be Acute Disseminated Encephalomyelitis (ADEM), Acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, Agammaglobulinemia, Alopecia areata, Amyloidosis, Ankylosing spondylitis, Anti-GBM/Anti-TBM nephritis, Antiphospholipid syndrome (APS), Autoimmune angioedema, Autoimmune aplastic anemia, Autoimmune dysautonomia, Autoimmune hepatitis, Autoimmune hyperlipidemia, Autoimmune immunodeficiency, Autoimmune inner ear disease (AIED), Autoimmune myocarditis, Autoimmune oophoritis, Autoimmune pancreatitis, Autoimmune retinopathy, Autoimmune thrombocytopenic purpura (ATP), Autoimmune thyroid disease, Autoimmune urticaria, Axonal & neuronal neuropathies, Balo disease, Behcet's disease, Bullous pemphigoid, Cardiomyopathy, Castleman disease, Celiac disease, Chagas disease, Chronic fatigue syndrome**, Chronic inflammatory demyelinating polyneuropathy (CIDP), Chronic recurrent multifocal ostomyelitis (CRMO), Churg-Strauss syndrome, Cicatricial pemphigoid/benign mucosal pemphigoid, Crohn's disease, Cogans syndrome, Cold agglutinin disease, Congenital heart block, Coxsackle myocarditis, CREST disease, Essential mixed cryoglobulinemia, Demyelinating neuropathies, Dermatitis herpetiformis, Dermatomyositis, Devic's disease (neuromyelitis optica), Discoid lupus, Dressler's syndrome, Endometriosis, Eosinophilic esophagitis, Eosinophilic fasciitis, Erythema nodosum, Experimental allergic encephalomyelitis, Evans syndrome, Fibromyalgia**, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, Glomerulonephritis, Goodpasture's syndrome, Granulomatosis with Polyangiitis (GPA) (formerly called Wegener's Granulomatosis), Graves' disease, Guillain-Barre syndrome, Hashimoto's encephalitis, Hashimoto's thyroiditis, Hemolytic anemia, Henoch-Schonlein purpura, Herpes gestationis, Hypogammaglobulinemia, Idiopathic thrombocytopenic purpura (ITP), IgA nephropathy, IgG4-related sclerosing disease, Immunoregulatory lipoproteins, Inclusion body myositis, Interstitial cystitis, Juvenile arthritis, Juvenile diabetes (Type 1 diabetes), Juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, Leukocytoclastic vasculitis, Lichen planus, Lichen sclerosus, Ligneous conjunctivitis, Linear IgA disease (LAD), Lupus (SLE), Lyme disease, chronic, Meniere's disease, Microscopic polyangiitis, Mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, Multiple sclerosis, Myasthenia gravis, Myositis, Narcolepsy, Neurormelitis optica (Devic's), Neutropenia, Ocular cicatricial pemphigoid, Optic neuritis, Palindromic rheumatism, PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcus), Paraneoplastic cerebellar degeneration, Paroxysmal nocturnal hemoglobnuria (PNH), Parry Romberg syndrome, Parsonnage-Turner syndrome, Pars planitis (peripheral uveitis), Pemphigus, Peripheral neuropathy, Perivenous encephalomyelitis, Pernicious anemia, POEMS syndrome, Polyarteritis nodosa, Type I, II, & III autoimmune polyglandular syndromes, Polymyalgia rheumatica, Polymyositis, Postmyocardial infarction syndrome, Postpericardiotomy syndrome, Progesterone dermatitis, Primary biliary cirrhosis, Primary sclerosing cholangitis, Psoriasis, Psoriatic arthritis, Idiopathic pulmonary fibrosis, Pyoderma gangrenosum, Pure red cell aplasia, Raynauds phenomenon, Reactive Arthritis, Reflex sympathetic dystrophy, Reiter's syndrome, Relapsing polychondritis, Restless legs syndrome, Retroperitoneal fibrosis, Rheumatic fever, Rheumatoid arthritis, Sarcoidosis, Schmidt syndrome, Scleritis, Scleroderma, Sjogren's syndrome, Sperm & testicular autoimmunity, Stiff person syndrome, Subacute bacterial endocarditis (SBE), Susac's syndrome, Sympathetic ophthalmia, Takayasu's arteritis, Temporal arteritis/Giant cell arteritis, Thrombocy topenic purpura (TTP), Tolosa-Hunt syndrome, Transverse myelitis, Ulcerative colitis, Undifferentiated connective tissue disease (UCTD), Uveitis, Vasculitis, Vesiculobullous dermatosis, Vitiligo, and Wegener's granulomatosis (now termed Granulomatosis with Polyangiitis (GPA).

Various kidney diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the kidney disease Abderhalden-Kaufmann-Lignac syndrome (Nephropathic Cystinosis), Abdominal Compartment Syndrome, Acute Kidney Failure/Acute Kidney Injury, Acute Lobar Nephronia, Acute Phosphate Nephropathy, Acute Tubular Necrosis, Adenine Phosphoribosyltransferase Deficiency, Adenovirus Nephritis, Alport Syndrome, Amyloidosis, ANCA Vasculitis Related to Endocarditis and Other Infections, Angiomyolipoma, Analgesic Nephropathy, Anorexia Nervosa and Kidney Disease, Angiotensin Antibodies and Focal Segmental Glomerulosclerosis, Antiphospholipid Syndrome, Anti-TNF-α Therapy-related Glomerulonephritis, APOL1 Mutations, Apparent Mineralocorticoid Excess Syndrome, Aristolochic Acid Nephropathy, Chinese Herbal Nephropathy, Balkan Endemic Nephropathy, Bartter Syndrome, Beeturia, β-Thalassemia Renal Disease, Bile Cast Nephropathy, BK Polyoma Virus Nephropathy in the Native Kidney, Bladder Rupture, Bladder Sphincter Dyssynergia, Bladder Tamponade, Border-Crossers' Nephropathy, Bourbon Virus and Acute Kidney Injury, Burnt Sugarcane Harvesting and Acute Renal Dysfunction, Byetta and Renal Failure, C1q Nephropathy, Cannabinoid Hyperemesis Acute Renal Failure, Cardiorenal syndrome, Carfilzomib-Induced Renal Injury, CFHR5 nephropathy, Charcot-Marie-Tooth Disease with Glomerulopathy, Cherry Concentrate and Acute Kidney Injury, Cholesterol Emboli, Churg-Strauss syndrome, Chyluria, Colistin Nephrotoxicity, Collagenofibrotic Glomerulopathy, Collapsing Glomerulopathy, Collapsing Glomerulopathy Related to CMV, Congenital Nephrotic Syndrome, Conorenal syndrome (Mainzer-Saldino Syndrome or Saldino-Mainzer Disease), Contrast Nephropathy, Copper Sulpfate Intoxication, Cortical Necrosis, Crizotinib-related Acute Kidney Injury, Cryoglobinemia, Crystalglobulin-Induced Nephropathy, Crystal-Induced Acute Kidney injury, Cystic Kidney Disease, Acquired, Cystinuria, Dasatinib-Induced Nephrotic-Range Proteinuria, Dense Deposit Disease (MPGN Type 2), Dent Disease (X-linked Recessive Nephrolithiasis), Dialysis Disequilibrium Syndrome, Diabetes and Diabetic Kidney Disease, Diabetes Insipidus, Dietary Supplements and Renal Failure, Drugs of Abuse and Kidney Disease, Duplicated Ureter, EAST syndrome, Ebola and the Kidney, Ectopic Kidney, Ectopic Ureter, Edema, Swelling, Erdheim-Chester Disease, Fabry's Disease, Familial Hypocalciuric Hypercalcemia, Fanconi Syndrome, Fraser syndrome, Fibronectin Glomerulopathy, Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy, Fraley syndrome, Focal Segmental Glomerulosclerosis, Focal Sclerosis, Focal Glomerulosclerosis, Galloway Mowat syndrome, Giant Cell (Temporal) Arteritis with Kidney Involvement, Gestational Hypertension, Gitelman Syndrome, Glomerular Diseases, Glomerular Tubular Reflux, Glycosuria, Goodpasture Syndrome, Hair Dye Ingestion and Acute Kidney Injury, Hantavirus Infection Podocytopathy, Hematuria (Blood in Urine), Hemolytic Urermic Syndrome (HUS), Atypical Hemolytic Uremic Syndrome (aHUS), Hemophagocytic Syndrome, Hemorrhagic Cystitis, Hemorrhagic Fever with Renal Syndrome (HFRS, Hantavirus Renal Disease, Korean Hemorrhagic Fever, Epidemic Hemorrhagic Fever, Nephropathis Epidemica), Hemosiderosis related to Paroxysmal Nocturnal Hemoglobinuria and Hemolytic Anemia, Hepatic Glomerulopathy, Hepatic Veno-Occlusive Disease, Sinusoidal Obstruction Syndrome, Hepatitis C-Associated Renal Disease, Hepatorenal Syndrome, Herbal Supplements and Kidney Disease, High Blood Pressure and Kidney Disease, HIV-Associated Nephropathy (HIVAN), Horseshoe Kidney (Renal Fusion), Hunner's Ulcer, Hyperaldosteronism, Hypercalcemia, Hyperkalemia, Hypermagnesemia, Hypermanesemia, Hypernatremia, Hyperoxaluria, Hyperphosphatemia, Hypocalcemia, Hypokalemia, Hypokalemia-induced renal dysfunction, Hypokalemic Periodic Paralysis, Hypomagnesemia, Hyponatremia, Hypophosphatemia, IgA Nephropathy, IgG4 Nephropathy, Interstitial Cystitis, Painful Bladder Syndrome (Questionnaire), Interstitial Nephritis, Ivemark's syndrome, Ketamine-Associated Bladder Dysfunction, Kidney Stones, Nephrolithiasis, Kombucha Tea Toxicity, Lead Nephropathy and Lead-Related Nephrotoxicity, Leptospirosis Renal Disease, Light Chain Deposition Disease, Monoclonal Immunoglobulin Deposition Disease, Liddle Syndrome, Lightwood-Albright Syndrome, Lipoprotein Glomerulopathy, Lithium Nephrotoxicity, LMXIB Mutations Cause Hereditary FSGS, Loin Pain Hematuria, Lupus, Systemic Lupus Erythematosis, Lupus Kidney Disease, Lupus Nephritis, Lupus Nephritis with Antineutrophil Cytoplasmic Antibody Seropositivity, Lyme Disease-Associated Glomerulonephritis, Malarial Nephropathy, Malignancy-Associated Renal Disease, Malignant Hypertension, Malakoplakia, Meatal Stenosis, Medullary Cystic Kidney Disease, Medullary Sponge Kidney, Megaureter, Melamine Toxicity and the Kidney, Membranoproliferative Glomerulonephritis, Membranous Nephropathy, MesoAmerican Nephropathy, Metabolic Acidosis, Metabolic Alkalosis, Methotrexate-related Renal Failure, Microscopic Polyangiitis, Milk-alkalai syndrome, Minimal Change Disease, MDMA (Molly, Ecstacy; 3,4-Methylenedioxymnethamphetamine) and Kidney Failure, Multicystic dysplastic kidney, Multiple Myeloma, Myeloproliferative Neoplasms and Glomerulopathy, Nail-patella Syndrome, Nephrocalcinosis, Nephrogenic Systemic Fibrosis, Nephroptosis (Floating Kidney, Renal Ptosis), Nephrotic Syndrome, Neurogenic Bladder, Nodular Glomerulosclerosis, NonGonococcal Urethritis, Nutcracker syndrome, Orofaciodigital Syndrome, Orotic Aciduria, Orthostatic Hypotension, Orthostatic Proteinurina, Osmotic Diuresis, Ovarian Hyperstimulation Syndrome, Page Kidney, Papillary Necrosis, Papillorenal Syndrome (Renal-Coloboma Syndrome, Isolated Renal Hypoplasia), Parvovirus B19 and the Kidney, The Peritoneal-Renal Syndrome, Posterior Urethral Valve, Post-infectious Glomerulonephritis, Post-streptococcal Glomerulonephritis, Polyarteritis Nodosa, Polycystic Kidney Disease, Posterior Urethral Valves, Preeclampsia, Propofol infusion syndrome, Proliferative Glomerulonephritis with Monoclonal IgG Deposits (Nasr Disease), Propolis (Honeybee Resin) Related Renal Failure, Proteinuria (Protein in Urine), Pseudohyperaldosteronism, Pseudohypobicarbonatemia, Pseudohypoparathyroidism, Pulmonary-Renal Syndrome, Pyelonephritis (Kidney Infection), Pyonephrosis, Radiation Nephropathy, Ranolazine and the Kidney, Refeeding syndrome, Reflux Nephropathy, Rapidly Progressive Glomerulonephritis, Renal Abscess, Peripnephric Abscess, Renal Agenesis, Renal Arcuate Vein Microthrombi-Associated Acute Kidney Injury, Renal Artery Aneurysm, Renal Artery Stenosis, Renal Cell Cancer, Renal Cyst, Renal Hypouricemia with Exercise-induced Acute Renal Failure, Renal Infarction, Renal Osteodystrophy, Renal Tubular Acidosis, Renin Secreting Tumors (Juxtaglomerular Cell Tumor), Reset Osmostat, Retrocaval Ureter, Retroperitoneal Fibrosis, Rhabdomyolysis, Rhabdomyolysis related to Bariatric Sugery, Rheumatoid Arthritis-Associated Renal Disease, Sarcoidosis Renal Disease, Salt Wasting, Renal and Cerebral, Schistosomiasis and Glomerular Disease, Schimke immuno-osseous dysplasia, Scleroderma Renal Crisis, Serpentine Fibula-Polycystic Kidney Syndrome, Exner Syndrome, Sickle Cell Nephropathy, Silica Exposure and Chronic Kidney Disease, Sri Lankan Farmers' Kidney Disease, Sjögren's Syndrome and Renal Disease, Synthetic Cannabinoid Use and Acute Kidney Injury, Kidney Disease Following Hematopoietic Cell Transplantation, Kidney Disease Related to Stem Cell Transplantation, Thin Basement Membrane Disease, Benign Familial Hematuria, Trigonitis, Tuberculosis, Genitourinary, Tuberous Sclerosis, Tubular Dysgenesis, Immune Complex Tubulointerstitial Nephritis Due to Autoantibodies to the Proximal Tubule Brush Border, Tumor Lysis Syndrome, Uremia, Uremic Optic Neuropathy, Ureteritis Cystica, Ureterocele, Urethral Caruncle, Urethral Stricture, Urinary Incontinence, Urinary Tract Infection, Urinary Tract Obstruction, Vesicointestinal Fistula, Vesicoureteral Reflux, Volatile Anesthetics and Acute Kidney Injury, Von Hippel-Lindau Disease, Waldenstrom's Macroglobulinemic Glomerulonephritis, Warfarin-Related Nephropathy, Wasp Stings and Acute Kidney Injury, Wegener's Granulomatosis, Granulomatosis with Polyangiitis, West Nile Virus and Chronic Kidney Disease, and Wunderlich syndrome.

Various cardiovascular diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the cardiovascular disease may be Ischemic heart disease also known as coronary artery disease, cerebrovascular disease (Stroke), Peripheral vascular disease, Heart failure, Rheumatic heart disease, and Congenital heart disease.

Various antibody deficiencies may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the antibody deficiencies may be X-Linked Agammaglobulinemia (XLA), Autosomal Recessive Agammaglobulinemia (ARA), Common Variable Immune Deficiency (CVID), IgG (IgG1, IgG2, IgG3 and IgG4) Subclass Deficiency, Selective IgA Deficiency, Specific Antibody Deficiency (SAD). Transient Hypogammaglobulinemia of Infancy, Antibody Deficiency with Normal or Elevated Immunoglobulins, Selective IgM Deficiency, Immunodeficiency with Thymoma (Good's Syndrome), Transcobalamin II Deficiency, Warts, Hypogammaglobulinemia, Infection, Myelokathexis (WHIM) Syndrome, Drug-Induced Antibody Deficiency, Kappa Chain Deficiency, Heavy Chain Deficiencies, Post-Meiotic Segregation (PMS2) Disorder, and Unspecified Hypogammaglobulinemia.

Various ocular diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the ocular disease may be thyroid eye disease (TED), Graves' disease (GD) and orbitopathy, Retina Degeneration. Cataract, optic atrophy, macular degeneration, Leber congenital amaurosis, retinal degeneration, cone-rod dystrophy, Usher syndrome, leopard syndrome, photophobia, and photoaversion.

Various neurological diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the neurological disease may be Absence of the Septum Pellucidum, Acid Lipase Disease, Acid Maltase Deficiency, Acquired Epileptiform Aphasia, Acute Disseminated Encephalomyelitis, Attention Deficit-Hyperactivity Disorder (ADHD), Adie's Pupil, Adle's Syndrome, Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, Aicardi Syndrome, Aicardi-Goutieres Syndrome Disorder, AIDS—Neurological Complications, Alexander Disease, Alpers' Disease, Alternating Hemiplegia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Anencephaly, Aneurysm, Angelman Syndrome, Angiomatosis, Anoxia, Antiphospholipid Syndrome, Aphasia, Apraxia, Arachnoid Cysts, Arachnoiditis, Amold-Chiari Malformation, Arteriovenous Malformation, Asperger Syndrome, Ataxia, Ataxia Telangiectasia, Ataxias and Cerebellar or Spinocerebellar Degeneration, Atrial Fibrillation and Stroke, Attention Deficit-Hyperactivity Disorder, Autism Spectrum Disorder, Autonomic Dysfunction, Back Pain, Barth Syndrome, Batten Disease, Becker's Myotonia, Behcet's Disease, Bell's Palsy, Benign Essential Blepharospasm, Benign Focal Amyotrophy, Benign Intracranial Hypertension, Bernhardt-Roth Syndrome, Binswanger's Disease, Blepharospasm, Bloch-Sulzberger Syndrome, Brachial Plexus Birth Injuries, Brachial Plexus Injuries, Bradbury-Eggleston Syndrome, Brain and Spinal Tumors, Brain Aneurysm, Brain Injury, Brown-Sequard Syndrome, Bulbospinal Muscular Atrophy, Cerebral Autosomal Dominant Arteriopathy with Sub-cortical Infarcts and Leukoencephalopathy (CADASIL), Canavan Disease, Carpal Tunnel Syndrome, Causalgia, Cavernomas, Cavernous Angioma, Cavernous Malformation, Central Cervical Cord Syndrome, Central Cord Syndrome, Central Pain Syndrome, Central Pontine Myelinolysis, Cephalic Disorders, Ceramidase Deficiency, Cerebellar Degeneration, Cerebellar Hypoplasia, Cerebral Aneurysms, Cerebral Arteriosclerosis, Cerebral Atrophy, Cerebral Beriberi, Cerebral Cavernous Malformation, Cerebral Gigantism, Cerebral Hypoxia, Cerebral Palsy, Cerebro-Oculo-Facio-Skeletal Syndrome (COFS), Charcot-Mane-Tooth Disease, Chian Malformation, Cholesterol Ester Storage Disease, Chorea, Choreoacanthocytosis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Chronic Orthostatic Intolerance, Chronic Pain, Cockayne Syndrome Type II, Coffin Lowry Syndrome, Colpocephaly, Coma, Complex Regional Pain Syndrome, Congenital Facial Diplegia, Congenital Myasthenia, Congenital Myopathy, Congenital Vascular Cavernous Malformations, Corticobasal Degeneration, Cranial Arteritis, Craniosynostosis, Cree encephalitis, Creutzfeldt-Jakob Disease, Cumulative Trauma Disorders, Cushing's Syndrome, Cytomegalic Inclusion Body Disease, Cytomegalovirus Infection, Dancing Eyes-Dancing Feet Syndrome, Dandy-Walker Syndrome, Dawson Disease, De Morsier's Syndrome, Dejerine-Klumpke Palsy, Dementia, Dementia—Multi-Infarct, Dementia—Semantic, Dementia—Subcortical, Dementia With Lewy Bodies, Dentate Cerebellar Ataxia, Dentatorubral Atrophy, Dermatomyositis, Developmental Dyspraxia, Devic's Syndrome, Diabetic Neuropathy, Diffuse Sclerosis, Dravet Syndrome, Dysautonomia, Dysgraphia, Dyslexia, Dysphagia, Dyspraxia, Dyssynergia Cerebellaris Myoclonica, Dyssynergia Cerebellaris Progressiva, Dystonias, Early Infantile Epileptic Encephalopathy, Empty Sella Syndrome, Encephalitis, Encephalitis Lethargica, Encephaloceles, Encephalopathy, Encephalopathy (familial infantile), Encephalotrigeminal Anglomatosis, Epilepsy, Epileptic Hermplegia, Erb's Palsy, Erb-Duchenne and Dejerine-Klumpke Palsies, Essential Tremor, Extrapontine Myelinolysis, Fabry Disease, Fahr's Syndrome, Fainting, Familial Dysautonomia, Familial Hemangioma, Familial Idiopathic Basal Ganglia Calcification, Familial Periodic Paralyses, Familial Spastic Paralysis, Farber's Disease, Febrile Seizures, Fibromuscular Dysplasia, Fisher Syndrome, Floppy Infant Syndrome, Foot Drop, Friedreich's Ataxia, Frontotemporal Dementia, Gaucher Disease, Generalized Gangliosidoses, Gerstmann's Syndrome, Gerstmann-Straussler-Scheinker Disease, Giant Axonal Neuropathy, Giant Cell Arteritis, Giant Cell Inclusion Disease, Globoid Cell Leukodystrophy, Glossopharyngeal Neuralgia, Glycogen Storage Disease, Guillain-Barre Syndrome, Hallervorden-Spatz Disease, Head Injury, Headache, Hemicrania Continua, Hemifacial Spasm, Hemiplegia Alterans, Hereditary Neuropathies, Hereditary Spastic Paraplegia, Heredopathia Atactica Polyneuritiformis, Herpes Zoster, Herpes Zoster Oticus, Hirayama Syndrome, Holmes-Adie syndrome, Holoprosencephaly, HTLV-1 Associated Myelopathy, Hughes Syndrome, Huntington's Disease, Hydranencephaly, Hydrocephalus, Hydrocephalus—Normal Pressure, Hydromyelia, Hypercortisolism, Hypersomnia, Hypertonia, Hypotonia, Hypoxia, Immune-Mediated Encephalomyelitis, Inclusion Body Myositis, Incontinentia Pigmenti, Infantile Hypotonia, Infantile Neuroaxonal Dystrophy, Infantile Phytanic Acid Storage Disease, Infantile Refsum Disease, Infantile Spasms, Inflammatory Myopathies, Iniencephaly, Intestinal Lipodystrophy, Intracranial Cysts, Intracranial Hypertension, Isaacs' Syndrome, Joubert Syndrome, Kearns-Savre Syndrome, Kennedy's Disease, Kinsbourne syndrome, Kleine-Levin Syndrome, Klippel-Feil Syndrome, Klippel-Trenaunay Syndrome (KTS), Klüver-Bucy Syndrome, Korsakoff's Amnesic Syndrome, Krabbe Disease, Kugelberg-Welander Disease, Kuru, Lambert-Eaton Myasthenic Syndrome, Landau-Kleffner Syndrome, Lateral Femoral Cutaneous Nerve Entrapment, Lateral Medullary Syndrome, Learning Disabilities, Leigh's Disease, Lennox-Gastaut Syndrome, Lesch-Nyhan Syndrome, Leukodystrophy, Levine-Critchley Syndrome, Lewy Body Dementia, Lipid Storage Diseases, Lipoid Proteinosis, Lissencephaly, Locked-In Syndrome, Lou Gehrig's Disease, Lupus—Neurological Sequelae, Lyme Disease—Neurological Complications, Machado-Joseph Disease, Macrencephaly, Megalencephaly, Melkersson-Rosenthal Syndrome, Meningitis, Meningitis and Encephalitis, Menkes Disease, Meralgia Paresthetica, Metachromatic Leukodystrophy, Microcephaly, Migraine, Miller Fisher Syndrome, Mini Stroke, Mitochondrial Myopathy, Moebius Syndrome, Monomelic Amyotrophy, Motor Neuron Diseases, Moyamoya Disease, Mucolipidoses, Mucopolysaccharidoses, Multi-Infarct Dementia, Multifocal Motor Neuropathy, Multiple Sclerosis, Multiple System Atrophy, Multiple System Atrophy with Orthostatic Hypotension, Muscular Dystrophy, Myasthenia—Congenital, Myasthenia Gravis, Myelinoclastic Diffuse Sclerosis, Myoclonic Encephalopathy of Infants, Myoclonus, Myopathy, Myopathy—Congenital, Myopathy—Thyrotoxic, Myotonia, Myotonia Congenita, Narcolepsy, Neuroacanthocytosis, Neurodegeneration with Brain Iron Accumulation, Neurofibromatosis, Neuroleptic Malignant Syndrome, Neurological Complications of AIDS, Neurological Complications of Lyme Disease, Neurological Consequences of Cytomegalovirus Infection, Neurological Manifestations of Pompe Disease, Neurological Sequelae Of Lupus, Neuromyelitis Optica, Neuromyotonia, Neuronal Ceroid Lipofuscinosis, Neuronal Migration Disorders, Neuropathy—Hereditary, Neurosarcoidosis, Neurosyphilis, Neurotoxicity, Nevus Cavernosus, Niemann-Pick Disease, O'Sullivan-McLeod Syndrome, Occipital Neuralgia, Ohtahara Syndrome, Olivopontocerebellar Atrophy, Opsoclonus Myoclonus, Orthostatic Hypotension, Overuse Syndrome, Pain—Chronic, Pantothenate Kinase-Associated Neurodegeneration, Paraneoplastic Syndromes, Paresthesia, Parkinson's Disease, Paroxysmal Choreoathetosis, Paroxysmal Hemicrania, Parry-Romberg, Pelizaeus-Merzbacher Disease, Pena Shokeir II Syndrome, Perineural Cysts, Periodic Paralyses, Peripheral Neuropathy, Periventricular Leukomalacia, Persistent Vegetative State, Pervasive Developmental Disorders, Phytanic Acid Storage Disease, Pick's Disease, Pinched Nerve, Piriformis Syndrome, Pituitary Tumors, Polymyositis, Pompe Disease, Porencephaly, Post-Polio Syndrome, Postherpetic Neuralgia, Postinfectious Encephalomyelitis, Postural Hypotension, Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Primary Dentatum Atrophy, Primary Lateral Sclerosis, Primary Progressive Aphasia, Prion Diseases, Progressive Hemifacial Atrophy, Progressive Locomotor Ataxia, Progressive Multifocal Leukoencephalopathy, Progressive Sclerosing Poliodystrophy, Progressive Supranuclear Palsy, Prosopagnosia, Pseudo-Torch syndrome, Pseudotoxoplasmosis syndrome, Pseudotumor Cerebri, Psychogenic Movement, Ramsay Hunt Syndrome I, Ramsay Hunt Syndrome II, Rasmussen's Encephalitis, Reflex Sympathetic Dystrophy Syndrome, Refsum Disease, Refsum Disease—Infantile, Repetitive Motion Disorders, Repetitive Stress Injuries, Restless Legs Syndrome, Retrovirus-Associated Myelopathy, Rett Syndrome, Reye's Syndrome, Rheumatic Encephalitis, Riley-Day Syndrome, Sacral Nerve Root Cysts, Saint Vitus Dance, Salivary Gland Disease, Sandhoff Disease, Schilder's Disease, Schizencephaly, Seitelberger Disease, Seizure Disorder, Semantic Dementia, Septo-Optic Dysplasia, Severe Myoclonic Epilepsy of Infancy (SMEI), Shaken Baby Syndrome, Shingles, Shy-Drager Syndrome, Sjögren's Syndrome, Sleep Apnea, Sleeping Sickness, Sotos Syndrome, Spasticity, Spina Bifida, Spinal Cord Infarction, Spinal Cord Injury, Spinal Cord Tumors, Spinal Muscular Atrophy, Spinocerebellar Atrophy, Spinocerebellar Degeneration, Steele-Richardson-Olszewski Syndrome, Stiff-Person Syndrome, Striatonigral Degeneration, Stroke, Sturge-Weber Syndrome, Subacute Sclerosing Panencephalitis, Subcortical Arteriosclerotic Encephalopathy, Short-lasting, Unilateral, Neuralgiform (SUNCT) Headache, Swallowing Disorders, Sydenham Chorea, Syncope, Syphilitic Spinal Sclerosis, Syringohydromyelia, Syrmgomyella, Systemic Lupus Erythematosus, Tabes Dorsalis, Tardive Dyskinesia, Tarlov, Cysts, Tay-Sachs Disease, Temporal Arteritis, Tethered Spinal Cord Syndrome, Thomsen's Myotonia, Thoracic Outlet Syndrome, Thyrotoxic Myopathy, Tic Douloureux, Todd's Paralysis, Tourette Syndrome, Transient Ischemic Attack, Transmissible Spongiform Encephalopathies, Transverse Myelitis, Traumatic Brain Injury, Tremor, Trigeminal Neuralgia, Tropical Spastic Paraparesis, Troyer Syndrome, Tuberous Sclerosis, Vascular Erectile Tumor, Vasculitis Syndromes of the Central and Peripheral Nervous Systems, Von Economo's Disease, Von Hippel-Lindau Disease (VHL), Von Recklinghausen's Disease, Wallenberg's Syndrome, Werdnig-Hoffman Disease, Wernicke-Korsakoff Syndrome, West Syndrome, Whiplash, Whipple's Disease, Williams Syndrome. Wilson Disease. Wolman's Disease. X-Linked Spinal and Bulbar Muscular Atrophy.

Various psychological disorders may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the psychological disorders may be Aboulia, Absence epilepsy, Acute stress Disorder, Adjustment Disorders, Adverse effects of medication NOS, Age related cognitive decline, Agoraphobia, Alcohol Addiction, Alzheimer's Disease, Amnesia (also known as Amnestic Disorder), Amphetamine Addiction, Anorexia Nervosa, Anterograde amnesia, Antisocial personality disorder (also known as Sociopathy), Anxiety Disorder (Also known as Generalized Anxiety Disorder), Anxiolytic related disorders, Asperger's Syndrome (now part of Autism Spectrum Disorder), Attention Deficit Disorder (Also known as ADD), Attention Deficit Hyperactivity Disorder (Also known as ADHD), Autism Spectrum Disorder (also known as Autism), Autophagia, Avoidant Personality Disorder, Barbiturate related disorders, Benzodiazepine related disorders, Bereavement, Bibliomania, Binge Eating Disorder, Bipolar disorder (also known as Manic Depression, includes Bipolar I and Bipolar II), Body Dysmorphic Disorder, Borderline intellectual functioning, Borderline Personality Disorder, Breathing-Related Sleep Disorder, Brief Psychotic Disorder, Bruxism, Bulimia Nervosa, Caffeine Addiction, Cannabis Addiction, Catatonic disorder, Catatonic schizophrenia, Childhood amnesia, Childhood Disintegrative Disorder (now part of Autism Spectrum Disorder), Childhood Onset Fluency Disorder (formerly known as Stuttering), Circadian Rhythm Disorders, Claustrophobia, Cocaine related disorders, Communication disorder, Conduct Disorder, Conversion Disorder, Cotard delusion, Cyclothymia (also known as Cyclothymic Disorder), Delerium, Delusional Disorder, dementia, Dependent Personality Disorder (also known as Asthenic Personality Disorder), Depersonalization disorder (now known as Depersonalization/Derealization Disorder), Depression (also known as Major Depressive Disorder), Depressive personality disorder, Derealization disorder (now known as Depersonalization/Derealization Disorder), Dermotillomania, Desynchronosis, Developmental coordination disorder, Diogenes Syndrome, Disorder of written expression, Dispareunia, Dissocial Personality Disorder, Dissociative Amnesia, Dissociative Fugue, Dissociative Identity Disorder (formerly known as Multiple Personality Disorder), Down syndrome, Dyslexia, Dyspareunia, Dysthymia (now known as Persistent Depressive Disorder), Eating disorder NOS, Ekbom's Syndrome (Delusional Parasitosis), Emotionally unstable personality disorder, Encopresis, Enuresis (bedwetting), Erotomania, Exhibitionistic Disorder, Expressive language disorder, Factitious Disorder, Female Sexual Disorders, Fetishistic Disorder, Folie à deux, Fregoli delusion, Frotteuristic Disorder, Fugue State, Ganser syndrome, Gambling Addiction, Gender Dysphoria (formerly known as Gender Identity Disorder), Generalized Anxiety Disorder, General adaptation syndrome, Grandiose delusions, Hallucinogen Addiction, Haltlose personality disorder, Histrionic Personality Disorder, Primary hypersomnia, IHuntington's Disease, Hypoactive sexual desire disorder, Hypochondriasis, Hypomania, Hyperkinetic syndrome, Hypersomnia, Hysteria, Impulse control disorder, Impulse control disorder NOS, Inhalant Addiction, Insomnia, Intellectual Development Disorder, Intermittent Explosive Disorder, Joubert syndrome, Kleptomania, Korsakoff's syndrome, Lacunar amnesia, Language Disorder, Learning Disorders, Major Depression (also known as Major Depressive Disorder), major depressive disorder, Male Sexual Disorders, Malingering, Mathematics disorder, Medication-related disorder, Melancholia, Mental Retardation (now known as Intellectual Development Disorder), Misophonia, Morbid jealousy, Multiple Personality Disorder (now known as Dissociative Identity Disorder), Munchausen Syndrome, Munchausen by Proxy, Narcissistic Personality Disorder, Narcolepsy, Neglect of child, Neurocognitive Disorder (formerly known as Dementia), Neuroleptic-related disorder, Nightmare Disorder, Non Rapid Eye Movement, Obsessive-Compulsive Disorder, Obsessive-Compulsive Personality Disorder (also known as Anankastic Personality Disorder), Oneirophrenia, Onychophagia, Opioid Addiction, Oppositional Defiant Disorder, Orthorexia (ON), Pain disorder, Panic attacks, Panic Disorder, Paranoid Personality Disorder, Parkinson's Disease, Partner relational problem, Passive-aggressive personality disorder, Pathological gambling, Pedophilic Disorder, Perfectionism, Persecutory delusion, Persistent Depressive Disorder (also known as Dysthymia), Personality change due to a general medical condition, Personality disorder, Pervasive developmental disorder (PDD), Phencyclidine related disorder, Phobic disorder, Phonological disorder, Physical abuse, Pica, Polysubstance related disorder, Postpartum Depression, Post-traumatic embitterment disorder (PTED), Post Traumatic Stress Disorder, Premature ejaculation, Premenstrual Dysphoric Disorder, Psychogenic amnesia, Psychological factor affecting medical condition, Psychoneurotic personality disorder, Psychotic disorder, not otherwise specified, Pyromania, Reactive Attachment Disorder, Reading disorder, Recurrent brief depression, Relational disorder, REM Sleep Behavior Disorder, Restless Leg Syndrome, Retrograde amnesia, Retts Disorder (now part of Autism Spectrum Disorder), Rumination syndrome, Sadistic personality disorder, Schizoaffective Disorder, Schizoid Personality Disorder, Schizophrenia, Schizophreniform disorder, Schizotypal Personality Disorder, Seasonal Affective Disorder, Sedative, Hypnotic, or Anxiolytic Addiction, Selective Mutism, Self-defeating personality disorder, Separation Anxiety Disorder, Sexual Disorders Female, Sexual Disorders Male, Sexual Addiction, Sexual Masochism Disorder, Sexual Sadism Disorder, Shared Psychotic Disorder, Sleep Arousal Disorders, Sleep Paralysis, Sleep Terror Disorder (now part of Nightmare Disorder, Social Anxiety Disorder, Somatization Disorder, Specific Phobias, Stendhal syndrome, Stereotypic movement disorder, Stimulant Addiction, Stuttering (now known as Childhood Onset Fluency Disorder), Substance related disorder, Tardive dyskinesia, Tobacco Addiction, Tourettes Syndrome, Transient tic disorder, Transient global amnesia, Transvestic Disorder, Trichotillomania, Undifferentiated Somatoform Disorder, Vaginismus, and Voyeunstic Disorder.

Various lung diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the lung diseases may be Asbestosis, Asthma, Bronchiectasis, Bronchitis, Chronic Cough, Chronic Obstructive Pulmonary Disease (COPD), Croup, Cystic Fibrosis, Hantavirus, Idiopathic Pulmonary Fibrosis, Pertussis, Pleurisy, Pneumonia, Pulmonary Embolism, Pulmonary Hypertension, Sarcoidosis, Sleep Apnea, Spirometry, Sudden Infant Death Syndrome (SIDS), Tuberculosis, Alagille Syndrome, Autoimmune Hepatitis, Biliary Atresia, Cirrhosis, ERCP (Endoscopic Retrograde Cholangiopancreatography), and Hemochromatosis, Nonalcoholic Steatohepatitis, Porphyria, Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis.

Various bone diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the bone diseases may be osteoporosis, neurofibromatosis, osteogenesis imperfecta (OI), rickets, osteosarcoma, achondroplasia, fracture, osteomyelitis, Ewing tumour of bone, osteomalacia, hip dysplasia, Paget disease of bone, marble bone disease, osteochondroma, bone cancer, bone disease, osteochondrosis, osteoma, fibrous dysplasia, cleidocranial dysostosis, osteoclastoma, bone cyst, metabolic bone disease, melorheostosis, callus, Caffey syndrome, and mandibulofacial dysostosis.

Various blood diseases may be treated with pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the blood diseases may be Anemia and CKD (for health care professionals), Aplastic Anemia and Myelodysplastic Syndromes, Deep Vein Thrombosis, Hemochromatosis, Hemophilia, Henoch-Schönlein Purpura, Idiopathic Thrombocytopenic Purpura, Iron-Deficiency Anemia, Pernicious Anemia, Pulmonary Embolism, Sickle Cell Anemia, Sickle Cell Trait and Other Hemoglobminopathies, Thalassemia, Thrombotic Thrombocytopenic Purpura, and Von Willebrand Disease.

Various diseases associated with TNF-alpha may be treated with the pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the disease may be respiratory disorder; asthma; allergic and nonallergic asthma; asthma due to infection; asthma due to infection with respiratory syncytial virus (RSV); chronic obstructive pulmonary disease (COPD); a condition involving airway inflammation; eosinophilia; fibrosis and excess mucus production; cystic fibrosis; pulmonary fibrosis; an atopic disorder; atopic dermatitis; urticaria, eczema; allergic rhinitis; allergic enterogastritis; an inflammatory and/or autoimmune condition of the skin; an inflammatory and/or autoimmune condition of gastrointestinal organs, inflammatory bowel diseases (IBD); ulcerative colitis; Crohn's disease; an inflammatory and/or autoimmune condition of the liver; liver cirrhosis; liver fibrosis; liver fibrosis caused by hepatitis B and/or C virus, scleroderma; tumors or cancers; hepatocellular carcinoma, glioblastoma; lymphoma; Hodgkin's lymphoma; a viral infection; a bacterial infection; a parasitic infection; HTLV-1 infection; suppression of expression of protective type 1 immune responses, and suppression of expression of a protective type 1 immune response during vaccination, rheumatoid arthritis, osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondyloarthropathy, systemic lupus erythematosus, Crohn's disease, ulcerative colitis, inflammatory bowel disease, insulin dependent diabetes mellitus, thyroiditis, asthma, allergic diseases, psoriasis, dermatitis scleroderma, graft versus host disease, organ transplant rejection, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlein purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, infectious diseases, parasitic diseases, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, malignancies, heart failure, myocardial infarction, Addison's disease, sporadic, polyglandular deficiency type I and polyglandular deficiency type II, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia greata, seronegative arthropathy, arthropathy, Reiter's disease, psoriatic arthropathy, ulcerative colitic arthropathy, enteropathic synovitis, chlamydia, yersinia and salmonella associated arthropathy, spondyloarthropathy, atheromatous disease/arteriosclerosis, atopic allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cyptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, hepatitis B, hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinemia), dilated cardiomyopathy, female infertility, ovarian failure, premature ovarian failure, fibrotic lung disease, cryptogenic fibrosing alveolitis, post-inflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjögren's disease associated lung disease, ankylosing spondylitis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, fibrosis, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, psoriasis type 1, psoriasis type 2, idiopathic leucopaenia, autoimmune neutropaenia, renal disease NOS, glomerulonephritides, microscopic vasculitis of the kidneys, Lyme disease, discoid lupus erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatic fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Sjörgren's syndrome, Takayasu's disease/arteritis, autoimmune thrombocytopaenia, idiopathic thrombocytopaenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoederma, phacogenic uveitis, primary vasculitis, vitiligo acute liver disease, chronic liver diseases, alcoholic cirrhosis, alcohol-induced liver injury, choleostasis, idiosyncratic liver disease, drug-Induced hepatitis, non-alcoholic steatohepatitis, allergy and asthma, group B streptococci (GBS) infection, mental disorders (e.g., depression and schizophrenia), Th2 Type and Th1 Type mediated diseases, acute and chronic pain (different forms of pain), and cancers such as lung, breast, stomach, bladder, colon, pancreas, ovarian, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma) abetalipoproteinemia, acrocyanosis, acute and chronic parasitic or infectious processes, acute leukemia, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute or chronic bacterial infection, acute pancreatitis, acute renal failure, adenocarcinomas, aerial ectopic beats, AIDS dementia complex, alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allograft rejection, alpha-1-antitrypsin deficiency, amyotrophic lateral sclerosis, anemia, angina pectoris, anterior horn cell degeneration, anti-CD3 therapy, antiphospholipid syndrome, anti-receptor hypersensitivity reactions, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, ataxia, atrial fibrillation (sustained or paroxysmal), atrial flutter, atrioventricular block, B cell lymphoma, bone graft rejection, bone marrow transplant (BMT) rejection, bundle branch block, Burkitt's lymphoma, burns, cardiac arrhythmias, cardiac stun syndrome, cardiac tumors, cardiomyopathy, cardiopulmonary bypass inflammation response, cartilage transplant rejection, cerebellar cortical degenerations, cerebellar disorders, chaotic or multifocal atrial tachycardia, chemotherapy associated disorders, chronic myelocytic leukemia (CML), chronic alcoholism, chronic inflammatory pathologies, chronic lymphocytic leukemia (CLL), chronic obstructive pulmonary disease (COPD), chronic salicylate intoxication, colorectal carcinoma, congestive heart failure, conjunctivitis, contact dermatitis, corpulmonale, coronary artery disease, Creutzfeldt-Jakob disease, culture negative sepsis, cystic fibrosis, cytokine therapy associated disorders, dementia pugilistica, demyelinating diseases, dengue hemorrhagic fever, dermatitis, dermatologic conditions, diabetes, diabetes mellitus, diabetic arteriosclerotic disease, Diffuse Lewy body disease, dilated congestive cardiomyopathy, disorders of the basal ganglia, Down's Syndrome in middle age, drug-induced movement disorders induced by drugs which block CNS dopamine receptors, drug sensitivity, eczema, encephalomyelitis, endocarditis, endocrinopathy, epiglottitis, Epstein-Barr virus infection, erythromelalgia, extrapyramidal and cerebellar disorders, familial hemophagocytic lymphohistiocytosis, fetal thymus implant rejection, Friedreich's ataxia, functional peripheral arterial disorders, fungal sepsis, gas gangrene, gastric ulcer, glomerular nephritis, graft rejection of any organ or tissue, gram negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, hairy cell leukemia, Hallervorden-Spatz disease, Hashimoto's thyroiditis, hay fever, heart transplant rejection, hemochromatosis, hemodialysis, hemolytic uremic syndrome/thrombolytic thrombocytopenic purpura, hemorrhage, hepatitis (A), His bundle arrhythmias, HIV infection/HIV neuropathy, Hodgkin's disease, hyperkinetic movement disorders, hypersensitivity reactions, hypersensitivity pneumonitis, hypertension, hypokinetic movement disorders, hypothalamic-pituitary-adrenal axis evaluation, idiopathic Addison's disease, idiopathic pulmonary fibrosis, antibody mediated cytotoxicity, asthenia, infantile spinal muscular atrophy, inflammation of the aorta, influenza a, ionizing radiation exposure, iridocyclitis/uveitis/optic neuritis, ischemia-reperfusion injury, ischemic stroke, juvenile rheumatoid arthritis (JRA), juvenile spinal muscular atrophy, Kaposi's sarcoma, kidney transplant rejection, legionella, leishmaniasis, leprosy, lesions of the corticospinal system, lipedema, liver transplant rejection, lymphedema, malaria, malignant lymphoma, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, metabolic/idiopathic, migraine headache, mitochondrial multi-system disorder, mixed connective tissue disease, monoclonal gammopathy, multiple myeloma, multiple systems degenerations (Menzel, Dejerine-Thomas, Shy-Drager, and Machado-Joseph), myasthenia gravis, Mycobacterium avium intracellulare, nmycobacterium tuberculosis, myelodysplastic syndrome, myocardial infarction, myocardial ischemic disorders, nasopharyngeal carcinoma, neonatal chronic lung disease, nephritis, nephrosis, neurodegenerative diseases, neurogenic I muscular atrophies, neutropenic fever, non-Hodgkins lymphoma, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, OKT3® therapy, orchitis/epidydimitis, orchitis/vasectomy reversal procedures, organomegaly, osteoporosis, pancreas transplant rejection, pancreatic carcinoma, paraneoplastic syndrome/hypercalcemia of malignancy, parathyroid transplant rejection, pelvic inflammatory disease, perennial rhinitis, pericardial disease, peripheral atherosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, Pneumocystis carinii pneumonia, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome), post perfusion syndrome, post pump syndrome, post-MI cardiotomy syndrome, preeclampsia, progressive supranucleo palsy, primary pulmonary hypertension, radiation therapy, Raynaud's phenomenon and disease, Raynaud's disease, Refsum's disease, regular narrow QRS tachycardia, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, sarcomas, scleroderma, senile chorea, senile dementia of Lewy body type, seronegative arthropathies, shock, sickle cell anemia, skin allograft rejection, skin changes syndrome, small bowel transplant rejection, solid tumors, specific arrhythmias, spinal ataxia, spinocerebellar degenerations, streptococcal myositis, structural lesions of the cerebellum, subacute sclerosing panencephalitis, syncope, syphilis of the cardiovascular system, systemic anaphylaxis, systemic inflammatory response syndrome, systemic onset juvenile rheumatoid arthritis, T-cell or FAB ALL, telangiectasia, thromboangitis obliterans, thrombocytopenia, toxicity, transplants, trauma/hemorrhage, type III hypersensitivity reactions, type IV hypersensitivity, unstable angina, uremia urosepsis, urticaria, valvular heart diseases, varicose veins, vasculitis, venous diseases, venous thrombosis, ventricular fibrillation, viral and fungal infections, viral encephalitis/aseptic meningitis, viral-associated hemophagocytic syndrome, Wemicke-Korsakoff syndrome, Wilson's disease, xenograft rejection of any organ or tissue, acute coronary syndromes, acute idiopathic polyneuritis, acute inflammatory demyelinating polyradiculoneuropathy, acute ischemia, adult Still's disease, alopecia greata, anaphylaxis, anti-phospholipid antibody syndrome, aplastic anemia, arteriosclerosis, atopic eczema, atopic dermatitis, autoimmune dermatitis, autoimmune disorder associated with streptococcus infection, autoimmune enteropathy, autoimmune hearing loss, autoimmune lymphoproliferative syndrome (ALPS), autoimmune myocarditis, autoimmune premature ovarian failure, blepharitis, bronchiectasis, bullous pemphigoid, cardiovascular disease, catastrophic antiphospholipid syndrome, celiac disease, cervical spondylosis, chronic ischemia, cicatricial pemphigoid, clinically isolated syndrome (CIS) with risk for multiple sclerosis, conjunctivitis, childhood onset psychiatric disorder, chronic obstructive pulmonary disease (COPD), dacryocytitis, dermatomyositis, diabetic retinopathy, diabetes mellitus, disk herniation, disk prolapse, drug induced immune hemolytic anemia, endocarditis, endometriosis, endophthalmitis, episcleritis, erythema multiforme, erythema multiforme major, gestational pemphigoid, Guillain-Barré syndrome (GBS), hay fever, Hughes syndrome, idiopathic Parkinson's disease, idiopathic interstitial pneumonia, IgE-mediated allergy, immune hemolytic anemia, inclusion body myositis, infectious ocular inflammatory disease, inflammatory demyelinating disease, inflammatory heart disease, inflammatory kidney disease, IPF/UIP, iritis, keratitis, keratojunctivitis sicca, Kussmaul disease or Kussmaul-Meier disease, Landry's paralysis, Langerhan's cell histiocytosis, livedo reticularis, macular degeneration, microscopic polyangiitis, morbus bechterev, motor neuron disorders, mucous membrane pemphigoid, multiple organ failure, myasthenia gravis, myelodysplastic syndrome, myocarditis, nerve root disorders, neuropathy, non-A non-B hepatitis, optic neuritis, osteolysis, ovarian cancer, pauciarticular JRA, peripheral artery occlusive disease (PAOD), peripheral vascular disease (PVD), peripheral artery disease (PAD), phlebitis, polyarteritis nodosa (or periarteritis nodosa), polychondritis, polymyalgia rheumatica, poliosis, polyarticular JRA, polyendocrine deficiency syndrome, polymyositis, polymyalgia rheumatica (PMR), post-pump syndrome, primary Parkinsonism, prostate and rectal cancer and hematopoietic malignancies (leukemia and lymphoma), prostatitis, pure red cell aplasia, primary adrenal insufficiency, recurrent neuromyelitis optica, restenosis, rheumatic heart disease, sapho (synovitis, acne, pustulosis, hyperostosis, and osteitis), scleroderma, secondary amyloidosis, shock lung, scleritis, sciatica, secondary adrenal insufficiency, silicone associated connective tissue disease, Sneddon-Wilkinson dermatosis, spondylitis ankylosans, Stevens-Johnson syndrome (SJS), systemic inflammatory response syndrome, temporal arteritis, toxoplasmic retinitis, toxic epidermal necrolysis, transverse myelitis, TRAPS (tumor necrosis factor receptor associated periodic syndrome), type 1 allergic reaction, type II diabetes, urticaria, usual interstitial pneumonia (UIP), vasculitis, vernal conjunctivitis, viral retinitis, Vogt-Koyanagi-Harada syndrome (VKH syndrome), wet macular degeneration, wound healing, yersinia or salmonella associated arthropathy.

Various receptor for advanced gly cation endproducts (RAGE) diseases may be treated with the pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the disease may be Amytropic Lateral Sclerosis, Brachial Plexus Injury, Brain Injury, including traumatic brain injury, Cerebral Palsy, Friedrich's Ataxia, Guillain Barre, Leukodystrophies, Multiple Sclerosis, Post Polio, Spina Bifida, Spinal Cord Injury, Spinal Muscle Atrophy, Spinal Tumors, Stroke, Transverse Myelitits, dementia, senile dementia, mild cognitive impairment, Alzheimer-related dementia, Huntington's chorea, tardive dyskinesia, hyperkinesias, manias, Morbus Parkinson, steel-Richard syndrome, Down's syndrome, myasthenia gravis, nerve trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis, glaucoma, Alzheimer's disease, diabetic nephropathy, sepsis, rheumatoid arthritis and related inflammatory diseases.

Various neurite degenerative diseases may be treated with the pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the disease may be multiple sclerosis, Parkinson's disease, Alzheimer's disease, Tay-Sachs disease, Niemann-Pick disease, Gaucher's disease, Hurler's syndrome, Huntington's disease, amyotrophic lateral sclerosis, idiopathic inflammatory demyelinating diseases, vitamin B12 deficiency, central pontine myelinolysis, tabes dorsalis, transverse myelitis, Devic's disease, progressive multifocal leukoencephalopathy, optic neuritis, traumatic injury to the CNS, an ischemic cerebral stroke, glaucoma, diabetic retinopathy, age-dependent macular degeneration, and a leukodystrophy.

Various neurological diseases may be treated with the pharmaceutical compositions, AAV particles, of the present invention. As a non-limiting example, the disease may be Amyotrophic Lateral Sclerosis, Brachial Plexus Injury, Brain Injury, including traumatic brain injury, Cerebral Palsy, Guillain Barre, Leukodystrophies, Multiple Sclerosis, Post Polio, Spina Bifida, Spinal Cord Injury, Spinal Muscle Atrophy, Spinal Tumors, Stroke, Transverse Myelitis; dementia, senile dementia, mild cognitive impairment, Alzheimer-related dementia, Huntington's chorea, tardive dyskinesia, hyperkinesias, manias, Morbus Parkinson, steel-Richard syndrome, Down's syndrome, myasthenia gravis, nerve trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, acute confusion disorder, amyotrophic lateral sclerosis, glaucoma and Alzheimer's disease.

Various cancers may be treated with pharmaceutical compositions, AAV particles, of the present invention. As used herein, the term “cancer” refers to any of various malignant neoplasms characterized by the proliferation of anaplastic cells that tend to invade surrounding tissue and metastasize to new body sites and also refers to the pathological condition characterized by such malignant neoplastic growths. Cancers may be tumors or hematological malignancies, and include but are not limited to, all types of lymphomas/leukemias, carcinomas and sarcomas, such as those cancers or tumors found in the anus, bladder, bile duct, bone, brain, breast, cervix, colon/rectum, endometrium, esophagus, eye, gallbladder, head and neck, liver, kidney, larynx, lung, mediastinum (chest), mouth, ovaries, pancreas, penis, prostate, skin, small intestine, stomach, spinal marrow, tailbone, testicles, thyroid and uterus.

Types of carcinomas which may be treated with the AAV particles of the present invention include, but are not limited to, papilloma/carcinoma, choriocarcinoma, endodermal sinus tumor, teratoma, adenoma/adenocarcinoma, melanoma, fibroma, lipoma, leiomyoma, rhabdomyoma, mesothelioma, angioma, osteoma, chondroma, glioma lymphoma/leukemia, squamous cell carcinoma, small cell carcinoma, large cell undifferentiated carcinomas, basal cell carcinoma and sinonasal undifferentiated carcinoma.

Types of sarcomas which may be treated with the AAV particles of the present invention include, but are not limited to, soft tissue sarcoma such as alveolar soft part sarcoma, angiosarcoma, dermatofibrosarcoma, desmoid tumor, desmoplastic small round cell tumor, extraskeletal chondrosarcoma, extraskeletal osteosarcoma, tibrosarcoma, hemangiopericytoma, hemangiosarcoma, Kaposi's sarcoma, leiomyosarcoma, liposarcoma, lymphangiosarcoma lymphosarcoma, malignant fibrous histiocytoma, neurofibrosarcoma, rhabdonyosarcoma, synovial sarcoma, and Askin's tumor, Ewing's sarcoma (primitive neuroectodermal tumor), malignant hemangioendothelioma, malignant schwannoma, osteosarcoma, and chondrosarcoma.

As a non-limiting example, the cancer which may be treated may be Acute granulocytic leukemia Acute lymphocytic leukemia, Acute myelogenous leukemia, Adenocarcinoma, Adenosarcoma, Adrenal cancer, Adrenocortical carcinoma, Anal cancer, Anaplastic astrocytoma, Angiosarcoma, Appendix cancer, Astrocytoma, Basal cell carcinoma, B-Cell lymphoma), Bile duct cancer, Bladder cancer, Bone cancer, Bowel cancer, Brain cancer, Brain stem glioma, Brain tumor, Breast cancer, Carcinoid tumors, Cervical cancer, Cholangiocarcinoma, Chondrosarcoma, Chronic lymphocytic leukemia, Chronic myelogenous leukemia, Colon cancer, Colorectal cancer, Craniopharyngioma, Cutaneous lymphoma, Cutaneous melanoma, Diffuse astrocytoma, Ductal carcinoma in situ, Endometrial cancer, Ependymoma, Epitheloid sarcoma, Esophageal cancer, Ewing sarcoma, Extrahepatic bile duct cancer, Eye cancer, Fallopian tube cancer, Fibrosarcoma, Gallbladder cancer, Gastric cancer, Gastrointestinal cancer, Gastrointestinal carcinoid cancer, Gastrointestinal stromal tumors, General, Germ cell tumor, Glioblastoma multiforme, Glioma, Hairy cell leukemia, Head and neck cancer, Hemangioendothelioma, Hodgkin lymphoma, Hodgkin's disease, Hodgkin's lymphoma, Hypopharyngeal cancer, Infiltrating ductal carcinoma, Infiltrating lobular carcinoma, Inflammatory breast cancer, Intestinal Cancer, Intrahepatic bile duct cancer, Invasive/infiltrating breast cancer, Islet cell cancer, Jaw cancer, Kaposi sarcoma, Kidney cancer, Laryngeal cancer, Leiomyosarcoma, Leptomeningeal metastases, Leukemia, Lip cancer, Liposarcoma, Liver cancer, Lobular carcinoma in situ, Low-grade astrocytoma, Lung cancer, Lymph node cancer, Lymphoma, Male breast cancer, Medullary carcinoma, Medulloblastoma, Melanoma, Meningioma, Merkel cell carcinoma, Mesenchy mal chondrosarcoma, Mesenchymous, Mesothelioma, Metastatic breast cancer, Metastatic melanoma, Metastatic squamous neck cancer, Mixed gliomas, Mouth cancer, Mucinous carcinoma, Mucosal melanoma, Multiple melanoma, Nasal cavity cancer, Nasopharyngeal cancer, Neck cancer, Neuroblastoma, Neuroendocrine tumors, Non-Hodgkin lymphoma, Non-Hodgkin's lymphoma, Non-small cell lung cancer, Oat cell cancer, Ocular cancer, Ocular melanoma, Oligodendroglioma, Oral cancer, Oral cavity cancer, Oropharyngeal cancer, Osteogenic sarcoma, Osteosarcoma, Ovarian cancer, Ovarian epithelial cancer, Ovarian germ cell tumor, Ovarian primary peritoneal carcinoma, Ovarian sex cord stromal tumor, Paget's disease, Pancreatic cancer, Papillary carcinoma, Paranasal sinus cancer, Parathyroid cancer, Pelvic cancer, Penile cancer, Peripheral nerve cancer, Peritoneal cancer, Pharyngeal cancer, Pheochromocytoma, Pilocytic astrocytoma, Pineal region tumor, Pineoblastoma, Pituitary gland cancer, Primary central nervous system lymphoma, Prostate cancer, Rectal cancer, Renal cell cancer, Renal pelvis cancer, Rhabdomyosarcoma, Salivary gland cancer, Sarcoma, Sarcoma, bone, Sarcoma, soft tissue, Sarcoma, uterine, Sinus cancer, Skin cancer, Small cell lung cancer, Small intestine cancer, Soft tissue sarcoma, Spinal cancer, Spinal column cancer, Spinal cord cancer, Spinal tumor, Squamous cell carcinoma, Stomach cancer, Synovial sarcoma, T-cell lymphoma), Testicular cancer, Throat cancer, Thymoma/thymic carcinoma, Thyroid cancer, Tongue cancer, Tonsil cancer, Transitional cell cancer, Transitional cell cancer, Transitional cell cancer, Triple-negative breast cancer, Tubal cancer, Tubular carcinoma, Ureteral cancer, Ureteral cancer, Urethral cancer, Uterine adenocarcinoma, Uterine cancer, Uterine sarcoma, Vaginal cancer, and Vulvar cancer.

The AAV particles or pharmaceutical compositions of the present invention useful in preventing or treating HIV and AIDS may alternatively, or in combination, encode an antibody that targets a different infectious agent (e.g., an infectious agent that is not HIV-1 or 2). Non-limiting examples of other target antigens include any of the following, including fragments or variants thereof, adenoviruses, Anaplasma phagocytophilium, Ascaris lumbricoides, Bacillus anthracis, Bacillus cereus, Bacteroides sp, Barmah Forest virus, Bartonella bacilliformis, Bartonella henselae, Bartonella quintona, beta-toxin of Clostridium perfringens, Bordetella pertussis, Bordetella parapertussis, Borrelia burgdorferi, Borrelia miyamotoi, Borrelia recurrentis, Borrelia sp., Botulinum toxin, Brucella sp., Burkholderia pseudomallei, California encephalitis virus, Campylobacter, Candida albicans, chikungunya virus, Chlamydia psittaci, Chlamydia trachomatis, Clonorchis sinensis, Clostridium difficile bacteria, Clostridium tetani, Colorado tick fever virus, Corynebacterium diphtheriae, Corynebacterium minutissimum, Coxiella burnetii, coxsackie A, coxsackie B, Crimean-Congo hemorrhagic fever virus, cytomegalovirus, dengue virus, Eastern Equine encephalitis virus, Ebola viruses, echovirus, Ehrlichia chaffeensis, Ehrlichia equi, Ehrlichia sp. Entamoeba histolytica, Enterobacter sp., Enterococcus feacalis, Enterovirus 71, Epstein-Barr virus (EBV), Erysipelothrix rhusiopathiae, Escherichia coli, Flavivirus, Fusobacterium necrophorum, Gardnerella vaginalis, Group B streptococcus, Haemophilus aegyptius, Haemophilus ducreyi, Haemophilus influenzae, hantavirus, Helicobacter pylori, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, herpes simplex virus 1 and 2, human herpes virus 6, human herpes Virus 8, human immunodeficiency virus 1 and 2, human T-cell leukemia viruses I and II, influenza viruses (A, B, C), Jamestown Canyon virus, Japanese encephalitis antigenic, Japanese encephalitis virus, John Cunninham virus, juninvirus, Kaposi's Sarcoma-associated Herpes Virus (KSHV), Klebsiella granulomatis, Klebsiella sp., Kyasanur Forest Disease virus, La Crosse virus, Lassavirus, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, lymphocytic choriomeningitis virus, lyssavirus, Machupovirus, Marburg virus, measles virus, MERS coronavirus (MERS-CoV), Mictococcus sedentarius, Mobiluncus sp., Molluscipoxvirus, Moraxella catarrhalis, Morbilli-Rubeola virus, Mumpsvirus, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycoplasma genitalium, Mycoplasma sp, Nairovirus, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia, Norwalk virus, norovirus, Omsk hemorrhagic fever virus, papilloma virus, parainfluenza viruses 1-3, parapoxvirus, parvovirus B19, Peptostreptococccus sp., Plasmodium sp., polioviruses types I, II, and III, Proteus sp., Pseudomonas aeruginosa, Pseudomonas pseudomallei, Pseudomonas sp., rabies virus, respiratory syncytial virus, ricin toxin, Rickettsia australis, Rickettsia conori, Rickettsia honei, Rickettsia prowazekii, Ross River Virus, rotavinrus, rubellavirus, Saint Louis encephalitis, Salmonella typhi, Sarcoptes scabiei, SARS-associated coronavirus (SARS-CoV), Serrana sp., Shiga toxin and Shiga-like toxin, Shigella sp., Sin Nombre Virus, Snowshoe hare virus, Staphylococcus aureus, Staphylococcus epidermidis, Streptobacillus moniliformis, Streptococcus pneumoniae, Streptococcus agalactiae, Streptococcus agalactiae, Streptococcus group A-H, Streptococcus pneumoniae, Streptococcus pyogenes, Treponema pallidum subsp. Pallidum, Treponema palladium var. carateum, Treponema pallidum var. endemicum, Tropheryma whippelii, Ureaplasma urealyticum, Varicella-Zoster virus, variola virus, Vibrio cholerae, West Nile virus, yellow fever virus, Yersinia enterocolitica, Yersinia pestis, Zika virus.

Diagnostic Applications

The AAV particles of the present invention may be used for diagnostic purposes or as diagnostic tools for any of the aforementioned diseases or disorders. As a non-limiting example, the AAV particles of the present invention or the antibodies encoded within the viral genome therein may be used as a biomarker for disease diagnosis. As a second non-limiting example, the AAV particles of the present invention or the antibodies encoded within the viral genome therein may be used for diagnostic imaging purposes, e.g., MRI. PET, CT or ultrasound.

Preventative Applications

The AAV particles of the present invention or the antibodies encoded by the viral genome therein may be used to prevent disease or stabilize the progression of disease. In one embodiment, the AAV particles of the present invention are used to as a prophylactic to prevent a disease or disorder in the future. In one embodiment, the AAV particles of the present invention are used to halt further progression of a disease or disorder. As a non-limiting example, the AAV particles of the invention may be used in a manner similar to that of a vaccine.

Research Applications

The AAV particles of the present invention or the antibodies encoded by the viral genome therein may also be used as research tools. The AAV particles of the invention may be used as in any research experiment, e.g., in vivo or in vitro experiments. In a non-limiting example, the AAV particles of the invention may be used in cultured cells. The cultured cells may be derived from any origin known to one with skill in the art, and may be as non-limiting examples, derived from a stable cell line, an animal model or a human patient or control subject. In a non-limiting example, the AAV particles of the invention may be used in in vivo experiments in animal models (i.e., mouse, rat, rabbit, dog, cat, non-human primate, guinea pig, ferret, c-elegans, drosophila, zebrafish, or any other animal used for research purposes, known in the art). In another non-limiting example, the AAV particles of the invention may be used in human research experiments or human clinical trials.

Combination Applications

The AAV particles of the invention may be used as a combination therapy with any other therapeutic molecule known in the art. The therapeutic molecule may be approved by the US Food and Drug Administration or may be in clinical trial or at the preclinical research stage. The therapeutic molecule may utilize any therapeutic modality known in the art, with non-limiting examples including gene silencing or interference (i.e., miRNA, siRNA, RNAi, shRNA), gene editing (i.e., TALEN, CRISPRCas9 systems, zinc finger nucleases), and gene, protein or enzyme replacement.

Therapeutic Applications: Infectious Diseases

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat infectious disease. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Tables 21-42 (SEQ ID NO: 4138-9220).

The methods, components and compositions of the present invention may be used to diagnose, prevent, treat and/or manage infectious diseases. Infectious diseases, also known as transmissible diseases or communicable diseases, are caused by invasion and multiplication of agents in the body. Infection agents are species typically not present within the body and may be, but are not limited to, viruses, bacteria, prions, nematodes, fungus, parasites or arthropods. Additionally, an infection or symptoms associated with an infection may be caused by one or more toxins produced by such agents. Humans, and other mammals, react to infections with an innate immune system response, often involving an inflammation. The illnesses and symptoms involved with infections vary according to the infectious agent. Many infections may be subclinical without presenting any definite or observable symptoms, whereas some infections cause severe symptoms, require hospitalization or may be life-threatening. Some infections are localized, whereas some may overcome the body through blood circulation or lymphatic vessels Some infections have long-term effects on wellbeing of infected individuals.

Infectious agents may be transmitted to humans via different routes. For example, infection agents may be transmitted by direct contact with an infected human, an infected animal, or an infected surface Infections may be transmitted by direct contact with bodily fluids of an infected human or an animal, e.g. blood, saliva, sweat, tears, mucus, female ejaculate, semen, vomit or urine. For example, infection may be transmitted by a fecal-oral route, referring to an infected person shedding the virus in fecal particles which then enters to person's mouth causing infection. The fecal-oral route is especially common transmission route in environments with poor sanitation and hygiene. Non-limiting examples of agents transmitted by the fecal-oral route include bacteria, e.g. shigella, Salmonella typhii and Vibrio Cholerae, virus, e.g. norovirus, rotavirus, enteroviruses, and hepatitis A, fungi, e.g. Entamadeba histolytica, parasites, tape worms, transmitted by contaminated food or beverage, leading to food poisoning or gastroenteritis. Infections may be transmitted by a respiratory route, referring to agents that are spread through the air. Typical examples include agents spread as small droplets of liquid or as aerosols, e.g. respiratory droplets expelled from the mouth and nose while coughing and sneezing. Typical examples of respiratory transmitted diseases include the common cold mostly implicated to rhinoviruses, influenza caused by influenza viruses, respiratory tract infections caused by e.g. respiratory syncytial virus (RSV). Infections may be transmitted by a sexual transmission route. Examples of common sexually transmitted infections include e.g. human immunodeficiency virus (HIV) causing acquired immune deficiency syndrome (AIDS), chlamydia caused by Neisseria gonorrhoeae bacteria, fungal infection Candidiasis caused by Candida yeast, and Herpes Simplex disease caused by herpes simplex virus Infections may be transmitted by an oral transmission route, e.g. by kissing or sharing a drinking glass. A common infection transmitted by oral transmission is an infectious mononucleosis caused by Epstein-Barr virus Infections may be transmitted by a vertical transmission, also known as “mother-to-child transmission.” from mother to an embryo, fetus or infant during pregnancy or childbirth. Examples of infection agents that may be transmitted vertically include HIV, chlamydia, rubella, Toxoplasma gondii, and herpes simplex virus. Infections may be transmitted by an iatrogenic route, referring to a transmission by medical procedures such as injection (contaminated reused needles and syringes), or transplantation of infected material, blood transfusions, or infection occurring during surgery. For example, methicillin-resistant Staphylococcus aureus (MRSA), which may cause several severe infections, may be transmitted via iatrogenic route during surgery. Infections may also be transmitted by vector-borne transmission, where a vector may be an organism transferring the infection agents from one host to another. Such vectors may be triatomine bugs, e.g. trypanosomes, parasites, animals, arthropods including e.g. mosquitos, flies, lice, flees, tick and mites or humans. Non-limiting examples of mosquito-borne infections include Dengue fever, West Nile virus related infections, Yellow fever and Chikungunya fever. Non-limiting examples of parasite-borne diseases include malaria, Human African trypanosomiasis and Lyme disease. Non-limiting examples of diseases spread by humans or mammals include HIV. Ebola hemorrhagic fever and Marburg fever.

Traditionally infectious diseases are treated with medications and/or good supportive care. Medical prevention, treatment and/or management of bacterial infections may include administration of antibiotics. Antibiotics may inhibit the colonization of bacteria or kill the bacteria. Antibiotics include e.g. penicillins, cephalosporins, macrolides, fluoroquinolones, sulfonamides, tetracyclines, and aminoglycosides. Antibiotics may be specific to a certain bacteria or act against broad spectrum of bacteria. Some types of bacteria are especially susceptible to antibiotics, whereas some bacteria are more resistant. Development of bacterial strain mutations that are resistant to antibiotics is an increasing concern. Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB) and Klebsiella pneumoniae carbapenemase-producing bacteria (KPC) are examples of bacteria that are resistant to most general antibiotics. Due to the emerging resistance, unnecessary administration and overdosing of antibiotics should be avoided. Medical prevention, treatment and/or management of viral infections may include administration of antiviral medications. Antiviral medications may be specific to a certain bacteria or act against a broad spectrum of viruses. Currently antiviral medications are available for e.g. HIV, influenza, hepatitis B and C Medical prevention, treatment and/or management of viral infections may include administration of antifungal medication. Antifungal medication kills or prevents the growth of fungi. Types of antifungal medications include e.g. imidazoles, triazoles and thiazoles, allylamines, and echinocandins. Development of antifungal medication capable of targeting fungal cells without affecting human cells is a challenge due to the similarities of human and fungal cell on the molecular level. Typically, medical treatment is combined with good supportive care, which includes provision of fluids, bed rest, medication to relieve pain and lower fever, supportive alternative medicine such as vitamins, antioxidants and other supplements important for wellbeing of patients.

Antibody therapies for infectious diseases have also been developed. Examples of commercial therapeutic antibodies include raxibacumab (developed by Cambridge Antibody Technology and Human Genome Sciences) which is an antibody for the prophylaxis and treatment of inhaled anthrax. SHIGAMAB™ (developed by Bellus Health Inc.) is a monoclonal antibody for treatment of Shiga toxin induced hemolytic uremic syndrome, and actoxumab and bezlotoxumab (developed by Medarex Inc, and the University of Massachusetts Medical School) are commercial human monoclonal antibodies targeting C. difficile toxin A and toxin B, respectively.

Infectious diseases and/or infection related diseases, disorders, and/or conditions that may be treated by methods, components and compositions of the present invention include, but are not limited to, 14-day measles, 5-day fever, acne, acquired immunodeficiency syndrome (AIDS), acrodermatitis chronica atrophicans (ACA), acute hemorrhagic conjunctivitis, acute hemorrhagic cystitis, acute rhinosinusitis, adult T-cell leukemia-lymphoma (ATLL). African sleeping sickness, alveolar hydatid, amebiasis, amebic meningoencephalitis, anaplasmosis, anthrax, arboviral, ascariasis, aseptic meningitis, Athlete's foot, Australian tick typhus, avian Influenza, babesiosis, bacillary angiomatosis, bacterial meningitis, bacterial vaginosis, balanitis, balantidiasis, Bang's disease, Barmah Forest virus, bartonellosis, bat lyssavirus, Bay sore, Baylisascaris, beaver fever, beef tapeworm, bejel, biphasic meningoencephalitis, black bane, black death, black piedra, Blackwater fever, blastomycosis, blennorrhea of the newborn, blephantis, boils, Bomholm disease, borrelia miyamotoi disease, botulism, boutonneuse fever, Brazilian purpuric fever, break bone fever, brill, bronchiolitis, bronchitis, brucellosis, bubonic, bubonic plague, bullous impetigo, Burkholderia mallei, Burkholderia pseudomallei, burly ulcers mycoburuli ulcers, Busse-Buschke disease, California group encephalitis, campylobacteriosis, candidiasis, canefield fever, canicola fever, capillariasis, carate, carbapenem-resistant enterobacteriaceae (CRE), Carrion's disease, cat scratch fever, cave disease, central Asian hemorrhagic fever, Central European tick, cervical cancer, Chagas disease, cancroid, Chicago disease, chickenpox, Chiclero's ulcer, chikungunya fever, chlamydial, cholera, chromoblastomy cosis, ciguatera, clap, clonorchiasis, Clostridium difficile, Clostridium perfringens, coccidioidomycosis fungal, coenurosis, colorado tick fever, condyloma accuminata, condyloma lata, Congo fever, Congo hemorrhagic fever virus, conjunctivitis, cowpox, crabs, Crimean disease, croup, crypto, cryptococcosis, cryptosporidiosis, cutaneous larval migrans, cyclosporiasis, cystic hydatid, cysticercosis, cystitis, Czechoslovak tick, d68 (EV-d68), dacnrocytitis, dandy fever, darling's disease, deer fly fever, dengue fever types 1, 2, 3, and 4, desert rheumatism, devil's grip, diphasic milk fever, diphtheria, disseminated intravascular coagulation, dog tapeworm, donovanosis, dracontiasis, dracunculosis, duke's disease, dum dum disease, Durand-Nicholas-Favre disease, dwarf tapeworm, E. coli, eastern equine encephalitis, Ebola hemorrhagic fever, Ebola virus disease (EVD), ectothrix, ehrlichiosis, encephalitis, endemic relapsing fever, endemic syphilis, endophthalmitis, endothrix, enterobiasis, enterotoxin-B poisoning (staph food poisoning), enterovirus, epidemic keratoconjunctivitis, epidemic relapsing fever, epidemic typhus, epiglottitis, epsilon toxin, erysipelas, erysipeloid, erysipelothricosis, erythema chronicum migrans, erythema infectiosum, erythema marginatum, erythema multiforme, erythema nodosum, erythema nodosum leprosum, erythrasma, espundia, eumycotic mycetoma, European blastomycosis, exanthem subitum, eyeworm, Far-Eastern tick, fascioliasis, fievre boutonneuse, fifth disease, Filatow-Dukes' disease, fish tapeworm, Fitz-Hugh-Curtis syndrome—perihepatitis, flinders island spotted fever, flu, folliculitis, four corners disease, frambesia, francis disease, furunculosis, gas gangrene, gastroenteritis, genital herpes, genital warts, German measles, Gerstmann-Straussler-Scheinker (GSS), giardiasis, Gilchrist's disease, gingivitis, gingivostomatitis, glanders, glandular fever, gnathostomiasis, gonococcal, gonorrhea, granuloma inguinale, guinea worm, haemophilus influenza disease, hamburger disease, Hansen's disease, Hantaan disease, Hantaan-Korean hemorrhagic fever, hantavirus pulmonary syndrome (UPS), hard chancre, hard measles, Haverhill fever, head and body lice, heartland fever, helicobacterosis, hemolytic uremic syndrome (HUS), hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, herpangina, herpes—genital, herpes labialis, herpes—neonatal, hidradenitis, histoplasmosis, histoplasmosis, his-werner disease, hiv, hookworms, hordeola, HTLV-associated myelopathy (HAM), human granulocytic ehrlichiosis, human monocytic ehrlichiosis, human papillomarivus (HPV), human pulmonary syndrome, human pulmonary syndrome (HPS), human T-cell lymphotrophic virus (HTLV), hydatid cyst, hydrophobia, impetigo, including congenital, inclusion conjunctivitis, infantile diarrhea, infectious mononucleosis, infectious myocarditis, infectious pericarditis, influenza, isosporiasis, Israeli spotted fever, Japanese encephalitis, jock itch, jorge lobo disease, jungle yellow fever, Junin Argentinian hemorrhagic fever, kala azar, Kaposi's sarcoma, keloidal blastomycosis, keratoconjunctivitis, kuru, Kyasanur forest disease, lacrosse encephalitis, lassa hemorrhagic fever, legionellosis, legionnaires disease, legionnaire's pneumonia, Lemierre's syndrome, lemming fever, leprosy, leptospirosis, listena, listeriosis, liver fluke, lobo's mycosis, lock jaw, lockjaw, loiasis, louping ill, Ludwig's angina, lung fluke, Lyme disease, lymphogranuloma venereum (LGV), Machupo Bolivian hemorrhagic fever, Madura foot, mal del pinto, malaria, malignant pustule, Malta fever, Marburg hemorrhagic fever, masters disease, maternal sepsis, measles, Mediterranean spotted fever, melioidosis, meningitis, meningococcal disease, Middle East Respiratory Syndrome (MERS), methicillin-resistant Staphylococcus aureus (MRSA), milker's nodule, molluscum contagiosum, moniliasis, monkeypox, mononucleosis, mononucleosis-like syndrome, Montezuma's revenge, morbilli, mucormycosis, multiple organ dysfunction syndrome (MODS), multiple-system atrophy (MSA), mumps, murine typhus, Murray Valley encephalitis (MVE), mycoburuli ulcers, mycotic vulvovagmitis, myositis, Nanukayami fever, necrotizing fasciitis, necrotizing fasciitis—type 1, necrotizing fasciitis—type 2, negishi, new world spotted fever, nocardiosis, nongonococcal urethritis, non-polio enterovirus, norovirus, North American blastomycosis, North Asian tick typhus, Norwalk virus, Norwegian itch, O'hara disease, Omsk hemorrhagic fever, onchoceriasis, onychomycosis, opisthorchiasis, opthalmia neonatorium, oral hairy leukoplakia, orf, oriental sore, oriental spotted fever, omithosis, Oroya fever, otitis externa, otitis media, pannus, paracoccidioidornycosis, paragonimiasis, paramfectious, paralytic shellfish poisoning, paronychia, parotitis, parrot fever, pediculosis, peliosis hepatica, pelvic inflammatory disease, pertussis, phaeohyphomycosis, pharyngoconjunctival fever, piedra, pigbel, pink eye conjunctivitis, pinta, pinworm, pitted keratolysis, pitvriasis versicolor, plague, pleurodynia, pneumococcal disease, pneumocystis pneumonia, pneumocystosis, pneumonia, polio, poliomyelitis, polycystic hydatid, Pontiac fever, pork tapeworm, Posada-Wernicke disease, postanginal septicemia, Powassan, progressive multifocal leukencephalopathy (PML), progressive rubella panencephalitis, prostatitis, pseudomembranous colitis, psittacosis, puerperal fever, pustular rash diseases, pyelonephritis, pylephlebitis, q-fever, quinsy, quintana fever, rabbit fever, rabies, racoon roundworm, rat bite fever, rat tapeworm, Reiter syndrome, relapsing fever, respiratory syncytial virus (RSV), rheumatic fever, rhodotorulosis, ricin poisoning, rickettsialpox, rickettsiosis, Rift valley fever, ringworm, Ritter's disease, river blindness, rocky mountain spotted fever, rose handler's disease, rose rash of infants, roseola, Ross river fever, rotavirus, roundworm s, rubella, rubeola, Russian spring, salmonellosis gastroenteritis, San Joaquin valley fever, Sao Paulo encephalitis, Sao Paulo fever, scabies infestation, scalded skin syndrome, scalded skin syndrome, scarlatina, scarlet fever, schistosomiasis, scombroid, scrub typhus, sennetsu fever, sepsis, septic shock, severe acute respiratory syndrome, severe acute respiratory syndrome (SARS), shiga toxigenic Escherichia coli, shigella, shigellosis gastroenteritis, shinbone fever, shingles, shipping fever, siberian tick typhus, sinusitis, sixth disease, slapped cheek disease, sleeping sickness, small pox, smallpox, snail fever, soft chancre, southern tick associated rash illness, sparganosis, Spelunker's disease, sporadic typhus, sporotrichosis, spotted fever, spring, St. Louis encephalitis, staphylococcal food poisoning, staphylococcal, strep, throat, streptococcal disease, streptococcal toxic-shock syndrome, strongyloiciasis, stye, subacute sclerosing panencephalitis (SSAPE), sudden acute respiratory syndrome, sudden rash, swimmer's ear, swimmer's itch, swimming pool conjunctivitis, Sylvatic yellow fever, syphilis, systemic inflammatory response syndrome (SIRS), tabes dorsalis, taeniasis, taiga encephalitis, tanner's disease, tapeworm s, temporal lobe encephalitis, tertiary syphilis, tetani, tetanus, threadworms, thrush, tick, tick typhus, tinea barbae, tinea capitis, tinea corporis, tinea cruris, tinea manuum, tinea nigra, Tinea pedis, tinea unguium, tinea versicolor, torulopsosis, torulosis, toxic shock syndrome, toxoplasmosis, transmissible spongioform, traveler's diarrhea, trench fever 5, trichinellosis, trichomoniasis, trichonycosis axillaris, trichuriasis, tropical spastic paraparesis (TSP), trypanosomiasis, tuberculosis (TB), tularenua, typhoid fever, typhus fever, ulcus molle, undulant fever, urban yellow fever, urethritis, vagmitis, vaginosis, valley fever, vancomycin intermediate (VISA), vancomycin resistant (VRSA), varbuncle, varicella, variola, varrion's disease, venezuelan equine encephalitis, Verruga peruana, vibrio, Vibrio cholerae, vibriosis, vincent's disease or trench mouth, viral conjunctivitis, viral meningitis, viral meningoencephalitis, viral rash, visceral larval migrans, vomito negro, vulvovaginitis, warts, Waterhouse, Weil's disease, West Nile fever, Western equine encephalitis, Whipple's disease, whipworm, white piedra, whitlow, Whitmore's disease, whooping cough, winter diarrhea, wolhynia fever, wool sorters' disease, yaws, yellow fever, yersinosis, zahorsky's disease, zika virus disease, zoster, zygomycosis, acute bacterial rhinosinusitis, lobomycosis, and/or any other infectious diseases, disorders or conditions.

John Cunningham Virus (JCV)

John Cunningham Virus is a common human polyomavirus. The transmission route of JCV is unknown. The virus is suspected to be spread by contaminated water and may be obtained through tonsils or by the gastrointestinal tract, 70-90% of humans are estimated to be infected by the virus, and for normal healthy individuals the infection is asymptomatic. However, for patients with weakened immune system. JCV may lead to Progressive multifocal leukoencephalopathy (PMI). PML is a condition characterized by multifocal progressive damage or inflammation of the white matter of the brain. The symptoms include clumsiness, progressive weakness and changes in visual, speech and personality. PLM has a mortality rate of 30-50% and patients who survive the disease are left with severe neurological disabilities. PML occurs in patients with a severe immunodeficiency, most commonly in patients with HIV/AIDS. As many as 5% of HIV/AIDS patients are affected by PML. Individuals with other autoimmune conditions such as multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus are also at risk, as well as individuals going through immunosuppressive therapy for cancer, e.g lymphoma or Hodgkin's disease, or organ transplant. PML associated with immunosuppressive therapy is an increasing concern. For example, commercial antibody natalizumab (TYSABR®, developed by Biogen Idec) for treatment of multiple sclerosis increases susceptibility to PML. Other drugs associated with increased risk of PML include Rituximab (RITUXAN®, developed by IDEC Pharmaceuticals), Efalizunab (RAPTIVAR® developed by Genentech and XOMA) and Mycophenolate mofetil (CELLCEPT®, developed by Genentech).

JCV is a nonenveloped, T=7 icosahedral virus with a closed circular, double-stranded DNA genome. The major capsid component is the viral protein VP1 is made of 72 pentamers formed by VP1 monomers linked through the C terminal end. VP1 starts the infection by binding to the receptor target cells. After initial infection, typically occurring in childhood or adolescence, the virus stays quiescent in the kidneys and the lymphoid organs. In healthy individuals, the virus may replicate in kidney without causing any symptoms. However, in patients with weakened immune system, JCV may cross the blood-brain barrier into the central nervous system causing PML.

As of today, there is no known cure for PML. Current therapies focus on reversing the immune deficiency to slow down or stop the progress of the disease. There remains a need for therapies neutralizing JVC for prevention, management and treatment of JCV infection and PML Goldmann et al. demonstrated that neutralizing activity with JCV VP1 protein in sera of a rabbit (see Goldmann C. et al., 1999, J. Virol.; 73(5): 4465-4469). Therapies based on neutralizing JCV antibodies could be applied for treatment, management and/or prevention of PML. Recently, immunological approaches have been under investigation and neutralizing antibodies binding to JC virus, especially targeting the VP1 protein, have been developed e.g. as described in US Patent Publication US2015/0191530. US2015/0056188 and US2015/0050271, the contents of each of which are incorporated herein by reference in their entirety. Such antibodies may cause reduction of JCV replication, proliferation or Infectivity. Antibodies may bind to a conformational epitope of JCV VP1 protein or to the sialic acid binding pocket of VP1 protein of JCV.

In some embodiments, methods of the present invention may be used to prevent, manage and/or treat JCV infection and/or PML.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat JCV As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 26 (SEQ ID NO: 6802-6865).

Influenza Virus

Influenza viruses cause a common respiratory infection called influenza (flu). Influenza viruses are categorized into three main groups, virus A, B and C Influenza viruses are negative-sense, single-stranded, segmented RNA viruses. Influenza A contains two proteins on the surface of the viral envelope; hemagglutinm (H), which is a protein responsible for red blood cell agglutination and neuraminidase (N), which is an enzyme cleaving the glycosidic bonds of neuraminic acid. Influenza A mutates at a faster rate than types B and C Several serotypes of H and subtypes of N have been identified. Influenza Type B, similarly to Type A, contains H and N protein. Type C influenza virus is a single stranded RNA virus with glycoprotein called hemagglutinin-esterase fusion Influenza strains vary according to geographical presentation.

Influenza in general is a highly contagious disease and may be transmitted by the respiratory route. Influenza symptoms include e.g. high fever, runny nose, headache, sore throat, muscle pain, cough and occasionally nausea and vomiting. Influenza may lead to other complications such as pneumonia or sinus infections. Influenza may be dangerous to young children, the elderly, pregnant women and individuals with chronic medical conditions or weakened immune system. According to Centers for Disease Control and Prevention (CDC), the estimated annual number of flu-associated deaths in the United States ranges between 3000 and 49,000, depending on the severity of the seasonal variations.

Influenza may be treated with good supportive care and antiviral medication. Antiviral medications include neuraminidase inhibitors, e.g. oseltamivir and zanarmvir and M2 protein inhibitors. However, some strains of influenza appear to be resistant to these antiviral medications. Seasonal vaccinations to influenza are very efficient in prevention of the disease and are recommended annually.

There remains a need for prevention and treatment therapies for influenza, especially for those providing long lasting and broad neutralization Therapeutic antibodies against influenza viruses have been developed. In general, antibody responses to different subtypes and serotypes of influenza A. B and C are unique. Some therapeutic antibodies are specific to an antibody type, whereas some have a broad coverage. Navivumab (developed by Celltrion, Inc.) taught in US Patent application US20140234336, firivumab (developed by Celltrion, Inc.) taught in US Patent application US20130004505 and diridavumab (developed by Jansen Biotech, Crucell and Johnson&Johnson) taught in International Patent application WO/2008/028946 are examples of therapeutically antibodies against influenza A hemagglutinin HA.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat influenza. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 21 (SEQ ID NO: 4138-5222).

Hepatitis

Hepatitis is an inflammation of the liver. Hepatitis may be caused by an infection of hepatitis viruses A, B, C, D or E. In some cases, hepatitis may be asymptotic. A typical symptom of hepatitis is jaundice, characterized by yellowing of the skin, mucous membrane and conjunctiva. Other symptoms include loss of appetite, diarrhea, nausea and fever. Hepatitis may lead to a liver failure. Acute form of hepatitis is healed within six months of infection. The inflammation may also progress to a chronic hepatitis, which may lead to liver complications such as fibrosis, cirrhosis or hepatocellular carcinoma. There is no specific treatment for hepatitis. Typically, acute hepatitis is treated with good supportive care, including good nutritional balance, fluid and rest. Chronic hepatitis may be treated with antiviral drugs. Hepatitis may be prevented by vaccinations.

Hepatitis A (HAV) virus belongs to the family of Picornaviridae. HAV is encapsidated in an icosahedral structure formed by 60 copies of three viral structural proteins (VP1, VP2 and VP3), (see e.g. Kim et al. 2004, Virlogy; 318(2):598-607, and references therein). HAV is spread by the fecal-oral-route. Typical transmission is through contaminated food or drink or in contact with an infected individual. Improperly cooked shellfish is a common source of HAV. Hepatitis A is more abundant in developing countries with poor sanitary conditions. According to the World Health Organization (WHO), an estimated 1.4 million people are infected by HAV every year.

Vaccines for prevention of HAV infection exists and are recommended to be administered to children under 1 year of age by CDC, As of today, there is no specific treatment for HAV infection. The treatment includes supportive therapy and may last for weeks or even months. There remains a need for treatment therapies for HAV. Antibodies for prevention and/or treatment of HAV have been developed. For example, U.S. Pat. No. 763,476, International Publication WO2011114353 and Kim et al in Virology. 2004 Jan. 20:318(2).598-607, the contents of each of which are incorporated herein by reference in their entirety, teach neutralizing antibodies targeting HAV antigens.

Hepatitis B (HBV) belongs to the family of Orthohepadnaviridae. HBV comprises a 3.2 kb-partially double-stranded circular DNA genome. HBV virus may be transmitted via the sexual transmission route, vertical transmission at birth, iatrogenic route (e.g. blood transfusions, contaminated reused needles and syringes), as well as via exposure to certain body fluids of an infected individual According to the WHO, an estimated 240 million people are chronically infected with hepatitis B annually, and more than 780 000 people die to associated complications.

HBV may be prevented by vaccination. The WHO recommends vaccination for all infants, as well as for adults living in increased risk of the infection. HBV infection may be treated with antiviral medications, e.g. tenofovir and entecavir. The medication does not cure the disease but suppresses the replication of the virus. Individuals with chronic hepatitis B infection are administered antiviral medications for life. There remains a need for therapies providing long lasting management and/or cure for HBV infection. Antibodies for prevention and/or treatment of HBV infection are described e.g. in US Patent publication US20120308580 and International publication WO2013165972, the contents of each of which are herein incorporated by their reference in their entirety.

Hepatitis C (HCV) belongs to the family of Flaviviridae. HCV is a positive-sense single-stranded RNA virus with an open reading frame with 9600 nucleotide bases. HCV is most commonly transmitted by the sexual transmission route or iatrogenic route. Hepatitis C may be transmitted also via the vertical route, though uncommon. According to WHO, 130-150 million people have a chronic HCV infection and approximately half a million people die from complications associated with HCV annually.

As of today, there is no vaccine for HCV infection. Traditional treatment of hepatitis C is based on antiviral medication therapy with e.g. ribavirin and interferon. More recently, direct antiviral agents (DAA) have been developed to treat hepatitis C infections. However, there remains a need for efficient prevention and treatment therapies for HCV infection.

Hepatitis D (HDV) is a small spherical enveloped RNA virus belonging to the genus of deltaviruses. HDV infection may only replicate in the presence of a HBV virus and therefore HDV infection has a dependency on HBV. HDV virus may be transmitted as coinfection with HBV or be superimposed on chronic HBV or HBV carrier state. HDV may be transmitted similarly to HBV, e.g. via the sexual transmission route, vertical transmission at birth, iatrogenic route, as well as via exposure to certain body fluids of an infected individual. Treatment and vaccination against HBV may be applied against HDV, and there remains a need for therapies to cure both infections.

Hepatitis E (HEV) is a linear, monoparte, single-stranded RNA virus belonging to the family of Hepeviridae. HEV may be transmitted via the fecal-oral route due to contaminated food or beverage, the iatrogenic route (e.g. blood transfusions, contaminated reused needles and syringes) or the vertical transmission route during pregnancy. Contaminated drinking water is the most common source of infection. Improperly cooked shellfish are a common source of HEV. The disease is present worldwide but is more abundant in East and South Asia, and especially in environments with poor sanitation and hygiene. According to WHO, an estimated 20 million HEV infections occur annually leading to 56 600 death associated with HEV complications.

There is no specific treatment for HEV. The disease is typically cured with good supportive care. As of today, vaccinations against 1-HEV are not globally available, though development in the field has been done. There remains a need for prevention and treatment therapies for HEV infection. Antibodies for prevention and treatment of HEV have been developed. For example, neutralizing antibodies targeting HEV have been taught in U.S. Pat. No. 7,148,323, Tang et al. 2011. Proc. Natl. Acad. Sci. U.S.A. 108 (25), 10266-10271 and Gu et al. 2015, Cell Res. 25 (5), 604-620, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by HAV, HBV, HCV, HDV and/or HEV.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HAV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 6 (SEQ ID NO: 3197-3237).

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HBV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 23 (SEQ ID NO: 6311-6627).

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HDV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 23 (SEQ ID NO: 6311-6627).

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HEV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 6 (SEQ ID NO: 3197-3237).

Respiratory Syncytial Virus (RSV)

Respiratory syncytial virus (RSV) is a single-stranded RNA virus belonging to the family of Paramyxoviridae. The RSV RNA is contained in a nucleocapsid made of 11 proteins and covered with a lipid envelope (see, e.g. Piedimonte, 2015, Cleve Clin J Med.; 82(11 Suppl 1):S13-8, and references therein). RSV attaches to the epithelial cells of the host airway cells with the surface glycoproteins G and F and merges the viral envelope to the membranes of adjacent cells G and F glycoproteins are the principal antigens exposed to the host immune system.

Respiratory syncytial virus (RSV) causes infections of the respiratory tract including the lungs and breathing passages. RSV is transmitted through the respiratory transmission route, in direct contact with nasal or oral secretions of infected individuals, or indirectly e.g. by touching a contaminated surface. The symptoms include a runny nose, decrease of appetite, coughing, sneezing, fever and wheezing. The infection may progress into a pneumonia or bronchiolitis Additionally, RSV infection may have a role in triggering asthma attacks and in the inception of asthma for individuals with a family history of asthma. In healthy adults, RSV infection is typically mild and does not require hospitalization. However, the infection may be dangerous for young children and infants, and for individuals with a weakened immune system. According to the CDC, almost all children under 3 years of age will acquire an RSV infection and up to 2% of cases require hospitalization. RSV infection the most common cause for bronchiolitis and pneumonia in children younger than 1-year-old.

As of today, there is no specific medical treatment for RSV infection on the market and typically the infection is treated with good supportive care. There remains a need for prevention and treatment therapies for RSV infections and associated complications. Antibodies for treatment and prevention of RSV infection have been developed. For example, palivizumab (developed by Medimmune) taught in U.S. Pat. No. 8,153,133, the contents of which are incorporated herein by reference in their entirety, is a nearly human monoclonal antibody targeting the RSV F glycoprotein. Palivizunumab is used for passive immunity for infants at risk for severe infection, including children with hemodynamically significant congenital heart defects, profound immunodeficiency and pulmonary or neuromuscular pathologies impairing airway clearance.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by RSV.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat RSV As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 22 (SEQ ID NO: 5223-6310).

Herpes Simplex Virus 1 and 2

Herpes simplex viruses 1 and 2 (HSV1 and HSV2), also known as human herpesvirus 1 and 2 (HHV-1 and HHV-2), belong to the family of Herpesviridae. Herpesviruses in general, consist of an icosahedral capsid surrounded by a membrane envelope. The capsid contains the viral double stranded DNA. The capsid is surrounded by an amorphous tegument of 30 viral proteins. The virion is enveloped by lipids with multiple viral glycoproteins and cellular proteins (see, e.g. McAllister and Schleiss, 2014, Expert Rev Vaccines.; 13(11):1349-1360, and references therein).

HSV1 and HSV2 cause an infection known as herpes, which is characterized by blisters in the skin, or mucous membranes of the mouth, lips, also known as “cold sores”, or genitals. Typically, the symptoms are mild or asymptomatic. However, HSV1 and HSV2 are neurotropic and neuroinvasive viruses persisting in the body by becoming latent, and sustain in the cell bodies of neurons. The infection is lifelong with outbreaks, or sporadic episodes of viral reactivation, when the virus in the nerve cells become active causing new blistering. The infection may be dangerous to individuals with weakened immune system. Neonatal herpes of infants may be fatal. Occasionally HSV1 infections may lead to encephalitis or keratitis. HSV1 and HSV2 are transmitted by contact with an infected area during reactivations of the virus. HSV1 is mainly transmitted by oral-to-oral contact, skin contact or the sexual transmission route. HSV1 may also be transmitted vertically during birth. HSV2 is transmitted via the sexual transmission route and is one of the most common sexually transmitted infections. According to the WHO, an estimated 67% of world's population aged under 50 years has an HSV-1 infection. An estimated 11% of world's population aged 15-49 years has an HSV2 infection.

As of today, there is no vaccination for prevention of HSV1 and HSV2 infections on the market. HSV1 and HSV2 infections may be treated with antiviral medications, such as acyclovir, famciclovir and valacyclovir. Antiviral medications do not cure the infection, but reduce the severity and frequency of symptoms. There remains a therapy for prevention and cure for these infections. Antibodies for prevention, treatment and management of HSV1 and HSV2, targeting the viral glycoproteins, have been developed, as described e.g. in U.S. Pat. No. 8,431,118, US Patent U.S. Pat. No. 5,646,041. Haynes US Patent Publication US201410302062, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by HSV1 and HSV2.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HSV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 24 (SEQ ID NO: 6628-6736).

Human Cytomegalovirus

Human Cytomegalovirus (HCMV) also known as human herpesvirus 5 (HHV-5) belongs to the family of Herpesviridae, a sub-family of Betaherpesvirinae. HCMV is a double-stranded DNA enveloped virus composed of a nucleocapsid surrounded by structured tegument layer and bounded by a trilaminate membrane envelope.

In most occasions, an initial HCMV infection is asymptomatic, or associated with mild symptoms e.g. sore throat, fatigue, flu-like symptoms, and fever. After initial infections, HCMV virus resides in mononuclear cells without detectable symptoms. HCMV infection may be dangerous to individuals with weakened immune system. HCMV may be transmitted by contact with certain body fluids of an infected individuals (e.g. saliva, urine, semen). HCMV may be transmitted vertically, especially if acquired during pregnancy, leading to a congenital HCMV infection. According to CDC, about 1 in 150 children are born with congenital CMV infection. In about 20% of cases, congenital HCMV infection may lead to premature birth, birth defects or developmental disabilities, e.g. liver, lung, spleen problems, small head size, small body size or seizures.

As of today, there is no specific treatment or prevention therapy for HCMV infection. In severe cases of congenital HCMV infection, infants may be treated with an antiviral drug, ganciclovir, to prevent hearing loss and developmental outcomes. However, the drug has serious side effects. There remains a need for prevention therapy and improved therapies for treatment and cure of HCMV infection. Antibodies neutralizing HCMV have been developed. Such antibodies are taught e.g. in International Patent Publication WO2010007463, U.S. Pat. Nos. 9,149,524, 8,492,529 and 8,202,518, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by HCMV.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HCMV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 24 (SEQ ID NO: 6628-6736).

Epstein-Barr Virus

Epstein-Barr virus (EBV), also known as human herpesvirus 4 (HHV-4) belongs to the family of Herpesviridae. EBV is a double-stranded DNA virus composed of a protein nucleocapsid surrounded by a tegument layer and bounded by an envelope containing lipids and surface projection of glycoproteins. EBV may enter B cells and epithelial cells.

EBV infection causes glandular fever known as infectious mononucleosis, also known as the kissing disease. Typical symptoms include e.g. sore throat, fever swollen lymph nodes in the neck, enlarged spleen, swollen liver, rash and fatigue. Additionally, EBV infection is associated with certain cancers, e.g. central nervous system lymphomas. Hodgkin's lymphoma, Burkitt's lymphoma, Guillain-Barre syndrome, multiple sclerosis, and higher susceptibility to certain autoimmune diseases. The virus is transmitted via contact with certain bodily fluids of an infected individual, especially through saliva. The infection affects majority of population. According to CDC, 90% of adult population have antibodies demonstrating current or past EBV infection.

As of today, there is no specific therapy for prevention or treatment of EBV infection on the market Typically, EBV infection is treated with good supportive care. Antibodies for prevention, management and treatment of EBV infection and associated diseases have been developed, e.g. by Wang and Fogg in US Patent publication US20150064174 and Fang et al, in Intervirology 50 (4), 254-263 (2007), the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by EBV.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat EBV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 31 (SEQ ID NO: 6898-6911).

Varicella Zoster Virus

Varicella zoster virus (VZV), also known as human herpes virus 3 (HHV-3) and chickenpox virus, belongs to the family of Herpesviridae. VZV is a linear duplex DNA molecule containing two segments (L and S) joined covalently. At least five clades of the virus have been identified.

VZV causes varicella, also known as chickenpox, which is an infection characterized by blister-like rash, itching, fatigue and fever. Chickenpox may be dangerous for babies, adults and individuals with weakened immune system. After primary phase of the infection, VZV resides in the nerves, including cranial nerve ganglia, dorsal root ganglia and autonomic ganglia, and may eventually lead to shingles, which is a viral disease characterized with a painful skin rash, blistering and occasionally nerve pain. Additionally, VZV has been associated with other complications, e.g. neurological conditions, inflammation of arteries, myelitis, Ramsay Hunt syndrome. Mollaret's meningitis VZV is transmitted by direct contact or by the respiratory route. VZV is highly contagious. According to CDC, before VZV vaccination, about 4 million people would be affected by chickenpox in the US annually, with more than 10,00KK hospitalized.

VZV infection may be prevented by a vaccination, which is recommended by CDC to all children and unvaccinated adults. Chickenpox may be treated with antiviral medications, e.g. acyclovir, valacyclovir and famciclovir, or with other symptom relieving medications and therapies. However, the present antiviral medications may have undesirable side effects. There remains a need for improved therapies to treat VZV infection, and its reactivation stages Antibodies targeting VZV have been developed, e.g. as described in U.S. Pat. No. 5,506,132, and US Patent application US20100074906, the contents of which are herein incorporated by their reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by VZV.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat VZV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 31 (SEQ ID NO: 6898-6911).

Corona Viruses

Coronaviruses are a diverse group of enveloped viruses belonging to the family of Coronaviridae. Coronaviruses contain an envelope, a helical capsid, and a single-stranded, positive-sense RNA genome. Coronaviruses have a characteristic structure with viral spike-shaped glycoprotein populating the surface of the virus and causing an appearance resembling the solar corona. Coronaviruses are a common cause of mammalian and avian infections causing upper respiratory tract, gastrointestinal and central nervous system diseases.

Human coronavirus 229E, OC-43, NL63, and HKU1 are a cause a behind typical, short term ‘common cold’ and affect individuals all over the world. Typical symptoms of the infections include coughing, sneezing, fatigue and fever. Occasionally the viruses can cause lower-respiratory tract illnesses, such as pneumonia. The viruses are spread by direct contact or by the respiratory route. The infections may be dangerous to the elderly and individuals with weakened immune system. There is no specific treatment or prevention therapy for these coronavirus infections.

Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) causes a viral respiratory illness. Typical symptoms of the infection include a high fever, headache, body aches, dry coughing and eventually pneumonia SARS-CoV was identified in 2003 in an outbreak starting from Asia. SARS-CoV is transmitted by direct contact with an infected individual or by the respirator route. According to the WHO, during the 2003 outbreak of SARS-CoV, 8098 people worldwide were infected with symptoms and out of them, 774 died. As of today, there is no specific treatment or prevention therapy for SARS on the market. Antiviral medication and steroids may be prescribed to certain patients. Antibodies targeting SARS-CoV have been developed, e.g. as described in U.S. Pat. No. 7,728,110 and US Patent publication US20110159001, the contents of each of which are herein incorporated by their reference in their entirety.

Middle East Respiratory syndrome coronavirus (MERS-CoV) causes an acute severe respiratory infection affecting the lungs and breathing tubes. MERS-CoV was identified in 2012. Typical symptoms include fever, cough and shortness of breath, eventually pneumonia and additionally gastrointestinal symptoms. MERS-CoV is highly dangerous to humans. According to the WHO, 36% of the infections are fatal. MERS-CoV is a zoonotic virus transmitted to humans from animals, e.g. bats and camels, or from human to human Camels are suggested to be a reservoir for MERS-CoV. Majority of MERS-CoV infection have occurred in the Arabian Peninsula, and especially in Saudi Arabia. As of today, no specific treatment of prevention therapy for MERS-CoV infection is available on the market. Antibodies targeting MERS-CoV have been developed, e.g. as described in International publication WO2015057942, the contents of which are herein incorporated by their reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by SARS-CoV. MERS-CoV and/or other coronaviruses.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat coronaviruses. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 25 (SEQ ID NO: 6737-6801).

Poxviruses

Poxviruses affecting humans include orthopoxvirus, parapoxvirus, yatapoxvirus and mollusipoxvirus. Poxviruses are typically brick-shaped, enveloped, single, liner or double-stranded viruses with DNA genome. Typically, poxvirus infections cause lesions, skin nodules, or disseminated rash Poxviruses may be transmitted by direct contact with contaminated humans, animals or materials. Diseases caused by poxviruses include e.g. smallpox, monkeypox, molluscum conagiosum, vaccinia virus and orf virus infection.

Smallpox virus infection is highly fatal, and though it does not occur in nature anymore, smallpox virus is considered to be a potential chemical or biological warfare agent. The threat of terrorism has created a need for efficient and improved methods for treatment and/or prevention of smallpox infection. The traditional vaccination for smallpox, also applicable against monkeypox, has a rare but severe side effect due to vaccinia virus, which is the active constituent of the vaccine that eradicated smallpox. Vaccinia Immune Globulin (VIG) is the only licensed therapeutic treatment for smallpox, but is highly variable and available in limited quantities Antibodies against smallpox have been developed, as described e.g. in U.S. Pat. No. 8,623,370 and US Patent publication US20140186370, the contents of each of which are herein incorporated by their reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by smallpox virus and/or other poxviruses.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat poxvirus. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 27 (SEQ ID NO: 6866-6875).

Enterovirus 71

Enterovirus 71 (EV71) belongs to the family of Picornaviridae Enterovirus 71 is a single-stranded RNA positive sense virus. The virus has approximately 7411 nucleotides. The RNA genome is enclosed in an icosahedral capsid of structural proteins VP1-VP4. (see, e.g. Tan et al., 2014, J. Biomed Sci; 21(1):140, and references therein).

EV71 infections typically cause hand, foot and mouth (HFMD), which is characterized by fever, mouth ulcers, and vesicles on the palms of the hands and feet. Additionally, EV7 causes severe neurological manifestations, including poliomyelitis-like acute flaccid paralysis, brainstem encephalitis in infants and children. These neurological manifestations may be fatal, or cause permanent neurological consequences, such as delayed neurodevelopment or reduced cognitive function in children. EV71 is transmitted through direct contact with certain bodily fluids, such as saliva, or the respiratory route, or the fecal-to-mouth route. Outbreaks of EV71 have been reported by WHO in the US, Europe, and more frequently in Asia-Pacific region in the past 30 year.

As of today, no specific treatment or prevention therapy for EV71 is on the market. Antiviral drugs, e.g. pleconaris and other capsid-function inhibitors (see, e.g. Tan et al J Biomed Sci. 2014; 21(1): 140), may be prescribed against EV71 infections, though their effectiveness is not well established. There remains a need for prevention and treatment therapies for EV71 infection. Antibodies neutralizing EV71 have been developed. Non-limiting examples include the anti-EV71 antibody MAB979 (developed by Merck Millipore) and those taught by Carderosa et al. in International Patent Publication WO2015092668, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by EV71.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat EV71. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 28 (SEQ ID NO: 6876-6891).

Rubella Virus

Rubella virus belongs to the family of Togaviridae. Rubella virus is a positive sense, single-stranded RNA virus with spike-like, hemagglutinin containing surface projections. The virus core is enveloped by glycosylated E1 and E2 proteins.

Rubella, also known as German measles or three-day measles, is a viral infection typically characterized by a rash, low fever, nausea, swollen lymph glands behind the ears and the neck, and mild conjunctivitis. At later stage, the infection may develop arthritis and pain in the joints. Typical symptoms of rubella infection are mild and affect children and young adults. Rubella virus is transmitted by the respiratory route and the virus replicates in the nasopharyngeal mucosa and local lymph nodes. However, when an infection is acquired during pregnancy, the virus is transmitted through vertical route with 90% chance and may cause fetal death or congenital defects known as congenital rubella syndrome (CRS). Infants with CRS may have hearing impairments, eye and heart defects, diabetes mellitus, thyroid dysfunction and/or autism. According to the WHO, about 10,000 infants with CRS are born every year, majority occurring in countries with low vaccine coverage.

As of today, there is no specific treatment for rubella. Rubella may be prevented with vaccination, and rubella has been part of the vaccination program for the past 40 years. However, the infection still persists and an increasing concern related to the life-time of vaccine efficiency exists. There remains a need for long lasting prevention therapy, as well as treatment for rubella virus infection. Antibodies against rubella have been described e.g. in US Patent US20100143376, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by rubella.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Rubella. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 29 (SEQ ID NO: 6892-6895).

Human Papilloma Virus

Human papilloma virus (HPV) is a non-enveloped double-stranded DNA virus belonging to the family of Papillomaviridae. Over 170 types of HPV have been identified.

HPV infections may be asymptomatic, or cause infection related to warts (e.g. plantar, flat or anogenital warts), oral infections such as papillomas or multifocal epithelial hyperplasia. The infection may be undetected, and clears from the body to low levels within two years. Infections caused by human papillomavirus (HPV) have been associated with certain cancers of stratified epithelial tissues, e.g. cervical, anal, vaginal, vulvar and penile cancers, lung and throat cancers. Especially HPV 16 and HPV 18 are known to be carcinogenic. According to the WHO, persistent genital HPV infection may cause cervical cancer which is the second most common cancer in women worldwide. In developing countries, cervical cancer counts for 13% of all female cancers, and survivor rate worldwide is approximately 50%. HPV is very common. CDC estimates that every one in four individuals in the US has an HPV infection Most commonly HPV is transmitted by the sexual route, but also the vertical transmission route, or by direct contact to infected blood, or objects may occur.

Cancers caused by HPV may be prevented by vaccines developed against certain HPV types. The vaccines are available worldwide and are recommended by CDC for all preteen aged children. As of today, there are no specific treatment for HPV infection. There remains a need for prevention and treatment therapy affecting a broad range of HPV infections Antibodies for HPV have been developed, e.g. as described in International publication WO2015096269, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by HPV

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat HPV. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 30 (SEQ ID NO: 6896 and 6897).

Pseudomonas aeruginosa

Pseudomonas Aeruginosa (P. aeruginosa) is a common Gram-negative, aerobic, rod-shaped bacterium belonging to the family of Pseudomonodaceae. P. aeruginosa is found in soil, water, skin, flora, and in most man-made environments around the world P. aeruginosa is considered as an opportunistic pathogen taking advantage of a weakened immune system.

P. aeruginosa may cause a variety of mild infections, such as, urinary tract infections, respiratory, system infections, dermatitis, soft tissue infections, bacteremia, bone and joint infections, gastrointestinal infections, blood infections, ear infections, skin rash, eye infections and a variety of systemic infections. P. aeruginosa is transmitted through water, contaminated hands, materials or objects. In general, P. aeruginosa infections in healthy individuals are very mild or asymptomatic. However, the infections expose a significant risk for individuals with weakened immunity, such as patients with other underlying illnesses or complications, and especially when in a hospital environment. For example, patients with cystic fibrosis have a susceptibility towards loss of lung function due to respiratory tract infection with the bacterium. Patients attached to breathing machines, patients with catheters, or with surgery wounds or burn wounds are potentially at risk for serious and life-threatening infections. P. Aeruginosa infection may lead to a fatal sepsis. According to CDC, approximately 51,000 health-care associated infection occur in the US every year, leading to approximately 400 deaths.

As of today, there are no prevention therapies for P. aeruginosa infection on the market. Some strains of P. aeruginosa may be treated with antibiotics, e.g. gentamicin, tobramycin, colistin, and amikacin. However, an increasing number of strains of P. aeruginosa, especially those affecting hospitalized patients, are resistant to antibiotics and no specific treatment therapy exists. There remains a need for improved treatment and prevention therapies against P. aeruginosa infections. Antibodies against P. aeruginosa have been developed, such as, panobacumab (developed by Kenta Biotech Inc.), which is an antibacterial antibody against P. aeruginosa.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by P. aeruginosa.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat P. aeruginosa. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 32 (SEQ ID NO: 6912-7196).

Streptococcus Bacteria

Streptococcus is a genus of gram-positive bacteria belonging to the family of Streptoccaceae. Species of Streptococcus are divided into alpha- and beta-hemolytic species Alpha-hemolytic species cause oxidation of iron in hemoglobin molecules within the red blood cells. Alpha-hemolytic streptococci include e.g. Streptococcus pneumoniae and Streptococcus virilans. Beta-hemolytic species cause complete rupture of the red blood cells and include e.g Lancefield groups A and B, also known as ‘group A strep’ and ‘group B strep’. Streptococcus genus includes overall more than 50 species. Streptococcus bacteria cause a variety of infections in humans, including dental caries, pneumonia, endocarditis, meningitis, respiratory tract infections, urinary tract infections, neonatal meningitis, pharyngitis and/or sepsis.

Streptococcus pneumoniae is a common bacterium causing, i.e. pneumonia, meningitis, bronchitis, acute sinusitis, conjunctivitis, osteomyelitis, endocarditis and/or septic arthritis. The bacteria is transmitted by direct contact or via the respiratory route. The bacteria resides in the nasopharynx of healthy carriers and proceeds into an infection under certain circumstances. The infection may be prevented by vaccines, e.g. conjugate vaccine or polysaccharide vaccines. The infection may be treated with antibiotics, e.g. broad-spectrum cephalosporin, and vancomycin, but there is a concern over increasing resistant towards antibodies. According to CDC, Streptococcus pneumoniae is currently resistant to one or more antibiotics in 30% of infections. Streptococcus pneumoniae is resistant to e.g. penicillins. There remains a need for improved, non-antibiotic, therapies for treatment of Streptococcus pneumoniae and other Streptococcus infections Antibodies for Streptococcus have been developed, as described e.g. in U.S. Pat. No. 5,686,070 and US Patent publication US20070003561, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Streptococcus pneumoniae and other Streptococcus bacteria.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Streptococcus pneumoniae. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 33 (SEQ ID NO: 6900-6902, 6905-6907, 6911, 7197-7229).

Staphylococcus Bacteria

Staphylococcus is a genus of gram-positive bacteria belonging to the family of Staphylococcacea. The genus includes overall approximately 40 species. Most species of the genus are harmless and reside in the skin and mucous membranes of humans. Staphylococcus bacteria may also be found in the soil. The bacteria may cause diseases either through toxin production or penetration. Staphylococcal toxins are a common cause of food poisoning. Staphylococcus bacteria may cause a variety of diseases, e.g. localized or diffuse skin infection, gastroenteritis, ear infections, septic arthritis, osteomrnyelitis, sinusitis, infective endocarditis and/or toxic shock syndrome.

Staphylococcus aureus (S. aureus) is typically residing in human nose asymptotically. In certain circumstances. S. aureus infections may affect many tissues and organs. Individuals with chronic conditions, e.g. diabetes, cancer, vascular disease, eczema and lung disease, have an increased susceptibility towards S. aureus infections. S. aureus may cause skin infections, such as, pimples, impetigo, atopic dermatitis, cellulitis folliculitis. More serious forms of infections include pneumonia, meningitis, osteomyelitis and endocarditis. S. aureus may also cause food poisoning. In severe cases, S. aureus infection may enter the blood stream causing bacteremia and/or sepsis. As of today, there is no medical therapy for prevention of the infection Some strains of S. aureus may be treated with antibiotics. However, increasing resistance towards antibiotics is a concern. Currently several antibiotic resistant forms of S aureus exist, including, but not limited to, Methicillin-resistant Staphylococcus aureus (MRSA). Vanconmycin-intermediate Staphylococcus aureus (VISA) and Vancomycin-resistant Staphylococcus aureus (VRSA) The drug resistant forms of S. aureus are more frequent in hospital environments.

Staphylococcus epidermidis (S. epidermidis) resides in the normal human skin flora and may cause an infection to individuals with weakened immune system, and to individuals who have catheters, prostheses or surgical implants. S. epidermidis has an ability to colonize on plastic materials or devices placed within the body. The infection may be treated with some antibiotics, but they do not remove the infection and can only be used to manage such infections. Many S. epidermis strains are resistant to antibiotics, such as penicillin, methicillin and/or amoxicillin, and increasing resistance to antibiotics in a concern.

There remains a need for prevention and/or improved treatment therapies against Staphylococcal infections. Antibodies targeting Staphylococcal bacteria have been developed. As an example, pagadaximab (developed by Medimnunune and AstraZeneca) is a monoclonal antibody for prevention of staphylococcal sepsis and may be administered to infants with low birth weight.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Staphylococcus bacteria.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Staphylococcal infections. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 34 (SEQ ID NO: 7230-7478).

Clostridium tetani

Clostridium tetani (C. tetani) is a rod-shaped, anaerobic, Gram-positive bacteria belonging to the family of Clostridiaccae. A matured bacterium develops a terminal spore, which is resistant to heat and common antiseptics. C. tetani produces tetanospasmin toxin. C. tetani is found as spores in soil and in the gastrointestinal tract of animals.

C. tetani infection spreads the tetanospamin toxin to the body, causing tetanus, also known as lock jaw. Tetanus is a dangerous disease characterized by painful tightening of the muscles. The disease may lead to locking of the jaw and neck, leading to inability to open mouth or swallow. The tightening may affect the whole body. In severe cases, the infection may lead to breathing difficulties, pneumonia, or pulmonary embolism. Even more serious is an infection acquired during pregnancy, leading to almost always fatal neonatal tetanus of an infant. The bacteria is typically transmitted through broken skin by direct contact with contaminated soil or objects, or saliva or feces of a contaminated animal. Especially susceptible are individuals with burns, puncture wounds, crush injuries or injuries with dead tissue, individuals having animal bites or scratches. Tetanus is fairly uncommon in developed countries. However, the WHO reported an estimated 50, 000 neonatal tetanus deaths in year 2008. A program form elimination of tetanus was started in 1989 by the WHO.

Tetanus may be prevented efficiently by a four vaccine combination, DTaP, Tdap, DT, and Td, given to children and adults. For adequate immunity, the primary vaccine is adrministered during childhood, a booster dose during adolescence and every 10 years thereafter during adulthood C. tetani infection may be treated with antibiotics, wound care and with human tetanus immune globulin (an antitoxin) Despite the existing treatment methods, approximately 10% of tetanus infections lead to death, according to CDC, There remains a need for longer lasting vaccine as well as improved treatment therapies against C. tetani infections. Antibodies against C. tetani have been developed, as described e.g. by Larrick. J. W. et al., 1992, Immunol Rev. 130, 69-85, and de Krulf. J. et al., 2009, J. Mol Biol. 387 (3), 548-558, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by C. tetani.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat C. tetani. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 35 (SEQ ID NO: 7479-7535).

Bordetella

Bordetella is a genus of Gram-negative, coccobacilli belonging to the family of Alcaliigenaceac. The structure of the bacteria consists of an outer membrane with lipopolysaccharides and phospholipids forming a capsule Bordetelia bacteria affecting humans include, but are not limited to, B. pertussis, B. parapertussis and B. bronchiseptica, B. pertussis resides in the upper air pathways, mostly the trachea and the bronchii, of humans. B. parapertussis resides in the upper air pathways of mammals. The bacteria release toxins that cause damage and swelling of the respiratory pathways.

Pertussis, also known as whooping cough, is a highly contagious infection of the respiratory track caused most commonly by B. pertussis, and occasionally by B. parapertussis. Typical symptoms of the infection include severe coughing and difficulty to breathe accompanied by a runny nose, apnea and fever. Additional complications for infants include pneumonia, convulsions, apnea, and encephalopathy. The bacteria are transmitted through the respiratory tract route. The disease is especially dangerous for infants According to CDC, about 30,0K00 infections were reported in the US in 2014. CDC reports 277 deaths occurring from 2000 through 2014, out of which 241 where infants less than 3 months of age.

Pertussis may be treated with antibiotics, such as, erythromycin, clarithromycin or azithromycin. However, an increasing resistance to antibiotics is a concern. Pertussis caused B. pertussis may be prevented by vaccination, e.g. by DTaP combination vaccine, which is recommended routinely for infants by CDC and WHO. Despite the widespread vaccination, the disease has insisted. The protection provided by the traditional vaccination is estimated to be 3-6 years. There remains a need for prevention therapies providing a longer lasting immunity, as well as for improved, non-antibiotic, treatments. Antibodies for prevention and/or treatment of pertussis have been developed, as described e.g. in International publication WO2014160098, and Hussein, A. H et al, 2007, Infect. Immun. 75 (11), 5476-5482, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by B. pertussis, B. parapertussis and/or other Bordetella bacteria.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Bordetella infection. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 36 (SEQ ID NO: 7536-7560).

Mycobacterium

Mycobacterium is a genus of nonmotile and aerobic bacteria, belonging to its own family of Myobacteriaceae. Mycobacteria have an outer membrane, and a hydrophobic and waxy cell wall with mycolic acid/mycolates. The cell wall is neither truly Gram-positive nor—negative. In general, the infections are difficult to treat and the bacteria is naturally resistant to many antibiotics, e.g. penicillin, due to the cell wall. Mycobacteria includes species, such as, but not limited to, M. tuberculosis, Nontuberculous mycobacteria (NTM), M. leprae, M. bovis, M. africanum, and M. micron.

M. tuberculosis is a genetically diverse bacterium and most common and dangerous of the mycobacteria family species. M. tuberculosis causes tuberculosis (TB) which is an infection mainly affecting the lungs. Typical early symptoms include cough, fever, night sweat, and weight loss. The disease may be mild for a period of time and therefore early diagnosis is difficult. Eventually the symptoms get more severe and coughing sputum and blood may occur. TB may be transmitted by the respiratory tract. TB affects all ages of the population, but is most dangerous to children, and individuals with weakened immune systems, e.g. HIV patients. According to the WHO, TB is referred to as a top infectious disease killer worldwide. WHO reports an estimated 9.6 million infections of TB in 2014, out of which 1.5 million cases were fatal. The disease is globally spread, but it is most abundant in the South-East Asia and Western Pacific Regions.

TB may be prevented by vaccinations, i.e. Bacille Clamette-Guerin vaccine. The vaccine is provided for children and adults exposed to environments with high risk of infection. However, the vaccine is not always efficient against TB, e.g. due to the diversity of strains geographically. TB may be treated with a 6 to 9 month course of combinational antimicrobial drug therapy Antimicrobial drugs effective against TB include e.g. isoniazid, rifampin, ethambutol, and pyrazinamide. However, an increasing resistance towards the medication is a concern. Certain strains of existing TB are identified as multi-drug resistant TB strains, which do not respond to therapy with e.g. isoniazid, rifampicin, or other common drugs. WHO reports an estimated 480 000 multidrug-resistant TB infections in 2014. There remains a need for prevention therapies protecting against broad spectrum of strains, as well as for improved treatment of M. tuberculosis and/or other mycobacteria. Antibodies against mycobacteria have been developed, as described e.g. in US Patent publications US20130309237, US20130309237, US20600229438, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by M. tuberculosis and/or other mycobacteria.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat mycobacterium related diseases. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 37 (SEQ ID NO: 7561-7576).

Francisella Tularensis

Francisella tularensis (F. tuliarensis) is a facultative intracellular Gram-negative, rod-shaped bacterium belonging to the family of Francisellaceae. F. tularensis resides in invertebrates, birds, reptiles, fish, and mammals, including humans. It is one of the most infectious and pathogenic bacteria known (see, e.g. Pechous et al., 2009, Microbiol Mol Biol Rev.; 73(4): 684-711).

F. yularensis causes infection called Tularemia. Severity of tularemia varies from mild to fatal. F. Tularensis may be transmitted to a human by direct skin or eye contact, by the respiratory route or by consumption of contaminated food or drink. Most commonly, the infection is acquired while handling infected animals Most common form of tularemia is ulceroglandular tularemia, characterized by skin ulcers on the site of infection accompanied by swelling or regional lymph glands. Ulceroglandular tularemia is typically acquire by a tick, or deer fly bite. Pneumonic tularemia is an infection of the respiratory tract characterized by a cough, chest pain, and difficulty of breathing. Pneumonic tularemia is transmitted through the respiratory route and may be fatal if not treated. Oropharyngeal tularemia is transmitted by contaminated food or beverage and causes a sore throat, mouth ulcers, tonsillitis and swelling of lymph glands in the neck. Other forms of tularemia include glandular, oculoglandular (affecting the eyes) and typhoidal (combination of the general symptoms). F. tularensis is considered to be a potential biological and chemical warfare agent.

As of today, there is not preventive therapy for tularemia infection on the market. Some vaccines have been under development (see, e.g. Pechous et al., Microbiol Mol Biol Rev. 2009 December; 73(4): 684-711). Tularemia may be treated with antibiotics, such as, streptomycin, gentamicin, doxycycline, and ciprofloxacin. However, increasing resistance against antibiotics is a concern There remains a need for improved prevention and treatment therapies for F. tularensis infections. Antibodies against F. tularensis have been developed, e.g. as described by Rynkiewicz, M. J. et al., 2012, Biochemistry, 51 (28), 5684-5694 and Lu. Z., et al., 2013. Immunology, 140 (3), 374-389, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by F. tularensis.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat F. tularensis related infections. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 38 (SEQ ID NO: 7577-7592).

Toxoplasma gondii

Toxoplasma gondii is a parasitic protozoan infecting warm-blooded animals, including humans. Domestic cats and other felines are the most desired hosts for Toxoplasma gondii, as they are the only hosts where the protozoan is capable of sexual reproduction. According to CDC, more than 60 million people in the US may be infected by Toxoplasma gondii.

Toxoplasma gondii causes toxoplasmosis, which is typically asymptomatic in healthy individuals and is controlled by the natural immune system. The infection may be obtained from undercooked, contaminated food, especially pork, lamb and venison, from food contaminated by utensils, or contaminated hands, occasionally from contaminated drinking water, or by the fecal-to-oral route from cat feces. Toxoplasma gondii may also be transmitted by vertical route, especially when the protozoan is acquired during pregnancy. Children infected during or just prior to pregnancy may have eye problems, or brain damage at birth, or may develop symptoms later in their lives. Toxoplasmosis may be dangerous to individuals with a weakened immune system, such as patients with AIDS, undergoing certain chemotherapies or having organ transplants.

Toxoplasmosis may be treated with certain medications such as antibiotics called sulfadiazine and pyrimethamine, which is an anti-parasite medication used for e.g. malaria. However, resistance to both of the medications is an increasing concern. There remains a need for improved treatment methods as well as prevention therapies against Toxoplasma gondii infection. Antibodies targeting Toxoplasma gondii have been developed, as described by e.g. Graille, M. et al., 2005, J. Mol. Biol. 354 (2), 447-458, the contents of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Toxoplasma gondii.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Toxoplasma gondii related infections. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 40 (SEQ ID NO: 7617 and 7618).

Candida Yeast

Typically, species of yeast are commensals and endosymbionts of human hosts, but may cause an infection under certain circumstances. C. albicans is a yeast belonging to the family of Saccharomycetaceae C. albicans causes infection of the mouth characterized by white patches on the tongue, mouth and throat. The infection of the mouth is most typical with new born babies, the elderly and individuals with weakened immune system, e.g. HIV/AIDS patients. Optionally, the infection may affect the nails, leading o brittle and defected nails. Optionally, the infection may cause an infection of the vagina, leading to genital burning or uncomfortable discharge. Typically, Candida albicans infections are mild and localized. However, the infection may be severe or fatal for individuals with underlying health problems and left untreated. Invasive candidiasis refers to an infection spreading to many parts of the body, including the heart, brain, eyes, bones and/or joints. Candidemia refers to an infection where candida yeast is present in the blood stream. Severe forms of C. albicans infections affect individuals in health care environments, e.g. patients with central venous catheter, patients treated at an intensive care unit, patients undergoing antibiotic treatments, treatments for kidney failure, recovering from a surgery, and patients with chronic diseases, e.g. diabetes and/or HIV/AIDS. C. albicans is typically transmitted from mother to an infant during childbirth and it remains as a species of human's normal microflora. It may also be transmitted through the sexual transmission route. Other species of candida yeast family include, e.g., C. glabrata, C. parapsilosis, C. tropicalis, C. krusei and C. lusitaniae.

C. albicans infection may be treated with antifungal drugs, e.g. nystatin, clotrimazole, amphotericin B oral suspension) or systemic oral azoles (e.g. fluconazole, itraconazole, or posaconazole). Despite the medical therapy available, some forms of C. albicans infections are dangerous, or life-threatening. There remains a need for improved prevention, and/or treatment therapies against C. albicans infections, for example by antibody therapies. Efungumab (developed by NeuTec Pharma) is an antibody for treatment of invasive C. albicans infection.

In some embodiment, methods of the present invention may be used to prevent and/or treat C. albicans infections.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat C. albicans related infections. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 41 (SEQ ID NO: 7619).

Human Immunodeficiency Virus (HIV)

Human immunodeficiency virus (HIV) is a roughly spherical enveloped RNA virus belonging to the family of Retroviridae. HIV is composed of two positive single-stranded RNA copies. The viral core contains a viral capsule protein, p24, which surrounds the two single stranded RNAs and the enzymes for HIV replication. The viral envelope consists of two lipid layers, the outer layer glycoprotein 120 (gp 120) and the transmembrane glycoprotein 41 (gp41). Gp 120 attached to the host cell whereas gp41 has a role in the cell fusion process. For replication, the virus needs a host cell and the RNA first transcribes into DNA by enzyme reverse transcriptase. HIV infects the CD4 lymphocyte (T cell) leading to depletion of CD4+ T cells and loss of CD4+ T-cell function, as infected cell loses its function and converts to a HIV-replicating cell. (see, e.g. Okoye and Picker, 2013, Immunol Rev.; 254(1): 54-64, and references therein) Additionally, HIV infection leads to B lymphocyte (B cell) hyper-activation and dysfunction (see, e.g. Moir and Fauci, 2009, Nat Rev Immunol.; 9(4): 235-245, and references therein). The virus may be transmitted through sexual transmission route, vertical transmission route, iatrogenic (medical procedure) route, or in direct contact with certain body fluids with high concentration of HIV, including e.g. blood, breast milk, semen, vaginal, and rectal secretions. Two types of HIV (HIV-1 and HIV-2) have been identified. HIV-1 has higher infectivity and has spread around the globe whereas HIV-2 is more localized to West Africa According to CDC, there is about 36.9 million people in the world with HIV/AIDS with about 2 million cases arising every year. The infection is most abundant in Sub-Saharan Africa.

In acute HIV infection stage, within 2-4 weeks after infection, infected patients experience flu-like illness. In the second stage the infection is asymptomatic and the HIV replication is at low level. The second stage may last for years or decades, especially when treated with HIV medication. Eventually, HIV causes acquired immune deficiency syndrome (AIDS), which is a clinical condition characterized by severe immunosuppression attacking the CD4 cells, making individuals susceptible to life-threatening malignancies and infections. Complications associated with HIV/AIDS include common bacterial and viral infections, parasite infections, certain cancers (e.g. Kaposi's sarcoma, Non-Hodgkin's lymphoma, and angiosarcoma), progressive multifocal leukoencephalopathy (PML) and wasting.

As of today, there is no prevention therapy or cure for HIV/AIDS. However, with antiretroviral (ART) therapy, the disease may be managed for a long period of time. ART therapy comprises of five classes of drugs used in different combinations to treat HIV. The drugs target the different phases of the retrovirus life-cycle. However, there remains a need for improved therapies for prevention, management and/or treatment of HIV/AIDS.

Antibodies for treatment and prevention of HIV infection have been developed. For example, commercial antibody Ibalizumab (developed by Taimed Biologics Inc.) is a non-immunosuppressive monoclonal antibody binding to CD4, Anaplasma phagocytophilium inhibiting the viral entry process. As another example, suvizumab (developed by Kaktsuden, Chemo-Sero Therapeutic Research Institute) is a humanized antibody targeting the HIV-1 envelope glycoprotein GP120. As a non-limiting example, any of the antibodies in Table 42, variants or fragments thereof may be used in the treatment and/or prevention of HIV.

Antibodies neutralizing HIV-1 and HIV-1 strains have been identified, but as of today, the researchers have not been able to develop a vaccination for HIV. HIV has a capability to evolve with unusually high somatic mutation and recombination rate. So far, conventional vaccines have not succeeded in eliciting analogues of the broadly neutralizing antibodies. An alternative approach suggested involves using adeno-associated vectored gene delivery for expression of antibodies from muscle tissue (e.g. Balasz et al, 2012. Nature Letter, 481, 81-84, Balasz et al. 2014, Nat Med.; 20(3): 296-300, Saunders et al., 2015, J Virol.; 89(16):8334-45, and US Patent publication US20030219733, the contents of which are herein incorporated by reference in their entirety). The studies have demonstrated efficient and long lasting protection from HIV infection by e.g. intravenous or mucosal surface transmission.

AAV Particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat I-IV infection and AIDS. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 42 (SEQ ID NO: 7620-9220).

Therapeutic Applications: Toxins

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat infectious disease. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Tables 14-17 (SEQ ID NO: 3549-3914).

Toxins are a group of substances that are highly poisonous and dangerous to humans. Toxins are infectious agents in form of bacteria, viruses, fungi, proteins, and other chemical and/or biological substances. Toxins may lead to fatal conditions Toxins are produced by nature, and may be produced synthetically. Exposure to toxins may be unintentional and occur when in contact with toxic plants, or contaminated food, water, livestock or animals. Due to the life-threatening impact of toxins, they are considered to be potential biological and/or chemical warfare agents that may be applied as weapons of mass destruction in war field. They also impose a threat to be used as means for terrorist attacks.

Ricin

Is a naturally occurring carbohydrate-binding lectin protein produced by castor oil plant growing in Eastern Africa, India, Southeastern Mediterranean basin area, and in tropical regions. Ricin may also be manufactured from the waste products when processing castor beans. Ricin has a globular structure with two toxin chains, chain A and chain B, which both need to be present for the cytotoxic affect. Ricin kills cells by inhibiting protein synthesis. Chain B penetrates to the cell whereas the disulfide bond joining chain A to chain B lectin has an affinity to bind to cell surface carbohydrates, (see, e.g. Friedman and Rasooly, 2013, Toxins (Basel); 5(4): 743-775). Ricin is highly toxic to humans with median lethal dose (LD₅₀) of 22 micrograms per kilogram of body weight. The exposure to Racin may be by inhaling, ingestion or by injection. The symptoms are dependent of the method of exposure. When inhaled, ricing causes severe inflammation of the lungs, causing would has symptoms including coughing, difficulty breathing, muscle ache and nausea. When ingested, ricin induces internal bleeding of the stomach and intestines leading to pain, vomiting and bloody diarrhea, and eventual failure of the kidneys, liver and spleen. When injected, ricin induces failure of the muscles and lymph nodes, and eventually failure of the liver, kidney and spleen. There is no known treatment for Ricin poisoning.

Unintentional poisoning by Ricin is uncommon. However, Ricin is a potential biological and chemical warfare agent creating a need for treatment and prevention therapies for ricin poisoning. Antibodies targeting ricin have been developed, as described e.g. in International publication WO2015100409, the contents of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by ricin.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Ricin related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 14 (SEQ ID NO: 3549-3568).

Bacillus anthracis

Bacillus anthracis is a Gram-positive, rod-shaped bacterium causing anthrax disease (see, e.g. Spencer, 2003, J Clin Pathol.; 56(3): 182-187, and references therein). Most animals, especially herbivores, are susceptible to infection of Bacillus anthracis. Anthrax may be infected via respiratory exposure, skin contact or eating contaminated food, in most cases meat. Inhaled anthrax causes flu-like symptoms, pneumonia and severe respiratory collapse. Gastrointestinal anthrax causes severe diarrhea, acute inflammation of the intestinal tract, and vomiting of blood. Skin exposure to the bacteria will lead to boil-like skin lesions forming an ulcer with black center. Typically, infection to humans occurs by eating contaminated meat or while handling infected animals or their product, such as skin, wool or meat. Bacillus anthracis is a potential biological warfare agent. In 2001, weeks following the September 11 terrorist attacks, letters containing Bacillus anthracis were mailed to news media offices and two U.S. Senators resulting in death of five people and infected many more.

Anthrax may be treated with antibiotics, such as penicillin and amoxicillin, and may be prevented by vaccines, developed both for humans and animals. However, due to increased threat of biological warfare and terrorism, improved methods of treatment are in demand. Anthrax may also be treated by antibody therapy. For example. Raxibacumab (developed by Cambridge Antibody Technology and Human Genome Sciences) is an antibody for the prophylaxis and treatment of inhaled anthrax.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Bacillus anthracis.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Bacillus anthracis related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 15 (SEQ ID NO: 3569-3813).

Shiga Toxin and Shiga-Like Toxin

Shiga toxin, including two major types Stx1 and Stx2, is a toxin produced by Shigella dysenteriae, a rod-shaped bacteria belonging to bacterial genus Shigella. Shiga toxin inhibits protein synthesis within cells. The toxin enters cell via a marcopinosome and inhibits the protein synthesis by cleaving a specific nucleobase RNA of the 60S subunit of ribosome. Shiga-like toxins 1 and 2 are structurally similar to Stx1 and Stx2 and are produced by enterohemorrhagic strains of Escherichia coli (EHEC) strains. (see, e.g. Friedman and Rasooly, Toxins (Basel). 2013 April; 5(4): 743-775) EHEC type 0157 is the most common pathogen causing E. Coli outbreaks in the US. Stx2 is considered to be orders of magnitude more toxic that Stx1. The severity of Shiga toxin foodborne illnesses range from mild diarrhea to a life-threatening complication known as hemolytic uremic syndrome (HUS). HUS is a disease associated with hemolytic anemia, acute kidney failure and low platelet count. Cattle is the major source or infection to humans, but the disease may be spread by birds or pigs. Shiga infection is typically obtained from contaminated food or drink, such as meat, unpasteurized milk, or contaminated water, or by contact with cattle Shiga toxin and Shiga-like toxins considered to be potential chemical and biological warfare agents.

As of today, there is no prevention therapy or specific treatment for Shiga and Shiga-like toxins. Recent developments have been made in antibody therapy of Shiga toxin induced HUS. For example, SHIGAMAB® (developed by Bellus Health Inc.) is a monoclonal antibody for treatment of Shiga toxin induced HUS.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Shigella dysenteriae.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Shigella dysenteriae related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 17 (SEQ ID NO: 3844-3914).

Botulinum Toxins

Botulinum toxins are neurotoxins produced by Clostridium bacteria and they cause a disease called botulism which is characterized by weakness, problems in vision, tiredness, and problems with speech, followed by weakness of the arms, chest muscles and legs. Botulism may be fatal. There are seven different botulinum neurotoxins with a four-domain structure varying in antigenic properties and interactions with intracellular targets. L-chain enters the cytosol, cleaves the synaptosomal protein and blocks neurotransmitter release resulting in peripheral neuromuscular blockade and flaccid paralysis in humans. (see, e.g. Friedman and Rasooly. Toxins (Basel) 2013 April; 5(4): 743-775) Botulinum neurotoxins are highly dangerous to humans, serotype A having a median lethal dose (LD₅₀) of 0.8 micrograms for a human of 70 kg weight. The bacteria is common in soil and water and may produce the botulinum toxins when exposed to low oxygen levels and certain temperatures. Outbreaks of foodborne botulism occur occasionally. Most susceptible to contamination by botulinum are baked products, fresh mussels, canned fruit and vegetables. Infant botulism occurs when the toxins are produced and released by bacteria in the infant's intestines. Botulism may also occur in wounds where the bacteria in the absence of oxygen produces and releases the toxins. Wound botulism is most common in cases where contaminated needles are used for injection. Botulinum toxins are potential biological and chemical warfare agents.

As of today, there is no prevention therapy for botulism. Botulism may be treated with antitoxins that block the circulation of toxins in the blood and prevent worsening of the disease. However, the antitoxins are expensive and not easily available. In cases of wound botulism, the area infected may be removed surgically. Additionally, good supportive care therapy is applied There remains a need for therapies to prevent and treat botulism. Antibodies targeting botulinum toxins are developed, as described e.g. in US Patent publication US20130058962, and International publication WO2015100409, the contents of each of which are herein incorporated by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by botulinum toxins.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat botulinum toxin related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 16 (SEQ ID NO: 3814-3843).

Therapeutic Applications: Neglected Tropical Diseases (NTDs)

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat infectious disease. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Tables 10-13 (SEQ ID NO: 3327-3548).

Neglected Tropical diseases (NTDs) are a diverse category of communicable diseases present in tropical and subtropical environments. NTDs affect more than one billion people in about 150 countries. NTDs are a significant public health problem costing the involved developing economies billions of dollars annually. The diseases affect mostly the populations with inadequate sanitation, and those in contact with infectious vectors, domestic animals and livestock. In May 2013, the 66^(th) WHO Assembly announced resolution WHA66.12 to integrate measures and plan investments to improve the wellbeing of populations affected by NTDs. NTDs include Buruli ulcer, Chagas disease, Dengue and Chikungunya, Dracunculiasis (guinea-worm disease). Echinococcosis, Endemic treponematoses (Yaws), Foodborne trematodiases, Human African trypanosomiasis (sleeping sickness), Leishmaniasis, Leprosy (Hansen disease), Lymphatic filariasis, Onchocerciasis (river blindness), Rabies, Schistosomiasis. Soil-transmitted helminthiases, Taeniasis/Cysticercosis and Trachoma.

Chikungunya Virus

Chikungunya virus is an arbovirus belonging to the Togoviridae family. The genome is a single-strand RNA molecule encoding four non-structural and three structural glycoproteins (C, E1, E2) (see, e.g. Caglioti et al., 2013, New Microbiol.; 36(3):211-27, and references therein). Chikungunya fever is a mosquito-borne disease caused by chikungunya virus. The symptoms include a fever lasting 2-7 days, rash and flu-like symptoms accompanied by a joint pain that may last for weeks, months or even years. The disease may be dangerous for the elderly and individuals with chronic medical problems. Chikungunya virus is spread by Aedes albopictus and Aedes aegypti. Outbreaks of chikungunya fever have occurred in Africa, Asia, Europe and Indian and Pacific Oceans, and more recently in islands in the Caribbean. As an example, according to the WHO, an outbreak of 1.9 million cases in India, Indonesia, Maldives, Myanmar and Thailand since 2005 has been reported. More recently, as of April 2015 more than million cases have reported in Caribbean Islands. Latin American countries and the United States.

As of today, there is no specific treatment or vaccination for chikungunya fever. The disease is typically treated with supportive care therapy, as well as anti-inflammatory drugs and medicines to relieve the symptoms. Research and development on vaccinations has been done but none has been approved for commercial use so far Antibodies for detection and treatment of Chikungunya have been developed. E.g. fully human antibodies binding to an epitope located in an antigenic site of the chikungunya virus E1 and E2 envelope proteins were in US Patent Publication US20130189279, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by chikungunya virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat chikungunya virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 13 (SEQ ID NO: 3543-3548).

Dengue virus

Dengue virus belongs to the family of Flaviviridae, genus of Flavivirus. It is an enveloped, positive strand RNA virus containing two integral membrane proteins envelope (E) and premembrane (prM) Dengue virus is closely related to e.g. Yellow fever. West Nile virus and St. Louis and Japanese encephalitis viruses. There are five serotypes of the virus that can cause dengue fever, which is a mosquito-borne tropical disease. Neutralizing antibodies target the protein E as it binds to the cellular receptors and mediates the viral entry into cells Infection with a serotype may produce a lifelong immunity to that serotype but no long-term immunity against other serotypes, (see e.g., Wahala and de Silva, 2011, Viruses.; 3(12): 2374-2395, and references therein). In fact, an infection by a second serotype may lead to a more severe form of disease, due to the complexity of the antibody respond and possible antibody dependent enhancement (ADE), which hypothesizes that weakly neutralizing antibodies from the first infection bind to the second serotype and enhance the infection. The symptoms of dengue fever are similar to flu, including fever, headache, muscle and joint pain and skin rash. The disease may also manifest as a potentially lethal complication called severe dengue, also known as dengue hemorrhagic fever. The disease may be dangerous to individuals with chronic diseases, such as diabetes or asthma, or children and the elderly. Dengue virus is spread by several mosquito species, out of which Aedes aegypti is the most common. Dengue may also be transmitted via infected blood or organ donation or by the vertical transmission route. According to the WHO, the estimated number of dengue infections annually could be as high as 390 million.

As of today, there is no specific treatment or prevention therapy for dengue fever. Antibodies targeting dengue virus have been developed. As an example, antibodies neutralizing four serotypes of dengue virus have been in US Patent publication US20150225474. US20150218255 and in U.S. Pat. No. 9,073,981, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by dengue virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Dengue virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 10 (SEQ ID NO: 3327-3449).

Trypanosoma cruzi

Trypanosoma cruzi (T. cruzi) is a species of parasitic euglenoid protozoan. T. cruzi causes Chagas disease, also known as American trypanosomiasis, which is a tropical parasitic disease. The symptoms of Chagas disease at the early stage include fever, swollen lymph nodes, headaches or local swelling at the site of bite. The chronic phase of Chagas starts after 8-12 weeks, which may be symptomless, or include enlargement of the ventricles of the heart, which may result in heart failure, or to an enlarged esophagus or enlarged colon. The severity of Chagas disease varies from almost unnoticeable to fatal. Chagas disease is spread by an insect vector triatomine bug. These bugs get infected with T. cruzi by feeding on the blood of an infected human or animals, and they spread it further by bites and ingestion of blood. The triatomine bug is also known as a “kissing bug” referring to its tendency to feed on people's faces T. cruzi may also be transmitted through blood transfusions or through breast milk. Chagas disease is present mainly in 12 Latin American countries, but has also spread to other continents. According The WHO, over 10 000 people die every year from Chagas disease, and 25 million people are in the risk of infection.

As of today, there is no specific prevention or treatment therapy for Chagas disease. The traditional therapies for Chagas have been involved with attempts to kill the parasite and treatment of the symptoms. For example, azole and nitro-derivative drugs have been used, but have not been successful in removal of the parasite fully. Other mechanisms to treat the disease have been under research. After infection in mammals, the parasite incorporates a charged carbohydrate (sialic acid) to survive to the chronic phase of the disease. To do so, the parasite scavenged sialic acid it from the host's sialoglycococonjugates, through a transglycosylation reaction catalyzed by an enzyme called trans-sialidase. The trans-sialidase has been identified as a potential target for drug development Buschiazzo et al. have reported an antibody inhibiting the T. cruzi trans-sialidase enzyme providing an antibody therapy mechanism for Chagas disease (see, Buschiazzo et al., 2012, PLoS Pathol. 8 (1), E1002474, and references therein).

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Chagas disease.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Chagas disease. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 12 (SEQ ID NO: 3541 and 3542).

Rabies Virus

Lyssaviruses are a genus of RNA viruses belonging to the family of Rhabdoviridae. Rabies virus is a neurotropic virus with cylindrical morphology After infection, rabies virus enters the peripheral nervous system, and further to central nervous system by retrograde axonal transport Rabies virus and Australian bat lyssavirus cause rabies Rabies affects humans and warm-blooded animals. The early stage symptoms include flu-like signs, but later the disease manifests as paralysis, anxiety, insomnia, abnormal behavior, hallucinations. Humans and animals infected may also experience hydrophobia, “fear of water”, which is considered a characteristic symptom of the disease Eventually the disease affects the central nervous system and brain, causing death. Humans are typically infected by being bitten, scratched or licked by an animal with the disease. Most commonly the infection is by dogs. Whereas efficient vaccination programs for animals have been able to reduce or even eliminate rabies in developing countries, the disease still affects poor population mainly in Africa and Asia. According to the WHO, post-bite treatment and vaccination is provided for 15 million people annually.

Rabies is a vaccine-preventable disease and especially systematic vaccination of dogs has been a cost-effective strategy for prevention of rabies. Post-exposure prophylaxis (PEP), the treatment of bite victims immediately after the exposure, includes local treatment of the wound, rabies vaccination and administration of rabies immunoglobulin. Though efficient vaccines for rabies have been developed, there remains a need for treatment/or management of rabies to prevent death after rabies virus has entered the central nervous system (see, e.g., Hicks et al., 2012, Clin Exp Immunol.; 169(3): 199-204, and references therein). The genome of rabies virus codes for five viral proteins. Out of the five. G protein, which is an external surface glycoprotein, forms protrusions that cover the outer surface of the virion envelope and is known to induce neutralizing antibodies. Also, nucleoprotein (N) molecules and the phospho-protein (NS) participate in immune responses. G protein has been the target of antibody developments. For example, therapeutic antibodies against rabies virus are taught in U.S. Pat. Nos. 7,071,319, 6,890,532, and 9,005,624, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by rabies virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat rabies virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 11 (SEQ ID NO: 3450-3540).

Therapeutic Applications: Tropical Diseases (TDs) and Vector-Borne Diseases

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat infectious disease. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Tables 10-13 (SEQ ID NO: 3327-3548).

Plasmodium falciparum

Plasmodium falciparum (P. falciparum) is a protozoan parasite belonging to Plasmodium parasite family. P. falciparum is the main cause of malaria and responsible for nearly all death cases in malaria. P. falciparum is released to the human bloodstream through mosquito saliva. The parasite has a high rate of replication and capability to alter. P. falciparum, among other Plasmodium parasites, cause malaria, which is a mosquito borne tropical disease. The early stage symptoms include fever, headache, chills and vomiting. If not treated at the early stage, malaria can progress to a life-threatening condition involving multiple organs, resulting in skin yellowing, seizures and coma. In children, malaria may cause severe anemia, respiratory distress in relation to metabolic acidosis, and/or cerebral malaria. The disease is especially dangerous for young children, pregnant women and individuals without immunity to the disease, such as travelers from non-malaria areas. An infection may develop a partial immunity, allowing the following infections to be asymptomatic According to the WHO, about half of world's population are at risk of malaria. Sub-Saharan Africa carries the highest density of malaria. In 2015, 88% of malaria cases and 90% of malaria deaths was in Sub-Saharan Africa Malaria is spread by female Anopheles mosquitos and caused by 5 different parasite species, out of which Plasmodium falciparum is the most prevalent and responsible for the severe cases of malaria.

Despite tremendous efforts, there is no commercial vaccination for malaria. Traditional treatment for malaria consists of antimalarial medicine therapies, such as artemisinin-based combination therapies, which consists of artemisinin combined with antimalarial drugs such as amodiaquine, lumefantrine, mefloquine and sulfadoxine/pyrimethamine. However, drug resistance has been a serious challenge in malaria treatment. Currently resistance is common for all antimalarial medications apart from artemisinin combination therapy. The cost of artemisinin treatment is high and there remains a need for prevention therapies and improved treatment against malaria.

Due to the polymorphic nature and high replication rate of P. falciparum, tolerance to malaria is achieved only after years of repeated infections Antibodies for prevention and treatment of malaria have been developed. For example, antibodies against P. falciparum are taught in U.S. Pat. No. 7,811,569, in US Patent publication US20150197562 and in International Patent publication WO2014087007, the contents of each of which are incorporated herein by reference in their entirety. A need for mechanism to deliver constant, effective concentration of malaria antibody for a long period is still in need Studies by Deal et al, demonstrate results on vectored immunoprophylaxis delivery of malaria antibodies to mice (see. Deal et al. PNAS, 2014, 111(34), 12528-12532).

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by P. falciparum.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat P. falciparum related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 18 (SEQ ID NO: 3915-3971).

Ebola Virus

Genus of Ebola virus includes five viruses. Zaire, Reston, Sudan. Tai Forest and Bundibygvo Ebola viruses, is a negative-sense RNA virus belonging to the family of filoviridae. The West Africa outbreak has been associated with Zaire Ebola virus. The genome of Ebolavirus encodes seven genes. The glycoprotein GP gene encodes two distinct gene products: sGP which is a dimeric and secreted glycoprotein and less abundant GP, which is a trimeric-virion attached, membrane embedded envelope glycoprotein and responsible for the virus attachment, fusion and entry during infection. Ebola virus disease is a hemorrhagic fever disease caused. The early symptoms include fever, sore throat, muscular pain, followed by a diarrhea and rash. Eventually the disease will affect the liver and kidney function, and cause internal bleeding. The disease is highly fatal, as about 50% infected individuals die. The Ebola virus is transmitted by direct contact with the blood and body fluids and tissues of an infected person or an animal, most commonly a chimpanzee, gorilla, fruit bat, monkey, forest antelope and porcupine. The disease is also transmitted when handling dead bodies of infected animals or humans. Also, sexual transmittance of the disease has been suggested. The WHO has reported more than 28 000 infections and 11 000 deaths in Ebola virus disease outbreak in West Africa (2014-present), mainly affecting Guinea, Sierra Leone and Liberia.

As of today, there is no licensed treatment or prevention therapy proven to neutralize the virus. Typically. Ebola virus disease is treated with a good supportive care. A variety of blood, immunological and drug therapies are under investigation, as well as preventive vaccines undergoing evaluations. However, a demand for effective therapies for treatment and prevention of Ebola virus disease remain.

Viral surface of GP has been identified as a target for neutralizing antibodies. Antibodies targeting GP of Ebola virus have been taught, e.g. in International Patent publication WO2015127136 and Olal. D., et al., 2012. J. Virol. 86 (5), 2809-2816, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Ebola virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Ebola related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 19 (SEQ ID NO: 3972-4024).

Marburg Virus

Marburg virus belongs to the filoviridae family of viruses with coiled, toroid or branched structures with seven proteins. The structure of Marburg virus is similar to Ebola virus, however, the involved antigens are different. The filoviruses express a single glycoprotein on their surface. The glycoprotein is responsible for the infection, as it is involved in the attachment and entry of the viruses causing infection. Marburg virus disease is a hemorrhaging fever disease caused by Marburg virus. It is highly fatal disease and related to Ebola virus diseases. The early symptoms of the disease include severe headache and malaise. Severe hemorrhagic manifestations in later stages include bleeding from multiple sites. The Marburg virus is transmitted by direct contact with the blood and body fluids and tissues of infected persons or animals, most commonly fruit bats and monkeys. The disease is also transmitted when handling dead the bodies of infected animals or humans. Marburg virus disease is uncommon, but outbreaks typically have a high rate of fatality. According to the WHO, the death rate was as high 80% in outbreaks of 1998-2000 in Democratic Republic of Congo and 2005 in Angola.

As of today, there is no preventive or treatment therapy for Marburg virus disease. The current treatment methods include good supportive treatment. The surface glycoprotein has been a target for development of antibodies for Marburg disease vaccines and treatments. For example, International Patent publication WO02015127140, and US Patent publication US20140356354, the contents of which are incorporated herein by reference in their entirety, teach therapeutic antibodies that recognize glycoprotein of filoviruses for different strains of Marburg, as well as Ebola.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Marburg virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Marburg related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Tables 3-42 (SEQ ID NO: 2948-9220).

West Nile Virus

West Nile virus (WNV) is a positive-stranded RNA of the flavivirus genome and member of the Japanese encephalitis serocomplex of flaviviruses. (see Throsby, M. J. Virol. 80 (14), 6982-6992 (2006)). Two lineages of the virus have been identified. The genome of the virus encodes a single polyprotein producing three structural proteins, capsid C, precursor membrane prM and envelope E as well as seven nonstructural proteins. WNV causes mosquito-borne infections with a variety of manifestations. Tough about 80% of WNV infections are symptomless and not harmful, in certain cases, the disease may lead to fatal neurological diseases. Infection of MNV may lead to a West Nile fever, which causes flu-like symptoms accompanied by high fever, headache, chills, excessive sweating, fatigue, weakness, swollen lymph nodes, and joint pains Infection by MNV may also occur as cutaneous manifestations, including rashes that may include punctate erythematous, macular and popular eruptions. West Nile infections may also affect the central nervous system resulting in West Nile neuroinvasive diseases, including meningitis, encephalitis, meningoencephalitis and poliomyelitis-like syndrome. These neuroinvasive forms of NWV infections occur in only about 1% of infections, but they may be life-threatening. WNV is commonly found in Africa. Europe, the Middle East. North America and West Asia. WNV is typically transmitted to humans and other mammals by mosquitos and is maintained in nature in a cycle involving transmission between birds and mosquitoes WNV is carried by different types of mosquitos, dependent on geographical distribution. Transmission to humans may also occur from birds, horses or other humans.

As of today, there is no specific treatment or prevention therapy for MNV infections. Current methods of treatment include good supportive care. Due to severity of some of the manifestations, there remains a need for such therapies. Envelope E has been a target of most antibody related studies. Antibodies targeting M and the first non-structural protein have also been investigated. As an example. Thorsby et al, 2006, J. Virol. 80 (14), 6982-6992, the contents of which are incorporated herein by reference in their entirety, teaches antibodies binding to E and prM proteins. U.S. Pat. Nos. 8,663,950 and 7,527,973, the contents of each of which are incorporated herein by reference in their entirety, teach antibodies binding to E protein of WNV.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by West Nile virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat West Nile virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442, 4025-4137).

Yellow Fever Virus

Yellow fever virus is an enveloped RNA virus belonging to the Flavivirus family Yellow fever, also known as Yellow Jack. Yellow Plague or Bronze John, is a mosquito-borne viral hemorrhagic disease. In most cases, the symptoms include fever, headache, chills, loss of appetite, nausea, and muscle pain. In some occasions, the disease progresses to a second stage which includes fever accompanied by abdominal pains, liver damage resulting in jaundice, kidney problems and/or bleeding. The disease is spread primarily by Aedes and Haemogogus type mosquitos. The disease is most typical in tropical environments. According to the WHO, there are 200 000 annual cases of yellow fever resulting in 30 000 deaths mainly in Africa and Latin America, 90% of cases occur in Africa.

Preventive live-attenuated vaccines for yellow fever are available. However, concern related to post-vaccine adverse events has decreased the popularity of the vaccines. The vaccination is not recommended to infants younger than 9 months, pregnant women and individuals with an immune deficiency. As of today, there is no specific treatment for yellow fever. Current methods for treatment involve with supportive care to treat dehydration, respiratory failure and fever There is a need for improved prevention and treatment therapies against yellow fever virus.

Envelope E glycoprotein of yellow fever virus has been identified as a potential target for antibody therapies. Neutralizing antibodies for yellow fever virus have been reported by Thibodeaux, B. A. et al, 2012, Antiviral Res. 94 (1), 1-8 and Daffis, S. et al., 2005, Virology, 337 (2), 262-272, the contents of each of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by yellow fever virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat yellow fever virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442, 4025-4137)

Japanese Encephalitis Virus

Japanese encephalitis virus is an enveloped positive sense single-stranded RNA virus belonging to Flavivirus family and closely related to St. Louis encephalitis and West Nile virus. The virus causes Japanese encephalitis, also known as Japanese B encephalitis. In majority of cases, the disease is symptomless. However, in less than 1% of infections, the disease leads to a life-threatening encephalitis. The early stage symptoms include fever, headache and malaise. As the disease progresses into an acute encephalitis, the symptoms include neck rigidity, cachexia, hemiparesis, convulsions and fever, accompanied by lifelong neurological problems such as deafness, and/or mental retardation. The disease is transmitted to humans via mosquitos of the Culex species. The virus exists in a transmission cycle between mosquitos, pigs, and water birds. The disease affects 24 countries in the South-East Asia and Western Pacific. According to the WHO, an estimated 68 000 clinical cases are reported annually, with case-fatality rate as high as 30%. Major outbreaks of the disease occur every 2-15 years.

The disease may be prevented by a vaccination, most common vaccination being a live attenuated vaccine. In general, the vaccines initially show high effectiveness, but the protection decreases over time. As of today, there is no specific treatment for the disease. Current treatment therapies include good supportive care. There remains a need for longer lasting, improved prevention therapies, and treatment for Japanese encephalitis virus infections.

Antibodies for treatment of Japanese encephalitis have been developed. For example, Hsieh et al, teach antibodies that target cellular receptors and interrupts their function in flavivirus infections in US Patent publication US20080292644, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Japanese encephalitis virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Japanese encephalitis virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442, 4025-4137).

St. Louis Encephalitis Virus

St. Louis encephalitis virus is a positive-stranded RNA virus and member of the Flavivirus family and closely related to Japanese encephalitis virus St Louis encephalitis is a mosquito-borne disease caused by the virus. In majority of cases, the disease is symptomless. However, in less than 1% of the cases, the disease may lead to encephalitis, which may be life-threatening, especially for the elderly. The early stage symptoms include fever, headache, dizziness, malaise and nausea. If the disease progresses to the central nervous system, symptoms include stiff neck, confusion, disorientation, dizziness, tremor and unsteadiness, and in severe cases coma or even death. St. Louis encephalitis virus is transmitted to humans through Culex mosquitos. The virus exists in a transmission cycle between mosquitos and birds. The disease mainly affects the USA, especially eastern and central states. The disease has also spread to Canada and Mexico.

As of today, there is no vaccine or specific treatment for St. Louis encephalitis. Current treatment therapies include good supportive care. There is a demand for preventive and treatment therapies for the disease. Neutralizing antibodies for St. Louis encephalitis virus have been reported in Thibodeaux, B. A. et al, 2012, Antiviral Res 94 (1), 1-8 and Daffis, S. et al., 2005, Virology 337 (2), 262-272, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by St. Louis encephalitis virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat St. Louis encephalitis virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 20 (SEQ ID NO: 3333, 3359, 3393, 3418, 3442, 4025-4137).

Therapeutic Application: Foodborne Illness and Gastroenteritis

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat infectious disease. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Tables 3-9 (SEQ ID NO: 2948-3326).

Foodborne illnesses, also known as food poisoning, are a common and costly public health problem. The illnesses are typically transmitted by the fecal-oral-route. The transmission to humans is by consuming contaminated food or beverage More than 250 different foodborne diseases, mostly infections caused by viruses, bacteria, parasites or fungus, are identified by the CDC, CDC estimates that approximately 48 million individuals are affected by foodborne illnesses annually in the United States. Gastroenteritis is an inflammation of the gastrointestinal tract involving stomach and small intestine. Gastroenteritis is also caused by an infection caused by viruses, bacteria, parasites or fungus. The transmission to humans is by person-to-person contact, or by consuming contaminated food or beverage. Foodborne illnesses and gastroenteritis have similar symptoms including diarrhea, vomiting, abdominal pain, dehydration. In some cases, the diseases may require hospitalization or be fatal. Both illnesses are best prevented by proper hand hygiene, proper hygiene while preparing food, treatments to kill bacteria such as pasteurizing, cooking or heating food, and proper methods to store food.

Rotavirus

Rotavirus is a double-stranded RNA virus belonging to the family of Reoviridae. The rotavirus genome consists of 10 segments coding for a single protein, and segment 11 coding for two proteins. The virions are non-enveloped, triple-layered and icosahedral in structure (see, e.g. Aiyegbo et al., 2013, Plos One 8, 61101, and references therein). The virus is spread by the fecal-oral-route. Rotavirus is very common especially among infants and young children and spreads easily. Almost all children worldwide are infected with rotavirus by the age of 5, and the disease leads to death of half a million children annually. Rotavirus causes rotavirus gastroenteritis with symptoms including nausea, vomiting, diarrhea and fever. Rotavirus is associated with dehydration. The disease is milder in adults and more severe in young children, infants and the elderly. Though infection does not provide full immunity to the virus, the first infection is typically the most severe in symptoms.

As of today, there is no specific treatment rotavirus infections. Present treatment includes good supportive care including drinking of fluids to prevent dehydration. In severe cases, the rotavirus gastroenteritis requires hospital care e.g. treatment with intravenous fluids. Vaccines for prevention of the disease have been developed and CDC recommends rotavirus vaccination for infants as part of the routine vaccinations There remains a need for medical treatment therapies for the infection. Development has been done in the field of antibodies. E.g. Aiyegbo et al., in Plos One 8, 61101 (2013, teach antibodies targeting the intermediate capsid layer of VP6 of the triple-layered particle and Frenken et al, teach anti-rotavirus antibodies in U.S. Pat. No. 8,105,592, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by rotavirus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat rotavirus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 8 (SEQ ID NO: 3286-3310).

Norwalk Virus/Norovirus

Norwalk virus, also known as winter vomiting bug, is the only member of genus norovirus belonging to the family of Caliciviridae Norwalk virus is a single-stranded RNA with three open-reading frames that encode a polyprotein precursor to non-structural proteins, and two polypeptides of different sizes (see e.g. Jiang et al., 1993, Virology; 195(1):51-61, and references therein) Norwalk virus is spread by the fecal-oral-route Norwalk virus is extremely contagious and can be transmitted through contaminated food or drink, touching contaminated surfaces or objects or from a contact with an infected individual. The Norwalk virus causes an inflammation of stomach and/or intestines. The symptoms associated with the infection include stomach pain, nausea, vomiting and diarrhea. The disease can be dangerous, especially for your children or young adults. According to CDC, every year 19-21 million infections occur leading to 570-800 deaths in the US.

As of today, there is no vaccine or specific treatment for Norwalk virus associated gastroenteritis. Antibodies for prevention and treatment of Norwalk virus have been developed. For example, International Patent publication WO2014126921 and WO2014183052, the contents of each of which are incorporated herein by reference in their entirety, teach neutralizing antibodies binding to the polypeptides of Norwalk virus.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by Norwalk virus.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat Norwalk virus related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 7 (SEQ ID NO. 3238-3285).

Campylobacter jejuni

Campylobacter jejuni (C. jejuni) is an oxidase-positive, catalase-positive, nonfermentative Gram-negative bacteria with a helical shape. The C. jejuni inhabits in the intestinal tract of animals (e.g. poultry, cattle, pigs, sheep, ostriches and shellfish), and in pets (e.g. cats and dogs). The bacteria may be transmitted to humans foodborne, e.g, when eating contaminated food or drink, such as unpasteurized milk. According to the WHO, campylobacter is the most common cause of gastroenteritis worldwide C. jejuni causes campylobacteriosis infection. The typical symptoms include diarrhea with blood in the feces, abdominal pain, fever, headache, nausea and/or vomiting. The infection may be dangerous to young children, the elderly and individuals with immunodeficiency and is most abundant with malnourished children. C. jejuni infections have been associated with severe long-term complications such as Guillain-Barre Syndrome, inflammatory bowel disease and reactive arthritis (see, e.g., Platts-Mills and Kosek, 2014, Curr Opin Infect Dis; 27(5): 444-450, and references therein).

Typically, C. jejuni infection does not require specific treatment in addition to good supportive care. In more severe cases, in humans and in poultry, the infection has been treated with antibiotics such as fluoroquinoles and macrolides. However, spread of antibiotic-resistant strains is an increasing concern. The treatment with antibiotics is recommended in cases where the bacteria has invaded the intestinal mucosa cell and damaged the tissues, or to eliminate the carrier state. There remains a need for prevention therapies, as well as improved, non-antibiotic, therapies for treatment of the infection Antibodies targeting C. jejuni have been taught e.g. in International Patent publication WO2014063253, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by C. jejuni.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat C. jejuni related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 4 (SEQ ID NO: 3089-3098).

Clostridium difficile

Clostridium difficile bacteria (C. difficile) is a Gram-positive, anaerobic spore-forming bacteria belonging to the genus of Clostridium. C. difficile inhabits in the soil. C. difficile produces toxins, most commonly enterotoxin A and cytotoxin B. Toxins A and B both have a C-terminal receptor-binding domain containing repeating sequences, a central hydrophobic domain and N-terminal glucosyltranferase domain. The toxins bind to the intestinal epithelial cells leading to glucosylation of target Rho GTPases, disruption of the cytoskeleton and cell death. C. difficile toxins A and B are a common cause C. difficile associated diarrhea and Clostridium difficile colitis, which is an inflammation of the large intestine. Typical symptoms of the colitis include flu-like symptoms, bloating, diarrhea, and/or abdominal pain. The disease may lead to dehydration, kidney failure, bowel perforation, toxic megacolon resulting in colon rupture. The elderly and individuals with a weakened immunity are more susceptible to severe and recurring infections which can be life-threatening. C. difficile is transmitted by the fecal-oral-route. Due to the ability to form heat-resistant spores, the bacteria is not killed by alcohol-based cleansers or routine surface cleaning. The bacteria may be cultured on almost any surface and survives in clinical environments, such as hospitals. C. difficile is one of the most common and severe healthcare-associated infections. According to CDC, an estimated about half a million infections occur in the United States annually. In 2011, 29, 000 deaths related to C. difficile were reported.

Currently C. difficile infections are treated with antibiotics such as vanconmycin and metronidazole. However, increasing an antibiotic-resistance to the bacteria is a concern. Especially in cases of recurring infections, antibiotic treatments have an incomplete response and they disrupt the normal colonic flora. There remains a need for prevention and improved treatment therapies for the infection. Antibodies targeting C. difficile have been developed. For example, actoxumab and bezlotoxumab (developed by Medarex Inc and the University of Massachusetts Medical School) are human monoclonal antibodies targeting C. difficile toxin A and toxin B, respectively. The antibodies may be administered as a combination for the prevention of recurring C. difficile infection.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by C. difficile.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat C. difficile related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 3 (SEQ ID NO: 2948-3088).

Entamoeba histolytica

Entamoeba histolytica (E. histolytica) is an anaerobic one-celled parasite protozoan belonging to the genus of Entamoeba. The active stage of the protozoan exists only in the host and in fresh feces. Cysts survive outside the host in water, soil and food in moist conditions. E. histolytica causes an infection called amebiasis, also known as ameobiasis or entamoebiasis. In majority of cases, amebiasis is symptomless. In 10-20% of individuals infected have symptoms that include loose feces, stomach pain and cramping. The severe more form of amebiasis called amebic dysentery is associated with stomach pain, blood stools and fever. In rare cases. E. histolytica invades the liver, forms an abscess and may spread to other parts of the body, such as the lungs or brain. The transmission to humans is mostly via the fecal-oral-route. The disease is typically caused by ingestion of mature cysts in contaminated food, water or via hands. The disease may also be transmitted in close person-to-person contact, e.g. sexual contact. E. histolytica infections are most common in tropical areas and especially in poor sanitary conditions. It is estimated that 50 million cases of amebiasis occur annually, leading to 100, 000 deaths.

As of today, there are no preventive vaccines for E. histolytica infections, though cellular immunity is important for the prevention of liver invasive amebiasis. Amebiasis is typically treated with amebicides, which are medicines targeting E. histolytica at specific parts of the body, e.g. the intestine tissue or liver. Optionally, the treatment may involve one or more antibiotics, as well as steroids. However, increasing antibiotic-resistance of E. histolytica is a concern. There remains a need for prevention therapy as well as for improved treatments. Antibodies targeting E. histolytica are taught in, e.g., 2009, Infect. Immun.; 77(1): 549-556, and Tachibana et al., 1999, Clin Diagn Lab Immunol.; 6(3):383-7, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by E. histolytica.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat E. histolytica related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 9 (SEQ ID NO: 3311-3326).

Helicobacter pylori

Helicobacter pylori (H. pylori) is a Gram-negative, spiral-shaped microaerophilic bacterium. H. pylori infection is typically asymptomatic and is suggested to be transmitted through the fecal-oral route or oral-oral route. According to CDC, two-thirds of the world's population is infected with H. pylori. The infection may cause chronic active, chronic, persistent, and atrophic gastritis, duodenal and gastric ulcers and is associated with cancer. CDC reposts 25 million Americans suffering from an ulcer during their lifetime. Typical symptoms associated with ulcer are gnawing or burning pain in the epigastrium, especially between meals. Additional symptoms include nausea, vomiting, loss of appetite, internal bleeding leading to anemia and fatigue.

Typical treatment for H. pylori infection involves antibiotics. Increasing antibiotic resistance and patient noncompliance are major challenges associated with the antibiotic treatment. There remains a need for improved, non-antibiotic, treatment and prevention therapies targeting H. pylori. Antibodies targeting H. pylori infection have been developed. For example. Boren et al, teach antibodies targeting the BAbA antigen expressed by H. pylori in US patent U.S. Pat. No. 8,025,880, the contents of which are incorporated herein by reference in their entirety.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by H. pylori.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat H. pylori related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 5 (SEQ ID NO: 3099-3196).

Enterotoxin B

Enterotoxin B is a toxin produced by certain strains of Gram-positive bacteria Staphylococcus aureus and is a common cause for food poisoning. Staphylococcus species thrive and produce toxins in unrefrigerated meats, dairy, and bakery products. The symptoms associated with enterotoxin B infection are severe diarrhea, nausea and intestinal cramping. The toxin may remain active in the human body after the bacteria has been killed. Enterotoxin B is a so-called superantigen. Superantigens are toxins that may activate T cells by forming a bridge between a MHC II on antigen presenting cells (APCs) and the T cell receptors (TCR). Due to binding of enterotoxin B, the T cells release large amount of cytokines leading to an inflammation and gastroenteritis. Though enterotoxin B infection is typically not life threatening, enterotoxin B has been identified as a potential chemical and biological warfare agent.

As of today, there is no specific prevention or treatment for enterotoxin B infection. Antibodies that neutralize enterotoxin B have been investigated, e.g. as described in U.S. Pat. No. 8,895,704.

In some embodiment, methods of the present invention may be used to prevent, manage and/or treat infections and complications caused by enterotoxin B.

AAV particles and methods of using the AAV particles described in the present invention may be used to prevent, manage and/or treat enterotoxin B related infections and/or conditions. As a non-limiting example, the AAV particles of the present invention comprise a nucleic acid sequence encoding at least one of the sequences described in Table 5 (SEQ ID NO: 3099-3196).

V. Kits and Devices

Kits

In one embodiment, the invention provides a variety of kits for conveniently and/or effectively carrying out methods of the present invention. Typically, kits will comprise sufficient amounts and/or numbers of components to allow a user to perform multiple treatments of a subject(s) and/or to perform multiple experiments.

Any of the AAV particles of the present invention may be comprised in a kit. In some embodiments, kits may further include reagents and/or instructions for creating and/or synthesizing compounds and/or compositions of the present invention. In some embodiments, kits may also include one or more buffers. In some embodiments, kits of the invention may include components for making protein or nucleic acid arrays or libraries and thus, may include, for example, solid supports.

In some embodiments, kit components may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there is more than one kit component. (labeling reagent and label may be packaged together), kits may also generally contain second, third or other additional containers into which additional components may be separately placed. In some embodiments, kits may also comprise second container means for containing sterile, pharmaceutically acceptable buffers and/or other diluents. In some embodiments, various combinations of components may be comprised in one or more vial. Kits of the present invention may also typically include means for containing compounds and/or compositions of the present invention, e.g., proteins, nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which desired vials are retained.

In some embodiments, kit components are provided in one and/or more liquid solutions. In some embodiments, liquid solutions are aqueous solutions, with sterile aqueous solutions being particularly preferred. In some embodiments, kit components may be provided as dried powder(s). When reagents and/or components are provided as dry powders, such powders may be reconstituted by the addition of suitable volumes of solvent. In some embodiments, it is envisioned that solvents may also be provided in another container means. In some embodiments, labeling dyes are provided as dried powders. In some embodiments, it is contemplated that 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600, 700, 800, 900, 1000 micrograms or at least or at most those amounts of dried dye are provided in kits of the invention. In such embodiments, dye may then be resuspended in any suitable solvent, such as DMSO.

In some embodiments, kits may include instructions for employing kit components as well the use of any other reagent not included in the kit. Instructions may include variations that may be implemented.

Devices

In one embodiment, the AAV particles may delivered to a subject using a device to deliver the AAV particles and a head fixation assembly. The head fixation assembly may be, but is not limited to, any of the head fixation assemblies sold by MRI interventions. As a non-limiting example, the head fixation assembly may be any of the assemblies described in U.S. Pat. Nos. 8,099,150, 8,548,569 and 9,031,636 and International Patent Publication Nos. WO201108495 and WO2014014585, the contents of each of which are incorporated by reference in their entireties. A head fixation assembly may be used in combination with an MRI compatible drill such as, but not limited to, the MRI compatible drills described in International Patent Publication No. WO2013181008 and US Patent Publication No US20130325012, the contents of which are herein incorporated by reference in its entirety.

In one embodiment, the AAV particles may be delivered using a method, system and/or computer program for positioning apparatus to a target point on a subject to deliver the AAV particles. As a non-limiting example, the method, system and/or computer program may be the methods, systems and/or computer programs described in U.S. Pat. No. 8,340,743, the contents of which are herein incorporated by reference in its entirety. The method may include: determining a target point in the body and a reference point, wherein the target point and the reference point define a planned trajectory line (PTL) extending through each; determining a visualization plane, wherein the PTL intersects the visualization plane at a sighting point; mounting the guide device relative to the body to move with respect to the PTL, wherein the guide device does not intersect the visualization plane; determining a point of intersection (GPP) between the guide axis and the visualization plane; and aligning the GPP with the sighting point in the visualization plane.

In one embodiment, the AAV particles may be delivered using an MRI-guided device Non-limiting examples of MRI-guided devices are described in U.S. Pat. Nos. 9,055,884, 9,042,958, 8,886,288, 8,768,433, 8,396,532, 8,369,930, 8,374,677 and 8,175,677 and US Patent Application No. US20140024927 the contents of each of which are herein incorporated by reference in their entireties. As a non-limiting example, the MRI-guided device may be able to provide data in real time such as those described in U.S. Pat. Nos. 8,886,288 and 8,768,433, the contents of each of which is herein incorporated by reference in its entirety. As another non-limiting example, the MRI-guided device or system may be used with a targeting cannula such as the systems described in U.S. Pat. Nos. 8,175,677 and 8,374,677, the contents of each of which are herein incorporated by reference in their entireties. As yet another non-limiting example, the MRI-guided device includes a trajectory guide frame for guiding an interventional device as described, for example, in U.S. Pat. No. 9,055,884 and US Patent Application No. US20140024927, the contents of each of which are herein incorporated by reference in their entireties.

In one embodiment, the AAV particles may be delivered using an MRI-compatible tip assembly. Non-limiting examples of MRI-compatible tip assemblies are described in US Patent Publication No. US20140275980, the contents of which is herein incorporated by reference in its entirety.

In one embodiment, the AAV particles may be delivered using a cannula which is MRI-compatible. Non-limiting examples of MRI-compatible cannulas include those taught in International Patent Publication No. WO2011130107, the contents of which are herein incorporated by reference in its entirety.

In one embodiment, the AAV particles may be delivered using a catheter which is MRI-compatible. Non-limiting examples of MRI-compatible catheters include those taught in International Patent Publication No. WO02012116265, U.S. Pat. No. 8,825,133 and US Patent Publication No. US20140024909, the contents of each of which are herein incorporated by reference in their entireties.

In one embodiment, the AAV particles may be delivered using a device with an elongated tubular body and a diaphragm as described in US Patent Publication Nos US20140276582 and US20140276614, the contents of each of which are herein incorporated by reference in their entireties.

In one embodiment, the AAV particles may be delivered using an MRI compatible localization and/or guidance system such as, but not limited to, those described in US Patent Publication Nos. US20150223905 and US20150230871, the contents of each of which are herein incorporated by reference in their entireties. As a non-limiting example, the MRI compatible localization and/or guidance systems may comprise a mount adapted for fixation to a patient, a targeting cannula with a lumen configured to attach to the mount so as to be able to controllably translate in at least three dimensions, and an elongate probe configured to snugly advance via slide and retract in the targeting cannula lumen, the elongate probe comprising at least one of a stimulation or recording electrode.

In one embodiment, the AAV particles may be delivered to a subject using a trajectory frame as described in US Patent Publication Nos. US20150031982 and US20140066750 and International Patent Publication Nos. WO2015057807 and WO2014039481, the contents of each of which are herein incorporated by reference in their entireties.

In one embodiment, the AAV particles may be delivered to a subject using a gene gun.

VI. Definitions

At various places in the present specification, substituents of compounds of the present disclosure are disclosed in groups or in ranges. It is specifically intended that the present disclosure include each and every individual subcombination of the members of such groups and ranges.

About: As used herein, the term “about” means+/−10% of the recited value.

Adeno-associated virus. The term “adeno-associated virus” or “AAV” as used herein refers to members of the dependovirus genus comprising any particle, sequence, gene, protein, or component derived therefrom.

AAV Particle: As used herein, an “AAV particle” is a virus which comprises a viral genome with at least one payload region and at least one ITR region, AAV vectors of the present disclosure may be produced recombinantly and may be based on adeno-associated virus (AAV) parent or reference sequences, AAV particle may be derived from any serotype, described herein or known in the art, including combinations of serotypes (i.e., “pseudotyped” AAV) or from various genomes (e.g., single stranded or self-complementary). In addition, the AAV particle may be replication defective and/or targeted.

Activity: As used herein, the term “activity” refers to the condition in which things are happening or being done. Compositions of the invention may have activity and this activity may involve one or more biological events.

Administered in combination: As used herein, the term “administered in combination” or “combined administration” means that two or more agents are administered to a subject at the same time or within an interval such that there may be an overlap of an effect of each agent on the patient. In some embodiments, they are administered within about 60, 30, 15, 10, 5, or 1 minute of one another. In some embodiments, the administrations of the agents are spaced sufficiently closely together such that a combinatorial (e.g., a synergistic) effect is achieved.

Amelioration: As used herein, the term “amelioration” or “ameliorating” refers to a lessening of severity of at least one indicator of a condition or disease. For example, in the context of neurodegeneration disorder, amelioration includes the reduction of neuron loss.

Animal: As used herein, the term “animal” refers to any member of the animal kingdom. In some embodiments. “animal” refers to humans at any stage of development. In some embodiments, “animal” refers to non-human animals at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g. a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, and worms. In some embodiments, the animal is a transgenic animal, genetically-engineered animal, or a clone.

Antibody: As used herein, the term “antibody” is referred to in the broadest sense and specifically covers various embodiments including, but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies formed from at least two intact antibodies), and antibody fragments (e.g., diabodies) so long as they exhibit a desired biological activity (e.g., “functional”). Antibodies are primarily amino-acid based molecules but may also comprise one or more modifications (including, but not limited to the addition of sugar moieties, fluorescent moieties, chemical tags, etc.). Non-limiting examples of antibodies or fragments thereof include V_(H) and V_(L) domains, scFvs, Fab, Fab′, F(ab′)₂, Fv fragment, diabodies, linear antibodies, single chain antibody molecules, multispecific antibodies, bispecific antibodies, intrabodies, monoclonal antibodies, polyclonal antibodies, humanized antibodies, codon-optimized antibodies, tandem scFv antibodies, bispecific T-cell engagers, mAb2 antibodies, chimeric antigen receptors (CAR), tetravalent bispecific antibodies, biosynthetic antibodies, native antibodies, miniaturized antibodies, unibodies, maxibodies, antibodies to senescent cells, antibodies to conformers, antibodies to disease specific epitopes or antibodies to innate defense molecules.

Antibody-based composition: As used herein, “antibody-based” or “antibody-derived” compositions are monomeric or multi-meric polypeptides which comprise at least one amino-acid region derived from a known or parental antibody sequence and at least one amino acid region derived from a non-antibody sequence, e.g., mammalian protein.

Approximately: As used herein, the term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).

Associated with: As used herein, the terms “associated with.” “conjugated.” “linked.” “attached.” and “tethered.” when used with respect to two or more moieties, means that the moieties are physically associated or connected with one another, either directly or via one or more additional moieties that serves as a linking agent, to form a structure that is sufficiently stable so that the moieties remain physically associated under the conditions in which the structure is used, e.g. physiological conditions. An “association” need not be strictly through direct covalent chemical bonding. It may also suggest ionic or hydrogen bonding or a hybridization based connectivity sufficiently stable such that the “associated” entities remain physically associated.

Bifunctional. As used herein, the term “bifunctional” refers to any substance, molecule or moiety which is capable of or maintains at least two functions. The functions may effect the same outcome or a different outcome. The structure that produces the function may be the same or different.

Biocompatible: As used herein, the term “biocompatible” means compatible with living cells, tissues, organs or systems posing little to no risk of injury, toxicity or rejection by the immune system.

Biodegradable: As used herein, the term “biodegradable” means capable of being broken down into innocuous products by the action of living things.

Biologically active: As used herein, the phrase “biologically active” refers to a characteristic of any substance that has activity in a biological system and/or organism. For instance, a substance that, when administered to an organism, has a biological effect on that organism, is considered to be biologically active. In particular embodiments, an AAV particle of the present invention may be considered biologically active if even a portion of the encoded payload is biologically active or mimics an activity considered biologically relevant.

Capsid: As used herein, the term “capsid” refers to the protein shell of a virus particle.

Chimeric antigen receptor (C4R). As used herein, the term “chimeric antigen receptor” or “CAR” refers to an artificial chimeric protein comprising at least one antigen specific targeting region (ASTR), a transmembrane domain and an intracellular signaling domain, wherein the antigen specific targeting region comprises a full-length antibody or a fragment thereof. As a non-limiting example the ASTR of a CAR may be any of the antibodies listed in Tables 3-42, antibody-based compositions or fragments thereof. Any molecule that is capable of binding a target antigen with high affinity can be used in the ASTR of a CAR, The CAR may optionally have an extracellular spacer domain and/or a co-stimulatory domain. A CAR may also be used to generate a cytotoxic cell carrying the CAR.

Complementary and substantially complementary: As used herein, the term “complementary” refers to the ability of polynucleotides to form base pairs with one another. Base pairs are typically formed by hydrogen bonds between nucleotide units in antiparallel polynucleotide strands. Complementary polynucleotide strands can form base pair in the Watson-Crick manner (e.g., A to T, A to U, C to G), or in any other manner that allows for the formation of duplexes. As persons skilled in the art are aware, when using RNA as opposed to DNA, uracil rather than thy mine is the base that is considered to be complementary to adenosine However, when a U is denoted in the context of the present invention, the ability to substitute a T is implied, unless otherwise stated. Perfect complementarity or 100% complementarity refers to the situation in which each nucleotide unit of one polynucleotide strand can form hydrogen bond with a nucleotide unit of a second polynucleotide strand. Less than perfect complementarity refers to the situation in which some, but not all, nucleotide units of two strands can form hydrogen bond with each other. For example, for two 20-mers, if only two base pairs on each strand can form hydrogen bond with each other, the polynucleotide strands exhibit 10% complementarity. In the same example, if 18 base pairs on each strand can form hydrogen bonds with each other, the polynucleotide strands exhibit 90% complementarity. As used herein, the term “substantially complementary” means that the siRNA has a sequence (e.g., in the antisense strand) which is sufficient to bind the desired target mRNA, and to trigger the RNA silencing of the target mRNA.

Compound Compounds of the present disclosure include all of the isotopes of the atoms occurring in the intermediate or final compounds. “Isotopes” refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium.

The compounds and salts of the present disclosure can be prepared in combination with solvent or water molecules to form solvates and hydrates by routine methods.

Comprehensive Positional Evolution (CPE™): As used herein, the term “comprehensive positional evolution” refers to an antibody evolution technology that allows for mapping of the effects of amino acid changes at every position along an antibody variable domain's sequence. This comprehensive mutagenesis technology can be used to enhance one or more antibody properties or characteristics.

Comprehensive Protein Synthesis (CPS™): As used herein, the term “comprehensive protein synthesis” refers to a combinatorial protein synthesis technology that can be used to optimize antibody properties or characteristics by combining the best properties into a new, high-performance antibody.

Conditionally active: As used herein, the term “conditionally active” refers to a mutant or variant of a wild-type polypeptide, wherein the mutant or variant is more or less active at physiological conditions than the parent polypeptide. Further, the conditionally active polypeptide may have increased or decreased activity at aberrant conditions as compared to the parent polypeptide. A conditionally active polypeptide may be reversibly or irreversibly inactivated at normal physiological conditions or aberrant conditions.

Conserved: As used herein, the term “conserved” refers to nucleotides or amino acid residues of a polynucleotide sequence or polypeptide sequence, respectively, that are those that occur unaltered in the same position of two or more sequences being compared. Nucleotides or amino acids that are relatively conserved are those that are conserved amongst more related sequences than nucleotides or amino acids appearing elsewhere in the sequences.

In some embodiments, two or more sequences are said to be “completely conserved” if they are 100% identical to one another. In some embodiments, two or more sequences are said to be “highly conserved” if they are at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some embodiments, two or more sequences are said to be “highly conserved” if they are about 70% identical, about 80% identical, about 90% identical, about 95%, about 98%, or about 99% identical to one another. In some embodiments, two or more sequences are said to be “conserved” if they are at least 30% identical, at least 40% identical, at least 50% identical, at least 60% identical, at least 70% identical, at least 80% identical, at least 90% identical, or at least 95% identical to one another. In some embodiments, two or more sequences are said to be “conserved” if they are about 30% identical, about 40% identical, about 50% identical, about 60% identical, about 70% identical, about 80% identical, about 90% identical, about 95% identical, about 98% identical, or about 99% identical to one another. Conservation of sequence may apply to the entire length of a polynucleotide or polypeptide or may apply to a portion, region or feature thereof.

Control Elements: As used herein, “control elements”, “regulatory control elements” or “regulatory sequences” refers to promoter regions, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites (“IRES”), enhancers, and the like, which provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control elements need always be present as long as the selected coding sequence is capable of being replicated, transcribed and/or translated in an appropriate host cell.

Controlled Release: As used herein, the term “controlled release” refers to a pharmaceutical composition or compound release profile that conforms to a particular pattern of release to effect a therapeutic outcome.

Cytostatic: As used herein, “cytostatic” refers to inhibiting, reducing, suppressing the growth, division, or multiplication of a cell (e.g., a mammalian cell (e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite, prion, or a combination thereof.

Cytotoxic: As used herein, “cytotoxic” refers to killing or causing injurious, toxic, or deadly effect on a cell (e.g., a mammalian cell (e.g., a human cell)), bacterium, virus, fungus, protozoan, parasite, prion, or a combination thereof.

Delivery: As used herein, “delivery” refers to the act or manner of delivering an AAV particle, a compound, substance, entity, moiety, cargo or pay load.

Delivery Agent: As used herein, “delivery agent” refers to any substance which facilitates, at least in part, the in vivo delivery of an AAV particle to targeted cells.

Destabilized: As used herein, the term “destable,” “destabilize,” or “destabilizing region” means a region or molecule that is less stable than a starting, wild-type or native form of the same region or molecule.

Detectable label: As used herein. “detectable label” refers to one or more markers, signals, or moieties which are attached, incorporated or associated with another entity that is readily detected by methods known in the art including radiography, fluorescence, chermluminescence, enzymatic activity, absorbance and the like. Detectable labels include radioisotopes, fluorophores, chromophores, enzymes, dyes, metal ions, ligands such as biotin, avidin, streptavidin and haptens, quantum dots, and the like. Detectable labels may be located at any position in the peptides or proteins disclosed herein. They may be within the amino acids, the peptides, or proteins, or located at the N- or C-termini.

Digest: As used herein, the term “digest” means to break apart into smaller pieces or components. When referring to polypeptides or proteins, digestion results in the production of peptides.

Distal: As used herein, the term “distal” means situated away from the center or away from a point or region of interest.

Dosing regimen: As used herein, a “dosing regimen” is a schedule of administration or physician determined regimen of treatment, prophylaxis, or palliative care.

Encapsulate: As used herein, the term “encapsulate” means to enclose, surround or encase.

Engineered: As used herein, embodiments of the invention are “engineered” when they are designed to have a feature or property, whether structural or chemical, that varies from a starting point, wild type or native molecule.

Effective Amount: As used herein, the term “effective amount” of an agent is that amount sufficient to effect beneficial or desired results, for example, clinical results, and, as such, an “effective amount” depends upon the context in which it is being applied. For example, in the context of administering an agent that treats cancer, an effective amount of an agent is, for example, an amount sufficient to achieve treatment, as defined herein, of cancer, as compared to the response obtained without administration of the agent.

Epitope: As used herein, an “epitope” refers to a surface or region on a molecule that is capable of interacting with a biomolecule. For example, a protein may contain one or more amino acids, e.g., an epitope, which interacts with an antibody, e.g., a biomolecule. In some embodiments, when referring to a protein or protein module, an epitope may comprise a linear stretch of amino acids or a three-dimensional structure formed by folded amino acid chains.

EvoMap™: As used herein, an EvoMap™ refers to a map of a polypeptide, wherein detailed informatics are presented about the effects of single amino acid mutations within the length of the polypeptide and their influence on the properties and characteristics of that polypeptide.

Expression: As used herein, “expression” of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g. by splicing, editing, 5′ cap formation, and/or 3′ end processing), (3) translation of an RNA into a polypeptide or protein, and (4) post-translational modification of a polypeptide or protein.

Feature: As used herein, a “feature” refers to a characteristic, a property, or a distinctive element.

Formulation: As used herein, a “formulation” includes at least one AAV particle and a delivery agent.

Fragment: A “fragment,” as used herein, refers to a portion. For example, fragments of proteins may comprise polypeptides obtained by digesting full-length protein isolated from cultured cells.

Functional: As used herein, a “functional” biological molecule is a biological molecule in a form in which it exhibits a property and/or activity by which it is characterized.

Gene expression: The term “gene expression” refers to the process by which a nucleic acid sequence undergoes successful transcription and in most instances translation to produce a protein or peptide. For clarity, when reference is made to measurement of “gene expression”, this should be understood to mean that measurements may be of the nucleic acid product of transcription, e.g. RNA or mRNA or of the amino acid product of translation, e.g., polypeptides or peptides. Methods of measuring the amount or levels of RNA, mRNA, polypeptides and peptides are well known in the art.

Homology: As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g. between polynucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical or similar. The term “homologous” necessarily refers to a comparison between at least two sequences (polynucleotide or polypeptide sequences). In accordance with the invention, two polynucleotide sequences are considered to be homologous if the polypeptides they encode are at least about 50%, 60%, 70%, 80%, 90%, 95%, or even 99% for at least one stretch of at least about 20 amino acids. In some embodiments, homologous polynucleotide sequences are characterized by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. For polynucleotide sequences less than 60 nucleotides in length, homology is determined by the ability to encode a stretch of at least 4-5 uniquely specified amino acids. In accordance with the invention, two protein sequences are considered to be homologous if the proteins are at least about 50%, 60%, 70%, 80%, or 90% identical for at least one stretch of at least about 20 amino acids.

Heterologous Region: As used herein the term “heterologous region” refers to a region which would not be considered a homologous region.

Homologous Region: As used herein the term “homologous region” refers to a region which is similar in position, structure, evolution origin, character, form or function.

Identity: As used herein, the term “identity” refers to the overall relatedness between polymeric molecules, e.g., between polynucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of the percent identity of two polynucleotide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed. Oxford University Press, New York; 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W, ed., Academic Press, New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of Sequence Data, Part I. Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press. New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48:1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)). BLASTP. BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).

Inhibit expression of a gene: As used herein, the phrase “inhibit expression of a gene” means to cause a reduction in the amount of an expression product of the gene. The expression product can be an RNA transcribed from the gene (e.g., an mRNA) or a polypeptide translated from an mRNA transcribed from the gene. Typically, a reduction in the level of an mRNA results in a reduction in the level of a polypeptide translated therefrom. The level of expression may be determined using standard techniques for measuring mRNA or protein.

In vitro: As used herein, the term “in vitro” refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).

In vivo: As used herein, the term “in vivo” refers to events that occur within an organism (e.g., animal, plant, or microbe or cell or tissue thereof).

Isolated: As used herein, the term “isolated” refers to a substance or entity that has been separated from at least some of the components with which it was associated (whether in nature or in an experimental setting) Isolated substances may have varying levels of purity in reference to the substances from which they have been associated. Isolated substances and/or entities may be separated from at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or more of the other components with which they were initially associated. In some embodiments, isolated agents are more than about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components.

Substantially isolated: By “substantially isolated” is meant that a substance is substantially separated from the environment in which it was formed or detected. Partial separation can include, for example, a composition enriched in the substance or AAV particles of the present disclosure. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99%, by weight of the compound of the present disclosure, or salt thereof. Methods for isolating compounds and their salts are routine in the art.

Linker: As used herein “linker” refers to a molecule or group of molecules which connects two molecules, such as a V_(H) chain and V_(L) chain or an antibody. A linker may be a nucleic acid sequence connecting two nucleic acid sequences encoding two different polypeptides. The linker may or may not be translated. The linker may be a cleavable linker.

MicroRNA (miRNA) binding site: As used herein, a microRNA (miRNA) binding site represents a nucleotide location or region of a nucleic acid transcript to which at least the “seed” region of a miRNA binds.

Modified: As used herein “modified” refers to a changed state or structure of a molecule of the invention. Molecules may be modified in many ways including chemically, structurally, and functionally.

Naturally Occurring: As used herein. “naturally occurring” or “wild-type” means existing in nature without artificial aid, or involvement of the hand of man.

Non-human vertebrate: As used herein, a “non-human vertebrate” includes all vertebrates except Homo sapiens, including wild and domesticated species. Examples of non-human vertebrates include, but are not limited to, mammals, such as alpaca, banteng, bison, camel, cat, cattle, deer, dog, donkey, gayal, goat, guinea pig, horse, llama, mule, pig, rabbit, reindeer, sheep water buffalo, and yak.

Off-target: As used herein, “off target” refers to any unintended effect on any one or more target, gene, or cellular transcript.

Open reading frame: As used herein, “open reading frame” or “ORF” refers to a sequence which does not contain a stop codon in a given reading frame.

Operably linked: As used herein, the phrase “operably linked” refers to a functional connection between two or more molecules, constructs, transcripts, entities, moieties or the like.

Particle: As used herein, a “particle” is a virus comprised of at least two components, a protein capsid and a polynucleotide sequence enclosed within the capsid.

Patient: As used herein. “patient” refers to a subject who may seek or be in need of treatment, requires treatment, is receiving treatment, will receive treatment, or a subject who is under care by a trained professional for a particular disease or condition.

Payload: As used herein, “payload” or “payload region” refers to one or more polynucleotides or polynucleotide regions encoded by or within a viral genome or an expression product of such polynucleotide or polynucleotide region, e.g., a transgene, a polynucleotide encoding a polypeptide or multi-polypeptide or a modulatory nucleic acid or regulatory nucleic acid.

Payload construct: As used herein, “payload construct” is one or more polynucleotide regions encoding or comprising a payload that is flanked on one or both sides by an inverted terminal repeat (ITR) sequence. The payload construct is a template that is replicated in a viral production cell to produce a viral genome.

Payload construct vector. As used herein, “payload construct vector” is a vector encoding or comprising a payload construct, and regulatory regions for replication and expression in bacterial cells.

Payload construct expression vector: As used herein, a “payload construct expression vector” is a vector encoding or comprising a payload construct and which further comprises one or more polynucleotide regions encoding or comprising components for viral expression in a viral replication cell.

Peptide: As used herein, “peptide” is less than or equal to 50 amino acids long, e.g., about 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50 amino acids long.

Pharmaceutically acceptable: The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.

Pharmaceutically acceptable excipients: The phrase “pharmaceutically acceptable excipient.” as used herein, refers any ingredient other than the compounds described herein (for example, a vehicle capable of suspending or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspensing or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked poly vinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.

Pharmaceutically acceptable salts: The present disclosure also includes pharmaceutically acceptable salts of the compounds described herein. As used herein, “pharmaceutically acceptable salts” refers to derivatives of the disclosed compounds wherein the parent compound is modified by converting an existing acid or base moiety to its salt form (e.g., by reacting the free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines: alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, acetic acid, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzene sulfonic acid, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two: generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences. 17^(th) ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418. Pharmaceutical Salts: Properties. Selection, and Use, P. H Stahl and C. G. Wermuth (eds.). Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.

Pharmaceutically acceptable solvate: The term “pharmaceutically acceptable solvate,” as used herein, means a compound of the invention wherein molecules of a suitable solvent are incorporated in the crystal lattice. A suitable solvent is physiologically tolerable at the dosage administered. For example, solvates may be prepared by crystallization, recrystallization, or precipitation from a solution that includes organic solvents, water, or a mixture thereof. Examples of suitable solvents are ethanol, water (for example, mono-, di-, and tri-hydrates), N-methylpyrrolidinone (NMP), dimethyl sulfoxide (DMSO), N,N′-dimethylformamide (DMF), N,N′-dimethylacetamide (DMAC), 1,3-dimethyl-2-imidazolidinone (DMEU), 1,3-dimethyl-3,4,5,6-tetrahydro-2-(1H)-pyrimidinone (DMPU), acetonitrile (ACN), propylene glycol, ethyl acetate, benzyl alcohol, 2-pyrrolidone, benzyl benzoate, and the like. When water is the solvent, the solvate is referred to as a “hydrate.”

Pharmacokinetic: As used herein, “pharmacokinetic” refers to any one or more properties of a molecule or compound as it relates to the determination of the fate of substances administered to a living organism. Pharmacokinetics is divided into several areas including the extent and rate of absorption, distribution, metabolism and excretion. This is commonly referred to as ADME where: (A) Absorption is the process of a substance entering the blood circulation; (D) Distribution is the dispersion or dissemination of substances throughout the fluids and tissues of the body: (M) Metabolism (or Biotransformation) is the irreversible transformation of parent compounds into daughter metabolites; and (E) Excretion (or Elimination) refers to the elimination of the substances from the body. In rare cases, some drugs irreversibly accumulate in body tissue.

Physicochemical: As used herein, “physicochemical” means of or relating to a physical and/or chemical property.

Preventing: As used herein, the term “preventing” refers to partially or completely delaying onset of an infection, disease, disorder and/or condition; partially or completely delaying onset of one or more symptoms, features, or clinical manifestations of a particular infection, disease, disorder, and/or condition, partially or completely delaying onset of one or more symptoms, features, or manifestations of a particular infection, disease, disorder, and/or condition, partially or completely delaying progression from an infection, a particular disease, disorder and/or condition; and/or decreasing the risk of developing pathology associated with the infection, the disease, disorder, and/or condition.

Proliferate: As used herein, the term “proliferate” means to grow, expand or increase or cause to grow, expand or increase rapidly. “Proliferative” means having the ability to proliferate. “Anti-proliferative” means having properties counter to or inapposite to proliferative properties.

Prophylactic: As used herein, “prophylactic” refers to a therapeutic or course of action used to prevent the spread of disease.

Prophylaxis: As used herein, a “prophylaxis” refers to a measure taken to maintain health and prevent the spread of disease.

Protein of interest: As used herein, the terms “proteins of interest” or “desired proteins” include those provided herein and fragments, mutants, variants, and alterations thereof.

Proximal: As used herein, the term “proximal” means situated nearer to the center or to a point or region of interest.

Purified: As used herein, “purify,” “purified,” “purification” means to make substantially pure or clear from unwanted components, material defilement, admixture or imperfection. “Purified” refers to the state of being pure. “Purification” refers to the process of making pure.

Region: As used herein, the term “region” refers to a zone or general area. In some embodiments, when referring to a protein or protein module, a region may comprise a linear sequence of amino acids along the protein or protein module or may comprise a three-dimensional area, an epitope and/or a cluster of epitopes. In some embodiments, regions comprise terminal regions. As used herein, the term “terminal region” refers to regions located at the ends or termini of a given agent. When referring to proteins, terminal regions may comprise N- and/or C-termini. N-termini refer to the end of a protein comprising an amino acid with a free amino group. C-termini refer to the end of a protein comprising an amino acid with a free carboxyl group. N- and/or C-terminal regions may there for comprise the N- and/or C-termini as well as surrounding amino acids. In some embodiments. N- and/or C-terminal regions comprise from about 3 amino acid to about 30 amino acids, from about 5 amino acids to about 40 amino acids, from about 10 amino acids to about 50 amino acids, from about 20 amino acids to about 100 amino acids and/or at least 100 amino acids. In some embodiments, N-terminal regions may comprise any length of amino acids that includes the N-terminus, but does not include the C-terminus. In some embodiments. C-terminal regions may comprise any length of amino acids, which include the C-terminus, but do not comprise the N-terminus.

In some embodiments, when referring to a polynucleotide, a region may comprise a linear sequence of nucleic acids along the polynucleotide or may comprise a three-dimensional area, secondary structure, or tertiary structure. In some embodiments, regions comprise terminal regions. As used herein, the term “terminal region” refers to regions located at the ends or termini of a given agent. When referring to polynucleotides, terminal regions may comprise 5′ and 3′ termini, 5′ termini refer to the end of a polynucleotide comprising a nucleic acid with a free phosphate group, 3′ termini refer to the end of a polynucleotide comprising a nucleic acid with a free hydroxyl group, 5′ and 3′ regions may there for comprise the 5′ and 3′ termini as well as surrounding nucleic acids. In some embodiments, 5′ and 3′ terminal regions comprise from about 9 nucleic acids to about 90 nucleic acids, from about 15 nucleic acids to about 120 nucleic acids, from about 30 nucleic acids to about 150 nucleic acids, from about 60 nucleic acids to about 300 nucleic acids and/or at least 300 nucleic acids. In some embodiments, 5′ regions may comprise any length of nucleic acids that includes the 5′ terminus, but does not include the 3′ terminus. In some embodiments, 3′ regions may comprise any length of nucleic acids, which include the 3′ terminus, but does not comprise the 5′ terminus.

RNA or RNA molecule: As used herein, the term “RNA” or “RNA molecule” or “ribonucleic acid molecule” refers to a polymer of ribonucleotides; the term “DNA” or “DNA molecule” or “deoxyribonucleic acid molecule” refers to a polymer of deoxyribonucleotides. DNA and RNA can be synthesized naturally, e.g., by DNA replication and transcription of DNA, respectively; or be chemically synthesized. DNA and RNA can be single-stranded (i.e., ssRNA or ssDNA, respectively) or multi-stranded (e.g., double stranded, i.e., dsRNA and dsDNA, respectively). The term “mRNA” or “messenger RNA”, as used herein, refers to a single stranded RNA that encodes the amino acid sequence of one or more polypeptide chains.

Sample: As used herein, the term “sample” or “biological sample” refers to a subset of its tissues, cells or component parts (e.g. body fluids, including but not limited to blood, mucus, lymphatic fluid, synovial fluid, cerebrospinal fluid, saliva, amniotic fluid, amniotic cord blood, urine, vaginal fluid and semen). A sample further may include a homogenate, lysate or extract prepared from a whole organism or a subset of its tissues, cells or component parts, or a fraction or portion thereof, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs. A sample further refers to a medium, such as a nutrient broth or gel, which may contain cellular components, such as proteins or nucleic acid molecule.

Self-complementary viral particle: As used herein, a “self-complementary viral particle” is a particle comprised of at least two components, a protein capsid and a polynucleotide sequence encoding a self-complementary genome enclosed within the capsid.

Signal Sequences: As used herein, the phrase “signal sequences” refers to a sequence which can direct the transport or localization of a protein.

Single unit dose: As used herein, a “single unit dose” is a dose of any therapeutic administered in one dose/at one time/single route/single point of contact, i.e., single administration event. In some embodiments, a single unit dose is provided as a discrete dosage form (e.g., a tablet, capsule, patch, loaded syringe, vial, etc.).

Similarity: As used herein, the term “similarity” refers to the overall relatedness between polymeric molecules, e.g. between polynucleotide molecules (e.g. DNA molecules and/or RNA molecules) and/or between polypeptide molecules. Calculation of percent similarity of polymeric molecules to one another can be performed in the same manner as a calculation of percent identity, except that calculation of percent similarity takes into account conservative substitutions as is understood in the art.

Split dose: As used herein, a “split dose” is the division of single unit dose or total daily dose into two or more doses.

Stable: As used herein “stable” refers to a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and preferably capable of formulation into an efficacious therapeutic agent.

Stabilized: As used herein, the term “stabilize”, “stabilized,” “stabilized region” means to make or become stable.

Subject. As used herein, the term “subject” or “patient” refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants.

Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.

Substantially equal: As used herein as it relates to time differences between doses, the term means plus/minus 2%.

Substantially simultaneously: As used herein and as it relates to plurality of doses, the term means within 2 seconds.

Suffering from: An individual who is “suffering from” a disease, disorder, and/or condition has been diagnosed with or displays one or more symptoms of a disease, disorder, and/or condition.

Susceptible to: An individual who is “susceptible to” a disease, disorder, and/or condition has not been diagnosed with and/or may not exhibit symptoms of the disease, disorder, and/or condition but harbors a propensity to develop a disease or its symptoms. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition (for example, cancer) may be characterized by one or more of the following: (1) a genetic mutation associated with development of the disease, disorder, and/or condition: (2) a genetic polymorphism associated with development of the disease, disorder, and/or condition: (3) increased and/or decreased expression and/or activity of a protein and/or nucleic acid associated with the disease, disorder, and/or condition; (4) habits and/or lifestyles associated with development of the disease, disorder, and/or condition: (5) a family history of the disease, disorder, and/or condition; and (6) exposure to and/or infection with a microbe associated with development of the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will develop the disease, disorder, and/or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and/or condition will not develop the disease, disorder, and/or condition.

Sustained release. As used herein, the term “sustained release” refers to a pharmaceutical composition or compound release profile that conforms to a release rate over a specific period of time.

Synthetic: The term “synthetic” means produced, prepared, and/or manufactured by the hand of man. Synthesis of polynucleotides or polypeptides or other molecules of the present invention may be chemical or enzymatic.

Targeting: As used herein, “targeting” means the process of design and selection of nucleic acid sequence that will hybridize to a target nucleic acid and induce a desired effect.

Targeted Cells: As used herein. “targeted cells” refers to any one or more cells of interest. The cells may be found in vitro, in vivo, in situ or in the tissue or organ of an organism. The organism may be an animal, preferably a mammal, more preferably a human and most preferably a patient.

Therapeutic Agent: The term “therapeutic agent” refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and/or prophylactic effect and/or elicits a desired biological and/or pharmacological effect.

Therapeutically effective amount: As used herein, the term “therapeutically effective amount” means an amount of an agent to be delivered (e.g., nucleic acid, drug, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition. In some embodiments, a therapeutically effective amount is provided in a single dose. In some embodiments, a therapeutically effective amount is administered in a dosage regimen comprising a plurality of doses. Those skilled in the art will appreciate that in some embodiments, a unit dosage form may be considered to comprise a therapeutically effective amount of a particular agent or entity if it comprises an amount that is effective when administered as part of such a dosage regimen.

Therapeutically effective outcome: As used herein, the term “therapeutically effective outcome” means an outcome that is sufficient in a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.

Total daily dose: As used herein, a “total daily dose” is an amount given or prescribed in 24 hr period. It may be administered as a single unit dose.

Transfection: As used herein, the term “transfection” refers to methods to introduce exogenous nucleic acids into a cell. Methods of transfection include, but are not limited to, chemical methods, physical treatments and cationic lipids or mixtures.

Treating: As used herein, the term “treating” refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of a particular infection, disease, disorder, and/or condition. For example, “treating” cancer may refer to inhibiting survival, growth, and/or spread of a tumor Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.

Unmodified: As used herein, “unmodified” refers to any substance, compound or molecule prior to being changed in any way Unmodified may, but does not always, refer to the wild type or native form of a biomolecule. Molecules may undergo a series of modifications whereby each modified molecule may serve as the “unmodified” starting molecule for a subsequent modification.

Vector: As used herein, a “vector” is any molecule or moiety which transports, transduces or otherwise acts as a carrier of a heterologous molecule. Vectors of the present invention may be produced recombinantly and may be based on and/or may comprise adeno-associated virus (AAV) parent or reference sequence Such parent or reference AAV sequences may serve as an original, second, third or subsequent sequence for engineering vectors. In non-limiting examples, such parent or reference AAV sequences may comprise any one or more of the following sequences: a polynucleotide sequence encoding a polypeptide or multi-polypeptide, which sequence may be wild-type or modified from wild-type and which sequence may encode full-length or partial sequence of a protein, protein domain, or one or more subunits of a protein; a polynucleotide comprising a modulatory or regulatory nucleic acid which sequence may be wild-type or modified from wild-type; and a transgene that may or may not be modified from wild-type sequence. These AAV sequences may serve as either the “donor” sequence of one or more codons (at the nucleic acid level) or amino acids (at the polypeptide level) or “acceptor” sequences of one or more codons (at the nucleic acid level) or amino acids (at the polypeptide level).

Viral genome: As used herein, a “viral genome” or “vector genome” is a polynucleotide comprising at least one inverted terminal repeat (ITR) and at least one encoded payload. A viral genome encodes at least one copy of the payload.

Described herein are compositions, methods, processes, kits and devices for the design, preparation, manufacture and/or formulation of AAV particles. In some embodiments, payloads, such as but not limited to AAV polynucleotides, may be encoded by payload constructs or contained within plasmids or vectors or recombinant adeno-associated viruses (AAVs).

The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any materials and methods similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred materials and methods are now described. Other features, objects and advantages of the invention will be apparent from the description. In the description, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In the case of conflict, the present description will control.

The present invention is further illustrated by the following non-limiting examples.

VII. Examples Example 1. Production and Purification of AAV Particles

AAV particles described herein may be produced using methods known in the art, such as, for example, triple transfection or baculovirus mediated virus production. Any suitable permissive or packaging cell known in the art may be employed to produce the vectors Mammalian cells are often preferred. Also preferred are trans-complementing packaging cell lines that provide functions deleted from a replication-defective helper virus, e.g., 293 cells or other E1a trans-complementing cells.

The gene cassette may contain some or all of the parvovirus (e.g., AAV) cap and rep genes. Preferably, however, some or all of the cap and rep functions are provided in trans by introducing a packaging vector(s) encoding the capsid and/or Rep proteins into the cell. Most preferably, the gene cassette does not encode the capsid or Rep proteins. Alternatively, a packaging cell line is used that is stably transformed to express the cap and/or rep genes

Recombinant AAV virus particles are, in some cases, produced and purified from culture supernatants according to the procedure as described in US20160032254, the contents of which are incorporated by reference Production may also involve methods known in the art including those using 293T cell, sf9 insect cells, triple transfection or any suitable production method.

In some cases, 293 cells are transfected with CaPO4 with plasmids required for production of AAV, i.e., AAV2 rep, an adenoviral helper construct and a ITR flanked transgene cassette. The AAV2 rep plasmid also contains the cap sequence of the particular virus being studied. Twenty-four hours after transfection, which occurs in serum containing DMEM, the medium is replaced with fresh medium with or without serum. Three (3) days after transfection, a sample is taken from the culture medium of the 293 adherent cells. Subsequently cells are scraped and transferred into a receptacle. After centrifugation to remove cellular pellet, a second sample is taken from the supernatant after scraping. Next cell lysis is achieved by three consecutive freeze-thaw cycles (−80 C. to 37 C.). Cellular debris is removed and sample 3 is taken from the medium. The samples are quantified for AAV particles by DNase resistant genome titration by Taqman™ PCR, The total production yield from such a transfection is equal to the particle concentration from sample 3.

AAV vector titers are measured according to genome copy number (genome particles per milliliter). Genome particle concentrations are based on Taqman® PCR of the vector DNA as previously reported (Clark et al. (1999) Hum. Gene Ther., 10:1031-1039; Veldwijk et al. (2002) Mol. Ther., 6:272-278).

Example 2. Tissue Specific Expression

To evaluate the expression of various encoded antibody payloads in tissues, a series of AAV particles carrying the encoded antibody sequences driven by a panel of ubiquitous and tissue-specific promoters are made. These particles are administered to the specific tissue, e.g., intramuscularly, via an appropriate route, e.g., a single injection in the gastrocnemius muscle and expression is monitored to determine the relative expression potential of the payload as well as of each promoter in this target tissue. Measurement of antibody production is performed using standard techniques, for example by ELISA.

In some cases, the cytomegalovirus immediate early promoter (CMV), chimeric chicken-beta-actin (CAG), and ubiquitin C (UBC), CBA, H1 promoters provide robust expression.

Example 3. Generation of Antibodies

Antibody Production by Hybridoma Technology

Host animals (e.g. mice, rabbits, goats, and llamas) are immunized by an injection with an antigenic protein to elicit lymphocytes that specifically bind to the antigen Lymphocytes are collected and fused with immortalized cell lines to generate hybridomas. Hybridomas are cultured in a suitable culture medium that is enriched with appropriate selection agents to promote growth.

Antibodies produced by the cultured hybridomas are subjected to analysis to determine binding specificity of the antibodies for the target antigen Once antibodies with desirable characteristics are identified, corresponding hybridomas are subcloned through limiting dilution procedures and grown by standard methods. Antibodies produced by these cells are isolated and purified using standard immunoglobulin purification procedures

Recombinant Antibody Production

Recombinant antibodies are produced using heavy and light chain variable region cDNA sequences selected from hybridomas or from other sources. Sequences encoding antibody variable domains expressed by hybridomas are determined by extracting RNA molecules from antibody-producing hybridoma cells and producing cDNA by reverse transcriptase polymerase chain reaction (PCR). PCR is used to amplify cDNA using primers specific for heavy and light chain sequences. PCR products are then subcloned into plasmids for sequence analysis. Antibodies are produced by insertion of resulting variable domain sequences into expression vectors.

Recombinant antibodies are also produced using phage display technology. Target antigens are screened, in vitro, using phage display libraries having millions to billions of phage particles expressing unique single chain variable fragments (scFvs) on their viral coat. Precipitated phage particles are analyzed and sequences encoding expressed scFvs are determined. Sequences encoding antibody variable domains and/or CDRs are inserted into expression vectors for antibody production.

Recombinant antibodies are further produced using yeast surface display technology, wherein antibody variable domain sequences are expressed on the cell surface of Saccharomyces cerevisae. Recombinant antibodies are developed by displaying the antibody fragment of interest as a fusion to e.g. Aga2p protein on the surface of the yeast, where the protein interacts with proteins and small molecules in a solution, scFvs with affinity towards desired receptors are isolated from the yeast surface using magnetic separation and flow cytometry. Several cycles of yeast surface display and isolation will be done to attain scFvs with desired properties through directed evolution.

Example 4. Optimization of the Encoded Antibody

To design an optimal framework for the expression of an antibody, the heavy and light chains of several antibodies separated by an F2A self-processing peptide sequence are cloned into a mammalian expression vector under the control of the CMV promoter. 293T cells or any suitable cell line transfected with these vectors exhibit secretion of human IgG into the culture supernatant that is then detected by ELISA.

To increase expression, the antibody chains and/or the processing peptide are codon optimized for mammalian expression. In some instances, a furin cleavage site at the N-terminus is inserted for better processing.

To improve secretion of the antibody, the endogenous signal sequences are replaced with a sequence which may or may not be codon optimized, derived from any gene. In some cases, the human growth hormone signal sequence is used. Any of the heavy, light or both chains may be driven by any signal sequence, whether the same or different. Antibody expression is confirmed using standard immunohistochemical techniques, including ELISA

Example 5. Vectored Antibodies

Viral genomes are designed for AAV delivery of antibodies to cells. The viral genome comprises a payload region and at least one inverted terminal repeat (ITR) region. The payload region may optionally encode regulatory elements e.g., a promoter region, an intronic region, or a polyadenylation sequence. The payload region comprises a sequence encoding one or more polypeptides selected from the group consisting of those listed in Table 3. An exemplary payload region comprises a sequence encoding an antibody heavy chain, a region encoding an antibody light chain and a region encoding a linker connecting the heavy and light chain sequences or polypeptides before further processing. A promoter is selected to target the desired tissue or for desired regulation of expression, or both. The promoter may be selected from human EF1α, CMV, CBA, and its derivative CAG, GUSB, UBC, or any other promoter known to one with skill in the art, or combinations thereof. The 5′ and 3′ ITRs may or may not be of the same serotype as the capsid of the AAV particle.

Payload regions may optionally encode a linker between light and heavy antibody chain sequences or polypeptides. Sequence encoding linkers are derived from an internal ribosome entry site (IRES; SEQ ID NO: 899), foot and mouth disease virus 2A (F2A, SEQ ID NO: 900), porcine teschovirus-1 virus 2A (P2A; SEQ ID NO:901), a furin cleavage site (F: SEQ ID NO: 902), or a 5xG4S (SEQ ID NO: 9221 encoded by SEQ ID NO: 903) linker sequence. In various payload regions, the order of heavy and light chains is alternated with respect to 5′ to 3′ direction. Payloads are further designed to encode protein signal sequences (to aid in protein processing, localization, and/or secretion) as well as an untranslated poly A tail.

Each viral genome is then incorporated into an AAV cloning vector to create payload expression vectors.

The payload expression vectors are expressed in e.g. Expi 293 cells. The supernatants are collected and expressed antibodies are purified using protein A/G beads. Supernatants are diluted with a loading buffer and applied to a column prepared with A/C beads. Unbound proteins are washed through with loading buffer Elution buffer is added to the column, fractions collected, and fractions containing proteins of interest are identified with absorption spectroscopy technique, pooled together, and neutralized. Western blotting techniques are used to identify payload regions producing the antibody proteins of interest Purified antibodies are then tested for their affinity to their specific target by e.g. ELISA essay technique and antibodies with the highest affinity are identified and selected.

Finally, the rAAVs are produced using, for example, HEK293T cells. The cells are transfected simultaneously with the viral genome of the present invention, a viral genome encoding helper proteins and a viral genome encoding replication and capsid proteins.

Example 6. In Vivo Expression and Efficacy of Antibody Payloads

To determine the efficacy or comparative expression of encoded antibodies, dose-dependent expression is determined at a series of time points. Samples from mice treated with AAV particles encoding antibodies or luciferase at various levels are examined for expression using standard techniques such as nucleic acid analyses for RNA levels, protein analyses for antibody levels and compared to the expression of the luciferase control.

Example 7. Treatment of Infectious Disease

AAV particles of the current invention encoding an antibody are administered to a patient who has been diagnosed with an infectious disease, disorder or condition. The purpose of the treatment may be aimed to manage the disease, prevent or slow the progression of the disease, treat the symptoms associated with the disease and/or cure the disease.

The AAV particles may be administered through an intramuscular injection to the skeletal muscle. The administration may include one or more injections over a period of time. The level and distribution of AAV particles and antibody expression is monitored by standard diagnostic techniques known in the art. Such diagnostic techniques include e.g. (e.g. from blood, urine, or saliva), cerebrospinal fluid (CSF) testing, or any other testing useful for monitoring antibody levels in the body.

Additionally, the progression of the disease and the health of the patient is monitored by standard diagnostic techniques known in the art. Such techniques may include diagnostic imaging (e.g. X-ray, MRA scans, Ultrasound scans, PET scans. Nuclear scans, mammography), biopsy, laboratory tests (e.g. from blood, urine, or saliva), cerebrospinal fluid (CSF) testing, vital signs, clinical tests (cognitive, motor or reflex tests) and other relevant techniques. Treatment with the AAV particles may results in cure of the non-infectious disease, slowing down or stabilizing the progression of the disease, or have no effect on the progression of the disease. Additionally, the treatment may reduce severity of one or more symptoms associated with the disease, eliminate one or more symptoms associated with the disease or have no effect on the symptoms.

Example 8. Treatment of HIV or AIDS

AAV particles of the current invention encoding an antibody are administered to a patient who has been diagnosed with HIV or AIDS. The purpose of the treatment may be aimed to manage the disease, prevent or slow the progression of the disease, treat the symptoms associated with the disease and/or cure the disease.

The AAV particles may be administered through an intramuscular injection to the skeletal muscle. The administration may include one or more injections over a period of time. The level and distribution of AAV particles and antibody expression is monitored by standard diagnostic techniques known in the art. Such diagnostic techniques include e.g. (e.g. from blood, urine, or saliva), cerebrospinal fluid (CSF) testing, or any other testing useful for monitoring antibody levels in the body.

Additionally, the progression of the disease and the health of the patient is monitored by standard diagnostic techniques known in the art. Such techniques may include diagnostic imaging (e.g. X-ray, MRA scans, Ultrasound scans, PET scans. Nuclear scans, mammography), biopsy, laboratory tests (e.g. from blood, urine, or saliva), cerebrospinal fluid (CSF) testing, vital signs, clinical tests (cognitive, motor or reflex tests) and other relevant techniques. Treatment with the AAV particles may results in cure of the non-infectious disease, slowing down or stabilizing the progression of the disease, or have no effect on the progression of the disease. Additionally, the treatment may reduce severity of one or more symptoms associated with the disease, eliminate one or more symptoms associated with the disease or have no effect on the symptoms.

VIII. Equivalents and Scope

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the invention described herein. The scope of the present invention is not intended to be limited to the above Description, but rather is as set forth in the appended claims.

In the claims, articles such as “a,” “an,” and “the” may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include “or” between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The invention includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The invention includes embodiments in which more than one, or the entire group members are present in, employed in, or otherwise relevant to a given product or process.

It is also noted that the term “comprising” is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term “comprising” is used herein, the term “consisting of” is thus also encompassed and disclosed.

Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or subrange within the stated ranges in different embodiments of the invention, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.

In addition, it is to be understood that any particular embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein. Any particular embodiment of the compositions of the invention (e.g., any antibiotic, therapeutic or active ingredient; any method of production; any method of use: etc.) can be excluded from any one or more claims, for any reason, whether or not related to the existence of prior art.

It is to be understood that the words which have been used are words of description rather than limitation, and that changes may be made within the purview of the appended claims without departing from the true scope and spirit of the invention in its broader aspects.

While the present invention has been described at some length and with some particularity with respect to the several described embodiments, it is not intended that it should be limited to any such particulars or embodiments or any particular embodiment, but it is to be construed with reference to the appended claims so as to provide the broadest possible interpretation of such claims in view of the prior art and, therefore, to effectively encompass the intended scope of the invention. 

The invention claimed is:
 1. An adeno associated virus (AAV) particle comprising a capsid and a viral genome, said viral genome comprising at least one inverted terminal repeat (ITR) region and a payload region, said payload region comprising a first nucleic acid segment encoding one or more payload antibody polypeptides which targets a Clostridium difficile toxin, wherein said one or more payload antibody polypeptides comprise an antibody heavy chain, an antibody light chain, and a linker; wherein said antibody heavy chain comprises the polypeptide of SEQ ID NO: 3072; and wherein said antibody light chain comprises the polypeptide of SEQ ID NO:
 3073. 2. The AAV particle of claim 1, wherein the viral genome is single stranded.
 3. The AAV particle of claim 1, wherein the viral genome is self-complementary.
 4. The AAV particle of claim 1, wherein the first nucleic acid segment is codon-optimized.
 5. The AAV particle of claim 1, wherein the linker is selected from the group consisting of: SEQ ID NOs: 899-2947, CHP, FKK, HAA, ERK, ARL, DWY, GGS, IDQ, NKV, SEA, DWK, SAV, LSD, DAG, NSG, TSA, VPR, ONK, LGI, IDY, PGS, ATK, ASK, ANR, YDP, DEG, ECF, AIS, QRE, EHV, LME, TVQ, KQI, YKR, HRG, SNP, DIT, NSD, TDT, KLR, QAA, RHP, KNL, EIY, KRP, DIR, HKN, QAV, GGK, QGM, SGC, DTF, LCA, ALS, MDA, SII, FSP, RQF, ALS, AGV, ELE, DHK, AGY, EES, IPI, KEL, PDL, ITP, EVV, SAP, RQP, SDP, G, S, GG, GS, GGS, GGG, YDK, GSV, GWK, IAE, KRQ, QDT, TPN, DSS, YEQ, KNA, VGF, NKP, KFA, AEP, PTL, ASE, QDP, VKL, ASN, AIF, FFI, VTQ, SLV, KST, GAE, ISE, DKC, SAS, ATE, HNA, RET, VRP, EGK, PAT, THW, EIP, CAY, ISP, ADT, AVG, TLI, ILM, EGV, LEL, DGV, DLT, LGL, YGT, DGL, IDL, RLK, LNF, QSN, LKS, SGE, LFR, YGM, IAI, ITF, LID, ING, LLA, VPL, WGI, SKE, TLQ, PEI, NAR, RNP, FTK, VNK, DRN, AIQ, PLP, TNG, DKA, KFR, CAA, YVP, FNP, SAL, VRL, ERV, QYP, ITD, LTE, RHA, QFD, ETG, NIT, SLT, VRE, SRR, NDE, SSF, AKP, EYF, RFE, LMQ, ADG, RQP, IDP, VPV, VSN, RRI, LEA, QMH, TLR, VHP, TAK, KSY, LDG, LLE, and TYS.
 6. The AAV particle of claim 1, wherein the first nucleic acid segment encodes from 5′ to 3′, the antibody heavy chain, the linker, and the antibody light chain.
 7. The AAV particle of claim 1, wherein the first nucleic acid segment encodes from 5′ to 3′, the antibody light chain, the linker, and the antibody heavy chain.
 8. A method of producing a functional antibody in a subject, comprising administering to said subject the AAV particle of claim
 1. 9. A pharmaceutical composition comprising an AAV particle of claim 8 and a pharmaceutically acceptable excipient.
 10. A method of treating Clostridium difficile infection in a subject, the method comprising administering to said subject the pharmaceutical composition of claim
 9. 11. The AAV particle of claim 6, wherein the first nucleic acid segment encoding the linker (a) comprises an internal ribosome entry site (IRES), (b) encodes a T2A peptide, an F2A peptide, a furin cleavage site, or a glycine serine linker, or (c) is a combination of (a) and (b).
 12. The AAV particle of claim 7, wherein the first nucleic acid segment encoding the linker (a) comprises an internal ribosome entry site (IRES), (b) encodes a T2A peptide, an F2A peptide, a furin cleavage site, or a glycine serine linker, or (c) is a combination of (a) and (b).
 13. The AAV particle of claim 1, wherein the capsid comprises an AAV9 capsid protein, an AAV2 capsid protein, or a functional variant thereof.
 14. The AAV particle of claim 1, wherein the viral genome further comprises a promoter operably linked to the payload region.
 15. The AAV particle of claim 14, wherein the promoter comprises a tissue-specific promoter or a ubiquitous promoter.
 16. The AAV particle of claim 14, wherein the promoter comprises an EF-1α promoter, a chicken β-actin (CBA) promoter and/or its derivative CAG, a cytomegalovirus (CMV) immediate-early enhancer and/or promoter, a β glucuronidase (GUSB) promoter, a ubiquitin C (UBC) promoter, a neuron-specific enolase (NSE), a platelet-derived growth factor (PDGF) promoter, a platelet-derived growth factor B-chain (PDGF-β) promoter, a synapsin (Syn) promoter, a methyl-CpG binding protein 2 (MeCP2) promoter, a Ca2⁺/calmodulin-dependent protein kinase II (CaMKII) promoter, a metabotropic glutamate receptor 2 (mGluR2) promoter, a neurofilament light (NFL) or heavy (NFH) promoter, a β-globin minigene nβ2 promoter, a preproenkephalin (PPE) promoter, an enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2), a glial fibrillary acidic protein (GFAP) promoter, a myelin basic protein (MBP) promoter or a functional variant thereof.
 17. The AAV particle of claim 1, wherein the viral genome further comprises: (i) an enhancer; (ii) an intron; (iii) a Kozak sequence; and/or (iv) a polyadenylation sequence.
 18. The AAV particle of claim 17, wherein the enhancer comprises a Cytomegalovirus Major Immediate-Early (CMVie) enhancer.
 19. The AAV particle of claim 17, wherein the intron comprises a β-globin SD/immunoglobulin heavy chain splice acceptor (β-globin intron), or an SV40 late splice donor/splice acceptor (SV40 intron).
 20. The AAV particle of claim 1, wherein the viral genome comprises a first ITR region positioned 5′ relative to the payload region, and a second ITR region positioned 3′ relative to the payload region. 